Clustering O 0 1.8774329873849638e-05
of O 0 8.811176712697488e-07
missense O 0 1.4201503290678374e-05
mutations O 0 6.384504303014182e-08
in O 0 1.0985073117808497e-07
the O 0 2.531072277633939e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
gene O 0 3.930978891730774e-06
in O 0 8.379029026173157e-08
a O 0 7.350663508987054e-07
sporadic B-Disease 0 2.8187938369228505e-05
T I-Disease 0 0.001975680934265256
- I-Disease 0 0.02315155602991581
cell I-Disease 0 0.23210522532463074
leukaemia I-Disease 1 0.9999796152114868
. O 0 5.4586382702837e-07

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999990463256836
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 3.824553829190336e-08
is O 0 1.414958816781109e-09
a O 0 2.0968661473830252e-08
recessive B-Disease 0 1.2479836186685134e-07
multi I-Disease 0 0.000992707209661603
- I-Disease 1 0.9999983310699463
system I-Disease 0 0.0033438694663345814
disorder I-Disease 0 0.034701600670814514
caused O 0 3.5818817423205473e-07
by O 0 7.036561111561923e-09
mutations O 0 2.8512441296868474e-09
in O 0 1.5020624744011002e-08
the O 0 2.892597308346012e-07
ATM O 0 1.7953907445189543e-05
gene O 0 1.546857752998676e-08
at O 0 1.6922651013828727e-07
11q22 O 0 1.8302908983969246e-06
- O 0 1.6268005538222496e-06
q23 O 0 4.285951490601292e-06
( O 0 1.2724436260214134e-07
ref O 0 8.83135840012983e-07
. O 0 2.7715227890467986e-09
3 O 0 4.62248799237841e-08
) O 0 1.543868854980701e-08
. O 0 3.7903131300254245e-08

The O 0 5.374292300075467e-07
risk O 0 1.3058356671535876e-06
of O 0 6.999631523285643e-07
cancer B-Disease 0 9.664729441283271e-05
, O 0 3.449855867643237e-08
especially O 0 4.1095157143899996e-07
lymphoid B-Disease 1 0.9999810457229614
neoplasias I-Disease 1 0.9999366998672485
, O 0 4.9914895328129205e-08
is O 0 1.226008361498998e-08
substantially O 0 1.285255564198451e-07
elevated O 0 4.5511876578530064e-07
in O 0 2.4862421810212254e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 1.25079952795204e-06
and O 0 3.853445562640445e-09
has O 0 1.4254637470401121e-09
long O 0 2.2717709935449193e-09
been O 0 1.5583588863776754e-09
associated O 0 8.150776942272842e-09
with O 0 6.484152326180492e-09
chromosomal O 1 1.0
instability O 1 1.0
. O 0 2.095284571623779e-06

By O 0 2.391449243077659e-07
analysing O 0 1.154503297584597e-05
tumour B-Disease 1 0.9999998807907104
DNA O 0 4.824432267014345e-07
from O 0 1.7693421838771428e-08
patients O 0 1.2781551372853528e-09
with O 0 6.080962955401503e-10
sporadic B-Disease 0 1.3212916201155167e-05
T I-Disease 0 0.0002831154561135918
- I-Disease 0 0.0001836871524574235
cell I-Disease 0 0.0001564047415740788
prolymphocytic I-Disease 0 0.0003333251515869051
leukaemia I-Disease 1 0.9851619601249695
( O 0 1.4298122152922588e-07
T B-Disease 0 8.028798106352042e-07
- I-Disease 0 1.5773719042044831e-06
PLL I-Disease 0 0.0003865497128572315
) O 0 2.1734853916655084e-09
, O 0 1.466652910231403e-10
a O 0 1.2387311176809135e-09
rare O 0 4.670965392250537e-09
clonal B-Disease 0 5.858454414919834e-07
malignancy I-Disease 0 7.337303941312712e-06
with O 0 1.10630304916981e-09
similarities O 0 3.611014065540985e-08
to O 0 9.371328602014728e-09
a O 0 1.3661994557878643e-07
mature B-Disease 0 6.142518600427138e-07
T I-Disease 0 4.69578844786156e-06
- I-Disease 0 4.63229071101523e-06
cell I-Disease 0 1.0750956789706834e-05
leukaemia I-Disease 0 0.0053129964508116245
seen O 0 2.7370242605684325e-07
in O 0 7.220061348789386e-08
A B-Disease 1 1.0
- I-Disease 0 0.06531199812889099
T I-Disease 1 0.9997774958610535
, O 0 2.752862160448899e-09
we O 0 4.088988703188079e-09
demonstrate O 0 1.4927117319984973e-08
a O 0 5.066167041434255e-09
high O 0 4.94548757501434e-09
frequency O 0 4.849241452831166e-09
of O 0 1.6704987615412392e-08
ATM O 0 2.3536802018497838e-06
mutations O 0 2.5432791872503913e-08
in O 0 3.539024362453347e-07
T B-Disease 0 9.183515794575214e-05
- I-Disease 0 0.0003566246887203306
PLL I-Disease 0 0.03462054580450058
. O 0 7.557457593065919e-07

In O 0 1.0095880043081706e-06
marked O 0 2.6634032224137627e-07
contrast O 0 6.212351877366018e-08
to O 0 1.0722661869522199e-08
the O 0 7.345030184069401e-08
ATM O 0 3.7799102301505627e-06
mutation O 0 2.648027797036434e-09
pattern O 0 3.528482039882874e-08
in O 0 1.0198944977446445e-07
A B-Disease 1 1.0
- I-Disease 1 0.9999951124191284
T I-Disease 1 1.0
, O 0 2.1910628866805837e-09
the O 0 4.674922671199511e-09
most O 0 2.1320187282292125e-10
frequent O 0 8.335759305033719e-10
nucleotide O 0 4.375329876182832e-09
changes O 0 3.834045025907784e-10
in O 0 2.9937257117751415e-09
this O 0 8.297882381214094e-09
leukaemia B-Disease 0 0.00021098442084621638
were O 0 2.1417911000298773e-07
missense O 0 6.0269967434578575e-06
mutations O 0 1.215698972600876e-07
. O 0 1.3301297485668329e-07

These O 0 3.186010530953354e-07
clustered O 0 2.8645572456298396e-06
in O 0 4.189728386450042e-08
the O 0 5.6984166718621054e-08
region O 0 7.97173882460811e-08
corresponding O 0 3.245696120757202e-07
to O 0 3.678290028119591e-08
the O 0 4.498284909004724e-07
kinase O 0 4.03478043153882e-05
domain O 0 1.7975915511669882e-07
, O 0 5.793987511992782e-11
which O 0 2.0316632057260087e-11
is O 0 9.436536274609608e-11
highly O 0 7.616739461369093e-10
conserved O 0 3.2708211250565e-08
in O 0 2.7964709659045184e-08
ATM O 0 8.458369848085567e-06
- O 0 1.0444112774621317e-07
related O 0 4.540748221870672e-08
proteins O 0 1.2478951205707745e-08
in O 0 1.7546826214243083e-08
mouse O 0 7.427047421515454e-08
, O 0 6.197517499195726e-10
yeast O 0 6.40267430185304e-08
and O 0 3.303240703189658e-08
Drosophila O 0 2.494585942258709e-06
. O 0 1.1885854434012799e-07

The O 0 5.12193992108223e-07
resulting O 0 1.584968885026683e-07
amino O 0 1.539626310886888e-07
- O 0 8.0108044642202e-08
acid O 0 1.635603297245325e-08
substitutions O 0 1.3043649715882566e-08
are O 0 1.3756665806496926e-09
predicted O 0 3.473274645671154e-08
to O 0 1.1339308159108441e-08
interfere O 0 2.9719808480876964e-07
with O 0 4.813085396904171e-08
ATP O 0 0.0014776501338928938
binding O 0 3.6945505144103663e-07
or O 0 1.5608412695655716e-07
substrate O 0 1.18993443720683e-06
recognition O 0 3.1999661587178707e-07
. O 0 2.2351619577420934e-07

Two O 0 1.9856653921124234e-07
of O 0 1.8556919201273558e-07
seventeen O 0 2.1108644432388246e-06
mutated O 0 7.915207902442489e-07
T B-Disease 0 8.467829502478708e-06
- I-Disease 0 3.3868020636873553e-06
PLL I-Disease 0 0.00021370408649090677
samples O 0 1.1511577469036638e-07
had O 0 7.888759512297838e-08
a O 0 5.4454169173823175e-08
previously O 0 4.324646738496085e-07
reported O 0 1.585346808496979e-06
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.8929543495178223
T I-Disease 1 0.9995404481887817
allele O 0 5.589338911704544e-07
. O 0 2.822945361913298e-07

In O 0 5.752712581852393e-07
contrast O 0 8.136490237120597e-08
, O 0 3.654748725878676e-09
no O 0 4.079733884054804e-09
mutations O 0 1.045450725989383e-09
were O 0 4.495923633385246e-09
detected O 0 2.2893932083434265e-08
in O 0 3.148770133520884e-09
the O 0 4.203031522820311e-08
p53 O 0 3.07064276228175e-08
gene O 0 1.3273130372581932e-09
, O 0 3.6605374287290715e-10
suggesting O 0 1.0161737229452683e-08
that O 0 1.1636537289305693e-09
this O 0 6.029792132267175e-08
tumour B-Disease 1 1.0
suppressor O 0 6.880662840558216e-05
is O 0 2.0487718188633153e-09
not O 0 5.953413872994417e-10
frequently O 0 3.835480377745171e-09
altered O 0 5.941732439396219e-09
in O 0 9.653253307817522e-09
this O 0 5.248305612326476e-08
leukaemia B-Disease 0 0.0022918221075087786
. O 0 6.596184221052681e-07

Occasional O 0 4.6920333261368796e-05
missense O 0 2.075545853585936e-05
mutations O 0 4.934259578703859e-08
in O 0 6.124151497033381e-08
ATM O 0 1.1151973012601957e-05
were O 0 5.616944775965749e-08
also O 0 3.612018018017693e-09
found O 0 3.8402823143712794e-09
in O 0 2.7101428656806092e-08
tumour B-Disease 1 0.9999995231628418
DNA O 0 7.691978254342757e-08
from O 0 5.185912144156646e-09
patients O 0 2.1852397669164247e-10
with O 0 7.938225077275263e-11
B B-Disease 0 9.795899131859187e-06
- I-Disease 0 1.4241323697206099e-05
cell I-Disease 0 0.00037170565337873995
non I-Disease 0 0.013406491838395596
- I-Disease 0 0.0004616720543708652
Hodgkins I-Disease 1 0.9999970197677612
lymphomas I-Disease 0 3.190448296663817e-06
( O 0 5.282489112801159e-09
B B-Disease 0 4.018631116764482e-08
- I-Disease 0 4.803050401847031e-09
NHL I-Disease 0 2.5128484182346256e-08
) O 0 5.496794686088435e-10
and O 0 3.187191899289843e-10
a O 0 5.366405986251266e-08
B B-Disease 0 1.7004166465994786e-06
- I-Disease 0 5.998104484206124e-07
NHL I-Disease 0 2.3366535515378928e-06
cell O 0 1.6694957594154403e-05
line O 0 1.590944521012716e-06
. O 0 3.8161383031365403e-07

The O 0 4.046891888265236e-07
evidence O 0 7.471491016985965e-07
of O 0 1.4380952961801086e-07
a O 0 1.2819768357985595e-08
significant O 0 7.706145055408342e-09
proportion O 0 1.819618411502688e-08
of O 0 5.163982663702882e-08
loss O 0 7.412357945213444e-07
- O 0 8.925080408062058e-08
of O 0 9.404786283084832e-07
- O 0 4.4832398771177395e-07
function O 0 7.263058421358437e-08
mutations O 0 2.8673635688036825e-10
and O 0 1.4524109692715115e-10
a O 0 2.0477053386258603e-09
complete O 0 1.807166860601228e-08
absence O 0 6.326439461190603e-08
of O 0 3.839537399130677e-08
the O 0 6.473056313183179e-09
normal O 0 2.300480872463595e-08
copy O 0 6.44182378550795e-08
of O 0 5.5652765951208494e-08
ATM O 0 7.561069423900335e-07
in O 0 1.4755821009515557e-09
the O 0 2.3237023416555758e-09
majority O 0 5.659611113095764e-10
of O 0 1.980016506308857e-08
mutated O 0 2.0293335012411262e-07
tumours B-Disease 1 0.9999985694885254
establishes O 0 7.42279979704108e-08
somatic O 0 1.8033688320429064e-08
inactivation O 0 4.487795379759518e-08
of O 0 5.144828563174997e-09
this O 0 9.154463853633388e-10
gene O 0 6.830962462345269e-10
in O 0 1.678328920284855e-09
the O 0 2.5298437122955875e-08
pathogenesis O 0 2.1832041966263205e-05
of O 0 4.139395514357602e-06
sporadic B-Disease 0 0.0013084374368190765
T I-Disease 0 0.04554850608110428
- I-Disease 0 0.00043672119500115514
PLL I-Disease 1 0.8508104085922241
and O 0 8.137294393861794e-09
suggests O 0 2.0835662084550677e-08
that O 0 1.9751196234096824e-09
ATM O 0 9.565426353219664e-07
acts O 0 2.1138239603146758e-08
as O 0 5.7428469091291845e-08
a O 0 2.4982068680401426e-06
tumour B-Disease 1 1.0
suppressor O 0 0.00012181908095953986
. O 0 1.463787668853911e-07

As O 0 2.3679130833897943e-07
constitutional O 0 1.0568937369725973e-07
DNA O 0 1.0421985052744276e-07
was O 0 3.409214954785966e-08
not O 0 6.175381317419237e-10
available O 0 3.4826594941250733e-09
, O 0 2.1002513062029493e-09
a O 0 1.4736708919826924e-07
putative O 0 2.6164454538957216e-05
hereditary O 1 0.6984888315200806
predisposition O 0 0.0009276890195906162
to O 0 1.5312538380385377e-05
T B-Disease 1 0.9907528162002563
- I-Disease 1 0.5701373219490051
PLL I-Disease 1 0.9658973813056946
will O 0 6.391080997758536e-09
require O 0 2.0396013766799115e-09
further O 0 5.544327663642434e-09
investigation O 0 1.3402400611539633e-07
. O 0 1.1920041842472529e-08
. O 0 7.889300945862487e-08

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
protein O 0 8.84941837284714e-05
kinase O 0 1.740970037644729e-05
is O 0 6.16411921505744e-10
involved O 0 5.01346797410207e-10
in O 0 1.0722779331118204e-09
the O 0 5.199282337997602e-09
modulation O 0 3.044945984242986e-08
of O 0 2.4197099435241398e-08
the O 0 8.342447443965284e-08
Ca2 O 0 8.312297723023221e-05
+ O 0 7.123445357137825e-06
homeostasis O 0 8.581325346312951e-06
in O 0 7.224249287673956e-08
skeletal O 0 0.005571707617491484
muscle O 0 1.0878805369429756e-05
cells O 0 1.0679689694370609e-05
. O 0 3.8675563018841785e-07

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9966700673103333
DM B-Disease 1 1.0
) O 0 6.01677498934805e-08
, O 0 8.787874872240309e-10
the O 0 8.028544051796871e-09
most O 0 6.037327526797753e-09
prevalent O 0 6.858062988612801e-05
muscular B-Disease 1 0.9995645880699158
disorder I-Disease 1 0.801960825920105
in O 0 6.652955164554442e-08
adults O 0 1.902961521693669e-08
, O 0 7.484763919762827e-10
is O 0 3.4599956233449802e-09
caused O 0 2.2954315781475998e-08
by O 0 1.3772267770661983e-08
( O 0 3.891552680101995e-08
CTG O 0 8.510064617439639e-06
) O 0 4.060031866259806e-09
n O 0 2.4974530887789115e-08
- O 0 7.455644102094539e-09
repeat O 0 1.1943391164948025e-08
expansion O 0 1.4172364615205879e-08
in O 0 1.1591081428008465e-09
a O 0 4.462169744812172e-09
gene O 0 6.011172115627517e-10
encoding O 0 2.4501933815201937e-09
a O 0 2.7843679362149487e-08
protein O 0 1.4766111178232677e-07
kinase O 0 1.1133037332911044e-05
( O 0 2.1908932978931261e-07
DM B-Disease 1 0.9999985694885254
protein O 0 8.580265671298548e-07
kinase O 0 2.2607293885812396e-06
; O 0 2.0554611346312868e-09
DMPK O 0 6.047101578587899e-06
) O 0 1.722440856610774e-09
and O 0 1.7098117366387555e-10
involves O 0 7.95959476107555e-09
changes O 0 1.7863400758599823e-09
in O 0 2.2452065095990292e-08
cytoarchitecture O 0 4.137027644901536e-06
and O 0 9.029562164641902e-08
ion O 0 5.181254164199345e-05
homeostasis O 0 0.12435568124055862
. O 0 1.8109438997271354e-06

To O 0 3.2376337344430794e-07
obtain O 0 3.576457743292849e-07
clues O 0 4.563662514556199e-06
to O 0 1.2134641735883633e-08
the O 0 1.7931888862676715e-08
normal O 0 2.8168244625703664e-07
biological O 0 4.64343543171708e-07
role O 0 3.572084779079887e-07
of O 0 2.401448909949977e-06
DMPK O 0 0.0017094152281060815
in O 0 3.1330014849118015e-07
cellular O 0 1.9961414636782138e-06
ion O 0 1.7135979533122736e-06
homeostasis O 0 0.0005035542417317629
, O 0 5.568161931535087e-09
we O 0 6.847610922733338e-09
have O 0 3.2873984090464603e-10
compared O 0 1.2821033124055248e-09
the O 0 3.2535409921763403e-09
resting O 0 4.811791427528078e-07
[ O 0 4.483833890844835e-07
Ca2 O 0 6.206099101291329e-07
+ O 0 5.277929560065786e-08
] O 0 8.469585033310523e-09
i O 0 2.554025879675237e-09
, O 0 2.0749819917842416e-10
the O 0 8.940644335986292e-10
amplitude O 0 9.251608368288089e-09
and O 0 2.961951794944184e-10
shape O 0 1.3051588254597846e-08
of O 0 3.5518585406180136e-08
depolarization O 0 2.638868465965061e-07
- O 0 3.868006501761556e-07
induced O 0 1.2066070667060558e-06
Ca2 O 0 1.6901390154089313e-06
+ O 0 5.723928353518204e-08
transients O 0 4.0000792012051534e-08
, O 0 1.379954761571156e-10
and O 0 8.319458316696782e-11
the O 0 2.0994184168898755e-09
content O 0 1.4557877570098299e-08
of O 0 2.2326948112549871e-07
ATP O 0 8.748113941692282e-06
- O 0 4.6015605903448886e-07
driven O 0 7.674786388633947e-07
ion O 0 2.2813581779246306e-07
pumps O 0 1.0906885705708191e-07
in O 0 6.405994401603721e-09
cultured O 0 2.0711506749648834e-06
skeletal O 0 0.00010830557584995404
muscle O 0 1.0040595554983156e-07
cells O 0 2.749127681056507e-08
of O 0 3.1691428148405976e-08
wild O 0 5.6949365223601944e-09
- O 0 1.0622509094559973e-08
type O 0 1.2703492480170553e-08
and O 0 2.6859445778626423e-09
DMPK O 0 4.726546649180818e-06
[ O 0 6.176859983497707e-07
- O 0 2.828485889949661e-07
/ O 0 8.891927336662775e-07
- O 0 4.3953480144409696e-07
] O 0 3.740693159670627e-07
knockout O 0 1.2293425243115053e-05
mice O 0 2.355085825911374e-06
. O 0 8.45890113509995e-08

In O 0 3.5017294521821896e-06
vitro O 0 2.3475693069485715e-06
- O 0 3.316663139685261e-07
differentiated O 0 2.2359763818258216e-07
DMPK O 0 2.1216708773863502e-05
[ O 0 1.5699254163337173e-06
- O 0 1.936691205628449e-06
/ O 0 4.176957190793473e-06
- O 0 1.4071943041926716e-06
] O 0 4.7547302983730333e-07
myotubes O 0 1.2268513955859817e-06
exhibit O 0 3.736471398951835e-08
a O 0 8.727959688314968e-09
higher O 0 1.3887778926857663e-08
resting O 0 3.859767048197682e-07
[ O 0 2.6793640017785947e-07
Ca2 O 0 2.7747040576286963e-07
+ O 0 1.808011518278363e-08
] O 0 6.192227175461085e-09
i O 0 3.719376140409736e-09
than O 0 5.034924144275976e-10
do O 0 3.7390768259371043e-10
wild O 0 5.098894195754156e-09
- O 0 2.9021846259524864e-08
type O 0 1.0576701470199623e-07
myotubes O 0 3.2945690691121854e-06
because O 0 3.908354528903146e-09
of O 0 5.9598246338055105e-09
an O 0 1.9009762652899553e-09
altered O 0 6.034771349305856e-09
open O 0 2.0535731337645302e-08
probability O 0 3.894010447424989e-08
of O 0 9.343521512050756e-09
voltage O 0 4.397519859367094e-08
- O 0 2.4036928891746356e-08
dependent O 0 9.43971798506027e-08
l O 0 1.4388629843153922e-08
- O 0 3.6426395233490894e-09
type O 0 1.9893894531719525e-08
Ca2 O 0 1.5414730114571285e-07
+ O 0 1.6227140520186367e-08
and O 0 2.824914302479442e-09
Na O 0 1.1790961252700072e-05
+ O 0 3.0549989560313406e-07
channels O 0 1.1787624032422173e-07
. O 0 3.076927512779548e-08

The O 0 3.760114168471773e-06
mutant O 0 6.964448402868584e-06
myotubes O 0 1.2820307347283233e-05
exhibit O 0 1.2232945323376043e-07
smaller O 0 1.529302906533303e-08
and O 0 3.3505762608854184e-09
slower O 0 3.444806679908652e-07
Ca2 O 0 9.180506026496005e-07
+ O 0 1.3927968112170674e-08
responses O 0 2.847166946651214e-10
upon O 0 3.0342883761136363e-09
triggering O 0 2.10771649022945e-08
by O 0 5.99063021411439e-09
acetylcholine O 0 2.1994640064804116e-07
or O 0 5.223216970051681e-09
high O 0 3.7881957126728594e-08
external O 0 1.093107130145654e-06
K O 0 9.5548002718715e-06
+ O 0 1.2797801218766836e-06
. O 0 6.344178160588854e-08

In O 0 9.97272309177788e-07
addition O 0 9.443175486012478e-08
, O 0 4.135436881824717e-09
we O 0 3.6780145595827207e-09
observed O 0 5.2894053581553635e-09
that O 0 1.8506242371874038e-10
these O 0 2.1356867385691203e-09
Ca2 O 0 2.8095400921301916e-06
+ O 0 5.523031063603412e-07
transients O 0 1.1170328662046813e-07
partially O 0 1.247090875011736e-08
result O 0 3.3724120718225947e-10
from O 0 3.3814812061550015e-10
an O 0 2.489722039644704e-10
influx O 0 2.717015057385197e-09
of O 0 1.1877260952530833e-08
extracellular O 0 4.2152024093411455e-07
Ca2 O 0 4.954119390276901e-07
+ O 0 1.519901715596461e-08
through O 0 1.5692456223348472e-09
the O 0 5.050864615441242e-09
l O 0 2.9513417487692095e-08
- O 0 1.2989774589300396e-08
type O 0 7.911648225444878e-08
Ca2 O 0 1.2271276546016452e-06
+ O 0 1.8937868162538507e-07
channel O 0 3.360925120432512e-07
. O 0 3.313450847031163e-08

Neither O 0 1.0270435268466827e-05
the O 0 1.4526207792187051e-07
content O 0 7.979998883911321e-08
nor O 0 6.605375091339738e-08
the O 0 1.2185482844984108e-08
activity O 0 5.084969600943623e-08
of O 0 6.732648927254559e-08
Na O 0 3.9998412830755115e-06
+ O 0 1.0466108335549507e-07
/ O 0 3.747519983221537e-08
K O 0 2.0402140421538206e-07
+ O 0 6.384102135825742e-08
ATPase O 0 1.3057161822871421e-06
and O 0 4.134206754713432e-09
sarcoplasmic O 0 4.2972719711542595e-06
reticulum O 0 4.865401479037246e-06
Ca2 O 0 2.547780923123355e-06
+ O 0 2.2014680212123494e-07
- O 0 9.458496919023673e-08
ATPase O 0 3.887142156600021e-06
are O 0 6.203690894324154e-10
affected O 0 3.4080953614790133e-09
by O 0 2.150878763984565e-08
DMPK O 0 0.000999819370917976
absence O 0 2.3498370865127072e-05
. O 0 1.8058922250929754e-06

In O 0 1.027675466502842e-06
conclusion O 0 1.124548475672782e-06
, O 0 2.1772290637045444e-08
our O 0 5.62577966434219e-08
data O 0 2.55490959943927e-07
suggest O 0 2.6884269033189412e-08
that O 0 4.351294879967327e-09
DMPK O 0 3.270844536018558e-05
is O 0 3.0592083533065306e-08
involved O 0 6.491802650998579e-08
in O 0 4.3788382697584893e-08
modulating O 0 1.8471898783900542e-06
the O 0 1.7975760613353486e-07
initial O 0 2.3227246970236592e-07
events O 0 2.850984515134769e-08
of O 0 4.0616765062395643e-08
excitation O 0 3.940227088605752e-06
- O 0 2.3839720597607084e-05
contraction O 0 2.4160426619346254e-06
coupling O 0 6.392705245161778e-07
in O 0 5.856449547536613e-08
skeletal O 0 0.0004786404606420547
muscle O 0 3.9070974366950395e-07
. O 0 3.478087506891825e-08
. O 0 1.1180133441257567e-07

Constitutional O 0 0.00015515906852670014
RB1 O 1 0.9854122996330261
- O 0 1.075863929145271e-05
gene O 0 1.1276200417853488e-08
mutations O 0 1.4787686630768349e-09
in O 0 1.3750265370759962e-09
patients O 0 6.104681204988083e-10
with O 0 1.0692614571539139e-09
isolated O 0 1.4449017271545017e-06
unilateral B-Disease 0 6.320276497717714e-07
retinoblastoma I-Disease 0 0.36549848318099976
. O 0 1.5496358400923782e-06

In O 0 7.170989988480869e-07
most O 0 8.653384675483267e-09
patients O 0 1.127054005678474e-09
with O 0 1.8787565947420148e-10
isolated O 0 4.5617902344474714e-08
unilateral B-Disease 0 3.239263790533187e-08
retinoblastoma I-Disease 0 0.00657849945127964
, O 0 1.0378061965354846e-08
tumor B-Disease 0 3.314362629680545e-06
development O 0 8.025607911577026e-08
is O 0 3.9935188489437223e-10
initiated O 0 1.8668411261302253e-09
by O 0 2.1197367472414186e-10
somatic O 0 4.1033487718777906e-09
inactivation O 0 1.4406094983598905e-08
of O 0 4.881908211018526e-09
both O 0 6.690756837457457e-10
alleles O 0 7.000694468572988e-10
of O 0 2.5247294033192702e-08
the O 0 3.2011627126848907e-07
RB1 O 0 0.0002542594447731972
gene O 0 4.4714417413160845e-07
. O 0 2.3536257742762245e-07

However O 0 5.383715802054212e-07
, O 0 4.0437333481690985e-09
some O 0 4.57865328984397e-10
of O 0 1.6515588896481859e-09
these O 0 1.135705085530958e-09
patients O 0 5.247982493017389e-09
can O 0 6.979099520521004e-09
transmit O 0 1.7265620044781826e-06
retinoblastoma B-Disease 1 0.99820876121521
predisposition O 0 0.20110493898391724
to O 0 1.0593762311827959e-07
their O 0 1.1326116577947687e-07
offspring O 0 6.654375965808867e-07
. O 0 7.627286890965479e-08

To O 0 9.753922824984329e-08
determine O 0 2.6001421460364327e-08
the O 0 1.555683937226604e-08
frequency O 0 4.1539692574588116e-08
and O 0 8.873267676179353e-10
nature O 0 6.711570676998235e-08
of O 0 1.4280828963819658e-07
constitutional O 0 1.7671486602921505e-06
RB1 O 0 0.0016174884513020515
- O 0 2.099423710433257e-07
gene O 0 1.2290726214558845e-09
mutations O 0 2.1607368672071914e-10
in O 0 3.5002720166765755e-10
patients O 0 1.4796679159712056e-10
with O 0 8.760056569023789e-11
isolated O 0 5.569641459146624e-08
unilateral B-Disease 0 1.7626426540573448e-08
retinoblastoma I-Disease 0 1.4842395330560976e-06
, O 0 2.355850237112378e-10
we O 0 2.147859251566686e-10
analyzed O 0 4.354067328904421e-09
DNA O 0 7.953949499039936e-09
from O 0 5.0480042368405975e-09
peripheral O 0 2.2668707799766707e-07
blood O 0 1.519724790455257e-08
and O 0 3.12043679784324e-09
from O 0 2.3019343586838659e-07
tumor B-Disease 0 0.0003674726758617908
tissue O 0 2.065761509584263e-05
. O 0 3.844293985366676e-07

The O 0 2.390528834439465e-06
analysis O 0 1.1789709333243081e-06
of O 0 1.267403490601282e-06
tumors B-Disease 1 1.0
from O 0 2.9297606829459255e-07
54 O 0 1.46098443565279e-07
( O 0 6.7873542342056226e-09
71 O 0 3.7131400176804163e-08
% O 0 1.2469664190106755e-09
) O 0 1.6372340982950817e-10
of O 0 1.2150292993950984e-09
76 O 0 5.671395086892517e-08
informative O 0 2.046356115670278e-07
patients O 0 5.026607574620812e-09
showed O 0 1.4157342853593491e-08
loss O 0 2.429317760288541e-07
of O 0 3.2576289754615573e-07
constitutional O 0 2.5485512651357567e-06
heterozygosity O 1 0.999200165271759
( O 0 0.00022165843984112144
LOH O 1 0.9999669790267944
) O 0 5.029957250712869e-08
at O 0 4.524701751051907e-07
intragenic O 0 1.6474923540954478e-05
loci O 0 1.2450988151613274e-06
. O 0 1.9086125746525795e-07

Three O 0 8.588649507146329e-07
of O 0 5.140466328157345e-07
13 O 0 3.9136784835136496e-06
uninformative O 0 0.006995062343776226
patients O 0 9.623812502468354e-07
had O 0 1.549288413116301e-07
constitutional O 0 8.55519829201512e-07
deletions O 0 3.1508168376603862e-06
. O 0 1.1527445167303085e-06

For O 0 1.7177082156649703e-07
39 O 0 1.2714697561477806e-07
randomly O 0 1.266174010083887e-08
selected O 0 2.315311604661474e-07
tumors B-Disease 1 1.0
, O 0 2.9056195671728346e-07
SSCP O 0 0.13864058256149292
, O 0 7.61381286906726e-08
hetero O 0 2.753247372311307e-06
- O 0 4.914272722089663e-08
duplex O 0 3.729821003162215e-07
analysis O 0 2.9787912136924888e-09
, O 0 5.453973730973338e-11
sequencing O 0 2.8000440854825115e-10
, O 0 1.4929636693583603e-10
and O 0 3.545479188016287e-10
Southern O 0 4.329837821615001e-08
blot O 0 8.072214541243738e-07
analysis O 0 4.19286259045748e-08
were O 0 5.788459933597778e-09
used O 0 1.886985012689024e-09
to O 0 2.586824310313318e-09
identify O 0 1.2132737481351796e-07
mutations O 0 1.8192700679264817e-07
. O 0 4.944773763781996e-07

Mutations O 0 2.3095874439604813e-06
were O 0 1.3585884062194964e-07
detected O 0 5.772916367163816e-08
in O 0 5.750472542587204e-09
21 O 0 7.988405315018099e-08
( O 0 7.425585923925837e-09
91 O 0 7.101511556584228e-08
% O 0 3.736861486913767e-09
) O 0 1.0204053157991666e-09
of O 0 2.8552726405450812e-08
23 O 0 7.050796557450667e-05
tumors B-Disease 1 1.0
with O 0 0.0011308479588478804
LOH O 1 1.0
. O 0 2.538402441132348e-06

In O 0 6.935542842256837e-07
6 O 0 5.515062184713315e-07
( O 0 9.844923987145648e-09
38 O 0 1.7092069981572422e-08
% O 0 1.7112220529469369e-09
) O 0 3.1083705054335553e-10
of O 0 6.9873311581147846e-09
16 O 0 3.991348421550356e-06
tumors B-Disease 1 1.0
without O 1 0.8377591371536255
LOH O 1 1.0
, O 0 6.336339453127948e-09
one O 0 2.9447275728955447e-09
mutation O 0 4.3225970025595473e-10
was O 0 1.3926373831907313e-08
detected O 0 1.0379447523689578e-08
, O 0 3.1781105525041653e-10
and O 0 3.336118326036086e-10
in O 0 4.631699468404804e-09
9 O 0 8.191550904257383e-08
( O 0 1.8913557386923685e-09
56 O 0 9.471129658322752e-09
% O 0 6.181980483077609e-10
) O 0 1.3942785814791137e-10
of O 0 1.7291822418386005e-09
the O 0 9.339993880530528e-07
tumors B-Disease 1 1.0
without O 1 0.9999430179595947
LOH O 1 1.0
, O 0 2.5320243679516352e-09
both O 0 8.081607050236528e-10
mutations O 0 1.493781986994236e-09
were O 0 1.2944611604837064e-08
found O 0 2.8810775987153647e-08
. O 0 8.91805171931992e-08

Thus O 0 3.413957074371865e-06
, O 0 2.3854923369981407e-08
a O 0 1.641923397244227e-08
total O 0 1.3869064119376162e-08
of O 0 1.2881461231017965e-08
45 O 0 2.000423826586939e-08
mutations O 0 9.666293321330954e-10
were O 0 4.809293407959103e-09
identified O 0 5.4143264094363985e-08
in O 0 3.801971217853861e-07
tumors B-Disease 1 1.0
of O 0 2.954280535050202e-05
36 O 0 1.8452232325216755e-05
patients O 0 1.7176198241486418e-07
. O 0 2.1015512174926698e-07

Thirty O 0 3.9885395381134003e-05
- O 0 8.413602472501225e-07
nine O 0 1.1017471024388215e-07
of O 0 2.0673242673296954e-08
the O 0 1.133385918450358e-08
mutations O 0 1.5952534848651112e-09
- O 0 2.2949764755253454e-08
including O 0 9.866650829692958e-10
34 O 0 2.500570595032059e-08
small O 0 4.841940182132021e-09
mutations O 0 1.4753765986696976e-09
, O 0 9.058637728820429e-10
2 O 0 1.7198711788068977e-08
large O 0 1.1111886522030545e-08
structural O 0 8.467998668493237e-06
alterations O 0 5.971592713649443e-07
, O 0 5.836195970942981e-09
and O 0 9.520321420097844e-09
hypermethylation O 0 0.00010931702854577452
in O 0 9.935869229593663e-07
3 O 0 0.00022506006644107401
tumors O 1 1.0
- O 0 1.5654118215024937e-06
were O 0 2.279632838053658e-08
not O 0 3.2509711589412404e-10
detected O 0 4.557787480763409e-09
in O 0 5.284481741085756e-10
the O 0 5.285290871626103e-09
corresponding O 0 1.7601622914753534e-07
peripheral O 0 3.989240212831646e-06
blood O 0 4.414925172113726e-07
DNA O 0 4.2183692130493e-06
. O 0 3.935000734145433e-07

In O 0 1.810888534237165e-06
6 O 0 4.3316634901202633e-07
( O 0 4.889307181343838e-09
17 O 0 6.8387748797249515e-09
% O 0 6.371992378184643e-10
) O 0 3.809143278576954e-11
of O 0 2.2141975752898446e-10
the O 0 1.3662373454792487e-09
36 O 0 3.156835859385865e-08
patients O 0 3.1189610893989084e-09
, O 0 4.664517105901211e-10
a O 0 3.711198459654952e-09
mutation O 0 1.1440014491270745e-09
was O 0 1.6246310963197175e-08
detected O 0 5.192879903859193e-09
in O 0 5.837885730386461e-10
constitutional O 0 6.209471159479563e-09
DNA O 0 3.974010098772851e-08
, O 0 3.100891488028168e-10
and O 0 1.932650289804272e-10
1 O 0 5.346898923619392e-09
of O 0 1.1037211145037418e-09
these O 0 2.0306763215405255e-10
mutations O 0 6.66326105402959e-10
is O 0 6.774572014478508e-10
known O 0 1.185419318261438e-09
to O 0 1.7759038684062034e-09
be O 0 4.220364502316443e-09
associated O 0 3.4967388984341596e-08
with O 0 4.557743960020844e-09
reduced O 0 1.236354705724807e-06
expressivity O 0 0.00011800693755503744
. O 0 7.738699423498474e-07

The O 0 8.72207124302804e-07
presence O 0 1.1742362460154254e-07
of O 0 2.221332238150353e-07
a O 0 8.999987954894095e-08
constitutional O 0 4.118695784427473e-08
mutation O 0 2.835251589061727e-09
was O 0 4.599516145731286e-08
not O 0 4.184517454763892e-10
associated O 0 1.7466011970057593e-09
with O 0 1.5305211265026486e-10
an O 0 8.40798630719064e-09
early O 0 1.0483949353101707e-07
age O 0 1.274956957786344e-07
at O 0 4.770905093209876e-07
treatment O 0 7.93682914945748e-08
. O 0 1.184337818926906e-07

In O 0 3.640835757323657e-07
1 O 0 4.4718811409438786e-07
patient O 0 1.5298928701668046e-07
, O 0 5.7460871616399345e-09
somatic O 0 4.821594075110625e-07
mosaicism O 0 8.119394624372944e-05
was O 0 9.417381363618915e-08
demonstrated O 0 6.6233756257361165e-09
by O 0 2.960415523833859e-10
molecular O 0 1.811531480377937e-09
analysis O 0 5.884009390833e-10
of O 0 1.5224685956383155e-09
DNA O 0 4.174857348715477e-09
and O 0 9.912278775559002e-10
RNA O 0 2.5849004714473267e-07
from O 0 6.413136333094371e-08
peripheral O 0 1.114705992222298e-05
blood O 0 1.3119471304889885e-06
. O 0 3.412481532905076e-07

In O 0 1.255407710232248e-06
2 O 0 9.195261441163893e-07
patients O 0 8.557040409584715e-09
without O 0 2.721091130197806e-09
a O 0 1.8833004489238192e-08
detectable O 0 7.331285019063216e-07
mutation O 0 9.743896356440018e-09
in O 0 1.3761344952456511e-08
peripheral O 0 3.389569974387996e-05
blood O 0 9.963681804947555e-06
, O 0 3.7853646972507704e-07
mosaicism O 1 0.9886454343795776
was O 0 2.356671984671266e-06
suggested O 0 2.821636257976934e-08
because O 0 9.277544288366357e-10
1 O 0 4.294698818796405e-09
of O 0 2.883973282408192e-09
the O 0 1.3625063743916144e-08
patients O 0 6.901346694121457e-08
showed O 0 5.5786094890208915e-05
multifocal O 1 1.0
tumors B-Disease 1 1.0
and O 0 1.501998667663429e-07
the O 0 1.1409735378720143e-07
other O 0 1.6061958429958167e-09
later O 0 5.323171592408471e-08
developed O 0 5.976902883730872e-08
bilateral B-Disease 0 2.896508021876798e-06
retinoblastoma I-Disease 0 0.0012314192717894912
. O 0 1.026349423227657e-06

In O 0 8.371343369617534e-07
conclusion O 0 1.0864039268199122e-06
, O 0 1.4126134928460488e-08
our O 0 3.4540565962970504e-08
results O 0 1.752565381707427e-08
emphasize O 0 1.503647517608897e-08
that O 0 5.270580638594424e-10
the O 0 1.013518069470365e-08
manifestation O 0 8.15465000414406e-07
and O 0 3.7114105122526553e-09
transmissibility O 0 3.753991450139438e-06
of O 0 5.793875246240532e-08
retinoblastoma B-Disease 0 5.1781935326289386e-06
depend O 0 5.734845132110422e-08
on O 0 1.273833394321855e-08
the O 0 5.857429208333542e-09
nature O 0 7.352781494773808e-08
of O 0 1.0637959846349077e-08
the O 0 3.4082643374233612e-09
first O 0 3.906260204189493e-09
mutation O 0 1.354165113376382e-10
, O 0 9.693540414801305e-11
its O 0 3.1947633427620303e-10
time O 0 2.1000670091808615e-09
in O 0 1.7673210672697337e-09
development O 0 1.199826158426731e-07
, O 0 7.457376383079861e-10
and O 0 2.2078887329524122e-10
the O 0 1.7910960492528716e-09
number O 0 5.667561420175105e-10
and O 0 1.3463795356383201e-10
types O 0 1.0069777234278376e-09
of O 0 2.3644959767921137e-08
cells O 0 9.347977503182392e-09
that O 0 1.6974122107882295e-10
are O 0 2.4231297524046624e-10
affected O 0 2.677030375153322e-09
. O 0 4.821766541596162e-09
. O 0 1.0479490697434812e-07

Hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 0.9996916055679321
the I-Disease 0 0.0001028044571285136
fifth I-Disease 0 0.00039877116796560585
component I-Disease 0 0.00010198932432103902
of I-Disease 0 9.979696642403724e-07
complement I-Disease 0 1.416579152646591e-06
in O 0 8.631289460936387e-07
man O 0 0.00018465581524651498
. O 0 4.29464580520289e-06

I O 0 0.0016470042755827308
. O 0 2.1580763132078573e-05

Clinical O 1 0.9185856580734253
, O 0 2.1726768295593502e-07
immunochemical O 0 0.0003012541274074465
, O 0 6.619791292905575e-08
and O 0 1.889399037224848e-08
family O 0 1.2204995982756373e-06
studies O 0 2.35338848142419e-06
. O 0 3.0902378966857214e-07

The O 0 1.1200895642105024e-06
first O 0 1.8333028606321022e-07
recognized O 0 1.412980452641932e-07
human O 0 1.6057134644142934e-07
kindred O 0 0.00526180537417531
with O 0 1.2222280929563567e-06
hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 1.0
the I-Disease 0 0.00016980372311081737
fifth I-Disease 0 5.78474864596501e-05
component I-Disease 0 1.2136573786847293e-05
of I-Disease 0 4.691379672294715e-06
complement I-Disease 0 1.1593636372708715e-05
( O 0 3.6412606277735904e-05
C5 O 0 0.0040767802856862545
) O 0 5.5487102912366026e-08
is O 0 2.0909153519710344e-08
described O 0 7.523049134761095e-07
. O 0 5.459143608277373e-07

The O 0 1.2423764928826131e-05
proband O 0 8.656721911393106e-05
, O 0 1.1354678974839771e-07
a O 0 1.5453294111011928e-07
20 O 0 1.1476566186274795e-07
- O 0 4.387792529314538e-08
year O 0 7.721008188354972e-08
- O 0 3.8264587942649086e-07
old O 0 4.331292018378008e-07
black O 0 2.6705800237891708e-08
female O 0 8.013616081825603e-08
with O 0 4.3928000792448074e-08
systemic B-Disease 1 1.0
lupus I-Disease 1 1.0
erythematosus I-Disease 1 1.0
since O 0 5.448665433505084e-06
age O 0 2.66205711341172e-06
11 O 0 6.409003958651738e-07
, O 0 7.784768385477037e-09
lacked O 0 2.727187847995083e-06
serum O 0 1.7187967387144454e-05
hemolytic O 0 0.019232844933867455
complement O 0 6.327432402031263e-06
activity O 1 0.8040214776992798
, O 0 1.2314385067213607e-08
even O 0 1.2204159460793562e-08
during O 0 4.801560180567321e-07
remission O 0 1.5288067515939474e-05
. O 0 1.7731031221046578e-07

C5 O 0 0.007202766835689545
was O 0 9.039795259013772e-06
undetectable O 0 7.907008694019169e-06
in O 0 6.318119005754852e-08
her O 0 1.0610668255139899e-07
serum O 0 1.923246486512653e-07
by O 0 1.4257226510494547e-08
both O 0 1.5545596809829476e-08
immunodiffusion O 0 7.5668353929359e-06
and O 0 1.7627273507514474e-07
hemolytic O 0 0.003303913865238428
assays O 0 7.376656867563725e-05
. O 0 2.8917086183355423e-06

Other O 0 2.306288848785698e-08
complement O 0 4.440505207981005e-08
components O 0 1.564113460972294e-07
were O 0 2.3513189617574426e-08
normal O 0 1.8429967951760773e-07
during O 0 4.08071656465836e-08
remission O 0 9.89966338238446e-07
of O 0 3.432849950968375e-07
lupus O 0 6.186716632328171e-07
, O 0 5.112839929211077e-09
but O 0 2.409982258200216e-08
C1 O 0 0.0005543200531974435
, O 0 7.419671277375528e-08
C4 O 0 0.000541487243026495
, O 0 6.885804992862177e-08
C2 O 0 2.5502613425487652e-05
, O 0 2.0905126518755424e-08
and O 0 9.099982634097614e-08
C3 O 0 0.037737805396318436
levels O 0 4.263794835424051e-05
fell O 0 0.037459682673215866
during O 0 7.820540304237511e-06
exacerbations O 0 0.008754171431064606
. O 0 1.755479729581566e-06

A O 0 5.3289859351934865e-05
younger O 0 1.826465592102977e-07
half O 0 4.3021904616580287e-07
- O 0 1.787343308023992e-06
sister O 0 5.534796855499735e-06
, O 0 2.038910196233701e-08
who O 0 7.343318397801113e-09
had O 0 9.944954371121639e-08
no O 0 3.4363219469923934e-07
underlying O 1 0.9999980926513672
disease O 0 0.1924111694097519
, O 0 4.540000819730494e-09
was O 0 1.7937571783477324e-06
also O 0 4.6346597670776646e-09
found O 0 1.0583558918142444e-08
to O 0 3.467687648139872e-08
lack O 0 6.846543783467496e-06
immunochemically O 0 0.001601910451427102
detectable O 0 0.0042768437415361404
C5 O 0 0.001319076749496162
. O 0 8.953679184742214e-07

By O 0 7.181110049714334e-06
hemolytic O 0 0.011661729775369167
assay O 0 1.221425372932572e-05
, O 0 4.2455731374957395e-08
she O 0 3.2269554139929824e-08
exhibited O 0 1.5448151202690497e-07
1 O 0 1.7003002028559422e-07
- O 0 6.236964367190012e-08
2 O 0 2.4367627915466983e-08
% O 0 1.525680692893161e-09
of O 0 6.631905025145102e-10
the O 0 3.331579678800267e-09
normal O 0 1.8656838562947087e-07
serum O 0 1.3273308923089644e-06
C5 O 0 1.930635880853515e-05
level O 0 1.7084875025830115e-07
and O 0 4.457999525087075e-10
normal O 0 1.1901208019082787e-08
concentrations O 0 1.20153185179106e-08
of O 0 3.3177998126632247e-09
other O 0 4.520608609670518e-10
complement O 0 5.876298914131439e-08
components O 0 1.6272629181912635e-06
. O 0 4.784450879924407e-07

C5 O 0 0.001253457274287939
levels O 0 2.864704583771527e-06
of O 0 3.096840259786404e-07
other O 0 1.0523212523594339e-08
family O 0 1.9783326976607896e-08
members O 0 1.069357269400939e-09
were O 0 6.686983411441361e-09
either O 0 1.0184594501083666e-08
normal O 0 2.1516179060654395e-07
or O 0 5.304732209054919e-09
approximately O 0 7.625494902185892e-09
half O 0 1.885493006170691e-08
- O 0 6.529528207011026e-08
normal O 0 2.8222714831827034e-08
, O 0 2.6155094756674657e-10
consistent O 0 6.119571960283565e-09
with O 0 4.2622180784768204e-10
autosomal O 0 1.299029861456802e-07
codominant O 0 1.0078236982735689e-06
inheritance O 0 6.438948929599064e-08
of O 0 2.0880657203292685e-08
the O 0 2.816662636462297e-08
gene O 0 1.143910850487373e-07
determining O 0 2.3166943719843403e-05
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 4.569101747620152e-06

Normal O 0 0.0032086067367345095
hemolytic O 1 0.825501561164856
titers O 0 0.001861536642536521
were O 0 1.0678606940928148e-06
restored O 0 5.302747467794688e-07
to O 0 1.5926669760801815e-08
both O 0 5.875671504895763e-08
homozygous O 0 6.345186193357222e-06
C5 B-Disease 1 1.0
- I-Disease 1 1.0
deficient I-Disease 1 1.0
( O 0 1.1236545105930418e-05
C5D B-Disease 1 1.0
) O 0 4.1216986801373423e-07
sera O 0 2.5949186692741932e-06
by O 0 1.3486985972477328e-09
addition O 0 2.3457182862784975e-09
of O 0 1.574775509993742e-08
highly O 0 1.2622224687675043e-07
purified O 0 3.834835297311656e-06
human O 0 9.918998102875776e-07
C5 O 0 9.714819316286594e-05
. O 0 2.156295266786401e-07

In O 0 1.3773903901892481e-06
specific O 0 6.658534061898536e-07
C5 O 0 0.00039238407043740153
titrations O 0 4.0813349187374115e-05
, O 0 6.071184444067512e-09
however O 0 5.2342770118229964e-09
, O 0 1.34723321387753e-09
it O 0 7.694128112412102e-10
was O 0 1.1137608169065061e-07
noted O 0 1.7351101888607445e-08
that O 0 1.8033981252774112e-10
when O 0 7.087716524800669e-10
limited O 0 1.2721550479710686e-09
amounts O 0 6.7827725658275995e-09
of O 0 1.3650209496063326e-07
C5 O 0 1.0594731975288596e-05
were O 0 5.350574028284427e-08
assayed O 0 2.1544690298469504e-06
in O 0 8.263782547146548e-09
the O 0 5.3546043154995004e-09
presence O 0 3.2047677844815325e-09
of O 0 2.309484514739779e-08
low O 0 3.716226331107464e-07
dilutions O 0 4.314020770834759e-06
of O 0 4.907640800411173e-07
either O 0 2.9964007808302995e-06
C5D B-Disease 1 1.0
serum O 0 0.0001686194445937872
, O 0 5.418300919046715e-09
curving O 0 8.857990252408854e-08
rather O 0 1.5046567325427418e-09
than O 0 3.7175440503744994e-10
linear O 0 5.507018396855301e-09
dose O 0 1.9628100034196905e-08
- O 0 1.3351569627673143e-08
response O 0 5.707899042306508e-09
plots O 0 7.052136652418994e-08
were O 0 1.148799366745834e-08
consistently O 0 1.764246881919007e-08
obtained O 0 2.1487219115101652e-08
, O 0 1.5730244884437639e-09
suggesting O 0 1.5733343516899367e-08
some O 0 7.977906668621415e-10
inhibitory O 0 2.8054094514118333e-07
effect O 0 4.921927043710639e-08
. O 0 7.18311170544439e-08

Further O 0 1.0159042176383082e-06
studies O 0 1.8742670704341435e-07
suggested O 0 4.3293752582940215e-08
that O 0 2.874012361431255e-09
low O 0 2.8194691026328655e-07
dilutions O 0 1.457699909224175e-05
of O 0 6.307953299256042e-06
C5D B-Disease 1 1.0
serum O 0 3.52160022885073e-05
contain O 0 9.346376828034408e-08
a O 0 5.676665892906385e-08
factor O 0 2.7659583068384563e-08
( O 0 6.55647924840963e-10
or O 0 8.318145616748041e-10
factors O 0 1.2001919458271004e-08
) O 0 1.4193159980635528e-09
interfering O 0 2.7388590950749858e-08
at O 0 3.7193775170862864e-08
some O 0 1.7704350208092023e-09
step O 0 2.8970189802635105e-08
in O 0 1.976560071170752e-08
the O 0 1.4656329483386799e-07
hemolytic O 0 0.00032052185270003974
assay O 0 1.5337145669036545e-05
of O 0 0.00010395666322438046
C5 O 1 0.6210454702377319
, O 0 6.9694152671218035e-09
rather O 0 1.0818309803539705e-08
than O 0 5.056223884025712e-09
a O 0 3.02057010515e-08
true O 0 3.5855592273037473e-07
C5 O 0 1.8859747797250748e-05
inhibitor O 0 1.2182202908661566e-06
or O 0 5.0959027220187636e-08
inactivator O 0 5.518484158528736e-06
. O 0 4.917160367767792e-07

Of O 0 7.99485860625282e-06
clinical O 0 7.159971573855728e-05
interest O 0 5.656611847371096e-06
are O 0 1.286501039032828e-08
( O 0 6.929544049683045e-09
a O 0 9.222977936929055e-09
) O 0 6.408191199902546e-10
the O 0 1.8991135330992392e-09
documentation O 0 1.5569357856293209e-06
of O 0 1.9538365449989215e-06
membranous O 1 1.0
glomerulonephritis B-Disease 1 1.0
, O 0 0.0033836800139397383
vasculitis B-Disease 1 1.0
, O 0 3.7103056911291787e-06
and O 0 0.00017695319547783583
arthritis B-Disease 1 1.0
in O 0 1.0207649211224634e-05
an O 0 3.7860760926378134e-07
individual O 0 9.481650522502605e-07
lacking O 0 0.0009857806144282222
C5 O 0 0.0005157646373845637
( O 0 1.4697572048305574e-08
and O 0 8.80149508830641e-10
its O 0 1.7150842968050029e-09
biologic O 0 1.1831841106868524e-07
functions O 0 1.7052343537216075e-08
) O 0 1.7676370089869664e-10
, O 0 1.1585814946313278e-10
and O 0 3.0627317348930205e-10
( O 0 1.4417694593760189e-08
b O 0 9.805592071643332e-08
) O 0 1.90093274454739e-09
a O 0 6.425206144911044e-09
remarkable O 0 8.720525812577762e-08
propensity O 0 4.792250365426298e-07
to O 0 2.1381497461447907e-08
bacterial B-Disease 1 1.0
infections I-Disease 1 1.0
in O 0 3.281194267401588e-07
the O 0 5.229465500633523e-07
proband O 0 4.9627335101831704e-05
, O 0 3.1892064544791765e-09
even O 0 4.4007375521459835e-10
during O 0 7.376911970169431e-09
periods O 0 2.6772875116876094e-07
of O 0 8.51175911975588e-08
low O 0 1.2604493804246886e-07
- O 0 1.5406419251462466e-08
dose O 0 3.411413729281776e-08
or O 0 2.5652351354210623e-09
alternate O 0 2.3030095164244813e-08
- O 0 5.384963941423848e-08
day O 0 7.138967106357086e-08
corticosteroid O 0 1.6024861906771548e-05
therapy O 0 2.6024972612503916e-05
. O 0 1.795573183471788e-07

Other O 0 1.7900660509440058e-07
observations O 0 1.7213895944223623e-06
indicate O 0 2.320559531199251e-07
that O 0 2.741021187802062e-09
the O 0 1.035129884030539e-07
C5D B-Disease 1 1.0
state O 0 2.49699585452845e-08
is O 0 3.389451386226483e-09
compatible O 0 4.347039173069334e-09
with O 0 1.8655729738803473e-10
normal O 0 1.3502724982572545e-07
coagulation O 0 4.4617002004088135e-07
function O 0 1.5128941299735743e-07
and O 0 1.4264999181889948e-09
the O 0 1.2682961347820765e-08
capacity O 0 8.961242059513097e-08
to O 0 1.977499053396059e-08
mount O 0 0.00010009720426751301
a O 0 4.50440757049364e-06
neutrophilic O 1 0.9692617058753967
leukocytosis O 0 0.0014649375807493925
during O 0 7.661340532649774e-06
pyogenic B-Disease 0 0.19769485294818878
infection I-Disease 0 1.709079515421763e-05
. O 0 1.850477993059485e-08
. O 0 6.353720749530112e-08

Susceptibility O 0 0.0013539495412260294
to O 0 1.1470845493022352e-05
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 0.000476259330753237
twins O 0 7.851972441130783e-06
: O 0 6.602916435838324e-09
the O 0 6.716280420704379e-09
role O 0 5.570161931700568e-08
of O 0 2.598734738512576e-07
genes O 0 3.86976921618043e-08
, O 0 2.2732848492523772e-08
HLA O 0 8.026991963561159e-06
, O 0 4.42897407637588e-09
and O 0 6.488729997755627e-09
the O 0 3.634546317243803e-07
environment O 0 4.822844857699238e-06
. O 0 6.306350428531005e-07

OBJECTIVE O 0 0.00023119563411455601
To O 0 4.1775518155873215e-08
determine O 0 1.684198025486694e-08
the O 0 4.430351197015625e-09
relative O 0 1.0061722122145511e-07
effects O 0 1.3890434047425515e-07
of O 0 3.732254683086467e-08
genetic O 0 6.542818198340683e-08
and O 0 1.1370359098705762e-09
environmental O 0 2.6936005426136944e-08
factors O 0 1.4957441507590374e-08
in O 0 6.1770215609158186e-09
susceptibility O 0 6.060867008272908e-07
to O 0 9.326918188889977e-07
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 1 0.998259961605072
AS B-Disease 1 0.9999997615814209
) O 0 6.331147517357749e-08
. O 0 8.620770586276194e-08

METHODS O 0 9.949976083589718e-05
Twins O 0 3.1003244657767937e-05
with O 0 3.937117298846715e-08
AS B-Disease 1 0.9999998807907104
were O 0 6.571345778638715e-08
identified O 0 2.3189306475046578e-08
from O 0 9.91544091277774e-09
the O 0 4.8798252549886456e-08
Royal O 0 0.0002258558670291677
National O 0 0.0006208798149600625
Hospital O 1 0.9997993111610413
for O 0 1.3065058510619565e-06
Rheumatic B-Disease 1 1.0
Diseases I-Disease 1 1.0
database O 1 0.908780038356781
. O 0 1.253621462637966e-06

Clinical O 0 0.00021091903909109533
and O 0 3.066019615971527e-08
radiographic O 0 8.93446213012794e-06
examinations O 0 5.032912304159254e-05
were O 0 1.720695479434653e-07
performed O 0 3.7966369603736894e-08
to O 0 2.1446755482656954e-09
establish O 0 1.1453058590404908e-07
diagnoses O 0 9.021003961606766e-07
, O 0 4.330777514383044e-09
and O 0 1.34410251817485e-08
disease O 0 4.373289812065195e-06
severity O 0 8.422350219916552e-06
was O 0 1.5862859754633973e-06
assessed O 0 1.8335651930101449e-07
using O 0 2.3991937325718027e-09
a O 0 3.1827103175174898e-09
combination O 0 1.6010817116551834e-09
of O 0 6.327643742309874e-09
validated O 0 2.2394377197088033e-07
scoring O 0 1.5691439614329283e-07
systems O 0 1.2219180689498899e-06
. O 0 2.2170127067511203e-07

HLA O 0 0.00010859680332941934
typing O 0 6.953285264899023e-06
for O 0 1.389788053529628e-07
HLA O 0 3.012377192135318e-06
- O 0 3.902222829310631e-07
B27 O 0 1.2364973827061476e-06
, O 0 2.4657406783035185e-08
HLA O 0 3.5624640304376953e-07
- O 0 5.607856223832641e-08
B60 O 0 5.529734607989667e-07
, O 0 5.380495160522969e-09
and O 0 1.872490607013333e-08
HLA O 0 2.1760639356216416e-05
- O 0 1.7945176296052523e-05
DR1 O 0 0.0017225268529728055
was O 0 1.6894865950689564e-07
performed O 0 1.6158574922542357e-08
by O 0 6.6277481280963e-09
polymerase O 0 2.1822768303536577e-07
chain O 0 1.4494069056070202e-08
reaction O 0 7.950305414006209e-10
with O 0 1.727559345576779e-10
sequence O 0 1.815454808706818e-08
- O 0 1.4817310933779027e-08
specific O 0 2.941325849548093e-09
primers O 0 5.827144988757027e-08
, O 0 2.1053769838630387e-09
and O 0 3.861376995928367e-09
zygosity O 0 3.6949384139006725e-06
was O 0 3.947607467580383e-07
assessed O 0 4.521445475802466e-07
using O 0 1.7559958109814033e-07
microsatellite O 0 1.540697121527046e-05
markers O 0 2.626914238135214e-06
. O 0 3.841999500764359e-07

Genetic O 0 9.47881653701188e-06
and O 0 7.405162261164833e-09
environmental O 0 2.6831504129631867e-08
variance O 0 6.356773329940779e-09
components O 0 8.664157036264442e-08
were O 0 1.2546180094830106e-08
assessed O 0 5.335430230957172e-08
with O 0 5.081445264565332e-10
the O 0 3.765159206636781e-08
program O 0 2.156941150133207e-07
Mx O 0 1.5670711945858784e-06
, O 0 2.125445097700407e-10
using O 0 3.349718558087744e-10
data O 0 3.591854147444451e-09
from O 0 2.9889088426493515e-10
this O 0 2.07540165608755e-10
and O 0 1.8471893459270916e-10
previous O 0 1.6579258854676482e-08
studies O 0 1.8072393359602756e-08
of O 0 2.9278044877401044e-08
twins O 0 1.9450004629106843e-07
with O 0 1.9879555779311886e-08
AS B-Disease 1 0.9999998807907104
. O 0 1.5819516647752607e-06

RESULTS O 0 1.3098670933686662e-05
Six O 0 1.1124292313979822e-06
of O 0 5.059777095084428e-07
8 O 0 2.7507594495546073e-06
monozygotic O 0 2.9046908821328543e-05
( O 0 2.628174570418196e-06
MZ O 0 0.010560773313045502
) O 0 6.304636457343804e-08
twin O 0 4.5076893684381503e-07
pairs O 0 4.471509740255897e-08
were O 0 3.789352263083856e-07
disease O 0 8.420474273407308e-07
concordant O 0 4.806659489986487e-06
, O 0 5.103408806661491e-09
compared O 0 7.700121429365936e-09
with O 0 5.488769438954932e-10
4 O 0 1.5344576809184218e-07
of O 0 1.0819717743970614e-07
15 O 0 8.41482474811528e-08
B27 O 0 3.419577296881471e-07
- O 0 1.527290720559904e-07
positive O 0 5.548890413820118e-08
dizygotic O 0 2.5716946765896864e-05
( O 0 1.7392991935594182e-07
DZ O 0 5.472338307299651e-05
) O 0 5.958051829679789e-09
twin O 0 6.072600200468514e-08
pairs O 0 1.0036738107288556e-09
( O 0 1.0728057331377272e-09
27 O 0 1.1161890078881243e-08
% O 0 2.2095074658778913e-09
) O 0 2.842451551909875e-10
and O 0 3.193709186000149e-10
4 O 0 2.0612883844250973e-08
of O 0 1.1647194497754754e-07
32 O 0 2.83559393210453e-06
DZ O 0 0.013663902878761292
twin O 0 6.123572347860318e-06
pairs O 0 2.989003178299754e-08
overall O 0 1.5955379240040202e-07
( O 0 1.964337137394523e-09
12 O 0 3.66519192773751e-09
. O 0 3.6697370142668717e-10
5 O 0 6.295117316312826e-09
% O 0 1.909756353057901e-09
) O 0 2.6081425907875655e-09
. O 0 8.570631315762967e-09

Nonsignificant O 0 0.0010694976663216949
increases O 0 2.3914151370263426e-07
in O 0 9.889697061282732e-09
similarity O 0 3.2344605216394484e-08
with O 0 7.593443651643383e-10
regard O 0 3.7075210457260255e-08
to O 0 2.177875879638691e-09
age O 0 2.2296327983895026e-07
at O 0 3.976656444137916e-06
disease O 0 2.7204080197407166e-06
onset O 0 1.0500141797820106e-05
and O 0 8.383305716286316e-10
all O 0 7.809361490807021e-10
of O 0 9.347782103930058e-09
the O 0 1.0258406568652845e-08
disease O 0 1.807418570365371e-08
severity O 0 1.8439244797718857e-08
scores O 0 2.2027244472866414e-09
assessed O 0 6.322914636314181e-09
were O 0 2.4322297509371538e-09
noted O 0 5.7374354156536356e-09
in O 0 1.8606920448860365e-08
disease O 0 1.0197111350862542e-06
- O 0 2.885917410822003e-06
concordant O 0 0.0003877297858707607
MZ O 0 0.011253577657043934
twins O 0 2.148508428945206e-06
compared O 0 2.2051683856716409e-07
with O 0 2.6224153515386206e-08
concordant O 0 0.000376170122763142
DZ O 1 0.9187214970588684
twins O 0 9.288126602768898e-05
. O 0 3.155420699840761e-06

HLA O 0 0.0014841880183666945
- O 0 2.9039485525572672e-05
B27 O 0 1.3913961993239354e-05
and O 0 5.072280018225683e-08
B60 O 0 6.043947905709501e-06
were O 0 1.0308072262432688e-07
associated O 0 4.59089157800463e-08
with O 0 2.285840405846784e-09
the O 0 2.057293613688671e-06
disease O 0 8.268444071291015e-05
in O 0 1.0311808296137315e-07
probands O 0 0.00606790604069829
, O 0 3.411255944385516e-09
and O 0 6.726468826379062e-10
the O 0 8.639284843070527e-09
rate O 0 1.5576472378597828e-07
of O 0 2.3282730410301156e-08
disease O 0 1.2770206581080856e-07
concordance O 0 3.5104790185869206e-07
was O 0 4.3170395258584904e-08
significantly O 0 5.27576249353956e-09
increased O 0 1.5470348557755642e-08
among O 0 2.7862910201292834e-08
DZ O 0 0.00037682196125388145
twin O 0 1.308765604335349e-06
pairs O 0 9.06823682811364e-09
in O 0 9.541263779055953e-09
which O 0 4.570828604499866e-09
the O 0 4.774409845254013e-08
co O 0 3.647675839602016e-06
- O 0 7.078211297084636e-07
twin O 0 6.920498663021135e-07
was O 0 1.1768035079740002e-07
positive O 0 2.0032331349284505e-09
for O 0 2.3462194409518133e-09
both O 0 1.3874831950033695e-08
B27 O 0 5.474269983096747e-06
and O 0 6.146186706246226e-07
DR1 O 1 0.7939424514770508
. O 0 1.2446429309420637e-06

Additive O 0 4.989489752915688e-06
genetic O 0 1.4170235829169542e-07
effects O 0 9.080442708864211e-08
were O 0 5.664732682930662e-09
estimated O 0 1.6810520753196556e-09
to O 0 2.7938021340823127e-10
contribute O 0 3.4864877651585857e-09
97 O 0 1.3372715557125048e-07
% O 0 4.998477742823582e-10
of O 0 3.0258834327057116e-10
the O 0 9.332491446301105e-10
population O 0 1.7726541068352475e-10
variance O 0 3.6298641870047277e-09
. O 0 1.5644708639683813e-08

CONCLUSION O 0 4.834822175325826e-05
Susceptibility O 0 5.7409924920648336e-05
to O 0 5.76948195885052e-08
AS B-Disease 1 0.9996910095214844
is O 0 6.00810334816515e-09
largely O 0 2.127625364778396e-08
genetically O 0 1.753386186242878e-10
determined O 0 7.211855113098409e-09
, O 0 4.5969328343886673e-10
and O 0 8.274929075291482e-10
the O 0 2.7730576945828034e-08
environmental O 0 2.3791177738985425e-07
trigger O 0 3.4531741022192364e-08
for O 0 3.4903600010238733e-09
the O 0 1.341795154985448e-07
disease O 0 4.976521267963108e-06
is O 0 6.480542324993621e-09
probably O 0 2.27942265951242e-07
ubiquitous O 0 7.979418228387658e-07
. O 0 1.8125595602214162e-07

HLA O 0 0.0008876310312189162
- O 0 1.1648992767732125e-05
B27 O 0 6.929480605322169e-06
accounts O 0 9.272988421571426e-08
for O 0 4.267426412241093e-09
a O 0 2.952101674225105e-08
minority O 0 4.434874245617948e-09
of O 0 7.121489176142859e-09
the O 0 2.5273164894201727e-08
overall O 0 5.368606252886821e-07
genetic O 0 1.5665631281081005e-07
susceptibility O 0 1.3996627501455805e-07
to O 0 5.545800974005033e-08
AS B-Disease 1 0.9999985694885254
. O 0 1.6719640143492143e-06

Cell O 0 0.0003368230536580086
cycle O 0 1.5544967027381063e-05
- O 0 3.154716523567913e-06
dependent O 0 1.654303218856512e-06
colocalization O 0 4.778500624524895e-06
of O 0 7.214444508463203e-07
BARD1 O 0 0.000604382948949933
and O 0 6.423481124784303e-08
BRCA1 O 0 9.23398246754914e-08
proteins O 0 6.477353764466898e-09
in O 0 1.128392490556962e-08
discrete O 0 7.027597348496784e-07
nuclear O 0 3.127117452095263e-05
domains O 0 3.951193139073439e-05
. O 0 1.0905571343755582e-06

Germ O 0 0.26121142506599426
- O 0 7.567031570943072e-05
line O 0 4.94326513944543e-07
mutations O 0 1.3211658433931461e-08
of O 0 9.658782573751523e-08
the O 0 3.3024790013769234e-07
BRCA1 O 0 1.0206821343672345e-06
gene O 0 2.1221985946340283e-08
predispose O 0 2.0860005633949186e-07
women O 0 2.9982742955070307e-09
to O 0 1.4344778698216487e-09
early O 0 1.5198239680103143e-06
- O 0 4.9362257414031774e-05
onset O 1 0.9999997615814209
breast B-Disease 1 1.0
and I-Disease 1 0.9999979734420776
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
by O 0 1.043312209958458e-07
compromising O 0 2.841405603248859e-06
the O 0 1.587677722625358e-08
genes O 0 7.351628639185037e-09
presumptive O 0 9.648011456420136e-08
function O 0 2.0368851494367846e-08
as O 0 3.0919871107926156e-09
a O 0 1.0247615023217804e-07
tumor B-Disease 0 3.2376970011682715e-06
suppressor O 0 7.66042012401158e-06
. O 0 8.53342783102562e-08

Although O 0 2.998962713718356e-07
the O 0 1.2483788225381431e-07
biochemical O 0 5.366761342884274e-06
properties O 0 4.0310500480700284e-05
of O 0 9.478862011746969e-06
BRCA1 O 0 7.323731097130803e-07
polypeptides O 0 1.9902117287529109e-07
are O 0 3.7335040614649984e-10
not O 0 3.8903388843714026e-10
understood O 0 1.8631318710049527e-08
, O 0 2.608912530455143e-10
their O 0 8.020091812888097e-10
expression O 0 2.039348689919507e-09
pattern O 0 8.085080160924463e-09
and O 0 1.2423040374187622e-09
subcellular O 0 9.482089808443561e-06
localization O 0 4.7713374442537315e-06
suggest O 0 2.66038178153849e-08
a O 0 7.566815618531564e-09
role O 0 2.4236175732994525e-08
in O 0 4.4744364657844926e-08
cell O 0 3.1282982035918394e-06
- O 0 9.537696996630984e-07
cycle O 0 7.4549811870383564e-06
regulation O 0 7.10522385816148e-07
. O 0 9.551135349283868e-08

When O 0 3.343018761370331e-06
resting O 0 0.00010563446267042309
cells O 0 8.005501968000317e-07
are O 0 6.954198106257081e-09
induced O 0 1.1560038615243684e-07
to O 0 4.975271750140564e-09
proliferate O 0 8.028624876033064e-08
, O 0 1.4767449485475481e-09
the O 0 2.0615871676454844e-08
steady O 0 3.0114781566226156e-06
- O 0 8.257180716952917e-09
state O 0 4.859924684907924e-10
levels O 0 4.00723987326046e-09
of O 0 3.523503711022613e-09
BRCA1 O 0 1.2233425383811891e-09
increase O 0 4.853005219906947e-10
in O 0 1.3406453724940093e-09
late O 0 3.7390165630313277e-07
G1 O 0 1.59482738126826e-06
and O 0 7.225069431626707e-10
reach O 0 1.6197640562154447e-08
a O 0 6.769899307812466e-09
maximum O 0 1.002073268807635e-08
during O 0 2.6788651297238175e-08
S O 0 5.513358019015868e-07
phase O 0 5.35794754341623e-07
. O 0 1.9634546788438456e-07

Moreover O 0 2.5729991648404393e-06
, O 0 1.095051072041997e-08
in O 0 2.888984873550271e-08
S O 0 8.645145612717897e-07
phase O 0 6.673314487670723e-07
cells O 0 2.4510879370609473e-07
, O 0 7.0311010347268166e-09
BRCA1 O 0 2.2322812043285012e-08
polypeptides O 0 3.5290675270971406e-08
are O 0 4.857987345729953e-10
hyperphosphorylated O 0 6.514090955533902e-08
and O 0 1.0453908849683557e-09
accumulate O 0 6.857364098777907e-08
into O 0 4.8766061411242845e-08
discrete O 0 2.7745211355068022e-06
subnuclear O 0 4.764600453199819e-05
foci O 0 9.330051398137584e-05
termed O 0 3.3663025078567443e-06
" O 0 7.857477157813264e-07
BRCA1 O 0 4.183719681805087e-07
nuclear O 0 9.482017958362121e-06
dots O 0 6.2230292314779945e-06
. O 0 9.318480920228467e-07

" O 0 3.5729499359149486e-05
BRCA1 O 0 3.172984725097194e-05
associates O 0 3.7949099350953475e-05
in O 0 6.64101165170905e-08
vivo O 0 1.90058744919952e-06
with O 0 1.868796895010405e-09
a O 0 1.6176235817511042e-07
structurally O 0 2.4099606434901943e-06
related O 0 1.7080965619697963e-07
protein O 0 1.9928700112359365e-06
termed O 0 1.0848771125893109e-05
BARD1 O 0 0.3571888208389282
. O 0 1.4157377563606133e-06

Here O 0 7.75818625697866e-06
we O 0 1.9156095731887035e-07
show O 0 1.0340840361777737e-07
that O 0 2.0510786402638814e-09
the O 0 2.3652900082993256e-08
steady O 0 6.898404535604641e-06
- O 0 3.46620652180718e-08
state O 0 1.7004136987353036e-09
levels O 0 1.706698604664325e-08
of O 0 2.8278806851744775e-08
BARD1 O 0 5.3705072787124664e-05
, O 0 1.5233632133515584e-09
unlike O 0 1.0456661092561603e-09
those O 0 3.1185132254307746e-10
of O 0 9.721100369119995e-09
BRCA1 O 0 7.80235343000868e-09
, O 0 4.027113365001611e-10
remain O 0 2.4218108407580985e-08
relatively O 0 1.218420386805974e-08
constant O 0 1.8594811024286173e-07
during O 0 1.2333417487297993e-07
cell O 0 1.282755420106696e-06
cycle O 0 1.4254692359827459e-06
progression O 0 2.93008929475036e-06
. O 0 1.3484759620041586e-07

However O 0 3.5511518490238814e-06
, O 0 3.2264387073155376e-07
immunostaining O 0 6.246204429771751e-05
revealed O 0 9.650782885728404e-06
that O 0 7.053185413496976e-08
BARD1 O 0 0.000512308906763792
resides O 0 5.973135557724163e-06
within O 0 4.744959483105049e-07
BRCA1 O 0 1.026013265459369e-07
nuclear O 0 1.4048878256289754e-06
dots O 0 1.3702745604859956e-07
during O 0 1.8728805173395813e-07
S O 0 7.628311777807539e-07
phase O 0 1.6331725305462896e-07
of O 0 3.7183845336130616e-08
the O 0 2.4394788411541413e-08
cell O 0 1.2357612888536096e-07
cycle O 0 5.197857433358877e-08
, O 0 1.030392993150997e-10
but O 0 9.661091371349073e-11
not O 0 2.959782974265579e-10
during O 0 4.7907747102726717e-08
the O 0 1.8266605650296697e-07
G1 O 0 7.579611065011704e-06
phase O 0 1.2865976941611734e-06
. O 0 2.3547438843252166e-07

Nevertheless O 0 3.885829937644303e-05
, O 0 3.7565982324849756e-07
BARD1 O 0 0.00010211642802460119
polypeptides O 0 6.953046067792457e-07
are O 0 1.4674090831334752e-09
found O 0 1.98556748820522e-09
exclusively O 0 1.3227265505122432e-08
in O 0 8.32111712867345e-09
the O 0 1.727857856792525e-08
nuclear O 0 6.407402679542429e-07
fractions O 0 5.992004048493982e-07
of O 0 1.6183194873065077e-07
both O 0 1.9139509532806187e-08
G1 O 0 7.619775601597212e-07
- O 0 2.002378352017331e-08
and O 0 5.687251114494529e-09
S O 0 6.544890425175254e-07
- O 0 7.352277009431418e-08
phase O 0 8.794403356660041e-07
cells O 0 5.704043246623769e-07
. O 0 1.0109370407462848e-07

Therefore O 0 5.399248834692116e-07
, O 0 1.4387641300572795e-08
progression O 0 1.5387543328415632e-07
to O 0 9.602973527478298e-09
S O 0 6.852604315099597e-07
phase O 0 3.26354324897693e-07
is O 0 3.842436591128262e-09
accompanied O 0 2.0979904036266817e-08
by O 0 3.763477085527711e-09
the O 0 2.134938625886207e-08
aggregation O 0 7.043129812700499e-08
of O 0 8.804962448039078e-08
nuclear O 0 1.081002028513467e-05
BARD1 O 0 0.0017918386729434133
polypeptides O 0 3.344833203300368e-06
into O 0 4.1213135659745603e-07
BRCA1 O 0 1.4669279835288762e-06
nuclear O 0 7.991839993337635e-06
dots O 0 6.550362286361633e-06
. O 0 6.708229989271786e-07

This O 0 6.290786700446915e-07
cell O 0 3.1139038583205547e-06
cycle O 0 1.7793669258026057e-06
- O 0 8.513316060998477e-07
dependent O 0 1.1646600341919111e-06
colocalization O 0 3.3975027236010646e-06
of O 0 7.777786095175543e-07
BARD1 O 0 0.0012371494667604566
and O 0 7.331425422307802e-08
BRCA1 O 0 1.8006095103828557e-07
indicates O 0 1.2898627232971194e-07
a O 0 9.220094021600289e-09
role O 0 1.4418959359829842e-08
for O 0 1.1546866574008163e-08
BARD1 O 0 0.00016320585564244539
in O 0 2.523555338029837e-07
BRCA1 O 0 3.381033764071617e-07
- O 0 1.5065159004734596e-06
mediated O 0 6.292518264672253e-06
tumor B-Disease 0 6.717789801768959e-05
suppression O 0 7.000325695116771e-06
. O 0 2.197482587007471e-07

Ethnic O 0 8.266227382591751e-07
differences O 0 3.157604169246042e-07
in O 0 2.8768087645403284e-07
the O 0 7.164256317082618e-07
HFE O 0 0.00022631909814663231
codon O 0 4.312137207307387e-06
282 O 0 3.4406477880111197e-06
( O 0 3.854929389035533e-07
Cys O 0 0.002189231337979436
/ O 0 1.781500941433478e-05
Tyr O 0 2.6100951799890026e-05
) O 0 7.054961770336377e-08
polymorphism O 0 1.63046604484407e-06
. O 0 1.232752566693307e-07

Recent O 0 9.911207143886713e-07
studies O 0 6.792459572579901e-08
have O 0 2.7430713256393346e-09
shown O 0 4.6704421663434914e-08
that O 0 2.7168408678335254e-07
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 1 1.0
HH B-Disease 1 1.0
) O 0 1.4548883875420415e-08
is O 0 1.8233871079686992e-09
likely O 0 1.6616796827406688e-09
to O 0 1.6853091144852783e-09
be O 0 8.776956939016145e-09
caused O 0 6.120227880046514e-08
by O 0 1.510782610125716e-08
homozygosity O 0 3.5665129871631507e-06
for O 0 1.1942388411512184e-08
a O 0 9.304719128522265e-08
Cys282Tyr O 0 8.324474038090557e-06
mutation O 0 8.859354139190145e-09
in O 0 7.347003005975239e-09
the O 0 1.0460301069770139e-07
HFE O 0 0.0002786766563076526
gene O 0 8.094912118394859e-08
located O 0 1.3187595016006526e-07
4 O 0 3.0099079140200047e-07
. O 0 1.1350716278002437e-07

5 O 0 8.692118717590347e-05
Mb O 0 0.0008242074982263148
telomeric O 0 8.159428398357704e-05
to O 0 1.5766065644129412e-06
HLA O 0 0.00010609802848193794
- O 0 1.0331794328521937e-05
A O 0 9.162267815554515e-06
. O 0 3.1878826689535344e-07

Population O 0 4.162543021379861e-08
studies O 0 1.9924881300426023e-08
of O 0 7.81508813219034e-09
this O 0 1.6234995570130195e-09
polymorphism O 0 5.784731982316771e-08
are O 0 3.870518350268526e-10
facilitated O 0 1.6523662438316933e-08
by O 0 1.013823025530769e-09
the O 0 8.653351812881738e-09
fact O 0 1.7283159792214065e-08
that O 0 4.782990670193499e-10
the O 0 1.8634374043813295e-08
Cys282Tyr O 0 1.1122095202154014e-05
mutation O 0 9.618481122686262e-09
creates O 0 3.219319921754504e-08
a O 0 8.631481307475042e-08
Rsal O 0 3.051427484024316e-05
restriction O 0 1.8378857191692077e-07
site O 0 5.581556479228311e-07
. O 0 1.1732143434528552e-07

We O 0 3.146838878365088e-07
have O 0 8.53155235347458e-09
studied O 0 1.0880809497848531e-07
the O 0 3.944107263009755e-08
codon O 0 2.1651827353252884e-07
282 O 0 7.526300009885745e-07
( O 0 1.370738687000994e-07
Cys O 0 0.0013174056075513363
/ O 0 3.2637753974995576e-06
Tyr O 0 2.2757676561013795e-06
) O 0 9.685616753074555e-10
polymorphism O 0 2.369745732977435e-09
in O 0 7.763526627124762e-11
different O 0 6.88020265759981e-11
ethnic O 0 2.572584811844081e-09
groups O 0 4.480146920116113e-09
. O 0 5.316829643220444e-08

In O 0 8.409511451645812e-07
agreement O 0 8.246513516496634e-08
with O 0 1.225342138866381e-08
previous O 0 6.681254944851389e-07
observations O 0 1.6970874412436388e-06
the O 0 1.7601270485556597e-07
Tyr O 0 1.030262228596257e-05
allele O 0 1.7492791215545367e-08
appeared O 0 1.8748350427699734e-08
to O 0 1.7583370315321645e-09
be O 0 4.055264568592065e-09
rare O 0 1.578365882437538e-08
or O 0 6.277529962517292e-08
absent O 0 3.460899336005241e-07
in O 0 6.035982380581117e-08
Asiatic O 0 4.0465023630531505e-05
( O 0 7.395878043325865e-08
Indian O 0 1.6511271496710833e-06
, O 0 5.42015143878416e-09
Chinese O 0 3.2477709055456216e-07
) O 0 4.021550648047878e-09
populations O 0 4.003633868876477e-09
. O 0 1.3715905744504653e-08

The O 0 1.4627288464907906e-06
highest O 0 5.94835682932171e-07
allele O 0 1.300842011886516e-08
frequency O 0 1.9681710483610004e-08
( O 0 1.0545790907201535e-09
7 O 0 2.419362488126353e-09
. O 0 7.83878725818532e-11
5 O 0 1.5984880086250541e-09
% O 0 2.49078091485444e-10
) O 0 6.375149713688799e-11
was O 0 2.5637090228514126e-09
found O 0 3.3829021806042192e-09
in O 0 1.1002053490472008e-08
Swedes O 0 3.4019512895611115e-06
. O 0 7.814314244569687e-07

Saamis O 0 0.000388362561352551
( O 0 2.4935982878560026e-07
2 O 0 2.3579752905789064e-07
% O 0 5.2507860281991725e-09
) O 0 3.472251097758061e-10
and O 0 7.009860469864293e-10
Mordvinians O 0 2.000194626816665e-06
( O 0 6.3018568141615106e-09
1 O 0 9.323618321843696e-09
. O 0 4.782041984618957e-10
8 O 0 7.839392246467014e-09
% O 0 1.0208686118673427e-09
) O 0 1.3134809906389933e-10
had O 0 4.2073422523714044e-10
significantly O 0 1.2379470781809232e-09
lower O 0 3.445257634737686e-09
frequencies O 0 4.712199963563535e-09
of O 0 3.0156019903415654e-08
the O 0 1.7323100109933876e-07
Tyr O 0 2.9945987989776768e-05
allele O 0 3.0055477395762864e-07
. O 0 1.7806694074806728e-07

Comparisons O 0 3.053245620776579e-07
with O 0 1.062722576605779e-09
allele O 0 4.1165497677297935e-09
frequencies O 0 1.0396527194700411e-08
based O 0 4.282266097277443e-09
on O 0 1.731057430731653e-08
prevalence O 0 4.293333404348232e-07
estimates O 0 3.0305592702006834e-08
of O 0 1.0948384243647524e-07
HH B-Disease 1 0.9999301433563232
showed O 0 3.342331922340236e-07
some O 0 1.7000828522739653e-09
disagreements O 0 6.060912483007996e-08
with O 0 5.498556054917003e-10
the O 0 3.572915474592264e-08
RFLP O 0 7.391942631329584e-07
data O 0 3.8559324622156055e-08
, O 0 3.05548475409978e-10
particularly O 0 2.751428862524108e-09
in O 0 3.0865674460756054e-08
Finns O 0 1.1433253348513972e-05
. O 0 8.080903057816613e-07

The O 0 4.210532097204123e-06
newly O 0 7.968688805704005e-06
described O 0 1.4261397154768929e-05
HFE O 0 0.01362815871834755
marker O 0 3.8901312109373976e-06
provides O 0 5.783694945193929e-08
a O 0 6.532578034068592e-09
new O 0 6.266362984064244e-10
approach O 0 1.22224701470941e-08
to O 0 2.14546114207792e-09
the O 0 7.639994414887497e-09
screening O 0 1.3810857346641114e-08
of O 0 1.1944276820941013e-06
HH B-Disease 1 0.9999995231628418
as O 0 3.0108953552598905e-08
well O 0 4.179159684980505e-09
as O 0 3.11849723821922e-09
studies O 0 2.3451558917031434e-08
of O 0 9.948764478906469e-09
the O 0 1.745732802760358e-08
relationship O 0 1.1910386632507652e-07
between O 0 1.0156199437005853e-07
the O 0 4.529550494680734e-07
HFE O 0 0.0023548610042780638
Tyr O 0 1.2925455848744605e-05
allele O 0 4.067783887506948e-09
and O 0 1.99530808542292e-10
different O 0 1.9819577090629537e-09
disorders O 0 0.43080273270606995
including O 0 5.648946171277203e-06
cancer B-Disease 1 0.9999997615814209

Autosomal B-Disease 1 0.9999998807907104
dominant I-Disease 1 0.9999966621398926
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999991655349731
associated O 0 1.8895923403761117e-07
with O 0 1.5227880068025001e-09
a O 0 4.043966583822112e-08
missense O 0 7.200436868970428e-08
mutation O 0 3.8365760568481733e-10
encoding O 0 1.7813386321563485e-09
Gly23 O 0 1.2497383750087465e-06
- O 0 1.994779040614958e-06
- O 0 1.1790466487582307e-05
> O 0 6.61389958622749e-06
Val O 0 6.348454917315394e-06
in O 0 2.9288247560543823e-07
neurophysin O 0 0.00023971291375346482
II O 1 0.9794446229934692
. O 0 3.6826747873419663e-06

Autosomal B-Disease 1 1.0
dominant I-Disease 1 0.9999997615814209
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 7.078221824485809e-05
ADNDI B-Disease 1 0.9999992847442627
) O 0 8.81817285858233e-08
is O 0 5.609522180094473e-09
an O 0 1.7452823897201597e-07
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 1 0.9999990463256836
by O 0 4.304334652260877e-05
progressive O 1 1.0
degeneration O 1 1.0
of O 0 3.139604814350605e-06
the O 0 1.0811222637130413e-06
magnocellular O 0 0.0008369105053134263
neurons O 0 6.8708095568581484e-06
of O 0 5.512832217391406e-07
the O 0 1.149558556789998e-06
hypothalamus O 0 4.35056681453716e-05
leading O 0 1.0938215382338967e-06
to O 0 1.151352613248946e-08
decreased O 0 9.095746236198465e-07
ability O 0 7.012351144197737e-09
to O 0 1.3110338370481145e-09
produce O 0 1.6330525820507091e-09
the O 0 3.431461337299879e-08
hormone O 0 7.9874297398419e-08
arginine O 0 6.023975629432243e-07
vasopressin O 0 1.6780581972852815e-06
( O 0 2.4261149533799653e-08
AVP O 0 3.0894002520653885e-06
) O 0 4.728134772591375e-09
. O 0 1.5216389925853946e-08

Affected O 0 1.4122168749963748e-06
individuals O 0 8.555735675486176e-09
are O 0 8.752445435078471e-10
not O 0 3.2274705130674874e-09
symptomatic O 0 4.011000953596522e-07
at O 0 5.462132435241074e-07
birth O 0 2.1057320509498823e-07
, O 0 1.361445733927269e-09
but O 0 4.0928568867393267e-10
usually O 0 1.3594898540247868e-08
develop O 0 2.503100404283032e-06
diabetes B-Disease 1 1.0
insipidus I-Disease 1 0.9999485015869141
at O 0 3.518139055813663e-05
1 O 0 1.1683149750751909e-05
- O 0 1.4349760704135406e-06
6 O 0 1.0399054417575826e-06
yr O 0 2.345768552913796e-05
of O 0 3.1204027806097656e-08
age O 0 3.1556021440337645e-07
. O 0 2.251807558195651e-07

The O 0 2.1939010821370175e-06
genetic O 0 1.8071551721732249e-06
locus O 0 1.2995320730624371e-06
of O 0 1.1863556892421911e-07
the O 0 3.242212756049412e-07
disease O 0 1.6937752661760896e-05
is O 0 2.1684844142555448e-08
the O 0 8.273049161289237e-07
AVP O 0 0.00029156013624742627
- O 0 1.7188141328006168e-06
neurophysin O 0 2.0738541934406385e-05
II O 0 0.003418498672544956
( O 0 4.321401831930416e-07
NPII O 0 6.820893031544983e-05
) O 0 4.862355851287248e-09
gene O 0 7.05487446239772e-10
, O 0 1.7705287236324807e-10
and O 0 7.432355286773884e-10
mutations O 0 7.410107638605723e-09
that O 0 4.868053515849624e-09
cause O 0 3.401030198801891e-06
ADNDI B-Disease 1 0.999222993850708
have O 0 7.118596379029896e-09
been O 0 4.085488392036041e-09
found O 0 1.726595200146619e-09
in O 0 1.421355921848999e-09
both O 0 1.3790870667662603e-09
the O 0 1.5799081154455052e-08
signal O 0 1.0480031420456726e-07
peptide O 0 1.2382264102939189e-08
of O 0 2.607557192391141e-08
the O 0 5.1093525854639665e-08
prepro O 0 2.993151247210335e-05
- O 0 0.0001568417064845562
AVP O 0 0.0021445120219141245
- O 0 4.944565716868965e-06
NPII O 0 7.912189175840467e-05
precursor O 0 9.423964115740091e-07
and O 0 1.3965635758950157e-08
within O 0 3.6836124195360753e-07
NPII O 0 0.0004201085539534688
itself O 0 9.092536856769584e-07
. O 0 4.969247697772516e-07

An O 0 1.5396394701383542e-06
affected O 0 4.364255232758296e-07
girl O 0 3.995392489741789e-06
who O 0 4.4211773797542264e-08
presented O 0 3.1350728590950894e-07
at O 0 4.2744936763483565e-06
9 O 0 7.657678793293599e-07
months O 0 5.245763645689294e-08
of O 0 2.2843900993052557e-08
age O 0 1.0546322926074936e-07
and O 0 7.061339957203927e-09
her O 0 7.934134771403478e-08
similarly O 0 6.272527741657541e-08
affected O 0 1.0970600428095167e-08
younger O 0 1.2650540170966451e-08
brother O 0 3.661623964035243e-07
and O 0 1.537193128342551e-08
father O 0 9.652251264924416e-07
were O 0 1.0498035862838151e-07
all O 0 2.1909249969809252e-09
found O 0 9.646088372505801e-10
to O 0 4.526199415266774e-10
have O 0 1.648414182930935e-10
a O 0 3.4776082014076337e-09
novel O 0 1.733971899398057e-08
missense O 0 8.793617212177196e-08
mutation O 0 2.3736212995117967e-10
( O 0 3.6019853766333654e-10
G1758 O 0 1.0530118110807507e-08
- O 0 4.5235974965862624e-08
- O 0 2.432092571780231e-07
> O 0 2.5395061697963683e-07
T O 0 2.3172725960307616e-08
) O 0 2.11067135991172e-10
encoding O 0 5.128190649905662e-10
the O 0 9.127352762483554e-10
amino O 0 3.7941307873268215e-09
acid O 0 3.169431606053763e-09
substitution O 0 5.276144854349241e-09
Gly23 O 0 1.6853923625603784e-06
- O 0 3.7871950553380884e-06
- O 0 1.133545629272703e-05
> O 0 4.777388312504627e-06
Val O 0 9.144006071437616e-06
within O 0 9.824834705796093e-07
NPII O 0 0.0012634118320420384
. O 0 9.781847438716795e-07

The O 0 1.7199340618390124e-06
mutation O 0 3.9092508785643076e-08
was O 0 1.2003572180674382e-07
confirmed O 0 8.621293012822662e-09
by O 0 3.984406138357599e-09
restriction O 0 3.1918368392780394e-08
endonuclease O 0 9.642268423704081e-07
analysis O 0 1.5558211430288793e-07
. O 0 7.146923763912127e-08

A O 0 7.84078220021911e-05
T1 O 0 0.00027549362857826054
- O 0 5.146671924194379e-07
weighted O 0 1.6866965779627208e-07
magnetic O 0 2.7519718059920706e-07
resonance O 0 4.0606079210192547e-07
imaging O 0 1.1782582305386313e-06
of O 0 2.388410962339549e-07
the O 0 4.7306634769483935e-06
fathers O 0 0.05004787817597389
pituitary O 0 0.0009794039651751518
gland O 0 2.259759412481799e-06
demonstrates O 0 1.917374987669973e-07
an O 0 2.4079650273733932e-08
attenuated O 0 6.366170055116527e-06
posterior O 0 1.9210194295737892e-05
pituitary O 0 6.863852468086407e-05
bright O 0 7.575795279990416e-06
spot O 0 1.5363071725005284e-05
. O 0 1.0978659474858432e-06

This O 0 1.6230721655574598e-07
mutation O 0 1.4626037270204506e-08
may O 0 3.299788220445521e-09
be O 0 6.526982287979877e-10
valuable O 0 2.0174404369299737e-08
for O 0 1.0079057588541218e-09
developing O 0 7.251110378803105e-09
models O 0 1.4532547609746871e-08
of O 0 2.1227475599516765e-07
dominantly B-Disease 1 0.9999165534973145
inherited I-Disease 1 1.0
neurodegeneration I-Disease 1 1.0
, O 0 2.250925064117837e-07
as O 0 5.048726325895814e-09
the O 0 2.4376356488886586e-09
early O 0 2.1409043426956487e-08
age O 0 6.612497571722997e-08
of O 0 9.819067514627022e-08
onset O 0 0.013791725039482117
of O 0 2.9023672141192947e-06
symptoms O 0 0.018927548080682755
suggests O 0 4.613195585534413e-07
that O 0 3.9358818981760635e-10
this O 0 8.609227220013338e-10
mutation O 0 5.666977997975664e-10
may O 0 6.067245594820747e-10
be O 0 6.113478612235212e-10
particularly O 0 5.764265065266727e-09
deleterious O 0 8.398934880915476e-08
to O 0 2.972878654361466e-08
the O 0 6.236393232939008e-07
magnocellular O 0 0.0003585798549465835
neuron O 0 3.486503192107193e-05
. O 0 5.5992309455632494e-08
. O 0 2.0165023784102232e-07

Frequent O 0 1.4021697097632568e-05
inactivation O 0 5.9215090004727244e-05
of O 0 0.00020738814782816917
PTEN O 1 0.9999996423721313
/ O 1 0.9999290704727173
MMAC1 O 1 0.9999961853027344
in O 0 2.2160469598020427e-05
primary O 1 1.0
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 7.210357580333948e-06

Sporadic B-Disease 1 1.0
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 1.1359502423147205e-06
the O 0 1.0808991390831579e-07
most O 0 9.531731848255731e-09
common O 0 1.5473032632939976e-08
male B-Disease 0 1.2566027862703777e-07
cancer I-Disease 0 1.1995579640711185e-08
in O 0 1.4087496502668273e-08
the O 0 7.014320857479106e-08
Western O 0 2.1033075370269216e-07
world O 0 1.0589454646492413e-08
, O 0 1.5668344399699663e-10
yet O 0 6.071783631433902e-10
many O 0 4.867426600663194e-11
of O 0 1.0933662863976679e-09
the O 0 2.0996826499697363e-09
major O 0 1.663725868183974e-08
genetic O 0 8.993378486366055e-09
events O 0 5.478208553455488e-09
involved O 0 2.2130588472890622e-09
in O 0 2.0532902045289347e-09
the O 0 4.123734242966748e-08
progression O 0 2.4913358629419236e-06
of O 0 1.4950654048107026e-08
this O 0 4.8984172273947024e-09
often O 0 3.2663884041994606e-08
fatal O 0 3.9036993257468566e-05
cancer B-Disease 0 2.5193933197442675e-06
remain O 0 6.982723448345496e-07
to O 0 1.325552734243729e-08
be O 0 8.965618292222644e-08
elucidated O 0 0.0007157001527957618
. O 0 6.974743769205816e-07

Numerous O 0 1.7661192032392137e-05
cytogenetic O 0 0.23756010830402374
and O 0 1.317243629728182e-07
allelotype O 0 0.00019010293181054294
studies O 0 2.3251279799296753e-06
have O 0 2.5752753263219574e-09
reported O 0 7.223615483553658e-08
frequent O 0 5.069330555329543e-08
loss O 0 5.513400651580014e-07
of O 0 4.109588189749047e-06
heterozygosity O 1 0.9999686479568481
on O 0 1.8767383153317496e-05
chromosomal O 0 0.002763348165899515
arm O 0 0.012434091418981552
10q O 0 0.0015555404825136065
in O 0 3.5801783724309644e-06
sporadic B-Disease 1 1.0
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.938080044463277e-05

Deletion O 0 1.95463599084178e-05
mapping O 0 2.0618408598238602e-06
studies O 0 1.4584064444989053e-07
have O 0 1.6603458607988841e-09
unambiguously O 0 3.654339408853957e-08
identified O 0 2.377402630315828e-08
a O 0 2.7670557400938378e-08
region O 0 2.784420871648763e-08
of O 0 2.8487133363341854e-07
chromosome O 0 8.648535185784567e-07
10q23 O 0 9.454093401473074e-07
to O 0 6.764117266300218e-09
be O 0 3.6644649537009855e-09
the O 0 3.8808270375056964e-08
minimal O 0 5.586404313362436e-06
area O 0 2.3587332975694153e-07
of O 0 3.2760726753622293e-07
loss O 0 4.110661393497139e-05
. O 0 1.5220678051264258e-06

A O 0 8.968489964900073e-06
new O 0 3.677683650948893e-07
tumor B-Disease 0 1.049427555699367e-05
suppressor O 0 3.957909029850271e-06
gene O 0 5.535475722240335e-08
, O 0 1.6122800872153675e-08
PTEN O 0 0.00022969279962126166
/ O 0 1.9397006326471455e-05
MMAC1 O 0 0.08214133232831955
, O 0 3.805431347814192e-08
was O 0 1.2936684470332693e-06
isolated O 0 8.104094604277634e-07
recently O 0 1.7742388891406335e-08
at O 0 2.3672983573419515e-08
this O 0 9.980136717047117e-10
region O 0 1.1016794587703771e-08
of O 0 8.206939838828475e-08
chromosome O 0 2.0055324512213701e-07
10q23 O 0 5.173561135052296e-07
and O 0 3.865459063945309e-09
found O 0 2.898045581289921e-09
to O 0 8.277423191316302e-10
be O 0 7.971928117633809e-10
inactivated O 0 7.849791927583283e-09
by O 0 1.5282816123729503e-09
mutation O 0 1.7485578540643587e-09
in O 0 3.4462699360915394e-09
three O 0 7.013356366769585e-07
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 1 0.999994158744812
lines O 0 6.188633051351644e-06
. O 0 2.3162900220086158e-07

We O 0 1.975412260435405e-06
screened O 0 7.131779057090171e-06
80 O 0 1.1545826055225916e-05
prostate B-Disease 0 0.02628359943628311
tumors I-Disease 1 1.0
by O 0 3.991893038346461e-08
microsatellite O 0 3.0232213248382322e-06
analysis O 0 3.22132827079713e-08
and O 0 4.4667319842872644e-10
found O 0 7.542637625590487e-09
chromosome O 0 5.067136044090148e-08
10q23 O 0 1.250227796845138e-07
to O 0 9.319387039852245e-09
be O 0 2.6945665254629603e-08
deleted O 0 2.842124615654029e-07
in O 0 7.59066764999261e-09
23 O 0 5.991546458972152e-08
cases O 0 1.0250465365402306e-08
. O 0 4.6438561440709236e-08

We O 0 2.8381293759593973e-07
then O 0 3.03327141182308e-08
proceeded O 0 4.963975186456082e-08
with O 0 1.5414458598428382e-10
sequence O 0 9.545049195480715e-09
analysis O 0 1.0658451898848398e-08
of O 0 8.72345040647815e-09
the O 0 5.224664789693634e-08
entire O 0 7.991664460860193e-06
PTEN O 0 0.0013245604932308197
/ O 0 6.6980037445318885e-06
MMAC1 O 0 5.5631397117394954e-05
coding O 0 5.608208653029578e-07
region O 0 1.3133370835305413e-08
and O 0 8.068222756563159e-10
tested O 0 1.977072061620788e-09
for O 0 1.564481988403088e-09
homozygous O 0 3.633564915617171e-08
deletion O 0 1.3844537072316143e-08
with O 0 2.0743884387997014e-10
new O 0 5.051539186951004e-09
intragenic O 0 3.725023998413235e-05
markers O 0 2.873389632895851e-07
in O 0 4.515095852752893e-09
these O 0 1.6969436966718376e-09
23 O 0 7.246301692021007e-08
cases O 0 5.029896943398171e-09
with O 0 4.750063897773771e-09
10q23 O 0 4.568071381072514e-05
loss O 0 0.00022850101231597364
of O 0 5.0926919357152656e-05
heterozygosity O 1 0.9999775886535645
. O 0 3.204444738003076e-06

The O 0 1.3640167253470281e-06
identification O 0 2.3227158862937358e-07
of O 0 2.776297378659365e-07
the O 0 2.401457379619387e-07
second O 0 2.4996415959321894e-06
mutational O 0 2.257093547086697e-05
event O 0 1.295719016525254e-07
in O 0 9.12119713092352e-09
10 O 0 5.6581890284235214e-09
( O 0 1.2743625044109308e-09
43 O 0 1.886399481065837e-08
% O 0 1.176504493827224e-08
) O 0 3.430283257443989e-08
tumors B-Disease 1 0.9999998807907104
establishes O 0 8.638514373160433e-06
PTEN O 1 0.9816210865974426
/ O 0 8.899652311811224e-05
MMAC1 O 0 0.00022427945805247873
as O 0 1.8838214543848153e-08
a O 0 2.4536273457442803e-08
main O 0 3.260226577594949e-08
inactivation O 0 1.3061143988579715e-07
target O 0 3.977665485876969e-08
of O 0 4.0574253290515117e-08
10q O 0 2.4725516141188564e-06
loss O 0 7.4909207796736155e-06
in O 0 1.5301906159947976e-06
sporadic B-Disease 1 1.0
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.6391281810210785e-07
. O 0 2.697994716527319e-07

Risk O 0 1.9961471480201e-05
reversals O 0 3.410094677747111e-06
in O 0 8.202210466379256e-09
predictive O 0 7.955364367262518e-08
testing O 0 1.929013748735997e-08
for O 0 3.3769734386623895e-07
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 6.8792405727435835e-06

The O 0 2.230717512929914e-07
first O 0 4.0231100228993455e-08
predictive O 0 1.0552621176884713e-07
testing O 0 3.189954522753169e-09
for O 0 2.225220363527569e-08
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 1.1874541314682574e-06
HD B-Disease 0 3.76328534912318e-05
) O 0 8.93893958853198e-10
was O 0 2.283787825518857e-09
based O 0 2.3044398334004512e-10
on O 0 6.302851018880062e-10
analysis O 0 2.0693313729225338e-09
of O 0 8.227291070639353e-10
linked O 0 3.113435198542902e-08
polymorphic O 0 3.240091928091715e-08
DNA O 0 5.0672618101543776e-08
markers O 0 1.7039988975398046e-08
to O 0 9.57918633304189e-10
estimate O 0 1.588331954849309e-08
the O 0 2.894156692079264e-09
likelihood O 0 8.396996520332323e-08
of O 0 3.108024060338721e-08
inheriting O 0 2.123972677736674e-07
the O 0 8.890873814948463e-09
mutation O 0 6.971991317605841e-10
for O 0 1.2877720001469584e-09
HD B-Disease 0 7.316712526517222e-06
. O 0 2.0835372538385855e-07

Limits O 0 5.893932666367618e-07
to O 0 8.118720806749025e-09
accuracy O 0 1.1704460689543339e-07
included O 0 4.815718490647214e-09
recombination O 0 1.579594766099035e-08
between O 0 9.693901681373518e-09
the O 0 1.985265285497917e-08
DNA O 0 6.430884980090923e-08
markers O 0 7.83886910937781e-09
and O 0 3.62254476415913e-10
the O 0 5.4246602765317675e-09
mutation O 0 3.5703997536273846e-09
, O 0 9.140802559315375e-10
pedigree O 0 5.358601384841677e-08
structure O 0 5.749181397618486e-08
, O 0 9.795694255743115e-10
and O 0 2.1107759984317909e-10
whether O 0 1.5111624174224403e-09
DNA O 0 1.0294785468545342e-08
samples O 0 1.6292009963336795e-09
were O 0 9.801605749260034e-09
available O 0 2.1367636549030067e-08
from O 0 4.508162376737346e-08
family O 0 9.164115510884585e-08
members O 0 2.2188247683629925e-08
. O 0 1.991637503806487e-07

With O 0 3.408421989092858e-08
direct O 0 2.9925910638439746e-08
tests O 0 8.282856622798818e-10
for O 0 7.458940687321558e-10
the O 0 1.393328208365574e-08
HD B-Disease 0 1.1391418865969172e-06
mutation O 0 1.1493423990316387e-09
, O 0 7.354341441390133e-11
we O 0 1.674407973384362e-10
have O 0 8.239142701427227e-11
assessed O 0 5.958767701486067e-09
the O 0 4.4774903784627895e-09
accuracy O 0 9.81079253392636e-08
of O 0 4.017188359739521e-09
results O 0 2.211649308136998e-09
obtained O 0 1.9910368465048123e-08
by O 0 3.811356563687696e-09
linkage O 0 1.1857527937308987e-07
approaches O 0 1.732946941501723e-08
when O 0 2.214718408666272e-09
requested O 0 3.325594377656671e-08
to O 0 1.1023331580872764e-08
do O 0 4.698495370547562e-09
so O 0 1.1349428064022504e-09
by O 0 8.749774793592735e-10
the O 0 6.001368735297774e-09
test O 0 8.952866892286693e-09
individuals O 0 1.344789701818172e-08
. O 0 1.0942330419538848e-07

For O 0 2.978007103138225e-07
six O 0 7.104478783048762e-08
such O 0 3.6251732726810815e-09
individuals O 0 1.9921918337217903e-08
, O 0 5.27780574799408e-09
there O 0 1.4436269069051377e-08
was O 0 5.9170353949866694e-08
significant O 0 8.095079273573447e-09
disparity O 0 3.601246945095227e-08
between O 0 6.148470177436138e-09
the O 0 6.725959345033061e-09
tests O 0 1.2732796150771719e-08
. O 0 7.67449535032938e-08

Three O 0 8.919020046960213e-07
went O 0 7.431170843119617e-07
from O 0 1.925969606020317e-08
a O 0 5.4312685904278624e-08
decreased O 0 2.4070709514489863e-06
risk O 0 3.487307509431048e-08
to O 0 1.5004438802534992e-09
an O 0 2.099562523838472e-09
increased O 0 2.0151636803689144e-08
risk O 0 1.0739715605723177e-07
, O 0 1.1345403505558238e-09
while O 0 5.34367705640193e-09
in O 0 5.599975594350326e-09
another O 0 9.854598914671442e-09
three O 0 4.190333857678752e-09
the O 0 8.118845151727783e-09
risk O 0 6.759386650401211e-08
was O 0 5.005853154216311e-07
decreased O 0 3.899387138517341e-06
. O 0 2.884118543988734e-07

Knowledge O 0 0.0004981542006134987
of O 0 2.2514154807140585e-06
the O 0 1.0123630289626817e-07
potential O 0 5.625350141258423e-08
reasons O 0 2.1374075842572893e-08
for O 0 7.597529272374004e-10
these O 0 1.327130072503735e-10
changes O 0 6.423230280994119e-10
in O 0 2.0350277019076657e-09
results O 0 2.3817401384462755e-09
and O 0 3.516888169574628e-10
impact O 0 1.6764357013698827e-08
of O 0 5.447865714103273e-09
these O 0 5.955276272118226e-10
risk O 0 2.8055371359414494e-08
reversals O 0 8.646821925140102e-08
on O 0 4.440028344987468e-09
both O 0 4.736888103984427e-10
patients O 0 2.6088778359856235e-10
and O 0 5.3648110259763016e-11
the O 0 4.781953055754684e-09
counseling O 0 2.7550697723199846e-08
team O 0 1.511946567944733e-09
can O 0 6.37347508103403e-10
assist O 0 1.828542295356783e-08
in O 0 1.0293686791840173e-08
the O 0 3.8296342097510205e-08
development O 0 3.828933756722108e-07
of O 0 1.0808987482846533e-08
strategies O 0 2.87476864535563e-09
for O 0 1.4361806188745163e-09
the O 0 1.669880766996812e-08
prevention O 0 3.062653490815137e-07
and O 0 2.3590160380670966e-10
, O 0 2.2724457038325596e-10
where O 0 5.504999234240415e-10
necessary O 0 2.4424958056101786e-08
, O 0 5.066243868867559e-09
management O 0 8.040255750074721e-08
of O 0 4.8717158307454156e-08
a O 0 4.805508879712761e-08
risk O 0 3.458070807482727e-08
reversal O 0 2.1342220435371928e-08
in O 0 6.244207373384825e-10
any O 0 4.663859298759121e-10
predictive O 0 3.5623934913076027e-09
testing O 0 3.4917832514302916e-10
program O 0 7.271996338431563e-09
. O 0 2.0787978005643026e-09
. O 0 3.211077626019687e-08

A O 0 5.242610768618761e-06
novel O 0 1.1456962738520815e-06
common O 0 6.897911930536793e-08
missense O 0 1.2990439017812605e-06
mutation O 0 2.0067869144213546e-08
G301C O 0 3.4228236245326116e-07
in O 0 3.768420953065288e-08
the O 0 1.2928725823257992e-07
N O 0 6.5321341935487e-06
- O 0 1.2993710925002233e-06
acetylgalactosamine O 0 9.686918019724544e-06
- O 0 2.818481789290672e-06
6 O 0 2.5814640594035154e-06
- O 0 3.6394752100932237e-07
sulfate O 0 9.519287118564534e-07
sulfatase O 0 9.59661410888657e-05
gene O 0 1.809623171311614e-07
in O 0 1.3489365358054783e-07
mucopolysaccharidosis B-Disease 0 0.00035073974868282676
IVA I-Disease 1 0.9974852800369263
. O 0 4.560095476335846e-06

Mucopolysaccharidosis B-Disease 1 0.9068040251731873
IVA I-Disease 1 0.9999983310699463
( O 0 0.0001702240842860192
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 6.688019738021467e-08
is O 0 3.037333939914788e-09
an O 0 3.0093104896877776e-08
autosomal B-Disease 1 0.6615390777587891
recessive I-Disease 1 0.9999973773956299
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 1 0.9995239973068237
by O 0 3.559237597983156e-07
a O 0 3.3555810659890994e-05
genetic B-Disease 1 1.0
defect I-Disease 1 0.9999991655349731
in O 0 2.2569113866666157e-07
N O 0 6.044841484253993e-06
- O 0 5.765856485595577e-07
acetylgalactosamine O 0 8.34202000987716e-06
- O 0 2.070629307127092e-06
6 O 0 3.4736472116492223e-06
- O 0 6.469318805102375e-07
sulfate O 0 2.3658958525629714e-06
sulfatase O 0 0.0007797516300342977
( O 0 4.4500524154500454e-07
GALNS O 0 0.0002320441126357764
) O 0 1.8726197481555573e-07
. O 0 1.6677394398811884e-07

In O 0 9.937594995790278e-07
previous O 0 5.022844220547995e-07
studies O 0 4.035795768686512e-07
, O 0 1.816437666946058e-09
we O 0 2.8094231385722424e-09
have O 0 1.5961412747067527e-10
found O 0 2.712405300364651e-10
two O 0 1.5902945627033205e-10
common O 0 2.6865684676913304e-10
mutations O 0 7.685444503024996e-10
in O 0 7.298648796449925e-09
Caucasians O 0 5.4966953655366524e-08
and O 0 1.0568812491840163e-08
Japanese O 0 6.694027251796797e-05
, O 0 1.1010597766869523e-08
respectively O 0 3.259260665799957e-07
. O 0 1.8679465085824631e-07

To O 0 5.764993034063082e-07
characterize O 0 2.1111823116370942e-06
the O 0 2.107598504608177e-07
mutational O 0 1.2710826922557317e-05
spectrum O 0 1.6918995981995977e-08
in O 0 5.944926217971158e-10
various O 0 4.947183773751362e-10
ethnic O 0 4.0407319157331756e-10
groups O 0 1.2301250296165023e-10
, O 0 8.022198877410958e-11
mutations O 0 1.3312548285959735e-10
in O 0 1.494200874141427e-09
the O 0 2.2105203001387963e-08
GALNS O 0 4.14459100284148e-05
gene O 0 6.097039317864983e-09
in O 0 7.93107535201898e-09
Colombian O 0 2.4373453015869018e-06
MPS B-Disease 1 0.9999998807907104
IVA I-Disease 1 1.0
patients O 0 8.291240760627261e-08
were O 0 2.7477422559485376e-09
investigated O 0 3.204023713010429e-08
, O 0 1.4453749308529495e-10
and O 0 2.21790447119119e-10
genetic O 0 2.849580571506749e-09
backgrounds O 0 1.6278529635371797e-09
were O 0 2.3584547648169973e-09
extensively O 0 4.4624592909769945e-09
analyzed O 0 4.1618659629705235e-09
to O 0 2.5794033575721187e-10
identify O 0 1.5771493000471537e-09
racial O 0 1.0777032599662562e-09
origin O 0 7.075951491408716e-10
, O 0 1.0326220434286881e-10
based O 0 4.0230521691775323e-10
on O 0 5.629415156249706e-09
mitochondrial O 0 1.2457523901332479e-08
DNA O 0 4.925662544508214e-09
( O 0 9.878249329631217e-10
mtDNA O 0 5.336180830539661e-09
) O 0 3.8632755328116275e-10
lineages O 0 5.968344929385694e-09
. O 0 3.5794960329127434e-09

Three O 0 1.5128696304600453e-06
novel O 0 8.497446287947241e-06
missense O 0 4.863242429564707e-05
mutations O 0 8.440898113803996e-08
never O 0 1.0898776281464961e-07
identified O 0 6.115560324815306e-08
previously O 0 3.641891410666176e-08
in O 0 2.187033665279614e-09
other O 0 1.438836827460932e-10
populations O 0 2.152181627357308e-10
and O 0 2.0132524813920583e-10
found O 0 2.230717832674145e-09
in O 0 8.16621259502881e-09
16 O 0 2.1818102879933576e-08
out O 0 1.945481331588894e-09
of O 0 1.727277876284461e-08
19 O 0 2.0795015132080152e-07
Colombian O 0 7.753785212116782e-06
MPS B-Disease 1 0.9999438524246216
IVA I-Disease 1 1.0
unrelated O 0 4.828192459171987e-07
alleles O 0 8.267325712907336e-10
account O 0 2.321699721363757e-09
for O 0 1.926519610506716e-09
84 O 0 2.905591998114687e-07
. O 0 1.6150323745023343e-07

2 O 0 5.701933787349844e-06
% O 0 6.373893768341077e-08
of O 0 1.3660868880549515e-08
the O 0 1.8152610081756393e-08
alleles O 0 3.75178021982947e-09
in O 0 5.9667852880807e-09
this O 0 1.1726557502811374e-08
study O 0 1.3565609435772785e-07
. O 0 1.3217032801549067e-07

The O 0 7.470047876267927e-06
G301C O 0 2.59496064245468e-05
and O 0 6.400696150876684e-08
S162F O 0 4.902452474198071e-06
mutations O 0 3.998309239250375e-08
account O 0 1.0892832591480328e-07
for O 0 3.79636198033495e-08
68 O 0 2.8741235382767627e-06
. O 0 4.7136495595623273e-07

4 O 0 8.256873115897179e-06
% O 0 8.973933773859244e-08
and O 0 1.9369478465591783e-08
10 O 0 2.4565335365878127e-07
. O 0 2.826320724125253e-07

5 O 0 6.98509438734618e-07
% O 0 1.1659625265281193e-08
of O 0 7.1657848543793534e-09
mutations O 0 5.757219145863246e-10
, O 0 4.875838621742901e-10
respectively O 0 4.102724915355793e-08
, O 0 1.691066398024077e-09
whereas O 0 1.0325424071311318e-08
the O 0 9.893942554128898e-09
remaining O 0 1.0455528354214039e-06
F69V O 0 8.805393736111e-05
is O 0 1.619732237223559e-09
limited O 0 2.1569579455871235e-09
to O 0 1.3956388267288844e-09
a O 0 1.2626289347394959e-08
single O 0 1.2436275120819573e-08
allele O 0 3.5379976282001735e-08
. O 0 3.946680848798678e-08

The O 0 4.178324957138102e-07
skewed O 0 5.699801590708375e-07
prevalence O 0 2.6052015300592757e-07
of O 0 1.2020040962568146e-08
G301C O 0 2.7288118076285173e-07
in O 0 1.4557175465057526e-09
only O 0 1.2996557163802436e-09
Colombian O 0 1.6856159845701768e-07
patients O 0 5.760041887903355e-10
and O 0 3.2874467037480315e-11
haplotype O 0 3.195800957200845e-09
analysis O 0 2.5860091845686384e-10
by O 0 7.477853752879682e-11
restriction O 0 1.956843131978303e-09
fragment O 0 5.9343028269154274e-09
length O 0 2.6714042089537315e-09
polymorphisms O 0 1.5518105911382918e-08
in O 0 1.2121982306823043e-09
the O 0 3.0834957698289145e-08
GALNS O 0 0.00034256992512382567
gene O 0 2.4228688388916453e-08
suggest O 0 7.591709483278919e-09
that O 0 5.829250970812438e-10
G301C O 0 4.5728936015621e-07
originated O 0 9.629938801936078e-08
from O 0 5.989841511677696e-09
a O 0 3.223448885592006e-08
common O 0 1.1796638332839393e-08
ancestor O 0 1.0340362450733664e-06
. O 0 1.983070916367069e-07

Investigation O 0 3.1140858482103795e-05
of O 0 6.215427674760576e-07
the O 0 8.552231633984775e-08
genetic O 0 1.1464806703997965e-07
background O 0 6.48605933406543e-08
by O 0 2.234307627801968e-09
means O 0 2.9399364720461563e-08
of O 0 5.5793808684256874e-08
mtDNA O 0 3.1858402849138656e-07
lineages O 0 1.2447192609954527e-08
indicate O 0 1.2427447959595384e-09
that O 0 4.381396634389745e-11
all O 0 2.1221517598757345e-10
our O 0 6.459957013760231e-09
patients O 0 1.262040805194431e-09
are O 0 1.3148897248793645e-10
probably O 0 1.3553629329976502e-08
of O 0 8.372543902623875e-08
native O 0 9.246439844901033e-07
American O 0 1.1902218830073252e-05
descent O 0 0.00017101017874665558

Low O 0 2.483765911165392e-06
frequency O 0 1.1522769938210331e-07
of O 0 7.137360569231532e-08
BRCA1 O 0 4.0588577121525304e-07
germline O 0 9.109853067457152e-07
mutations O 0 1.1737649741050404e-09
in O 0 1.8018621039672666e-09
45 O 0 9.869331307754692e-08
German O 1 0.9999998807907104
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 9.008512051877915e-07
. O 0 8.353991631793178e-08

In O 0 3.6018727200826106e-07
this O 0 4.209334658611397e-09
study O 0 4.0498848719039415e-09
we O 0 7.064475116003166e-10
investigated O 0 4.407747411505625e-08
45 O 0 1.4750094123883173e-07
German O 1 0.9999902248382568
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.5576226530811255e-08
for O 0 1.1683930489780892e-09
germline O 0 8.253419423454034e-07
mutations O 0 2.0236750053470587e-09
in O 0 1.1680832967542187e-09
the O 0 4.614982174189208e-08
BRCA1 O 0 2.5249175905628363e-07
gene O 0 6.449790390661292e-08
. O 0 4.9517954181510504e-08

We O 0 1.6028539562285005e-07
identified O 0 8.492655467762233e-08
four O 0 9.763973451981656e-08
germline O 0 2.57579790741147e-06
mutations O 0 6.921183182129198e-09
in O 0 7.111349731303562e-09
three O 0 6.781300498914788e-08
breast B-Disease 0 0.004402623977512121
cancer I-Disease 0 0.00023594923550263047
families O 0 1.7371366567431323e-08
and O 0 8.044517052496758e-09
in O 0 1.128385974880075e-06
one O 1 0.9761121273040771
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 0.01386614516377449
. O 0 5.335069053202801e-10
among O 0 4.3046587128170444e-11
these O 0 4.5467123122033826e-11
were O 0 2.8570363852509217e-09
one O 0 2.9646549659645416e-09
frameshift O 0 1.0293945962303042e-07
mutation O 0 5.04133401690865e-10
, O 0 2.7683622061402957e-10
one O 0 4.38810010550128e-09
nonsense O 0 6.38003655240027e-07
mutation O 0 8.364526848936293e-09
, O 0 2.0354198326799633e-09
one O 0 5.059098473481072e-09
novel O 0 5.185519285078044e-07
splice O 0 4.114835064683575e-06
site O 0 1.601868291345454e-07
mutation O 0 3.1947040568525154e-09
, O 0 5.876248376779358e-10
and O 0 1.323127163388449e-09
one O 0 7.053683503954744e-08
missense O 0 6.162847512314329e-06
mutation O 0 8.513138993748726e-08
. O 0 1.7873830415737757e-07

The O 0 1.0077102160721552e-05
missense O 0 3.531137190293521e-05
mutation O 0 3.492526445825206e-08
was O 0 2.434306338727765e-07
also O 0 2.618225636297211e-09
found O 0 4.67675986826066e-09
in O 0 2.580715019462332e-08
2 O 0 1.4289890941654448e-06
. O 0 3.900586023064534e-07

8 O 0 5.772690656158375e-06
% O 0 5.3136364641659384e-08
of O 0 1.3736536352837447e-08
the O 0 1.081080203135798e-08
general O 0 4.1112006243793076e-08
population O 0 5.442569062097391e-09
, O 0 1.0887858392649719e-09
suggesting O 0 2.057957004808486e-08
that O 0 1.8325801987018053e-10
it O 0 1.5077240844707518e-10
is O 0 2.603325333083717e-10
not O 0 1.300692331618336e-09
disease O 0 4.2657518406485906e-08
associated O 0 2.6874687364397687e-07
. O 0 9.972569614546956e-07

The O 0 1.254236053682689e-06
average O 0 3.2557653639742057e-07
age O 0 4.084119353819915e-08
of O 0 1.8294134918050986e-07
disease O 0 2.9350083423196338e-05
onset O 0 0.18776658177375793
in O 0 6.883060876816671e-08
those O 0 7.3860206839526654e-09
families O 0 1.8823667957690304e-08
harbouring O 0 0.00015924879699014127
causative O 0 7.18525261618197e-05
mutations O 0 3.103906820456359e-08
was O 0 3.492340283628437e-07
between O 0 2.836930832472717e-07
32 O 0 2.985478886330384e-06
. O 0 4.859202249463124e-07

3 O 0 5.899573352508014e-06
and O 0 8.435940657136598e-08
37 O 0 3.2648181331751402e-06
. O 0 7.051846750982804e-07

4 O 0 1.9013199334949604e-06
years O 0 9.921537014179194e-08
, O 0 2.810789823115556e-09
whereas O 0 2.843284008235969e-08
the O 0 6.416917130991351e-08
family O 0 2.425153411422798e-07
harbouring O 0 4.778661605087109e-05
the O 0 6.574229018951883e-07
missense O 0 6.896293143654475e-06
mutation O 0 7.708820248808479e-09
had O 0 9.885303242640475e-09
an O 0 1.6278963732574425e-09
average O 0 1.840600560854e-08
age O 0 1.261858528778248e-08
of O 0 1.5571021094729076e-07
onset O 0 0.0005179049330763519
of O 0 1.3510131793736946e-05
51 O 0 2.1320476662367582e-05
. O 0 6.831104428783874e-07

2 O 0 2.2393562176148407e-05
years O 0 2.148522753486759e-06
. O 0 8.339971486748254e-07

These O 0 6.564656018781534e-08
findings O 0 1.561899978241854e-07
show O 0 5.392024959860464e-08
that O 0 2.5698041472566047e-09
BRCA1 O 0 3.7683776099584065e-08
is O 0 4.234507411382538e-09
implicated O 0 4.0776821919052963e-08
in O 0 5.1400226297459994e-09
a O 0 7.28225391100068e-09
small O 0 2.3083603917228857e-09
fraction O 0 3.1266402800156357e-08
of O 0 1.6882953786989674e-05
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.3487255046129576e-07
suggesting O 0 1.381172776149242e-08
the O 0 1.5611733017451002e-09
involvement O 0 1.0698800956276955e-08
of O 0 8.134873219489691e-09
another O 0 7.121122358455523e-09
susceptibility O 0 2.5851882412553095e-08
gene O 0 7.365382970192513e-09
( O 0 1.2156116113715143e-08
s O 0 5.407679282143363e-07
) O 0 2.9233245868454105e-07

Paternal O 1 0.9140380620956421
transmission O 1 0.9999778270721436
of O 1 0.9999899864196777
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.00017616097466088831

We O 0 2.1905850644543534e-06
report O 0 2.0301600045513624e-07
a O 0 1.5565179367627024e-08
rare O 0 4.7346779830093055e-09
case O 0 9.034054393453061e-09
of O 0 1.2355455680790328e-07
paternally O 1 0.9999874830245972
transmitted O 1 1.0
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9997658133506775
DM B-Disease 1 1.0
) O 0 5.839038408339547e-07
. O 0 2.7671725888467336e-07

The O 0 2.619681072246749e-05
proband O 0 0.00033212456037290394
is O 0 1.440101726757348e-07
a O 0 4.9297440796181036e-08
23 O 0 6.903558613657879e-08
year O 0 8.075955904018883e-09
old O 0 3.0722824249096448e-06
, O 0 6.939108629921975e-07
mentally B-Disease 1 1.0
retarded I-Disease 1 1.0
male O 0 9.636891627451405e-05
who O 0 9.59415231704952e-08
suffers O 0 0.00893202144652605
severe O 1 0.9960038065910339
muscular B-Disease 1 1.0
weakness I-Disease 1 1.0
. O 0 8.859610716172028e-06

He O 0 1.7539819054945838e-06
presented O 0 1.4908046068740077e-06
with O 0 9.144679893324792e-07
respiratory O 1 1.0
and O 0 6.775197789465892e-07
feeding O 0 0.039592571556568146
difficulties O 1 0.9998295307159424
at O 0 0.000998075702227652
birth O 0 2.553296144469641e-05
. O 0 3.578310270313523e-07

His O 0 2.236259388155304e-05
two O 0 2.321835381735582e-06
sibs O 1 0.9998117089271545
suffer O 0 1.6989553841995075e-05
from O 0 1.587239239597693e-06
childhood O 1 0.9999821186065674
onset O 1 1.0
DM B-Disease 1 1.0
. O 0 7.4148638304905035e-06

Their O 0 1.0503599696676247e-06
late O 0 9.465060429647565e-06
father O 0 6.792043905079481e-07
had O 0 8.917780291994859e-08
the O 0 1.44601335350103e-08
adult O 0 1.2972715346393215e-08
type O 0 1.3910755569668254e-07
of O 0 3.670185833470896e-05
DM B-Disease 1 1.0
, O 0 9.007217727230454e-08
with O 0 1.1183626469346564e-08
onset O 0 0.12386954575777054
around O 0 2.645856511662714e-07
30 O 0 5.718461437709266e-08
years O 0 5.6670806714009814e-08
. O 0 6.778300587484409e-08

Only O 0 1.4532970737946016e-07
six O 0 1.0007630280028934e-08
other O 0 1.6990123197224705e-10
cases O 0 3.2734703836467816e-10
of O 0 1.833221929814499e-08
paternal O 0 0.0001354483247268945
transmission O 1 0.9999542236328125
of O 1 1.0
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 5.421453806775389e-06
been O 0 1.0431948282985104e-07
reported O 0 1.388542756330935e-07
recently O 0 1.4154406358102278e-07
. O 0 2.0250860188752995e-07

We O 0 4.2757633877954504e-07
review O 0 1.2108543501199165e-07
the O 0 1.1237167640842927e-08
sex O 0 1.0781355364031242e-08
related O 0 2.108983210291626e-08
effects O 0 4.179142081284226e-07
on O 0 3.600952425131254e-07
transmission O 0 0.0012874704552814364
of O 0 0.015594500117003918
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 5.6703956943238154e-05

Decreased O 0 0.08218716084957123
fertility O 0 7.058581104502082e-06
of O 0 6.799962370962476e-09
males O 0 3.2953711981420497e-10
with O 0 1.3913351026850762e-10
adult O 0 1.303659047380279e-07
onset O 1 0.9864177703857422
DM B-Disease 1 1.0
and O 0 2.2548411138245683e-08
contraction O 0 1.634213191437084e-07
of O 0 2.5522579605308238e-09
the O 0 2.458554249074041e-09
repeat O 0 9.8687626959304e-09
upon O 0 1.924453130186521e-08
male O 0 1.3921009234252324e-08
transmission O 0 6.6544627586040406e-09
contribute O 0 2.729416970215226e-10
to O 0 5.246518774981723e-10
the O 0 2.800627507681952e-09
almost O 0 2.026182599479398e-08
absent O 0 4.283959142981075e-08
occurrence O 0 6.395899987410303e-08
of O 0 1.725749854131209e-08
paternal O 0 4.622365395334782e-06
transmission O 0 7.716170512139797e-05
of O 0 0.020815635100007057
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.00030014695948921144

Also O 0 4.3500691049302986e-07
the O 0 1.6603220842625888e-07
fathers O 0 1.0153377161259414e-06
of O 0 1.94628455574275e-07
the O 0 2.3523691083937592e-07
reported O 0 2.597312686702935e-06
congenitally O 0 0.00014340324560180306
affected O 0 3.270365667162878e-08
children O 0 4.141214926534076e-09
showed O 0 4.431722544495642e-08
, O 0 7.499182386183634e-10
on O 0 3.4247786828700555e-08
average O 0 2.2795812526510417e-07
, O 0 4.163517530741956e-09
shorter O 0 2.2174123159857118e-07
CTG O 0 0.0002483714197296649
repeat O 0 3.628814226885879e-07
lengths O 0 2.732394705162733e-06
and O 0 2.413389266209265e-09
hence O 0 2.8879712843377092e-08
less O 0 1.0952808437991735e-08
severe O 0 1.2581303110437148e-07
clinical O 0 2.889723646148923e-06
symptoms O 0 3.567645308066858e-07
than O 0 1.0941151318277775e-09
the O 0 1.564996132685792e-08
mothers O 0 2.0789375554386424e-08
of O 0 4.953436771870656e-09
children O 0 7.603854434989898e-09
with O 0 7.962104575653939e-08
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 1.8616614397615194e-05

We O 0 1.0789037787617417e-06
conclude O 0 3.342744321344071e-06
that O 0 1.9108505000531295e-08
paternal O 0 1.2924506336275954e-05
transmission O 0 0.0015041433507576585
of O 1 0.9791435599327087
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 4.620399977284251e-06
rare O 0 3.753135047190881e-08
and O 0 5.709899775219185e-10
preferentially O 0 1.3466428860908763e-08
occurs O 0 2.491314488040075e-09
with O 0 5.101868372214824e-10
onset O 1 0.5980436205863953
of O 1 0.7828307151794434
DM B-Disease 1 1.0
past O 0 2.5875347091641743e-06
30 O 0 3.3406362121013444e-08
years O 0 4.098624106774196e-09
in O 0 2.3103514656952484e-09
the O 0 9.512172383097095e-09
father O 0 1.712458015390439e-07
. O 0 1.562344742467303e-08
. O 0 6.093949167507162e-08

The O 0 1.79133076017024e-05
RB1 O 0 0.001395267085172236
gene O 0 1.2507274504969246e-07
mutation O 0 8.828703990104714e-09
in O 0 6.147485187568691e-09
a O 0 5.503608946355598e-08
child O 0 5.079779157313169e-07
with O 0 4.334498555635946e-07
ectopic B-Disease 1 1.0
intracranial I-Disease 1 1.0
retinoblastoma I-Disease 1 0.9999998807907104
. O 0 1.6870786566869356e-05

The O 0 3.0109553335933015e-05
RB1 O 0 0.0014125730376690626
gene O 0 9.50959915257954e-08
mutation O 0 9.790730892689226e-09
was O 0 8.29160455850797e-08
investigated O 0 2.4577403223702277e-07
in O 0 3.687689087428225e-08
a O 0 1.6275487269012956e-07
child O 0 5.158460680831922e-07
with O 0 2.627909054808697e-07
ectopic B-Disease 1 0.9999904632568359
intracranial I-Disease 1 0.9999998807907104
retinoblastoma I-Disease 0 0.0002194315893575549
using O 0 4.7186958340716956e-08
DNA O 0 1.9469707623898103e-08
obtained O 0 2.4486856986527528e-08
from O 0 5.520532475600248e-09
both O 0 2.944199550825033e-09
the O 0 6.689091236466993e-08
pineal B-Disease 1 0.9077625274658203
and I-Disease 0 3.54777682787244e-07
retinal I-Disease 1 0.9999867677688599
tumours I-Disease 1 1.0
of O 0 1.3476185813487973e-05
the O 0 4.112936494493624e-06
patient O 0 4.03359517804347e-05
. O 0 2.423142007046408e-07

A O 0 2.399955701548606e-05
nonsense O 0 1.95338943740353e-05
mutation O 0 8.504959225774655e-08
in O 0 9.313117033116214e-08
exon O 0 8.440469514425786e-07
17 O 0 3.194343491941254e-07
( O 0 1.6548897363577453e-08
codon O 0 1.725145182263077e-07
556 O 0 2.971246715333109e-07
) O 0 8.190391476148307e-09
of O 0 7.108355504215069e-08
the O 0 9.072813327293261e-07
RB1 O 0 0.0010079212952405214
gene O 0 7.012916114490508e-08
was O 0 2.7283482495477074e-07
found O 0 5.808145520092012e-09
to O 0 2.338744753416222e-09
be O 0 5.4798183768411945e-09
present O 0 6.134251862022211e-08
homozygously O 0 1.75161512743216e-05
in O 0 7.065465013056382e-08
both O 0 4.0308371751507366e-08
the O 0 4.639544499696058e-07
retinal B-Disease 0 5.207572030485608e-05
and I-Disease 0 7.828727177638939e-08
the I-Disease 0 1.788800727808848e-05
pineal I-Disease 1 1.0
tumours I-Disease 1 1.0
. O 0 3.0385638183361152e-06

The O 0 5.315709472597518e-07
same O 0 3.8112204947537975e-08
mutation O 0 4.806899767118011e-09
was O 0 4.571746359260942e-08
present O 0 1.437814933780146e-08
heterozygously O 0 1.2959282003066619e-06
in O 0 1.1653555453960962e-08
the O 0 8.120889738449932e-09
DNA O 0 1.7275052499599042e-08
from O 0 2.9381859167898483e-09
the O 0 2.4366966222544306e-09
constitutional O 0 7.745253327584578e-09
cells O 0 2.785875086175338e-09
of O 0 1.6595226304261246e-09
the O 0 5.752677889603319e-09
patient O 0 7.420661773949178e-08
, O 0 4.998945146716949e-10
proving O 0 9.896852759538888e-08
it O 0 1.532302895679294e-10
to O 0 4.963137678615226e-10
be O 0 8.432281539683117e-10
of O 0 3.2283711703939844e-08
germline O 0 1.674598593126575e-06
origin O 0 1.8017225045241503e-07
. O 0 2.65988006731277e-07

The O 0 2.188401140301721e-06
initial O 0 8.247620257861854e-07
mutation O 0 1.4019547300847535e-08
was O 0 7.663904710852876e-08
shown O 0 1.1878597661052481e-08
to O 0 3.894001121551582e-09
have O 0 1.2103499313909083e-09
occurred O 0 1.0681596052108944e-07
in O 0 3.032517792433964e-09
the O 0 2.2771166285906475e-08
paternally O 0 2.4845098778314423e-06
derived O 0 8.69277414494718e-07
RB1 O 0 7.003747305134311e-05
allele O 0 2.2348507400238304e-07
. O 0 7.142713087660013e-08

The O 0 4.86360193008295e-07
mutation O 0 1.747418387765265e-08
is O 0 1.2085874523393159e-09
in O 0 1.8397432466343844e-09
an O 0 3.051141783672051e-09
area O 0 8.775739246402736e-08
of O 0 1.1498597274339772e-07
the O 0 2.0426436719844787e-07
gene O 0 1.4138938908558885e-08
that O 0 9.891655272653566e-10
encodes O 0 2.3668784265851173e-08
the O 0 4.8089905391179855e-09
protein O 0 1.3432489787135182e-08
- O 0 9.532568512327089e-09
binding O 0 7.951310720955007e-09
region O 0 5.012679693550126e-08
known O 0 5.612682230093924e-08
as O 0 1.9282044405599663e-08
the O 0 2.3299061524539866e-07
pocket O 0 0.0005784028326161206
region O 0 1.4876886780257337e-06
and O 0 1.4865660702412242e-08
has O 0 2.2231105845094135e-09
been O 0 4.547133336529896e-09
detected O 0 1.1636875463238994e-08
in O 0 9.021016156296469e-10
other O 0 2.3437896068401187e-10
cases O 0 2.22374252345503e-09
of O 0 5.230477384543519e-08
retinoblastoma B-Disease 0 0.00011243751941947266
. O 0 1.2813735850158992e-07
. O 0 3.6985798601563147e-07

Low O 0 6.726315859850729e-06
levels O 0 2.546055952734605e-07
of O 0 2.651658803642931e-07
beta O 0 4.834928859054344e-06
hexosaminidase O 0 1.0887637472478673e-05
A O 0 3.3789899589464767e-07
in O 0 6.196622326370971e-09
healthy O 0 1.9615450597143536e-08
individuals O 0 1.9903589887348971e-10
with O 0 3.7015962517372714e-10
apparent O 0 2.6824658561963588e-05
deficiency O 1 0.9996503591537476
of O 0 1.124814480135683e-05
this O 0 8.571780085731007e-08
enzyme O 0 4.5067912424201495e-07
. O 0 1.3501669116067205e-07

Appreciable O 0 0.0003445813781581819
beta O 0 3.223866588086821e-05
hexosaminidase O 0 2.6681302188080736e-05
A O 0 8.500793228449766e-06
( O 0 9.730008088126851e-08
hex O 0 3.1568804388371063e-06
A O 0 8.184060789062642e-07
) O 0 6.3241447634254655e-09
activity O 0 5.516514534065209e-08
has O 0 4.5873857490441594e-10
been O 0 1.149791817312007e-09
detected O 0 1.333055088537094e-08
in O 0 9.79065628570197e-09
cultured O 0 8.329236879944801e-05
skin O 0 9.176818275591359e-05
fibroblasts O 1 0.9574105143547058
and O 0 5.005103389521537e-07
melanoma B-Disease 1 0.999991774559021
tissue O 0 3.219767677364871e-05
from O 0 1.3277509935960552e-07
healthy O 0 2.021113516548212e-07
individuals O 0 4.5286774330577373e-10
previously O 0 1.0927809768190855e-08
reported O 0 1.9320808064549055e-08
as O 0 2.9710969240426266e-09
having O 0 4.35016033861757e-07
deficiency B-Disease 1 0.9281972646713257
of I-Disease 0 0.0001971224119188264
hex I-Disease 0 0.0004889078554697335
A I-Disease 0 1.9174460703652585e-06
activity O 0 1.5158634880663158e-07
indistinguishable O 0 1.6301777705507448e-08
from O 0 3.5544572840606747e-10
that O 0 3.063682293968917e-11
of O 0 2.6387003693173483e-09
patients O 0 3.67757269081892e-09
with O 0 2.4067281856332556e-07
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 3.113633738394128e-06
TSD B-Disease 0 0.0908237025141716
) O 0 4.1151071883405166e-08
. O 0 3.7573894218212445e-08

Identification O 0 5.780623723694589e-06
and O 0 1.1821713030712999e-07
quantitation O 0 0.0009547807858325541
of O 0 0.00010922523506451398
hex O 0 0.000757507688831538
A O 0 5.8518613514024764e-05
, O 0 2.0213267504232135e-08
amounting O 0 6.30947226909484e-07
to O 0 3.7526625362716004e-08
3 O 0 1.1477150110295042e-06
. O 0 3.492084204026469e-07

5 O 0 5.075792159914272e-06
% O 0 3.903879246536235e-07
- O 0 5.759442842645512e-07
6 O 0 1.095180550692021e-06
. O 0 1.5553166576864896e-07

9 O 0 2.5059644030989148e-06
% O 0 1.365664914487752e-08
of O 0 1.0165226882463685e-08
total O 0 8.271560147932178e-08
beta O 0 8.915567377698608e-07
hexosaminidase O 0 1.8783410951073165e-06
activity O 0 2.806683312428504e-07
, O 0 1.0893757007579552e-09
has O 0 7.642289578946304e-11
been O 0 3.4106686919166407e-10
obtained O 0 7.268377455460495e-09
by O 0 8.466063405876412e-09
cellulose O 0 3.003851134053548e-06
acetate O 0 3.8366169974324293e-07
gel O 0 2.511840477836813e-07
electrophoresis O 0 6.95382880167017e-07
, O 0 3.362075418067434e-08
DEAE O 0 3.9615762943867594e-05
- O 0 3.2316570468537975e-06
cellulose O 0 2.9162456485209987e-06
ion O 0 3.535067889970378e-06
- O 0 1.1047915904782712e-05
exchange O 0 2.7352385586709715e-05
chromatography O 0 0.0003265263221692294
, O 0 1.7332553170490428e-07
radial O 0 4.376731794764055e-06
immunodiffusion O 0 4.9434383981861174e-05
, O 0 6.954572029371775e-08
and O 0 1.5028253130822122e-07
radioimmunoassay O 0 0.0025101639330387115
. O 0 7.5472116805030964e-06

Previous O 0 0.0006249459693208337
family O 0 2.3946679448272334e-06
studies O 0 1.2500227342115977e-07
suggested O 0 7.33373006767124e-09
that O 0 4.737319911352067e-11
these O 0 1.2467732402043907e-10
individuals O 0 5.295288096895945e-10
may O 0 1.585189535191489e-09
be O 0 7.369177268401472e-09
compound O 0 6.338638627312321e-07
heterozygotes O 0 3.073601817504823e-08
for O 0 6.502826055410083e-10
the O 0 6.050215439756812e-09
common O 0 6.7799530434342614e-09
mutant O 0 1.257722828995611e-06
TSD B-Disease 0 0.00019112633890472353
gene O 0 7.705777349542586e-09
and O 0 4.2173531333844494e-10
a O 0 7.932648316000268e-09
rare O 0 6.322312007256414e-09
( O 0 3.825719296912666e-09
allelic O 0 6.324340517949167e-08
) O 0 8.430515840984754e-09
mutant O 0 1.9157593555974017e-07
gene O 0 6.906785188220965e-08
. O 0 6.319083212247278e-08

Thus O 0 2.1528423985728296e-06
, O 0 1.8001315993387834e-08
the O 0 2.6594380031497167e-08
postulated O 0 2.3418515411322005e-06
rate O 0 2.049760468025852e-07
mutant O 0 9.320510230281798e-08
gene O 0 3.7379095374490134e-09
appears O 0 2.6634876526543394e-09
to O 0 4.4266998400210866e-10
code O 0 4.3511097502779705e-10
for O 0 7.427675141613577e-11
the O 0 1.9774415438433834e-09
expression O 0 1.2925565506805015e-08
of O 0 1.68464779903843e-08
low O 0 7.89015857094455e-08
amounts O 0 4.6946819765025793e-08
of O 0 5.686076747224433e-07
hex O 0 3.902675598510541e-05
A O 0 1.2245930520293768e-05
. O 0 2.605733016025624e-07

Heterozygotes O 0 9.32643233682029e-05
for O 0 5.7343644499496804e-08
the O 0 6.031159927033514e-08
rare O 0 1.0500198754925805e-07
mutant O 0 2.7179916628483625e-07
may O 0 5.7870908065638105e-09
be O 0 1.1153286072485002e-09
indistinguishable O 0 4.025650568451056e-08
from O 0 2.0753114782223747e-09
heterozygotes O 0 3.777625323664324e-08
for O 0 1.7068833013667017e-09
the O 0 5.2772147540736114e-08
common O 0 1.6807138081276207e-07
TSD B-Disease 0 0.0009457297855988145
mutant O 0 1.0059463420475367e-05
. O 0 4.4544088950715377e-07

However O 0 2.44060572640592e-07
, O 0 5.359334753762823e-09
direct O 0 9.503851572389976e-08
visualization O 0 2.3917737053125165e-05
and O 0 5.997343066610483e-08
quantitation O 0 0.0552341490983963
of O 0 4.8421316023450345e-05
hex O 0 0.00033245302620343864
A O 0 1.1263711030551349e-06
by O 0 2.3372597190984834e-09
the O 0 3.3852645131560166e-09
methods O 0 6.379254902100229e-09
described O 0 1.0590061272353068e-08
may O 0 1.3154523026415177e-09
prevent O 0 3.5266503051190057e-09
false O 0 4.875992232200588e-08
- O 0 1.6316709761099446e-08
positive O 0 4.849047385846461e-09
prenatal O 0 6.406583565876645e-07
diagnosis O 0 1.4591422825560585e-07
of O 0 9.594481298336177e-08
TSD B-Disease 0 0.11904346197843552
in O 0 1.0415465823143677e-07
fetuses O 0 3.883126566961437e-07
having O 0 5.5747424454466454e-08
the O 0 1.6422671933469246e-07
incomplete O 0 1.0369650226493832e-05
hex B-Disease 0 0.00012904869799967855
A I-Disease 0 6.51246082270518e-05
deficiency I-Disease 0 0.352202832698822
of O 0 6.313002813840285e-06
the O 0 9.04352873476455e-07
type O 0 2.5952724172384478e-05
described O 0 4.058169054133032e-07
in O 0 2.157572076555425e-08
the O 0 6.506491700974948e-08
four O 0 1.2081228817351075e-07
healthy O 0 4.906190724796033e-07
individuals O 0 1.9074954593634175e-07

The O 0 1.0203084457316436e-05
tumor B-Disease 0 8.458633965346962e-05
suppressor O 0 3.759881656151265e-05
gene O 0 3.562280426194775e-07
Smad4 O 0 0.0001332216925220564
/ O 0 9.931901331583504e-06
Dpc4 O 0 2.371674963796977e-05
is O 0 2.705328183694178e-09
required O 0 9.216080121277059e-10
for O 0 2.8807516372353348e-09
gastrulation O 0 2.039888386207167e-06
and O 0 4.458435398646543e-09
later O 0 1.1070892469433602e-07
for O 0 1.9354779112745746e-08
anterior O 0 7.189085863501532e-06
development O 0 2.149670763174072e-06
of O 0 5.055566134615219e-07
the O 0 5.034454488850315e-07
mouse O 0 7.99773317794461e-07
embryo O 0 2.667683816071076e-07
. O 0 4.856037350009501e-08

Mutations O 0 2.6226412046526093e-06
in O 0 2.397491698502563e-07
the O 0 1.7603044852876337e-06
SMAD4 O 1 0.9998776912689209
/ O 1 0.5614516139030457
DPC4 O 1 0.9386640787124634
tumor B-Disease 0 0.00010186335566686466
suppressor O 0 2.7483940812089713e-06
gene O 0 3.452612196142013e-09
, O 0 2.3599069920443583e-10
a O 0 2.8857012335237187e-09
key O 0 3.233436629557218e-08
signal O 0 9.093406561078154e-08
transducer O 0 1.1218775597399144e-07
in O 0 7.180821270935667e-09
most O 0 6.273948471857693e-09
TGFbeta O 0 4.870853808824904e-05
- O 0 2.2176416223373963e-06
related O 0 5.266730113362428e-06
pathways O 0 2.8946644192728854e-07
, O 0 5.845618433752975e-10
are O 0 4.681164136877136e-11
involved O 0 8.897842462829431e-10
in O 0 1.9910890713958906e-09
50 O 0 3.8260861146000025e-08
% O 0 1.4127752301362762e-08
of O 0 2.496606157365022e-07
pancreatic B-Disease 1 0.9999997615814209
cancers I-Disease 1 0.9991635084152222
. O 0 4.588844149111537e-06

Homozygous O 0 0.00028198189102113247
Smad4 O 0 0.004314466379582882
mutant O 0 3.487217691144906e-05
mice O 0 2.716392600632389e-06
die O 0 3.7749032344436273e-07
before O 0 1.6097304467166396e-07
day O 0 1.6225643548750668e-06
7 O 0 2.1088703761051875e-06
. O 0 2.3173349461558246e-07

5 O 0 9.540268365526572e-06
of O 0 3.4575778045109473e-06
embryogenesis O 0 0.00012509763473644853
. O 0 2.27961027121637e-06

Mutant O 0 2.4950759325292893e-05
embryos O 0 1.5067028868998023e-07
have O 0 1.9383810112572064e-09
reduced O 0 5.086247867325255e-09
size O 0 1.546916728045744e-08
, O 0 5.95191806951334e-09
fail O 0 1.9613287349784514e-07
to O 0 5.2160913810439524e-08
gastrulate O 0 5.121489448356442e-05
or O 0 1.533492195449071e-07
express O 0 5.9569636334799725e-08
a O 0 7.231224685710913e-08
mesodermal O 0 2.2965191419643816e-06
marker O 0 1.7119222661676758e-07
, O 0 2.1975208319702233e-09
and O 0 5.784508427808532e-09
show O 0 3.199001810116897e-07
abnormal O 0 1.0791623026307207e-05
visceral O 0 4.635343884729082e-06
endoderm O 0 0.00018964651098940521
development O 0 8.957839781942312e-06
. O 0 6.726846777382889e-07

Growth B-Disease 1 1.0
retardation I-Disease 1 1.0
of O 0 1.8372482372797094e-05
the O 0 4.753836947202217e-06
Smad4 O 1 0.999953031539917
- O 0 0.0007022871868684888
deficient O 0 2.326842832189868e-06
embryos O 0 4.360716232554296e-09
results O 0 7.743373720003888e-10
from O 0 8.652159544375593e-10
reduced O 0 1.8596136186488366e-08
cell O 0 3.132520589588239e-07
proliferation O 0 2.457482537465694e-07
rather O 0 5.975053785078899e-09
than O 0 8.973103926557258e-10
increased O 0 2.202935611705925e-08
apoptosis O 0 5.522951482817007e-07
. O 0 4.232587968999724e-08

Aggregation O 0 1.3437608686217573e-05
of O 0 7.576422262900451e-07
mutant O 0 4.888516286882805e-06
Smad4 O 0 0.024843355640769005
ES O 0 0.000729414343368262
cells O 0 5.906793720811265e-09
with O 0 2.2174984071199333e-10
wild O 0 1.2381271119465964e-08
- O 0 1.5403649911149842e-07
type O 0 3.225159161956981e-07
tetraploid O 0 7.13104509486584e-06
morulae O 0 6.529393431264907e-05
rescues O 0 1.3186304386181291e-05
the O 0 3.601886362503137e-07
gastrulation B-Disease 0 0.0002832831523846835
defect I-Disease 0 6.643863889621571e-05
. O 0 4.25769684397892e-07

These O 0 1.449529207775413e-07
results O 0 8.06716826673437e-08
indicate O 0 9.240977050239962e-08
that O 0 2.361367101855194e-09
Smad4 O 0 2.6772722776513547e-06
is O 0 3.2378724146298055e-09
initially O 0 4.542859421974299e-09
required O 0 2.7285231851692515e-09
for O 0 9.80337699907352e-10
the O 0 2.0716937498832522e-08
differentiation O 0 1.0710544984249282e-07
of O 0 3.446508500815071e-08
the O 0 4.788947194356297e-08
visceral O 0 5.624984851237969e-07
endoderm O 0 8.933406206779182e-06
and O 0 5.836730654351641e-09
that O 0 1.3957319744406504e-09
the O 0 5.567792982219544e-08
gastrulation B-Disease 0 7.506980909965932e-05
defect I-Disease 0 3.6025878671352984e-06
in O 0 2.3011127225913697e-08
the O 0 8.604441603665691e-08
epiblast O 0 0.00012883021554443985
is O 0 1.1995625825989009e-08
secondary O 0 4.1816176121756143e-07
and O 0 1.617035216838758e-08
non O 0 5.608672654489055e-05
- O 0 8.85596964508295e-05
cell O 0 6.360808038152754e-05
autonomous O 0 1.0838976777449716e-05
. O 0 1.6303248173699103e-07

Rescued O 0 0.0019227252341806889
embryos O 0 4.613179044099525e-06
show O 0 1.8803323200700106e-06
severe O 0 2.8703545922326157e-06
anterior O 0 4.700126009993255e-05
truncations O 0 0.16396021842956543
, O 0 6.497463687082927e-07
indicating O 0 6.021268745826092e-06
a O 0 2.0170948289433e-07
second O 0 2.3512791358371032e-07
important O 0 8.608447643609907e-08
role O 0 3.0298949127427477e-07
for O 0 1.4456279018304485e-07
Smad4 O 0 0.34835928678512573
in O 0 1.0101600764755858e-06
anterior O 0 0.00016383483307436109
patterning O 0 0.00019478808098938316
during O 0 9.168789256364107e-05
embryogenesis O 0 0.0005038958042860031
. O 0 2.0204806787660345e-06

Prevalence O 0 0.00030122773023322225
of O 0 1.7080197949326248e-06
p16 O 0 6.6024049374391325e-06
and O 0 2.474311031619436e-07
CDK4 O 0 0.11344335228204727
germline O 0 8.060809341259301e-05
mutations O 0 1.3090454942243923e-08
in O 0 2.631785633866457e-08
48 O 0 2.421955286990851e-06
melanoma B-Disease 1 0.604926347732544
- O 0 0.0005180950975045562
prone O 0 8.268885721918195e-05
families O 0 2.1070814426593643e-08
in O 0 4.146765419932308e-08
France O 0 4.4220814743312076e-06
. O 0 2.4529733764211414e-06

The O 0 2.1157145965844393e-05
French O 0 0.0014827174600213766
Familial B-Disease 1 1.0
Melanoma I-Disease 1 1.0
Study O 0 0.00031723585561849177
Group O 0 1.7972452042158693e-06
. O 0 1.6624673548903957e-07

Germline O 0 0.0015741714742034674
mutations O 0 3.2290336093865335e-07
in O 0 4.480405735307613e-08
the O 0 1.1380610231981336e-07
p16 O 0 2.514515472284984e-06
and O 0 7.710235649938113e-08
CDK4 O 0 0.053041331470012665
genes O 0 7.70222570167789e-08
have O 0 9.146505219881362e-10
been O 0 4.8279225062231035e-09
reported O 0 7.947732250102035e-09
in O 0 2.7963573678846387e-09
a O 0 2.6830479171735533e-08
subset O 0 3.8872431673553365e-07
of O 0 1.3541230714508856e-07
melanoma B-Disease 0 0.0006168856634758413
pedigrees O 0 7.3295345828228164e-06
, O 0 3.363715750381857e-09
but O 0 9.268789069594163e-10
their O 0 4.891592020328517e-09
prevalence O 0 2.1322084364783223e-07
is O 0 1.2498715395992122e-09
not O 0 8.784640237458063e-10
well O 0 1.0045840603822853e-08
known O 0 1.299669349918986e-07
. O 0 2.2834325363874086e-07

We O 0 4.97509404340235e-07
searched O 0 1.8184356349593145e-06
for O 0 9.02762931076495e-09
such O 0 8.725646871710069e-09
germline O 0 7.613465641043149e-06
mutations O 0 1.3846967128472443e-08
in O 0 2.683570166084337e-08
48 O 0 3.965118366977549e-07
French O 0 7.53125932533294e-05
melanoma B-Disease 1 0.9999630451202393
- O 0 0.00023108809546101838
prone O 0 3.771484443859663e-06
families O 0 2.421444600386735e-09
selected O 0 2.711878943628676e-09
according O 0 5.500132349567366e-09
to O 0 9.478933193918238e-10
two O 0 1.0539517036889379e-09
major O 0 1.1450062231688207e-08
criteria O 0 1.0374915149213848e-08
families O 0 1.4277192761369406e-09
with O 0 2.528336151552679e-10
at O 0 1.0779467629618011e-07
least O 0 4.882168891384708e-09
three O 0 2.0019954583005983e-09
affected O 0 9.56246526406801e-10
members O 0 7.097280541046302e-10
( O 0 2.65335664551003e-09
n O 0 7.670909241141999e-08
= O 0 5.9007387420706436e-08
20 O 0 9.04134722645722e-09
) O 0 4.2886064144376235e-10
or O 0 6.030522747835221e-10
families O 0 5.970923061537903e-11
with O 0 2.1066925981472195e-11
two O 0 6.013810005534026e-10
affected O 0 4.230624295331609e-09
members O 0 5.714235751241858e-10
, O 0 4.157897082190942e-10
one O 0 1.385245473883856e-09
of O 0 3.5416822807832204e-09
them O 0 1.4360491684684007e-09
affected O 0 6.556082343678327e-09
before O 0 1.5102928685450934e-08
the O 0 4.701213995872422e-08
age O 0 3.757568833862024e-08
of O 0 5.961555160638454e-08
50 O 0 1.6662664137356842e-08
( O 0 1.0875778055918772e-09
n O 0 7.825170733610776e-09
= O 0 1.351021605699998e-08
28 O 0 4.168412282012923e-09
) O 0 1.5756572435687843e-10
, O 0 4.5380744301271037e-11
and O 0 6.725054541023567e-11
one O 0 9.859840721659907e-10
additional O 0 7.549747493840187e-09
minor O 0 2.9310012905625626e-07
criterion O 0 2.4644941731821746e-05
. O 0 1.0815626865223749e-06

Sixteen O 0 1.4012714018463157e-05
different O 0 1.2038871943786944e-07
p16 O 0 1.7368243788951077e-05
germline O 0 9.704293006507214e-06
mutations O 0 1.912753866406547e-08
were O 0 9.058953587270935e-09
found O 0 1.917765057868337e-09
in O 0 2.5556241567414872e-09
21 O 0 4.382080476261763e-08
families O 0 2.5717410423453657e-09
, O 0 7.296751536323143e-10
while O 0 4.808183629023688e-09
one O 0 1.7185563194743736e-08
germline O 0 1.5566893125651404e-06
mutation O 0 6.820602749257887e-09
, O 0 3.800772585549339e-09
Arg24His O 0 1.59747687575873e-05
, O 0 1.0965977459420628e-08
was O 0 3.2028023611019307e-07
detected O 0 2.021184712930335e-07
in O 0 2.4474996251910852e-08
the O 0 5.375460432333057e-07
CDK4 O 0 0.005271870642900467
gene O 0 8.191377673938405e-07
. O 0 2.7313762984704226e-07

The O 0 4.081729230165365e-07
frequency O 0 1.0978516939985639e-07
of O 0 3.984332153095238e-08
p16 O 0 4.014066234958591e-07
gene O 0 3.4992591047000587e-09
mutation O 0 1.0182802379077316e-09
in O 0 6.785965678268724e-10
our O 0 1.3403896881314381e-09
sample O 0 1.0214276091602414e-09
( O 0 1.0021836693852038e-09
44 O 0 5.775028011356653e-09
% O 0 1.6934645907795698e-09
) O 0 1.0824614121718312e-10
is O 0 9.375788340149072e-11
among O 0 3.239617255013094e-11
the O 0 4.431582600883388e-10
highest O 0 1.2079659050812097e-08
rates O 0 5.261332702843902e-09
yet O 0 2.3531616655247944e-09
reported O 0 5.5998259362866065e-09
and O 0 5.784119294638401e-10
the O 0 2.3460954068355022e-08
CDK4 O 0 2.8987909900024533e-05
mutation O 0 3.774454082616785e-09
is O 0 3.8332842455801597e-10
the O 0 1.399018234593541e-09
second O 0 1.7873565738568686e-08
mutation O 0 1.889423284495706e-09
detected O 0 5.030242444803434e-09
in O 0 7.899864651328414e-10
this O 0 3.978725793274407e-09
gene O 0 1.7329206514204998e-08
worldwide O 0 2.0936729683285193e-08
. O 0 7.216977593316187e-08

In O 0 9.303917636316328e-07
summary O 0 1.030066778184846e-05
, O 0 1.8948087543435577e-08
our O 0 8.8833012057421e-08
results O 0 4.1049162291528773e-08
show O 0 5.235268218939382e-08
frequent O 0 4.207025483538018e-08
involvement O 0 3.426385930538345e-08
of O 0 4.266109954187414e-08
the O 0 1.2170923469057016e-07
p16 O 0 2.0149291231064126e-06
gene O 0 5.012717707586489e-08
in O 0 8.574428278507185e-08
familial B-Disease 0 0.0001743668399285525
melanoma I-Disease 0 0.0013081339420750737
and O 0 1.791848625032344e-08
confirm O 0 2.6200262936981744e-07
the O 0 1.558341011786979e-07
role O 0 3.4349554312029795e-07
of O 0 8.27042185846949e-07
the O 0 1.377814783154463e-06
CDK4 O 0 0.004660333506762981
gene O 0 3.1328010408060436e-08
as O 0 2.0750553275661332e-08
a O 0 4.034545213471574e-07
melanoma B-Disease 0 0.00011713549611158669
- O 0 8.725817679078318e-06
predisposing O 0 2.5344294044771232e-05
gene O 0 5.651828516306523e-08
. O 0 8.192063027934182e-09
. O 0 1.4375508783359692e-07

Progression O 0 0.00037900370080024004
of O 0 3.5797547752736136e-06
somatic O 0 3.2243187888525426e-05
CTG O 0 0.0034669802989810705
repeat O 0 1.1914606830032426e-06
length O 0 1.4469424058916047e-07
heterogeneity O 0 2.8025854703628283e-07
in O 0 2.651621366922541e-09
the O 0 1.3066657977844898e-08
blood O 0 2.0181434479127347e-07
cells O 0 9.883315215120092e-07
of O 0 5.1013634219998494e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 5.597046765615232e-05
. O 0 6.367259430817285e-08

The O 0 4.926163228446967e-07
genetic O 0 1.581144744022822e-07
basis O 0 6.01413091771974e-07
of O 0 1.5923007595119998e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.03388311341404915
DM B-Disease 1 1.0
) O 0 1.0770215830291363e-08
is O 0 4.4911477314890647e-10
the O 0 1.6381438427970352e-09
expansion O 0 4.24682831123846e-08
of O 0 5.515546419587736e-08
an O 0 8.935334250281812e-08
unstable O 0 6.346824375214055e-05
CTG O 0 0.0032618807163089514
repeat O 0 1.242342364093929e-06
in O 0 2.2960183088116537e-08
the O 0 5.76326790735493e-08
34 O 0 2.0834120562085445e-07
UTR O 0 6.264564581215382e-05
of O 0 2.629736570725072e-07
the O 0 1.91529488802189e-06
DM B-Disease 1 1.0
protein O 0 2.2431918296206277e-06
kinase O 0 3.6743465443578316e-06
gene O 0 2.466868265216249e-09
on O 0 5.031384198161959e-09
chromosome O 0 4.8138385722040766e-08
19 O 0 3.1845920034356823e-07
. O 0 1.7849420430593455e-07

One O 0 8.445711046078941e-07
of O 0 2.3222662548505468e-07
the O 0 6.327176294007586e-08
principal O 0 8.327427167387214e-06
features O 0 7.374846688890102e-08
of O 0 3.9419344943780743e-07
the O 0 1.0218518582405522e-05
DM B-Disease 1 1.0
mutation O 0 1.8591807204870747e-08
is O 0 6.501486571330872e-10
an O 0 3.739340781461209e-10
extraordinarily O 0 1.8205799534598555e-08
high O 0 3.526376346485449e-08
level O 0 3.274036259881541e-07
of O 0 1.6268705849142862e-07
somatic O 0 4.483377324504545e-06
mosaicism O 0 0.0160639900714159
, O 0 9.287941971081182e-09
due O 0 6.078486336491551e-08
to O 0 1.8478316654579885e-09
an O 0 1.5229186800524985e-09
extremely O 0 3.642361745548328e-09
high O 0 3.7037448663568284e-09
degree O 0 2.223409296675527e-07
of O 0 1.9580687293796473e-08
somatic O 0 4.2932188648592273e-07
instability O 0 3.193246982391429e-07
both O 0 9.865069872105892e-10
within O 0 5.0591082434436885e-09
and O 0 4.5389422775876653e-10
between O 0 3.593491948450378e-09
different O 0 1.2737599863754667e-09
tissues O 0 2.3243424607244378e-07
. O 0 1.13062590401114e-07

This O 0 7.246840141306166e-07
instability O 0 6.714887604175601e-06
appears O 0 1.7243128525024076e-07
to O 0 3.991799779612393e-09
be O 0 2.8153022135768424e-09
biased O 0 3.217760635720879e-08
towards O 0 5.544348979924507e-09
further O 0 1.6949155412504524e-09
expansion O 0 5.240200717793186e-09
and O 0 5.653181256448647e-10
continuous O 0 4.1160421915265033e-07
throughout O 0 3.853974916978586e-09
the O 0 6.7942704795598274e-09
life O 0 2.365190709952003e-08
of O 0 7.624389120053365e-09
an O 0 1.0283084383999608e-09
individual O 0 7.434765580960345e-10
, O 0 3.1825631019444245e-10
features O 0 2.465241122351358e-09
that O 0 9.367280562333491e-11
could O 0 6.640664684809394e-10
be O 0 1.8651611366493626e-09
associated O 0 1.0390698967910339e-08
with O 0 1.2568952545422007e-09
the O 0 4.0125121358869364e-07
progressive O 0 4.695891675510211e-06
nature O 0 2.36594033253823e-07
of O 0 6.95613806556139e-08
the O 0 2.2640772101567563e-07
disease O 0 1.8863726154449978e-06
. O 0 7.936525747709311e-08

Although O 0 1.0737954170281228e-07
increasing O 0 4.799984765213594e-08
measured O 0 5.218280918484197e-08
allele O 0 2.7405089308984998e-09
size O 0 1.4423903182958497e-09
between O 0 3.329083231307095e-09
patients O 0 2.388755415694277e-09
clearly O 0 7.476777419412883e-09
correlates O 0 2.9028599968228264e-08
with O 0 2.8214652836311416e-11
an O 0 2.5008828341555045e-10
increased O 0 9.67213975577863e-10
severity O 0 1.8178250016376296e-08
of O 0 9.49429956875747e-09
symptoms O 0 8.419351615884807e-08
and O 0 5.401530334125937e-10
an O 0 7.418815561877068e-10
earlier O 0 2.5427007166456406e-09
age O 0 5.954427173548993e-09
of O 0 1.107392932908624e-08
onset O 0 6.129714620328741e-07
, O 0 4.3249967496272745e-10
this O 0 7.4296058194534e-10
correlation O 0 1.655382142473627e-08
is O 0 1.155994466817134e-10
not O 0 2.940930138306541e-11
precise O 0 2.2249770914584133e-09
and O 0 1.2650237801725694e-10
measured O 0 5.713802764262255e-09
allele O 0 1.4184466101685445e-10
length O 0 1.2274187222161004e-09
cannot O 0 1.5055006130637594e-09
be O 0 3.7944322683891585e-10
used O 0 1.153686701726997e-09
as O 0 1.087586132264562e-09
an O 0 2.3485611233553527e-09
accurate O 0 1.3478691585078195e-07
predictor O 0 6.003432417855947e-07
of O 0 5.817502479743553e-09
age O 0 1.2728236242764979e-07
of O 0 1.1001549182765302e-06
onset O 0 0.010744950734078884
. O 0 1.5398655932585825e-06

In O 0 4.7623677801311715e-07
order O 0 3.765230971453093e-08
to O 0 2.9600557560627294e-09
further O 0 5.037164907406577e-09
characterize O 0 8.389360317551109e-08
the O 0 2.4394461561882963e-08
dynamics O 0 3.6488622754404787e-06
of O 0 1.8187276509706862e-05
DM B-Disease 1 1.0
CTG O 1 0.6509389281272888
repeat O 0 1.4180064908941858e-06
somatic O 0 7.647140591870993e-07
instability O 0 7.229521088447655e-07
, O 0 1.612697642094929e-09
we O 0 1.825729123439146e-09
have O 0 3.0252833571609017e-10
studied O 0 1.6349732234743897e-08
repeat O 0 1.0722232879345484e-08
length O 0 2.578499413985469e-09
changes O 0 1.948677885721395e-10
over O 0 4.267554087888925e-10
time O 0 4.103536621613557e-09
in O 0 1.410370842336306e-08
111 O 0 6.025460970704444e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 4.20654178157065e-09
with O 0 1.2639088560473244e-11
varying O 0 1.3759448025396637e-09
clinical O 0 9.051806415527608e-08
severity O 0 1.4498832001663686e-07
and O 0 9.880138485129919e-09
CTG O 0 5.011461325921118e-05
repeat O 0 3.6577770146095645e-08
size O 0 7.353030628820534e-09
over O 0 7.558071390967314e-10
time O 0 2.902996953935144e-09
intervals O 0 4.3523677106804826e-08
of O 0 5.759256538340196e-08
1 O 0 9.31214074739728e-08
- O 0 8.562660980260262e-08
7 O 0 1.1815040323881476e-07
years O 0 6.882168435140557e-08
. O 0 8.107304694249251e-08

We O 0 8.567575946472061e-07
have O 0 8.064764855930662e-09
found O 0 7.848159455647874e-09
a O 0 1.3285876399038443e-08
direct O 0 4.3138047800539425e-08
progression O 0 4.3244443759249407e-07
of O 0 1.6286984205748922e-08
the O 0 9.151815305585842e-09
size O 0 9.900888997549373e-09
heterogeneity O 0 6.237903704686687e-08
over O 0 4.9086681386256714e-09
time O 0 2.1325414323314362e-08
related O 0 6.130415641791842e-08
to O 0 6.238234373512341e-09
initial O 0 5.954293555987533e-07
CTG O 0 5.5552674893988296e-05
repeat O 0 1.11961590221199e-07
size O 0 1.927998383166596e-08
and O 0 7.136319868372709e-10
the O 0 4.752891413772886e-09
time O 0 1.0979287701218254e-08
interval O 0 2.2169176361330756e-07
and O 0 1.883881495245987e-09
always O 0 5.985353546122951e-09
biased O 0 1.3592954317687145e-08
towards O 0 8.391981332067644e-09
further O 0 6.722240097900567e-09
expansion O 0 4.861398679167905e-07
. O 0 2.8955835773558647e-07

Attempts O 0 2.8622932859434513e-06
to O 0 1.4337946829812154e-08
mathematically O 0 5.290634703669639e-07
model O 0 9.714560889051427e-08
the O 0 2.3625215561651203e-08
dynamics O 0 1.1497820196382236e-05
have O 0 4.691930843847558e-09
proved O 0 3.451564509759919e-07
only O 0 7.364554299726933e-09
partially O 0 3.3780492003643303e-07
successful O 0 2.5888990506928167e-08
suggesting O 0 1.1304712721482701e-08
that O 0 3.361647071820073e-11
individual O 0 3.097414685848676e-11
specific O 0 1.191441528769488e-10
genetic O 0 1.680176997531646e-09
and O 0 2.2375530317475523e-09
/ O 0 3.209399210390984e-06
or O 0 7.943037871882552e-08
environmental O 0 1.600277101942993e-07
factors O 0 2.9797362799399707e-08
also O 0 3.887764832288809e-10
play O 0 5.2172430820007776e-09
a O 0 2.2884634631736844e-08
role O 0 5.19730214421088e-08
in O 0 7.820577963002506e-08
somatic O 0 4.278808773960918e-06
mosaicism O 0 6.58923527225852e-05
. O 0 1.296105835990602e-07
. O 0 3.083679018800467e-07

Aspartylglucosaminuria B-Disease 1 1.0
among O 0 2.511122147552669e-06
Palestinian O 0 0.00033583547337912023
Arabs O 0 9.919198419083841e-06
. O 0 8.14431359685841e-07

Aspartylglucosaminuria B-Disease 1 1.0
( O 1 0.9998193383216858
AGU B-Disease 1 1.0
) O 0 1.1144194900225557e-07
is O 0 3.4531588699593385e-09
a O 0 1.4672868253740035e-08
rare O 0 5.937508831266314e-07
disorder B-Disease 1 0.9947472214698792
of I-Disease 1 0.9964035749435425
glycoprotein I-Disease 1 1.0
metabolism I-Disease 1 1.0
caused O 0 1.624715696380008e-05
by O 0 1.4933068115396964e-08
the O 0 2.0701973824088782e-07
deficiency B-Disease 1 0.7466684579849243
of I-Disease 0 2.3554772269562818e-05
the I-Disease 0 1.2199981028970797e-05
lysosomal I-Disease 1 0.9999884366989136
enzyme I-Disease 0 8.123051884467714e-06
aspartylglucosaminidase I-Disease 0 0.00018628632824402303
( O 0 5.469790380630002e-07
AGA O 0 0.0004769546212628484
) O 0 1.8870117912683781e-07
. O 0 2.4430113398921094e-07

AGU B-Disease 1 1.0
is O 0 8.784646183812583e-07
inherited O 0 3.4205702831968665e-05
as O 0 9.776589848797812e-08
an O 0 6.076794534237706e-07
autosomal O 0 0.29230552911758423
recessive O 0 3.978476888732985e-05
trait O 0 1.2869792271885672e-06
and O 0 8.944691209933353e-09
occurs O 0 9.984639603999312e-08
with O 0 1.3214070948563972e-09
a O 0 1.1340588912389649e-07
high O 0 3.1972419378689665e-07
frequency O 0 1.7706528865346627e-07
in O 0 1.4658349201113197e-08
Finland O 0 4.229045487136318e-07
because O 0 1.460019927179701e-08
of O 0 3.326590842789301e-07
a O 0 5.728307428398693e-07
founder O 0 4.063977030455135e-06
effect O 0 4.476403887565539e-07
. O 0 2.494882949122257e-07

While O 0 1.1516236781972111e-06
very O 0 3.495705058753629e-08
few O 0 5.456281471083457e-08
patients O 0 2.5019252447577855e-08
with O 0 9.703871484134652e-09
AGU B-Disease 1 1.0
have O 0 2.0273811074389414e-08
been O 0 1.1135649735649622e-08
reported O 0 8.669292839158516e-09
from O 0 3.735486142630862e-09
non O 0 1.9493792535740795e-07
- O 0 7.777826027677293e-08
Finnish O 0 2.418174972262932e-06
origin O 0 1.3920000263567545e-08
, O 0 4.542859421974299e-09
we O 0 6.391948659256741e-08
diagnosed O 0 2.9479376735253027e-06
the O 0 2.3202717613912682e-07
disorder O 0 2.6265954147675075e-05
in O 0 3.313172669550113e-08
8 O 0 2.627069477512123e-07
patients O 0 6.135768004789099e-10
originating O 0 2.4500905748681134e-09
from O 0 4.0692968994449075e-09
3 O 0 3.4639725754459505e-08
unrelated O 0 6.164677301967458e-08
families O 0 1.6581620521094464e-09
, O 0 1.807302918432896e-10
all O 0 7.337503937776546e-10
Palestinian O 0 3.6919934700563317e-06
Arabs O 0 5.116276469152581e-08
from O 0 2.2208306305060432e-09
the O 0 4.403661435503636e-09
region O 0 1.1697292912060675e-08
of O 0 2.0721371640775033e-07
Jerusalem O 0 0.0003301265824120492
. O 0 1.199544044538925e-06

The O 0 1.9503738712955965e-06
clinical O 0 0.0004377435543574393
diagnosis O 1 0.9980660080909729
of O 0 0.4825550615787506
AGU B-Disease 1 1.0
is O 0 5.336504500519368e-07
often O 0 5.984954309923296e-09
difficult O 0 1.1820648460059147e-08
, O 0 2.42901232461179e-09
in O 0 4.864953329075661e-09
particular O 0 9.950756663101856e-09
early O 0 1.3530645048831502e-07
in O 0 8.608378010421802e-09
the O 0 2.42671660544147e-08
course O 0 2.0781889986665192e-07
of O 0 2.7697275584159797e-08
the O 0 2.86340995359069e-08
disease O 0 2.1678935979707603e-07
, O 0 2.994592351868164e-10
and O 0 3.2019739637512146e-10
most O 0 2.916598351720978e-10
of O 0 3.2175870856576694e-09
the O 0 5.294596050475775e-08
patients O 0 1.6986771100846454e-08
are O 0 5.946899084285917e-10
diagnosed O 0 3.368153400629126e-08
after O 0 3.8554254899736407e-08
the O 0 1.432237297649408e-07
age O 0 2.9780096610920737e-07
of O 0 3.642336139364488e-07
5 O 0 1.1687451006991978e-07
years O 0 7.930654533083725e-08
. O 0 9.346144480559815e-08

However O 0 4.7325588070634694e-07
, O 0 2.394329623456315e-09
since O 0 2.318089276087676e-09
these O 0 3.5744182613761666e-10
patients O 0 1.1785792342067225e-09
excrete O 0 3.033410322927921e-08
early O 0 1.3368566698090945e-08
large O 0 2.0381976106875754e-09
amounts O 0 9.374188536526162e-09
of O 0 8.906611981274182e-08
aspartylglucosamine O 0 4.64986578663229e-06
in O 0 1.117158099361859e-08
urine O 0 9.706536907572172e-09
, O 0 1.0620396784233321e-09
biochemical O 0 5.054702967299818e-08
screening O 0 5.635786060054215e-09
is O 0 9.788299060176087e-10
easy O 0 8.9604865749493e-09
by O 0 2.1081498768893425e-09
urine O 0 3.831212325167144e-08
chromatography O 0 1.0500421922188252e-05
. O 0 1.1623680507000245e-07
. O 0 2.3175759622517944e-07

Detection O 0 6.56477050142712e-06
of O 0 2.3081422284576547e-07
heterozygous O 0 1.4662187197700405e-07
carriers O 0 6.831252452599301e-09
of O 0 2.832891539128468e-07
the O 0 2.4915569156291895e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 5.0705559260677546e-05
ATM O 0 1.71274077729322e-05
) O 0 2.4545623311666986e-09
gene O 0 6.678478325916615e-10
by O 0 2.1966282126584247e-09
G2 O 0 4.038004135509254e-06
phase O 0 9.112537782129948e-07
chromosomal O 0 5.0793023547157645e-06
radiosensitivity O 0 1.7478039808338508e-05
of O 0 6.103096438891953e-06
peripheral O 0 0.0019018828170374036
blood O 0 5.786635301774368e-05
lymphocytes O 0 2.632478208397515e-05
. O 0 1.3253172710392391e-06

In O 0 0.0005379845970310271
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999995231628418
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 5.576369943582904e-08
patients O 0 2.1676231920508826e-09
, O 0 1.8750476171724983e-10
mutations O 0 1.330039134384009e-10
in O 0 7.816425284801198e-10
a O 0 5.0496895553919785e-09
single O 0 2.735067505810207e-09
gene O 0 2.8134489182818356e-10
, O 0 1.3190797065742998e-10
ATM O 0 1.8078895891449065e-07
, O 0 1.1694827051211831e-10
result O 0 2.367545492987233e-09
in O 0 1.9760738823038082e-08
an O 0 0.0005593173555098474
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 2.001561227871207e-08
embraces O 0 1.3008617294474334e-08
a O 0 1.135003424579395e-09
variety O 0 2.447165525776285e-10
of O 0 3.484514721208143e-08
clinical O 0 2.7047417461290024e-06
features O 0 2.1701890062786333e-08
and O 0 1.8201624651936754e-09
manifests O 0 1.0962928342905798e-07
extreme O 0 9.141147643276781e-07
radiosensitivity O 0 5.747971954406239e-05
and O 0 3.655698677107466e-08
a O 0 3.436924771449412e-07
strong O 0 2.1330993149604183e-07
pre O 0 2.6671405066736042e-05
- O 0 3.114194896625122e-06
disposition O 0 1.8960337911266834e-05
to O 0 8.235869586314948e-07
malignancy B-Disease 0 0.4694056510925293
. O 0 1.2701865443887073e-06

Heterozygotes O 0 4.7761917812749743e-05
for O 0 8.59922479889974e-08
the O 0 4.635899983895797e-07
ATM O 0 5.999590575811453e-05
gene O 0 2.2013226796957497e-08
have O 0 6.833751342583128e-10
no O 0 1.7833307053294334e-09
clinical O 0 5.9622713877161e-08
expression O 0 4.0312368554396016e-08
of O 0 2.5837027806119295e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
but O 0 1.4664921721418978e-08
may O 0 1.0918017601113661e-08
be O 0 1.3981654056749449e-08
cancer B-Disease 0 9.82920141723298e-07
prone O 0 1.736670327545653e-07
with O 0 6.717494338559504e-10
a O 0 5.506622358097957e-08
moderate O 0 2.1696013874361597e-08
increase O 0 7.115931732748493e-10
in O 0 2.393571563175101e-09
in O 0 3.3755949147007414e-08
vitro O 0 3.670455271276296e-06
radiosensitivity O 0 1.656701169849839e-05
. O 0 1.729271303929636e-07

We O 0 1.0788122608573758e-06
performed O 0 9.031600711750798e-07
a O 0 5.87691488362907e-07
blind O 0 2.4609682895970764e-06
chromosomal O 0 5.172278179088607e-07
analysis O 0 1.8860869488435128e-07
on O 0 1.2059278731157974e-07
G2 O 0 5.721440174966119e-06
- O 0 6.995654189267952e-08
phase O 0 2.776694714157202e-07
lymphocytes O 0 3.2310694564330333e-08
from O 0 2.46137066284291e-08
7 O 0 3.6285788951317954e-07
unrelated O 0 3.3561859709152486e-06
A B-Disease 1 1.0
- I-Disease 1 0.9999995231628418
T I-Disease 1 1.0
patients O 0 1.6757826415414456e-07
, O 0 6.476983394065883e-09
13 O 0 1.1130515531476703e-07
obligate O 0 1.9012110215044231e-06
A B-Disease 1 1.0
- I-Disease 1 0.9999659061431885
T I-Disease 1 0.9999973773956299
heterozygotes O 0 3.068718797294423e-06
( O 0 4.743563319919986e-09
parents O 0 1.1716937420302997e-09
of O 0 4.460144698015256e-09
the O 0 9.730338312863296e-09
patients O 0 1.4303797035708499e-09
) O 0 2.71919098349116e-10
, O 0 1.9506933568447238e-10
and O 0 5.731219943072574e-10
14 O 0 4.7648299528191274e-08
normal O 0 1.467522423581613e-07
controls O 0 1.222279610857413e-08
following O 0 6.999643087368668e-09
X O 0 6.072299356674193e-07
- O 0 1.22455716677905e-08
irradiation O 0 4.525780994413253e-08
with O 0 1.6739969410650701e-09
1 O 0 2.524130309211614e-07
Gy O 0 1.6759930076659657e-05
in O 0 9.661813571426592e-10
order O 0 8.972385612260325e-10
to O 0 4.622306981616475e-10
evaluate O 0 2.8602766377616717e-08
this O 0 9.308869231006156e-09
cytogenetic O 0 3.050278792215977e-06
method O 0 6.20341253920742e-08
as O 0 2.3249613345655007e-09
a O 0 4.778616169431871e-09
tool O 0 5.224545063242658e-08
for O 0 6.674505392822994e-10
detection O 0 1.421685311697729e-07
of O 0 2.0488418783770612e-07
ATM O 0 0.0006001063738949597
carriers O 0 3.6692128446702554e-07
. O 0 5.990638669572945e-07

Both O 0 4.89728590764571e-05
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
homozygotes O 0 0.00025947793619707227
and O 0 1.7645598759941095e-08
heterozygotes O 0 7.219268809421919e-07
showed O 0 3.013986216160447e-08
significantly O 0 1.2688448070008462e-09
increased O 0 5.069683006730941e-10
levels O 0 1.7436753152466622e-09
of O 0 1.0240870373934285e-08
radiation O 0 3.4490909456508234e-05
- O 0 3.796123337451718e-06
induced O 0 1.882560354715679e-05
chromatid O 0 0.0008509564795531332
damage O 0 2.3458683244825806e-06
relative O 0 9.865981098755583e-08
to O 0 8.62012072833096e-10
that O 0 4.28631685700509e-10
of O 0 3.0071074519355534e-08
normal O 0 6.679904345219256e-07
controls O 0 9.91143338069378e-07
. O 0 3.853690770938556e-07

These O 0 1.1967955515501671e-07
results O 0 2.98511757534925e-08
show O 0 3.255578917560342e-08
that O 0 2.3615382982455912e-09
the O 0 7.635511423131902e-08
G2 O 0 2.33957362070214e-05
- O 0 3.571628326426435e-07
phase O 0 1.855700247688219e-06
chromosomal O 0 4.006805284006987e-06
radiosensitivity O 0 3.5892787764169043e-06
assay O 0 1.3446440050302044e-07
can O 0 9.905078979244308e-10
be O 0 6.407921970819075e-10
used O 0 9.206996276489576e-10
for O 0 1.2562720863584786e-09
the O 0 2.9755106822904054e-08
detection O 0 1.6279395822493825e-06
of O 0 3.974495120928623e-05
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 4.6638444473501295e-05
. O 0 4.780131916959363e-07

In O 0 1.5601268898990384e-07
combination O 0 2.0491363272867602e-08
with O 0 1.9471333434495364e-09
molecular O 0 1.393813931827026e-06
genetic O 0 2.187294114719407e-07
analyses O 0 7.100346977040317e-08
, O 0 1.7656219541972717e-10
this O 0 1.6936672897482907e-10
test O 0 2.6256408158786826e-10
may O 0 2.1816082274028759e-10
be O 0 1.1773698682659983e-10
of O 0 8.242919680157001e-10
value O 0 4.599478575784133e-09
in O 0 5.731788377261182e-10
studies O 0 1.4816379234616761e-08
of O 0 2.0648691645419603e-08
familial B-Disease 0 1.8234769640912418e-06
and I-Disease 0 2.174087576634065e-08
sporadic I-Disease 0 0.0002920394472312182
cancers I-Disease 0 2.342275001865346e-05
aimed O 0 3.0426474495470757e-07
at O 0 2.2257343346154812e-07
determination O 0 7.675358659753329e-08
of O 0 1.1334940097640356e-08
the O 0 5.5594915338019746e-09
potential O 0 1.2428118978391467e-08
involvement O 0 8.449257649090214e-08
of O 0 1.5229346672640531e-07
ATM O 0 6.156208110041916e-05
mutations O 0 1.8497862797062226e-08
in O 0 1.886647638116301e-08
tumor B-Disease 0 7.457606261596084e-05
risk O 0 3.824273449026805e-07
or O 0 2.356841655171138e-08
development O 0 6.366603884089272e-07
. O 0 1.4272844239826554e-08
. O 0 1.0069093292486286e-07

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
: O 0 2.3774778412644082e-07
identification O 0 5.398405278356222e-08
and O 0 4.496241157170289e-09
detection O 0 5.206425157666672e-07
of O 0 1.187297925753228e-06
founder O 0 0.0017466339049860835
- O 0 1.267635525437072e-06
effect O 0 6.256933460235814e-08
mutations O 0 1.2865886134250104e-09
in O 0 7.112621047689061e-10
the O 0 1.343149147459144e-08
ATM O 0 2.6163186248595593e-06
gene O 0 8.424066444412404e-10
in O 0 5.93525062431155e-10
ethnic O 0 2.88714896434783e-09
populations O 0 1.6431014771001173e-08
. O 0 5.426971227961985e-08

To O 0 9.131470335432823e-08
facilitate O 0 7.302160298650051e-08
the O 0 2.8461053958039884e-08
evaluation O 0 3.1363077823698404e-07
of O 0 7.856727961552679e-07
ATM O 0 0.0002910535840783268
heterozygotes O 0 1.2177800954304985e-06
for O 0 6.885408243562097e-09
susceptibility O 0 4.6602312409049773e-07
to O 0 2.9520550448580707e-09
other O 0 2.645534014078521e-09
diseases O 0 0.0002944858861155808
, O 0 9.701831560349206e-10
such O 0 1.0245534420860736e-09
as O 0 3.256538718687807e-07
breast B-Disease 0 0.031261030584573746
cancer I-Disease 0 4.377154618850909e-05
, O 0 6.007805364305341e-09
we O 0 2.4064085835107107e-08
have O 0 1.2758023526515672e-09
attempted O 0 4.0870258288805417e-08
to O 0 1.836307439440077e-09
define O 0 1.1519436071694145e-08
the O 0 2.3728663478550516e-09
most O 0 6.569694788183256e-11
common O 0 6.361302457014162e-11
mutations O 0 3.545842439112157e-11
and O 0 3.507113349732194e-11
their O 0 3.65278141067904e-10
frequencies O 0 5.920802959025195e-09
in O 0 8.143150864725612e-08
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
( O 1 0.999964714050293
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 2.6418341292355763e-08
homozygotes O 0 1.6221360965573695e-07
from O 0 8.178648314149939e-10
10 O 0 1.0189835641938316e-09
ethnic O 0 2.0058328331629127e-09
populations O 0 6.663352980496029e-09
. O 0 2.3721346664729026e-08

Both O 0 4.6844309764537684e-08
genomic O 0 2.130222753748967e-07
mutations O 0 3.029766215689733e-09
and O 0 4.988096602431824e-10
their O 0 2.6729025659477657e-09
effects O 0 1.7243604588657035e-07
on O 0 1.5756896232232975e-07
cDNA O 0 1.003220745587896e-06
were O 0 2.4227578165891828e-08
characterized O 0 7.535637536193462e-08
. O 0 8.031948084408214e-08

Protein O 0 6.456636583607178e-06
- O 0 6.563973329321016e-07
truncation O 0 2.657669028849341e-06
testing O 0 3.8167708993341876e-08
of O 0 6.832623711261476e-08
the O 0 8.114390226410251e-08
entire O 0 1.22020855997107e-06
ATM O 0 7.166373052314157e-06
cDNA O 0 2.986256788517494e-07
detected O 0 7.115772859833669e-09
92 O 0 1.9991080790759952e-08
( O 0 5.818986403838267e-10
66 O 0 1.4440923123970606e-08
% O 0 8.824760366898943e-10
) O 0 2.121039038849304e-10
truncating O 0 4.8635921956474704e-08
mutations O 0 6.288202181181646e-10
in O 0 1.4531820191621136e-09
140 O 0 3.3581788017045255e-08
mutant O 0 5.9685859810088e-08
alleles O 0 1.094124080225356e-08
screened O 0 2.0731097549742117e-07
. O 0 1.4583589802441566e-07

The O 0 1.3152859537512995e-05
haplotyping O 0 0.0005751813296228647
of O 0 2.615462790345191e-06
patients O 0 3.6991508522987715e-08
with O 0 9.289709002047175e-10
identical O 0 3.5078886639894336e-07
mutations O 0 5.334595698514022e-08
indicates O 0 1.1934639587707352e-07
that O 0 2.6091812044271023e-10
almost O 0 4.112429508040805e-09
all O 0 3.149002725244543e-10
of O 0 5.376143419333346e-10
these O 0 6.171162886259296e-11
represent O 0 1.0178589082698863e-09
common O 0 2.82047785127304e-09
ancestry O 0 6.67827793066067e-09
and O 0 2.666780407611924e-10
that O 0 1.7549720010556769e-10
very O 0 2.5401121206414246e-09
few O 0 1.268898675022001e-08
spontaneously O 0 3.7005204944762227e-07
recurring O 0 1.9589560906752013e-05
ATM O 0 4.882182474830188e-05
mutations O 0 1.1656607057375368e-07
exist O 0 4.212565727357287e-07
. O 0 5.044137765253254e-07

Assays O 0 2.495323542461847e-06
requiring O 0 2.7046382911066758e-08
minimal O 0 7.934694679079257e-08
amounts O 0 4.5103965007342595e-09
of O 0 8.21028667274959e-09
genomic O 0 2.4079881200123054e-08
DNA O 0 2.0351142993035864e-08
were O 0 1.2132853610680172e-09
designed O 0 1.0851576304204968e-09
to O 0 2.2093335494410837e-10
allow O 0 6.024739596099948e-10
rapid O 0 1.990649600713823e-08
screening O 0 1.4211390952922898e-09
for O 0 3.614318011546658e-10
common O 0 7.21329607156207e-10
ethnic O 0 2.0447821214020223e-09
mutations O 0 2.291953649091738e-08
. O 0 5.523263268969458e-08

These O 0 7.075660590771804e-08
rapid O 0 1.7085380932257976e-07
assays O 0 6.548885522761339e-08
detected O 0 1.8118640809916542e-08
mutations O 0 4.420388777237605e-10
in O 0 7.412874758472299e-10
76 O 0 7.824785797083678e-08
% O 0 3.3891860429235976e-09
of O 0 1.6171586736390964e-08
Costa O 0 9.476952556042306e-08
Rican O 0 3.2229453950094467e-07
patients O 0 3.477541810070761e-09
( O 0 2.5615570775627816e-10
3 O 0 1.0460171617765468e-09
) O 0 8.354027886126048e-11
, O 0 7.790612599478663e-11
50 O 0 9.60313273346003e-10
% O 0 3.333834597274432e-10
of O 0 1.927666470891154e-09
Norwegian O 0 1.7907483197632246e-05
patients O 0 7.901963527956468e-09
( O 0 9.152945068535701e-10
1 O 0 4.935697184293986e-09
) O 0 1.6412581016478356e-10
, O 0 6.330776181062703e-11
25 O 0 9.58157997388298e-10
% O 0 4.598529057542322e-10
of O 0 2.0265218392268025e-09
Polish O 0 4.500610657487414e-07
patients O 0 2.5852918028590466e-08
( O 0 1.4543077853090836e-09
4 O 0 7.547098057614221e-09
) O 0 1.9032390941031707e-10
, O 0 4.090138991386105e-11
and O 0 9.500974312848243e-11
14 O 0 2.94185320548479e-09
% O 0 6.043349709550228e-10
of O 0 1.5376849793469205e-09
Italian O 0 8.216525770876615e-08
patients O 0 4.139540710212941e-09
( O 0 4.3048989373239976e-10
1 O 0 3.493896949535724e-09
) O 0 9.746860263337709e-11
, O 0 2.1345361242430805e-11
as O 0 1.7122397943936107e-10
well O 0 4.2491171692304874e-10
as O 0 5.735922292693374e-10
in O 0 2.0528907462846746e-09
patients O 0 1.2597752840903809e-09
of O 0 4.536480346928329e-08
Amish O 0 0.00016089154814835638
/ O 0 4.9596674216445535e-05
Mennonite O 0 6.276524072745815e-05
and O 0 1.2624555623119704e-08
Irish O 0 4.2053326865243434e-07
English O 0 1.4030749753146665e-06
backgrounds O 0 7.891210316302022e-07
. O 0 2.4399679432463017e-07

Additional O 0 2.095443392136076e-07
mutations O 0 9.92660531551337e-09
were O 0 1.1556032575299469e-08
observed O 0 9.749882678988797e-09
in O 0 1.8424270109562713e-08
Japanese O 0 1.9697858078870922e-05
, O 0 1.5112467721678513e-08
Utah O 0 2.853253135981504e-06
Mormon O 0 1.0292782235410414e-06
, O 0 5.556351490021427e-10
and O 0 5.827561766480471e-10
African O 0 5.0852996480443835e-08
American O 0 5.746872488998633e-07
patients O 0 1.722852438490463e-08
. O 0 3.499180678545599e-08

These O 0 1.0526865601434565e-08
assays O 0 3.215784971644098e-08
should O 0 8.838404452760074e-10
facilitate O 0 1.1560926438392016e-08
screening O 0 2.6592809732051137e-08
for O 0 2.870185369374667e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 2.6815653200173983e-06
in O 0 3.7309075828773075e-09
the O 0 2.042540581115304e-09
populations O 0 8.733634926372247e-10
studied O 0 2.8631477633211944e-08
. O 0 6.022329746002697e-09
. O 0 5.833083349671142e-08

The O 0 6.429672794183716e-05
von B-Disease 1 0.999677300453186
Hippel I-Disease 1 0.999998927116394
- I-Disease 1 0.9999932050704956
Lindau I-Disease 1 0.9999939203262329
tumor I-Disease 0 0.0010491546709090471
suppressor O 0 4.008896212326363e-06
gene O 0 1.525194859297585e-09
is O 0 7.323001233183746e-11
required O 0 4.274348375243875e-10
for O 0 1.7040500122078583e-09
cell O 0 1.8824462699740252e-07
cycle O 0 1.930858530840851e-07
exit O 0 1.6933684676700977e-08
upon O 0 1.3404618748324992e-08
serum O 0 3.4353257660768577e-07
withdrawal O 0 3.256038780818926e-07
. O 0 4.740779786516214e-07

The O 0 5.3790845413459465e-06
inactivation O 0 1.365994739899179e-05
of O 0 2.2862834612169536e-06
the O 0 1.748495606079814e-06
von B-Disease 1 0.9999945163726807
Hippel I-Disease 1 1.0
- I-Disease 1 1.0
Lindau I-Disease 1 1.0
( I-Disease 0 2.6856194381252863e-05
VHL I-Disease 0 0.15475282073020935
) I-Disease 0 7.54187738039036e-07
tumor I-Disease 0 1.3065833627479151e-05
suppressor O 0 9.166716154140886e-06
gene O 0 1.451664566332056e-08
predisposes O 0 6.477368685864349e-08
affected O 0 1.5498425876003807e-09
individuals O 0 1.8725387906926017e-10
to O 0 6.694573229104606e-10
the O 0 2.409128114777559e-07
human O 0 0.4127908945083618
VHL B-Disease 1 1.0
cancer I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 2.5240298739959144e-09
is O 0 9.380426435612321e-10
associated O 0 5.103525602123682e-09
with O 0 8.717029764682138e-09
sporadic B-Disease 1 0.999998927116394
renal I-Disease 1 1.0
cell I-Disease 1 1.0
carcinomas I-Disease 1 1.0
( O 0 0.04171642288565636
RCC B-Disease 1 0.9999998807907104
) O 0 2.73166534725533e-07
and O 0 2.288117144644275e-07
brain B-Disease 1 0.9998898506164551
hemangioblastomas I-Disease 1 0.9986826777458191
. O 0 5.94389348407276e-06

VHL O 0 0.005165064241737127
- O 0 6.2584389525e-05
negative O 0 7.265355634444859e-06
786 O 0 2.4566403226344846e-05
- O 0 5.7575989558245055e-06
0 O 0 6.993172974034678e-07
RCC B-Disease 0 0.0003472795942798257
cells O 0 3.7516969086937024e-07
are O 0 5.670938385549107e-09
tumorigenic O 0 1.286530550714815e-05
in O 0 2.7347124387233634e-07
nude O 0 0.0007240629056468606
mice O 0 2.9248360533529194e-07
which O 0 6.335876823193587e-10
is O 0 6.486078341083612e-10
suppressed O 0 1.9256978234238886e-08
by O 0 1.9215105062642124e-09
the O 0 2.2058872062302726e-08
reintroduction O 0 4.02707570401617e-07
of O 0 4.573547585096094e-07
VHL B-Disease 0 0.0003024008765351027
. O 0 1.465364789510204e-06

Remarkably O 0 0.0036716503091156483
, O 0 5.741616959653584e-09
this O 0 8.605057222332846e-10
occurs O 0 2.100003060334643e-09
without O 0 4.756954830043014e-09
affecting O 0 8.252079020110159e-09
the O 0 1.981572239628804e-09
growth O 0 3.032114648249262e-08
rate O 0 1.933186766223116e-08
and O 0 1.2065652921222636e-09
cell O 0 3.3507063790239044e-07
cycle O 0 4.5198717657513043e-07
profile O 0 5.480455644857329e-09
of O 0 2.0251926802217213e-09
these O 0 4.1337788747597415e-10
cells O 0 7.733444107316245e-09
in O 0 5.064514585484403e-09
culture O 0 3.6524897950585e-07
. O 0 1.1252185316834584e-07

The O 0 6.131560439825989e-06
786 O 0 1.4060154171602335e-05
- O 0 9.830298495216994e-07
0 O 0 7.683912883749144e-08
cell O 0 4.886624438427134e-08
line O 0 1.2841475438563066e-08
, O 0 5.424192206504586e-10
like O 0 1.251555636905266e-09
many O 0 2.4576962687206105e-09
cancer B-Disease 0 9.060943995109483e-08
cells O 0 2.349489847119912e-08
, O 0 2.864369630373176e-09
fails O 0 3.795384628801912e-08
to O 0 1.812673033896317e-08
exit O 0 2.398715253093542e-07
the O 0 4.7383210244333895e-08
cell O 0 1.2871311128037632e-07
cycle O 0 6.898451232473235e-08
upon O 0 1.0308976072792575e-07
serum O 0 2.729009111135383e-06
withdrawal O 0 1.192797526528011e-06
. O 0 4.768417056766339e-07

Here O 0 5.427154519566102e-06
, O 0 1.1763945373388651e-08
it O 0 1.0396065119877562e-09
is O 0 5.507750922006949e-10
shown O 0 1.1279013278908678e-09
that O 0 1.5728107705115235e-10
reintroduction O 0 5.388742785328304e-09
of O 0 4.078341220292714e-09
the O 0 1.2314479214126095e-08
wild O 0 3.1099808950330043e-08
- O 0 2.8382621053424373e-07
type O 0 7.846110179343668e-07
VHL B-Disease 0 4.2247418605256826e-05
gene O 0 2.731232129349337e-08
restores O 0 7.944825597405725e-08
the O 0 2.147037214683678e-09
ability O 0 6.1493850012084295e-09
of O 0 1.879922137959511e-07
VHL O 0 0.0008977233665063977
- O 0 0.00014135082892607898
negative O 0 2.824835064529907e-06
RCC B-Disease 0 0.1531493365764618
cancer I-Disease 0 5.655375616697711e-07
cells O 0 3.5242162521598175e-09
to O 0 1.4669725434401926e-09
exit O 0 1.6444371198076624e-08
the O 0 6.542553609989454e-09
cell O 0 5.6991773078607366e-08
cycle O 0 4.7500119393362183e-08
and O 0 4.861781199849702e-09
enter O 0 1.1834679298772244e-06
G0 O 0 0.0639595165848732
/ O 0 5.0371418183203787e-05
quiescence O 0 4.6155510062817484e-05
in O 0 6.216749426357637e-08
low O 0 5.996314484946197e-07
serum O 0 4.811800863535609e-06
. O 0 2.2464452342774166e-07

Both O 0 2.6406964934722055e-06
VHL O 0 0.00026128298486582935
- O 0 2.485782488292898e-06
positive O 0 7.233473553469594e-08
and O 0 2.375924523789763e-08
VHL O 0 0.000134877220261842
- O 0 5.641311872750521e-06
negative O 0 8.128034778565052e-07
RCC B-Disease 0 0.00018334577907808125
cells O 0 1.4646660417838575e-07
exit O 0 9.655522603679856e-08
the O 0 1.9671050566216763e-08
cell O 0 2.1540365935379668e-07
cycle O 0 1.287807691596754e-07
by O 0 1.0348767176537876e-08
contact O 0 4.760655883728759e-06
inhibition O 0 3.1301988201448694e-05
. O 0 3.179375482886826e-07

The O 0 6.8175227170286234e-06
cyclin O 0 0.00024722793023101985
- O 0 4.319001618569018e-06
dependent O 0 1.8441288602843997e-06
kinase O 0 2.6548746063781437e-06
inhibitor O 0 6.925926498979607e-08
, O 0 6.380943551320684e-10
p27 O 0 1.0491950774849101e-07
, O 0 2.5778293388789564e-10
accumulates O 0 2.0809013179245994e-08
upon O 0 6.393251261727073e-09
serum O 0 1.1589444426363116e-07
withdrawal O 0 2.6887345683235253e-08
, O 0 6.961706211505714e-10
only O 0 3.5209421489490467e-10
in O 0 7.803897528191328e-10
the O 0 3.0553348739914554e-09
presence O 0 1.856126630173094e-08
of O 0 4.256056627127691e-07
VHL B-Disease 0 0.0005343701341189444
, O 0 6.169145194689918e-09
as O 0 4.534479458584428e-09
a O 0 5.0744062285446034e-09
result O 0 1.2511213176580327e-09
of O 0 3.5920186824967004e-09
the O 0 5.646104028755872e-09
stabilization O 0 2.3683422512021934e-07
of O 0 6.41776196630417e-08
the O 0 1.6802442814878304e-07
protein O 0 5.9494800552784e-07
. O 0 1.9749856505768548e-07

We O 0 9.142176509158162e-07
propose O 0 3.711714100518293e-07
that O 0 1.7514292238729467e-08
the O 0 3.938814785442446e-08
loss O 0 8.195065106519905e-07
of O 0 5.763893682342314e-07
wild O 0 8.216867968258157e-07
- O 0 3.4755357773974538e-06
type O 0 2.4557400593039347e-06
VHL B-Disease 0 0.0001078529458027333
gene O 0 8.400853346302029e-09
results O 0 2.0928574429035507e-09
in O 0 5.151424287141992e-10
a O 0 4.236688777581321e-09
specific O 0 8.839926124437625e-09
cellular O 0 2.3631216095054697e-07
defect O 0 4.9868837947997235e-08
in O 0 4.4366763596315195e-09
serum O 0 5.416074145614402e-06
- O 0 0.00016627104196231812
dependent O 0 0.0001567031431477517
growth O 0 1.822317727828704e-07
control O 0 1.6237605038327274e-08
, O 0 2.0339635531385625e-10
which O 0 1.767124641061102e-10
may O 0 2.6000068764631123e-09
initiate O 0 4.419390009502422e-08
tumor B-Disease 0 1.7651071857471834e-06
formation O 0 3.215592414562707e-07
. O 0 4.475878938592359e-07

This O 0 4.032844458379259e-07
is O 0 2.1081669743239217e-08
corrected O 0 4.108481164166733e-07
by O 0 3.408732407450543e-09
the O 0 1.7917939132416905e-08
reintroduction O 0 3.226339728712446e-08
of O 0 2.0012253187928764e-08
wild O 0 7.09961582856522e-08
- O 0 2.5485974219918717e-06
type O 0 1.134116519097006e-05
VHL B-Disease 1 0.9543672204017639
, O 0 4.408769598285289e-07
implicating O 0 0.013438163325190544
VHL B-Disease 0 0.0018507165368646383
as O 0 6.945041519657025e-08
the O 0 2.7765826970949092e-08
first O 0 6.183920220337313e-08
tumor B-Disease 0 4.776459263666766e-07
suppressor O 0 3.879998757838621e-07
involved O 0 1.0531725713747164e-08
in O 0 5.1686308566445405e-09
the O 0 1.946595773461013e-08
regulation O 0 4.3891567713671975e-08
of O 0 3.8088515452727734e-08
cell O 0 1.85150227594022e-07
cycle O 0 8.422033914712301e-08
exit O 0 7.821201464253136e-09
, O 0 1.0068235828386563e-10
which O 0 9.215091190117874e-11
is O 0 7.504046828366029e-10
consistent O 0 2.1863801435983987e-08
with O 0 3.5506156348397155e-10
its O 0 5.038855999117686e-09
gatekeeper O 0 5.516103556146845e-07
function O 0 9.510488041541976e-08
in O 0 8.347313951162505e-09
the O 0 1.8546195690305467e-07
kidney O 0 1.3824814232066274e-05
. O 0 5.179173356850697e-08
. O 0 4.174094954123575e-07

Piebaldism B-Disease 1 1.0
with O 1 0.6835628151893616
deafness B-Disease 1 1.0
: O 0 3.562691688330233e-07
molecular O 0 1.2745475714837085e-06
evidence O 0 2.1633933044995501e-07
for O 0 8.433508114080723e-09
an O 0 3.4394815884297714e-08
expanded O 0 5.185260761209065e-06
syndrome O 1 0.9903579354286194
. O 0 6.920894293216406e-07

In O 0 1.1984921002294868e-06
a O 0 7.131787924663513e-07
South O 0 5.043733608545153e-07
African O 0 2.883321030822117e-07
girl O 0 1.281683012166468e-06
of O 0 3.3142222832793777e-07
Xhosa O 0 0.13885682821273804
stock O 0 8.803566515780403e-07
with O 0 4.406047526828161e-09
severe O 0 5.363271338865161e-05
piebaldism B-Disease 1 0.9997994303703308
and O 0 2.0888421659037704e-06
profound O 1 1.0
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 4.799335329153109e-06
identified O 0 4.863054527959321e-07
a O 0 9.782316112705303e-08
novel O 0 1.3857766134606209e-07
missense O 0 8.904121386876795e-07
substitution O 0 2.516824793019623e-08
at O 0 8.964968856162159e-08
a O 0 1.1393507470813802e-08
highly O 0 1.586600006930894e-08
conserved O 0 3.252730493841227e-07
residue O 0 1.5519356111326488e-06
in O 0 5.437332362134839e-08
the O 0 2.6436393341100484e-07
intracellular O 0 4.982022801414132e-05
kinase O 0 4.0000624721869826e-05
domain O 0 5.541380119211681e-07
of O 0 4.654674867765607e-08
the O 0 1.0937030481272814e-07
KIT O 0 0.0004682921280618757
proto O 0 0.0036297438200563192
- O 0 0.00029451484442688525
oncogene O 0 0.0006955833523534238
, O 0 1.2662469828228495e-07
R796G O 0 3.102406844845973e-05
. O 0 1.130632881540805e-06

Though O 0 7.831376933609135e-06
auditory B-Disease 0 0.010689672082662582
anomalies I-Disease 0 0.05870065093040466
have O 0 2.0520227295151017e-08
been O 0 4.526764740830913e-08
observed O 0 1.377314049477718e-07
in O 0 8.972495635362066e-08
mice O 0 8.428076370137205e-08
with O 0 2.972757817687466e-09
dominant O 0 1.575111127749551e-06
white O 0 8.371169712972915e-08
spotting O 0 3.386577736819163e-05
( O 0 1.7621973711356986e-06
W O 0 0.01707318238914013
) O 0 2.6150017706783046e-09
due O 0 1.6460750984492734e-08
to O 0 1.3345128557773478e-08
KIT O 1 0.9475077986717224
mutations O 0 6.468677020166069e-05
, O 0 5.836351556354202e-05
deafness B-Disease 1 1.0
is O 0 2.7127805779514347e-08
not O 0 2.025613676792659e-09
typical O 0 1.9652736682473915e-07
in O 0 3.2755849588284036e-08
human O 0 1.9075645241173333e-07
piebaldism B-Disease 0 4.81297611258924e-05
. O 0 4.21504950054441e-07

Thus O 0 2.80054405266128e-06
, O 0 1.13721867478489e-08
the O 0 5.333354735626017e-08
occurrence O 0 3.7972804420860484e-05
of O 0 0.1133795902132988
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
in O 0 7.123461546143517e-05
this O 0 1.6160431925982266e-07
patient O 0 1.2289629012229852e-06
extends O 0 1.4422811389636081e-08
considerably O 0 7.000163559922612e-09
the O 0 1.1410877798212482e-09
phenotypic O 0 1.3152146038919454e-08
range O 0 1.666832361024717e-08
of O 0 3.120676694834401e-08
piebaldism B-Disease 0 3.092979113716865e-06
due O 0 1.4707448769968323e-07
to O 0 2.4105291984710675e-08
KIT O 0 1.1120166163891554e-05
gene O 0 1.3918275421076487e-08
mutation O 0 4.919951113180332e-10
in O 0 7.253015965602572e-10
humans O 0 7.323413875326423e-09
and O 0 2.1181372211742655e-09
tightens O 0 4.0964689418387934e-08
the O 0 2.8217801428809253e-09
clinical O 0 2.328786621319523e-07
similarity O 0 5.29225410161871e-08
between O 0 3.667004833118881e-08
piebaldism B-Disease 0 8.028077900235076e-06
and O 0 1.3711505264524249e-09
the O 0 1.3076224547603488e-09
various O 0 7.305204219321126e-10
forms O 0 1.5441575129671037e-08
of O 0 5.718914508179296e-06
Waardenburg B-Disease 1 1.0
syndrome I-Disease 1 0.9999997615814209
. O 0 7.727106776656001e-08
. O 0 2.7230612431594636e-07

Cycloheximide O 0 0.0009036758565343916
facilitates O 0 3.434415702940896e-06
the O 0 5.802268887578066e-08
identification O 0 3.320561603459282e-08
of O 0 1.0081507895165487e-07
aberrant O 0 1.2148929044997203e-06
transcripts O 0 1.457473672417109e-06
resulting O 0 7.215188446707543e-08
from O 0 4.0826162006624145e-08
a O 0 6.154749598863418e-08
novel O 0 8.065734959927795e-07
splice O 0 4.414783234096831e-06
- O 0 6.957171763133374e-07
site O 0 2.8656424433393113e-07
mutation O 0 1.3370810236779107e-08
in O 0 3.545273230542989e-08
COL17A1 O 0 0.001380637288093567
in O 0 4.232910555401759e-08
a O 0 6.918466510796861e-08
patient O 0 1.5447326973117015e-07
with O 0 3.133486581319289e-09
generalized O 0 0.00012753752525895834
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999972581863403
. O 0 6.666776698693866e-06

Patients O 0 1.4357303371070884e-05
with O 0 4.841314904524552e-08
generalized O 0 0.0018002111464738846
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
often O 0 1.8520532307775284e-07
show O 0 1.1485062145766278e-07
decreased O 0 1.0652211130945943e-06
expression O 0 3.191879471842185e-08
of O 0 6.722871148667764e-08
type O 0 3.147261168123805e-06
XVII O 1 0.9879584312438965
collagen O 0 0.001265924540348351
, O 0 7.291041015378141e-08
a O 0 2.2778253594424314e-07
transmembrane O 0 8.108508154691663e-06
hemidesmosomal O 0 5.908762432227377e-06
protein O 0 9.93630848711291e-08
encoded O 0 5.800431779334758e-08
by O 0 3.788253621905824e-08
COL17A1 O 0 0.00012932354002259672
. O 0 5.371540510168415e-07

This O 0 1.0662151908036321e-06
report O 0 2.1158433582968428e-07
documents O 0 1.4669294614577666e-06
a O 0 2.327561077208884e-07
novel O 0 1.0818247346833232e-06
splice O 0 5.772151325800223e-06
- O 0 6.050564138604386e-07
site O 0 2.3535315563094628e-07
mutation O 0 1.0152438889576842e-08
in O 0 2.4303203005615615e-08
COL17A1 O 0 0.0007987980498000979
in O 0 2.977815860560895e-08
a O 0 8.943807472405751e-08
patient O 0 1.8325563644339127e-07
with O 0 4.018153809681735e-09
generalized O 0 0.00018353450286667794
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999988079071045
, O 0 1.376777714057198e-08
and O 0 1.447720943126285e-09
applies O 0 1.5395404062701346e-08
a O 0 5.7038072043269494e-09
new O 0 1.4400373116174592e-09
methodology O 0 1.3358656758555298e-07
to O 0 1.9011647811595367e-09
define O 0 3.3428158019432885e-08
and O 0 3.3991494063911887e-09
characterize O 0 2.4447567170682305e-07
the O 0 5.5192401759995846e-08
resulting O 0 2.4494755734849605e-07
mRNA O 0 1.4158769090499845e-06
splice O 0 1.7943336843018187e-06
variants O 0 1.4443104134898022e-07
. O 0 8.645470472856687e-08

Mutational O 0 0.0017340024933218956
analysis O 0 4.11350902140839e-06
of O 0 1.4262742524806526e-06
COL17A1 O 0 0.0009355408838018775
identified O 0 1.4700090105179697e-06
a O 0 3.0737666634195193e-07
maternally O 0 1.933605517479009e-06
inherited O 0 5.62064815312624e-06
G O 0 2.3808412151993252e-05
- O 0 2.3289073851628928e-06
to O 0 5.534451474886737e-07
- O 0 3.311399996164255e-05
T O 0 8.266296390502248e-06
transversion O 0 5.317373961588601e-06
at O 0 5.415952273324365e-07
the O 0 1.3014665967148176e-07
- O 0 1.137813612217542e-07
1 O 0 1.2469473631426808e-07
position O 0 3.3253601827709645e-07
of O 0 3.317052232887363e-07
exon O 0 1.291666308134154e-06
32 O 0 4.4451664393818646e-07
. O 0 1.6028279503643716e-07

This O 0 8.35368666685099e-07
acceptor O 0 3.3420576528442325e-07
splice O 0 5.663650881615467e-06
- O 0 1.3312177316038287e-06
site O 0 3.7864913338125916e-07
mutation O 0 6.154078135978125e-09
led O 0 9.47806899631587e-09
to O 0 3.558746630716314e-09
the O 0 3.70370436542089e-08
formation O 0 1.6952078567555873e-06
of O 0 1.3714797205466311e-05
aberrant O 0 6.951813702471554e-06
transcripts O 0 3.432834091654513e-06
present O 0 6.225720738939344e-08
at O 0 4.0222357711172663e-07
extremely O 0 1.3541372823056008e-07
low O 0 8.37888364912942e-07
levels O 0 7.139143463064102e-07
. O 0 3.4434796702953463e-07

Based O 0 1.4985447478466085e-06
on O 0 1.3350148719837307e-07
our O 0 3.5573233247987446e-08
recent O 0 6.030537402779146e-09
finding O 0 3.288693761760442e-08
that O 0 1.1216904072242073e-09
cycloheximide O 0 1.6079245597211411e-06
stabilized O 0 1.8112279576598667e-05
mutant O 0 1.340671246907732e-06
COL17A1 O 0 3.5486838896758854e-05
transcripts O 0 1.2784577165803057e-06
in O 0 1.1091220386560963e-08
keratinocytes O 0 1.4085030386468134e-07
homozygous O 0 3.1199622441135944e-08
for O 0 1.84603510255954e-09
a O 0 4.9661537104839226e-08
frameshift O 0 1.3123476492182817e-06
mutation O 0 1.8606379770247372e-09
, O 0 4.056748270642174e-10
the O 0 5.969107430559006e-09
effects O 0 8.594769838055072e-07
of O 0 1.2274869050088455e-06
the O 0 8.777996640674246e-07
splice O 0 5.637214599119034e-06
- O 0 3.6251546475796204e-07
site O 0 1.626347767569314e-07
mutation O 0 2.8263640317049976e-09
on O 0 1.1204764227557007e-08
splicing O 0 9.937350142763535e-08
of O 0 1.0565732821987694e-07
COL17A1 O 0 3.3955871913349256e-05
transcripts O 0 9.06384570953378e-07
were O 0 1.0907817760141825e-08
determined O 0 5.490510268657545e-09
using O 0 3.045478758068043e-09
reverse O 0 6.938143570778266e-08
transcriptase O 0 1.8276921309734462e-07
polymerase O 0 4.0359910968845725e-08
chain O 0 7.405049018416321e-09
reaction O 0 4.967749545059519e-10
of O 0 1.0863780097736253e-08
total O 0 8.343943136424059e-08
RNA O 0 2.94595736249903e-07
from O 0 9.531222922021243e-09
keratinocytes O 0 1.3441260193758353e-07
incubated O 0 2.186472443099774e-07
for O 0 5.2732276323297356e-09
2 O 0 2.3728863141059264e-07
. O 0 8.64443094883427e-08

5 O 0 1.4054819075681735e-05
h O 0 2.5532367544656154e-06
in O 0 5.3487070772462175e-08
the O 0 5.088967114375009e-08
presence O 0 1.6425036619693856e-07
or O 0 9.261957956141487e-08
absence O 0 6.092706144045223e-07
of O 0 5.867853474228468e-07
10 O 0 3.1840116321291134e-07
microg O 0 8.146510481310543e-06
cycloheximide O 0 8.880547284206841e-06
per O 0 1.1286108474450884e-06
ml O 0 4.227083991281688e-06
. O 0 1.84077819653794e-07

Using O 0 3.4004034432655317e-07
this O 0 2.3496063761285768e-08
approach O 0 1.4621329569308728e-07
, O 0 8.527518247092303e-09
an O 0 4.521250929201415e-08
abnormally O 0 5.554026756726671e-06
spliced O 0 3.487465392026934e-06
transcript O 0 6.706837211822858e-06
was O 0 1.7934391394192062e-07
identified O 0 1.3968513457029985e-08
that O 0 1.5302584199794467e-10
contains O 0 5.78300518583319e-10
an O 0 4.5160064576776904e-10
extra O 0 5.9505333993570275e-09
264 O 0 3.634202627722516e-08
bases O 0 3.464871412006687e-08
upstream O 0 4.331828904469148e-07
from O 0 2.2592537618493225e-08
exon O 0 1.2384241188101441e-07
32 O 0 3.36198553441136e-08
, O 0 8.159919406836025e-10
resulting O 0 1.4741313059118966e-08
in O 0 1.5257775487498293e-08
a O 0 1.5161121780238318e-07
premature O 0 5.017500939175079e-07
termination O 0 1.9631977465905948e-06
codon O 0 2.514258994779084e-06
27 O 0 4.932509000354912e-06
bp O 0 1.2198712283861823e-05
downstream O 0 6.877849955344573e-06
from O 0 1.8369010490459914e-07
the O 0 7.156253900575393e-07
cryptic O 0 2.120722274412401e-05
splice O 0 4.487228943617083e-05
site O 0 7.0394689828390256e-06
. O 0 5.957656412647339e-07

Three O 0 9.483395615461632e-07
other O 0 2.580616431657745e-08
splice O 0 4.4507359575618466e-07
variants O 0 3.337515153134518e-08
, O 0 2.437059221094273e-09
including O 0 1.0008578410491964e-09
one O 0 3.0187714550322653e-09
derived O 0 3.670090720220287e-08
from O 0 1.5511536943790816e-08
the O 0 4.5578417484648526e-08
skipping O 0 1.666327591465233e-07
of O 0 1.669548765903528e-07
exon O 0 3.0708952181157656e-07
32 O 0 9.725517458036848e-08
, O 0 4.79250861218361e-09
were O 0 5.0481702373872395e-08
also O 0 5.459363094928449e-08
identified O 0 1.206337856274331e-06
. O 0 1.1040175422749599e-06

These O 0 2.0848291626407445e-07
results O 0 1.496346868634646e-07
indicate O 0 8.322216160649987e-08
the O 0 1.8255942535461145e-08
usefulness O 0 3.684459102260007e-07
of O 0 1.2361969226049041e-08
cycloheximide O 0 4.7214328446898435e-07
treatment O 0 2.1426314056327556e-09
in O 0 7.048580052959608e-10
evaluating O 0 7.93584131741909e-09
the O 0 3.015215410684391e-09
abnormal O 0 5.156915605653012e-08
processing O 0 4.540176234968385e-08
of O 0 6.212506065139678e-08
mRNA O 0 1.5512755169311276e-07
due O 0 9.489432528653197e-08
to O 0 2.0515845022828216e-08
splice O 0 9.028586305248609e-07
- O 0 1.2216437994538865e-07
site O 0 4.4225185291679736e-08
mutations O 0 1.750840472602988e-09
, O 0 5.907241362734794e-10
because O 0 2.221364425736283e-09
( O 0 9.073305662354869e-09
i O 0 6.533515062301376e-08
) O 0 1.8250581490519835e-08
aberrant O 0 1.0920000192982116e-07
splicing O 0 5.6862674568947114e-08
often O 0 1.2062109089328032e-09
generates O 0 4.8755248727161415e-09
a O 0 5.110382783612977e-09
premature O 0 2.0641051534653343e-08
termination O 0 6.311518774282376e-08
codon O 0 1.1081328921136446e-07
, O 0 5.2652073811998434e-09
( O 0 7.807101631840396e-09
ii O 0 1.324528739132802e-06
) O 0 4.0745568696820555e-08
transcripts O 0 3.7046268630547274e-07
with O 0 1.580341191242951e-09
premature O 0 4.705403569005284e-07
termination O 0 2.2729514626007585e-07
codons O 0 4.9495291420953436e-08
can O 0 1.3633660866929631e-09
occur O 0 1.081637002187108e-08
at O 0 2.9756705544059514e-07
low O 0 5.163564082977246e-07
or O 0 7.87956810910373e-09
undetectable O 0 2.84993859622773e-07
levels O 0 2.159717205074685e-08
due O 0 2.5074671228253465e-08
to O 0 3.783507285248788e-09
nonsense O 0 4.1755126289899636e-07
- O 0 5.065435360052106e-08
mediated O 0 7.014788394599236e-08
mRNA O 0 3.124083036709635e-08
decay O 0 7.290415027227937e-08
, O 0 3.485382260581815e-10
and O 0 1.7371548644007362e-10
( O 0 1.3587347913457393e-09
iii O 0 5.167510153114563e-08
) O 0 2.2012291989170762e-09
the O 0 4.012991716706438e-09
levels O 0 2.293348622117719e-08
of O 0 3.798018344269849e-09
these O 0 6.476312264247497e-10
transcripts O 0 9.15831463998984e-08
can O 0 1.236707958263139e-09
be O 0 3.5374494444795346e-09
increased O 0 1.22043459782617e-08
by O 0 2.6962837296196085e-08
cycloheximide O 0 6.076932913856581e-05
. O 0 9.424539939573151e-07

A O 0 1.0488211046322249e-05
deletion O 0 2.2539204564964166e-06
mutation O 0 7.52833955175447e-08
in O 0 8.149132924017977e-08
COL17A1 O 0 0.0010656035738065839
in O 0 1.0407026707071054e-07
five O 0 6.710457256531299e-08
Austrian O 0 1.0224484867649153e-05
families O 0 1.6096500132789515e-08
with O 0 5.09461717257409e-09
generalized O 0 2.7889291231986135e-05
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999676942825317
represents O 0 4.468116969746916e-07
propagation O 0 1.7044105788954766e-06
of O 0 7.73422925703926e-08
an O 0 1.882205822312244e-07
ancestral O 0 3.223042585887015e-05
allele O 0 1.147721604866092e-06
. O 0 9.521203310214332e-07

Patients O 0 7.413612365780864e-06
with O 0 3.485272870307199e-08
generalized O 0 0.0007112228777259588
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
, O 0 3.303190254655419e-08
a O 0 1.7212133940347485e-08
usually O 0 5.003726322172497e-09
nonlethal O 0 3.451989130098809e-07
form O 0 8.242959381732362e-08
of O 0 0.000493579835165292
junctional B-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
, O 0 6.191520895981739e-08
have O 0 4.143585030647046e-09
generalized O 0 1.6603028996087232e-07
blistering B-Disease 0 1.0392271178716328e-05
, O 0 4.187643867226143e-07
nail B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 1.0
, O 0 5.012990004615858e-05
patchy B-Disease 1 1.0
alopecia I-Disease 1 1.0
, O 0 8.404304935538676e-06
and O 0 0.0005221387255005538
dental B-Disease 1 1.0
abnormalities I-Disease 1 1.0
. O 1 0.6144156455993652

Skin B-Disease 1 0.9999704360961914
fragility I-Disease 1 0.9999676942825317
in O 0 4.776085305024935e-08
most O 0 1.4977675766303378e-09
cases O 0 4.3311221276098877e-10
is O 0 1.747536559904006e-10
due O 0 1.901788504454771e-09
to O 0 4.500897710091323e-10
mutations O 0 3.6305686235138523e-10
in O 0 1.5701259181710725e-09
the O 0 7.756193021180025e-09
gene O 0 1.4500864953248538e-09
encoding O 0 7.79154163410567e-09
type O 0 1.578970341142849e-07
XVII O 0 0.0006955127464607358
collagen O 0 0.0002974373637698591
( O 0 4.360350430943072e-06
COL17A1 O 0 0.003006695071235299
) O 0 1.1595447801937553e-07
. O 0 1.692516917728426e-07

Recently O 0 3.7861074815737084e-05
, O 0 1.0232927394326907e-07
we O 0 5.72491103412176e-08
reported O 0 7.853299166526995e-08
five O 0 1.27882406886215e-08
Austrian O 0 1.6200132222365937e-06
families O 0 4.531954811426431e-09
with O 0 4.696300237583273e-09
generalized O 0 3.4524407965363935e-05
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
who O 0 4.885674229626602e-07
share O 0 2.3514876090757753e-07
the O 0 3.4364987300250505e-07
same O 0 6.259834322008828e-07
COL17A1 O 0 0.003602466080337763
mutation O 0 9.103226830120548e-07
. O 0 3.238208137190668e-07

Affected O 0 8.962563811110158e-07
individuals O 0 3.3372720142921253e-09
in O 0 2.993228997993924e-09
three O 0 7.014915870406924e-10
families O 0 6.064815871731355e-10
are O 0 1.154676770864782e-10
homozygous O 0 1.3748823191050974e-09
for O 0 7.987315808755113e-10
4003delTC O 0 1.4682937887755543e-07
, O 0 3.450571384178147e-09
whereas O 0 2.9057849459945828e-08
those O 0 1.9496231296045607e-09
in O 0 6.786616157938852e-09
two O 0 3.4879310550905984e-09
others O 0 9.903005526723518e-09
are O 0 4.003534836982681e-09
compound O 0 4.6217305680329446e-06
heterozygotes O 0 7.196432306955103e-06
. O 0 6.506473368972365e-07

To O 0 1.461146155179449e-07
determine O 0 1.508818030515613e-07
if O 0 1.8424410441753025e-08
the O 0 2.8101696969429213e-08
occurrence O 0 9.45219994719082e-07
of O 0 4.7347164411348786e-08
4003delTC O 0 1.543482426313858e-07
in O 0 1.039434094352032e-09
these O 0 1.4320496177777642e-10
unrelated O 0 2.7052882600742123e-08
families O 0 6.52867537809243e-10
signifies O 0 4.993200963809841e-09
propagation O 0 3.69287675994201e-08
of O 0 7.238604826653727e-09
an O 0 9.739697048871676e-09
ancestral O 0 8.214564672925917e-07
allele O 0 1.8399440193661576e-08
or O 0 1.978091290766315e-08
a O 0 8.114838578876515e-08
mutational O 0 7.0462865551235154e-06
hot O 0 5.470400878948567e-07
spot O 0 3.896745113252109e-07
, O 0 3.342699228525703e-09
haplotypes O 0 6.81037448657662e-08
were O 0 3.1132671995948158e-09
determined O 0 1.1977839164956094e-08
for O 0 5.906219513462929e-09
polymorphisms O 0 1.2551834061014233e-07
both O 0 1.0985782061823102e-08
within O 0 4.322168649650848e-07
and O 0 8.079163649199472e-08
flanking O 0 0.00016017210145946592
COL17A1 O 1 0.9980788230895996
. O 0 5.506655725184828e-06

Five O 0 7.122685019567143e-06
intragenic O 0 5.017548392061144e-05
polymorphisms O 0 3.447348035479081e-06
were O 0 7.802579915505703e-08
chosen O 0 4.4304208302037296e-08
based O 0 5.320076112980132e-08
on O 0 2.7316602313476324e-07
their O 0 1.7211550584761426e-07
informativeness O 0 0.00013911988935433328
. O 0 2.5888107302307617e-06

One O 0 1.7386768149663112e-06
of O 0 1.8741920371212473e-07
these O 0 8.536011897319895e-09
, O 0 5.026473459679437e-09
not O 0 6.199246449511975e-09
previously O 0 1.5544937070899323e-07
reported O 0 1.970744705204197e-07
, O 0 8.250599314862939e-09
was O 0 2.2392591745301615e-06
2988 O 0 1.7268734154640697e-05
A O 0 7.6234123298490886e-06
or O 0 1.1241480990520358e-07
C O 0 2.575920916569885e-06
that O 0 8.7933071934998e-10
introduces O 0 8.542739848849124e-09
a O 0 3.350870469986944e-09
new O 0 6.04119476665943e-10
restriction O 0 1.6687090820255435e-08
site O 0 9.09888910882728e-08
for O 0 7.262709544875179e-09
Eco0109 O 0 1.3185448551666923e-05
I O 0 5.171943485038355e-05
. O 0 3.0593712381232763e-06

All O 0 3.707942255459784e-07
the O 0 1.6551680914744793e-07
4003delTC O 0 1.4961186707296292e-06
alleles O 0 2.6650031514918737e-08
showed O 0 1.9910368465048123e-08
the O 0 8.082905900153037e-09
same O 0 1.2599945975466653e-08
haplotype O 0 5.7357972593763407e-08
for O 0 3.5690228550322445e-10
these O 0 3.458080488627502e-10
five O 0 1.927248405309001e-08
polymorphic O 0 1.4362244371568522e-07
markers O 0 5.038417043579102e-07
. O 0 2.0011133017305838e-07

Fourteen O 0 1.714350401016418e-05
microsatellite O 0 3.9558908611070365e-05
polymorphisms O 0 6.340790719150391e-07
were O 0 1.287288942108944e-08
selected O 0 8.529811523771968e-09
based O 0 1.6398015389995635e-08
on O 0 4.864603297960457e-08
their O 0 1.1416218193005534e-08
high O 0 3.730824289505108e-07
heterozygosity O 0 8.638629515189677e-05
and O 0 7.922291267448145e-09
their O 0 5.453896001483827e-09
location O 0 3.414050695482729e-07
within O 0 1.2016607797704637e-07
10q23 O 0 5.168720690562623e-06
- O 0 6.393902367562987e-06
q25 O 0 2.8043070415151305e-05
near O 0 4.342422107583843e-05
COL17A1 O 0 0.0012633204460144043
. O 0 1.7158710079456796e-06

Three O 0 7.21692856586742e-07
families O 0 9.123288435830545e-08
shared O 0 4.5391286107587803e-07
microsatellite O 0 5.707236414309591e-05
polymorphisms O 0 8.945205081545282e-06
covering O 0 2.245652285637334e-05
at O 0 1.1359610653016716e-05
most O 0 2.317816338859302e-08
19 O 0 1.1467168548051632e-07
cM O 0 1.846658079784902e-07
, O 0 1.3525731645813721e-09
whereas O 0 5.9965632459579865e-09
the O 0 6.235486793570999e-09
others O 0 1.3170993184985491e-09
shared O 0 3.806234882830495e-09
smaller O 0 1.0195667643486672e-09
regions O 0 2.284415323572375e-09
consistent O 0 3.9446337751769533e-08
with O 0 6.558480425411517e-10
cross O 0 4.590716784491633e-08
- O 0 1.1515211895130051e-07
over O 0 6.959200327116832e-09
events O 0 2.1174921371880373e-08
during O 0 1.9101216608419236e-08
passage O 0 2.3854877184703582e-08
of O 0 1.1397588428607719e-09
this O 0 1.1982465020210498e-10
mutation O 0 1.4206451293130584e-10
through O 0 4.754974747278595e-10
several O 0 3.2543168160259484e-09
generations O 0 6.09339139145959e-08
. O 0 8.19434831100807e-08

These O 0 1.855553648510977e-07
results O 0 1.156465785356886e-07
indicate O 0 7.934286117006195e-08
that O 0 7.48856199273007e-10
4003delTC O 0 1.652948640185059e-07
occurs O 0 6.219095460835433e-09
on O 0 9.93448523445295e-09
a O 0 1.8798337109160457e-08
single O 0 1.1967151714031843e-08
ancestral O 0 3.0142339824124065e-07
allele O 0 1.0913145942481606e-08
. O 0 5.882721865191343e-09
. O 0 5.653661361293416e-08

The O 0 7.531379196734633e-06
haptoglobin O 0 0.0003444703761488199
- O 0 9.924610822054092e-06
gene O 0 8.902349435402357e-08
deletion O 0 3.655650573364255e-07
responsible O 0 8.397797301995524e-08
for O 0 5.153965432214136e-08
anhaptoglobinemia B-Disease 0 0.0011675957357510924
. O 0 1.9775932287302567e-06

We O 0 9.068661483979668e-07
have O 0 1.0193806687652796e-08
found O 0 6.1680975882438815e-09
an O 0 3.894825351125064e-09
allelic O 0 2.3836690843381803e-07
deletion O 0 1.213110607523049e-07
of O 0 4.225707357363717e-07
the O 0 9.318623028775619e-07
haptoglobin O 0 0.0005306561361066997
( O 0 1.4360136901814258e-06
Hp O 0 2.9871675906179007e-06
) O 0 2.5605813025464386e-09
gene O 0 4.4527986853282187e-10
from O 0 1.0674233719143444e-09
an O 0 4.1061984923373984e-09
individual O 0 1.1288316059676617e-08
with O 0 1.38515368064418e-08
anhaptoglobinemia B-Disease 0 0.0009144900250248611
. O 0 2.164197212550789e-06

The O 0 3.976944208261557e-05
Hp O 0 5.34823011548724e-05
gene O 0 3.1375908093878024e-08
cluster O 0 1.5583358603521447e-08
consists O 0 2.4585649072150773e-08
of O 0 3.969639692513738e-07
coding O 0 9.02276769920718e-06
regions O 0 8.845547228020223e-08
of O 0 2.8145093438070035e-06
the O 0 1.381807123834733e-06
alpha O 0 3.8333226257236674e-05
chain O 0 1.583897528689704e-07
and O 0 3.3113198849576975e-09
beta O 0 7.520889653278573e-07
chain O 0 2.7920791012547852e-08
of O 0 1.673665650514522e-08
the O 0 3.217742161609749e-08
haptoglobin O 0 1.0364638001192361e-05
gene O 0 2.8726438117132602e-08
( O 0 5.144593195893776e-09
Hp O 0 7.583869177096858e-08
) O 0 2.4219329319841165e-10
and O 0 2.2684876199718929e-10
of O 0 6.850890077458871e-09
the O 0 8.806659224092073e-08
alpha O 0 3.061259349124157e-06
chain O 0 9.443661497243738e-08
and O 0 2.6197743974165633e-09
beta O 0 4.1048701859836e-07
chain O 0 4.1827821206652516e-08
of O 0 1.5239278283729618e-08
the O 0 5.612874787175315e-08
haptoglobin O 0 1.0604971976135857e-05
- O 0 4.438316523192043e-07
related O 0 1.9417905150476145e-07
gene O 0 1.7969894017255683e-08
( O 0 7.1955330582795796e-09
Hpr O 0 8.026662499105441e-07
) O 0 1.4808686499279133e-09
, O 0 4.103738182603678e-10
in O 0 8.556420461047765e-09
tandem O 0 6.008564241710701e-07
from O 0 7.370698540398735e-08
the O 0 2.2107357722234156e-07
5 O 0 3.316498862204753e-07
side O 0 2.3208737331970042e-07
. O 0 5.350523792913009e-07

Southern O 0 1.2964997040398885e-05
blot O 0 1.4288459169620182e-05
and O 0 5.826422722066127e-08
PCR O 0 5.229659905126027e-07
analyses O 0 1.707479242440968e-07
have O 0 7.42600758663059e-10
indicated O 0 1.4757285393685038e-09
that O 0 1.0712512127364349e-10
the O 0 1.5227473726397989e-09
individual O 0 3.3378685926344076e-10
with O 0 2.9652927335810375e-10
anhaptoglobinemia B-Disease 0 4.900910539618053e-07
was O 0 1.0258644778105008e-07
homozygous O 0 4.591397040343281e-09
for O 0 3.0071845014134624e-10
the O 0 3.238421975026995e-09
gene O 0 1.0500871283625202e-09
deletion O 0 4.984941348595839e-09
and O 0 1.805290916756519e-10
that O 0 1.4639754686296413e-10
the O 0 9.068669371004034e-09
gene O 0 4.941584030859758e-09
deletion O 0 2.2441662750338764e-08
was O 0 6.5994690601201e-08
included O 0 8.217227787099546e-09
at O 0 1.2960006756657094e-07
least O 0 3.133139969691001e-09
from O 0 3.8398795254579454e-09
the O 0 2.284451205980531e-08
promoter O 0 8.627907277514169e-07
region O 0 4.996690563530137e-07
of O 0 9.777792911336292e-06
Hp O 0 7.475307211279869e-05
to O 0 3.667123849027121e-08
Hpr O 0 2.0339970433269627e-05
alpha O 0 9.307893833465641e-07
but O 0 2.03665861953084e-09
not O 0 1.2403625904156002e-09
to O 0 1.4034958084607752e-08
Hpr O 0 1.2198445801914204e-05
beta O 0 3.0002322546351934e-06
( O 0 4.4371354590566625e-08
Hpdel O 0 6.106001364969416e-06
) O 0 3.263573944423115e-08
. O 0 4.337293546541332e-08

In O 0 4.560015725019184e-07
addition O 0 5.698927552089117e-08
, O 0 4.5061137043944655e-09
we O 0 8.344671620363897e-09
found O 0 6.046454004149382e-09
seven O 0 6.928249085547122e-09
individuals O 0 7.861129525110755e-10
with O 0 8.881005375549478e-10
hypohaptoglobinemia B-Disease 0 1.7983680891120457e-06
in O 0 2.3649741720532802e-08
three O 0 5.789674073497508e-09
families O 0 2.16606088621063e-09
, O 0 8.059640177471294e-10
and O 0 1.0456022714322444e-09
the O 0 7.256024758817148e-08
genotypes O 0 2.0504407416410686e-07
of O 0 1.018454014456438e-07
six O 0 6.418471798497194e-08
of O 0 4.607101899978261e-08
the O 0 2.5936387260117044e-08
seven O 0 2.104454743800943e-08
individuals O 0 5.013114368068727e-10
were O 0 3.657719460647968e-09
found O 0 1.1383032294531858e-09
to O 0 3.5138258969169556e-09
be O 0 9.505990306024614e-08
Hp2 O 0 0.01983376406133175
/ O 0 0.001640940667130053
Hpdel O 0 0.007466058246791363
. O 0 3.890605967171723e-06

The O 0 3.4580195915623335e-06
phenotypes O 0 3.855466275126673e-06
and O 0 2.361521289628854e-08
genotypes O 0 6.62082641156303e-07
in O 0 2.0108213760750004e-08
one O 0 4.63058658084492e-09
of O 0 7.290245296331932e-09
these O 0 6.959555709507015e-10
three O 0 3.2707758723660163e-09
families O 0 2.2148323175485984e-09
showed O 0 1.938307825355423e-08
the O 0 1.9474535761787592e-08
father O 0 1.8826007419647794e-07
to O 0 2.8376170746469143e-08
be O 0 6.819200137897496e-08
hypohaptoglobinemic B-Disease 0 8.838580470182933e-06
( O 0 1.0214207435410572e-07
Hp2 O 0 3.5461496281641303e-06
) O 0 9.128645395151125e-09
and O 0 8.089213743289747e-09
Hp2 O 0 0.0002268031967105344
/ O 0 2.015439713431988e-05
Hpdel O 0 0.00021615704463329166
, O 0 3.669152803809084e-08
the O 0 9.978052872838816e-08
mother O 0 1.921411296734732e-07
to O 0 1.1258642906852856e-08
be O 0 1.3335128556946074e-08
Hp2 O 0 3.4743659398372984e-06
- O 0 2.450445322210726e-07
1 O 0 1.0654533610932049e-07
and O 0 7.77113484673464e-09
Hp1 O 0 0.00010101640509674326
/ O 0 3.2003124488255708e-06
Hp2 O 0 3.2099724194267765e-05
, O 0 4.19081347402539e-09
one O 0 1.3626770822838807e-09
of O 0 3.009400950659824e-09
the O 0 5.2309534481764786e-09
two O 0 1.0049399090661382e-09
children O 0 1.0742554623632827e-09
to O 0 3.794166758552819e-09
be O 0 2.175278090987831e-08
hypohaptoglobinemic B-Disease 0 3.339398972457275e-06
( O 0 6.486233417035692e-08
Hp2 O 0 6.609864158235723e-06
) O 0 6.617251635532284e-09
and O 0 3.974751194846249e-09
Hp2 O 0 0.0001522907114122063
/ O 0 1.2047928976244293e-05
Hpdel O 0 0.00022845830244477838
, O 0 8.178184351947948e-09
and O 0 1.2048773090356235e-09
the O 0 9.717541438192256e-09
other O 0 1.2162186813213793e-09
child O 0 6.693325449447229e-09
to O 0 3.2581985998092478e-09
be O 0 1.21524532659123e-08
Hp1 O 0 1.707186493149493e-05
and O 0 1.0080027834646899e-07
Hp1 O 1 0.9502606391906738
/ O 0 0.0007260933634825051
Hpdel O 0 0.0015971580287441611
, O 0 2.269277565858374e-08
showing O 0 9.0734999957931e-08
an O 0 1.104336533330752e-08
anomalous O 0 3.266048224759288e-06
inheritance O 0 4.207966867397772e-06
of O 0 2.308382318005897e-05
Hp O 0 0.001344411401078105
phenotypes O 0 6.640517540290602e-07
in O 0 2.089169370833588e-08
the O 0 5.776749389951874e-08
child O 0 3.168001114772778e-07
with O 0 7.435708226921633e-08
Hp1 O 1 0.9715893268585205
. O 0 4.006106337328674e-06

The O 0 6.466850754804909e-05
Hp2 O 1 0.9994871616363525
/ O 0 0.10736799240112305
Hpdel O 0 0.09070334583520889
individuals O 0 5.5433471146670854e-08
had O 0 8.169488552312032e-08
an O 0 1.1767962604380955e-08
extremely O 0 8.388271766079924e-08
low O 0 3.557405534593272e-07
level O 0 1.4659631233371329e-06
of O 0 3.150418308450753e-07
Hp O 0 1.2643720310734352e-06
( O 0 1.3817411659289291e-09
mean O 0 8.833791476092756e-09
+ O 0 1.1090543594605151e-08
/ O 0 4.3451824360829505e-09
- O 0 5.140944114856438e-09
SD O 0 8.240287030503168e-08
= O 0 5.517132528609636e-09
0 O 0 2.335769910821739e-10
. O 0 3.1208324119402775e-11
049 O 0 7.993157247199179e-09
+ O 0 2.3237378687923638e-09
/ O 0 1.1031129343308521e-09
- O 0 1.2182361786017282e-09
0 O 0 3.9959416331392106e-10
. O 0 1.0139269285280861e-10
043 O 0 5.478880638065675e-08
mg O 0 1.44931853185426e-08
/ O 0 5.0855781807968015e-09
ml O 0 3.283088911842924e-09
; O 0 7.691160208711523e-11
n O 0 7.745785346457978e-09
= O 0 7.544708857665228e-09
6 O 0 2.7921576162270867e-09
) O 0 1.0301335479079299e-10
, O 0 9.390822147681277e-11
compared O 0 4.625305694005988e-10
with O 0 7.008907343397652e-11
the O 0 8.040804466702411e-09
level O 0 1.4845181794953533e-07
( O 0 6.328848001224685e-10
1 O 0 8.667950246454836e-10
. O 0 3.568306067291971e-11
64 O 0 8.805021711744132e-10
+ O 0 1.5190457780533961e-09
/ O 0 1.0871775701914999e-09
- O 0 1.2869175725072068e-09
1 O 0 2.4162725154042164e-09
. O 0 1.7955212316955738e-10
07 O 0 5.217425069758974e-08
mg O 0 7.753297381896118e-08
/ O 0 1.7119965889378363e-08
ml O 0 9.514803167576247e-09
) O 0 4.5573482487792916e-11
obtained O 0 8.883190849573452e-10
from O 0 6.957524556483463e-10
52 O 0 1.3009660015939062e-08
healthy O 0 2.2962197476772417e-08
volunteers O 0 2.1721850984590674e-08
having O 0 1.3950332800050091e-07
phenotype O 0 4.973358045390341e-07
Hp2 O 0 7.580811143270694e-06
, O 0 8.089753755768925e-09
whereas O 0 4.713263024314074e-08
the O 0 2.922894459800318e-08
serum O 0 2.9787784114887472e-06
Hp O 0 4.9034770199796185e-06
level O 0 3.595242503706686e-07
of O 0 2.1377868364425012e-08
an O 0 2.7956585935129397e-09
individual O 0 2.7780326927739907e-09
with O 0 5.7240345796572e-09
Hp1 O 0 0.0002533947117626667
/ O 0 1.42907765621203e-05
Hpdel O 0 4.2140578443650156e-05
was O 0 1.885940832835331e-06
0 O 0 1.5466960689991538e-07
. O 0 2.476855343047646e-08

50 O 0 3.13234340865165e-06
mg O 0 3.2477537388331257e-06
/ O 0 2.006065415116609e-06
ml O 0 6.770559934921039e-07
, O 0 8.654287841913799e-10
which O 0 9.368781445084906e-11
was O 0 4.375738438255894e-09
approximately O 0 1.780530056727514e-09
half O 0 1.7607331148639105e-09
the O 0 1.1493319185262862e-08
level O 0 9.967825462808833e-07
of O 0 4.603715808570996e-07
Hp O 0 5.474735189636704e-06
in O 0 5.028892502423332e-08
control O 0 8.61882824665372e-07
sera O 0 1.643546966079157e-05
from O 0 3.822672312026043e-08
the O 0 9.696586289464904e-08
Hp1 O 0 1.1625976185314357e-05
phenotype O 0 5.835876137894047e-08
( O 0 1.7154638820571222e-09
1 O 0 2.582357883085251e-09
. O 0 2.3950455507737445e-10
26 O 0 9.250320509579524e-09
+ O 0 1.0733138822160981e-08
/ O 0 4.348208459958869e-09
- O 0 2.69379962780647e-09
0 O 0 3.8231059984461524e-10
. O 0 3.594365777237485e-11
33 O 0 1.2876100186076656e-09
mg O 0 7.620696074184252e-09
/ O 0 3.4985516705887676e-09
ml O 0 3.2092759560953255e-09
; O 0 9.256011235247996e-11
n O 0 6.393287677042281e-09
= O 0 1.2338837507286371e-08
9 O 0 2.705833779259592e-09
) O 0 2.5158480854159393e-10
, O 0 1.0285295531931027e-10
showing O 0 1.0670635930409844e-08
a O 0 2.1522700066611833e-08
gene O 0 3.064766662674856e-09
- O 0 2.1794644311512457e-08
dosage O 0 2.6149888299187296e-07
effect O 0 2.5197698505508015e-07
. O 0 2.402634891041089e-07

The O 0 9.860992804533453e-07
other O 0 2.893830952643839e-09
allele O 0 2.376087770983304e-08
( O 0 1.6253409285127418e-08
Hp2 O 0 3.3387048006261466e-06
) O 0 6.115044914878354e-09
of O 0 7.904676913028652e-09
individuals O 0 4.058978930743251e-09
with O 0 1.0273915052039229e-08
Hp2 O 1 0.9999864101409912
/ O 0 0.03381351754069328
Hpdel O 0 0.002190792467445135
was O 0 5.590501359620248e-07
found O 0 3.913412260914129e-09
to O 0 7.634600729389263e-10
have O 0 1.4062918884949482e-10
, O 0 2.209936122987699e-10
in O 0 1.5317660473357364e-09
all O 0 4.190877422871608e-09
exons O 0 2.090979123181569e-08
, O 0 2.266939275186175e-10
no O 0 7.337825902453687e-10
mutation O 0 6.222815318590591e-11
, O 0 4.213684609566393e-11
by O 0 4.4718895253481605e-10
DNA O 0 3.247751578783209e-08
sequencing O 0 7.147632885562416e-08
. O 0 1.0058766974907485e-07

On O 0 1.2200038099763333e-06
the O 0 6.350837367108397e-08
basis O 0 3.6622736843128223e-07
of O 0 3.7726639590118793e-08
the O 0 1.1457030879569174e-08
present O 0 1.5562864774665286e-08
study O 0 2.651567143630018e-08
, O 0 4.957044774656083e-10
the O 0 1.6488364007472e-09
mechanism O 0 1.1017093726195526e-07
of O 0 7.531886581091385e-08
anhaptoglobinemia B-Disease 0 6.061738531570882e-06
and O 0 2.5793061020351615e-09
the O 0 1.444026143104793e-08
mechanism O 0 3.773477601498598e-07
of O 0 8.558089348298381e-08
anomalous O 0 8.508027349307667e-06
inheritance O 0 4.564015398500487e-06
of O 0 1.396921925334027e-05
Hp O 0 0.00022175587946549058
phenotypes O 0 5.566528784584079e-07
were O 0 5.709589956381933e-08
well O 0 4.238145834278839e-08
explained O 0 1.2055879778927192e-06
. O 0 5.633364708046429e-07

However O 0 2.2334345430863323e-06
, O 0 2.3780737379297534e-08
the O 0 1.8245986055376306e-08
mechanism O 0 1.38067707666778e-06
of O 0 3.2670732252881862e-06
hypohaptoglobinemia B-Disease 0 0.007047970313578844
remains O 0 0.00010523210221435875
unknown O 0 0.0007236188976094127

ATM O 0 0.000213006540434435
mutations O 0 9.415298762860402e-08
and O 0 1.9981358789777914e-08
phenotypes O 0 2.525226364014088e-06
in O 0 1.847633939178195e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
families O 0 3.410154386074282e-05
in O 0 7.649212818705564e-08
the O 0 1.2420788664257998e-07
British O 0 7.72857333686261e-07
Isles O 0 2.3308161871682387e-06
: O 0 2.9344449092860714e-09
expression O 0 5.8564242344516515e-09
of O 0 6.237746763559926e-09
mutant O 0 1.2261655513157166e-07
ATM O 0 1.7915995158546139e-06
and O 0 1.1173472147518737e-09
the O 0 7.335577034695007e-09
risk O 0 4.527758079575506e-08
of O 0 7.076685619722412e-07
leukemia B-Disease 1 1.0
, O 0 0.3240567147731781
lymphoma B-Disease 1 1.0
, O 0 0.000149140803841874
and O 0 4.365960921859369e-05
breast B-Disease 1 1.0
cancer I-Disease 1 0.9998733997344971
. O 0 2.7748228603741154e-06

We O 0 8.056233582465211e-07
report O 0 1.896711268045692e-07
the O 0 1.3374330087856379e-08
spectrum O 0 2.9681984869966982e-08
of O 0 1.1279862377477912e-07
59 O 0 2.1743960587627953e-06
ATM O 0 1.723058448988013e-05
mutations O 0 1.0530359695337665e-08
observed O 0 6.520393469600094e-08
in O 0 1.5107473245734582e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9984867572784424
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
) O 0 4.6230343997422096e-08
patients O 0 5.236204358993746e-09
in O 0 2.0593615701614e-09
the O 0 1.1921797238301224e-07
British O 0 9.71138524619164e-06
Isles O 0 8.51962249726057e-05
. O 0 6.636219040956348e-07

Of O 0 5.901446456846315e-06
51 O 0 2.4757205210335087e-06
ATM O 0 1.4794805792917032e-05
mutations O 0 1.895510060023753e-08
identified O 0 2.939443000116171e-08
in O 0 2.4604085879786908e-08
families O 0 1.6270094604919905e-08
native O 0 1.6483999942806804e-08
to O 0 1.1551405165732831e-08
the O 0 1.7413671571375744e-07
British O 0 4.40893472841708e-06
Isles O 0 1.841724952100776e-05
, O 0 6.1614779944818565e-09
11 O 0 4.093938343885384e-08
were O 0 1.5861219893054113e-08
founder O 0 8.611696671323443e-07
mutations O 0 2.3655322145543778e-09
, O 0 6.268036645273867e-10
and O 0 9.476582851775106e-10
2 O 0 9.231253272901085e-08
of O 0 2.164298606999182e-08
these O 0 2.3082549205355463e-09
11 O 0 3.901191547583949e-08
conferred O 0 3.3781386576947625e-08
a O 0 4.439283607382549e-09
milder O 0 2.0128003708208553e-09
clinical O 0 2.0611153672689397e-08
phenotype O 0 2.575226032419664e-09
with O 0 5.170222930339641e-11
respect O 0 1.4315914009799258e-09
to O 0 1.0395575067434493e-08
both O 0 2.7534682089935814e-07
cerebellar B-Disease 1 1.0
degeneration I-Disease 1 1.0
and O 0 4.0011974533626926e-07
cellular O 0 1.3504438356903847e-05
features O 0 8.456930231659499e-07
. O 0 3.890721984589618e-07

We O 0 1.0250073501083534e-06
report O 0 2.0637122588595957e-07
, O 0 4.2899830354770074e-09
in O 0 1.1432123692145524e-08
two O 0 2.3959481509905345e-08
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.7440490126609802
T I-Disease 1 0.9999982118606567
families O 0 1.2472287203024734e-08
, O 0 1.856465536853591e-09
an O 0 5.125220692292487e-09
ATM O 0 4.816800469598093e-07
mutation O 0 6.337810831702484e-10
( O 0 3.983568197529763e-10
7271T O 0 5.810427694541431e-09
- O 0 1.7332643764689237e-08
- O 0 1.4507297407817532e-07
> O 0 2.7647195111057954e-07
G O 0 1.8506567300846655e-07
) O 0 6.236220984057184e-10
that O 0 4.5086368666291676e-11
may O 0 2.5918803214786124e-10
be O 0 4.387085139612168e-10
associated O 0 4.650936080707879e-09
with O 0 6.805612323690369e-11
an O 0 9.675036327649877e-10
increased O 0 3.531456238548003e-09
risk O 0 8.39235312355413e-08
of O 0 1.0429157555336133e-06
breast B-Disease 0 0.19139364361763
cancer I-Disease 0 5.3796129577676766e-06
in O 0 4.929443164769509e-08
both O 0 2.3674292748410153e-08
homozygotes O 0 2.5503650249447674e-06
and O 0 3.413664018125928e-09
heterozygotes O 0 2.57963307603859e-07
( O 0 1.7706275334816723e-09
relative O 0 2.6164350686030957e-08
risk O 0 6.783341888194627e-09
12 O 0 1.3947101251687855e-09
. O 0 7.687039199621992e-11
7 O 0 3.1763849328569904e-09
; O 0 2.6076935055741046e-10
P O 0 7.895530984569632e-07
= O 0 5.8953162351826904e-08
. O 0 6.351327797027295e-10
0025 O 0 3.498167302495858e-07
) O 0 2.5997676234013056e-10
, O 0 3.35300225084989e-11
although O 0 7.855370520726268e-11
there O 0 8.893804026577357e-10
is O 0 1.2513695635263389e-09
a O 0 7.66989671774354e-09
less O 0 2.297888990199226e-08
severe O 0 7.106312750693178e-06
A B-Disease 1 1.0
- I-Disease 1 0.9999992847442627
T I-Disease 1 0.9999995231628418
phenotype O 0 1.2408700911237247e-07
in O 0 1.276393768456785e-09
terms O 0 7.677654068061202e-09
of O 0 9.315245463881183e-09
the O 0 7.417177982915746e-09
degree O 0 7.3573792178649455e-06
of O 0 3.7789768612128682e-06
cerebellar B-Disease 1 0.9999995231628418
degeneration I-Disease 1 1.0
. O 0 1.643222617531137e-06

This O 0 1.0277289419491353e-07
mutation O 0 3.5574978518582157e-09
( O 0 1.5837480216163158e-09
7271T O 0 2.4576552348776204e-08
- O 0 6.430995824757701e-08
- O 0 1.3926525355145714e-07
> O 0 2.0873436312740523e-07
G O 0 8.780544646924682e-08
) O 0 3.249297220175862e-10
also O 0 5.1323174876660715e-11
allows O 0 6.705407062934654e-11
expression O 0 1.6478931552654785e-09
of O 0 4.802482411747633e-09
full O 0 6.11605059930298e-08
- O 0 2.412293440556823e-07
length O 0 1.7444887134843157e-07
ATM O 0 4.556547992251581e-06
protein O 0 4.9813419167321626e-08
at O 0 2.0678330159284997e-08
a O 0 7.193611484268558e-09
level O 0 3.672786874631129e-08
comparable O 0 3.9129510298607784e-08
with O 0 1.5479156845188413e-10
that O 0 3.3406072352804017e-10
in O 0 5.2841215847365675e-09
unaffected O 0 4.592678521930793e-07
individuals O 0 8.028880671417937e-09
. O 0 5.750190723574633e-08

In O 0 3.2529970894756843e-07
addition O 0 3.184922547916358e-08
, O 0 5.885808285199801e-09
we O 0 8.794988737292897e-09
have O 0 1.0976790587591267e-09
studied O 0 1.0594004606900853e-07
18 O 0 2.6942896056425525e-06
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 3.239461676685096e-08
, O 0 4.4341869065434025e-10
in O 0 9.487832741683633e-10
15 O 0 4.896642202822932e-09
families O 0 7.095520837552272e-10
, O 0 2.451987501927988e-10
who O 0 1.2725021036885664e-09
developed O 0 5.489894761012692e-07
leukemia B-Disease 1 1.0
, O 0 0.0016204346902668476
lymphoma B-Disease 1 1.0
, O 0 4.403279672260396e-05
preleukemic O 1 0.9999995231628418
T O 1 0.9992501139640808
- O 0 0.0005943733849562705
cell O 0 0.0009497227729298174
proliferation O 0 0.09407712519168854
, O 0 8.170828635911676e-08
or O 0 0.0018338669324293733
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 5.284865096655267e-07
mostly O 0 1.1215224304805815e-07
in O 0 1.0279171647198382e-07
childhood O 0 0.00016120282816700637
. O 0 1.4292180594566162e-06

A O 0 3.977498636231758e-06
wide O 0 4.217244864435088e-08
variety O 0 9.718227111932265e-09
of O 0 1.6884895615021378e-07
ATM O 0 1.5742802133900113e-05
mutation O 0 2.381676633689267e-09
types O 0 2.6956343823769657e-09
, O 0 8.689171604459034e-10
including O 0 2.9412472457579497e-09
missense O 0 2.848378244380001e-06
mutations O 0 2.1662520666154705e-08
and O 0 1.1180897097062825e-08
in O 0 5.588848352999776e-07
- O 0 9.46775071497541e-06
frame O 0 0.00016195404168684036
deletions O 0 2.712080231503933e-07
, O 0 5.322904783611193e-09
were O 0 2.4180305757681708e-08
seen O 0 3.445246576916361e-08
in O 0 2.604628068780812e-09
these O 0 3.736626119632547e-09
patients O 0 1.7133132246271998e-08
. O 0 1.0421965157547675e-07

We O 0 1.6791755115264095e-06
also O 0 4.279181808897192e-08
show O 0 2.771323437400497e-08
that O 0 5.544938397328281e-10
25 O 0 1.4209392773523177e-08
% O 0 3.2911267044966053e-09
of O 0 1.2336013988090144e-08
all O 0 5.1735653983087104e-08
A B-Disease 1 1.0
- I-Disease 1 0.9999994039535522
T I-Disease 1 1.0
patients O 0 2.818478961330584e-08
carried O 0 1.8451208561032217e-08
in O 0 5.639821409886281e-08
- O 0 1.128831513597106e-06
frame O 0 1.4338584151118994e-05
deletions O 0 3.5397533793002367e-07
or O 0 4.668304498522957e-08
missense O 0 4.1859067323457566e-07
mutations O 0 5.40291411610383e-09
, O 0 1.1128552523942403e-09
many O 0 3.171649054500847e-10
of O 0 1.3832633705135322e-08
which O 0 9.940849254874706e-10
were O 0 6.7980554518953795e-09
also O 0 7.192907935937853e-10
associated O 0 5.8161493399211395e-09
with O 0 4.904042727460478e-10
expression O 0 4.35338876059177e-08
of O 0 1.8654577615961898e-07
mutant O 0 8.416074592787481e-07
ATM O 0 1.3548025890486315e-05
protein O 0 2.3680215122112713e-07
. O 0 4.264930453246052e-08

The O 0 7.131874554033857e-06
DMPK O 0 0.00224553095176816
gene O 0 4.2403493694109784e-07
of O 0 4.909925337415189e-07
severely O 0 0.23348349332809448
affected O 0 0.0015248175477609038
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.0033882195129990578
is O 0 2.6038444289611107e-08
hypermethylated O 0 1.2164266991021577e-05
proximal O 0 3.963026756537147e-06
to O 0 1.4844581563977499e-08
the O 0 7.440787896939582e-08
largely O 0 1.2741586488118628e-06
expanded O 0 9.342095950160001e-07
CTG O 0 0.0004055741592310369
repeat O 0 5.276271167531377e-06
. O 0 3.9495506598541397e-07

Using O 0 1.5871953564783325e-06
methylation O 0 1.4066441735849367e-06
- O 0 1.403289161316934e-06
sensitive O 0 1.314559767706669e-06
restriction O 0 9.715191140458046e-08
enzymes O 0 4.093155592244102e-09
, O 0 1.1413773259860704e-09
we O 0 3.0549385243716642e-09
characterized O 0 2.5159176075817413e-08
the O 0 1.3738265636220603e-08
methylation O 0 1.3593736980510585e-07
pattern O 0 1.5472774350655527e-07
on O 0 5.332032770866135e-08
the O 0 2.975226998103153e-08
5 O 0 2.3719220365592264e-08
side O 0 1.0089583390993084e-08
of O 0 8.577782040219972e-08
the O 0 3.5757111049861123e-07
CTG O 0 0.0007835243013687432
repeat O 0 1.2167341765234596e-06
in O 0 2.8868477386367886e-08
the O 0 4.102943762518407e-08
DMPK O 0 4.785502460435964e-05
gene O 0 4.1501579950420364e-09
of O 0 4.680240195398255e-09
normal O 0 5.928671598098845e-08
individuals O 0 1.770113500221271e-10
and O 0 2.341560001450915e-10
of O 0 3.416206340034478e-08
patients O 0 4.862766544988517e-08
affected O 0 5.064662644826967e-08
with O 0 4.474982517876924e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 8.368819415238704e-09
showing O 0 1.4661454272868468e-08
expansions O 0 1.5601262504105762e-08
of O 0 5.6133111492329135e-09
the O 0 1.3790668162982911e-08
repetitive O 0 8.099296451291593e-07
sequence O 0 7.496486205127439e-07
. O 0 1.7829854925821564e-07

The O 0 1.759258907441108e-06
gene O 0 5.834807836890832e-08
segment O 0 5.704484706825497e-08
analyzed O 0 4.9889010256265465e-08
corresponds O 0 3.1882407824923575e-08
to O 0 4.259684160956567e-09
the O 0 4.186932400784826e-08
genomic O 0 1.9962176338594873e-06
SacI O 0 0.0003379304544068873
- O 0 9.023000302477158e-07
HindIII O 0 7.981809176271781e-06
fragment O 0 3.041585614482756e-07
carrying O 0 3.923009828099566e-08
exons O 0 5.439790484729201e-08
11 O 0 9.985114957089536e-08
- O 0 8.406467344457269e-08
15 O 0 1.598183274609255e-07
. O 0 1.3561728451350064e-07

There O 0 1.158728309746948e-06
is O 0 4.4726274239792474e-08
constitutive O 0 3.135514134555706e-06
methylation O 0 1.3675673926627496e-06
in O 0 2.0804755251901952e-07
intron O 0 7.933443157526199e-06
12 O 0 2.497006050816708e-07
at O 0 1.3721066238758794e-07
restriction O 0 1.0536467698329943e-08
sites O 0 1.3612854843358946e-08
of O 0 2.6916181283809237e-08
SacII O 0 6.752093668183079e-06
and O 0 2.5732338926331977e-08
HhaI O 0 3.0778446671320125e-05
, O 0 8.398546746946067e-09
localized O 0 2.9792246891702234e-08
1 O 0 1.2149556916085658e-08
, O 0 1.514479930353474e-10
159 O 0 1.915878344860289e-09
- O 0 2.881477056959625e-09
1 O 0 7.97476129577035e-09
, O 0 5.787242352006672e-10
232 O 0 2.065483606372709e-08
bp O 0 2.9651383215423266e-07
upstream O 0 5.435517209662066e-07
of O 0 7.197168372385931e-08
the O 0 3.60538507493402e-07
CTG O 0 0.00030839157989248633
repeat O 0 3.67625972330643e-07
, O 0 2.174381119601776e-09
whereas O 0 7.031905724375065e-09
most O 0 3.5954236810020745e-10
, O 0 8.133514695085609e-11
if O 0 3.318424979248391e-10
not O 0 5.620410803430786e-10
all O 0 1.5744834325204238e-09
, O 0 1.2297620699541767e-09
of O 0 1.4244887047709653e-08
the O 0 1.4877233667220935e-08
other O 0 8.725775657580925e-10
sites O 0 2.6026429011949404e-08
of O 0 1.200432819814523e-07
SacII O 0 9.561346814734861e-05
, O 0 4.365412564766302e-08
HhaI O 0 6.102502811700106e-05
, O 0 1.3549287025682588e-08
and O 0 9.286737601144068e-09
HpaII O 0 4.2523643060121685e-05
in O 0 9.841619963424364e-09
this O 0 1.9760693081849467e-09
region O 0 1.1425846047075083e-08
are O 0 8.044512278537752e-10
unmethylated O 0 1.3915853287471691e-06
, O 0 4.886584914487457e-09
in O 0 7.684188396694935e-09
normal O 0 1.954414585725317e-07
individuals O 0 1.426810114502075e-09
and O 0 8.638209036959665e-10
most O 0 8.201627155202118e-10
of O 0 6.2652190102596705e-09
the O 0 1.0971190533837216e-07
patients O 0 3.6208490428180085e-08
. O 0 8.498570736037436e-08

In O 0 1.1644833648460917e-06
a O 0 5.7567969946603625e-08
number O 0 3.989151231564847e-09
of O 0 8.358450820367125e-09
young O 0 9.941422796089228e-09
and O 0 5.186544971280682e-09
severely O 0 1.4534534784615971e-05
affected O 0 4.902064887346569e-08
patients O 0 2.54545673428197e-09
, O 0 2.2987590997392005e-10
however O 0 2.2345079120356104e-09
, O 0 4.731127711821159e-10
complete O 0 2.1608297373632013e-08
methylation O 0 5.4323667342259796e-08
of O 0 1.2510073865712457e-08
these O 0 7.650781674861662e-10
restriction O 0 1.3607196258647036e-08
sites O 0 3.559771588612648e-09
was O 0 1.1662672605439184e-08
found O 0 1.2312217911869539e-09
in O 0 2.9058389028335796e-09
the O 0 1.992290599162061e-08
mutated O 0 3.2499265500973706e-08
allele O 0 3.164353046258839e-08
. O 0 8.133247320074588e-08

In O 0 4.840132987737888e-07
most O 0 2.3371349300305155e-09
of O 0 2.523269371224046e-09
these O 0 7.942727031640118e-10
patients O 0 3.5815994614551983e-09
, O 0 3.0599989209179057e-10
the O 0 1.3411984411959565e-08
onset O 0 0.0003291260509286076
of O 0 2.440503976686159e-06
the O 0 1.0793033652589656e-05
disease O 1 0.9999512434005737
was O 1 0.9995585083961487
congenital O 1 1.0
. O 0 2.8430240490706638e-06

Preliminary O 0 9.330253305961378e-06
in O 0 6.695440788462292e-07
vivo O 0 7.024194928817451e-05
footprinting O 0 0.00031363798188976943
data O 0 1.561493263579905e-07
gave O 0 7.735008189513337e-09
evidence O 0 1.299636576135299e-08
for O 0 1.7252158590608246e-09
protein O 0 3.192652542338692e-08
- O 0 5.259730073703395e-08
DNA O 0 6.793366225110731e-08
contact O 0 3.366731391452049e-07
in O 0 1.1554247336675871e-08
normal O 0 5.700176757272857e-07
genes O 0 9.507945541997742e-09
at O 0 6.756254578021981e-08
an O 0 1.4601035935868367e-08
Sp1 O 0 1.507491788288462e-06
consensus O 0 2.2448512382311492e-08
binding O 0 9.695749980664914e-09
site O 0 5.2812222151032984e-08
upstream O 0 1.1569049007675858e-07
of O 0 3.251886226962597e-08
the O 0 1.9776072690547153e-07
CTG O 0 0.000546111143194139
repeat O 0 3.689202117129753e-07
and O 0 3.0880147328105068e-09
for O 0 1.7183260370146058e-09
a O 0 7.220347875147581e-09
significant O 0 5.053138352195674e-09
reduction O 0 1.6868213492671202e-08
of O 0 2.0404934630846583e-08
this O 0 3.7408978137420945e-09
interaction O 0 3.9538385010473576e-08
in O 0 5.6300275552700896e-09
cells O 0 4.721430357790268e-09
with O 0 9.255328170532096e-10
a O 0 1.9000370343746908e-07
hypermethylated O 0 2.437534749333281e-05
DMPK O 0 0.00011741652997443452
gene O 0 4.416735421841622e-08
. O 0 6.400010299500991e-09
. O 0 4.945905729414335e-08

The O 0 0.0004434285219758749
hemochromatosis B-Disease 1 1.0
gene O 0 1.8227067357656779e-06
product O 0 1.3166057044600166e-07
complexes O 0 1.8896662368206307e-07
with O 0 3.960629602062227e-09
the O 0 2.8442693178476475e-07
transferrin O 0 6.178968033054844e-05
receptor O 0 7.021367309789639e-07
and O 0 1.5851351342632825e-09
lowers O 0 2.853247593748165e-08
its O 0 8.113577587565146e-10
affinity O 0 5.802830216339316e-09
for O 0 2.7925783907534196e-09
ligand O 0 2.4314732627317426e-07
binding O 0 1.2082809064395406e-07
. O 0 1.322128042602344e-07

We O 0 5.11170037498232e-06
recently O 0 1.2224566035001772e-06
reported O 0 3.0344526180670073e-07
the O 0 3.131361125952026e-08
positional O 0 2.5591381813683256e-07
cloning O 0 6.848423339533838e-08
of O 0 1.8619061847857665e-08
a O 0 7.620830899668363e-08
candidate O 0 5.211099818325238e-08
gene O 0 6.660966533900137e-08
for O 0 3.092571887464146e-06
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 1 1.0
HFE O 1 1.0
. O 0 6.700814992655069e-06

The O 0 1.3068996622678242e-06
gene O 0 5.662402458028737e-08
product O 0 2.357039541323047e-08
, O 0 3.755675326289065e-09
a O 0 4.43579857289933e-08
member O 0 7.671348356552699e-08
of O 0 3.629174045727268e-07
the O 0 3.035207782886573e-07
major O 0 1.3909085510022123e-06
histocompatibility O 0 3.809554982581176e-05
complex O 0 0.01367354579269886
class O 0 1.1288850146229379e-05
I O 0 3.166509486618452e-05
- O 0 2.6342522687627934e-06
like O 0 4.794650365624875e-08
family O 0 1.922617371974411e-07
, O 0 3.982081331344034e-09
was O 0 2.2249790276873682e-07
found O 0 8.159533493312665e-09
to O 0 5.648140177783034e-09
have O 0 1.5696528521402797e-09
a O 0 9.536496037299003e-09
mutation O 0 8.346354163357717e-10
, O 0 1.8943524526804367e-09
Cys O 0 4.1556600081094075e-06
- O 0 5.674251610798819e-07
282 O 0 9.593948107067263e-07
- O 0 1.3831402156938566e-06
- O 0 1.8195856910097064e-06
> O 0 7.163498025875015e-07
Tyr O 0 1.6870936860868824e-06
( O 0 3.0416009710876324e-09
C282Y O 0 2.6415468923346452e-08
) O 0 1.3790338315722295e-10
, O 0 4.940127820707296e-11
in O 0 3.3115266084848827e-10
85 O 0 2.166070167675116e-08
% O 0 3.474604604036813e-09
of O 0 1.6370327315939903e-08
patient O 0 2.289212801542817e-07
chromosomes O 0 1.439785819457029e-07
. O 0 4.961183108775913e-08

This O 0 2.0314770665663673e-07
mutation O 0 2.513510111157302e-08
eliminates O 0 1.170779881931594e-07
the O 0 4.2377333642207304e-08
ability O 0 9.70034079728066e-08
of O 0 1.955118705154746e-06
HFE O 0 0.05036391690373421
to O 0 1.8547822833170358e-07
associate O 0 3.4913921354018385e-06
with O 0 1.8807519097663317e-08
beta2 O 0 0.0001644204749027267
- O 0 5.4201940656639636e-05
microglobulin O 0 0.00011677962174871936
( O 0 1.2736541066260543e-07
beta2m O 0 2.964107807201799e-06
) O 0 6.828933418745464e-09
and O 0 2.1666517469043356e-09
prevents O 0 8.460949629807146e-08
cell O 0 7.358143648161786e-06
- O 0 1.531803945908905e-06
surface O 0 1.840183358581271e-05
expression O 0 9.219521416525822e-06
. O 0 5.798241318188957e-07

A O 0 2.2571517547476105e-05
second O 0 4.0894752828535275e-07
mutation O 0 1.2391714321324798e-08
that O 0 1.5801965291828424e-09
has O 0 1.0484300094759647e-09
no O 0 4.276095477706576e-09
effect O 0 2.5532868264122044e-08
on O 0 1.877388910997979e-07
beta2m O 0 2.6429828722029924e-05
association O 0 3.615739103679516e-07
, O 0 2.8228258841522802e-08
H63D O 0 0.000556837534531951
, O 0 2.0965300606690107e-08
was O 0 2.650104136137088e-07
found O 0 7.365958953897689e-09
in O 0 2.1603754341015247e-09
eight O 0 5.388320900578947e-09
out O 0 1.018493955839972e-09
of O 0 8.824764918813344e-09
nine O 0 7.077753139128617e-08
patients O 0 2.909288143726485e-09
heterozygous O 0 3.0989657506808044e-09
for O 0 1.316948550211805e-09
the O 0 7.867887319434885e-08
C282Y O 0 8.739208169572521e-06
mutant O 0 7.593502687086584e-06
. O 0 3.863928839109576e-07

In O 0 2.7060269758294453e-07
this O 0 8.023798514500413e-09
report O 0 1.649740077880324e-08
, O 0 4.244160023425536e-10
we O 0 5.805406710912564e-10
demonstrate O 0 1.219880729763645e-08
in O 0 7.296991899607974e-09
cultured O 0 3.4067133469761757e-07
293 O 0 4.4218523953531985e-07
cells O 0 6.407365304994528e-08
overexpressing O 0 1.8145135527447565e-06
wild O 0 2.2005670174962688e-08
- O 0 1.0673959138784994e-07
type O 0 2.8609295554815617e-07
or O 0 4.744895676367378e-08
mutant O 0 1.4268700851971516e-06
HFE O 0 0.00011111066851299256
proteins O 0 1.979222563619487e-09
that O 0 1.6072186637128283e-10
both O 0 1.519253750581484e-10
the O 0 2.180976954591074e-09
wild O 0 1.9056455968780028e-08
- O 0 2.122006748095373e-07
type O 0 2.810459704960522e-07
and O 0 8.01754467261162e-08
H63D O 1 0.9264830350875854
HFE O 0 0.0022781898733228445
proteins O 0 2.770858387179942e-08
form O 0 8.02724287041201e-09
stable O 0 3.124040631519165e-06
complexes O 0 5.888000842446672e-08
with O 0 1.7123452655809501e-09
the O 0 1.927623998199124e-07
transferrin O 0 3.998899046564475e-05
receptor O 0 4.6350082811841276e-06
( O 0 5.716356810125944e-08
TfR O 0 1.2387905371724628e-05
) O 0 9.700207748153389e-09
. O 0 2.364613216343514e-08

The O 0 5.032442004448967e-06
C282Y O 0 1.2648432857531589e-05
mutation O 0 3.9234887339034685e-08
nearly O 0 6.342884262267035e-08
completely O 0 2.0589233429291198e-07
prevents O 0 2.285488420739057e-08
the O 0 1.4015376414988623e-08
association O 0 1.9310824939111626e-08
of O 0 6.021620180263199e-08
the O 0 3.2275406169901544e-07
mutant O 0 7.102924882929074e-06
HFE O 0 0.00023105878790374845
protein O 0 5.2825928520405796e-08
with O 0 1.818725725577508e-09
the O 0 2.983694571412343e-07
TfR O 0 0.008518436923623085
. O 0 5.115983867653995e-07

Studies O 0 4.5346550905378535e-05
on O 0 2.015251993725542e-06
cell O 0 1.1228093171666842e-05
- O 0 7.901127787590667e-07
associated O 0 3.756548210276378e-07
transferrin O 0 5.864782451681094e-06
at O 0 2.623334012241685e-07
37 O 0 5.582382556212906e-08
degrees O 0 5.067242341283418e-07
C O 0 5.587047553490265e-07
suggest O 0 6.331000612647131e-09
that O 0 1.3747294969057577e-10
the O 0 7.533148327354411e-09
overexpressed O 0 1.525295147075667e-06
wild O 0 9.345984608444269e-08
- O 0 2.619501628942089e-07
type O 0 3.3645460462139454e-07
HFE O 0 4.2277115426259115e-05
protein O 0 5.945748426938735e-08
decreases O 0 1.3117548824936875e-08
the O 0 1.0773826275567444e-09
affinity O 0 4.682115140042242e-09
of O 0 1.0017369156400946e-08
the O 0 3.769384093743611e-08
TfR O 0 6.378484977176413e-05
for O 0 1.7677939112559216e-08
transferrin O 0 1.4274975001171697e-05
. O 0 2.3363656964647816e-07

The O 0 3.4143296943511814e-05
overexpressed O 0 0.2025732547044754
H63D O 0 0.20954376459121704
protein O 0 2.14102851714415e-06
does O 0 2.8759810088985205e-09
not O 0 4.2727671401010525e-10
have O 0 9.047340654433356e-11
this O 0 1.1638128655233615e-10
effect O 0 3.784799140760242e-09
, O 0 1.1021664692023592e-09
providing O 0 5.756508159038276e-09
the O 0 2.830242928908433e-09
first O 0 2.2101227514781385e-09
direct O 0 3.6454614882330816e-09
evidence O 0 4.4597108228572324e-09
for O 0 4.978838452629475e-10
a O 0 8.289055664079115e-09
functional O 0 2.5558213678777975e-07
consequence O 0 3.093968246048462e-07
of O 0 7.587717476553735e-08
the O 0 1.71763787193413e-07
H63D O 0 0.00027878585387952626
mutation O 0 1.279978647517055e-07
. O 0 7.70019781271003e-08

Addition O 0 1.1586907930905e-06
of O 0 6.554290621352266e-07
soluble O 0 3.533153403623146e-06
wild O 0 7.498530862903863e-07
- O 0 3.507048313622363e-05
type O 0 0.0008369783172383904
HFE O 1 1.0
/ O 1 0.9928687214851379
beta2m O 0 0.00026434267056174576
heterodimers O 0 1.3519257663574535e-05
to O 0 5.9200267799042194e-08
cultured O 0 5.186060661799274e-06
cells O 0 1.2185255116037297e-07
also O 0 2.853463687557678e-09
decreased O 0 1.125776663002398e-07
the O 0 6.209399661116777e-09
apparent O 0 3.3708527524822784e-08
affinity O 0 1.843502595022528e-08
of O 0 2.1658886240061292e-08
the O 0 5.9281060060811797e-08
TfR O 0 1.5104510566743556e-05
for O 0 9.226808761475525e-10
its O 0 1.186966858135463e-09
ligand O 0 1.7230298965387192e-08
under O 0 1.2815343453098649e-08
steady O 0 3.082742978222086e-06
- O 0 8.018994357428255e-09
state O 0 1.0612885015248708e-09
conditions O 0 6.4540208732921656e-09
, O 0 3.3321817527465214e-10
both O 0 4.2090600449462556e-10
in O 0 1.911447222724405e-09
293 O 0 3.135556525535321e-08
cells O 0 3.0462570244083054e-09
and O 0 1.290102691342554e-09
in O 0 7.240996779955822e-08
HeLa O 0 0.0004325786721892655
cells O 0 7.071322443152894e-07
. O 0 7.110755717576467e-08

Furthermore O 0 6.513037078548223e-06
, O 0 3.480429811020258e-08
at O 0 1.5678111253691895e-07
4 O 0 6.626019199984512e-08
degrees O 0 1.012902657748782e-06
C O 0 1.6046769815147854e-06
, O 0 8.345049651303782e-10
the O 0 7.510007726807544e-09
added O 0 3.527567216110583e-08
soluble O 0 4.1092334868153557e-07
complex O 0 4.143074363582855e-07
of O 0 8.646069318274385e-07
HFE O 1 0.9995775818824768
/ O 0 0.0002881332766264677
beta2m O 0 2.3909662559162825e-05
inhibited O 0 4.298282192394254e-07
binding O 0 1.3737635917721036e-08
of O 0 4.412533627373705e-08
transferrin O 0 5.619244348054053e-06
to O 0 2.6458513957550167e-07
HeLa O 0 0.007423181552439928
cell O 0 4.875306331086904e-05
TfR O 0 0.00013653587666340172
in O 0 4.676991682828202e-09
a O 0 1.1932962173943906e-08
concentration O 0 9.671364750829525e-06
- O 0 1.774551208200137e-07
dependent O 0 2.4504242901457474e-07
manner O 0 2.3720627950751805e-07
. O 0 8.777078619459644e-08

Scatchard O 0 0.0007374309352599084
plots O 0 2.6423037979839137e-06
of O 0 9.96989086843314e-08
these O 0 3.568793260910752e-09
data O 0 1.3943868282240146e-07
indicate O 0 2.2992743708982744e-08
that O 0 5.246118539581346e-10
the O 0 1.01623962578401e-08
added O 0 5.7504976780364814e-08
heterodimer O 0 5.59091688501212e-07
substantially O 0 3.1538867517610925e-08
reduced O 0 1.0335827305141265e-08
the O 0 5.84022696870079e-09
affinity O 0 8.326042433282055e-08
of O 0 4.917366709378257e-07
TfR O 0 0.0003027935163117945
for O 0 2.80214180747862e-07
transferrin O 0 0.00015532426186837256
. O 0 8.78922151059669e-07

These O 0 1.0219663693078473e-07
results O 0 8.669248074966163e-08
establish O 0 2.406891326245386e-07
a O 0 1.0723627497100097e-07
molecular O 0 1.176318164652912e-06
link O 0 1.366386186418822e-06
between O 0 2.829246739111113e-07
HFE O 1 0.7448041439056396
and O 0 2.8728736722882786e-08
a O 0 1.6516170830982446e-07
key O 0 3.4118144753847446e-07
protein O 0 6.953126785447239e-08
involved O 0 4.0649158705718946e-08
in O 0 2.7024363191685552e-08
iron O 0 0.00010900682536885142
transport O 0 2.8735355954268016e-05
, O 0 1.2598052023804485e-07
the O 0 3.0104818051768234e-06
TfR O 1 0.9999873638153076
, O 0 1.1797628651777359e-08
and O 0 1.937272120500211e-09
raise O 0 3.1669010525092745e-08
the O 0 1.2871145926851568e-08
possibility O 0 5.4908902313854924e-08
that O 0 1.5559709076740091e-09
alterations O 0 6.752685521860258e-08
in O 0 5.773265421282758e-09
this O 0 2.337932958340616e-09
regulatory O 0 6.140081154626387e-08
mechanism O 0 2.7550808567866625e-07
may O 0 2.076492400249208e-08
play O 0 5.1494261299467325e-08
a O 0 7.981764582609685e-08
role O 0 1.485254585986695e-07
in O 0 5.7491270410992e-08
the O 0 5.675333909493929e-07
pathogenesis O 1 0.9999880790710449
of O 1 0.9999949932098389
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.002219113055616617
. O 0 2.0912159470753977e-06

Genomic O 0 1.6311661966028623e-05
organization O 0 5.622152912110323e-07
of O 0 6.981724709476111e-07
the O 0 1.8082722590406775e-06
UBE3A O 0 0.017333613708615303
/ O 0 3.481449675746262e-05
E6 O 0 2.245829364255769e-06
- O 0 5.962220370747673e-07
AP O 0 8.74912348081125e-06
gene O 0 4.404719700090709e-09
and O 0 5.958094018154725e-10
related O 0 9.287094826504472e-08
pseudogenes O 0 2.6505865662329597e-06
. O 0 2.6766696237245924e-07

The O 0 1.9827277355943806e-05
UBE3A O 0 0.0014390763826668262
gene O 0 8.846708396959002e-07
encodes O 0 2.0839166836594814e-07
the O 0 5.43439782063615e-08
E6 O 0 8.747294373279146e-07
- O 0 5.848032742505893e-07
AP O 0 4.310837175580673e-05
ubiquitin O 0 2.7240480449108873e-06
- O 0 1.4475318721451913e-06
protein O 0 2.2613841110796784e-07
ligase O 0 3.9879364521766547e-07
and O 0 7.137616719887774e-09
has O 0 4.129714348266589e-09
recently O 0 1.4321766883540477e-08
been O 0 5.547141412876044e-09
shown O 0 2.251367758887568e-09
to O 0 6.539244146175349e-10
be O 0 1.968688101428029e-09
mutated O 0 4.828717692362261e-08
in O 0 3.4927177239296725e-06
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.9754499197006226
who O 0 1.7398134843915614e-07
lack O 0 5.7388471759622917e-05
15q11 O 0 0.0001839747856138274
- O 0 3.8261499867076054e-05
q13 O 0 4.030015770695172e-05
deletions O 0 1.989772727029049e-06
or O 0 3.8931381141082966e-07
chromosome O 0 1.9500464532029582e-06
15 O 0 1.993305204450735e-06
paternal O 0 0.004530469886958599
uniparental B-Disease 1 0.9999969005584717
disomy I-Disease 1 0.8096311688423157
. O 0 5.835197043779772e-06

Previous O 0 9.821903222473338e-05
UBE3A O 0 0.001198523328639567
cDNA O 0 2.5055149308172986e-05
analysis O 0 2.660752613792283e-07
has O 0 3.8833555815465104e-10
shown O 0 2.451806313530369e-09
a O 0 1.3920000263567545e-08
coding O 0 2.0301678205214557e-07
region O 0 1.9248679095085208e-08
of O 0 6.681720776668953e-08
approximately O 0 3.5250218388682697e-07
2 O 0 1.8641842416400323e-06
. O 0 2.029188408414484e-07

6 O 0 5.3570660384139046e-05
kb O 0 0.0001243302394868806
and O 0 6.589633017028973e-08
a O 0 2.239388692260036e-07
3 O 0 5.388199610933952e-07
- O 0 5.425459335128835e-07
untranslated O 0 5.7000244851224124e-05
region O 0 4.730316049972316e-07
( O 0 6.470885693943274e-08
UTR O 0 1.0628371455823071e-05
) O 0 3.513638491270399e-09
of O 0 2.336191329277426e-08
< O 0 5.825166908834944e-07
50 O 0 3.253219915677619e-08
bp O 0 1.2276480276796065e-07
, O 0 1.6402511571200762e-09
whereas O 0 1.1857546056148749e-08
Northern O 0 4.268714448585342e-08
analysis O 0 2.556083877891524e-08
has O 0 2.163318274517323e-10
indicated O 0 9.06714259230057e-10
mRNA O 0 4.1320937782529654e-09
sizes O 0 1.9069026357954044e-09
of O 0 2.1321712395661052e-08
5 O 0 9.26819652136146e-08
- O 0 2.061149331211709e-07
8 O 0 1.0188945225308998e-06
kb O 0 4.848081880481914e-05
. O 0 2.8548598152156046e-07

We O 0 2.066065434291886e-07
have O 0 6.214728731634978e-10
analyzed O 0 9.810396051079806e-09
additional O 0 1.1799068388995693e-08
cDNA O 0 7.175716518759145e-07
clones O 0 1.9814670793039113e-08
and O 0 9.92470272631607e-11
provide O 0 3.081200017351904e-10
evidence O 0 8.350212077345986e-09
for O 0 3.6170078043795684e-10
an O 0 1.4597714148578689e-09
additional O 0 1.2193991594244835e-08
0 O 0 1.0808538064566164e-07
. O 0 5.2436629260910195e-08

5 O 0 1.9960536519647576e-05
kb O 0 7.427918171742931e-05
of O 0 1.4084321264817845e-06
5 O 0 1.171923145193432e-06
- O 0 1.1796591934398748e-06
UTR O 0 5.15768988407217e-05
and O 0 2.992688408198774e-08
> O 0 1.2512370517470117e-07
2 O 0 5.334717911864573e-08
kb O 0 2.6862028335017385e-06
of O 0 2.2880297478877765e-07
3 O 0 1.7248355561605422e-06
- O 0 3.90855393561651e-06
UTR O 0 0.00034145108656957746
. O 0 3.00254271223821e-07

We O 0 1.2588988056450034e-06
have O 0 1.4178367813144632e-08
established O 0 4.162217237535515e-08
the O 0 1.682627903676348e-08
genomic O 0 1.287616129275193e-07
organization O 0 6.651280415326255e-08
of O 0 1.6406093550358491e-07
UBE3A O 0 0.00010476712486706674
and O 0 9.386712740422354e-09
the O 0 2.1578312470182937e-08
sequence O 0 1.2834465223932057e-07
of O 0 4.0038960946731095e-07
intron O 0 2.3052454707794823e-05
- O 0 8.294416147691663e-06
exon O 0 3.875592938129557e-06
borders O 0 1.1970455204846076e-07
. O 0 1.8186993600011192e-07

We O 0 3.0411033549171407e-06
have O 0 1.1639383679096227e-08
also O 0 2.952466049421787e-09
mapped O 0 2.528903131349125e-08
two O 0 1.4490249000687072e-09
highly O 0 1.4445220131165115e-08
homologous O 0 1.7160177279151867e-08
processed O 0 3.503347656419464e-08
pseudogenes O 0 4.693799837696133e-07
, O 0 1.1925021858871787e-08
UBE3AP1 O 0 4.6635690523544326e-05
and O 0 5.171079209276286e-08
UBE3AP2 O 0 0.007455666549503803
, O 0 2.3223787337656177e-08
to O 0 5.666991764741169e-09
chromosomes O 0 1.0630008873135921e-08
2 O 0 9.91816495599096e-09
and O 0 5.509873668430032e-10
21 O 0 7.759744846680405e-09
, O 0 3.851019225731278e-10
respectively O 0 7.098069243482996e-09
, O 0 4.865786107366432e-10
and O 0 4.902939165774001e-10
determined O 0 1.233013247059489e-08
their O 0 6.190691959062633e-09
genomic O 0 2.193079779999607e-07
organization O 0 8.498845716076175e-08
. O 0 1.062148058394996e-07

These O 0 1.9552852847937174e-07
results O 0 2.732618042955437e-08
will O 0 3.9984118793690016e-10
form O 0 2.3256432890583767e-10
the O 0 8.449895227968796e-10
basis O 0 1.0959432472645858e-08
for O 0 2.0813001322395053e-10
studies O 0 2.0624315588690934e-09
of O 0 1.6994410323434295e-09
mutation O 0 7.444840854908819e-10
and O 0 8.464412504238794e-10
imprinting O 0 1.9662293198052794e-06
of O 0 2.7160738227394177e-06
UBE3A O 0 0.2111765593290329
. O 0 1.1921334817088791e-06

Mutation O 0 5.477944569065585e-07
spectrum O 0 1.3290468814375345e-07
and O 0 1.4823191563095861e-08
genotype O 0 8.161185292010487e-07
- O 0 8.75785360676673e-07
phenotype O 0 1.4924519575743034e-07
analyses O 0 1.7539974805913516e-07
in O 0 2.3551878669536563e-08
Cowden B-Disease 1 0.9975851774215698
disease I-Disease 0 0.00015658825577702373
and O 0 1.3721694358537206e-07
Bannayan B-Disease 1 1.0
- I-Disease 1 1.0
Zonana I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 1.607112842805236e-08
two O 0 4.7919627377268625e-08
hamartoma B-Disease 1 0.961978554725647
syndromes I-Disease 0 0.0001335979759460315
with O 0 9.770901669980958e-07
germline O 1 0.9999985694885254
PTEN O 1 0.9998282194137573
mutation O 0 2.3145332761487225e-06
. O 0 4.6679087972734123e-07

The O 0 0.0002131542278220877
tumour B-Disease 1 1.0
suppressor O 1 0.9950571060180664
gene O 0 5.0382236622681376e-06
PTEN O 0 3.736875805770978e-05
, O 0 3.590559849442343e-09
which O 0 9.62818602623372e-10
maps O 0 7.239795252189651e-08
to O 0 5.318168661005984e-08
10q23 O 0 5.248989327810705e-05
. O 0 2.698509206311428e-06

3 O 0 1.3540148984247935e-06
and O 0 1.8842275295583022e-08
encodes O 0 8.739375090272006e-08
a O 0 1.2837410245936098e-08
403 O 0 1.5743010450819384e-08
amino O 0 1.184895470629499e-08
acid O 0 3.429851602732015e-08
dual O 0 5.983478672533238e-07
specificity O 0 6.188640782056609e-07
phosphatase O 0 0.006568342447280884
( O 0 3.547171161244478e-07
protein O 0 7.019526151452737e-07
tyrosine O 0 8.270706643997983e-07
phosphatase O 0 2.659783604030963e-06
; O 0 1.9140520279847806e-09
PTPase O 0 1.5751892306070658e-06
) O 0 3.533733528016114e-09
, O 0 5.987531581652661e-10
was O 0 5.2505281900039336e-08
shown O 0 1.7585859879432064e-08
recently O 0 1.1745292738396529e-08
to O 0 2.9001467893863264e-09
play O 0 4.537379894031801e-08
a O 0 4.48093580018849e-08
broad O 0 1.3533634657392213e-08
role O 0 4.38564207172476e-08
in O 0 6.248406947406693e-08
human O 0 3.609320629038848e-07
malignancy B-Disease 0 0.00035265961196273565
. O 0 5.277909735923458e-07

Somatic O 0 0.003343698102980852
PTEN O 0 0.0016518591437488794
deletions O 0 3.557429124612099e-07
and O 0 3.981139418129942e-09
mutations O 0 3.790029179384646e-09
were O 0 4.061550207268283e-09
observed O 0 9.454237392958476e-09
in O 0 1.7593977830188123e-08
sporadic B-Disease 0 0.0005610513035207987
breast I-Disease 1 0.8010958433151245
, I-Disease 0 1.8500579699320951e-06
brain I-Disease 1 1.0
, I-Disease 0 1.2455914657039102e-05
prostate I-Disease 1 0.9999998807907104
and I-Disease 1 0.9903456568717957
kidney I-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 1 1.0
lines O 0 3.6950862067897106e-06
and O 0 3.805276982404848e-09
in O 0 9.546105239621738e-09
several O 0 2.2021289680651535e-08
primary O 1 0.6822999715805054
tumours B-Disease 1 1.0
such O 0 5.277174608409041e-08
as O 0 0.0008272475097328424
endometrial B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 1 0.9999961853027344
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 1.0
thyroid B-Disease 1 1.0
tumours I-Disease 1 1.0
. O 0 0.0012394489021971822

In O 0 1.225568553309131e-06
addition O 0 6.124070068835863e-07
, O 0 2.009817450243645e-07
PTEN O 0 0.0002851245808415115
was O 0 2.2251360576319712e-07
identified O 0 2.2711221348004074e-08
as O 0 9.706476733484237e-10
the O 0 2.6692548171780572e-09
susceptibility O 0 2.7955643133736885e-08
gene O 0 1.4533343417610922e-09
for O 0 2.1866417565519214e-09
two O 0 1.9472869894343603e-07
hamartoma B-Disease 1 1.0
syndromes I-Disease 1 0.9999994039535522
Cowden B-Disease 1 1.0
disease I-Disease 1 0.9999874830245972
( O 0 3.584560772651457e-07
CD B-Disease 0 1.4839755749562755e-05
; O 0 4.8825441467670316e-08
MIM O 0 0.0003449023643042892
158350 O 0 6.482574917754391e-06
) O 0 8.765180581349341e-09
and O 0 7.958076864156283e-09
Bannayan B-Disease 0 0.0006623882800340652
- I-Disease 0 0.001106408890336752
Zonana I-Disease 1 0.9956367611885071
( I-Disease 0 1.5222856291075004e-06
BZS I-Disease 0 0.0010604413691908121
) I-Disease 0 3.3189408554790134e-08
or I-Disease 0 1.0618742329882025e-08
Ruvalcaba I-Disease 0 7.156101673899684e-06
- I-Disease 0 4.278241249267012e-06
Riley I-Disease 0 3.581280543585308e-05
- I-Disease 0 0.15440018475055695
Smith I-Disease 1 0.9225600361824036
syndrome I-Disease 1 1.0
( O 0 2.6477762730792165e-05
MIM O 1 0.999842643737793
153480 O 0 0.0011359492782503366
) O 0 4.30015205665768e-07
. O 0 2.9571802429018135e-07

Constitutive O 0 5.709664401365444e-05
DNA O 0 1.3129347280482762e-06
from O 0 4.5509441548574614e-08
37 O 0 1.127792543798023e-07
CD B-Disease 0 7.434176154674788e-07
families O 0 2.00573713193819e-09
and O 0 1.5924626062258085e-09
seven O 0 1.638889131072574e-07
BZS B-Disease 0 0.003723158733919263
families O 0 9.478901219495128e-09
was O 0 7.271944468811853e-08
screened O 0 8.389055494717468e-08
for O 0 1.2355408784969768e-07
germline O 0 0.0008420964586548507
PTEN O 0 0.002670795191079378
mutations O 0 1.6286850268443231e-06
. O 0 3.94361876487892e-07

PTEN O 0 0.010951878502964973
mutations O 0 4.2454843196537695e-07
were O 0 2.1231848279512633e-07
identified O 0 1.255979640291116e-07
in O 0 2.8235476179361285e-08
30 O 0 5.6122541280956284e-08
of O 0 5.505309275122272e-08
37 O 0 3.4500597934084e-08
( O 0 1.8739583218518874e-09
81 O 0 1.4063416209353363e-08
% O 0 5.945016701147665e-10
) O 0 1.4518514168671004e-10
CD B-Disease 0 2.1131427274667658e-08
families O 0 5.304516825788141e-10
, O 0 1.8600017359649001e-10
including O 0 1.2733275545073752e-09
missense O 0 6.606930469388317e-07
and O 0 2.145470467951327e-08
nonsense O 0 6.911344371474115e-06
point O 0 6.461432349169627e-07
mutations O 0 8.780155269505485e-09
, O 0 6.890370496392961e-10
deletions O 0 1.529889281925989e-08
, O 0 3.5654592611678027e-09
insertions O 0 1.420156792164562e-07
, O 0 4.8162971388876485e-09
a O 0 1.8306978688542586e-07
deletion O 0 1.8339111420573317e-06
/ O 0 9.754192433319986e-06
insertion O 0 1.8858113435271662e-06
and O 0 1.719557047863418e-07
splice O 0 6.82887839502655e-05
site O 0 9.378191862197127e-06
mutations O 0 6.49218634407589e-07
. O 0 9.198620318784378e-07

These O 0 1.1969164859237935e-07
mutations O 0 5.247744994107961e-08
were O 0 7.533409984716855e-08
scattered O 0 9.996110605925423e-08
over O 0 2.0829304503422463e-08
the O 0 7.028475579318183e-08
entire O 0 5.058165584159724e-07
length O 0 2.3033923923776456e-07
of O 0 3.895117686170124e-07
PTEN O 0 1.1766899660869967e-05
, O 0 1.8229419085358245e-09
with O 0 2.825893685720615e-10
the O 0 1.6110444533978807e-08
exception O 0 3.427653894050309e-08
of O 0 2.516330610546902e-08
the O 0 2.2576038816168875e-08
first O 0 5.0001990103965e-08
, O 0 4.981348666888152e-09
fourth O 0 6.425827905331971e-07
and O 0 4.190256319702712e-08
last O 0 1.2298256706344546e-06
exons O 0 5.578025138675002e-06
. O 0 4.7123822355388256e-07

A O 0 6.55019175610505e-05
hot O 0 6.100088285165839e-06
spot O 0 1.1931525705222157e-06
for O 0 6.323593026991148e-08
PTEN O 0 1.997275830945e-05
mutation O 0 1.0473632627849838e-08
in O 0 9.649057552962859e-09
CD B-Disease 0 1.6891834775378811e-06
was O 0 5.307508104124281e-07
identified O 0 7.196413776000554e-08
in O 0 2.6687674292702468e-08
exon O 0 1.4074826992782619e-07
5 O 0 1.0343281786617808e-08
that O 0 1.8463194861872978e-10
contains O 0 3.768246159552291e-09
the O 0 3.785480018336784e-08
PTPase O 0 0.0001186806257464923
core O 0 2.0239027435309254e-05
motif O 0 6.27128883934347e-07
, O 0 1.385623282779136e-09
with O 0 1.8255714995252248e-10
13 O 0 1.1112056164108708e-08
of O 0 1.565005014469989e-08
30 O 0 2.0626568897341713e-08
( O 0 1.172771324498001e-09
43 O 0 4.002046249951263e-09
% O 0 5.033167216339507e-10
) O 0 2.392411269092065e-10
CD B-Disease 0 1.5922022811309944e-08
mutations O 0 2.3109453239911204e-10
identified O 0 1.5705272637944745e-09
in O 0 4.4870485105263924e-09
this O 0 3.887346267106295e-08
exon O 0 2.3562156457046513e-06
. O 0 3.575472646843991e-07

Seven O 0 1.1308656212349888e-05
of O 0 2.244510369564523e-06
30 O 0 5.302140380081255e-07
( O 0 1.697821971902158e-08
23 O 0 5.7293679134318154e-08
% O 0 3.75966058285826e-09
) O 0 2.529696452313601e-10
were O 0 1.0136006478589366e-09
within O 0 6.678354314004764e-09
the O 0 3.5598887393462064e-08
core O 0 1.388459622830851e-06
motif O 0 1.5057059954415308e-07
, O 0 6.358407134143818e-10
the O 0 3.125356862199169e-09
majority O 0 4.872027226099362e-10
( O 0 7.715966199306479e-10
five O 0 1.44398137891244e-09
of O 0 9.25444965105271e-09
seven O 0 2.6987121870547526e-08
) O 0 1.3986873881322026e-09
of O 0 3.1206868200683857e-09
which O 0 7.525762235616185e-10
were O 0 1.4658601443784391e-08
missense O 0 7.997481361599057e-07
mutations O 0 1.3589766645338841e-08
, O 0 5.2052953058989715e-09
possibly O 0 5.200217856327072e-07
pointing O 0 3.5578366350819124e-06
to O 0 1.3207300142425993e-08
the O 0 8.694650688312322e-08
functional O 0 4.179562893114053e-06
significance O 0 9.97804022517812e-07
of O 0 2.1739597855230386e-07
this O 0 3.5471938275577486e-08
region O 0 6.68245945689705e-07
. O 0 4.921683398606547e-07

Germline O 1 0.9999547004699707
PTEN O 0 0.018780134618282318
mutations O 0 3.2919859904723126e-07
were O 0 5.528301372237365e-08
identified O 0 2.4159099609732948e-08
in O 0 5.715329098876509e-09
four O 0 6.955497955374312e-09
of O 0 7.377730781854552e-08
seven O 0 5.5661260489614506e-08
( O 0 1.9580836507770982e-08
57 O 0 1.4672131953830103e-07
% O 0 3.5904310635714864e-08
) O 0 2.8929163065072316e-08
BZS B-Disease 0 0.0008228064398281276
families O 0 3.562354322639294e-08
studied O 0 1.8270942518938682e-06
. O 0 4.965737048223673e-07

Interestingly O 0 1.639928996155504e-05
, O 0 1.8127215284380327e-08
none O 0 3.7974121624984036e-08
of O 0 2.1163131691537274e-08
these O 0 3.5183864710575108e-09
mutations O 0 1.3632601714164139e-08
was O 0 3.8130022517179896e-07
observed O 0 1.2784805392129783e-07
in O 0 7.745818209059507e-08
the O 0 1.296786194870947e-06
PTPase O 0 0.44440722465515137
core O 0 0.0004569758311845362
motif O 0 1.9119981516269036e-05
. O 0 3.5318495861247357e-07

It O 0 2.8138927632426203e-07
is O 0 2.5381568846682967e-08
also O 0 3.27609561701081e-09
worthy O 0 4.9492836495801384e-08
of O 0 8.899242232018878e-08
note O 0 2.0345287055079098e-07
that O 0 2.0479864470956954e-09
a O 0 3.546301030610266e-08
single O 0 6.04115371061198e-08
nonsense O 0 1.376483055537392e-06
point O 0 3.1176426773527055e-07
mutation O 0 3.767297585000051e-09
, O 0 9.903643460873468e-10
R233X O 0 3.4063037901432835e-07
, O 0 7.377277899678347e-09
was O 0 1.5349817772403185e-07
observed O 0 3.793039837773904e-08
in O 0 5.463411945072494e-09
the O 0 1.8451418171139267e-08
germline O 0 9.349226388621901e-07
DNA O 0 4.595675306973135e-08
from O 0 5.2464113053929395e-09
two O 0 2.2269557309329002e-09
unrelated O 0 1.57360076968871e-07
CD B-Disease 0 1.5645207440684317e-06
families O 0 8.47693826244722e-09
and O 0 1.0198669464500654e-08
one O 0 5.160650289326441e-07
BZS B-Disease 0 0.4881104528903961
family O 0 8.986178727354854e-06
. O 0 1.1248961300225346e-06

Genotype O 0 7.582423859275877e-05
- O 0 5.161268290976295e-06
phenotype O 0 2.3790498460130038e-07
studies O 0 8.436407483713992e-08
were O 0 7.835774695763575e-09
not O 0 1.7099105464879472e-09
performed O 0 1.2522607839571265e-08
on O 0 1.1631216878527084e-08
this O 0 1.6039181094384958e-09
small O 0 7.252908496013788e-09
group O 0 2.1560788709962253e-08
of O 0 5.674164640367962e-07
BZS B-Disease 1 0.9998025298118591
families O 0 1.2996536042919615e-06
. O 0 8.935161872614117e-07

However O 0 4.157418231898191e-07
, O 0 2.1187201326711147e-08
genotype O 0 3.802246624218242e-07
- O 0 2.207091398531702e-07
phenotype O 0 1.1410605083028713e-07
analysis O 0 7.269295565492939e-08
inthe O 0 2.600891775728087e-06
group O 0 4.612658699443273e-08
of O 0 1.5672624442686356e-07
CD B-Disease 0 4.689385968958959e-05
families O 0 6.394738960580071e-09
revealed O 0 2.982960367603482e-08
two O 0 1.053967801922795e-09
possible O 0 3.6991278928866222e-09
associations O 0 4.138735576475483e-09
worthy O 0 6.424889420486579e-08
of O 0 4.948056542275481e-08
follow O 0 3.929914882405683e-08
- O 0 5.849371476074339e-08
up O 0 1.847667085996818e-08
in O 0 7.092466614011528e-09
independent O 0 1.0099984848466192e-07
analyses O 0 1.2532688060673536e-06
. O 0 1.6558438176161872e-07

The O 0 7.471850494766841e-06
first O 0 9.676398349256488e-07
was O 0 3.3089493172155926e-06
an O 0 1.4183999041961215e-07
association O 0 1.094320651873204e-07
noted O 0 6.016878728587471e-08
in O 0 2.4158270051088948e-08
the O 0 6.180972178526645e-08
group O 0 2.2450610259738824e-08
of O 0 1.9027878295219125e-07
CD B-Disease 0 5.515692464541644e-05
families O 0 1.7958276643526006e-08
with O 0 5.929191715381421e-08
breast B-Disease 1 0.9516792297363281
disease I-Disease 0 0.02508990466594696
. O 0 9.413544717062905e-07

A O 0 1.4565242963726632e-05
correlation O 0 1.5556681773887249e-06
was O 0 9.448868354411388e-08
observed O 0 4.693515354148303e-09
between O 0 1.99043981297109e-09
the O 0 1.8371281385043403e-08
presence O 0 8.954629748814114e-08
/ O 0 1.320801402471261e-06
absence O 0 2.253766950843783e-07
of O 0 2.776562268991256e-07
a O 0 7.158751600400137e-07
PTEN O 0 1.0364884474256542e-05
mutation O 0 5.927240920300392e-10
and O 0 5.7191175406590133e-11
the O 0 4.237203921064747e-10
type O 0 1.2977565688743198e-08
of O 0 1.6106396572013182e-07
breast O 0 3.4959619370056316e-05
involvement O 0 0.0009775703074410558
( O 0 8.203870152101445e-07
unaffected O 0 1.1625354090938345e-05
versus O 0 1.62979013111908e-05
benign O 0 0.00018274311150889844
versus O 0 1.9737117327167653e-05
malignant O 0 0.0002126990439137444
) O 0 7.428153026012296e-08
. O 0 1.1087057316672144e-07

Specifically O 0 9.563601679474232e-07
and O 0 9.774348441737857e-09
more O 0 1.1356574569632016e-09
directly O 0 3.183707519838208e-08
, O 0 4.299312905686747e-09
an O 0 2.0545918744119263e-08
association O 0 1.1882250561257024e-07
was O 0 1.1080711601607618e-06
also O 0 5.623802312726411e-09
observed O 0 1.1727138371497858e-08
between O 0 4.475996018271644e-09
the O 0 4.272157738682836e-09
presence O 0 9.132651079823972e-09
of O 0 7.862861650664854e-08
a O 0 5.347217779672064e-07
PTEN O 0 0.0017292695119976997
mutation O 0 1.547918060396114e-07
and O 0 1.2320063547122118e-07
malignant B-Disease 1 1.0
breast I-Disease 1 1.0
disease I-Disease 1 0.9999995231628418
. O 0 9.50549804201728e-07

Secondly O 0 0.0006699691293761134
, O 0 1.4358258226820908e-07
there O 0 3.5294849709543996e-08
appeared O 0 1.0763113778011757e-07
to O 0 3.863527719971671e-09
be O 0 1.1280007150560323e-08
an O 0 5.032317673681064e-08
interdependent O 0 5.257701559457928e-06
association O 0 3.110229940261888e-08
between O 0 1.5425385413436743e-08
mutations O 0 2.1292615670631676e-08
upstream O 0 6.565024932569941e-07
and O 0 1.053646170312561e-09
within O 0 9.469219719449029e-08
the O 0 2.400060736817977e-07
PTPase O 0 0.12044459581375122
core O 0 3.060041490243748e-05
motif O 0 8.794856398708362e-07
, O 0 1.4269516679377148e-09
the O 0 7.925434530875464e-09
core O 0 2.6898737814917695e-07
motif O 0 2.4340780058196287e-08
containing O 0 1.0363874203278556e-09
the O 0 1.8050886341214323e-09
majority O 0 4.764852401528685e-10
of O 0 1.894982304406767e-08
missense O 0 4.0993580796566675e-07
mutations O 0 3.3970106727565508e-09
, O 0 4.967512512443761e-10
and O 0 4.2878375849930705e-10
the O 0 1.8727764228287924e-08
involvement O 0 4.567101257180184e-07
of O 0 3.2697303709028347e-07
all O 0 1.0949403161930604e-08
major O 0 3.0798318562119675e-07
organ O 1 0.7307588458061218
systems O 1 0.9222890138626099
( O 0 3.279796146671288e-05
central O 1 0.9999791383743286
nervous O 1 0.9999948740005493
system O 0 0.00975219439715147
, O 0 9.438256256544264e-07
thyroid O 1 1.0
, O 0 0.00016560681979171932
breast O 1 1.0
, O 0 9.258765931008384e-05
skin O 1 0.9999998807907104
and O 1 0.8886280655860901
gastrointestinal O 1 1.0
tract O 1 1.0
) O 0 2.781399234663695e-05
. O 0 1.8721925698628183e-06

However O 0 1.0033700164058246e-06
, O 0 1.3716638491700905e-08
these O 0 1.846056196797008e-09
observations O 0 3.687056846501946e-07
would O 0 7.534225687777507e-09
need O 0 2.5235257439248926e-08
to O 0 8.779535320968535e-09
be O 0 4.658136099067178e-09
confirmed O 0 3.727926856100794e-09
by O 0 1.8175050353619326e-09
studying O 0 6.7135808023977e-08
a O 0 7.302519478002978e-09
larger O 0 8.262974193762318e-10
number O 0 1.1217866635604423e-09
of O 0 6.663620322200359e-09
CD B-Disease 0 1.709333105281985e-06
families O 0 3.552529292960571e-08
. O 0 9.0082657777657e-08

Molecular O 1 0.9999958276748657
defects O 1 0.9999902248382568
leading O 0 2.395186356807244e-06
to O 0 1.1695753698859335e-08
human O 0 7.590815442881649e-08
complement B-Disease 0 2.8845013730460778e-05
component I-Disease 1 1.0
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 3.7604945646307897e-07
an O 0 2.859632886043073e-08
African O 0 5.824055619996216e-07
- O 0 8.747210813453421e-07
American O 0 9.08041386082914e-07
family O 0 7.437367912643822e-07
. O 0 1.1502589813972008e-07

Complement B-Disease 0 0.0005372794694267213
component I-Disease 1 0.9999998807907104
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 1.1227889444853645e-05
C6D B-Disease 0 0.06512240320444107
) O 0 4.431274547300745e-08
was O 0 6.370892151608132e-07
diagnosed O 0 2.9374933774306555e-07
in O 0 2.269277565858374e-08
a O 0 1.3930285547303356e-07
16 O 0 8.302507836788209e-08
- O 0 1.6664571944602358e-08
year O 0 1.2631950596642127e-08
- O 0 4.169686462773825e-08
old O 0 4.938166853207804e-07
African O 0 1.7295775478487485e-06
- O 0 6.833632824054803e-07
American O 0 6.802364538316397e-08
male O 0 6.185592926755135e-09
with O 0 1.2080758615695686e-09
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 6.258610483200755e-07

The O 0 7.380238912446657e-06
patients O 0 5.192046046431642e-07
father O 0 4.810754603568057e-07
and O 0 4.9847155736415516e-08
two O 0 9.781663123931139e-08
brothers O 0 2.1165540601941757e-05
also O 0 1.7950800668131706e-07
had O 0 9.776139222594793e-07
C6D B-Disease 0 0.07836854457855225
, O 0 2.2246387842983495e-08
but O 0 3.2310922826184196e-09
gave O 0 3.2383990600237667e-08
no O 0 8.051685540522158e-09
history O 0 6.25285352384708e-08
of O 0 7.556074024250847e-07
meningitis B-Disease 1 0.9999998807907104
or O 0 3.4347237942711217e-06
other O 0 1.4530031933190912e-07
neisserial B-Disease 1 0.9993218183517456
infection I-Disease 1 0.7064833641052246
. O 0 1.915391749207629e-06

By O 0 3.358406956976978e-07
using O 0 8.306436427574226e-08
exon O 0 1.7446251376895816e-07
- O 0 9.865676275921942e-09
specific O 0 1.7022439013913981e-09
polymerase O 0 1.4848092533270574e-08
chain O 0 4.878212944703364e-09
reaction O 0 4.570268330450489e-10
( O 0 4.112921669907621e-10
PCR O 0 8.884037949741241e-10
) O 0 1.4230751299582067e-10
/ O 0 3.097317069489236e-09
single O 0 2.4865007830499053e-09
- O 0 1.3026644651858987e-08
strand O 0 2.857473724304782e-08
conformation O 0 1.179717834531857e-08
polymorphism O 0 4.30845803478519e-09
as O 0 7.705887317133175e-11
a O 0 2.41098196962497e-10
screening O 0 8.631682868465163e-11
step O 0 2.677661981032031e-10
and O 0 1.3291692746442152e-10
nucleotide O 0 1.5392643604172918e-08
sequencing O 0 6.460499690774668e-09
of O 0 1.0448411913444033e-08
target O 0 1.7245522343500852e-08
exons O 0 5.2002837591658135e-09
, O 0 2.5734178676906083e-10
we O 0 9.519336430230396e-10
determined O 0 1.8926415989994894e-08
that O 0 2.0022015156939688e-09
the O 0 6.233634053387505e-08
proband O 0 6.59133866065531e-06
was O 0 1.2836720770792454e-06
a O 0 1.831391074347266e-07
compound O 0 1.5084410733834375e-06
heterozygote O 0 5.735566901421407e-07
for O 0 6.104742933388252e-09
two O 0 4.8740208313802214e-08
C6 O 0 0.00012651871656998992
gene O 0 9.830310432334954e-08
mutations O 0 5.757268795036907e-08
. O 0 6.961207787981039e-08

The O 0 3.78573645321012e-06
first O 0 4.2923591081489576e-07
, O 0 1.9966005737614978e-08
1195delC O 0 9.492199524174794e-07
located O 0 2.0918932364111242e-07
in O 0 4.447506540827817e-08
exon O 0 3.0845907872389944e-07
7 O 0 1.2983350927697757e-07
, O 0 8.512043292441263e-10
is O 0 2.7844604399973605e-10
a O 0 1.8810666357893524e-09
novel O 0 9.008743084848447e-09
mutation O 0 2.7985488926240976e-10
, O 0 1.5259710162141005e-10
while O 0 6.924308348921215e-10
the O 0 6.390995732630245e-09
second O 0 3.4357050537892064e-08
, O 0 2.5847330942241342e-09
1936delG O 0 1.3453161784582335e-07
in O 0 1.6894391663413444e-08
exon O 0 9.394704392207132e-08
12 O 0 2.003211108103642e-08
, O 0 2.438351742739542e-09
has O 0 5.939111979991196e-10
been O 0 2.76965228529491e-09
described O 0 1.2218762890370272e-08
before O 0 2.9127765088787783e-08
to O 0 4.523122854038775e-08
cause O 0 1.9980614069936564e-06
C6D B-Disease 0 0.0011292804265394807
in O 0 4.9041037897268325e-08
an O 0 1.6396514368466342e-08
unrelated O 0 4.0780952303975937e-07
African O 0 4.6727859626116697e-07
- O 0 3.1498174735133944e-07
American O 0 4.1800146277637396e-07
individual O 0 8.422981778721805e-08
. O 0 7.806747959193672e-08

Both O 0 1.4553691585206252e-07
mutations O 0 3.0689506047565374e-08
result O 0 1.803527105437297e-08
in O 0 3.1058608129796994e-08
premature O 0 7.852592602830555e-07
termination O 0 1.1656778724500327e-06
codons O 0 9.189466823045223e-07
and O 0 1.5599721336911898e-07
C6 O 0 0.00022438169980887324
null O 0 1.1831702977360692e-05
alleles O 0 2.5779482371035556e-07
. O 0 1.7085640990899265e-07

Allele O 0 2.2161468677950324e-06
- O 0 4.2596502680680715e-07
specific O 0 5.279167680782848e-08
PCR O 0 2.243105541310797e-07
indicated O 0 4.4725673831180757e-08
that O 0 1.1198135752010785e-09
the O 0 5.688697157779643e-08
probands O 0 1.600633368070703e-05
two O 0 6.165394950130576e-08
brothers O 0 2.042465666818316e-06
also O 0 1.761190837612503e-08
inherited O 0 1.881801949821238e-07
the O 0 1.2663834070281155e-07
1195delC O 0 2.506234295651666e-07
mutation O 0 1.407022387489576e-09
from O 0 2.2361750229293875e-09
their O 0 1.0834203534315634e-09
heterozygous O 0 2.524608966325559e-08
mother O 0 1.2026461604364158e-08
and O 0 1.41012801435636e-09
the O 0 1.9095971026672487e-08
1936delG O 0 1.5351881188507832e-07
mutation O 0 2.474200622160083e-09
from O 0 2.755362382700355e-09
their O 0 4.219994131915428e-09
homozygous O 0 4.604844505706751e-08
father O 0 3.821400866854674e-07
. O 0 3.509755330810549e-08
. O 0 1.7932423190814006e-07

PAX6 O 0 0.01934272050857544
mutations O 0 8.226691534218844e-06
reviewed O 0 2.524438241380267e-05
. O 0 1.7328053445453406e-06

Mutations O 0 6.451318768085912e-06
in O 0 3.8657606182823656e-07
PAX6 O 0 0.0002625337801873684
are O 0 3.6271927683628746e-09
responsible O 0 4.013422483239992e-08
for O 0 5.045263407055245e-08
human O 0 0.001295139198191464
aniridia B-Disease 1 1.0
and O 0 8.545185323782789e-07
have O 0 6.788506201615974e-09
also O 0 8.984801236344708e-10
been O 0 1.3167776868883152e-09
found O 0 2.4867130576922136e-10
in O 0 1.116241654663952e-09
patients O 0 6.124356022318977e-10
with O 0 7.254786216215336e-10
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 8.36245476421027e-07
with O 0 0.0007208538590930402
congenital B-Disease 1 1.0
cataracts I-Disease 1 1.0
, O 0 6.77164425724186e-05
with O 0 4.111900125280954e-05
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
keratitis I-Disease 1 1.0
, O 0 3.5532687547856767e-07
and O 0 1.4740814435754146e-07
with O 0 1.4422431377170142e-05
isolated B-Disease 1 1.0
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 0 0.011527573689818382

No O 0 4.819015430257423e-06
locus O 0 1.5856778645684244e-06
other O 0 2.943885357709064e-09
than O 0 2.8127311590964155e-09
chromosome O 0 4.592187963226024e-08
11p13 O 0 7.27027952507342e-07
has O 0 4.105329409753722e-09
been O 0 1.745359767824084e-08
implicated O 0 1.0746109069259546e-07
in O 0 3.752763291231531e-07
aniridia B-Disease 1 1.0
, O 0 2.270100765144889e-07
and O 0 6.62972325926603e-08
PAX6 O 0 0.016731414943933487
is O 0 9.254418387172336e-08
clearly O 0 3.789727642811158e-08
the O 0 2.033453583294431e-08
major O 0 1.086322498622394e-07
, O 0 5.975118733125839e-10
if O 0 6.968933208284511e-10
not O 0 4.868330183427361e-10
only O 0 1.2315647390792606e-09
, O 0 1.069394017783054e-09
gene O 0 6.06532779556801e-09
responsible O 0 2.8824439368690946e-07
. O 0 5.594346248471993e-07

Twenty O 0 2.5971616196329705e-05
- O 0 1.0234504088657559e-06
eight O 0 5.9380194983305046e-08
percent O 0 1.4058642250347475e-08
of O 0 6.643391170513269e-09
identified O 0 5.9355052428600175e-08
PAX6 O 0 1.0233088687527925e-05
mutations O 0 1.0341032918859128e-08
are O 0 3.833608097636443e-09
C O 0 5.525303549802629e-06
- O 0 8.26006998977391e-06
T O 0 9.733161050462513e-07
changes O 0 1.0929873006659818e-08
at O 0 1.078258833331347e-06
CpG O 0 5.545437034015777e-06
dinucleotides O 0 4.321241249272134e-07
, O 0 9.189995986425004e-10
20 O 0 2.7966453597372265e-09
% O 0 5.582131423764736e-10
are O 0 3.265461859247587e-11
splicing O 0 5.689225535121523e-09
errors O 0 1.2948160588166502e-07
, O 0 1.3483231198208045e-09
and O 0 3.402884085623725e-10
more O 0 2.282423555710622e-10
than O 0 3.1383537435480946e-10
30 O 0 5.208999898087541e-09
% O 0 1.067449906244633e-09
are O 0 1.594218368428102e-10
deletion O 0 1.5126627062045372e-08
or O 0 1.3654825714581875e-08
insertion O 0 3.4593284681250225e-07
events O 0 4.130907029775699e-07
. O 0 5.112111693961197e-07

There O 0 3.893274879374076e-06
is O 0 1.451123949891553e-07
a O 0 3.5946251841778576e-07
noticeably O 0 1.70956786860188e-06
elevated O 0 7.129842742870096e-07
level O 0 6.223298214536044e-07
of O 0 3.06275786954302e-08
mutation O 0 5.677778691648427e-09
in O 0 5.028640615023505e-09
the O 0 2.8332040713507922e-08
paired O 0 1.3457884051604196e-07
domain O 0 3.5050797464464267e-07
compared O 0 3.617064647798429e-09
with O 0 1.1987516534972542e-10
the O 0 3.940255233203516e-09
rest O 0 3.6029923933256214e-08
of O 0 9.407364132130169e-08
the O 0 1.3457126613047876e-07
gene O 0 1.6361468624381814e-07
. O 0 1.1129729671210953e-07

Increased O 0 1.8889325019699754e-06
mutation O 0 5.163411387343331e-08
in O 0 6.569200294848088e-09
the O 0 2.3990256892147954e-08
homeodomain O 0 7.676069799344987e-06
is O 0 3.5895393324381075e-09
accounted O 0 1.6650719913968715e-08
for O 0 3.5127653563726824e-10
by O 0 2.539424226455367e-09
the O 0 1.8574162652384985e-07
hypermutable O 0 3.560942423064262e-05
CpG O 0 1.8892222215072252e-05
dinucleotide O 0 6.237181878532283e-06
in O 0 6.393204898813565e-08
codon O 0 8.25907306989393e-07
240 O 0 5.275816192806815e-07
. O 0 1.2201208221540583e-07

Very O 0 2.0817039114717772e-07
nearly O 0 4.534516406806688e-08
all O 0 1.4410758142346936e-09
mutations O 0 1.384659054082249e-09
appear O 0 1.1610205241652238e-08
to O 0 1.1252695664154544e-08
cause O 0 6.066082960387575e-07
loss O 0 3.6994620131736156e-06
of O 0 2.539283741498366e-06
function O 0 3.2029352041718084e-06
of O 0 1.4668326286937372e-07
the O 0 1.4239046386421705e-08
mutant O 0 1.801388727074027e-08
allele O 0 6.03815331068347e-10
, O 0 3.170286602682815e-11
and O 0 2.1721653989392742e-11
more O 0 6.757762318482241e-12
than O 0 1.6774630295923743e-11
80 O 0 1.0265956973398715e-09
% O 0 5.050977969212056e-10
of O 0 2.2612356431750413e-09
exonic O 0 3.2305368335983076e-07
substitutions O 0 2.1688400408947928e-08
result O 0 1.676662719773958e-08
in O 0 5.196588404032809e-08
nonsense O 0 1.0599097549857106e-05
codons O 0 2.2685951535095228e-06
. O 0 4.105050379621389e-07

In O 0 2.4042101358645596e-06
a O 0 2.3741856125525373e-07
gene O 0 2.6373017103509255e-09
with O 0 7.366977167189148e-11
such O 0 7.036731752840808e-10
extraordinarily O 0 3.489969913061941e-07
high O 0 3.375414436845858e-08
sequence O 0 1.58683608475485e-08
conservation O 0 4.804443065609121e-09
throughout O 0 8.513764693240944e-10
evolution O 0 3.3305505020564397e-09
, O 0 8.565752968037188e-11
there O 0 3.995682951174473e-10
are O 0 3.765973921598942e-10
presumed O 0 7.200910090432444e-07
undiscovered O 0 0.00022881712357047945
missense O 0 3.244283561798511e-06
mutations O 0 6.935732432822306e-09
, O 0 4.3848183417516395e-10
these O 0 4.4336118110166467e-10
are O 0 7.012213587564986e-10
hypothesized O 0 3.203425080755551e-08
to O 0 2.6932600594165024e-09
exist O 0 7.641134658342708e-08
in O 0 3.722252017723804e-08
as O 0 1.0949261053383452e-07
- O 0 2.613727190237114e-07
yet O 0 5.4101768398595595e-08
unidentified O 0 9.69401571637718e-06
phenotypes O 0 1.8964183823300118e-07
. O 0 7.211553132435711e-09
. O 0 4.451928248272452e-08

Genetic O 0 9.922699064190965e-06
heterogeneity O 0 3.5934606330556562e-06
and O 0 1.7765145798875892e-08
penetrance O 0 4.355782948550768e-06
analysis O 0 6.698475374378177e-08
of O 0 3.872242615443611e-08
the O 0 2.2849573610983498e-07
BRCA1 O 0 3.9356388015221455e-07
and O 0 4.6014374532887814e-08
BRCA2 O 0 1.0468238542671315e-06
genes O 0 9.36404163098814e-08
in O 0 4.151653172357328e-07
breast B-Disease 1 0.9986459612846375
cancer I-Disease 1 0.9336577653884888
families O 0 1.7442870330341975e-06
. O 0 8.040782404350466e-07

The O 0 0.04045308381319046
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 1 0.9996217489242554
Consortium O 0 1.9345321561559103e-05
. O 0 1.6478004738473828e-07

The O 0 8.871226668816234e-07
contribution O 0 1.0608659977151547e-06
of O 0 9.958048394764774e-07
BRCA1 O 0 8.204996788663266e-07
and O 0 5.566720773231282e-08
BRCA2 O 0 4.353573785920162e-06
to O 0 7.600115168315824e-07
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 0.0005231848917901516
assessed O 0 1.4392696812137729e-07
by O 0 1.517736825107363e-09
linkage O 0 1.3245746721679552e-08
and O 0 5.2744295042650435e-11
mutation O 0 7.282538461161892e-11
analysis O 0 6.973773225560365e-10
in O 0 7.651190792046236e-10
237 O 0 1.6429668292516908e-08
families O 0 6.487315129533044e-10
, O 0 2.4317323155109705e-10
each O 0 3.67444380477977e-10
with O 0 5.076669085113394e-10
at O 0 1.7237866245523037e-07
least O 0 7.508901278541202e-10
four O 0 7.958073089397999e-10
cases O 0 2.788398678621462e-10
of O 0 6.319493195405812e-08
breast B-Disease 0 0.0003069407830480486
cancer I-Disease 0 1.5126430525924661e-06
, O 0 9.789866695086857e-10
collected O 0 1.1910451291896607e-08
by O 0 1.905929281065255e-08
the O 0 1.1607696251303423e-05
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 0.0002762403164524585
Consortium O 0 1.0646372174960561e-06
. O 0 4.769549022398678e-08

Families O 0 4.0694314407119236e-07
were O 0 3.816268900891373e-08
included O 0 2.0316081261739782e-08
without O 0 2.4271333387559935e-08
regard O 0 6.326403223511079e-08
to O 0 3.6043994455781103e-09
the O 0 1.9306259702034367e-08
occurrence O 0 1.5414848348882515e-06
of O 0 1.4248182196752168e-05
ovarian B-Disease 1 1.0
or I-Disease 0 1.589451676409226e-05
other I-Disease 0 1.4373959800195735e-07
cancers I-Disease 0 0.28512418270111084
. O 0 1.0450842182763154e-06

Overall O 0 0.0003397303225938231
, O 0 1.4862140460536466e-06
disease O 0 2.7096086341771297e-05
was O 0 1.6443387721665204e-05
linked O 0 2.0723931811517105e-05
to O 0 6.35518730973672e-08
BRCA1 O 0 4.3938893412587277e-08
in O 0 4.113975382580293e-09
an O 0 1.2242108438087485e-09
estimated O 0 2.5776389911413844e-09
52 O 0 9.035846737504016e-09
% O 0 9.178328652659218e-10
of O 0 3.3014626588112606e-09
families O 0 2.053204051222224e-09
, O 0 6.037991773233387e-10
to O 0 3.5495406613961222e-09
BRCA2 O 0 8.056585620863643e-09
in O 0 1.7725976242388697e-09
32 O 0 7.997488005173636e-09
% O 0 5.98720018007981e-10
of O 0 1.0952552198517651e-09
families O 0 2.2354830486737143e-10
, O 0 6.444026562357763e-11
and O 0 8.835635695314537e-11
to O 0 1.5767643857245162e-09
neither O 0 4.547100829199735e-08
gene O 0 6.780518368998401e-10
in O 0 9.276358570176058e-10
16 O 0 5.767234245723785e-09
% O 0 4.1708120290806505e-10
( O 0 9.371104586763934e-11
95 O 0 1.6215127018881503e-09
% O 0 2.1862568699848595e-10
confidence O 0 1.1503298757986613e-08
interval O 0 4.3848979203175986e-07
[ O 0 8.684496606292669e-07
CI O 0 5.834242983837612e-05
] O 0 1.0789567284064105e-07
6 O 0 1.9712516063918883e-08
% O 0 9.223500851973654e-10
- O 0 4.4732459403284963e-10
28 O 0 1.8694494841042797e-09
% O 0 6.006817265813424e-10
) O 0 7.092432197097764e-11
, O 0 5.110046413792091e-11
suggesting O 0 4.2940762057241955e-09
other O 0 6.18535334062642e-10
predisposition O 0 4.93426853154233e-07
genes O 0 9.57303996074188e-08
. O 0 1.0494812840988743e-07

The O 0 4.137467328746425e-07
majority O 0 1.0871096911557743e-08
( O 0 5.292816407376222e-09
81 O 0 3.7699233956800526e-08
% O 0 1.7399511831328596e-09
) O 0 1.951869360583558e-10
of O 0 2.0471155881551795e-09
the O 0 3.942099624509865e-07
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.6521669010671758e-07
were O 0 5.6489155575434324e-09
due O 0 2.3989388253653487e-08
to O 0 6.678176234231614e-09
BRCA1 O 0 4.325807712035612e-09
, O 0 1.7811745134377333e-10
with O 0 1.057777615498523e-10
most O 0 5.13523779055447e-10
others O 0 1.1930089138800781e-09
( O 0 3.280397287142023e-09
14 O 0 2.194062531657437e-08
% O 0 4.303128076088569e-09
) O 0 9.79584413585144e-10
due O 0 3.449401830835086e-08
to O 0 1.3727270697927452e-07
BRCA2 O 0 2.1953953819320304e-06
. O 0 3.9738441159897775e-07

Conversely O 0 2.62393423327012e-05
, O 0 5.497783117647259e-09
the O 0 7.424736381267394e-09
majority O 0 7.290532622050705e-10
of O 0 1.833071472390202e-08
families O 0 3.3989937531231362e-09
with O 0 2.9913056476260635e-09
male B-Disease 0 1.1967081263719592e-06
and I-Disease 0 2.5242814061243735e-08
female I-Disease 0 6.473786197602749e-05
breast I-Disease 0 0.00011943731078645214
cancer I-Disease 0 3.976841981057078e-06
were O 0 1.9616804536326526e-07
due O 0 1.7066213331418112e-07
to O 0 1.5610311265845667e-08
BRCA2 O 0 3.919315005873614e-08
( O 0 3.3501739160612942e-09
76 O 0 2.5083089383315382e-08
% O 0 3.250390179232454e-09
) O 0 3.066778164750872e-09
. O 0 1.5172078704495107e-08

The O 0 4.676647222368047e-06
largest O 0 4.770645318785682e-07
proportion O 0 6.007922337403215e-08
( O 0 4.586163449005198e-09
67 O 0 3.421755678800764e-08
% O 0 1.939890026392277e-09
) O 0 2.3769014534380517e-10
of O 0 3.0225626446167553e-09
families O 0 1.1430069113416153e-09
due O 0 1.1651111186949947e-08
to O 0 1.9598127565245704e-09
other O 0 9.417696622548988e-10
genes O 0 2.5420605620496417e-09
was O 0 9.43104367934211e-08
found O 0 8.958298991501579e-09
in O 0 5.599762431529598e-09
families O 0 1.0372080971876585e-09
with O 0 4.746782966691399e-10
four O 0 2.235131368877319e-08
or O 0 2.978224777905325e-08
five O 0 3.845325391438337e-09
cases O 0 1.693154505488792e-09
of O 0 4.887482418780564e-07
female O 0 0.008299455046653748
breast B-Disease 0 0.14856751263141632
cancer I-Disease 0 1.28460942505626e-05
only O 0 4.6221792615597224e-08
. O 0 6.298242283264699e-08

These O 0 1.734576500211915e-07
estimates O 0 1.159633313818631e-07
were O 0 6.928566165242955e-09
not O 0 7.760243558863067e-10
substantially O 0 1.5166493838592032e-08
affected O 0 2.165936985321082e-09
either O 0 1.716295106035659e-09
by O 0 3.3719635972317974e-09
changing O 0 7.158519821359732e-08
the O 0 2.8089479187087818e-08
assumed O 0 2.91059762957957e-07
penetrance O 0 1.3836428252034239e-06
model O 0 3.13765653459086e-08
for O 0 5.376812328705682e-09
BRCA1 O 0 5.91122351067952e-09
or O 0 1.0400844629998574e-09
by O 0 1.0253139448579418e-09
including O 0 3.415669969086821e-09
or O 0 6.376033923061186e-08
excluding O 0 9.922489425662206e-07
BRCA1 O 0 2.661803364389925e-07
mutation O 0 2.2991912373981904e-08
data O 0 1.9099692849522398e-07
. O 0 6.777227667953412e-08

Among O 0 4.989091095808362e-08
those O 0 1.945759553478865e-09
families O 0 1.2873742072372352e-09
with O 0 1.6374815947628463e-09
disease O 0 8.383011845580768e-06
due O 0 1.193424850498559e-05
to O 0 1.767427164622859e-07
BRCA1 O 0 2.6651049367387714e-08
that O 0 3.5486996674549687e-10
were O 0 2.2671737820445514e-09
tested O 0 4.2996470273060083e-10
by O 0 4.3447076492064696e-10
one O 0 1.0576731712674814e-09
of O 0 9.090294628144591e-10
the O 0 1.1280583134265498e-09
standard O 0 2.522383857339605e-09
screening O 0 8.29464621987519e-11
methods O 0 9.343517071158658e-10
, O 0 8.660080291766903e-11
mutations O 0 1.0956893031766057e-10
were O 0 6.814994124582086e-10
detected O 0 3.959844452339212e-09
in O 0 8.081236790857815e-10
the O 0 1.3079224814305235e-08
coding O 0 2.202442601628718e-07
sequence O 0 1.511423306510551e-07
or O 0 4.767075623135497e-08
splice O 0 1.9499871939387958e-07
sites O 0 5.167014371920686e-09
in O 0 8.02788169274038e-10
an O 0 1.1313464609585822e-09
estimated O 0 1.6222521104225507e-09
63 O 0 9.639234299640975e-09
% O 0 1.910801961102493e-09
( O 0 1.822809791995894e-09
95 O 0 3.0020068209068995e-08
% O 0 4.71648009536807e-09
CI O 0 2.456742549838964e-06
51 O 0 1.5993183666296318e-08
% O 0 1.1300933522306877e-09
- O 0 2.3925263992197188e-09
77 O 0 1.091506085515448e-08
% O 0 1.6073420372464398e-09
) O 0 1.1509656561159431e-09
. O 0 9.706815795595958e-09

The O 0 6.085493851060164e-07
estimated O 0 6.504469496348975e-08
sensitivity O 0 7.707486560093457e-08
was O 0 2.9008784707684754e-08
identical O 0 1.04354214158775e-09
for O 0 2.87328716375157e-10
direct O 0 3.2139191308289128e-09
sequencing O 0 2.23216933825654e-09
and O 0 3.5724825875327326e-10
other O 0 3.8930411672133403e-10
techniques O 0 1.0606444220684352e-06
. O 0 3.5497734529599256e-07

The O 0 9.299605153501034e-06
penetrance O 0 0.00015107823128346354
of O 0 1.8444525267113931e-06
BRCA2 O 0 6.526117317662283e-07
was O 0 2.438602564325265e-07
estimated O 0 6.299201160686607e-09
by O 0 1.0775840220134114e-09
maximizing O 0 6.325075787572132e-07
the O 0 9.27282854945588e-08
LOD O 0 0.00013596241478808224
score O 0 1.1627206930597822e-07
in O 0 2.8854495681684966e-08
BRCA2 O 0 8.703941745125121e-08
- O 0 3.381039448413503e-08
mutation O 0 1.5000631847783552e-09
families O 0 7.374924559933049e-10
, O 0 1.7434283183792587e-10
over O 0 8.81375861183642e-10
all O 0 1.5391286023458406e-09
possible O 0 4.910721074224966e-08
penetrance O 0 1.0624539754644502e-05
functions O 0 6.345920837702579e-07
. O 0 1.6180200645976583e-07

The O 0 2.7654868972604163e-07
estimated O 0 3.264625902943408e-08
cumulative O 0 1.3914564078731928e-07
risk O 0 1.2382209035877167e-07
of O 0 4.0489490515938087e-07
breast B-Disease 0 0.00013711032806895673
cancer I-Disease 0 8.727778890715854e-07
reached O 0 1.699901076790411e-06
28 O 0 2.3405938520681957e-07
% O 0 2.4084736427454345e-09
( O 0 2.9616467611681685e-10
95 O 0 7.561333781325175e-09
% O 0 1.2643753821706127e-09
CI O 0 7.109920829861949e-07
9 O 0 2.6690321064393174e-08
% O 0 7.865073592405736e-10
- O 0 4.596424629799145e-10
44 O 0 8.646385274424517e-10
% O 0 1.0201577083090996e-10
) O 0 9.393791300382759e-12
by O 0 2.954321856596387e-11
age O 0 8.165897957823631e-10
50 O 0 1.8687149605511877e-09
years O 0 3.5011799015549627e-10
and O 0 1.938549876179252e-10
84 O 0 7.745518892932068e-09
% O 0 6.317655287801927e-10
( O 0 4.169189438130161e-10
95 O 0 8.605193002608758e-09
% O 0 1.432634899600771e-09
CI O 0 8.89231728251616e-07
43 O 0 1.2481378597328785e-08
% O 0 9.79461067807108e-10
- O 0 1.5730575730898977e-09
95 O 0 7.602142915175136e-09
% O 0 1.995658083231433e-10
) O 0 1.6737462110727463e-11
by O 0 2.7295407253880022e-11
age O 0 3.853327878999835e-09
70 O 0 1.3653002284286231e-08
years O 0 1.91110931524463e-08
. O 0 7.807626190015071e-08

The O 0 1.0709349226090126e-05
corresponding O 1 0.999764621257782
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 0.022802826017141342
were O 0 4.19433433762606e-07
0 O 0 1.4323848063213518e-07
. O 0 2.8764706172523802e-08

4 O 0 3.158377239742549e-06
% O 0 4.05162552397087e-08
( O 0 5.2283204432512775e-09
95 O 0 2.7528635371254495e-08
% O 0 4.296878408638349e-09
CI O 0 1.4407902426682995e-06
0 O 0 3.791489788795843e-09
% O 0 5.36548916407753e-10
- O 0 4.66256033782031e-10
1 O 0 2.1119972437588785e-09
% O 0 1.7440136834689923e-10
) O 0 1.0021806301496738e-11
by O 0 3.275542337366488e-11
age O 0 1.2917696912140286e-09
50 O 0 1.7186667644608633e-09
years O 0 4.3052439391289e-10
and O 0 2.0896455399377345e-10
27 O 0 5.210261999621935e-09
% O 0 4.966281275109452e-10
( O 0 2.556617417770468e-10
95 O 0 2.651778130413618e-09
% O 0 4.6477505177833223e-10
CI O 0 3.255889851061511e-07
0 O 0 1.03993580413686e-09
% O 0 2.2590747328354865e-10
- O 0 3.309619522884333e-10
47 O 0 4.6151384935910755e-09
% O 0 4.0292880143510956e-10
) O 0 3.942115731070395e-11
by O 0 7.550127884003999e-11
age O 0 8.414900776188006e-09
70 O 0 4.652526897075404e-08
years O 0 3.5841161150074186e-08
. O 0 9.519126820123347e-08

The O 0 1.1731308404705487e-06
lifetime O 0 1.2328366210567765e-05
risk O 0 1.5650100976927206e-05
of O 0 0.00011113652726635337
breast B-Disease 1 0.9999996423721313
cancer I-Disease 0 0.006960794795304537
appears O 0 1.885587010974632e-07
similar O 0 1.0299572306138316e-09
to O 0 8.582698995951432e-10
the O 0 1.614834665986109e-08
risk O 0 1.6348523956821737e-07
in O 0 9.838053927069268e-09
BRCA1 O 0 1.0844588338443373e-08
carriers O 0 6.336590141486909e-10
, O 0 4.303732925592385e-10
but O 0 3.6914432621770743e-10
there O 0 1.883665889934605e-09
was O 0 3.62123593333763e-08
some O 0 3.9403286189454434e-10
suggestion O 0 8.86642048669728e-09
of O 0 9.603339456987214e-09
a O 0 1.6411782155500987e-08
lower O 0 5.201864183845828e-08
risk O 0 4.5135568171872364e-08
in O 0 1.7327355550378343e-08
BRCA2 O 0 4.780733675602278e-08
carriers O 0 1.1047685433140941e-08
< O 0 4.2271904021617956e-07
50 O 0 8.544384755282408e-09
years O 0 2.457082315387993e-09
of O 0 2.0858088589648105e-08
age O 0 6.249926514101389e-07
. O 0 5.018376327825536e-07

Eye B-Disease 1 0.9987429976463318
movement I-Disease 0 1.2201435310998932e-05
abnormalities I-Disease 0 0.00019353730021975935
correlate O 0 4.4420769995667797e-07
with O 0 3.952314031607784e-09
genotype O 0 7.321168595808558e-07
in O 0 9.334493000778821e-08
autosomal O 0 0.0001281777222175151
dominant O 0 0.0008889510063454509
cerebellar B-Disease 1 0.9999938011169434
ataxia I-Disease 1 0.9999998807907104
type I-Disease 1 1.0
I I-Disease 1 0.9999986886978149
. O 0 1.7680253222351894e-05

We O 0 1.1935941301999264e-06
compared O 0 8.564177278458374e-07
horizontal O 0 3.276205916336039e-06
eye O 0 1.2205146958876867e-05
movements O 0 3.4032356666102714e-07
( O 0 5.002927494501819e-08
visually O 0 1.161672145144621e-07
guided O 0 5.762662453889789e-07
saccades O 0 6.39044628769625e-06
, O 0 5.354205523389055e-09
antisaccades O 0 5.053739187133033e-07
, O 0 2.723469227916553e-09
and O 0 4.022555621929769e-09
smooth O 0 1.5356025073742785e-07
pursuit O 0 2.987401103382581e-06
) O 0 4.765809080709005e-09
in O 0 5.1333111095175354e-09
control O 0 1.566101026639899e-08
subjects O 0 1.5317090173994075e-07
( O 0 1.3564749323791148e-08
n O 0 8.398085071803507e-08
= O 0 5.781764400580869e-08
14 O 0 5.37403410660886e-09
) O 0 2.601454052175711e-10
and O 0 7.479594027470782e-11
patients O 0 5.661486557340112e-11
with O 0 4.338128814507236e-12
three O 0 2.418918121360747e-10
forms O 0 3.405457027483294e-09
of O 0 5.1381807679717895e-06
autosomal O 0 0.00047283482854254544
dominant O 0 0.00012254691682755947
cerebellar B-Disease 1 0.9429720640182495
ataxias I-Disease 1 0.9983053207397461
type I-Disease 1 0.9980000853538513
I I-Disease 0 0.3528132140636444
spinocerebellar B-Disease 1 0.504517674446106
ataxias I-Disease 0 0.0002137831470463425
1 I-Disease 0 1.040638721860887e-06
and I-Disease 0 1.0517413606692116e-08
2 I-Disease 0 2.2506181096559885e-07
( O 0 2.5734451014614024e-08
SCA1 B-Disease 0 1.893195758384536e-06
, O 0 5.137983816183578e-09
n O 0 8.467358725283702e-08
= O 0 5.990415274936822e-08
11 O 0 5.521280321829636e-09
; O 0 2.2910290331523697e-10
SCA2 B-Disease 0 3.331645359594404e-07
, O 0 5.841516714788497e-10
n O 0 2.081850070112523e-08
= O 0 1.8201911089477107e-08
10 O 0 2.77131140258291e-09
) O 0 8.818466512572343e-10
and O 0 1.2302248109108405e-08
SCA3 B-Disease 1 1.0
/ O 0 0.00010875568113988265
Machado B-Disease 0 5.711425274057547e-06
- I-Disease 0 3.7976258226990467e-06
Joseph I-Disease 0 7.493656448787078e-05
disease I-Disease 0 0.00899850856512785
( O 0 2.1592646248791425e-07
MJD B-Disease 1 1.0
) O 0 2.06453822926278e-08
( O 0 2.4957567124062052e-09
n O 0 2.920068986611568e-08
= O 0 5.968062311012545e-08
16 O 0 2.2968812629642343e-08
) O 0 9.187862026749372e-09
. O 0 3.7854942291914995e-08

In O 0 1.224728566739941e-05
SCA1 B-Disease 0 0.00249419710598886
, O 0 2.4524652530999447e-07
saccade O 0 4.09845270041842e-05
amplitude O 0 7.266390866789152e-07
was O 0 8.090991343578935e-08
significantly O 0 5.879614572990022e-09
increased O 0 4.478028614585128e-09
, O 0 7.095250498245775e-10
resulting O 0 1.370021873725591e-08
in O 0 6.463854873572927e-08
hypermetria B-Disease 0 2.267858144477941e-05
. O 0 5.041118242843368e-07

The O 0 8.365306712221354e-06
smooth O 0 1.1842845196952112e-05
pursuit O 0 6.426902109524235e-05
gain O 0 3.530905087245628e-05
was O 0 6.114900315878913e-06
decreased O 0 1.5244853784679435e-05
. O 0 3.3847632607830747e-07

In O 0 1.7169862985610962e-05
SCA2 B-Disease 0 0.0013993678148835897
, O 0 2.3565993956253806e-07
saccade O 0 2.8089614716009237e-05
velocity O 0 2.511383172532078e-06
was O 0 8.975899277174904e-07
markedly O 0 8.720008395357581e-07
decreased O 0 2.3654356482438743e-06
. O 0 1.684494321807506e-07

The O 0 3.581510327421711e-06
percentage O 0 3.331249672555714e-06
of O 0 3.2636026503496396e-07
errors O 0 8.208869985537603e-06
in O 0 4.324077451656194e-07
antisaccades O 0 0.0009547361987642944
was O 0 7.809055205143522e-06
greatly O 0 1.506185753896716e-07
increased O 0 6.594310519858482e-08
and O 0 1.6601431340745876e-09
was O 0 6.335931601597622e-08
significantly O 0 2.2257582443785395e-09
correlated O 0 1.3978906920897316e-08
with O 0 1.8421335290508267e-10
age O 0 6.032978205894324e-08
at O 0 1.7002238337227027e-06
disease O 0 3.1803958790987963e-06
onset O 0 0.00016702072753105313
. O 0 1.8240214672005095e-07

In O 0 7.777237556183536e-07
addition O 0 5.996382412831736e-08
, O 0 5.576398454110176e-09
a O 0 1.2679502781054452e-08
correlation O 0 3.678290028119591e-08
between O 0 2.0091651009579437e-08
smooth O 0 1.5829340327400132e-07
pursuit O 0 4.061664185428526e-06
gain O 0 9.082431802198698e-07
and O 0 6.630425097853276e-10
the O 0 7.08398983917391e-09
number O 0 9.053633398536931e-09
of O 0 8.7649830504688e-08
trinucleotide O 0 1.4680219464935362e-05
repeats O 0 9.6502162705292e-07
was O 0 1.8909637446995475e-06
found O 0 2.1679225881143793e-07
. O 0 1.7835093046869588e-07

In O 0 0.0001889325212687254
SCA3 B-Disease 1 1.0
, O 0 3.194726104993606e-06
gaze B-Disease 0 0.0007569347508251667
- I-Disease 0 0.00011739693582057953
evoked I-Disease 0 1.4879545233270619e-05
nystagmus I-Disease 0 7.924202509457245e-05
was O 0 6.969530659262091e-07
often O 0 4.818686338836642e-09
present O 0 1.4831958772276721e-08
as O 0 4.021299560008629e-08
was O 0 2.707619387365412e-06
saccade O 0 3.5190350899938494e-05
hypometria O 0 2.206304998253472e-05
and O 0 2.8117707984165463e-07
smooth O 0 8.554548003303353e-06
pursuit O 0 0.00013627068256027997
gain O 0 4.542523674899712e-05
was O 0 2.970990635731141e-06
markedly O 0 2.677931206562789e-06
decreased O 0 2.3255404357769294e-06
. O 0 1.2684854766575882e-07

Three O 0 3.376116808340157e-07
major O 0 1.3417374589153042e-07
criteria O 0 4.642616246997022e-08
, O 0 1.1497551355432734e-08
saccade O 0 4.431259185366798e-06
amplitude O 0 2.065257831418421e-07
, O 0 5.0121897743338195e-09
saccade O 0 1.8309316374143236e-06
velocity O 0 3.5680432119988836e-07
, O 0 1.519494863266857e-09
and O 0 1.3255723185778834e-09
presence O 0 5.044955742050661e-08
of O 0 2.576500719442265e-06
gaze B-Disease 0 0.0007144867558963597
- I-Disease 0 2.1740605006925762e-05
evoked I-Disease 0 1.7138137309302692e-06
nystagmus I-Disease 0 1.5601611949023209e-06
, O 0 1.8996133555049255e-09
permitted O 0 5.4536153371032015e-09
the O 0 1.8819961145055686e-09
correct O 0 1.7195628032595778e-08
assignment O 0 6.466419222306286e-08
of O 0 4.874792480791257e-08
90 O 0 5.2237979275560065e-08
% O 0 8.248711935721076e-09
of O 0 1.3542361898544186e-08
the O 0 4.307038636852667e-08
SCA1 B-Disease 0 2.8730559279210865e-05
, O 0 2.3823762962393857e-09
90 O 0 1.711177155527821e-08
% O 0 1.10793962893041e-09
of O 0 4.310685586261798e-09
the O 0 2.085593919787243e-08
SCA2 B-Disease 0 7.877894859120715e-06
, O 0 8.132200468580209e-10
and O 0 5.389284574164321e-10
93 O 0 3.643315693580007e-08
% O 0 7.738500951148808e-10
of O 0 7.970620830022312e-10
the O 0 4.530260611090853e-09
patients O 0 1.8658727896081473e-09
with O 0 4.692235489045515e-09
SCA3 B-Disease 1 1.0
to O 0 4.498559391663548e-08
their O 0 2.7375832711840076e-09
genetically O 0 3.5136565879057e-10
confirmed O 0 8.027039588576201e-10
patient O 0 4.186325597288487e-08
group O 0 1.2964124218584061e-09
and O 0 7.863709128308471e-10
, O 0 1.282800421442687e-09
therefore O 0 3.098707068716067e-08
, O 0 3.040545148991214e-09
may O 0 1.1463019866653212e-08
help O 0 7.730999129762495e-08
orient O 0 0.0006037013372406363
diagnoses O 0 1.984729578907718e-06
of O 0 8.343177455572004e-07
SCA1 B-Disease 0 0.08389251679182053
, O 0 3.9693588860245654e-08
SCA2 B-Disease 0 0.0022005506325513124
, O 0 2.844184443517861e-08
and O 0 1.0793931437547144e-07
SCA3 B-Disease 1 1.0
at O 0 3.416614845264121e-06
early O 0 1.8929669920453307e-07
clinical O 0 1.7080900249766273e-07
stages O 0 1.1749295936169801e-07
of O 0 1.1738387684090412e-07
the O 0 3.9102954474401486e-07
diseases O 0 7.810358511051163e-05
. O 0 2.8149225173024206e-08
. O 0 2.371784688648404e-07

Genetic O 0 1.4139768609311432e-06
basis O 0 2.2077357186844893e-07
and O 0 2.5742734610645357e-09
molecular O 0 1.212978730791292e-07
mechanism O 0 2.078471425193129e-06
for O 0 4.053970769746229e-06
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
. O 0 1.4864384866086766e-05

Ventricular B-Disease 1 1.0
fibrillation I-Disease 1 0.9999681711196899
causes O 0 1.027677512865921e-06
more O 0 9.331156958225506e-10
than O 0 1.0232605873738976e-09
300 O 0 6.629492954601801e-09
, O 0 1.5015746424040799e-09
000 O 0 1.0821512574921144e-07
sudden O 0 7.84026354949674e-08
deaths O 0 4.115388030356826e-09
each O 0 4.2841916125802015e-10
year O 0 2.408712562740334e-09
in O 0 7.655164502295975e-09
the O 0 2.963362817354209e-07
USA O 0 1.8877872207667679e-06
alone O 0 3.523022371609841e-07
. O 0 1.0439650566240744e-07

In O 0 1.4725275150340167e-06
approximately O 0 1.5604824454840127e-07
5 O 0 9.070627982055157e-08
- O 0 2.678057953175994e-08
12 O 0 7.574122662390437e-09
% O 0 3.711812246454116e-10
of O 0 1.4088208377671663e-10
these O 0 4.069082917834699e-11
cases O 0 2.0428007896367006e-10
, O 0 8.608106588647857e-11
there O 0 7.695507009408686e-10
are O 0 3.5581201873746693e-10
no O 0 8.964589071069895e-09
demonstrable O 0 8.099295882857405e-06
cardiac O 0 0.006375657394528389
or O 0 1.5643880146853917e-07
non O 0 0.006426047068089247
- O 1 0.5597776770591736
cardiac O 1 1.0
causes O 0 2.828237768426334e-07
to O 0 4.053718249963367e-09
account O 0 5.25404466600321e-08
for O 0 1.6628686205777399e-09
the O 0 2.1412432715806062e-08
episode O 0 4.5581202812172705e-07
, O 0 4.4826067857606233e-10
which O 0 1.7106328506488744e-11
is O 0 2.564596451870571e-11
therefore O 0 3.109953961022427e-10
classified O 0 3.665571313149485e-08
as O 0 2.6551609266789455e-07
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
( O 1 0.9610124230384827
IVF B-Disease 1 1.0
) O 0 5.605203341474407e-07
. O 0 4.017137200662546e-07

A O 0 8.292035090562422e-06
distinct O 0 1.5254290985922125e-07
group O 0 1.0959625029727249e-07
of O 0 2.9160089979995973e-05
IVF B-Disease 1 1.0
patients O 0 2.9921686746092746e-06
has O 0 9.829458358368015e-10
been O 0 2.5709512296856474e-09
found O 0 1.475008004625522e-09
to O 0 9.578529081011311e-10
present O 0 4.6961208255424935e-09
with O 0 2.01134975341688e-09
a O 0 1.611035855830778e-07
characteristic O 0 6.922749093973835e-07
electrocardiographic O 0 4.664471998694353e-05
pattern O 0 4.90261618324439e-06
. O 0 4.3799536797450855e-07

Because O 0 8.006784355529817e-07
of O 0 1.8814753843798826e-07
the O 0 3.008891624745047e-08
small O 0 6.638730010166682e-09
size O 0 1.1585981951611757e-08
of O 0 3.848555607532944e-08
most O 0 3.346342092314103e-09
pedigrees O 0 3.653859153018857e-07
and O 0 2.105079888181649e-09
the O 0 1.2524303372174472e-08
high O 0 1.1705633085057343e-07
incidence O 0 5.928535529164947e-07
of O 0 1.757988954409484e-08
sudden B-Disease 0 4.834550964005757e-07
death I-Disease 0 1.6866540164528487e-08
, O 0 1.4529095981874462e-10
however O 0 2.622522754514023e-10
, O 0 8.851559069045223e-11
molecular O 0 1.0235324587881678e-08
genetic O 0 5.154975557530861e-09
studies O 0 3.9167442622556337e-08
of O 0 1.161390173365362e-06
IVF B-Disease 1 1.0
have O 0 1.2068022137157186e-09
not O 0 4.547729137716061e-10
yet O 0 5.309722883595214e-09
been O 0 1.862360932136653e-08
done O 0 1.408953238524191e-07
. O 0 1.8824805181338888e-07

Because O 0 2.1398349417722784e-05
IVF B-Disease 1 1.0
causes O 0 8.47371484269388e-05
cardiac O 1 1.0
rhythm O 1 0.999998927116394
disturbance O 1 0.9830337166786194
, O 0 5.660024005038622e-09
we O 0 7.190799511391788e-09
investigated O 0 3.797339900302177e-07
whether O 0 5.47311493903635e-08
malfunction O 0 0.0028118090704083443
of O 0 1.114984570449451e-06
ion O 0 2.662340375536587e-05
channels O 0 2.3418819182552397e-05
could O 0 5.486576881708061e-08
cause O 0 3.0233604775276035e-07
the O 0 4.105589823666378e-08
disorder O 0 1.6764637678079453e-07
by O 0 6.586560741261849e-10
studying O 0 1.900186852310526e-08
mutations O 0 6.66066868326709e-10
in O 0 1.0920718773732574e-09
the O 0 3.779044988050373e-08
cardiac O 0 1.9001228793058544e-05
sodium O 0 1.6844445838160027e-07
channel O 0 1.5697141861892305e-06
gene O 0 1.4992464514307358e-07
SCN5A O 0 5.936464003752917e-05
. O 0 4.104662707504758e-07

We O 0 1.7438761688026716e-06
have O 0 1.0882797774058872e-08
now O 0 1.386628767363618e-08
identified O 0 5.2394838689906464e-08
a O 0 1.5049249668663833e-07
missense O 0 9.5099778718577e-07
mutation O 0 5.7580678003432695e-09
, O 0 2.6705992972608783e-09
a O 0 4.2350265516688523e-08
splice O 0 3.2983371056616306e-07
- O 0 7.284868530632593e-08
donor O 0 7.608526253477521e-09
mutation O 0 2.0798527344823015e-09
, O 0 1.6953155546062249e-10
and O 0 4.086359306487708e-10
a O 0 1.4001856563083948e-08
frameshift O 0 2.4273515464301454e-07
mutation O 0 6.636068361487446e-10
in O 0 1.2266182514153456e-09
the O 0 9.382631560583832e-09
coding O 0 2.137999359774767e-07
region O 0 4.792584107349285e-08
of O 0 1.0079255616801674e-06
SCN5A O 1 0.7750177383422852
in O 0 4.5729237285740965e-07
three O 0 1.5944730193950818e-06
IVF B-Disease 1 1.0
families O 0 6.415339015575228e-08
. O 0 5.710569794814546e-08

We O 0 2.4585702362855955e-07
show O 0 3.1679466161449454e-08
that O 0 2.3293814099822896e-10
sodium O 0 2.1006598682760114e-09
channels O 0 3.820498140072459e-09
with O 0 1.1365627189396932e-10
the O 0 6.137245822657178e-09
missense O 0 1.7725552936553868e-07
mutation O 0 1.2652124903311801e-09
recover O 0 8.410813023829178e-08
from O 0 4.60822491277213e-09
inactivation O 0 1.7322174983291916e-07
more O 0 2.01263422594522e-10
rapidly O 0 7.252383138478535e-09
than O 0 6.637827509869965e-10
normal O 0 1.0234914249451776e-08
and O 0 1.8660070710829757e-10
that O 0 1.251046766181929e-10
the O 0 1.4280196580784832e-08
frameshift O 0 8.41488656533329e-07
mutation O 0 1.5665901909045488e-09
causes O 0 8.846195997946893e-10
the O 0 1.0217862111971954e-09
sodium O 0 1.8308063953753617e-09
channel O 0 2.5197884667704784e-08
to O 0 8.432441966910176e-10
be O 0 5.737260444504955e-09
non O 0 1.1713523235812318e-06
- O 0 1.284125119127566e-06
functional O 0 7.621471013408154e-06
. O 0 3.324038004848262e-07

Our O 0 1.999128699026187e-06
results O 0 3.853212504623116e-08
indicate O 0 1.1549378342579075e-08
that O 0 2.289578804326453e-10
mutations O 0 5.500748190279126e-10
in O 0 4.65342075983699e-09
cardiac O 0 1.5478767636523116e-06
ion O 0 6.773608447474544e-07
- O 0 8.290335244964808e-06
channel O 0 2.812765842463705e-07
genes O 0 1.2443387431559927e-09
contribute O 0 2.7972948957177834e-10
to O 0 1.1667533605930203e-10
the O 0 1.976536490033709e-09
risk O 0 1.2052709053023136e-08
of O 0 4.603746361908634e-08
developing O 0 5.001824774808483e-06
IVF B-Disease 1 1.0
. O 0 1.3128461873179731e-08
. O 0 3.447218688279463e-08

Molecular O 0 3.334444045322016e-05
heterogeneity O 0 1.061360217136098e-05
in O 0 4.019865968984959e-07
mucopolysaccharidosis B-Disease 0 0.00014355825260281563
IVA I-Disease 0 0.02642965316772461
in O 0 1.1279990985713084e-07
Australia O 0 1.3102395612918372e-08
and O 0 1.873257771123349e-09
Northern O 0 1.337382027344347e-08
Ireland O 0 1.1477611749910466e-08
: O 0 1.0551867157815309e-09
nine O 0 4.629137961842389e-09
novel O 0 8.109265259292897e-09
mutations O 0 1.3507993612549285e-09
including O 0 1.947140670921499e-09
T312S O 0 1.8880823517974932e-06
, O 0 9.8848129681528e-09
a O 0 6.297184995673888e-08
common O 0 4.499595362972286e-09
allele O 0 5.692742721663535e-09
that O 0 7.047853967101503e-10
confers O 0 6.345606351487731e-08
a O 0 3.796376546461033e-08
mild O 0 2.220717902901015e-07
phenotype O 0 7.774723940201511e-07
. O 0 1.365678485854005e-07

Mucopolysaccharidosis B-Disease 1 0.9936161041259766
IVA I-Disease 1 0.9999994039535522
( O 0 0.00021256241598166525
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 1.0553929996603983e-07
is O 0 2.2674853106252613e-09
an O 0 1.492116830092982e-08
autosomal B-Disease 1 0.8863871693611145
recessive I-Disease 1 0.9999765157699585
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 1 0.9999825954437256
by O 0 9.54878260017722e-07
a O 0 0.00017829118587542325
genetic B-Disease 1 1.0
defect I-Disease 1 0.9999983310699463
in O 0 1.8624322706273233e-07
N O 0 5.092198989586905e-06
- O 0 2.731032395786315e-07
acetylgalactosamine O 0 7.11638404027326e-06
- O 0 2.6344657726440346e-06
6 O 0 4.2811107050511055e-06
- O 0 1.3485675935953623e-06
sulfate O 0 5.2081213652854785e-06
sulfatase O 0 0.0013505856040865183
( O 0 9.739809456732473e-07
GALNS O 0 0.00038026756374165416
) O 0 1.4846527562895062e-07
. O 0 1.656068064903593e-07

Previous O 0 5.606119884760119e-06
studies O 0 2.0510920251126663e-07
of O 0 4.669551501024216e-08
patients O 0 5.640507172444131e-09
from O 0 4.155369826008837e-09
a O 0 4.5741973764279464e-08
British O 0 1.107264097299776e-06
- O 0 2.0124737432070106e-07
Irish O 0 1.470084498578217e-07
population O 0 4.045305201927363e-10
showed O 0 1.1506275932049448e-09
that O 0 3.823497768395967e-11
the O 0 1.4208030307827357e-09
I113F O 0 1.9049339528010023e-07
mutation O 0 5.680028669630133e-10
is O 0 6.114525552547434e-11
the O 0 1.7547276132123812e-10
most O 0 5.970764160867503e-11
common O 0 1.7431790733102304e-10
single O 0 1.366015855985836e-09
mutation O 0 8.908506710092468e-10
among O 0 3.455524311135605e-09
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 1.074797455657972e-05
and O 0 6.585330059039052e-10
produces O 0 1.0428159447073426e-09
a O 0 1.3665038878230007e-08
severe O 0 1.0763217517251178e-07
clinical O 0 1.3116331274432014e-06
phenotype O 0 7.253609624058299e-07
. O 0 7.037301941181795e-08

We O 0 2.0977847725589527e-07
studied O 0 6.338107141345972e-07
mutations O 0 2.6799076735528615e-08
in O 0 2.302992108127455e-08
the O 0 1.4190263186719676e-07
GALNS O 0 0.0002229715755674988
gene O 0 1.4270258752446807e-08
from O 0 5.390953017325728e-09
23 O 0 5.758608878636551e-08
additional O 0 5.451434148540102e-08
MPS B-Disease 1 0.999997615814209
IVA I-Disease 1 1.0
patients O 0 2.623393982048583e-07
( O 0 1.0033847086532433e-09
15 O 0 1.1072783800969432e-09
from O 0 7.827136716542782e-10
Australia O 0 2.4397333042713854e-09
, O 0 3.5644376339405426e-10
8 O 0 3.0021942709623772e-09
from O 0 2.1263624194745034e-09
Northern O 0 1.1763631846406497e-08
Ireland O 0 5.80273074035631e-09
) O 0 1.5669419928254769e-10
, O 0 1.8799170553585043e-11
with O 0 7.903126937602867e-12
various O 0 1.228006474285337e-09
clinical O 0 1.674657323746942e-05
phenotypes O 0 2.950705493276473e-06
( O 0 4.0542769141893586e-08
severe O 0 2.111853945052644e-07
, O 0 7.718174432902458e-10
16 O 0 5.576845651944495e-09
cases O 0 5.047144924219538e-10
; O 0 6.891865550473497e-11
intermediate O 0 2.231008444653071e-08
, O 0 1.633606305784241e-10
4 O 0 3.894677025328974e-09
cases O 0 2.2747094485797703e-10
; O 0 1.2912393376751652e-10
mild O 0 1.006344518827973e-08
, O 0 1.1048227888110773e-09
3 O 0 1.7061225321413076e-08
cases O 0 2.5834172578953485e-09
) O 0 8.045468291584257e-09
. O 0 4.2463341287657386e-08

We O 0 3.236403472328675e-06
found O 0 1.1195305660294252e-07
two O 0 5.777958556052454e-09
common O 0 5.03292030273883e-09
mutations O 0 1.8591550521307454e-09
that O 0 3.115356583816009e-10
together O 0 4.02077571237669e-09
accounted O 0 9.66055111462083e-08
for O 0 4.223633887079359e-09
32 O 0 1.0369874559046366e-07
% O 0 9.646443643873681e-09
of O 0 5.250425427760774e-09
the O 0 1.1135436572828894e-08
44 O 0 1.1533527910501107e-08
unrelated O 0 2.2134777566407138e-08
alleles O 0 1.4262788172736407e-10
in O 0 1.856733794491916e-10
these O 0 2.7957000603429094e-10
patients O 0 2.509393803862281e-09
. O 0 2.5577321594028035e-08

One O 0 3.2453081075800583e-06
is O 0 5.23800522955753e-08
the O 0 6.965444754314376e-08
T312S O 0 1.2714548574876972e-05
mutation O 0 4.689428578785737e-08
, O 0 2.2129449384067357e-09
a O 0 1.111154812605264e-08
novel O 0 3.425484251806665e-08
mutation O 0 1.1181743309052194e-09
found O 0 8.025202724581959e-10
exclusively O 0 3.802316683731988e-09
in O 0 7.181027328329037e-09
milder O 0 4.815812815195386e-08
patients O 0 7.77677229280016e-08
. O 0 1.909293558810532e-07

The O 0 2.9655104754056083e-06
other O 0 2.830049972146753e-08
is O 0 1.0269956440822625e-08
the O 0 2.1114022530355214e-08
previously O 0 2.3276298577457055e-07
described O 0 2.085431702880669e-07
I113F O 0 1.0759937367765815e-06
that O 0 1.421339601570537e-09
produces O 0 4.471473413758531e-09
a O 0 2.7567464755406945e-08
severe O 0 4.4024420731147984e-07
phenotype O 0 1.2325275520197465e-06
. O 0 3.265831480803172e-07

The O 0 1.001587042992469e-05
I113F O 0 3.0005128792254254e-05
and O 0 1.0520567172989104e-07
T312S O 0 3.0454041279881494e-06
mutations O 0 1.5804294761778692e-08
accounted O 0 1.6166889338364854e-07
for O 0 5.444946715726928e-09
8 O 0 1.5309628054183122e-07
( O 0 6.992316947673771e-09
18 O 0 1.8053649242233405e-08
% O 0 1.9309047694093806e-09
) O 0 1.3423333278250738e-10
and O 0 6.746986302985647e-11
6 O 0 7.954495728768052e-09
( O 0 1.6422421200701365e-09
14 O 0 3.9033629661844316e-09
% O 0 1.0754979129501407e-09
) O 0 1.0793237137374234e-10
of O 0 8.598396439296607e-10
44 O 0 3.0696809538710568e-09
unrelated O 0 1.988881059844516e-08
alleles O 0 4.923067509210455e-10
, O 0 1.574222086020427e-09
respectively O 0 1.8966207449011563e-07
. O 0 4.0024912095759646e-07

The O 0 2.30988689509104e-06
relatively O 0 7.91501179264742e-07
high O 0 1.2236614566063508e-06
residual O 0 0.00011916906078113243
GALNS O 0 0.09884528070688248
activity O 0 6.040213975211373e-06
seen O 0 3.372711532279027e-08
when O 0 1.4632670630732036e-09
the O 0 3.1706770542427876e-09
T312S O 0 2.1172563435811753e-07
mutant O 0 5.331849450840309e-08
cDNA O 0 2.6256867613483337e-07
is O 0 5.137177905290002e-10
overexpressed O 0 1.2696037288151274e-07
in O 0 9.458488436919765e-10
mutant O 0 2.3149974381908578e-08
cells O 0 3.428292982832204e-09
provides O 0 7.094709264521271e-10
an O 0 1.4513697188522912e-10
explanation O 0 3.4242935154082943e-09
for O 0 1.7429163667870284e-10
the O 0 4.4318722025593615e-09
mild O 0 6.568726718114704e-08
phenotype O 0 2.7668551894066695e-08
in O 0 1.5076557779991617e-09
patients O 0 3.302141338146214e-10
with O 0 4.1496077407554566e-11
this O 0 3.778992230252243e-09
mutation O 0 9.340100248778072e-09
. O 0 1.4885465304814716e-08

The O 0 2.0772617403963523e-07
distribution O 0 8.014652053134341e-09
and O 0 1.5252298313228607e-09
relative O 0 8.381682903291221e-08
frequencies O 0 1.2837630514184184e-08
of O 0 1.6323371099247197e-08
the O 0 5.4287827566668057e-08
I113F O 0 1.4609247500629863e-06
and O 0 5.211116871350896e-09
T312S O 0 8.525437920070544e-07
mutations O 0 2.2481920769479302e-09
in O 0 2.76950440358803e-09
Australia O 0 4.278836840398981e-09
corresponded O 0 1.045369479868441e-08
to O 0 1.0073579748137718e-09
those O 0 4.1154565866285964e-10
observed O 0 6.428393373170138e-09
in O 0 4.5795549574734196e-09
Northern O 0 4.16653840318304e-08
Ireland O 0 1.777314473372371e-08
and O 0 1.6365854227373688e-09
are O 0 1.5464313163349175e-10
unique O 0 3.7866676461106863e-10
to O 0 9.137590684105135e-11
these O 0 4.998074870643521e-11
two O 0 1.5956116983240065e-10
populations O 0 1.384188319519808e-10
, O 0 6.907078381468423e-11
suggesting O 0 2.1661930027505605e-09
that O 0 6.464967450270365e-11
both O 0 2.9274885293695263e-10
mutations O 0 2.3165055984541993e-10
were O 0 2.818036914931099e-09
probably O 0 5.786671142260502e-09
introduced O 0 1.1568376256931856e-09
to O 0 1.2545241512285088e-09
Australia O 0 4.241888174050246e-09
by O 0 2.125146059128724e-09
Irish O 0 7.557387249335079e-08
migrants O 0 3.3709234514844866e-08
during O 0 5.663353164209184e-08
the O 0 5.760553278832958e-08
19th O 0 1.4630217037847615e-06
century O 0 1.0328680218663067e-05
. O 0 5.573891144194931e-07

Haplotype O 0 7.004174403846264e-05
analysis O 0 4.6157217070685874e-07
using O 0 7.404657509368917e-08
6 O 0 4.230771821767121e-07
RFLPs O 0 1.1626486411842052e-05
provides O 0 6.094341920004354e-09
additional O 0 4.107397089114784e-09
data O 0 2.5885729115771028e-08
that O 0 1.7164318577567172e-10
the O 0 9.125930233722102e-09
I113F O 0 1.0417925295769237e-06
mutation O 0 9.55462997609402e-09
originated O 0 7.571525628691234e-08
from O 0 2.7413781467089393e-08
a O 0 8.913698934520653e-08
common O 0 3.256199576640029e-08
ancestor O 0 1.1268180060142186e-06
. O 0 1.888444813857859e-07

The O 0 2.2997364794719033e-06
other O 0 1.0286620444333039e-08
9 O 0 1.3333607284948812e-07
novel O 0 5.1683969104487915e-08
mutations O 0 4.307299406036691e-09
identified O 0 4.96266627791897e-09
in O 0 1.916002689839047e-09
these O 0 6.101875671404855e-10
23 O 0 6.161620547118218e-08
patients O 0 1.6268814073683302e-09
were O 0 2.8575486421544838e-09
each O 0 1.0631037161701329e-09
limited O 0 9.018818580841526e-09
to O 0 8.002401408191417e-09
a O 0 1.0621156576462454e-07
single O 0 1.0656179938450805e-07
family O 0 1.1862211124480382e-07
. O 0 7.776609578513671e-08

These O 0 1.639610580639328e-08
data O 0 5.087472487730338e-08
provide O 0 1.7752909142743079e-09
further O 0 1.114359049481095e-09
evidence O 0 6.824194098697944e-09
for O 0 6.214420644745644e-10
extensive O 0 3.169795803614761e-08
allelic O 0 1.4164479011924413e-07
heterogeneity O 0 7.747738095531531e-07
in O 0 3.8850342320984055e-07
MPS B-Disease 1 0.9999444484710693
IVA I-Disease 1 1.0
in O 0 1.1054497406348673e-07
British O 0 5.357360350899398e-07
- O 0 3.045840912818676e-07
Irish O 0 1.4980517448748287e-07
patients O 0 1.5911875150820265e-09
and O 0 1.0977811021328776e-10
provide O 0 2.0539951961495717e-09
evidence O 0 2.799608900261319e-08
for O 0 2.987451397373775e-09
their O 0 5.55056001161347e-09
transmission O 0 1.897553758567483e-08
to O 0 1.0420504459318636e-09
Australia O 0 3.0458040534142583e-09
by O 0 3.3599583115773157e-09
British O 0 7.983193768268393e-07
- O 0 4.091222933766403e-07
Irish O 0 8.238752684519568e-07
migrants O 0 6.4925700371532e-08
. O 0 2.895018003101768e-09
. O 0 4.088585114914167e-08

Identification O 0 5.20122739544604e-06
of O 0 8.073754997894866e-07
constitutional O 0 6.99985821484006e-06
WT1 O 0 0.22263701260089874
mutations O 0 4.6308009871154354e-08
, O 0 8.315115818113838e-10
in O 0 9.58386481286766e-10
patients O 0 5.283383175402889e-10
with O 0 7.277543012662591e-10
isolated O 0 0.0002951124042738229
diffuse B-Disease 1 0.9999986886978149
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 8.795554840013153e-10
and O 0 7.836499504865202e-11
analysis O 0 1.901469426357494e-09
of O 0 1.2332484367050256e-08
genotype O 0 9.614354894438293e-07
/ O 0 1.415919996361481e-06
phenotype O 0 2.964786638415262e-08
correlations O 0 2.5423284810699442e-08
by O 0 7.758793052481394e-10
use O 0 1.840943619768609e-09
of O 0 1.1350343775973215e-08
a O 0 3.576549545414309e-08
computerized O 0 5.082293910163571e-07
mutation O 0 1.682441741479579e-08
database O 0 6.306271984612977e-07
. O 0 8.230406223219688e-08

Constitutional O 0 1.0117072633875068e-05
mutations O 0 3.0965983910391515e-07
of O 0 4.185882858109835e-07
the O 0 4.472576051739452e-07
WT1 O 0 4.320381412981078e-05
gene O 0 9.933216027491198e-09
, O 0 1.0300712505184606e-09
encoding O 0 1.2659421955163452e-08
a O 0 8.156737152376081e-08
zinc O 0 2.0929815946146846e-05
- O 0 6.113331892265705e-06
finger O 0 5.399573637987487e-05
transcription O 0 2.789120662782807e-05
factor O 0 7.540051427668004e-08
involved O 0 1.7529028895069132e-08
in O 0 1.3111549890254537e-07
renal O 1 1.0
and O 0 1.0844712505786447e-06
gonadal O 1 1.0
development O 1 0.9999996423721313
, O 0 7.896116649419582e-09
are O 0 2.768932583219197e-10
found O 0 9.582183935208377e-10
in O 0 1.7648282835125428e-09
most O 0 1.0572839270750478e-09
patients O 0 1.038348185211646e-09
with O 0 3.6544978154751107e-09
Denys B-Disease 1 1.0
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.0016309641068801284
DDS B-Disease 1 1.0
) O 0 4.3240856228976554e-08
, O 0 2.553850464437346e-09
or O 0 1.5257069208018947e-07
diffuse B-Disease 1 0.9682047367095947
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 0.0006676000775769353
DMS B-Disease 1 0.9927558302879333
) O 0 2.842816204662313e-09
associated O 0 1.750504097230987e-08
with O 0 1.2076227129398376e-08
pseudohermaphroditism B-Disease 1 1.0
and O 0 0.0017668993677943945
/ O 1 0.9999992847442627
or O 0 0.012426652014255524
Wilms B-Disease 1 1.0
tumor I-Disease 1 0.9999998807907104
( O 0 2.6107874873559922e-05
WT B-Disease 1 1.0
) O 0 2.742749245498999e-07
. O 0 1.964664591014298e-07

Most O 0 3.097868557233596e-07
mutations O 0 2.4845448365340417e-07
in O 0 1.5880766568443505e-06
DDS B-Disease 1 1.0
patients O 0 3.349781036376953e-05
lie O 0 0.00048127362970262766
in O 0 1.0749158718681429e-06
exon O 0 1.8515440842747921e-06
8 O 0 5.673613259205013e-07
or O 0 4.3085833567602094e-08
exon O 0 1.1016147993814229e-07
9 O 0 6.676331310018213e-08
, O 0 3.4098637247126362e-09
encoding O 0 9.048768134789498e-08
zinc O 0 0.00020558552932925522
finger O 0 0.004717986565083265
2 O 0 0.0009975937427952886
or O 0 2.6710629754234105e-05
zinc O 0 0.4225935935974121
finger O 0 0.0017032923642545938
3 O 0 3.7471095311047975e-06
, O 0 5.311221684678458e-09
respectively O 0 6.731442425689238e-08
, O 0 1.0566851837978675e-09
with O 0 5.673142511319895e-10
a O 0 2.1224094837180019e-07
hot O 0 8.965915299086191e-07
spot O 0 7.296270609913336e-07
( O 0 1.953156214540286e-08
R394W O 0 5.318341322890774e-07
) O 0 9.210882723209579e-09
in O 0 2.7236058741664237e-08
exon O 0 1.4948378748158575e-06
9 O 0 1.4772816712138592e-06
. O 0 2.607706903745566e-07

We O 0 1.2628597687580623e-06
analyzed O 0 1.8871643305828911e-06
a O 0 1.9449930732662324e-07
series O 0 4.158852817681691e-08
of O 0 5.467167696338038e-08
24 O 0 2.0371788878037478e-07
patients O 0 7.52634043976741e-09
, O 0 6.992140200168251e-10
10 O 0 8.930593153877453e-09
with O 0 6.024352128264354e-09
isolated B-Disease 0 0.000520195928402245
DMS I-Disease 1 0.999998927116394
( O 0 2.4376497549383203e-06
IDMS B-Disease 0 0.06781105697154999
) O 0 5.160946781046505e-09
, O 0 5.949576942221313e-10
10 O 0 5.328705032781045e-09
with O 0 1.057669773985026e-08
DDS B-Disease 1 1.0
, O 0 1.7444012456735436e-08
and O 0 5.523639323712359e-09
4 O 0 1.4662801106624102e-07
with O 0 8.474173363026694e-09
urogenital B-Disease 0 0.02235797606408596
abnormalities I-Disease 1 0.9992135763168335
and O 0 1.9924307707697153e-05
/ O 1 0.9999957084655762
or O 0 0.49208948016166687
WT B-Disease 1 1.0
. O 0 1.0127344467036892e-05

We O 0 2.314641278644558e-06
report O 0 1.8650217725735274e-06
WT1 O 0 0.00019387344946153462
heterozygous O 0 3.491421409762552e-07
mutations O 0 6.951307085500957e-09
in O 0 5.821565451924471e-09
16 O 0 9.754164409514487e-08
patients O 0 1.4798557046447058e-08
, O 0 1.2656059533711073e-09
4 O 0 1.8936277967895876e-07
of O 0 1.5552424770248763e-07
whom O 0 3.9018910769073045e-08
presented O 0 7.237889008138154e-07
with O 0 6.105037186898699e-07
IDMS B-Disease 1 0.999985933303833
. O 0 2.3358404632745078e-06

One O 0 3.228016112188925e-06
male O 0 2.6967575195158133e-07
and O 0 2.994976489034684e-09
two O 0 2.4935024711680853e-08
female O 0 2.047532461801893e-06
IDMS B-Disease 1 0.9999792575836182
patients O 0 5.876119857362028e-08
with O 0 1.5073574388679845e-08
WT1 O 1 0.999997615814209
mutations O 0 5.0043390729115345e-06
underwent O 0 2.964092345791869e-05
normal O 0 0.00025917505263350904
puberty O 0 0.00010434309660922736
. O 0 2.4609465754110715e-07

Two O 0 6.243039933906402e-07
mutations O 0 2.1450493647989788e-07
associated O 0 3.3849667602225963e-07
with O 0 8.448597554888693e-08
IDMS B-Disease 1 1.0
are O 0 1.3285540445551192e-09
different O 0 2.013390704158624e-10
from O 0 1.5044845369516224e-09
those O 0 1.3942526022603374e-09
described O 0 8.993227140763338e-08
in O 0 2.3160721411841223e-06
DDS B-Disease 1 1.0
patients O 0 3.724876705746283e-06
. O 0 3.418716403302824e-07

No O 0 4.548748620436527e-05
WT1 O 0 0.0005775954923592508
mutations O 0 1.1888961637396278e-07
were O 0 4.3165620411400596e-08
detected O 0 2.4796820596861835e-08
in O 0 2.6060045232867424e-09
the O 0 6.010349551388572e-09
six O 0 5.0504240789450705e-08
other O 0 9.023911395900086e-09
IDMS B-Disease 1 1.0
patients O 0 1.9046142085699103e-07
, O 0 1.5786962848096664e-09
suggesting O 0 1.2960971673692256e-07
genetic O 0 1.954384742930415e-07
heterogeneity O 0 8.350898497155868e-07
of O 0 1.564574461099255e-07
this O 0 9.755764551755419e-08
disease O 0 3.846259460260626e-06
. O 0 1.3814235444442602e-07

We O 0 4.5734296350019576e-07
analyzed O 0 1.313051143370103e-06
genotype O 0 7.368389105977258e-06
/ O 0 2.0653615138144232e-06
phenotype O 0 9.286067381708563e-08
correlations O 0 1.30726462543862e-07
, O 0 8.906808068864791e-10
on O 0 3.1034610437075116e-09
the O 0 2.5209603293774308e-09
basis O 0 4.2741078232211294e-08
of O 0 2.646179719789643e-09
the O 0 2.455334824347233e-09
constitution O 0 5.116837509255845e-10
of O 0 9.816273127682962e-09
a O 0 3.2421194617882065e-08
WT1 O 0 2.0267007130314596e-06
mutation O 0 2.2207713445965283e-09
database O 0 1.740685462436886e-08
of O 0 7.97366617177886e-09
84 O 0 2.471839479767368e-07
germ O 0 0.05474933981895447
- O 0 0.0006444013561122119
line O 0 1.2170916079412564e-06
mutations O 0 4.313547741219281e-09
, O 0 4.2348125006697046e-10
to O 0 3.6370417788589293e-10
compare O 0 8.741571910775292e-09
the O 0 3.5443041834781752e-09
distribution O 0 6.203339175669953e-09
and O 0 9.102214537648479e-10
type O 0 1.6635456745461852e-07
of O 0 4.464019696115429e-07
mutations O 0 9.466434747196217e-09
, O 0 7.639495147593323e-10
according O 0 3.4393028425228067e-09
to O 0 4.843286327549379e-10
the O 0 2.4236717077741332e-09
different O 0 2.288505829284304e-09
symptoms O 0 1.3935824938471342e-07
. O 0 1.3497162854037015e-07

This O 0 3.6821899129790836e-07
demonstrated O 0 2.6916163164969475e-07
( O 0 2.6305459144282395e-08
1 O 0 5.3617810635842034e-08
) O 0 1.6122855273081882e-09
the O 0 2.5859858698851212e-09
association O 0 7.246437228047853e-09
between O 0 1.3596869408161183e-08
mutations O 0 6.60352084125293e-09
in O 0 2.736065596309345e-08
exons O 0 7.103679422471032e-08
8 O 0 3.267098946935221e-08
and O 0 2.5442288276167346e-09
9 O 0 7.076740615730159e-08
and O 0 5.463120622550832e-09
DMS B-Disease 0 1.832369525800459e-05
; O 0 1.2444764108110462e-09
( O 0 1.9478167967434956e-09
2 O 0 6.161618770761379e-09
) O 0 2.261851400620074e-10
among O 0 8.147442442929531e-11
patients O 0 3.8202047081270507e-10
with O 0 6.694343968050021e-10
DMS B-Disease 0 0.02575240470468998
, O 0 3.1336420125427367e-09
a O 0 5.658167712141449e-09
higher O 0 6.489695447697841e-09
frequency O 0 4.861985036797023e-09
of O 0 2.62741073342454e-09
exon O 0 1.6479473785580012e-08
8 O 0 2.8448015054749476e-09
mutations O 0 8.394742539996614e-11
among O 0 4.345343876388519e-11
46 O 0 8.411547014475218e-09
, O 0 1.8926151756915033e-09
XY O 1 0.6861556172370911
patients O 0 1.1765000529351255e-08
with O 0 4.3130024551807367e-10
female O 0 4.1298896746866376e-08
phenotype O 0 4.041905476981356e-09
than O 0 4.3051756604128855e-11
among O 0 5.096711247487562e-11
46 O 0 6.378416017582822e-09
, O 0 4.960186927860377e-09
XY O 1 0.971805214881897
patients O 0 6.746079250774528e-09
with O 0 2.5135168946199826e-10
sexual O 0 3.680521487581245e-08
ambiguity O 0 1.0570045816393758e-07
or O 0 2.1773120195689444e-08
male O 0 2.415254440890635e-09
phenotype O 0 4.826024024850994e-10
; O 0 1.8205355625799946e-11
and O 0 1.4637213663348803e-10
( O 0 1.735877108721695e-09
3 O 0 6.517929751481688e-09
) O 0 1.4028733730242493e-10
statistically O 0 3.6512212697736857e-10
significant O 0 3.168619810978157e-10
evidence O 0 4.891545835050692e-09
that O 0 4.4985118408114033e-10
mutations O 0 1.075063038591395e-09
in O 0 6.11973538511279e-09
exons O 0 3.876654375289945e-08
8 O 0 1.7898676318850448e-08
and O 0 1.515434333576593e-09
9 O 0 1.4678409598900544e-08
preferentially O 0 1.269535410131084e-08
affect O 0 7.420885683728784e-09
amino O 0 3.4520066805043825e-09
acids O 0 3.5846456358790135e-10
with O 0 2.233904901338679e-11
different O 0 1.3180133373591474e-10
functions O 0 2.7498721522078995e-08
. O 0 1.0571917563595434e-08
. O 0 1.4206511878001038e-07

The O 0 1.8226515749120153e-05
185delAG O 0 5.3154450142756104e-05
BRCA1 O 0 5.94937773712445e-07
mutation O 0 3.359317268802897e-09
originated O 0 1.1878144690058434e-08
before O 0 4.73019134972219e-09
the O 0 9.395382249977047e-09
dispersion O 0 1.1922864473490336e-07
of O 0 7.367381016365471e-08
Jews O 0 6.138161268154363e-08
in O 0 1.0951909601430998e-08
the O 0 2.2819124367856602e-08
diaspora O 0 2.1075075906651364e-08
and O 0 1.4337228071426011e-09
is O 0 1.0608290912372809e-09
not O 0 7.10528524905385e-10
limited O 0 7.78111619581523e-09
to O 0 6.642760297381756e-08
Ashkenazim O 0 2.9174972951295786e-05
. O 0 5.770735924670589e-07

The O 0 1.0639490710673272e-06
185delAG O 0 2.347099098187755e-06
mutation O 0 1.533743088089068e-08
in O 0 1.2380184877258671e-08
BRCA1 O 0 2.224553874441426e-08
is O 0 5.468392405560962e-10
detected O 0 6.5617369315873475e-09
in O 0 3.057666564387773e-09
Ashkenazi O 0 5.180111770641815e-07
Jews O 0 2.6128992303142695e-08
both O 0 3.6772922484828996e-09
in O 0 3.836638384768776e-08
familial B-Disease 1 0.9995330572128296
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 9.804971341509372e-07
in O 0 4.350284399379234e-08
the O 0 2.0158980262863224e-08
general O 0 3.527661363023071e-08
population O 0 2.7928126478116155e-09
. O 0 1.442468100520955e-08

All O 0 4.098791066553531e-07
tested O 0 3.360611060543306e-07
Ashkenazi O 0 2.0665220290538855e-06
mutation O 0 2.9940814272322314e-08
carriers O 0 5.580282458339525e-09
share O 0 1.188834453103027e-08
the O 0 7.728932160944169e-09
same O 0 9.45250633321848e-09
allelic O 0 2.8532920737234235e-07
pattern O 0 3.772045999994589e-07
at O 0 1.0251989124299143e-06
the O 0 3.008806004345388e-07
BRCA1 O 0 9.972484349418664e-07
locus O 0 1.0089883062391891e-06
. O 0 7.880052521613834e-08

Our O 0 6.404343821486691e-06
previous O 0 7.779285056130902e-07
study O 0 6.074500191743937e-08
showed O 0 1.587668663205477e-08
that O 0 1.4249681989930707e-10
this O 0 1.1469596383761882e-09
Ashkenazi O 0 5.2231701630489624e-08
mutation O 0 2.6531832286735835e-10
also O 0 1.319930414966919e-10
occurs O 0 1.065954435830463e-09
in O 0 4.037452150384979e-09
Iraqi O 0 5.69549365536659e-06
Jews O 0 1.1878830008527075e-07
with O 0 1.0905524261417554e-09
a O 0 2.210233418509233e-08
similar O 0 4.186323732113806e-09
allelic O 0 3.9215365177369677e-07
pattern O 0 1.971783376575331e-06
. O 0 4.43979814690465e-07

We O 0 5.893151637792471e-07
extended O 0 1.5430806854510593e-07
our O 0 5.1302599501923396e-08
analysis O 0 1.29475257182321e-08
to O 0 1.1534820876235585e-09
other O 0 4.972242617640177e-10
non O 0 5.259448698780034e-08
- O 0 5.382571544032544e-08
Ashkenazi O 0 1.1610651995397347e-07
subsets O 0 1.2199905086163199e-07
354 O 0 1.0875020706180294e-07
of O 0 4.473162285023591e-09
Moroccan O 0 4.7681757564532745e-07
origin O 0 1.2005216376564931e-08
, O 0 2.2896367024571873e-09
200 O 0 2.5925158908535195e-08
Yemenites O 0 1.5069902019604342e-06
and O 0 4.754940885476344e-09
150 O 0 6.675835351188653e-08
Iranian O 0 1.4059252180231852e-06
Jews O 0 6.220046770977206e-07
. O 0 1.339016080237343e-07

Heteroduplex O 0 0.00015077603165991604
analysis O 0 2.638755347561528e-07
complemented O 0 5.4247255576456155e-08
by O 0 1.7993481149503054e-09
direct O 0 8.331820566809256e-09
DNA O 0 9.818408308603921e-09
sequencing O 0 3.406561477348191e-09
of O 0 1.0299224584287003e-08
abnormally O 0 7.095906084941817e-08
migrating O 0 3.5984921709086848e-09
bands O 0 1.681543615461578e-08
were O 0 6.863042756322102e-08
employed O 0 2.4862922600732418e-06
. O 0 3.652918110219616e-07

Four O 0 2.0866837076027878e-06
of O 0 4.2865175942097267e-07
Moroccan O 0 7.833640665921848e-06
origin O 0 1.9121264571708707e-08
( O 0 2.336354887333414e-09
1 O 0 2.8754707503964028e-09
. O 0 7.386449785151683e-11
1 O 0 2.093883733067514e-09
% O 0 2.3068232046785653e-10
) O 0 3.7914931610982805e-11
and O 0 4.009315102138089e-11
none O 0 6.555181730760751e-09
of O 0 1.852208164621061e-08
the O 0 9.932897881981262e-08
Yemenites O 0 0.00012443496962077916
or O 0 2.0813207868286554e-07
Iranians O 0 3.491387872145424e-07
was O 0 1.1779588504623462e-07
a O 0 2.7514564848729606e-08
carrier O 0 1.2540988691966959e-08
of O 0 4.3115097270174374e-08
the O 0 1.0954483542491289e-07
185delAG O 0 4.623750101018231e-06
mutation O 0 1.4199048337104614e-07
. O 0 1.1823674128663697e-07

BRCA1 O 0 2.9315115170902573e-05
allelic O 0 4.781121333508054e-06
patterns O 0 3.455052421941218e-07
were O 0 7.25947160162832e-08
determined O 0 3.05952347900984e-08
for O 0 6.775945138315365e-09
four O 0 1.0662579263964744e-08
of O 0 9.429564684637626e-09
these O 0 3.100980305870138e-10
individuals O 0 2.3350038569347475e-10
and O 0 2.01206232230966e-10
for O 0 7.379835076370966e-10
12 O 0 9.838991843480471e-09
additional O 0 4.546829579510359e-09
non O 0 5.892089802728151e-07
- O 0 1.9997455069642456e-07
Ashkenazi O 0 1.9642338600078801e-07
185delAG O 0 1.227891601729425e-07
mutation O 0 2.4567776701900357e-09
carriers O 0 1.2492756829018958e-09
who O 0 5.406284753206592e-09
had O 0 5.857897849637084e-05
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0002401688543614

Six O 0 1.7921645849128254e-05
non O 0 0.00012386636808514595
- O 0 5.378684363677166e-06
Ashkenazi O 0 1.4226498024072498e-06
individuals O 0 1.4999773645385517e-09
shared O 0 3.398736225790344e-08
the O 0 2.1603515421020347e-08
common O 0 2.438585511299607e-08
Ashkenazi O 0 1.5784975175847649e-06
haplotype O 0 7.248333417919639e-07
, O 0 8.800711270851025e-09
four O 0 3.30374483326068e-08
had O 0 7.10293406314122e-08
a O 0 4.7372367362186196e-08
closely O 0 1.7613318803455513e-08
related O 0 7.202180540843983e-08
pattern O 0 4.195638609871821e-07
, O 0 1.4238060730420443e-09
and O 0 1.3303442791823272e-09
the O 0 2.5941087500314097e-08
rest O 0 1.1888099749057801e-07
( O 0 1.9259330130694252e-08
n O 0 1.266864302351678e-07
= O 0 2.312778093482848e-07
6 O 0 3.092525346914954e-08
) O 0 2.435668611244779e-10
displayed O 0 6.479145664428643e-09
a O 0 1.9560715713851096e-08
distinct O 0 1.4246598567524416e-08
BRCA1 O 0 1.638456268437949e-07
allelic O 0 6.915029189258348e-07
pattern O 0 2.0221693830535514e-06
. O 0 6.657537028331717e-07

We O 0 1.1181385843883618e-06
conclude O 0 1.6605071095909807e-06
that O 0 1.2124555581749519e-08
the O 0 1.216542244719676e-07
185delAG O 0 4.265847564965952e-06
BRCA1 O 0 4.841592016191498e-08
mutation O 0 4.122621688473771e-10
occurs O 0 3.7703154487367385e-10
in O 0 3.161255146544306e-10
some O 0 7.971259763372984e-10
non O 0 1.7176212168124039e-06
- O 0 7.791015832481207e-07
Ashkenazi O 0 7.905921961537388e-07
populations O 0 1.3943217691547716e-09
at O 0 8.985558963559015e-09
rates O 0 2.8370530369414837e-09
comparable O 0 5.903820543551319e-09
with O 0 1.3279123634024614e-10
that O 0 8.596657830040044e-10
of O 0 8.846879495649773e-08
Ashkenazim O 0 1.0830824066943023e-05
. O 0 3.9955733655006043e-07

The O 0 1.3637135225508246e-06
majority O 0 1.4785634938618841e-08
of O 0 1.3634310391807958e-07
Jewish O 0 3.817095148406224e-06
185delAG O 0 6.272668542806059e-06
mutation O 0 3.2157359441953304e-08
carriers O 0 6.533998675450903e-09
have O 0 4.846428258709068e-10
a O 0 5.586394902223901e-09
common O 0 4.0988585858769966e-09
allelic O 0 1.0441284103990256e-07
pattern O 0 8.446951937912672e-07
, O 0 1.2354191447627727e-08
supporting O 0 2.1726312127157144e-07
the O 0 1.568490120007482e-07
founder O 0 3.643882337200921e-06
effect O 0 3.257976288750797e-08
notion O 0 5.9221616055538107e-08
, O 0 7.058400530723929e-10
but O 0 3.998366360224992e-10
dating O 0 2.6567256838916364e-08
the O 0 1.945425820437663e-09
mutations O 0 3.0750529900203105e-10
origin O 0 5.421451620968298e-10
to O 0 1.2957696027271481e-09
an O 0 2.3553303751810972e-09
earlier O 0 1.0525178950615555e-08
date O 0 3.93353687400122e-08
than O 0 9.145406654198496e-10
currently O 0 3.4547467109291574e-09
estimated O 0 3.8863678497591536e-08
. O 0 8.262713890871964e-08

However O 0 6.09464734679932e-07
, O 0 4.8183554923753036e-09
the O 0 2.5001780645794724e-09
different O 0 1.3837085921508674e-09
allelic O 0 2.38253491602336e-07
pattern O 0 8.490896448165586e-07
at O 0 8.273704565908702e-07
the O 0 2.642661343088548e-07
BRCA1 O 0 5.322237939253682e-07
locus O 0 1.7186947331992997e-07
even O 0 5.850615547586813e-10
in O 0 3.852576591079071e-10
some O 0 3.2889915790867974e-10
Jewish O 0 3.061508024870818e-08
mutation O 0 1.991635967257821e-09
carriers O 0 1.2447944897076013e-09
, O 0 9.008567225521347e-10
might O 0 5.09038189377975e-09
suggest O 0 3.43485311304903e-08
that O 0 7.683494951393754e-10
the O 0 2.1472633449093337e-08
mutation O 0 2.0085817453718846e-09
arose O 0 4.480611082158248e-08
independently O 0 7.573605387278803e-08
. O 0 2.2422964818247237e-08
. O 0 9.488509533639444e-08

Crystal O 0 0.002941620536148548
structure O 0 0.0001147061848314479
of O 0 0.0005031207110732794
the O 0 0.3174267113208771
hemochromatosis B-Disease 1 1.0
protein O 1 0.9999990463256836
HFE O 1 0.9999997615814209
and O 0 1.0453359777784499e-07
characterization O 0 1.8336506855121115e-06
of O 0 1.7278931352393556e-07
its O 0 1.3512483576505474e-08
interaction O 0 1.1252034681774603e-07
with O 0 4.860983615628811e-09
transferrin O 0 3.0425735531025566e-05
receptor O 0 7.373309472313849e-06
. O 0 1.2980751762370346e-07

HFE O 1 0.9983144998550415
is O 0 8.893479161997675e-07
an O 0 9.94984930002829e-08
MHC O 0 3.4652659905987093e-06
- O 0 6.603186920983717e-05
related O 0 4.97108976560412e-06
protein O 0 5.536879825740471e-07
that O 0 8.917737659430713e-10
is O 0 5.243898093532096e-10
mutated O 0 2.4280071286852944e-09
in O 0 1.7590119583132946e-08
the O 0 2.096275693475036e-06
iron B-Disease 1 1.0
- I-Disease 1 1.0
overload I-Disease 1 1.0
disease I-Disease 1 1.0
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 1 0.9894691705703735

HFE O 0 0.013807632029056549
binds O 0 6.649676834058482e-06
to O 0 1.7709180610836484e-07
transferrin O 0 2.1384663341450505e-05
receptor O 0 4.63076185042155e-06
( O 0 4.293521627118935e-08
TfR O 0 9.174132173939142e-06
) O 0 1.3199410453523797e-09
and O 0 3.878765642006954e-10
reduces O 0 9.392120858819908e-09
its O 0 2.809557031469012e-09
affinity O 0 3.952149540964456e-08
for O 0 4.147667453935355e-08
iron O 0 0.00012326992873568088
- O 0 1.5072710993990768e-05
loaded O 0 3.394905661480152e-06
transferrin O 0 9.524473716737702e-05
, O 0 1.664407420776115e-07
implicating O 0 0.0003211387956980616
HFE O 1 0.9975057244300842
in O 0 9.031720765051432e-06
iron O 1 0.9987853169441223
metabolism O 1 0.9999740123748779
. O 0 3.1942081477609463e-06

The O 0 3.068194564548321e-05
2 O 0 1.8102176909451373e-05
. O 0 1.4059038448976935e-06

6 O 0 0.0002869842865038663
A O 0 3.773491334868595e-05
crystal O 0 0.00014435866614803672
structure O 0 0.00019579470972530544
of O 0 0.00023674809199292213
HFE O 1 0.9999804496765137
reveals O 0 4.880895630776649e-06
the O 0 9.668865175171959e-08
locations O 0 3.916789808044996e-07
of O 0 3.754027420654893e-05
hemochromatosis B-Disease 1 1.0
mutations O 0 8.208752115024254e-05
and O 0 6.175699240884569e-07
a O 0 1.4069731150812004e-05
patch O 0 0.000158801325596869
of O 0 0.0003172073920723051
histidines O 1 0.944904625415802
that O 0 1.2567520357720241e-08
could O 0 4.9819188774336e-09
be O 0 4.8135606611765525e-09
involved O 0 4.7283720050472766e-08
in O 0 9.532753608709754e-08
pH O 0 2.6499739760765806e-05
- O 0 7.523238764406415e-06
dependent O 0 2.5966044177039294e-06
interactions O 0 9.731342061058967e-07
. O 0 1.471788806384211e-07

We O 0 1.0928205256277579e-06
also O 0 3.3054341486149497e-08
demonstrate O 0 2.467270121542242e-07
that O 0 7.302494253735858e-08
soluble O 0 0.00011388095299480483
TfR O 1 0.6761664748191833
and O 0 6.043574671821261e-07
HFE O 0 0.0023592542856931686
bind O 0 1.4076048273636843e-06
tightly O 0 2.589442829048494e-06
at O 0 1.759828194280999e-07
the O 0 3.0630442182655315e-08
basic O 0 3.634452809819777e-07
pH O 0 4.2683728906922624e-07
of O 0 5.6220248012550655e-08
the O 0 1.1881162720328575e-07
cell O 0 1.0446079841130995e-06
surface O 0 3.4034562190754514e-07
, O 0 3.588491948036676e-09
but O 0 2.5733504216418623e-09
not O 0 7.783877542522077e-09
at O 0 1.6583501860623073e-07
the O 0 7.602523055538768e-08
acidic O 0 1.717876784823602e-06
pH O 0 5.553640676225768e-06
of O 0 1.1830830999315367e-06
intracellular O 0 0.0001042228759615682
vesicles O 0 0.00034493437851779163
. O 0 3.522723773130565e-06

TfR O 1 0.9991772770881653
HFE O 0 0.025474827736616135
stoichiometry O 0 2.704834878386464e-05
( O 0 5.102842237647565e-07
2 O 0 1.266372606778532e-07
1 O 0 4.675531783959741e-08
) O 0 1.5360082095128291e-09
differs O 0 5.570743422111946e-09
from O 0 8.941757556613084e-09
TfR O 0 2.222743751190137e-05
transferrin O 0 1.2843186141253682e-06
stoichiometry O 0 7.544510793877635e-08
( O 0 2.1770785174624052e-09
2 O 0 3.925777480873194e-09
2 O 0 4.301716316490456e-09
) O 0 1.9654530780677248e-10
, O 0 4.6646398549343715e-11
implying O 0 1.817699324391242e-09
a O 0 4.084730609310583e-10
different O 0 2.175963749462273e-11
mode O 0 1.5954427112774283e-08
of O 0 1.929491011409823e-09
binding O 0 6.0838427629050784e-09
for O 0 1.4225338240692054e-08
HFE O 0 0.00029710744274780154
and O 0 3.8446600569841394e-08
transferrin O 0 1.8903827367466874e-05
to O 0 9.856332638946697e-08
TfR O 0 0.012324996292591095
, O 0 7.72333219600796e-09
consistent O 0 6.802831364893791e-08
with O 0 5.104963674007479e-10
our O 0 7.294281800795943e-08
demonstration O 0 1.6190665519388858e-07
that O 0 2.2755177742084243e-09
HFE O 0 1.831452209444251e-05
, O 0 5.499922739460317e-09
transferrin O 0 1.6506958218087675e-06
, O 0 4.214942617153383e-09
and O 0 1.597842569367458e-08
TfR O 0 0.00021048850612714887
form O 0 1.0308897913091641e-07
a O 0 6.85161069213791e-07
ternary O 0 3.466428825049661e-05
complex O 0 0.00012043239985359833
. O 0 2.7085493456979748e-06

Identification O 0 8.457672606709821e-07
of O 0 1.3585119518211286e-07
three O 0 9.930166022797948e-09
novel O 0 1.4861075214867014e-07
mutations O 0 6.852026945836087e-09
and O 0 1.6183797635349606e-09
a O 0 7.894325193547047e-09
high O 0 2.387499620226663e-08
frequency O 0 2.849663438553307e-08
of O 0 1.8405653889885798e-08
the O 0 7.404431556778945e-08
Arg778Leu O 0 0.0001413257559761405
mutation O 0 1.0053391896747144e-08
in O 0 1.3681938249021641e-08
Korean O 0 0.0004154822672717273
patients O 0 7.724922923557642e-09
with O 0 3.5892724348229876e-09
Wilson B-Disease 0 0.00012544944183900952
disease I-Disease 0 9.562267950968817e-05
. O 0 2.2225485452054272e-07

Four O 0 1.0159780003959895e-06
mutations O 0 2.3790535763623666e-08
- O 0 2.811634089994186e-07
- O 0 5.977940418233629e-07
R778L O 0 1.9332385363668436e-06
, O 0 9.94132864917674e-09
A874V O 0 5.474351496559393e-07
, O 0 4.305623857447927e-09
L1083F O 0 2.3570085261326312e-07
, O 0 2.930305775805664e-09
and O 0 1.729136056560776e-09
2304delC O 0 1.8013824387708155e-07
- O 0 2.3164224671745615e-07
- O 0 5.514873535616971e-08
in O 0 1.4149918570183218e-08
the O 0 3.4046792052322417e-08
copper O 0 1.3917166370447376e-06
- O 0 7.747207320107918e-08
transporting O 0 1.424199922439584e-07
enzyme O 0 4.454756918903513e-08
, O 0 6.413476860700484e-09
P O 0 8.578150300309062e-06
- O 0 4.2445046233297035e-07
type O 0 4.504205207922496e-06
ATPase O 0 0.028478166088461876
( O 0 2.8872770840848716e-08
ATP7B O 0 3.438427256696741e-06
) O 0 5.543827619192143e-10
, O 0 8.704759829614162e-11
were O 0 7.285514413979399e-10
identified O 0 5.598566055198262e-09
in O 0 1.9307952570102316e-08
Korean O 0 0.24242085218429565
Patients O 0 8.724335742726907e-08
with O 0 4.036944112328911e-09
Wilson B-Disease 0 0.00044413708383217454
disease I-Disease 0 0.00019108792184852064
. O 0 5.91263585647539e-07

Arg778Leu O 0 0.014175336807966232
, O 0 7.922611189314921e-08
the O 0 3.197003550781119e-08
most O 0 2.6830262456201126e-09
frequently O 0 3.3798772669513255e-09
reported O 0 5.603704611445437e-09
mutation O 0 3.2636765512350507e-10
of O 0 3.5357292649251804e-09
this O 0 1.9439050369385313e-09
enzyme O 0 3.871127773891203e-08
, O 0 2.89899637628821e-09
was O 0 1.341885962347078e-07
found O 0 5.191929108860904e-09
in O 0 2.8146205366397226e-09
six O 0 1.003791094689177e-08
of O 0 1.7834880239320228e-08
eight O 0 2.4802117692956926e-08
unrelated O 0 2.2558246826065442e-07
patients O 0 2.2923762887927523e-09
studied O 0 3.0480489243700504e-08
, O 0 4.5794476544180895e-10
an O 0 1.2080066946751344e-09
allele O 0 7.165097959394018e-10
frequency O 0 8.038871790461144e-09
of O 0 3.256292657738413e-08
37 O 0 1.176202545138949e-06
. O 0 4.826010240321921e-07

5 O 0 4.0428863030683715e-06
% O 0 4.735962733093402e-08
, O 0 9.669686162894209e-10
which O 0 1.8279058822123773e-10
is O 0 1.9989609967296929e-10
considerably O 0 2.795295994673097e-09
higher O 0 6.405016961252841e-09
than O 0 9.736306899599256e-11
those O 0 5.7766305627815484e-11
in O 0 3.633789935619802e-10
other O 0 3.2910749125925065e-10
Asian O 0 8.203152646046874e-08
populations O 0 5.02880359576352e-09
. O 0 1.9815731278072235e-08

The O 0 5.136732283972378e-07
novel O 0 4.318052617691137e-07
single O 0 1.9581085552999866e-07
nucleotide O 0 6.636681177951687e-07
deletion O 0 1.3635806794809469e-07
, O 0 3.590847397205721e-09
2304delC O 0 1.2220866096868122e-07
, O 0 3.825544325763985e-09
was O 0 1.592621998725008e-07
found O 0 1.5434862277174943e-08
in O 0 2.1576504138920427e-08
one O 0 8.615378987997246e-08
patient O 0 2.1702676349377725e-06
. O 0 3.5327317959854554e-07

Since O 0 1.2115074241592083e-06
a O 0 6.10125283628804e-08
mutation O 0 2.387889885824279e-09
at O 0 1.6216534959312412e-07
cDNA O 0 1.8404833781460184e-06
nucleotide O 0 1.6180707689272822e-06
2302 O 0 1.5144723874982446e-05
( O 0 1.5103159611840056e-08
2302insC O 0 1.0256492544158391e-07
) O 0 3.181459984347157e-09
had O 0 5.948717518577951e-09
been O 0 5.035656780449926e-09
previously O 0 1.2956962613941414e-08
described O 0 3.3560144885314e-08
, O 0 1.3822208932978697e-09
this O 0 1.9240669058007143e-09
region O 0 2.9470328399838763e-08
of O 0 2.0896160890515603e-07
the O 0 9.95419441096601e-07
ATP7B O 1 0.9999396800994873
gene O 0 3.501831358221352e-08
may O 0 3.484872390657756e-09
be O 0 1.4460981301311904e-09
susceptible O 0 1.8229254550305996e-08
to O 0 1.64187348161704e-08
gene O 0 2.589432881450193e-07
rearrangements O 0 2.054231481452007e-05
causing O 0 0.010691246017813683
Wilson B-Disease 1 0.8989214301109314
disease I-Disease 1 0.8758091926574707
. O 0 1.3895033816879732e-06

Disruption O 0 0.0022625173442065716
of O 0 8.746354069444351e-06
splicing O 0 5.225399945629761e-06
regulated O 0 1.79144751655258e-06
by O 0 7.93917536157096e-08
a O 0 6.495840239040263e-07
CUG O 0 0.0001531062152935192
- O 0 3.1292182711695204e-07
binding O 0 5.830257876482392e-08
protein O 0 5.007853474126023e-07
in O 0 6.351606316457037e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 2.3460047486878466e-06

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.959609866142273
DM B-Disease 1 1.0
) O 0 2.912366596774518e-07
is O 0 1.3030321710516546e-08
caused O 0 4.2146634626760715e-08
by O 0 1.2572602514637765e-08
a O 0 4.2954877699230565e-07
CTG O 0 0.0004758636059705168
expansion O 0 4.409488383316784e-07
in O 0 1.896030710213381e-08
the O 0 2.449573344165401e-08
3 O 0 9.777242837571976e-08
untranslated O 0 1.768635593180079e-05
region O 0 1.58964198249123e-07
of O 0 7.623301030434959e-07
the O 0 2.1114938135724515e-05
DM B-Disease 1 1.0
gene O 0 3.7166164474911056e-06
. O 0 5.481493303705065e-07

One O 0 1.1912402442249004e-06
model O 0 5.973785732749093e-07
of O 0 1.1044187886000145e-05
DM B-Disease 1 1.0
pathogenesis O 1 0.9999991655349731
suggests O 0 5.119887191540329e-06
that O 0 1.9736745571208303e-08
RNAs O 0 1.0713058145483956e-05
from O 0 2.4667379250331578e-08
the O 0 9.285267665859465e-09
expanded O 0 1.4450896479445419e-08
allele O 0 2.212383609645485e-09
create O 0 2.066475435213988e-09
a O 0 1.6495198096322383e-08
gain O 0 2.7332029617355147e-07
- O 0 2.9288209191236092e-08
of O 0 1.9395955064283044e-07
- O 0 1.384500620815743e-07
function O 0 4.074277271115534e-08
mutation O 0 5.105567635332875e-10
by O 0 3.121304326114682e-10
the O 0 2.5465543007641145e-09
inappropriate O 0 1.639782709617066e-08
binding O 0 5.002352310157221e-09
of O 0 9.973120107531486e-09
proteins O 0 4.493017513595987e-09
to O 0 9.331944106349965e-09
the O 0 3.4696830653047073e-07
CUG O 0 0.004825735464692116
repeats O 0 1.1908236956514884e-05
. O 0 1.5569446532026632e-06

Data O 0 1.1570948117878288e-05
presented O 0 5.38310416686727e-07
here O 0 2.314126135161132e-07
indicate O 0 6.971465182914471e-08
that O 0 7.168460824935607e-10
the O 0 8.069195978066546e-09
conserved O 0 4.02615057737421e-07
heterogeneous O 0 8.923495329327125e-07
nuclear O 0 4.264852395863272e-05
ribonucleoprotein O 0 0.003822725499048829
, O 0 1.0834090602429569e-07
CUG O 0 5.160907676327042e-05
- O 0 2.65396863596834e-07
binding O 0 3.932089143177109e-08
protein O 0 9.027099423519758e-08
( O 0 1.0394504812438754e-08
CUG O 0 3.50478967447998e-06
- O 0 7.234983741000178e-07
BP O 0 6.02528962190263e-06
) O 0 6.028605170627088e-09
, O 0 1.5850021295449324e-09
may O 0 1.4797372216435178e-08
mediate O 0 5.047891704634822e-07
the O 0 1.8659490308436943e-07
trans O 0 5.579528874477546e-07
- O 0 1.3459992942443932e-06
dominant O 0 1.0282877838108107e-07
effect O 0 2.116006214691879e-08
of O 0 3.9271796481443744e-08
the O 0 1.0124672655820177e-07
RNA O 0 3.3655899187579053e-06
. O 0 7.899494391949702e-08

CUG O 0 0.48322975635528564
- O 0 0.0026324160862714052
BP O 0 0.000411343906307593
was O 0 1.2870922319052625e-06
found O 0 1.7604318003350272e-08
to O 0 2.807708954222221e-09
bind O 0 1.8549940250522923e-08
to O 0 8.258094652546788e-09
the O 0 2.085771910742551e-07
human O 0 1.0572804285402526e-06
cardiac O 0 0.0033209819812327623
troponin O 0 0.00012437600526027381
T O 0 1.031434931064723e-05
( O 0 2.757577277634482e-08
cTNT O 0 5.962174896012584e-07
) O 0 3.795440850495879e-09
pre O 0 1.7590295442460047e-07
- O 0 7.04743001733732e-08
messenger O 0 2.403833434527769e-07
RNA O 0 8.82815243130608e-08
and O 0 3.653095048683497e-10
regulate O 0 2.4830504319339752e-09
its O 0 1.3960754774444695e-09
alternative O 0 3.157907713102759e-08
splicing O 0 1.0889295936067356e-06
. O 0 1.4440693973938323e-07

Splicing O 0 4.187761805951595e-05
of O 0 3.880563781422097e-06
cTNT O 0 7.438429747708142e-05
was O 0 2.151560147467535e-05
disrupted O 0 0.00011939438263652846
in O 0 8.251528015534859e-06
DM B-Disease 1 1.0
striated O 0 0.3953448235988617
muscle O 0 1.1431660823291168e-05
and O 0 2.641390572932778e-08
in O 0 1.1119269061055093e-07
normal O 0 6.84099541103933e-06
cells O 0 1.5570618927540636e-07
expressing O 0 4.8850591127802545e-08
transcripts O 0 7.972527100719162e-07
that O 0 3.675566961902632e-09
contain O 0 8.82675479374484e-08
CUG O 0 0.00019626552239060402
repeats O 0 5.851452442584559e-06
. O 0 4.575231571379845e-07

Altered O 0 6.84557653585216e-06
expression O 0 6.351982051455707e-07
of O 0 2.1098004765462974e-07
genes O 0 6.706528665745282e-08
regulated O 0 3.2370840585826954e-07
posttranscriptionally O 0 1.4965680747991428e-06
by O 0 7.084330633233549e-08
CUG O 0 0.02615230903029442
- O 0 2.741649586823769e-05
BP O 0 1.4148795344226528e-05
therefore O 0 3.499320655464544e-08
may O 0 6.944654629137403e-09
contribute O 0 2.851647984414285e-08
to O 0 9.3948182211534e-07
DM B-Disease 1 1.0
pathogenesis O 1 0.9997842907905579
. O 0 3.644090611487627e-07
. O 0 3.6868246411358996e-07

Identification O 0 3.041660193048301e-06
of O 0 3.062515929741494e-07
a O 0 1.2942123817083484e-07
novel O 0 2.777528891328984e-07
nonsense O 0 1.126074607782357e-06
mutation O 0 4.000763720313216e-09
and O 0 4.3861730913974384e-10
a O 0 1.5591385960078696e-08
missense O 0 9.871703809949395e-08
substitution O 0 4.669308939497796e-09
in O 0 9.15839848403266e-09
the O 0 7.391873424467121e-08
vasopressin O 0 1.0760574014057056e-06
- O 0 8.541909437553841e-07
neurophysin O 0 6.503367330878973e-06
II O 0 6.999634933890775e-05
gene O 0 2.5334363940032745e-08
in O 0 6.133875185554416e-09
two O 0 3.6611884635107117e-09
Spanish O 0 5.292405944601342e-07
kindreds O 0 8.945528861659113e-06
with O 0 4.311082335561878e-08
familial B-Disease 1 0.9999954700469971
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
. O 0 1.6229064385697711e-06

Familial B-Disease 1 1.0
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 0.43066927790641785
FNDI B-Disease 1 1.0
) O 0 2.1455875298670435e-07
is O 0 7.727929407508327e-09
an O 0 5.6668756798217146e-08
autosomal B-Disease 1 0.9999984502792358
dominant I-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 0.0012740998063236475
by O 0 3.6242386158846784e-07
deficiency O 1 0.9999998807907104
in O 0 1.7948198092199164e-06
the O 0 2.0989302811358357e-06
antidiuretic O 0 4.1078714275499806e-05
hormone O 0 3.621650535023946e-08
arginine O 0 2.454912930716091e-07
vasopressin O 0 3.385079594409035e-07
( O 0 7.726013606657034e-09
AVP O 0 4.042201169340842e-07
) O 0 2.6454366475192614e-10
encoded O 0 6.741702196499944e-10
by O 0 1.1147799350297305e-09
the O 0 8.264447615147219e-08
AVP O 0 1.755397897795774e-05
- O 0 8.721688686819107e-07
neurophysin O 0 1.3672276509169023e-05
II O 0 0.13145513832569122
( O 0 3.930109414795879e-06
AVP O 0 0.0002641101600602269
- O 0 5.008058451494435e-06
NPII O 0 8.755299495533109e-05
) O 0 3.2964809548730045e-08
gene O 0 5.810649739146356e-09
on O 0 2.833355416953509e-08
chromosome O 0 5.647140142173157e-07
20p13 O 0 1.4937740161258262e-05
. O 0 9.52032223722199e-07

In O 0 2.8388251394062536e-07
this O 0 9.49192724419845e-09
study O 0 8.9126244162685e-09
, O 0 3.609399168436056e-10
we O 0 5.336239228270756e-10
analyzed O 0 1.1114472009410292e-08
two O 0 8.691956043804794e-10
families O 0 7.17590264986967e-10
with O 0 2.5879101084314016e-09
FNDI B-Disease 1 0.9999998807907104
using O 0 5.9039471977939684e-08
direct O 0 4.7347434417588374e-08
automated O 0 3.446285461450316e-07
fluorescent O 0 2.0978492276668703e-09
, O 0 3.4148345262607904e-10
solid O 0 5.585127471618989e-09
phase O 0 5.1896449804189615e-08
, O 0 1.0522885895980494e-09
single O 0 2.540305965581524e-09
- O 0 7.913396160574848e-09
stranded O 0 1.1585561843219239e-08
DNA O 0 6.326240642451353e-10
sequencing O 0 5.749657971954036e-10
of O 0 1.1202542005150917e-08
PCR O 0 6.964766896544461e-08
- O 0 3.6019827120981063e-07
amplified O 0 5.444229827844538e-06
AVP O 0 5.98634869675152e-05
- O 0 1.0994731383107137e-06
NPII O 0 5.8852379879681394e-05
DNA O 0 1.727606104395818e-06
. O 0 1.7129382001712656e-07

In O 0 1.3934857179265236e-06
one O 0 2.825998990374501e-08
of O 0 2.5380503032579327e-08
the O 0 1.4687651095357523e-08
families O 0 2.2443791269921576e-09
, O 0 3.476876841990162e-10
affected O 0 5.88495252529242e-10
individuals O 0 1.967470769637103e-10
presented O 0 1.2642965785403248e-08
a O 0 3.586495722629479e-08
novel O 0 4.028146705081781e-08
nonsense O 0 2.440363573441573e-07
mutation O 0 1.0528627969463855e-09
in O 0 3.4572844587188456e-09
exon O 0 5.2446431197950005e-08
3 O 0 1.0064501232420753e-08
of O 0 4.591012014998341e-09
the O 0 3.2568006069766398e-09
gene O 0 6.114855288785748e-10
, O 0 1.199424171094421e-10
consisting O 0 2.680468735860586e-09
in O 0 1.185736486775113e-08
a O 0 1.8046975469587778e-07
G O 0 1.2672874163399683e-06
to O 0 9.784891830122433e-08
T O 0 1.0369474239269039e-06
transition O 0 5.67406743812171e-07
at O 0 1.1065125136155984e-06
nucleotide O 0 2.5375964014529018e-06
2101 O 0 6.949360795260873e-06
, O 0 1.045163622315215e-09
which O 0 1.2412589012189557e-10
produces O 0 2.0654185306501205e-10
a O 0 2.3608985877388022e-09
stop O 0 3.966390327292402e-09
signal O 0 7.346725539036925e-08
in O 0 6.958285059255331e-09
codon O 0 3.0788419280725066e-07
82 O 0 7.946021014504367e-07
( O 0 8.948449448098472e-08
Glu O 0 2.9856080800527707e-05
) O 0 1.3967739853626426e-08
of O 0 1.1616765505095827e-07
NPII O 0 0.0012739665107801557
. O 0 1.9438189156062435e-06

The O 0 6.02250929659931e-06
premature O 0 2.425413185846992e-06
termination O 0 1.1416716461098986e-06
eliminates O 0 1.5388350504963455e-07
part O 0 4.359737459935786e-08
of O 0 1.2390407277962368e-07
the O 0 4.136717848268745e-07
C O 0 0.0007709342753514647
- O 0 1.0313109669368714e-05
terminal O 0 7.348193321377039e-06
domain O 0 5.090033937449334e-06
of O 0 5.587995701716864e-07
NPII O 0 0.0011241339379921556
, O 0 1.3536371135103309e-08
including O 0 2.5017332649923674e-09
a O 0 3.083678379312005e-08
cysteine O 0 5.642371547764924e-08
residue O 0 4.229017349643982e-07
in O 0 9.155149527373396e-09
position O 0 7.825726555665824e-08
85 O 0 6.738391533644972e-08
, O 0 8.530473549761552e-10
which O 0 3.188857788938293e-10
could O 0 1.2744112432017118e-09
be O 0 3.6140992420996554e-09
involved O 0 4.2558536250680845e-08
in O 0 3.238139711925214e-08
the O 0 2.4704252155061113e-07
correct O 0 3.929333615815267e-06
folding O 0 2.641939681780059e-05
of O 0 2.3887307634140598e-06
the O 0 5.033603429183131e-06
prohormone O 0 0.022092977538704872
. O 0 3.876110440614866e-06

In O 0 2.988487040056498e-06
the O 0 5.039829602537793e-07
second O 0 1.2444294270608225e-06
family O 0 3.0085419666647795e-07
, O 0 5.0667852136143665e-09
a O 0 2.4157902345223192e-08
G279A O 0 1.7847037270257715e-07
substitution O 0 2.4830944411746714e-08
at O 0 7.997385154112635e-08
position O 0 1.560930513733183e-07
- O 0 4.874597436810291e-08
1 O 0 3.808284532169637e-08
of O 0 1.4073345155907191e-08
the O 0 2.1559719343144934e-08
signal O 0 2.6502203809286584e-07
peptide O 0 3.062693565425434e-08
was O 0 2.9127432910058815e-08
observed O 0 7.2468795409008635e-09
in O 0 1.246609815375166e-09
all O 0 1.6468876262720755e-09
affected O 0 1.3254390474060074e-08
individuals O 0 1.4634688128012385e-08
. O 0 1.3234539153472724e-07

This O 0 1.3353387657843996e-06
missense O 0 1.977830834221095e-05
mutation O 0 1.0001870265341495e-07
, O 0 7.503607513115185e-09
which O 0 7.422499059828169e-09
replaces O 0 3.0111450541880913e-06
Ala O 0 0.00047810966498218477
with O 0 7.502866594677471e-08
Thr O 1 0.500812292098999
, O 0 3.6558521543383904e-08
is O 0 1.1488519469082803e-08
frequent O 0 5.5722658487411536e-08
among O 0 3.5860715286162304e-08
FNDI B-Disease 1 1.0
patients O 0 1.6089543350972235e-05
and O 0 1.7061648094340853e-08
is O 0 1.212351463664163e-08
thought O 0 1.4583083185470969e-08
to O 0 1.7127339546618714e-09
reduce O 0 1.1165488977837867e-08
the O 0 5.253894386214597e-08
efficiency O 0 2.6562349830783205e-07
of O 0 8.018141528509659e-08
cleavage O 0 5.619612011287245e-07
by O 0 4.700093469978128e-08
signal O 0 2.8225838377693435e-06
peptidases O 0 1.409679498465266e-05
. O 0 3.904198919713053e-08
. O 0 1.4449538809913065e-07

Genetic O 0 8.645799971418455e-05
heterogeneity O 0 4.5437154767569155e-05
of O 0 0.0002218519221059978
Saethre B-Disease 1 1.0
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 3.4522255276669966e-08
due O 0 7.852068506508658e-07
to O 0 8.548154539766983e-08
TWIST O 0 8.163056190824136e-05
and O 0 2.6270544140061247e-07
FGFR O 0 0.08713191747665405
mutations O 0 5.356670840228617e-07
. O 0 3.3453613923484227e-07

Thirty O 0 0.001519303652457893
- O 0 1.318504655500874e-05
two O 0 3.7211869141628995e-08
unrelated O 0 1.3731187209486961e-06
patients O 0 5.885797182969554e-09
with O 0 4.1230382996637616e-10
features O 0 7.497001064393771e-08
of O 0 8.316276944242418e-05
Saethre B-Disease 1 1.0
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 8.487535119172662e-09
a O 0 2.8290244813433674e-08
common O 0 4.368310868585468e-08
autosomal B-Disease 0 2.2084181182435714e-05
dominant I-Disease 0 1.3234480320534203e-05
condition I-Disease 0 0.002695750445127487
of O 0 0.10180126130580902
craniosynostosis B-Disease 1 1.0
and O 0 0.0003874227695632726
limb B-Disease 1 1.0
anomalies I-Disease 1 0.9999990463256836
, O 0 8.209836011019433e-08
were O 0 1.4486614929865027e-07
screened O 0 1.4305692275229376e-07
for O 0 1.7824168807578644e-08
mutations O 0 1.5943173892196683e-08
in O 0 9.12227875460303e-08
TWIST O 0 0.00013061240315437317
, O 0 2.406941632671078e-07
FGFR2 O 1 0.8394544720649719
, O 0 1.497657535765029e-07
and O 0 2.068701547841556e-07
FGFR3 O 1 0.9988150596618652
. O 0 4.6852314881107304e-06

Nine O 0 9.322906407760456e-06
novel O 0 8.590729976276634e-07
and O 0 5.0873463663947405e-08
three O 0 1.2290995243802172e-07
recurrent O 0 3.710105738718994e-05
TWIST O 0 2.0066998331458308e-05
mutations O 0 4.219344518219259e-08
were O 0 3.010820393001268e-08
found O 0 1.0705415220968462e-08
in O 0 1.6628439070132117e-08
12 O 0 2.6676332254282897e-07
families O 0 2.506778606914395e-08
. O 0 2.7741828034777427e-07

Seven O 0 9.035365110321436e-06
families O 0 3.361293110515362e-08
were O 0 3.195936670863375e-08
found O 0 3.3414626621208754e-09
to O 0 5.131852720552388e-09
have O 0 3.0993674293711138e-09
the O 0 1.1490639195699259e-07
FGFR3 O 0 0.00031561258947476745
P250R O 0 1.2920088465762092e-06
mutation O 0 4.028974931458151e-09
, O 0 4.819860621729788e-10
and O 0 7.937093204901657e-10
one O 0 4.150340071618075e-09
individual O 0 2.611457938783701e-09
was O 0 1.5194210334357194e-07
found O 0 6.074103442443857e-09
to O 0 3.0310955967394193e-09
have O 0 1.935403171060557e-09
an O 0 4.254928143154757e-08
FGFR2 O 0 4.687597174779512e-05
VV269 O 0 6.483835932158399e-06
- O 0 4.264721155777806e-06
270 O 0 1.7090397932406631e-06
deletion O 0 1.0855152368094423e-06
. O 0 2.131578185071703e-07

To O 0 9.50504741581426e-08
date O 0 1.7001202934352477e-07
, O 0 1.5807362085951127e-09
our O 0 4.025709987587334e-09
detection O 0 1.5516507190227458e-08
rate O 0 1.041281993963139e-08
for O 0 1.2595494647271721e-09
TWIST O 0 1.836289470702468e-06
or O 0 6.84649066329257e-08
FGFR O 0 1.3498798580258153e-05
mutations O 0 3.6335492392680635e-09
is O 0 1.4612533405511385e-09
68 O 0 2.1719532838915256e-08
% O 0 2.4012354327140883e-09
in O 0 4.0890433261608905e-09
our O 0 2.7395546453590214e-07
Saethre B-Disease 1 0.9999970197677612
- I-Disease 1 0.9999972581863403
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 8.71520526857239e-08
, O 0 5.240938238948445e-10
including O 0 1.244671032907263e-09
our O 0 5.629772203974426e-08
five O 0 1.9424232888809456e-08
patients O 0 1.15182663407154e-09
elsewhere O 0 9.572926451539843e-09
reported O 0 1.4471196685406085e-08
with O 0 1.598402743496763e-09
TWIST O 0 7.700896276219282e-06
mutations O 0 1.1847852476876142e-07
. O 0 1.0723933741019209e-07

More O 0 1.907922353439062e-08
than O 0 1.4139417414682498e-09
35 O 0 2.766906703755012e-09
different O 0 1.2397706472544456e-10
TWIST O 0 9.322589278326632e-08
mutations O 0 3.505184364982483e-09
are O 0 3.4963085204786637e-10
now O 0 2.0044292892151816e-09
known O 0 8.081719293784317e-09
in O 0 1.456773723873539e-08
the O 0 1.6764539623181918e-07
literature O 0 2.918933432738413e-06
. O 0 5.372365308176086e-07

The O 0 1.276586431231408e-06
most O 0 9.638682740842341e-09
common O 0 3.796714942438939e-09
phenotypic O 0 3.110681134899096e-08
features O 0 7.230673304547963e-08
, O 0 1.3039812563064856e-09
present O 0 3.6850014151212918e-09
in O 0 4.093475780564404e-09
more O 0 2.8760122061655125e-10
than O 0 3.258482650370098e-10
a O 0 1.8868986373377084e-09
third O 0 8.3338242973241e-09
of O 0 5.400709213176924e-09
our O 0 1.4134328374382221e-08
patients O 0 9.550508162092797e-10
with O 0 1.8055079653578332e-10
TWIST O 0 9.26093036923703e-07
mutations O 0 1.138998673155811e-08
, O 0 1.9431560804861192e-09
are O 0 2.5017188320930472e-09
coronal B-Disease 0 2.090344605676364e-05
synostosis I-Disease 0 0.00018776535580400378
, O 0 9.510252141353703e-08
brachycephaly B-Disease 0 0.0011187280761078
, O 0 5.470077439895249e-07
low B-Disease 1 0.9084241986274719
frontal I-Disease 1 1.0
hairline I-Disease 1 1.0
, O 0 1.2889075833300012e-06
facial B-Disease 1 0.8181511163711548
asymmetry I-Disease 1 0.9999997615814209
, O 0 5.895962203794625e-06
ptosis B-Disease 1 0.9999994039535522
, O 0 2.6988952868123306e-06
hypertelorism B-Disease 1 0.9999303817749023
, O 0 5.32167916844628e-07
broad B-Disease 0 9.242588566849008e-05
great I-Disease 1 0.999958872795105
toes I-Disease 1 0.9999994039535522
, O 0 2.7668480129250383e-07
and O 0 5.906611022510333e-07
clinodactyly B-Disease 1 0.9921064376831055
. O 0 2.9171493224566802e-05

Significant O 0 1.1275714314251672e-05
intra O 0 0.01936746947467327
- O 0 3.137823659926653e-05
and O 0 1.623388889981925e-08
interfamilial O 0 7.442373316735029e-06
phenotypic O 0 5.252882715467422e-07
variability O 0 8.303662752950913e-07
is O 0 1.8219025177401704e-09
present O 0 1.0763001601077349e-09
for O 0 1.4156147365440575e-09
either O 0 5.3211412165410366e-08
TWIST O 0 7.064803867251612e-06
mutations O 0 7.427473036614174e-08
or O 0 9.989001625854144e-08
FGFR O 0 0.0002008340525208041
mutations O 0 1.2935412030401494e-07
. O 0 1.7742127056408208e-07

The O 0 1.4048865750737605e-06
overlap O 0 2.0719276960790012e-07
in O 0 1.4734594877552354e-08
clinical O 0 3.2082837719826784e-07
features O 0 9.087057328827086e-09
and O 0 4.5024692307826797e-10
the O 0 8.186596289760928e-09
presence O 0 9.345481721823035e-09
, O 0 1.1684175849069334e-09
in O 0 1.0187075627499098e-09
the O 0 2.7177249339871423e-09
same O 0 1.2380745317841502e-09
genes O 0 1.978021496595872e-10
, O 0 1.6914710951332346e-11
of O 0 2.389036746208717e-10
mutations O 0 8.399866913144649e-11
for O 0 2.929745335222833e-10
more O 0 1.2755242695394742e-10
than O 0 5.813661774212164e-10
one O 0 2.580039293320624e-09
craniosynostotic B-Disease 0 6.065973252589174e-07
condition I-Disease 0 5.155844178261759e-07
- O 0 3.2848820552544566e-08
such O 0 2.766948670185343e-09
as O 0 1.115168046794679e-07
Saethre B-Disease 0 0.00013932008005212992
- I-Disease 0 8.444434570265003e-06
Chotzen I-Disease 0 0.00013777872663922608
, I-Disease 0 3.491154032531085e-08
Crouzon I-Disease 0 5.3340147132985294e-05
, I-Disease 0 3.378660551334178e-08
and I-Disease 0 4.491717575660914e-08
Pfeiffer I-Disease 0 0.012151725590229034
syndromes I-Disease 0 0.00020733872952405363
- O 0 5.561537363973912e-06
support O 0 4.4417081568326466e-08
the O 0 4.577234236080585e-08
hypothesis O 0 9.243920828794217e-08
that O 0 1.7916930439287881e-10
TWIST O 0 4.955952803697983e-08
and O 0 1.2788183845202639e-09
FGFRs O 0 1.5635333738828194e-06
are O 0 5.836616190357802e-10
components O 0 1.8306257842937157e-08
of O 0 2.0842538361875995e-08
the O 0 1.868530574711258e-08
same O 0 1.4781292634324927e-08
molecular O 0 2.0329053995737922e-07
pathway O 0 6.52387655009079e-08
involved O 0 3.618051191978111e-09
in O 0 1.0558672824956261e-09
the O 0 1.0490426305409528e-08
modulation O 0 2.0747630458117783e-07
of O 0 5.42329701147537e-07
craniofacial O 1 1.0
and O 0 1.3523835150408559e-05
limb O 1 1.0
development O 0 0.11123001575469971
in O 0 1.5912542039586697e-07
humans O 0 1.510292264583768e-07
. O 0 9.267131950707608e-09
. O 0 7.634025678271428e-08

Mutation O 0 7.501406003029842e-07
analysis O 0 4.618945297352184e-07
of O 0 5.078810545455781e-07
UBE3A O 1 0.999998927116394
in O 0 0.4101922810077667
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.46987196803092957
. O 0 4.744126727018738e-07

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9999934434890747
AS B-Disease 1 1.0
) O 0 4.226182852562488e-07
is O 0 2.6152026322279198e-08
caused O 0 7.101146337618047e-08
by O 0 3.984894547670592e-08
chromosome O 0 2.7722280719899572e-06
15q11 O 0 3.161808490403928e-05
- O 0 1.1102788448624779e-05
q13 O 0 1.2121974577894434e-05
deletions O 0 3.232308642964199e-07
of O 0 1.1330902793815767e-07
maternal O 0 1.46207321449765e-06
origin O 0 3.593082453789975e-08
, O 0 1.035394081583263e-08
by O 0 1.0936529548644103e-07
paternal O 0 0.012540656141936779
uniparental B-Disease 1 0.9999994039535522
disomy I-Disease 1 0.999976396560669
( O 0 0.0001979772059712559
UPD B-Disease 1 1.0
) O 0 1.1270689981301985e-07
15 O 0 9.575231274538964e-08
, O 0 2.7042807992927465e-09
by O 0 3.489330069328389e-08
imprinting O 0 0.03260846436023712
defects O 1 0.9126113653182983
, O 0 5.062515295861658e-09
and O 0 3.612445231837569e-09
by O 0 1.5311650614080463e-08
mutations O 0 1.7981550470835828e-08
in O 0 5.2069864864279225e-08
the O 0 2.1902280877839075e-06
UBE3A O 0 0.12050940841436386
gene O 0 1.2291797020225204e-06
. O 0 2.221092785248402e-07

UBE3A O 1 0.6955574750900269
encodes O 0 4.2591866076691076e-05
a O 0 1.5819878171896562e-06
ubiquitin O 0 3.6620956507249502e-06
- O 0 1.975400891751633e-06
protein O 0 1.478189233239391e-07
ligase O 0 2.0061884242750239e-07
and O 0 3.305060447544861e-09
shows O 0 1.2845633534652734e-07
brain O 0 7.039448973955587e-05
- O 0 3.707316693635221e-07
specific O 0 1.0079431689291596e-07
imprinting O 0 3.638417547335848e-05
. O 0 5.962533577985596e-07

Here O 0 1.8389690694675664e-06
we O 0 9.625384933542591e-08
describe O 0 1.611651896382682e-06
UBE3A O 0 0.0003683475952129811
coding O 0 1.4578639820683748e-05
- O 0 7.955544560900307e-07
region O 0 1.9129362982539533e-08
mutations O 0 6.491540194275558e-09
detected O 0 1.632629853531853e-08
by O 0 1.4631330591541314e-09
SSCP O 0 0.00027920110733248293
analysis O 0 1.0439233477654852e-07
in O 0 5.445424555716727e-09
13 O 0 6.4145794453907e-08
AS B-Disease 1 0.9987316727638245
individuals O 0 9.024014424596771e-09
or O 0 2.090181716596362e-08
families O 0 1.8337534157808477e-08
. O 0 7.731205897698601e-08

Two O 0 4.166308826825116e-07
identical O 0 2.0022949343001528e-07
de O 0 7.021252258709865e-06
novo O 0 3.2154525797523092e-06
5 O 0 4.172895842202706e-06
- O 0 4.1080525079451036e-06
bp O 0 9.831070201471448e-06
duplications O 0 5.9416433941805735e-06
in O 0 3.4251615943503566e-07
exon O 0 1.2940546412210097e-06
16 O 0 2.639437184370763e-07
were O 0 1.0681493733954994e-07
found O 0 1.9464069112018478e-07
. O 0 6.880828209432366e-07

Among O 0 8.913272040445008e-07
the O 0 7.023624704061149e-08
other O 0 2.253618847092298e-09
11 O 0 2.8346093472464418e-08
unique O 0 9.909239651051394e-09
mutations O 0 2.9719358085600334e-09
, O 0 1.2492756829018958e-09
8 O 0 4.115970853035833e-08
were O 0 1.680229111400422e-08
small O 0 1.8237880539118123e-08
deletions O 0 5.849873829788521e-08
or O 0 1.0856824417260214e-07
insertions O 0 2.7518456136021996e-06
predicted O 0 9.183009979096823e-07
to O 0 5.302731764800228e-08
cause O 0 1.5986526022970793e-06
frameshifts O 0 5.476295336848125e-05
, O 0 2.918448771538351e-08
1 O 0 1.3869016868284234e-07
was O 0 8.035472376377584e-08
a O 0 6.885119585575694e-09
mutation O 0 2.0688803448187798e-10
to O 0 3.680419857765571e-10
a O 0 9.369272468973122e-09
stop O 0 1.3223432127063006e-08
codon O 0 1.3434558354674664e-07
, O 0 6.922939110864945e-09
1 O 0 6.91700208221846e-08
was O 0 1.8646929333954176e-07
a O 0 2.4000049947403568e-08
missense O 0 5.4467673038516295e-08
mutation O 0 6.141435138218299e-10
, O 0 2.5203628073455775e-10
and O 0 3.461987641006914e-10
1 O 0 9.922388244376634e-08
was O 0 4.915941644867416e-07
predicted O 0 1.3539165877318737e-07
to O 0 6.405065811065924e-09
cause O 0 8.087258152045251e-08
insertion O 0 2.423668945539248e-07
of O 0 3.761391269563319e-07
an O 0 2.0621854446289944e-07
isoleucine O 0 4.226078817737289e-05
in O 0 1.3909867391248554e-07
the O 0 2.487019798991241e-07
hect O 0 4.799317684955895e-05
domain O 0 4.17090222981642e-06
of O 0 6.681682407361222e-08
the O 0 2.1443376851948415e-07
UBE3A O 0 0.0003850249631796032
protein O 0 1.538369929221517e-07
, O 0 4.397598951655368e-10
which O 0 1.4340502396681387e-10
functions O 0 6.126778195891802e-09
in O 0 7.81043851816321e-09
E2 O 0 1.0771919960461673e-06
binding O 0 2.718167024795548e-08
and O 0 3.6082170584705864e-09
ubiquitin O 0 3.2450896014779573e-07
transfer O 0 1.7194273596032872e-06
. O 0 1.8665929246708401e-06

Eight O 0 3.048362259505666e-06
of O 0 1.7119714357249904e-07
the O 0 2.72996132366643e-08
cases O 0 1.0928851601477163e-08
were O 0 1.0498357028154714e-07
familial O 0 5.955087999609532e-06
, O 0 1.577998709478834e-08
and O 0 6.425549425870258e-09
five O 0 9.822569779771584e-08
were O 0 2.5703306505420187e-07
sporadic O 0 4.016913862869842e-06
. O 0 4.814352791981946e-07

In O 0 1.7697644807412871e-06
two O 0 3.944649051845772e-08
familial O 0 2.4609869342384627e-06
cases O 0 2.284294353671612e-08
and O 0 1.6204275699038817e-09
one O 0 5.895830490487697e-09
sporadic O 0 2.5680813564576965e-07
case O 0 3.683591032199729e-08
, O 0 1.4700208161855244e-08
mosaicism O 0 4.885214366368018e-05
for O 0 1.043636643771606e-07
UBE3A O 0 0.0011673031840473413
mutations O 0 4.310136603180581e-08
was O 0 5.4106305213963424e-08
detected O 0 2.1397285721036496e-08
in O 0 2.3057864506625947e-09
the O 0 2.388692976751372e-08
mother O 0 2.940433603271231e-07
of O 0 1.0430062502564397e-06
three O 0 3.3699214441185177e-07
AS B-Disease 1 1.0
sons O 0 0.0001736065314617008
, O 0 2.1580742526339236e-08
in O 0 2.8183606559650798e-08
the O 0 3.002153334819013e-07
maternal O 0 4.0227016143035144e-05
grandfather O 0 0.0001337029825663194
of O 0 2.1883881345274858e-05
two O 0 2.795151772261306e-07
AS B-Disease 1 0.9999998807907104
first O 0 1.2114219316572417e-06
cousins O 0 5.973312795504171e-07
, O 0 8.246037630499359e-09
and O 0 1.1325431259479046e-08
in O 0 2.2703562763126683e-07
the O 0 2.320122121091117e-06
mother O 0 1.2328777302172966e-05
of O 0 1.884119410533458e-05
an O 0 6.857004336779937e-06
AS B-Disease 1 1.0
daughter O 0 0.13482430577278137
. O 0 9.321679499407765e-06

The O 0 7.248160045492114e-07
frequencies O 0 6.884465619805269e-08
with O 0 6.081693482151707e-10
which O 0 1.0228898839059752e-09
we O 0 4.179175672192059e-09
detected O 0 1.5067481484720702e-08
mutations O 0 6.694930720918535e-10
were O 0 1.0167533481819646e-08
5 O 0 1.329373500169595e-08
( O 0 8.213368318799041e-10
14 O 0 4.634279626714033e-09
% O 0 7.370747345802897e-10
) O 0 8.074853979911367e-11
of O 0 9.582877824598768e-10
35 O 0 5.64211033449169e-09
in O 0 1.9040677923243265e-09
sporadic O 0 3.6637683109574937e-08
cases O 0 1.659782200569282e-09
and O 0 3.837703210773924e-10
8 O 0 1.7173636734924003e-08
( O 0 9.751700558169318e-10
80 O 0 2.753670846900036e-09
% O 0 3.6777672574039855e-10
) O 0 5.4711860042466753e-11
of O 0 5.420872639660956e-10
10 O 0 9.216923890775774e-10
in O 0 1.4302868889259912e-09
familial O 0 1.4554009908351873e-07
cases O 0 6.24398399651227e-09
. O 0 7.203332597072176e-09
. O 0 1.0244449555329993e-07

The O 0 5.686050280928612e-05
hemochromatosis B-Disease 1 0.9999922513961792
845 O 0 1.7967011444852687e-05
G O 0 3.834440576611087e-06
- O 0 6.354059678415069e-07
- O 0 4.102666935068555e-07
> O 0 1.2836166263241466e-07
A O 0 1.988816578091246e-08
and O 0 8.053719496858847e-11
187 O 0 4.0861330985464406e-10
C O 0 4.998270686229489e-09
- O 0 6.682329800611342e-09
- O 0 2.9803615575474396e-08
> O 0 5.763718391449402e-08
G O 0 4.1125336025515935e-08
mutations O 0 8.407870510929172e-10
: O 0 1.9245208204843323e-10
prevalence O 0 5.353981258338081e-09
in O 0 1.7022958598289506e-09
non O 0 4.4805511834056233e-07
- O 0 5.462257490762568e-07
Caucasian O 0 2.2840104065835476e-06
populations O 0 5.253213331002371e-08
. O 0 3.965098827052316e-08

Hemochromatosis B-Disease 1 1.0
, O 0 3.3820087992353365e-06
the O 0 0.0006239868816919625
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 1 1.0
iron I-Disease 1 1.0
metabolism I-Disease 1 1.0
, O 0 9.790900321604568e-07
leads O 0 2.1245775769784814e-06
, O 0 9.513533072436076e-09
if O 0 6.865753476859027e-08
untreated O 1 0.5155417323112488
, O 0 1.4223166644455887e-08
to O 0 2.5449878648942104e-07
progressive O 1 0.9999816417694092
iron B-Disease 1 1.0
overload I-Disease 1 1.0
and O 0 1.8060559341392945e-06
premature B-Disease 0 0.00012876588152721524
death I-Disease 0 1.4314701729745138e-05
. O 0 1.1053776916014613e-06

The O 0 0.0006282005924731493
hemochromatosis B-Disease 1 1.0
gene O 0 4.3382911826483905e-05
, O 0 9.061408263733028e-07
HFE O 1 0.9998807907104492
, O 0 5.146578629933174e-08
recently O 0 5.168613981254566e-08
has O 0 8.126122552631898e-10
been O 0 1.1390546283962522e-09
identified O 0 3.4958502759252497e-09
, O 0 5.977968675630052e-10
and O 0 1.238520952462352e-09
characterization O 0 6.285904987635149e-07
of O 0 2.1098610147873842e-07
this O 0 2.5085578059247382e-08
gene O 0 6.242102834619345e-09
has O 0 1.804784793835168e-10
shown O 0 1.6444227923795296e-10
that O 0 1.6542118369544667e-11
it O 0 9.369919770629842e-12
contains O 0 2.5874040757156713e-11
two O 0 4.2749817574794235e-11
mutations O 0 1.2164029332406567e-11
that O 0 8.597731034065692e-12
result O 0 3.398745729299435e-10
in O 0 1.212512645842878e-09
amino O 0 2.864664727653121e-09
acid O 0 3.4981513241660878e-09
substitutions O 0 6.000590691002117e-09
- O 0 3.8890224374199533e-08
cDNA O 0 1.7798747364849987e-07
nucleotides O 0 7.717146921493168e-09
845 O 0 6.154714782269366e-08
G O 0 3.392893788145557e-08
- O 0 2.8202858715076218e-08
- O 0 8.143600638277348e-08
> O 0 1.0028690411445496e-07
A O 0 1.6603853225660714e-07
( O 0 1.547072359109336e-09
C282Y O 0 2.2605597393976495e-08
) O 0 1.4765949574169213e-10
and O 0 1.279740063919732e-10
187 O 0 2.0619006502187176e-09
C O 0 1.1843260594446292e-08
- O 0 7.150916747633573e-09
- O 0 5.8231453436974334e-08
> O 0 1.3630605621983705e-07
G O 0 3.075690244713769e-07
( O 0 2.7601874563742967e-08
H63D O 0 1.0242471944366116e-05
) O 0 3.213497734577686e-08
. O 0 2.5846311757504736e-08

Although O 0 0.0021056942641735077
hemochromatosis B-Disease 1 1.0
is O 0 2.0214045548527793e-07
common O 0 1.1360870466603501e-08
in O 0 9.010117985042143e-09
Caucasians O 0 8.406787088688361e-08
, O 0 9.38860655885776e-10
affecting O 0 1.9121118910447876e-08
> O 0 1.754307810131195e-08
= O 0 1.7392650875081017e-08
1 O 0 1.3130791565174604e-08
/ O 0 3.776175372394164e-09
300 O 0 6.990473200296776e-10
individuals O 0 5.977669054191281e-11
of O 0 1.5559650234919786e-09
northern O 0 1.4290870709032788e-09
European O 0 4.890454263772881e-09
origin O 0 8.625602454515047e-09
, O 0 4.0842945692176613e-10
it O 0 8.835096543258203e-11
has O 0 4.51433335157958e-11
not O 0 7.173518029590653e-11
been O 0 7.355706044265276e-10
recognized O 0 4.758422544881569e-10
in O 0 5.633676858352032e-10
other O 0 3.71527586473519e-10
populations O 0 3.53998030888647e-09
. O 0 2.944493004974902e-08

The O 0 3.3601207860556315e-07
present O 0 1.8365676979215095e-08
study O 0 4.350398707941849e-09
used O 0 1.123236170741393e-09
PCR O 0 2.2158042067843553e-09
and O 0 1.8709893356838592e-10
restriction O 0 4.200945369348119e-09
- O 0 1.943864180731225e-09
enzyme O 0 1.4657811631124673e-09
digestion O 0 2.646200147893296e-09
to O 0 1.0717354781419886e-10
analyze O 0 5.289153115484169e-09
the O 0 4.219688154449841e-09
frequency O 0 1.1002073918575661e-08
of O 0 7.463128781637351e-09
the O 0 1.205264066328482e-08
845 O 0 6.017831566396126e-08
G O 0 4.353521987354725e-08
- O 0 1.7701928811675316e-08
- O 0 1.8206183227675865e-08
> O 0 1.4368390921504215e-08
A O 0 6.9150472015167e-09
and O 0 5.2440149445054374e-11
187 O 0 3.707771867311749e-10
C O 0 1.9296604314433807e-09
- O 0 8.028019360395433e-10
- O 0 7.670306167995022e-09
> O 0 2.3877500865410184e-08
G O 0 2.0377866505327802e-08
mutations O 0 4.727699898232629e-10
in O 0 1.964704399171069e-09
HLA O 0 2.815534649869278e-08
- O 0 3.399681203219984e-09
typed O 0 1.951648087583635e-08
samples O 0 5.26494348118689e-10
from O 0 1.8196001372317028e-09
non O 0 6.166935406781704e-08
- O 0 3.8884884645540296e-08
Caucasian O 0 4.972816824988513e-08
populations O 0 2.9763988496078753e-10
, O 0 8.794711486848072e-11
comprising O 0 4.998632618935517e-09
Australian O 0 1.2539334193206741e-06
Aboriginal O 0 4.3331115193723235e-06
, O 0 5.106095990470294e-09
Chinese O 0 1.4099586564952915e-07
, O 0 7.618367048323194e-10
and O 0 3.758541922138647e-09
Pacific O 0 1.1379735269656521e-06
Islanders O 0 1.4062121636015945e-06
. O 0 2.7797943857876817e-07

Results O 0 3.0932769732316956e-06
showed O 0 2.870918933695066e-07
that O 0 4.517749285781747e-09
the O 0 4.3217603717948805e-08
845 O 0 4.907280413135595e-07
G O 0 5.092176706966711e-07
- O 0 5.953697836957872e-07
- O 0 9.275540833186824e-07
> O 0 2.4417951749455824e-07
A O 0 4.212549598037185e-08
mutation O 0 2.9038427218353036e-10
was O 0 1.3175062152370742e-09
present O 0 8.745615343030977e-11
in O 0 1.3113558849919826e-10
these O 0 1.3182847868886682e-10
populations O 0 2.582327129907469e-10
( O 0 1.1595719523471715e-10
allele O 0 1.3356675487852243e-10
frequency O 0 9.310214821312002e-10
0 O 0 1.207011157688953e-10
. O 0 1.2813930472255208e-11
32 O 0 2.653542663377806e-10
% O 0 7.38770433716951e-11
) O 0 4.393958460968683e-11
, O 0 2.7545925609939736e-11
and O 0 6.367712607202591e-11
, O 0 3.6345731979636753e-10
furthermore O 0 1.0013319062807113e-08
, O 0 1.335581645278694e-09
it O 0 6.833203447520475e-10
was O 0 8.659134209665353e-08
always O 0 1.3921540364947305e-08
seen O 0 2.3045693353651586e-08
in O 0 2.1141979278382905e-09
conjunction O 0 5.5731479875476e-08
with O 0 1.9329251088606725e-08
HLA O 0 0.0001733479875838384
haplotypes O 0 5.61723311420792e-07
common O 0 5.269497727056205e-09
in O 0 4.32151914253609e-09
Caucasians O 0 6.589771572862446e-08
, O 0 1.5676722142643484e-09
suggesting O 0 1.782012404305533e-08
that O 0 3.8431235971359e-10
845 O 0 4.949548326749209e-08
G O 0 1.887402305555952e-07
- O 0 2.519733754979825e-07
- O 0 1.4425376093640807e-06
> O 0 8.227359558077296e-07
A O 0 3.5488460525812116e-07
may O 0 5.627407428931974e-09
have O 0 3.8074601804716224e-10
been O 0 3.311438068198669e-10
introduced O 0 7.142689217864984e-11
into O 0 1.5624682103698717e-10
these O 0 4.52686187146778e-11
populations O 0 3.404987680699634e-10
by O 0 2.652891017973502e-09
Caucasian O 0 3.365708835190162e-06
admixture O 0 4.427947715157643e-06
. O 0 3.0442495813076675e-07

187 O 0 1.7564123027113965e-06
C O 0 9.081392704501923e-07
- O 0 2.463480086589698e-07
- O 0 4.194606333385309e-07
> O 0 4.58425489568981e-07
G O 0 2.3455099551483727e-07
was O 0 4.671716169468709e-08
present O 0 5.122327895179524e-09
at O 0 1.0862971855374326e-08
an O 0 8.935291950784574e-10
allele O 0 1.2164181883989045e-09
frequency O 0 9.086849495076876e-09
of O 0 3.796021630364521e-08
2 O 0 8.514306841789221e-07
. O 0 3.7013745668446063e-07

68 O 0 1.6745518223615363e-05
% O 0 7.142590163766727e-08
in O 0 1.8923300704187795e-09
the O 0 2.7446831474264854e-09
two O 0 2.13489143030543e-10
populations O 0 1.8167001236690794e-10
analyzed O 0 1.0426115970574301e-08
( O 0 5.418673065804569e-09
Australian O 0 9.80390609583992e-07
Aboriginal O 0 2.0708700958493864e-06
and O 0 1.1207029970705662e-08
Chinese O 0 1.0691170473364764e-06
) O 0 1.7663850826465932e-08
. O 0 3.176089791168124e-08

In O 0 1.3566880170401419e-06
the O 0 2.369311289385223e-07
Australian O 0 8.028422939787561e-07
Aboriginal O 0 1.427618485649873e-07
samples O 0 2.1317148046762213e-09
, O 0 2.9034660786741995e-10
187 O 0 1.662843196470476e-09
C O 0 8.86890649809402e-09
- O 0 6.756328829737868e-09
- O 0 4.514805240773967e-08
> O 0 1.296868816780261e-07
G O 0 6.670718732948444e-08
was O 0 1.431980045651926e-08
found O 0 4.159411981508043e-10
to O 0 1.4753871735440072e-10
be O 0 9.559584235319107e-10
associated O 0 4.4889766570577194e-08
with O 0 4.6896964533971186e-08
HLA O 0 0.4074150025844574
haplotypes O 0 2.3503266675106715e-06
common O 0 1.4858659191929746e-08
in O 0 1.4002230486198641e-08
Caucasians O 0 3.791347751302965e-07
, O 0 2.6248410112117426e-09
suggesting O 0 3.4954119598751276e-08
that O 0 4.902677153140189e-10
it O 0 5.536716085607907e-10
was O 0 1.3783252761356835e-08
introduced O 0 2.6979283251904462e-09
by O 0 2.830393919239782e-09
recent O 0 4.120825636277914e-08
admixture O 0 1.26739860206726e-06
. O 0 1.4620283650401689e-07

In O 0 9.138506698036508e-07
the O 0 1.6094772092856147e-07
Chinese O 0 1.1260118526479346e-07
samples O 0 1.4875863874053152e-09
analyzed O 0 9.323316341180998e-09
, O 0 3.542342807971721e-10
187 O 0 8.20444323590408e-10
C O 0 5.003974568040803e-09
- O 0 4.0707481829826975e-09
- O 0 4.6266869446753844e-08
> O 0 9.981935988889745e-08
G O 0 7.214335084881895e-08
was O 0 4.46876420312492e-08
present O 0 6.3405707351194e-09
in O 0 5.396085800413175e-09
association O 0 6.053377799020154e-09
with O 0 2.4453461477946803e-10
a O 0 1.560194640148893e-08
wide O 0 2.773484775175916e-09
variety O 0 1.298514096248482e-08
of O 0 1.365622892990359e-06
HLA O 0 9.422968287253752e-05
haplotypes O 0 4.5769641587867227e-07
, O 0 6.130878027477138e-10
showing O 0 9.865450678603338e-09
this O 0 1.807833882594423e-10
mutation O 0 1.84594527163906e-11
to O 0 9.491555458263079e-11
be O 0 5.419322213207067e-10
widespread O 0 4.985968082849013e-09
and O 0 1.2471995658458468e-09
likely O 0 8.431062958891289e-09
to O 0 5.739777542146385e-09
predate O 0 4.037177632199018e-07
the O 0 6.030859367456287e-09
more O 0 1.3978333768260853e-10
genetically O 0 1.0968728009208562e-10
restricted O 0 1.1848134695569001e-09
845 O 0 4.135391762360996e-08
G O 0 1.1883520301125827e-07
- O 0 1.5301365863251704e-07
- O 0 4.6519059537786234e-07
> O 0 2.617458960685326e-07
A O 0 7.416303304808025e-08
mutation O 0 1.3110445173936114e-08
. O 0 1.123594550733742e-08

Genotype O 0 9.377200331073254e-05
- O 0 7.194627869466785e-06
phenotype O 0 7.21531137060083e-07
correlations O 0 3.3557828373886878e-06
in O 0 9.211138944920094e-07
attenuated B-Disease 1 0.9971323013305664
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 0.9999998807907104
. O 0 3.2284533517668024e-06

Germ O 1 0.9963635802268982
- O 0 0.0001581806573085487
line O 0 7.596549380650686e-07
mutations O 0 1.2066556642764681e-08
of O 0 4.678529208490545e-08
the O 0 2.301122208336892e-07
tumor B-Disease 0 2.3845108444220386e-05
suppressor O 0 2.9855340471840464e-05
APC O 0 1.1228944885033343e-07
are O 0 5.37513866749606e-10
implicated O 0 4.805609421509871e-08
in O 0 3.9048248368089844e-07
attenuated B-Disease 1 0.9956426620483398
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 1 0.9899319410324097
AAPC B-Disease 1 1.0
) O 0 9.646447551858728e-08
, O 0 3.1405227307601535e-09
a O 0 5.763927291013715e-08
variant O 0 6.525569347104465e-07
of O 0 0.23907114565372467
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.9998689889907837
FAP B-Disease 0 0.000638140132650733
) O 0 5.754051244366565e-07
. O 0 4.973310296918498e-07

AAPC B-Disease 1 1.0
is O 0 3.4504785162425833e-07
recognized O 0 2.016328615184193e-08
by O 0 2.4678943333356074e-09
the O 0 4.397483710505412e-09
occurrence O 0 3.0185518085090735e-07
of O 0 3.293019119610108e-07
< O 0 3.652400118880905e-05
100 O 0 1.9376980162633117e-06
colonic B-Disease 0 0.0006766552687622607
adenomas I-Disease 0 5.761592910857871e-05
and O 0 4.757625848839098e-09
a O 0 9.747930462822296e-09
later O 0 8.458529521249147e-08
onset O 0 0.3553839921951294
of O 1 0.9999964237213135
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 1.1746959671654622e-06
age O 0 4.951389200869016e-07
> O 0 8.532565232144407e-08
40 O 0 7.2758257196881004e-09
years O 0 5.180750939359768e-09
) O 0 5.078821807558143e-09
. O 0 2.945650479091455e-08

The O 0 2.5873125650832662e-06
aim O 0 1.6349348470612313e-06
of O 0 1.0100447411787172e-07
this O 0 4.097889583221104e-09
study O 0 1.3248248720287847e-08
was O 0 2.7298675320253096e-08
to O 0 2.5744304466002177e-09
assess O 0 2.4537823151149496e-07
genotype O 0 3.0284154490800574e-06
- O 0 1.7568679595569847e-06
phenotype O 0 6.433443786590942e-07
correlations O 0 8.424606676271651e-06
in O 0 3.819822723016841e-06
AAPC B-Disease 1 1.0
families O 0 1.8474577245797263e-06
. O 0 6.328937729449535e-07

By O 0 5.041214308221242e-07
protein O 0 1.8203029128471826e-07
- O 0 9.364631381458821e-08
truncation O 0 1.0807007129187696e-06
test O 0 1.6857157447702775e-07
( O 0 2.4116309305100003e-07
PTT O 0 2.911801857408136e-05
) O 0 1.8086590003463243e-09
assay O 0 6.341683622679284e-09
, O 0 8.979399862552029e-11
the O 0 6.5072180976955e-10
entire O 0 4.350624749349663e-08
coding O 0 1.386916181900233e-07
region O 0 2.3954912720114407e-08
of O 0 9.223121821833047e-08
the O 0 6.438102104766585e-07
APC B-Disease 0 1.0431465398141881e-06
gene O 0 1.7030233889769875e-09
was O 0 5.736505048759e-09
screened O 0 4.305623857447927e-09
in O 0 1.7787108452793632e-09
affected O 0 2.299444412656726e-09
individuals O 0 1.2949247230054084e-09
from O 0 9.712818638263343e-08
11 O 0 0.0002236561122117564
AAPC B-Disease 1 1.0
kindreds O 1 0.5046849846839905
, O 0 1.008835237570338e-08
and O 0 9.377510989949656e-10
their O 0 2.2816630806943294e-09
phenotypic O 0 5.705398464783684e-08
differences O 0 8.245066140943891e-08
were O 0 2.517502366572444e-07
examined O 0 7.489863946830155e-06
. O 0 1.0507457091080141e-06

Five O 0 3.275184099038597e-06
novel O 0 5.586266070167767e-06
germ O 0 0.01981513388454914
- O 0 0.0010357961291447282
line O 0 5.793173386337003e-06
APC B-Disease 0 1.5375353541458026e-06
mutations O 0 1.0115712711922242e-08
were O 0 1.8344914920476185e-08
identified O 0 5.535898495168112e-08
in O 0 5.502926114786533e-08
seven O 0 1.1694903605530271e-06
kindreds O 0 4.1494677134323865e-05
. O 0 7.375281825261482e-07

Mutations O 0 1.4910306163073983e-06
were O 0 4.179050279162766e-07
located O 0 6.914298467108893e-08
in O 0 2.1388706361591403e-09
three O 0 3.124651926089683e-10
different O 0 1.0634865210690236e-10
regions O 0 2.9980684601582652e-09
of O 0 1.753131186887913e-07
the O 0 1.0785519179989933e-06
APC B-Disease 0 7.138918931559601e-07
gene O 0 2.846006319501271e-09
( O 0 6.02349892186993e-10
1 O 0 5.282086323887825e-09
) O 0 6.832526211475454e-10
at O 0 1.3548615562797295e-08
the O 0 5.952236037387593e-09
5 O 0 1.6354972487420127e-08
end O 0 5.753339138436786e-08
spanning O 0 5.539255880648852e-07
exons O 0 6.10493131603107e-08
4 O 0 1.3127435138926558e-08
and O 0 9.212635099231647e-10
5 O 0 4.196284653090743e-09
, O 0 1.0230069014127707e-09
( O 0 9.289425895175896e-10
2 O 0 2.6473006009553046e-09
) O 0 2.609385207907877e-10
within O 0 2.130877474471049e-09
exon O 0 4.7250519052965956e-09
9 O 0 3.417299110353156e-09
, O 0 9.790888932936781e-11
and O 0 4.5126657965965933e-10
( O 0 1.167245855526744e-09
3 O 0 6.689572895623996e-09
) O 0 4.171830658705744e-10
at O 0 6.148165088148971e-09
the O 0 7.452346295622192e-09
3 O 0 4.741033166055786e-08
distal O 0 6.472811264757183e-08
end O 0 2.658053510629088e-08
of O 0 6.519162099039022e-08
the O 0 4.470921624033508e-07
gene O 0 1.9841340304083133e-07
. O 0 1.6044336348386423e-07

Variability O 0 9.026988118421286e-05
in O 0 4.147279852872998e-08
the O 0 3.277197180295843e-08
number O 0 1.1785229503402661e-07
of O 0 0.0108049800619483
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 0.0002584244357421994
most O 0 3.1983253823142377e-09
apparent O 0 1.4988742691457446e-08
in O 0 8.784656890803433e-10
individuals O 0 1.6170119410130468e-10
with O 0 2.6108987194461974e-10
mutations O 0 1.1309926328806341e-09
in O 0 1.5070412473505712e-08
region O 0 3.826218062386033e-07
1 O 0 4.651489234674955e-06
, O 0 5.729058560888234e-09
and O 0 1.4168932693792158e-08
upper O 1 0.9999983310699463
- O 1 0.9995192289352417
gastrointestinal O 0 0.16868171095848083
manifestations O 0 0.4031945765018463
were O 0 3.035019631170144e-07
more O 0 6.632588367416759e-10
severe O 0 2.987350455896376e-08
in O 0 9.852287874423382e-09
them O 0 4.4755886108305276e-08
. O 0 3.0473719903056917e-07

In O 0 3.1906077424537216e-07
individuals O 0 4.285959143146556e-09
with O 0 7.615287289652883e-10
mutations O 0 1.4984475882329207e-09
in O 0 7.221050424277564e-09
either O 0 5.053170681890151e-08
region O 0 2.92437846383109e-07
2 O 0 9.796092399483314e-07
or O 0 3.941001480711748e-08
region O 0 3.757769562184876e-08
3 O 0 4.846340573294583e-08
, O 0 3.998030795315799e-10
the O 0 2.003702981312472e-09
average O 0 1.4148380245160297e-08
number O 0 1.3725085512561463e-09
of O 0 2.1021520524300286e-08
adenomas B-Disease 0 5.097310804558219e-06
tended O 0 4.5301252526996905e-08
to O 0 3.2449389841815446e-09
be O 0 4.961928201652199e-09
lower O 0 3.007784243891365e-08
than O 0 3.971195039476072e-10
those O 0 1.0947533851668467e-10
in O 0 5.943939229702266e-10
individuals O 0 1.9780629911814174e-10
with O 0 7.279177954844229e-11
mutations O 0 7.198494023086255e-10
in O 0 3.5306346735097804e-09
region O 0 3.330729825279377e-08
1 O 0 1.4830692407485913e-07
, O 0 6.855003786832015e-10
although O 0 9.219526253545496e-10
age O 0 2.1457568166738383e-08
at O 0 1.3283474231684522e-07
diagnosis O 0 3.192631936599355e-07
was O 0 5.375389733330849e-08
similar O 0 9.867068939684032e-09
. O 0 8.802980744349043e-08

In O 0 1.3615910575026646e-05
all O 0 1.1760728739318438e-05
AAPC B-Disease 1 1.0
kindreds O 0 0.01007932797074318
, O 0 5.343394349210939e-08
a O 0 1.9935188788622327e-07
predominance O 0 8.316109415318351e-06
of O 0 2.9755230571026914e-05
right O 1 0.9989287257194519
- O 1 1.0
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 0 0.3448261618614197
rectal B-Disease 1 1.0
polyp I-Disease 1 0.8580442070960999
sparing O 0 5.644928478432121e-06
was O 0 1.6799363038444426e-06
observed O 0 6.919548241057782e-07
. O 0 2.895984039241739e-07

No O 0 0.024669302627444267
desmoid B-Disease 1 0.9999998807907104
tumors I-Disease 1 1.0
were O 0 3.7063023228256498e-06
found O 0 6.174715139195541e-08
in O 0 4.4244000463322664e-08
these O 0 5.464394448040366e-08
kindreds O 0 6.410675268853083e-05
. O 0 1.1520444331836188e-06

Our O 0 5.440637778519886e-06
data O 0 1.1014693654942675e-06
suggest O 0 1.214446427866278e-07
that O 0 2.6582500645133678e-09
, O 0 4.949262333298066e-09
in O 0 3.843736351427651e-07
AAPC B-Disease 1 1.0
families O 0 1.794347497252602e-07
, O 0 5.050373008685938e-09
the O 0 1.7850025457732954e-08
location O 0 5.979548518553202e-07
of O 0 1.1452775083853339e-07
the O 0 1.0321839454263682e-06
APC B-Disease 0 6.494127319456311e-06
mutation O 0 5.936521496607838e-09
may O 0 3.0768498859856663e-09
partially O 0 1.3971994405892474e-07
predict O 0 1.8655818223578535e-08
specific O 0 2.0046166948617383e-09
phenotypic O 0 2.1572742525677313e-07
expression O 0 3.2901687063713325e-07
. O 0 8.095622661130619e-08

This O 0 2.4625359174024197e-07
should O 0 2.1088586876771842e-08
help O 0 2.7342030861632338e-08
in O 0 5.54985035705613e-09
the O 0 1.4130419501157121e-08
design O 0 1.1346191541861117e-07
of O 0 2.7552694348287332e-08
tailored O 0 6.678101982515727e-08
clinical O 0 3.198251215508208e-05
- O 0 1.5876964880590094e-06
management O 0 1.830308491435062e-07
protocols O 0 9.079334262196426e-08
in O 0 1.9743815471429116e-09
this O 0 2.121088638062929e-09
subset O 0 1.3856377734100533e-07
of O 0 5.345840747850161e-08
FAP B-Disease 0 1.2882611599707161e-06
patients O 0 6.424838883134498e-09
. O 0 4.317811441723052e-09
. O 0 1.0432366082113731e-07

Wilms B-Disease 1 0.9999948740005493
' I-Disease 0 0.00013154029147699475
tumor I-Disease 0 1.0385138921265025e-05
1 O 0 4.064206962084427e-07
and O 0 5.522020174453246e-08
Dax O 0 0.0003765755973290652
- O 0 3.8194954754544597e-07
1 O 0 9.998398553534571e-08
modulate O 0 1.2634473023354076e-07
the O 0 8.186455957570615e-09
orphan O 0 8.647647575799056e-08
nuclear O 0 5.823300170959556e-07
receptor O 0 1.8903236878031748e-06
SF O 0 1.9600416635512374e-05
- O 0 1.3299060519500472e-08
1 O 0 3.189601693875943e-09
in O 0 3.6722297425129113e-10
sex O 0 6.157409582208118e-10
- O 0 3.0745253565278574e-10
specific O 0 8.84757545005499e-11
gene O 0 3.447091723174367e-09
expression O 0 2.2661632570475376e-08
. O 0 3.471029330626152e-08

Products O 0 4.068523367095622e-07
of O 0 1.5097851928658201e-06
steroidogenic O 0 9.071428939932957e-05
factor O 0 1.5263036630130955e-06
1 O 0 2.728689310060872e-07
( O 0 2.9288935721183407e-08
SF O 0 1.0721295438997913e-05
- O 0 9.641535569926418e-08
1 O 0 3.073924403906858e-08
) O 0 1.674638760995606e-09
and O 0 3.1513356368861878e-09
Wilms B-Disease 0 0.00028307607863098383
tumor I-Disease 0 2.6316508865420474e-06
1 O 0 1.6311987849348952e-07
( O 0 4.854127322317936e-09
WT1 O 0 1.696586053867577e-07
) O 0 8.036472182171295e-11
genes O 0 3.914841367747002e-11
are O 0 7.361607851086305e-12
essential O 0 9.37028676872842e-10
for O 0 1.1674863298338778e-09
mammalian O 0 1.965796627700911e-07
gonadogenesis O 0 1.2501496939876233e-06
prior O 0 1.955807391595954e-07
to O 0 7.770912802129715e-09
sexual O 0 1.2918299319153448e-07
differentiation O 0 7.828770662854367e-07
. O 0 1.3528452313948947e-07

In O 0 4.0858651573216775e-07
males O 0 4.382230756050376e-08
, O 0 4.2509697095738375e-08
SF O 0 0.013095016591250896
- O 0 1.191333467431832e-06
1 O 0 1.0617935686241253e-07
participates O 0 1.1001360711304642e-08
in O 0 6.732835400313775e-10
sexual O 0 3.384967639519232e-09
development O 0 3.403197501583577e-09
by O 0 5.286679427563001e-10
regulating O 0 9.047729676581184e-09
expression O 0 3.0103421977401013e-09
of O 0 2.90443136208296e-09
the O 0 2.995178149944877e-08
polypeptide O 0 1.0583361472527031e-05
hormone O 0 2.9025812864347245e-07
Mullerian O 0 4.7829475079197437e-05
inhibiting O 0 3.206301641967002e-07
substance O 0 1.9451969990313955e-07
( O 0 7.818221803290726e-08
MIS O 0 2.8128779376856983e-05
) O 0 1.71289169514921e-08
. O 0 3.53778197847987e-08

Here O 0 1.2851988685724791e-05
, O 0 7.781995492450733e-08
we O 0 5.325283680690518e-08
show O 0 8.623155167697405e-08
that O 0 1.0238116132654795e-08
WT1 O 0 0.00014515013026539236
- O 0 4.692404763773084e-05
KTS O 0 0.005663252901285887
isoforms O 0 2.784955484003149e-07
associate O 0 2.161621779350753e-07
and O 0 1.0281672180312285e-09
synergize O 0 3.522605425132497e-07
with O 0 3.919539182106746e-08
SF O 1 0.991582453250885
- O 0 4.351680672698421e-06
1 O 0 1.645743026301716e-07
to O 0 1.501687130200935e-08
promote O 0 4.4804400545217504e-07
MIS O 0 0.0006985521176829934
expression O 0 4.1304420506094175e-07
. O 0 8.224333214457147e-08

In O 0 5.455489713313e-07
contrast O 0 3.6263165270611353e-07
, O 0 1.1654705645014474e-07
WT1 O 0 0.0005142679437994957
missense O 0 7.774985533615109e-06
mutations O 0 1.421907036558423e-08
, O 0 5.736338071216096e-10
associated O 0 1.8118813116529964e-08
with O 0 2.1404511940659177e-08
male B-Disease 0 0.0002634100674185902
pseudohermaphroditism I-Disease 1 1.0
in O 0 1.0499560630705673e-05
Denys B-Disease 1 1.0
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 1.3246624064322532e-07
fail O 0 7.242923061312467e-07
to O 0 4.870173597737448e-08
synergize O 0 2.283261164848227e-05
with O 0 1.5772380947964848e-06
SF O 1 1.0
- O 0 0.00120850361417979
1 O 0 1.2042380149068777e-05
. O 0 4.1336025446980784e-07

Additionally O 0 1.6022577256080694e-06
, O 0 1.0520523119339487e-08
the O 0 3.5088383754100505e-08
X O 0 6.007726824464044e-06
- O 0 7.967889814608498e-07
linked O 0 3.8484387232529116e-07
, O 0 1.108567349028533e-09
candidate O 0 1.7295516130388933e-09
dosage O 0 4.2505966746375634e-08
- O 0 5.780661993526337e-08
sensitive O 0 8.588767030914823e-08
sex O 0 6.6206475857200076e-09
- O 0 1.2576464314406621e-08
reversal O 0 4.220591875991886e-08
gene O 0 1.1461942506230116e-09
, O 0 2.803219434355242e-09
Dax O 0 3.52995193679817e-05
- O 0 2.69291803078886e-07
1 O 0 9.284686797172981e-08
, O 0 4.683830212570683e-09
antagonizes O 0 6.147054136818042e-07
synergy O 0 2.0285652624352224e-07
between O 0 1.89308977383007e-07
SF O 0 7.137080683605745e-05
- O 0 2.4346775262529263e-07
1 O 0 8.376392912623487e-08
and O 0 5.861810592477923e-09
WT1 O 0 9.616788702260237e-06
, O 0 4.3879158084791925e-09
most O 0 6.005121955254822e-10
likely O 0 1.668886473460418e-09
through O 0 2.1232258173853324e-09
a O 0 8.351868530098727e-09
direct O 0 5.693481242019516e-09
interaction O 0 4.138847842227733e-08
with O 0 1.0214767698357718e-08
SF O 0 0.030737077817320824
- O 0 9.751774086907972e-06
1 O 0 1.8765221057037706e-06
. O 0 1.999001710828452e-07

We O 0 2.705500264710281e-06
propose O 0 9.560883427184308e-07
that O 0 5.6716331187089963e-08
WT1 O 0 2.387209315202199e-05
and O 0 2.476350573488162e-07
Dax O 1 0.5535964369773865
- O 0 3.957984517910518e-06
1 O 0 4.562086246551189e-07
functionally O 0 1.597026795252532e-07
oppose O 0 1.0701571850901814e-09
each O 0 2.682717659130418e-10
other O 0 1.548207950730074e-10
in O 0 2.4731341419226283e-09
testis O 0 9.046806894730253e-07
development O 0 3.573290285885378e-08
by O 0 1.3689769318148137e-08
modulating O 0 1.645317638576671e-06
SF O 0 0.00038616263191215694
- O 0 1.0407062518424937e-06
1 O 0 6.248912995943101e-07
- O 0 2.532079577122204e-07
mediated O 0 6.957245091143704e-07
transactivation O 0 1.5817427993169986e-05
. O 0 1.2252066028395348e-08
. O 0 3.052726427199559e-08

A O 0 1.023192726279376e-05
mouse O 0 6.061722501726763e-07
model O 0 1.0245738479852662e-07
for O 0 2.829573020335374e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 1 0.9999586343765259
- O 0 0.353391170501709
centre O 0 3.0364371923496947e-05
mutations O 0 4.051293842621817e-07
. O 0 3.416526226374117e-07

Imprinting O 0 0.0005577923147939146
in O 0 6.831554060227063e-07
the O 0 3.101131937910395e-07
15q11 O 0 1.6567028069403023e-05
- O 0 2.041308789557661e-06
q13 O 0 2.7873013550561154e-06
region O 0 4.424492416887915e-08
involves O 0 4.492111216336525e-08
an O 0 1.4641444501251044e-08
imprinting O 0 2.3230536498886067e-06
centre O 0 3.653636213130085e-06
( O 0 6.79495997246704e-08
IC O 0 1.7921190647030016e-06
) O 0 3.372838452975202e-09
, O 0 6.190216672585791e-10
mapping O 0 8.77097079410305e-08
in O 0 7.569529891782167e-09
part O 0 2.2465945548333366e-08
to O 0 3.9506424798219086e-08
the O 0 3.9055774436747015e-07
promoter O 0 2.607926035125274e-06
and O 0 4.1559662378176654e-08
first O 0 1.022989749799308e-06
exon O 0 5.268322183837881e-06
of O 0 2.991672317875782e-06
SNRPN O 0 0.0021630164701491594
. O 0 2.823105887728161e-06

Deletion O 0 1.926251206896268e-05
of O 0 4.534014976798062e-07
this O 0 3.666047021511076e-08
IC O 0 4.6534328248526435e-06
abolishes O 0 1.9259260852777516e-07
local O 0 1.3536836540595232e-08
paternally O 0 8.566799465370423e-07
derived O 0 2.23433431756348e-08
gene O 0 2.062482851172831e-09
expression O 0 1.3478962390678362e-09
and O 0 2.197653864444149e-10
results O 0 1.0274797013209991e-08
in O 0 3.7649010664608795e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9664270281791687
PWS B-Disease 1 1.0
) O 0 1.3033163668296766e-06
. O 0 2.779683256903809e-07

We O 0 8.455148758912401e-07
have O 0 3.743502841047075e-09
created O 0 9.481034624059248e-09
two O 0 5.296957095168864e-09
deletion O 0 8.751585767186043e-08
mutations O 0 4.45880088406625e-09
in O 0 2.8733012413795223e-08
mice O 0 1.0808475536805418e-07
to O 0 5.544742975871486e-08
understand O 0 0.00011279425962129608
PWS B-Disease 1 1.0
and O 0 9.374156206831685e-08
the O 0 6.703881894054575e-08
mechanism O 0 5.224924279900733e-07
of O 0 9.191423089305317e-08
this O 0 8.707760912329832e-08
IC O 0 4.039291889057495e-05
. O 0 5.710917889700795e-07

Mice O 0 0.009029721841216087
harbouring O 0 0.0016078094486147165
an O 0 3.2349052503377607e-07
intragenic O 0 5.9724643506342545e-05
deletion O 0 2.9608024760818807e-06
in O 0 1.1713125758205933e-07
Snrpn O 0 0.0036882241256535053
are O 0 1.799771176536069e-08
phenotypically O 0 7.00251530361129e-06
normal O 0 1.6405263068008935e-06
, O 0 1.2083570810617061e-09
suggesting O 0 2.087249484361564e-08
that O 0 1.4498043876542965e-09
mutations O 0 4.9642379096326295e-09
of O 0 1.181110818038178e-07
SNRPN O 0 0.18220984935760498
are O 0 4.994810787195547e-09
not O 0 3.0755884505850872e-09
sufficient O 0 2.0848430892783654e-07
to O 0 6.746274721081136e-07
induce O 0 0.00045022802078165114
PWS B-Disease 1 1.0
. O 0 8.906414223019965e-06

Mice O 0 5.4337375331670046e-05
with O 0 5.138885761368783e-09
a O 0 3.635242507016301e-08
larger O 0 1.0783370640865542e-08
deletion O 0 5.8668021551966376e-08
involving O 0 4.690269506113509e-08
both O 0 8.9311047446472e-09
Snrpn O 0 0.00012211728608235717
and O 0 3.228605294225417e-08
the O 0 1.0102226042363327e-06
putative O 0 0.0003056002897210419
PWS O 1 1.0
- O 0 0.00038447955739684403
IC O 0 0.00014777490287087858
lack O 0 4.016585819499596e-07
expression O 0 4.310770052029511e-08
of O 0 1.1179958292473202e-08
the O 0 1.2891343104115549e-08
imprinted O 0 6.257781137719576e-07
genes O 0 8.952358854230624e-08
Zfp127 O 0 3.305071732029319e-05
( O 0 1.4023149219610787e-07
mouse O 0 1.2195263821013214e-07
homologue O 0 3.0275035101112735e-07
of O 0 1.0951224282962357e-07
ZNF127 O 0 8.082098793238401e-05
) O 0 5.725424401248347e-08
, O 0 2.6194658886424804e-08
Ndn O 0 0.00011347790859872475
and O 0 1.1385061071678138e-07
Ipw O 0 0.0006870694924145937
, O 0 2.6037849210069908e-08
and O 0 3.962572048266111e-09
manifest O 0 1.9114338556391886e-06
several O 0 6.331872270948224e-08
phenotypes O 0 1.6068821651060716e-06
common O 0 1.229038559813489e-07
to O 0 4.120615813008044e-06
PWS B-Disease 1 1.0
infants O 1 0.9974502921104431
. O 0 1.13328621864639e-06

These O 0 1.4594164099435147e-07
data O 0 2.2834650792447064e-07
demonstrate O 0 6.03141359079018e-08
that O 0 1.521432202444828e-09
both O 0 6.9247745315692555e-09
the O 0 4.5911804136267165e-08
position O 0 2.1398862770638516e-07
of O 0 1.254168751074758e-07
the O 0 1.346109286259889e-07
IC O 0 4.680654001276707e-06
and O 0 2.3344037813899376e-09
its O 0 2.842436730432496e-09
role O 0 1.5033952749377022e-08
in O 0 3.482280908073676e-09
the O 0 3.213465715745656e-09
coordinate O 0 1.9860681987893258e-08
expression O 0 2.543555588374602e-08
of O 0 1.1270008037911339e-08
genes O 0 3.548315641310751e-09
is O 0 4.6123377339668536e-10
conserved O 0 1.2354426814908948e-08
between O 0 8.781210425468089e-09
mouse O 0 5.054876339727343e-08
and O 0 1.9179101362620798e-10
human O 0 5.797796465145666e-09
, O 0 2.5051843932644147e-10
and O 0 4.859775915022624e-10
indicate O 0 2.2005167465977138e-08
that O 0 4.5914827495607824e-10
the O 0 8.844311061295684e-09
mouse O 0 1.577056885082584e-08
is O 0 2.114463049096571e-10
a O 0 6.814045439007543e-10
suitable O 0 5.9002176477918056e-09
model O 0 1.290135287490557e-08
system O 0 3.677151916292587e-09
in O 0 1.7522870932040746e-09
which O 0 3.1223701402183224e-10
to O 0 4.837469869123368e-10
investigate O 0 3.9373276194965e-08
the O 0 3.2311433528775524e-08
molecular O 0 2.956399214326666e-07
mechanisms O 0 2.3684731331741204e-07
of O 0 7.075782804122355e-08
imprinting O 0 7.457992978743277e-07
in O 0 2.929914533211786e-09
this O 0 8.047121302645621e-10
region O 0 4.056812219488393e-09
of O 0 1.7607945324016328e-08
the O 0 4.9948422287116045e-08
genome O 0 5.655699908402312e-08
. O 0 1.1190454785037218e-08
. O 0 9.777745901828894e-08

Mutations O 0 1.539748154755216e-06
of O 0 3.64112054285215e-07
the O 0 2.6240871875415905e-07
ATM O 0 3.198876584065147e-05
gene O 0 2.058173009800157e-08
detected O 0 4.8886196424291484e-08
in O 0 7.373819954636929e-08
Japanese O 1 0.9999998807907104
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 0.0001330025988863781
: O 0 2.80451373235735e-09
possible O 0 1.218215928133759e-08
preponderance O 0 2.1150328393559903e-05
of O 0 1.2316434094827855e-07
the O 0 5.340582021062801e-08
two O 0 2.8828640807887496e-08
founder O 0 4.149197138758609e-06
mutations O 0 4.982291912369874e-08
4612del165 O 0 2.1880964595766272e-06
and O 0 1.9074917645411915e-07
7883del5 O 0 5.3879797633271664e-05
. O 0 2.770238097582478e-06

The O 0 1.0782284334709402e-05
ATM O 0 0.00021351994655560702
( O 0 3.730081061803503e-06
A O 1 1.0
- O 1 0.9998661279678345
T O 1 0.9999637603759766
, O 0 8.638939341665264e-09
mutated O 0 2.0082495666429168e-08
) O 0 2.078397232097018e-09
gene O 0 1.3635454987337425e-09
on O 0 7.744530350350942e-09
human O 0 2.872227256034421e-08
chromosome O 0 3.595715725168702e-07
11q22 O 0 4.692820311902324e-06
. O 0 3.362573295362381e-07

3 O 0 1.1117313079012092e-05
has O 0 2.779518126772018e-08
recently O 0 3.089571265491031e-08
been O 0 4.867487302107065e-09
identified O 0 5.187752005753055e-09
as O 0 7.290477110899474e-10
the O 0 4.579170820306899e-09
gene O 0 5.378717471415939e-10
responsible O 0 1.2669270077481087e-09
for O 0 5.755583232236461e-10
the O 0 1.2132944959830638e-07
human O 0 2.5236196961486712e-05
recessive B-Disease 1 0.9780424237251282
disease I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999998807907104
A B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
T I-Disease 1 0.9999998807907104
) O 0 7.131454538011894e-08
. O 0 4.8233051330726084e-08

In O 0 9.590380614099558e-07
order O 0 3.535434345280919e-08
to O 0 1.2000134219647407e-08
define O 0 4.833195532683021e-08
the O 0 1.6071648900606306e-08
types O 0 1.4609086385064529e-08
of O 0 1.6162493921001442e-06
disease O 1 0.8249713182449341
- O 0 1.363857609248953e-05
causing O 0 2.8664044293691404e-06
ATM O 0 2.8685384677373804e-05
mutations O 0 3.121216618495737e-09
in O 0 1.7383298356321575e-08
Japanese O 0 0.0007722022128291428
A B-Disease 1 1.0
- I-Disease 1 0.9999963045120239
T I-Disease 1 1.0
patients O 0 5.946720893490465e-09
as O 0 9.414714563504845e-10
well O 0 5.059675456386969e-10
as O 0 6.332059321323413e-10
to O 0 3.935896886186896e-10
look O 0 1.620900524912372e-09
for O 0 6.621465042933039e-10
possible O 0 2.176705926615341e-08
mutational O 0 3.8593066165049095e-06
hotspots O 0 1.3219553807175544e-07
, O 0 1.9457075950413127e-09
reverse O 0 4.468858350037408e-08
- O 0 1.2169182639354403e-07
transcribed O 0 9.60339548328193e-07
RNA O 0 8.256208161583345e-08
derived O 0 3.2880522748968133e-09
from O 0 8.380890981207756e-10
ten O 0 1.78632735270412e-08
patients O 0 3.121704672537362e-09
belonging O 0 2.4709947865630966e-08
to O 0 4.367033845653623e-09
eight O 0 1.0118436932771147e-07
unrelated O 0 3.836313226202037e-06
Japanese O 1 0.9948776960372925
A B-Disease 1 1.0
- I-Disease 1 0.9999933242797852
T I-Disease 1 0.9999792575836182
families O 0 7.950063385386841e-10
was O 0 3.436109397014775e-09
analyzed O 0 2.942330379340774e-09
for O 0 1.6644002842625127e-10
mutations O 0 2.7459909346383427e-10
by O 0 4.41344683022038e-10
the O 0 3.661551728484369e-09
restriction O 0 2.1844002162652032e-08
endonuclease O 0 1.5865295210915065e-07
fingerprinting O 0 8.319640976139908e-09
method O 0 5.969610583633767e-08
. O 0 8.387695515921223e-08

As O 0 1.7366733118251432e-06
has O 0 6.439302868699315e-09
been O 0 5.3869029237318955e-09
reported O 0 3.838268813893819e-09
by O 0 9.647137533264072e-10
others O 0 3.2194471533131264e-09
, O 0 1.523828063731969e-09
mutations O 0 2.128034193304984e-09
that O 0 1.0853832277391007e-09
lead O 0 7.569504134607996e-08
to O 0 1.0455114818341826e-07
exon O 0 3.7838883599761175e-06
skipping O 0 1.4769506151424139e-06
or O 0 9.65160040777846e-08
premature O 0 2.89777432271876e-07
protein O 0 8.160580478033808e-08
truncation O 0 2.9764044029434444e-06
were O 0 2.1232193603282212e-07
also O 0 2.6338241809753526e-08
predominant O 0 8.419494292866148e-07
in O 0 9.436693204634139e-08
our O 0 1.1940335298277205e-06
mutants O 0 5.930259248998482e-06
. O 0 3.0482672741527495e-07

Six O 0 3.6112385259912116e-07
different O 0 1.882764388838609e-09
mutations O 0 2.4550865784789266e-09
were O 0 1.7979285615865592e-08
identified O 0 3.566685080613752e-08
on O 0 6.44812985228782e-08
12 O 0 1.2007568273020297e-07
of O 0 1.0890131818541704e-07
the O 0 1.0321981847027928e-07
16 O 0 1.7244312289221853e-07
alleles O 0 7.440330573871279e-09
examined O 0 4.912430995318573e-07
. O 0 2.60991868117344e-07

Four O 0 2.1166376882320037e-06
were O 0 2.873987341445172e-07
deletions O 0 4.384689020753285e-07
involving O 0 3.3091751561187266e-07
a O 0 6.731339112775458e-07
loss O 0 7.493236353184329e-06
of O 0 2.2718821128364652e-05
a O 0 2.2546964828507043e-06
single O 0 1.0965475212287856e-06
exon O 0 1.185609676213062e-06
exon O 0 4.004591289685777e-07
7 O 0 2.280742421589821e-07
, O 0 7.651457245572146e-09
exon O 0 1.6631111066089943e-07
16 O 0 1.1512290853943341e-07
, O 0 1.5480265957990014e-08
exon O 0 7.688412324569072e-07
33 O 0 6.822451723564882e-07
or O 0 3.7866070101699734e-07
exon O 0 5.029069143347442e-06
35 O 0 6.289494649536209e-06
. O 0 1.2848772712459322e-06

The O 0 3.9289589039981365e-06
others O 0 7.477094499108716e-08
were O 0 4.757846383540709e-08
minute O 0 1.531796556264453e-07
deletions O 0 1.10602343283972e-07
, O 0 8.86221140916632e-09
4649delA O 0 4.880756137026765e-07
in O 0 1.5184795643108373e-07
exon O 0 5.679746095665905e-07
33 O 0 1.896604544526781e-07
and O 0 1.3002565246722497e-08
7883del5 O 0 1.7584604847797891e-06
in O 0 4.476903541217325e-07
exon O 0 7.014727088971995e-06
55 O 0 2.8047265914210584e-06
. O 0 4.908347364107613e-07

The O 0 3.001669028890319e-06
mutations O 0 1.8185016870120307e-07
4612del165 O 0 2.7117671379528474e-06
and O 0 3.5898356287589195e-08
7883del5 O 0 2.5509366423648316e-06
were O 0 2.0737402905979252e-07
found O 0 1.3268782517172895e-08
in O 0 3.5956997379571476e-09
more O 0 1.7218880488112376e-10
than O 0 7.735589946378241e-11
two O 0 1.707804037076599e-10
unrelated O 0 1.055380494108249e-08
families O 0 1.8364607057286264e-10
; O 0 5.7229148503479266e-11
44 O 0 4.739321823876708e-09
% O 0 3.0052420552095782e-09
( O 0 1.056824294742853e-09
7 O 0 1.6703459948530508e-08
of O 0 1.2016464268072014e-08
16 O 0 1.3887647476451548e-08
) O 0 1.100532220910111e-09
of O 0 2.560644807303447e-09
the O 0 7.345181352036434e-09
mutant O 0 7.488126385624128e-08
alleles O 0 1.614673617034157e-09
had O 0 3.289871486344964e-09
one O 0 1.033846452891396e-09
of O 0 4.767509498293521e-09
the O 0 7.419837633193538e-09
two O 0 1.2240691127374248e-08
mutations O 0 4.100839134935086e-08
. O 0 1.0162089836285304e-07

The O 0 3.6437538710742956e-06
4612del165 O 0 5.539311587199336e-06
mutations O 0 9.38977429143506e-09
in O 0 2.15348849863517e-09
three O 0 4.5394099590367887e-10
different O 0 2.2135220045793602e-10
families O 0 9.310321402722366e-10
were O 0 4.771039119333409e-09
all O 0 2.5808020165385415e-09
ascribed O 0 1.6061453322890884e-07
to O 0 3.316990015989063e-09
the O 0 1.528171544862289e-08
same O 0 1.544325378688427e-08
T O 0 6.37564454564199e-08
- O 0 5.656821500110709e-08
- O 0 2.1106276903992693e-07
> O 0 1.365996382673984e-07
A O 0 1.516771064302702e-08
substitution O 0 6.852131750889612e-09
at O 0 2.6848294254477878e-08
the O 0 3.253344260656377e-08
splice O 0 1.3403158618530142e-06
donor O 0 4.596718383709231e-08
site O 0 1.0437381803285462e-07
in O 0 5.917847900605011e-08
intron O 0 2.348829002585262e-05
33 O 0 4.86747603645199e-06
. O 0 5.717784574699181e-07

Microsatellite O 0 0.002358397003263235
genotyping O 0 5.4986558097880334e-05
around O 0 8.197191618819488e-07
the O 0 6.900937705722754e-07
ATM O 0 0.0005644261837005615
locus O 0 2.622671217977768e-06
also O 0 3.3558720247128804e-09
indicated O 0 7.114144384701149e-09
that O 0 6.540254449127758e-10
a O 0 1.5445580814343884e-08
common O 0 4.334710812514686e-09
haplotype O 0 1.2814273020467226e-07
was O 0 7.119250966525215e-08
shared O 0 1.42709932759999e-08
by O 0 1.431040064225897e-09
the O 0 1.3499707129938088e-08
mutant O 0 1.7157820053625983e-08
alleles O 0 6.037669253444733e-10
in O 0 1.3121747022282193e-09
both O 0 6.526811979767899e-09
mutations O 0 4.9290484582797944e-08
. O 0 2.0212908680150576e-07

This O 0 1.1731766562661505e-06
suggests O 0 5.732564432037179e-07
that O 0 1.913055713842482e-09
these O 0 2.0794916899546934e-09
two O 0 1.515654801664823e-08
founder O 0 2.2592314508074196e-06
mutations O 0 5.878683762006176e-09
may O 0 2.2828472445723946e-09
be O 0 2.9720153005285965e-09
predominant O 0 5.013817627741446e-08
among O 0 5.4413442640566245e-09
Japanese O 0 2.440880962240044e-06
ATM O 0 8.273236744571477e-06
mutant O 0 3.9205193047564535e-07
alleles O 0 6.339047509129614e-09
. O 0 2.4895058459151187e-08

W474C O 0 6.151389243314043e-05
amino O 0 8.509355211572256e-07
acid O 0 3.2460796717259655e-08
substitution O 0 1.061371968091862e-08
affects O 0 2.6264888042248913e-09
early O 0 3.1174027803615445e-09
processing O 0 2.1242232861595767e-08
of O 0 2.694114442647333e-08
the O 0 1.5354494564689958e-08
alpha O 0 1.402548974738238e-07
- O 0 4.23298907037406e-09
subunit O 0 3.725071806570668e-08
of O 0 8.666862783002216e-09
beta O 0 1.1873812155727137e-07
- O 0 2.2479104799799643e-08
hexosaminidase O 0 4.523476775375457e-07
A O 0 7.173363769652497e-08
and O 0 3.1446334425311306e-10
is O 0 8.895331138347728e-10
associated O 0 6.113085593284495e-09
with O 0 2.9042042104521215e-09
subacute O 0 0.0005137240514159203
G B-Disease 0 0.07307080179452896
( I-Disease 0 4.766884558193851e-06
M2 I-Disease 0 0.0007966681150719523
) I-Disease 0 8.317375232991253e-08
gangliosidosis I-Disease 0 1.0425377695355564e-05
. O 0 3.4528912351561303e-07

Mutations O 0 1.0622893569234293e-06
in O 0 4.9708159366446125e-08
the O 0 7.501392929043504e-08
HEXA O 0 2.7863983632414602e-05
gene O 0 1.6271638481057948e-09
, O 0 1.732442939106349e-10
encoding O 0 4.0933254008557185e-10
the O 0 2.556282296950485e-09
alpha O 0 3.2404258831775223e-08
- O 0 3.0964664166077682e-09
subunit O 0 3.402900716764634e-08
of O 0 9.600317874003395e-09
beta O 0 1.3189746539410407e-07
- O 0 5.204444519790741e-08
hexosaminidase O 0 2.071646576951025e-06
A O 0 1.960051122296136e-06
( O 0 2.3987237085520974e-08
Hex O 0 2.0371703612909187e-06
A O 0 3.6182120766170556e-07
) O 0 1.396975757295138e-09
, O 0 1.6742771058453343e-10
that O 0 1.2711187657998835e-10
abolish O 0 7.038027405315006e-08
Hex O 0 8.378240636375267e-06
A O 0 1.6153697401932732e-07
enzyme O 0 9.443049009405513e-08
activity O 0 4.455039288586704e-06
cause O 0 0.010197271592915058
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 8.895938776731782e-07
TSD B-Disease 0 0.4321296215057373
) O 0 4.387196383959235e-09
, O 0 4.969294420398285e-10
the O 0 1.0264395555736883e-08
fatal O 0 1.356308985123178e-06
infantile B-Disease 0 2.1325460863863555e-07
form I-Disease 0 7.971020288266573e-09
of I-Disease 0 2.222511284344364e-06
G I-Disease 0 0.0001143111294368282
( I-Disease 0 1.4874985936330631e-06
M2 I-Disease 0 0.0004984570550732315
) I-Disease 0 3.241649437768501e-08
gangliosidosis I-Disease 0 1.1891676194863976e-06
, I-Disease 0 7.960385239869083e-09
Type I-Disease 0 5.327397047949489e-07
1 I-Disease 0 1.3896637938159984e-06
. O 0 1.8197664530816837e-07

Less O 0 3.1505974220635835e-06
severe O 0 1.1134311534988228e-05
, O 0 7.506931609668754e-08
subacute O 0 0.042557910084724426
( O 0 2.8572885639732704e-06
juvenile O 0 0.000383448030333966
- O 0 4.192156848148443e-05
onset O 1 0.9998894929885864
) O 0 6.289742771059537e-08
and O 0 2.6137465525266634e-08
chronic O 1 0.999997615814209
( O 0 5.493236017173331e-07
adult O 0 3.262764039391186e-06
- O 0 1.304999159401632e-06
onset O 0 0.00113963324110955
) O 0 7.977921656632248e-10
variants O 0 9.289071178919528e-10
are O 0 9.577774684466078e-11
characterized O 0 1.2268616123023435e-09
by O 0 4.526941876914492e-10
a O 0 4.716147472549892e-09
broad O 0 9.975835713049719e-10
spectrum O 0 1.8928933975814743e-09
of O 0 4.218006832701349e-09
clinical O 0 1.4461795672104927e-07
manifestations O 0 1.820451984713145e-07
and O 0 1.6551918724516668e-09
are O 0 5.463367536151509e-10
associated O 0 7.874850105338282e-09
with O 0 1.0264976646467971e-09
residual O 0 4.138509029871784e-05
levels O 0 1.101841235140455e-06
of O 0 2.3904894419501943e-07
Hex O 0 1.1325482773827389e-05
A O 0 3.6303026718087494e-07
enzyme O 0 6.970321919652633e-08
activity O 0 4.404655271628144e-07
. O 0 4.0334054318691415e-08

We O 0 1.776415047061164e-06
identified O 0 2.684548690012889e-07
a O 0 2.981632576393167e-07
1422 O 0 3.475665153018781e-06
G O 0 7.136216595426959e-07
- O 0 2.5424068894608354e-07
- O 0 4.6564952072003507e-07
> O 0 2.8539341201394564e-07
C O 0 5.697106075785996e-07
( O 0 2.7820943326872793e-09
amino O 0 3.813363846916218e-09
acid O 0 2.31051022758777e-09
W474C O 0 4.4998639481264036e-08
) O 0 1.48999368398961e-10
substitution O 0 7.212787034305279e-10
in O 0 2.0577988202319375e-09
the O 0 6.836048616065682e-09
first O 0 3.450086438760991e-08
position O 0 1.862279646047682e-07
of O 0 1.6018653070659639e-07
exon O 0 5.080103733234864e-07
13 O 0 1.7943612817816756e-07
of O 0 2.9725447348027956e-07
HEXA O 0 0.0002473634958732873
of O 0 1.1008140745616402e-06
a O 0 4.2445128656254383e-07
non O 0 5.061889623902971e-06
- O 0 2.0263817077648127e-06
Jewish O 0 3.915500201401301e-06
proband O 0 9.598225733498111e-05
who O 0 4.073779535929134e-08
manifested O 0 1.0052780226033065e-06
a O 0 2.1589475807104463e-07
subacute O 0 7.693753104831558e-06
variant O 0 1.7777340133307007e-07
of O 0 6.314399342954857e-06
G B-Disease 0 0.0003876285336446017
( I-Disease 0 4.426537088875193e-06
M2 I-Disease 0 0.006183529272675514
) I-Disease 0 2.8325592893452267e-07
gangliosidosis I-Disease 0 4.407762025948614e-05
. O 0 8.08382424111187e-07

On O 0 4.932061983708991e-06
the O 0 3.0532396522175986e-07
second O 0 9.242860414815368e-07
maternally O 0 1.1076675946242176e-05
inherited O 0 2.775495204332401e-06
allele O 0 2.258064668581028e-08
, O 0 2.3253117209520724e-09
we O 0 2.330164505792709e-09
identified O 0 1.3787196273540303e-08
the O 0 3.774326629013558e-08
common O 0 6.063260684641136e-07
infantile O 1 0.8084849119186401
disease O 0 0.015058265067636967
- O 0 2.1916864625382004e-06
causing O 0 1.7919002175403875e-06
4 O 0 6.063287855795352e-06
- O 0 6.183685172800324e-07
bp O 0 1.3715862223762088e-06
insertion O 0 3.6187091723149933e-07
, O 0 4.014800580875999e-08
+ O 0 1.7030424714903347e-06
TATC O 0 0.00021416058007162064
1278 O 0 0.00010010055120801553
, O 0 2.2389501808106615e-08
in O 0 5.515736134498184e-08
exon O 0 1.5178931107584503e-06
11 O 0 8.250200380643946e-07
. O 0 2.0492677776928758e-07

Pulse O 0 0.0009768048767000437
- O 0 8.91968284122413e-06
chase O 0 1.1736523219951778e-06
analysis O 0 5.519966705946899e-08
using O 0 4.800085307010704e-08
proband O 0 1.678336047916673e-05
fibroblasts O 0 3.6350356822367758e-06
revealed O 0 7.833214112906717e-07
that O 0 2.474710214528386e-09
the O 0 1.0520041726636009e-08
W474C O 0 1.1505980523907056e-07
- O 0 1.3645505170245542e-08
containing O 0 8.207608814814193e-09
alpha O 0 1.8367066445534874e-07
- O 0 2.645661467681748e-08
subunit O 0 1.9947836449318856e-07
precursor O 0 1.3710472046568611e-07
was O 0 3.5491904526452345e-08
normally O 0 3.6198388730923625e-09
synthesized O 0 4.3167432295376784e-08
, O 0 9.76849157119375e-10
but O 0 3.9839026522159315e-10
not O 0 3.257600300621277e-10
phosphorylated O 0 5.137594527582223e-08
or O 0 4.82737005924605e-09
secreted O 0 2.2724568893295327e-08
, O 0 2.585244518460428e-10
and O 0 4.0862735417590557e-10
the O 0 1.9479291069046667e-08
mature O 0 4.4821453570875747e-07
lysosomal O 0 0.00026698471629060805
alpha O 0 4.702098067355109e-06
- O 0 1.3486226180248195e-07
subunit O 0 4.244439821832202e-07
was O 0 4.198303926727931e-08
not O 0 1.7513214212172556e-09
detected O 0 8.055836531184468e-08
. O 0 4.3017266193601245e-08

When O 0 1.401613189955242e-06
the O 0 1.8208757524007524e-07
W474C O 0 7.554928060926613e-07
- O 0 6.320782830471217e-08
containing O 0 2.072934890406941e-08
alpha O 0 2.656655340160796e-07
- O 0 3.673298110129508e-08
subunit O 0 2.27290598786567e-07
was O 0 1.0467365285649066e-07
transiently O 0 4.709443715000816e-07
co O 0 3.047671555123088e-07
- O 0 2.56743923898739e-08
expressed O 0 3.621365207706617e-09
with O 0 4.153719590505034e-10
the O 0 1.5924483065532513e-08
beta O 0 7.675519952954346e-08
- O 0 7.238369459372507e-09
subunit O 0 1.1346058315098162e-08
to O 0 7.280152591881972e-10
produce O 0 2.9930864453575623e-09
Hex O 0 3.1985916848498164e-06
A O 0 1.147691023106745e-06
( O 0 7.490623232797589e-09
alphabeta O 0 2.7636809818432084e-07
) O 0 3.361509515187322e-09
in O 0 1.4828960281931813e-08
COS O 0 1.2371577213343699e-05
- O 0 3.189099118117156e-07
7 O 0 1.4395030234481965e-07
cells O 0 6.6121415009945395e-09
, O 0 2.1700834185178763e-10
the O 0 1.532683646665589e-09
mature O 0 5.4107514024792636e-09
alpha O 0 1.218523095758428e-07
- O 0 4.458035718357678e-09
subunit O 0 2.9559217296082352e-08
was O 0 5.8314562068062514e-09
present O 0 1.948645467209076e-09
, O 0 3.82923609487662e-10
but O 0 2.93666618800259e-10
its O 0 1.7506734950600844e-09
level O 0 1.4425512517846073e-07
was O 0 8.042510302175288e-08
much O 0 1.1080858897116741e-08
lower O 0 1.2174586672131227e-08
than O 0 1.694339252233945e-10
that O 0 2.9242618743152704e-11
from O 0 6.368905958176185e-10
normal O 0 1.7299219834399082e-08
alpha O 0 8.873259105257603e-08
- O 0 1.3405027310398054e-08
subunit O 0 9.004521217548245e-08
transfections O 0 9.087840879828946e-08
, O 0 9.125780686680685e-11
although O 0 4.5371224138834876e-11
higher O 0 8.716992128121603e-10
than O 0 1.7513640537814013e-10
in O 0 5.285812343380769e-10
those O 0 6.803162477808655e-10
cells O 0 4.95413576828696e-09
transfected O 0 6.242236594289352e-08
with O 0 3.239347123873415e-10
an O 0 2.4692126121550473e-09
alpha O 0 9.919928345425433e-08
- O 0 1.5422912724716298e-08
subunit O 0 1.1991467374627973e-07
associated O 0 3.6751483634134274e-08
with O 0 8.210099267103033e-09
infantile O 0 0.00024283822858706117
TSD B-Disease 0 0.002876380691304803
. O 0 8.771569923737843e-07

Furthermore O 0 7.330856533371843e-06
, O 0 2.3171002894173398e-08
the O 0 2.0618859508658716e-08
precursor O 0 4.332721346145263e-07
level O 0 9.310539326179423e-07
of O 0 5.271591163591438e-08
the O 0 4.812819298649629e-08
W474C O 0 7.615844879182987e-07
alpha O 0 5.797925837214279e-07
- O 0 2.4611876980884517e-08
subunit O 0 1.3750356231412297e-07
was O 0 1.2986900443934246e-08
found O 0 7.847317795572906e-10
to O 0 5.83974590906422e-10
accumulate O 0 2.1313296016955974e-08
in O 0 6.198395130496692e-09
comparison O 0 1.8885918606770247e-08
to O 0 3.440608242755161e-09
the O 0 3.384401026096384e-08
normal O 0 5.960299063190178e-07
alpha O 0 1.1063225429097656e-06
- O 0 4.907415984689578e-08
subunit O 0 2.5854282625914493e-07
precursor O 0 6.156324161565863e-07
levels O 0 2.8775139071512967e-07
. O 0 1.5202589054297277e-07

We O 0 9.170914836431621e-07
conclude O 0 2.7123023755848408e-06
that O 0 1.5966087119068106e-08
the O 0 4.370386008645255e-08
1422 O 0 6.0622473938565236e-06
G O 0 9.977097761293408e-07
- O 0 3.5981099699711194e-07
- O 0 3.936457062536647e-07
> O 0 2.2803054378073284e-07
C O 0 1.8133859214231052e-07
mutation O 0 9.929858046930917e-10
is O 0 1.4067855214072722e-10
the O 0 1.2006240446282845e-09
cause O 0 4.433692524230537e-08
of O 0 5.259489626041614e-07
Hex B-Disease 1 0.964668869972229
A I-Disease 1 0.9780893921852112
enzyme I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 5.967061156297859e-07
the O 0 1.0461791362104123e-06
proband O 0 5.846150452271104e-05
. O 0 5.267822302812419e-07

The O 0 1.2511957265815e-06
resulting O 0 2.548825648318598e-07
W474C O 0 1.5882220623097965e-06
substitution O 0 7.266287838092467e-08
clearly O 0 7.752025510399108e-08
interferes O 0 3.1233799546726004e-08
with O 0 1.7568206611695558e-10
alpha O 0 3.102373824503957e-08
- O 0 2.394229259294889e-09
subunit O 0 2.198226312088991e-08
processing O 0 1.9648327409527155e-08
, O 0 1.5206626235997334e-10
but O 0 9.614473106545063e-11
because O 0 2.9387001165837034e-10
the O 0 9.621430319128876e-10
base O 0 1.2793167414315576e-08
substitution O 0 1.3740728554978432e-08
falls O 0 1.168020276054449e-06
at O 0 1.0574281361641624e-07
the O 0 1.364930479752502e-08
first O 0 1.5606172354409864e-08
position O 0 5.156541860174002e-08
of O 0 1.057704395179826e-07
exon O 0 1.2699392470949533e-07
13 O 0 2.24468852394466e-08
, O 0 1.174450203755839e-09
aberrant O 0 3.989784502778093e-08
splicing O 0 2.6088356364084575e-08
may O 0 4.7143036141505945e-09
also O 0 1.0323882859708533e-09
contribute O 0 1.4667270953339084e-08
to O 0 2.281786635194294e-07
Hex B-Disease 1 0.8418712615966797
A I-Disease 0 0.018625160679221153
deficiency I-Disease 1 0.9810662269592285
in O 0 1.395315365471106e-07
this O 0 6.103348226815797e-08
proband O 0 1.6644260540488176e-05
. O 0 6.523018214465992e-08
. O 0 2.2697608415001014e-07

Two O 0 1.726736627460923e-06
frequent O 0 2.311464868398616e-06
missense O 0 6.544197822222486e-05
mutations O 0 2.6868024178838823e-06
in O 0 5.487200542120263e-05
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 4.1046605474548414e-05

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 4.8802652599988505e-05
an O 1 0.871985912322998
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.9995192289352417
by O 0 9.46838838444819e-08
early O 1 0.5429226160049438
childhood O 1 1.0
deafness B-Disease 1 1.0
and O 1 0.9999994039535522
goiter B-Disease 1 1.0
. O 0 0.003284790087491274

A O 0 1.244859868165804e-05
century O 0 7.778098165545089e-07
after O 0 2.274789956402401e-08
its O 0 1.8286601122241564e-09
recognition O 0 1.890068546117618e-09
as O 0 2.8664792761645685e-09
a O 0 3.347728849689702e-08
syndrome O 0 2.4223055561378715e-07
by O 0 4.006002196632608e-09
Vaughan O 0 2.4530763766961172e-06
Pendred O 0 0.0002652080438565463
, O 0 2.513433194906156e-08
the O 0 1.8739311258286762e-07
disease O 0 1.5897494449745864e-06
gene O 0 5.5481180538663466e-08
( O 0 6.274345878409804e-07
PDS O 0 2.1333005861379206e-05
) O 0 3.668674919410364e-09
was O 0 4.123907615394273e-08
mapped O 0 6.239903171945116e-08
to O 0 1.1325603566092468e-08
chromosome O 0 3.354309683345491e-07
7q22 O 0 7.638359420525376e-06
- O 0 1.1949190593441017e-05
q31 O 0 0.00012567141675390303
. O 0 9.772653584150248e-07

1 O 0 4.890176569460891e-06
and O 0 3.7079736614487047e-08
, O 0 9.431435188389514e-09
recently O 0 2.8739481905404318e-08
, O 0 9.954927993049978e-10
found O 0 3.4510587720859576e-09
to O 0 7.920598399380196e-09
encode O 0 1.0119788385054562e-07
a O 0 2.2016969580818113e-07
putative O 0 4.917994829156669e-06
sulfate O 0 8.456918294541538e-06
transporter O 0 0.0005701721529476345
. O 0 1.0918548696281505e-06

We O 0 3.4248577662765456e-07
performed O 0 3.563713590892803e-08
mutation O 0 4.572345613240714e-09
analysis O 0 1.4591736707814107e-08
of O 0 3.67799515288425e-08
the O 0 2.8901212090204353e-07
PDS B-Disease 0 3.94227281503845e-05
gene O 0 4.688335053515402e-09
in O 0 4.116997409653322e-09
patients O 0 1.3495683459652241e-09
from O 0 4.445986245826816e-09
14 O 0 2.0865017802407237e-07
Pendred B-Disease 0 0.0009615921298973262
families O 0 8.015049068887947e-09
originating O 0 3.5082962313026655e-08
from O 0 3.4584453079133937e-09
seven O 0 3.177469620752049e-09
countries O 0 1.4399871572923217e-10
and O 0 2.917789343470645e-10
identified O 0 8.533310058567167e-09
all O 0 7.878214525192107e-09
mutations O 0 1.3427238876317915e-08
. O 0 4.162646050076546e-08

The O 0 8.481807753923931e-07
mutations O 0 2.3843050200866855e-08
include O 0 4.080309867759979e-09
three O 0 5.591735963150768e-09
single O 0 1.8559353165414905e-08
base O 0 7.851726735452758e-08
deletions O 0 1.801227824671514e-07
, O 0 1.055738874100598e-08
one O 0 2.3423664785582332e-08
splice O 0 1.4956991662984365e-06
site O 0 1.1964507962147763e-07
mutation O 0 3.2351623602266955e-09
and O 0 4.787675589312812e-09
10 O 0 2.376986003582715e-07
missense O 0 1.245662679139059e-05
mutations O 0 3.28986743625137e-07
. O 0 4.208145014672482e-07

One O 0 6.416895303118508e-06
missense O 0 1.4507820196740795e-05
mutation O 0 6.975295718802954e-08
( O 0 3.2349049661206664e-08
L236P O 0 8.774180173531931e-07
) O 0 1.663138959884236e-08
was O 0 1.2145854100253928e-07
found O 0 2.1562639673788908e-08
in O 0 1.131470028781223e-08
a O 0 2.322117431674542e-08
homozygous O 0 3.1266207400904023e-09
state O 0 1.0640510694770455e-09
in O 0 3.153855177018272e-09
two O 0 3.5015825794459943e-09
consanguineous O 0 1.0809483683260623e-05
families O 0 2.4615385285642333e-09
and O 0 5.566120342415104e-10
in O 0 5.6563762562689135e-09
a O 0 2.280533095699866e-08
heterozygous O 0 5.3223971896443345e-09
state O 0 2.504252638590998e-10
in O 0 2.6272087283452095e-10
five O 0 7.420938308300151e-10
additional O 0 3.116047420093082e-09
non O 0 4.248159257258521e-06
- O 0 1.5610150512657128e-05
consanguineous O 0 0.0006569192046299577
families O 0 2.510386991616542e-07
. O 0 1.8405448543035163e-07

Another O 0 1.1299061952740885e-05
missense O 0 1.2651955330511555e-05
mutation O 0 8.669942985761736e-08
( O 0 2.3976395979730114e-08
T416P O 0 7.219358622023719e-07
) O 0 1.598363752464138e-08
was O 0 1.850252573376565e-07
found O 0 1.431207330426787e-08
in O 0 1.90763866925181e-08
a O 0 5.378641176889687e-08
homozygous O 0 6.328706447789045e-09
state O 0 9.850065207928083e-10
in O 0 1.2264925963734186e-08
one O 0 2.7679845970851602e-08
family O 0 3.670300685598704e-08
and O 0 2.009033828187512e-09
in O 0 2.2050290482411583e-08
a O 0 1.1717036585423557e-07
heterozygous O 0 2.1627799995371788e-08
state O 0 4.730985825318612e-09
in O 0 3.5779532669977243e-09
four O 0 3.3563601675723476e-08
families O 0 4.008770915220339e-08
. O 0 1.5489989380057523e-07

Pendred B-Disease 1 0.9033565521240234
patients O 0 1.2170103218522854e-06
in O 0 2.8282476804974976e-08
three O 0 2.2576900349235984e-08
non O 0 1.90239825315075e-05
- O 0 4.070148406754015e-06
consanguineous O 0 0.010699888691306114
families O 0 6.490574300244134e-09
were O 0 5.042355422091305e-09
shown O 0 4.043062329373015e-09
to O 0 1.6427401661189833e-09
be O 0 1.3881874316723497e-08
compound O 0 1.1542813354026293e-06
heterozygotes O 0 1.174545332105481e-07
for O 0 1.1558501711306235e-08
L236P O 0 2.4268847482744604e-06
and O 0 9.137464473951695e-08
T416P O 0 9.51609545154497e-05
. O 0 2.192696229030844e-06

In O 0 1.2691766642092261e-06
total O 0 4.591973379319825e-07
, O 0 9.08879105310234e-09
one O 0 9.423487767890038e-09
or O 0 5.570371275354091e-09
both O 0 6.601703628206224e-10
of O 0 4.401041753254731e-09
these O 0 4.724562963076551e-10
mutations O 0 1.1011075384814717e-09
were O 0 9.251237997887074e-09
found O 0 6.736962543385516e-09
in O 0 9.118674704211571e-09
nine O 0 1.6570727723319578e-07
of O 0 1.0876161127271189e-07
the O 0 1.0195366684229157e-07
14 O 0 2.881611180782784e-07
families O 0 1.0489666024682265e-08
analyzed O 0 1.6685156367657328e-07
. O 0 1.815396615256759e-07

The O 0 5.072048452348099e-07
identification O 0 1.6017230564102647e-07
of O 0 4.967773392650088e-08
two O 0 1.867091192764292e-08
frequent O 0 2.445493691993761e-07
PDS B-Disease 0 2.359712652832968e-06
mutations O 0 4.83551421126549e-10
will O 0 5.933775693023335e-11
facilitate O 0 3.6076803766604826e-09
the O 0 1.4258749736484333e-08
molecular O 0 6.959587608434958e-06
diagnosis O 0 0.0031044213101267815
of O 1 0.5849778056144714
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 6.190202839206904e-06

Insertional O 0 0.000362435937859118
mutation O 0 1.3580675783941842e-07
by O 0 2.772306650911105e-08
transposable O 0 8.293601240438875e-06
element O 0 3.433721531109768e-06
, O 0 9.364917019638597e-08
L1 O 0 3.456592094153166e-05
, O 0 7.1802737089399216e-09
in O 0 3.209449062069325e-08
the O 0 6.26642872703087e-07
DMD B-Disease 1 1.0
gene O 0 2.00932994687264e-08
results O 0 1.3112095409439917e-08
in O 0 5.966492011566515e-08
X B-Disease 1 0.9822851419448853
- I-Disease 1 0.9005372524261475
linked I-Disease 1 0.9954853057861328
dilated I-Disease 1 0.9999841451644897
cardiomyopathy I-Disease 1 1.0
. O 0 1.970475068446831e-06

X B-Disease 1 0.9999990463256836
- I-Disease 1 0.9999934434890747
linked I-Disease 1 0.9999903440475464
dilated I-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
( O 0 4.629066097550094e-05
XLDCM B-Disease 1 0.9999035596847534
) O 0 1.7875816382684206e-08
is O 0 2.567388968088835e-09
a O 0 9.189333738390815e-09
clinical O 0 5.571382644120604e-07
phenotype O 0 1.7865103529857151e-07
of O 0 3.875524043905898e-07
dystrophinopathy B-Disease 0 0.0005551462527364492
which O 0 1.0210789991305091e-09
is O 0 4.489246197003638e-10
characterized O 0 1.4819395710574668e-09
by O 0 1.7870558366439582e-09
preferential O 0 4.536787514552998e-07
myocardial B-Disease 1 1.0
involvement I-Disease 0 1.0601215763017535e-06
without O 0 1.3309083612966788e-08
any O 0 4.676403264625151e-09
overt O 0 5.1813074719575525e-08
clinical O 0 5.940987080066407e-07
signs O 0 2.9057690653644386e-07
of O 0 8.910164615372196e-05
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 0 0.0014674311969429255

To O 0 3.9018168251914176e-08
date O 0 8.341937984823744e-08
, O 0 1.0182045206974522e-09
several O 0 8.64457117000228e-10
mutations O 0 1.915692049436757e-09
in O 0 1.2253352110747073e-08
the O 0 6.144589860923588e-06
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 0.9999208450317383
gene O 0 9.85521978691395e-07
, O 0 2.1755070633844298e-07
DMD O 1 1.0
, O 0 6.556407416979937e-09
have O 0 3.198360465361816e-10
been O 0 4.667881636777338e-10
identified O 0 2.054586945021697e-09
in O 0 3.915532342801953e-09
patients O 0 1.3234502382886149e-09
with O 0 1.3075276417140458e-09
XLDCM B-Disease 1 0.9999992847442627
, O 0 9.053806593328773e-09
but O 0 7.978652183382451e-10
a O 0 7.249005284926113e-10
pathogenic O 0 5.308019024319321e-10
correlation O 0 4.14031475770571e-09
of O 0 4.5932696535189166e-10
these O 0 3.018171268465153e-10
cardiospecific O 0 1.0085351505040308e-06
mutations O 0 1.3451437297362645e-08
in O 0 1.4079068932915106e-07
DMD O 1 1.0
with O 0 2.7119630985339427e-08
the O 0 1.4771394489798695e-06
XLDCM B-Disease 1 0.998710036277771
phenotype O 0 1.5247817373165162e-06
has O 0 5.016167925475656e-09
remained O 0 9.88726824857622e-08
to O 0 2.446182145732223e-09
be O 0 2.0180985771389715e-08
elucidated O 0 0.00013190129538998008
. O 0 1.468865434617328e-06

We O 0 1.1614688446570653e-06
report O 0 2.2294479151696578e-07
here O 0 2.0740975159583286e-08
the O 0 1.0450544429829733e-08
identification O 0 1.0402001038301023e-08
of O 0 1.093869439472428e-08
a O 0 3.3911856434087895e-08
unique O 0 5.9360260706853296e-08
de O 0 6.22731568000745e-06
novo O 0 7.993044164322782e-06
L1 O 0 4.048300252179615e-05
insertion O 0 3.065259761569905e-07
in O 0 2.8026542864267867e-08
the O 0 4.4182772995782216e-08
muscle O 0 1.3637860263315815e-07
exon O 0 5.403957175076357e-07
1 O 0 3.278935878370248e-07
in O 0 9.895815367144678e-08
DMD O 1 1.0
in O 0 7.723232897660637e-08
three O 0 6.662694573833505e-08
XLDCM B-Disease 0 0.07379114627838135
patients O 0 2.0847270576496157e-08
from O 0 3.0096993786088433e-09
two O 0 3.898883438324674e-09
unrelated O 0 4.270897591140965e-07
Japanese O 0 2.8744947485392913e-05
families O 0 5.23137551056152e-08
. O 0 1.2450438191535795e-07

The O 0 1.0467806532687973e-05
insertion O 0 3.1896663585939677e-06
was O 0 1.855912614701083e-06
a O 0 3.7791102158735157e-07
5 O 0 1.968025173937349e-07
- O 0 2.9289884295735646e-08
truncated O 0 6.866080326517476e-08
form O 0 2.2982078462518984e-09
of O 0 3.6900253519434045e-08
human O 0 3.2832534913040945e-08
L1 O 0 4.408569111546967e-06
inversely O 0 1.662449875539096e-07
integrated O 0 2.7079630626758444e-07
in O 0 9.27091470259711e-09
the O 0 1.5073373660356992e-08
5 O 0 1.2697175577613962e-07
- O 0 4.474948411825608e-08
untranslated O 0 1.611673906154465e-05
region O 0 1.5744788584015623e-07
in O 0 2.3003227767048884e-08
the O 0 8.37519422702826e-08
muscle O 0 1.203190436172008e-07
exon O 0 1.439504444533668e-07
1 O 0 1.655104142628261e-08
, O 0 9.651623944506582e-11
which O 0 6.490950832382936e-11
affected O 0 5.916600542832384e-10
the O 0 3.1601476990772426e-09
transcription O 0 2.057412018530158e-07
or O 0 2.7152120551932057e-09
the O 0 5.705047101400851e-09
stability O 0 3.6435901051845576e-07
of O 0 6.643786321092193e-08
the O 0 8.572564524911286e-08
muscle O 0 2.5971683470515927e-08
form O 0 5.363404831371099e-09
of O 0 6.769616902602138e-07
dystrophin O 0 4.159402578807203e-06
transcripts O 0 1.909631919261301e-06
but O 0 1.712319064317569e-09
not O 0 6.025245302687665e-10
that O 0 3.089768718655961e-10
of O 0 1.6397889268660037e-08
the O 0 4.865503910878033e-07
brain O 0 0.48481976985931396
or O 0 2.9178675049479352e-06
Purkinje O 1 0.9965792298316956
cell O 0 0.00010854659194592386
form O 0 5.1661402267200174e-08
, O 0 1.3611089144660582e-08
probably O 0 1.0948906492558308e-07
due O 0 2.423973910481436e-07
to O 0 1.6853958229035015e-09
its O 0 1.7832728627098504e-09
unique O 0 5.702752048364346e-09
site O 0 1.5862248403664125e-08
of O 0 2.240017948906825e-08
integration O 0 8.960523700807244e-08
. O 0 2.7916644285141956e-07

We O 0 5.271108989290951e-07
speculate O 0 3.8315749861794757e-07
that O 0 9.941607537200525e-10
this O 0 2.085251082917239e-09
insertion O 0 5.526519686327447e-08
of O 0 8.178609078868249e-08
an O 0 7.33062819335828e-08
L1 O 0 6.0171802033437416e-05
sequence O 0 1.2771696447089198e-06
in O 0 1.3139731436240254e-06
DMD O 1 1.0
is O 0 7.105549570951553e-08
responsible O 0 6.179192268973566e-08
for O 0 1.6770105304431127e-09
some O 0 6.881741843045575e-10
of O 0 7.731409290556712e-09
the O 0 6.578052325068029e-09
population O 0 1.9757742664161526e-10
of O 0 5.599868568850752e-09
Japanese O 0 2.189952283515595e-06
patients O 0 3.809597970416689e-09
with O 0 9.759105745743568e-10
XLDCM B-Disease 0 0.0012142776977270842
. O 0 9.989172866653462e-08
. O 0 1.1619226114589765e-07

Severe O 0 0.05296475067734718
early O 0 0.0015320173697546124
- O 1 0.9771326780319214
onset O 1 1.0
obesity B-Disease 1 1.0
, O 0 0.00033040836569853127
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 1.5005201930762269e-05
red O 0 7.436067971866578e-05
hair O 0 0.16217614710330963
pigmentation O 1 0.9525697231292725
caused O 0 0.00017005049448926002
by O 0 1.9506862827256555e-06
POMC O 1 0.9999954700469971
mutations O 0 7.727018669356767e-08
in O 0 4.1552848273340715e-08
humans O 0 2.1613453782265424e-07
. O 0 1.4331527609101613e-07

Sequential O 0 3.6898942198604345e-05
cleavage O 0 6.841700269433204e-06
of O 0 3.7724703361163847e-07
the O 0 1.087993837245449e-07
precursor O 0 2.4047483293543337e-07
protein O 0 4.039318213244769e-08
pre O 0 1.102399437513668e-06
- O 0 1.1186185702172224e-06
pro O 0 1.0002459021052346e-06
- O 0 1.3148669495421927e-06
opiomelanocortin O 0 6.215591838554246e-06
( O 0 1.0651486093138374e-07
POMC O 0 7.291830570466118e-06
) O 0 1.1133393096329769e-09
generates O 0 4.125274344346508e-09
the O 0 9.685972024442435e-09
melanocortin O 0 4.3365844248910435e-06
peptides O 0 2.009089143939491e-07
adrenocorticotrophin O 0 4.650367372960318e-06
( O 0 7.73976296386536e-08
ACTH O 0 2.869848003683728e-06
) O 0 5.624435139850448e-09
, O 0 4.507454853808213e-09
melanocyte O 0 5.8059713410330005e-06
- O 0 3.029512981811422e-06
stimulating O 0 2.1169080355321057e-06
hormones O 0 6.41273274482046e-08
( O 0 3.153704630776133e-09
MSH O 0 1.5889021653947566e-07
) O 0 1.2406742300186124e-10
alpha O 0 2.9556666003571763e-09
, O 0 5.0099764614675024e-11
beta O 0 1.3255115893784364e-09
and O 0 3.124161693235372e-11
gamma O 0 4.942583231581921e-09
as O 0 2.1578210052108915e-10
well O 0 1.751113420933592e-10
as O 0 1.3543485777312014e-10
the O 0 1.8707477789092763e-09
opioid O 0 9.555982671827223e-08
- O 0 4.879080961472937e-08
receptor O 0 9.501930264832481e-08
ligand O 0 2.3692955153364892e-07
beta O 0 8.860420166456606e-07
- O 0 5.381461960496381e-07
endorphin O 0 4.829035242437385e-05
. O 0 1.8531716250436148e-07

While O 0 1.5202109580059187e-06
a O 0 6.314793665751495e-08
few O 0 7.106007338109066e-09
cases O 0 2.1607051703398383e-09
of O 0 4.1142604345623113e-07
isolated O 1 0.956761360168457
ACTH B-Disease 1 1.0
deficiency I-Disease 1 1.0
have O 0 2.1468702371407744e-08
been O 0 3.045404994850287e-08
reported O 0 2.1745218248270248e-07
( O 0 1.2975391427971772e-07
OMIM O 0 0.00016082006914075464
201400 O 0 2.5731685582286445e-06
) O 0 1.226352264183106e-08
, O 0 3.5022773570148047e-09
an O 0 9.412425328036989e-08
inherited O 1 0.999997615814209
POMC O 1 1.0
defect O 1 0.9999997615814209
has O 0 3.6235711320387054e-08
not O 0 3.1289715263227436e-09
been O 0 1.8689297220930712e-08
described O 0 4.854704016565847e-08
so O 0 2.477838201286886e-08
far O 0 1.095914399229514e-07
. O 0 3.6383644896886835e-07

Recent O 0 2.6782529403135413e-06
studies O 0 1.714057447088635e-07
in O 0 3.088709732423922e-09
animal O 0 5.432498451085621e-09
models O 0 3.6271790015973693e-09
elucidated O 0 3.1206104722514283e-06
a O 0 5.3674497735300974e-08
central O 0 5.242002742988916e-08
role O 0 7.691479453342254e-08
of O 0 3.893661926213099e-07
alpha O 0 2.2686497686663643e-05
- O 0 3.991592166130431e-06
MSH O 0 7.545212429249659e-05
in O 0 6.1050342559099136e-09
the O 0 1.3868421966378719e-09
regulation O 0 4.5991890296193105e-09
of O 0 3.3887399553123032e-09
food O 0 2.2434545332572498e-09
intake O 0 5.025342364461949e-09
by O 0 6.758877901802407e-10
activation O 0 3.018508110130824e-08
of O 0 3.585346775025755e-08
the O 0 1.4039889606465294e-07
brain O 0 2.1776645553472918e-06
melanocortin O 0 3.23499011756212e-06
- O 0 1.3489930950072448e-07
4 O 0 8.300070675204552e-08
- O 0 2.1459614529817372e-08
receptor O 0 3.43977006878049e-08
( O 0 1.5133660991040188e-09
MC4 O 0 1.1477237649160088e-06
- O 0 2.666716802934843e-08
R O 0 1.8446638705427176e-07
; O 0 6.567580368432857e-10
refs O 0 3.484614552462517e-08
3 O 0 1.002310323627853e-08
- O 0 4.574421730296763e-09
5 O 0 3.510617130331184e-09
) O 0 1.5984659429424397e-10
and O 0 3.743649140686145e-11
the O 0 2.152010347700184e-09
linkage O 0 2.0115334109505056e-07
of O 0 4.2852583703734126e-08
human O 0 3.382933471129945e-07
obesity B-Disease 1 0.9999983310699463
to O 0 4.972434908268042e-09
chromosome O 0 1.1704524460753873e-08
2 O 0 1.2367440405114394e-08
in O 0 5.385865087248476e-09
close O 0 2.765951023775415e-07
proximity O 0 2.1591947074739437e-07
to O 0 1.122063242320337e-08
the O 0 3.7240491224110883e-07
POMC O 0 0.001568284467794001
locus O 0 2.8979698072362226e-06
, O 0 2.783516750426429e-09
led O 0 1.1203653116353962e-08
to O 0 3.670676873568368e-09
the O 0 1.1284225998053898e-08
proposal O 0 1.6012169368195828e-08
of O 0 3.44472717017652e-08
an O 0 5.2450932486181046e-08
association O 0 1.1078306272338523e-07
of O 0 1.2254120065335883e-06
POMC O 1 0.9494993090629578
with O 0 7.180139505180705e-08
human O 0 9.428991324966773e-05
obesity B-Disease 1 1.0
. O 0 2.438983983665821e-07

The O 0 2.80008998743142e-06
dual O 0 3.4861884614656447e-06
role O 0 1.4505693570754374e-06
of O 0 1.085660551325418e-05
alpha O 0 0.006876899395138025
- O 0 0.00023735583818051964
MSH O 0 0.001368641504086554
in O 0 1.4284445626344677e-08
regulating O 0 2.1118056281466124e-07
food O 0 1.2823734607536608e-07
intake O 0 7.358470384133398e-07
and O 0 1.3818920230335152e-08
influencing O 0 1.466681351303123e-05
hair O 0 7.443546201102436e-05
pigmentation O 0 0.00018896206165663898
predicts O 0 2.52851805271348e-07
that O 0 4.951035137423787e-10
the O 0 7.311718341895812e-09
phenotype O 0 7.110375577212835e-08
associated O 0 1.400030757991999e-08
with O 0 1.978520680623319e-09
a O 0 6.221364401426399e-07
defect O 0 6.111390575824771e-06
in O 0 1.5398670427657635e-07
POMC O 1 0.6035656929016113
function O 0 5.846906105944072e-07
would O 0 7.706171256671723e-10
include O 0 5.748040976527591e-08
obesity B-Disease 1 1.0
, O 0 1.0787711168802616e-08
alteration O 0 1.4213887880032416e-05
in O 0 2.732999462295993e-07
pigmentation O 0 0.0005455487407743931
and O 0 3.852650934277335e-06
ACTH B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 4.120065568713471e-06

The O 0 3.9782685234968085e-06
observation O 0 0.00016569510626140982
of O 0 3.7784255368933373e-07
these O 0 1.697964258084994e-08
symptoms O 0 2.6667682959669037e-06
in O 0 1.4842915163626458e-07
two O 0 6.204950864230341e-08
probands O 0 4.972577153239399e-05
prompted O 0 2.551417992435745e-07
us O 0 1.8637219767470015e-08
to O 0 5.711969230937086e-10
search O 0 1.1592789839198758e-08
for O 0 8.440439458468063e-10
mutations O 0 6.451621015202136e-09
within O 0 1.2790221148861747e-07
their O 0 1.1078073924863929e-07
POMC O 0 0.0021045345347374678
genes O 0 5.122682296132552e-07
. O 0 1.1570626412549245e-07

Patient O 0 0.0004660894919652492
1 O 0 8.558184845242067e-07
was O 0 1.8728376005583414e-07
found O 0 5.4849422781444446e-09
to O 0 1.0650216264451728e-09
be O 0 2.752305494624352e-09
a O 0 5.0482860558531684e-08
compound O 0 4.934151434099476e-07
heterozygote O 0 5.3549950251863265e-08
for O 0 2.4679969179430827e-10
two O 0 5.26536592104776e-10
mutations O 0 8.315782507040126e-10
in O 0 1.0049826748570467e-08
exon O 0 1.7719773381941195e-07
3 O 0 1.9003685736151965e-07
( O 0 1.592590948007455e-08
G7013T O 0 2.245198658101799e-07
, O 0 7.018908121381173e-09
C7133delta O 0 2.9588125016744016e-06
) O 0 2.2610242567111527e-09
which O 0 1.268933708109543e-10
interfere O 0 3.1587055193682545e-10
with O 0 4.6492375921358686e-11
appropriate O 0 9.691164315484002e-09
synthesis O 0 1.6524049328836554e-07
of O 0 1.672425185006432e-07
ACTH O 0 1.0593833394523244e-05
and O 0 6.393570117779745e-08
alpha O 0 6.715478957630694e-05
- O 0 3.1373627280117944e-05
MSH O 0 0.0007986914715729654
. O 0 4.2607271666383895e-07

Patient O 0 0.00025074314908124506
2 O 0 8.578302299611096e-07
was O 0 2.0239063758253906e-07
homozygous O 0 2.186559555639178e-08
for O 0 1.698047702447525e-09
a O 0 1.08749542704345e-08
mutation O 0 1.9618360269646473e-09
in O 0 1.7362721038693962e-08
exon O 0 2.1362751567721716e-07
2 O 0 3.579525582608767e-07
( O 0 3.6125708646750354e-08
C3804A O 0 5.569438599195564e-07
) O 0 1.106312019771849e-08
which O 0 4.0741037210523245e-09
abolishes O 0 1.3865409300706233e-06
POMC O 0 0.00028674196801148355
translation O 0 1.641844391997438e-05
. O 0 4.647816922442871e-07

These O 0 5.682873549517353e-08
findings O 0 1.546056012102781e-07
represent O 0 2.0935651434683678e-08
the O 0 1.1719871295667872e-08
first O 0 6.206440250622336e-09
examples O 0 2.4178737234592518e-08
of O 0 5.8617462883603366e-08
a O 0 4.393436938698869e-07
genetic B-Disease 1 0.9999998807907104
defect I-Disease 1 0.9999785423278809
within O 0 9.145659163323216e-08
the O 0 9.39581568104586e-08
POMC O 0 9.167066309601068e-05
gene O 0 1.82597637010673e-09
and O 0 2.5352414612100915e-10
define O 0 1.8222197084583058e-08
a O 0 2.439194979331205e-08
new O 0 1.0522212789965124e-07
monogenic B-Disease 1 1.0
endocrine I-Disease 1 1.0
disorder I-Disease 1 0.996619701385498
resulting O 0 1.2871289527538465e-06
in O 0 7.614422514734542e-08
early O 0 0.005700212903320789
- O 1 0.9973236322402954
onset O 1 1.0
obesity B-Disease 1 1.0
, O 0 0.15911152958869934
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 4.5618107833433896e-05
red O 0 4.929822898702696e-05
hair O 0 0.00045516638783738017
pigmentation O 0 0.0005012039327993989
. O 0 3.239823627154692e-07
. O 0 7.271278263942804e-07

A O 0 1.3060162018518895e-06
European O 0 7.292612025366907e-08
multicenter O 0 0.00016989799041766673
study O 0 3.8965296766946267e-07
of O 0 7.765433110762388e-06
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 2.631785633866457e-08
classification O 0 7.157319004136298e-08
of O 0 5.0465146728129184e-08
105 O 0 4.176468451078108e-07
mutations O 0 1.877783040171721e-09
and O 0 3.1463490146599327e-10
a O 0 7.199349116859821e-09
general O 0 1.1531549048982015e-08
system O 0 6.572935085102927e-09
for O 0 1.1608206618163308e-09
genotype O 0 5.686603188337358e-08
- O 0 4.4494836259900694e-08
based O 0 8.33767188623824e-09
prediction O 0 9.442118198421667e-07
of O 0 5.969929617322123e-08
metabolic O 0 4.665824235416949e-05
phenotype O 0 1.1723803936547483e-06
. O 0 2.157803180580231e-07

Phenylketonuria B-Disease 1 0.9971185922622681
( O 0 4.6066106733633205e-06
PKU B-Disease 0 0.00010786404891405255
) O 0 1.7892700654442706e-08
and O 0 1.0683751661133556e-08
mild B-Disease 0 0.00023587995383422822
hyperphenylalaninemia I-Disease 1 1.0
( O 1 1.0
MHP B-Disease 1 1.0
) O 0 1.4983831420067872e-07
are O 0 8.712923715847865e-09
allelic B-Disease 0 8.642032480565831e-05
disorders I-Disease 1 0.999980092048645
caused O 0 5.399979841058666e-07
by O 0 4.15814449539198e-09
mutations O 0 9.97983251593837e-10
in O 0 1.9470627332651702e-09
the O 0 2.871865767417603e-08
gene O 0 2.276925670230412e-08
encoding O 0 1.168209138313614e-07
phenylalanine O 0 1.0852558261831291e-05
hydroxylase O 0 7.190502947196364e-05
( O 0 6.221280841600674e-07
PAH O 0 0.0011127997422590852
) O 0 2.2945107502891915e-07
. O 0 2.2227351337278378e-07

Previous O 0 5.73529650864657e-05
studies O 0 9.039019346346322e-07
have O 0 7.171168103781156e-10
suggested O 0 1.0631868718746773e-09
that O 0 1.5386514978787957e-11
the O 0 3.5112379670465543e-10
highly O 0 4.276650145129679e-09
variable O 0 7.028502295725048e-07
metabolic O 0 0.0001453321019653231
phenotypes O 0 4.867693860433064e-06
of O 0 0.0008978819823823869
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
correlate O 0 0.0009368343162350357
with O 0 1.6208276747420314e-06
PAH O 1 1.0
genotypes O 0 0.00029677426209673285
. O 0 8.72142209118465e-07

We O 0 4.048540063195105e-07
identified O 0 6.586943612774121e-08
both O 0 3.1228140073835675e-08
causative O 0 6.182733613968594e-06
mutations O 0 2.4820669963787623e-08
in O 0 3.690130867539665e-08
686 O 0 5.238967332843458e-06
patients O 0 8.909173843107965e-09
from O 0 7.03147673419835e-09
seven O 0 7.90283962714966e-08
European O 0 1.6837233829392062e-07
centers O 0 3.018168968083046e-07
. O 0 1.4861215902328695e-07

On O 0 1.8558629335529986e-06
the O 0 3.582202268148649e-08
basis O 0 1.5577570877667313e-07
of O 0 1.7959614240226074e-08
the O 0 8.720089539338005e-09
phenotypic O 0 5.592976393131721e-08
characteristics O 0 3.0230829395350156e-08
of O 0 3.5479789772807635e-08
297 O 0 1.6013443371321046e-07
functionally O 0 2.0796719013560505e-07
hemizygous O 0 7.886004027568561e-07
patients O 0 4.231576866686737e-09
, O 0 2.9685748303975856e-10
105 O 0 4.7085364940357977e-08
of O 0 2.142861177389932e-08
the O 0 1.9949217389125806e-08
mutations O 0 1.903414315052032e-09
were O 0 7.639004095949531e-09
assigned O 0 4.6662037789246824e-08
to O 0 4.81306505761836e-09
one O 0 7.971172166776341e-09
of O 0 1.4117651048195512e-08
four O 0 4.585926749456348e-09
arbitrary O 0 1.330999754856066e-08
phenotype O 0 2.9322640315854187e-08
categories O 0 3.357493483235885e-08
. O 0 3.3168522151072466e-08

We O 0 6.955227718208334e-07
proposed O 0 1.0237456393724642e-07
and O 0 7.005506397206318e-09
tested O 0 9.86195125562972e-09
a O 0 6.677692176992878e-09
simple O 0 3.7181986378698184e-09
model O 0 1.2715388741924016e-09
for O 0 1.0541563455479519e-10
correlation O 0 4.014339083369123e-09
between O 0 1.1382923492675445e-09
genotype O 0 1.814015071488484e-08
and O 0 7.263038503957375e-10
phenotypic O 0 9.337592388192206e-08
outcome O 0 8.064458256740181e-07
. O 0 3.3776305485844205e-07

The O 0 5.703357714992308e-07
observed O 0 3.9759819969731325e-07
phenotype O 0 1.841689680759373e-07
matched O 0 1.2015345873805927e-07
the O 0 2.1788077120277194e-08
predicted O 0 4.727055369357913e-08
phenotype O 0 3.6680871673411275e-09
in O 0 1.439482533172054e-09
79 O 0 2.3518929026522528e-08
% O 0 1.0388433446806289e-09
of O 0 1.5849537238210587e-09
the O 0 1.6386688672653804e-09
cases O 0 7.66538776897363e-10
, O 0 9.695944047649618e-11
and O 0 1.7137721797233496e-10
in O 0 9.937645151225638e-10
only O 0 1.5123389207616356e-09
5 O 0 3.6485776622185995e-09
of O 0 3.3066431814887665e-09
184 O 0 1.7052734335720743e-08
patients O 0 1.22685694936564e-09
was O 0 7.690170278351616e-09
the O 0 3.651111635250004e-09
observed O 0 7.747396502111314e-09
phenotype O 0 2.2413162437118217e-09
more O 0 5.06813341294432e-11
than O 0 8.437183590670472e-11
one O 0 9.743110762627794e-10
category O 0 1.5652288354317534e-08
away O 0 6.984213207772427e-09
from O 0 2.5711131002026377e-09
that O 0 4.733528569111911e-10
expected O 0 4.442707535190493e-08
. O 0 2.6555863996691187e-07

Among O 0 2.028526608910397e-07
the O 0 3.090031341912436e-08
seven O 0 3.021538219627473e-08
contributing O 0 3.92137224025646e-07
centers O 0 1.5900779359867556e-08
, O 0 2.1109411441067039e-10
the O 0 7.057404660670841e-10
proportion O 0 1.175257580143807e-08
of O 0 1.0703128161537734e-08
patients O 0 8.898538017554358e-10
for O 0 5.993438523255179e-10
whom O 0 5.733518992911968e-09
the O 0 1.939321059296617e-08
observed O 0 3.421148875304425e-08
phenotype O 0 2.06726902263199e-08
did O 0 1.0754075407959363e-09
not O 0 5.537307834480032e-10
match O 0 2.4003941945238694e-08
the O 0 7.697349246882368e-08
predicted O 0 2.928408378011227e-07
phenotype O 0 1.9844438980953782e-08
was O 0 5.910854383728292e-08
4 O 0 3.316966257216336e-08
% O 0 1.525861215156965e-09
- O 0 7.007828206617717e-10
23 O 0 6.3068950062472595e-09
% O 0 1.1625865825592996e-09
( O 0 5.872572983456337e-10
P O 0 5.255458290776005e-07
< O 0 6.901056792685267e-08
. O 0 7.231439336230494e-10
0001 O 0 1.8723391121966415e-06
) O 0 6.312452227597021e-10
, O 0 1.0431416147538286e-10
suggesting O 0 1.0314041842818256e-09
that O 0 2.704221395422035e-11
differences O 0 2.906574425587394e-10
in O 0 2.4875621007502957e-10
methods O 0 3.5242162521598175e-09
used O 0 8.69636695988163e-10
for O 0 5.662612601042838e-10
mutation O 0 1.857216380685145e-09
detection O 0 8.186896138795419e-08
or O 0 3.874614407095578e-08
phenotype O 0 1.6773400091096846e-07
classification O 0 1.0000992745062831e-07
may O 0 9.742075590679633e-09
account O 0 1.7268495966504815e-08
for O 0 1.9722585786752234e-09
a O 0 1.3287270839157372e-08
considerable O 0 1.0097904379335887e-07
proportion O 0 5.531507341061115e-08
of O 0 1.560832316727101e-07
genotype O 0 1.4762761111342115e-06
- O 0 1.8359602336204262e-06
phenotype O 0 1.25920735172258e-06
inconsistencies O 0 5.309469088388141e-06
. O 0 7.482829005311942e-07

Our O 0 1.8447709635438514e-06
data O 0 3.7394661944745167e-07
indicate O 0 6.017234710498087e-08
that O 0 8.684399310787683e-10
the O 0 5.71751215261429e-08
PAH O 0 0.00020769010006915778
- O 0 2.5747175413926016e-07
mutation O 0 3.511333668271277e-09
genotype O 0 8.704004628157236e-09
is O 0 2.42109721160233e-10
the O 0 8.986018040779697e-10
main O 0 7.964625581280416e-08
determinant O 0 9.936447895597667e-07
of O 0 8.422178865430396e-08
metabolic O 0 6.773950735805556e-05
phenotype O 0 4.183436175253519e-08
in O 0 3.6164713446140695e-09
most O 0 4.804589615048371e-09
patients O 0 2.1721604070989997e-08
with O 0 4.0131013179234287e-07
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 3.43783431162592e-05

In O 0 7.702415132371243e-07
the O 0 4.7165453764819176e-08
present O 0 2.4455443892179574e-08
study O 0 1.6217672538232364e-08
, O 0 8.363182368853472e-10
the O 0 8.695276498826843e-09
classification O 0 1.9692961927830765e-07
of O 0 7.445826781804499e-07
105 O 0 0.00025352303055115044
PAH O 1 0.9999048709869385
mutations O 0 5.450124263006728e-08
may O 0 6.369480498591429e-09
allow O 0 2.6517072981846468e-09
the O 0 1.4839032225211213e-08
prediction O 0 3.87212139685289e-07
of O 0 1.396651416740724e-08
the O 0 3.232696954569292e-08
biochemical O 0 4.610882626820967e-07
phenotype O 0 1.1014256529051636e-07
in O 0 2.988564418160422e-08
> O 0 7.473387597656256e-08
10 O 0 5.3765663032834254e-09
, O 0 1.0102557679303459e-09
000 O 0 1.0796978244798083e-07
genotypes O 0 7.874703555899032e-08
, O 0 4.934574415749182e-10
which O 0 1.8532840539986495e-10
may O 0 5.226303834149348e-10
be O 0 9.744151041601867e-10
useful O 0 3.632996836699931e-08
for O 0 2.0785797527622663e-09
the O 0 5.8118718726518637e-08
management O 0 3.1068589123606216e-06
of O 0 8.381653060496319e-06
hyperphenylalaninemia B-Disease 1 1.0
in O 0 5.975608019070933e-06
newborns O 0 5.767110906162998e-06
. O 0 3.909520103206887e-07

Somatic O 0 8.929984323913231e-05
instability O 0 2.674289862625301e-05
of O 0 2.8362103421386564e-06
the O 0 6.239323738554958e-06
CTG O 1 0.99798583984375
repeat O 0 7.587798336317064e-06
in O 0 1.927125907741356e-07
mice O 0 1.9824337016416393e-07
transgenic O 0 1.0173376807642853e-07
for O 0 6.012849773640028e-09
the O 0 7.635533620486967e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 1.1962698636125424e-06
is O 0 2.2243449304681917e-09
age O 0 6.795696005923446e-09
dependent O 0 3.518576008332275e-08
but O 0 1.5136482345301516e-10
not O 0 1.966540402742467e-10
correlated O 0 1.0209762812962708e-08
to O 0 4.424015320747543e-10
the O 0 7.505926546969022e-09
relative O 0 1.5102690440471633e-06
intertissue O 0 1.753274591465015e-05
transcription O 0 6.331099484668812e-07
levels O 0 4.519802487834568e-08
and O 0 9.95421078897607e-09
proliferative O 0 0.00026927446015179157
capacities O 0 3.6978275602450594e-05
. O 0 9.258449154003756e-07

A O 0 0.0006680786609649658
( O 0 3.8912889976927545e-06
CTG O 0 0.0009155318257398903
) O 0 1.1770189445314827e-07
nexpansion O 0 2.2664610241918126e-06
in O 0 4.464436642592773e-08
the O 0 3.5481210858279155e-08
3 O 0 2.1091769042413944e-07
- O 0 1.1359401241861633e-07
untranslated O 0 1.0241308700642549e-05
region O 0 6.37487858057284e-08
( O 0 4.558137334242929e-08
UTR O 0 2.5146589905489236e-05
) O 0 3.315914876012016e-09
of O 0 1.5495331240344967e-08
the O 0 4.3720621079046396e-07
DM O 1 1.0
protein O 0 2.416667257421068e-06
kinase O 0 5.257721568341367e-06
gene O 0 8.975161946978005e-09
( O 0 3.6101928113652093e-09
DMPK O 0 1.5740239405204193e-06
) O 0 1.5271859332699478e-09
is O 0 3.0663085959226066e-10
responsible O 0 7.2693895347697435e-09
for O 0 6.637593230607308e-08
causing O 1 0.9964448809623718
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9806555509567261
DM B-Disease 1 1.0
) O 0 2.996289936163521e-07
. O 0 1.912920595259493e-07

Major O 0 0.0008121878490783274
instability O 0 0.22753123939037323
, O 0 3.9698736742366236e-08
with O 0 2.407770871570847e-09
very O 0 1.3555542466292536e-08
large O 0 2.4229427353361643e-08
expansions O 0 1.1487495044093521e-07
between O 0 1.3566561207767336e-08
generations O 0 7.761432385677836e-09
and O 0 2.918379149452477e-10
high O 0 7.1604295825977715e-09
levels O 0 9.973633474658072e-09
of O 0 2.3629587175832967e-08
somatic O 0 2.996058299231663e-07
mosaicism O 0 2.015702921198681e-05
, O 0 8.445254495725862e-10
is O 0 5.14989217936801e-10
observed O 0 3.847430818382236e-09
in O 0 1.2152360895356651e-08
patients O 0 1.896280110713633e-08
. O 0 6.394679985533003e-08

There O 0 2.806142219924368e-06
is O 0 6.12440800296099e-08
a O 0 1.4431979877826961e-07
good O 0 1.759959076252926e-07
correlation O 0 3.242024320115888e-07
between O 0 4.736802949878438e-08
repeat O 0 8.58627728916872e-08
size O 0 7.917444833083209e-08
( O 0 4.189726787728887e-09
at O 0 2.3930935455496183e-08
least O 0 1.4863725805724926e-09
in O 0 9.59227808294827e-10
leucocytes O 0 3.2511891845388163e-07
) O 0 1.1868536153869513e-09
, O 0 2.457976322478572e-10
clinical O 0 1.2626386158842706e-08
severity O 0 3.823080518827737e-08
and O 0 1.6298973282147244e-09
age O 0 1.299487166761537e-07
of O 0 5.458367695609923e-07
onset O 0 0.00046747818123549223
. O 0 3.8583465311603504e-07

The O 0 6.022968591423705e-06
trinucleotide O 0 0.00043658007052727044
repeat O 0 8.245133358286694e-06
instability O 0 1.50663154272479e-05
mechanisms O 0 8.914928912417963e-06
involved O 0 1.5452498018930783e-06
in O 0 3.4443350159563124e-05
DM B-Disease 1 1.0
and O 0 3.314170982093856e-08
other O 0 5.169892958178934e-09
human O 0 3.5181744806322968e-06
genetic B-Disease 1 1.0
diseases I-Disease 1 1.0
are O 0 1.3222599015705327e-08
unknown O 0 1.1544449989742134e-05
. O 0 1.2622682277196873e-07

We O 0 1.933150741706413e-07
studied O 0 1.2202656307636062e-06
somatic O 0 3.268195087002823e-06
instability O 0 2.485694722054177e-06
by O 0 7.804634094554785e-08
measuring O 0 8.385166438529268e-05
the O 0 6.757477990504412e-07
CTG O 0 0.006670179311186075
repeat O 0 6.238915375433862e-07
length O 0 3.583268437523657e-08
at O 0 7.336373730737478e-09
several O 0 1.5660157892671833e-10
ages O 0 4.186145874385261e-10
in O 0 2.496193529655244e-10
various O 0 1.132168803152922e-09
tissues O 0 1.4987856289394585e-08
of O 0 1.1101214170139428e-07
transgenic O 0 4.63472872525017e-07
mice O 0 1.4808072101857306e-08
carrying O 0 5.816393144897347e-09
a O 0 9.287573021765638e-08
( O 0 5.5293554623858654e-08
CTG O 0 0.00010749541979748756
) O 0 2.6149432841293674e-08
55expansion O 0 1.3956203019915847e-06
surrounded O 0 3.771937713281659e-07
by O 0 1.694961504483672e-08
45 O 0 7.513090594102323e-08
kb O 0 3.3383862501068506e-06
of O 0 1.273238723342729e-07
the O 0 2.244363770387281e-07
human O 0 2.843267793650739e-06
DM B-Disease 1 1.0
region O 0 5.858415264015093e-08
, O 0 9.427563174568832e-10
using O 0 3.0507578685501358e-09
small O 0 2.855599312567847e-08
- O 0 1.4801669578901056e-07
pool O 0 5.125925326865399e-06
PCR O 0 2.9036712021479616e-06
. O 0 2.0555842183966888e-07

These O 0 5.262278932605113e-07
mice O 0 8.763317396187631e-07
have O 0 7.15654813188138e-10
been O 0 1.0647880355207917e-09
shown O 0 1.2711242058927041e-09
to O 0 4.557002830640755e-10
reproduce O 0 1.1920405107446186e-08
the O 0 9.72733271709103e-09
intergenerational O 0 8.0329591867212e-08
and O 0 8.667057627143038e-10
somatic O 0 1.5006126830030553e-07
instability O 0 5.508723006641958e-07
of O 0 1.5348587112384848e-07
the O 0 2.540836021580617e-07
55 O 0 4.2280480556655675e-06
CTG O 0 0.009625083766877651
repeat O 0 5.69130122585193e-07
suggesting O 0 5.9039585664777405e-08
that O 0 9.213755453041372e-11
surrounding O 0 6.756509129957067e-09
sequences O 0 1.1750558748246931e-08
and O 0 6.796470053416215e-10
the O 0 6.407485209081187e-09
chromatin O 0 1.1419804479828599e-07
environment O 0 5.890595744517668e-08
are O 0 3.1392519139750164e-10
involved O 0 4.952699583782305e-09
in O 0 1.4442465889885625e-08
instability O 0 3.820197889581323e-06
mechanisms O 0 2.006343856919557e-05
. O 0 7.158669745876978e-07

As O 0 3.45184787420294e-07
observed O 0 1.0977657893818105e-07
in O 0 1.0117063631298606e-08
some O 0 1.0811744832750492e-09
of O 0 9.236216236274686e-09
the O 0 2.406105714669593e-08
tissues O 0 1.1746652006650038e-07
of O 0 8.946536399889737e-05
DM B-Disease 1 1.0
patients O 0 2.9165180421841796e-06
, O 0 6.161368637513931e-10
there O 0 3.3265317167519015e-09
is O 0 1.3711609625488563e-09
a O 0 5.376515233024293e-09
tendency O 0 6.886038850240084e-09
for O 0 1.3335045290219227e-09
repeat O 0 2.699288614849138e-08
length O 0 2.0199854233737824e-08
and O 0 3.819055738318866e-09
somatic O 0 3.9345954405689554e-07
mosaicism O 0 4.524146788753569e-06
to O 0 2.761813222562637e-09
increase O 0 2.5371489353887e-09
with O 0 2.472119176033516e-10
the O 0 1.2454625775148997e-08
age O 0 1.3589408354164334e-07
of O 0 1.5317615975618537e-07
the O 0 4.925861958327005e-07
mouse O 0 1.4047914191905875e-06
. O 0 1.0375256209727013e-07

Furthermore O 0 7.820562132110354e-06
, O 0 1.7895807502554817e-08
we O 0 7.596967499523544e-09
observed O 0 1.661743809222571e-08
no O 0 6.125667972867177e-09
correlation O 0 6.172581556995738e-09
between O 0 9.586168525643757e-10
the O 0 7.67175101223927e-10
somatic O 0 1.3925311570517351e-08
mutation O 0 5.261691082836251e-10
rate O 0 7.904254140100875e-09
and O 0 1.0407433803649724e-09
tissue O 0 2.7423254778113915e-07
proliferation O 0 9.720361413201317e-05
capacity O 0 1.6849788153194822e-05
. O 0 6.055736321286531e-07

The O 0 5.102058935335663e-07
somatic O 0 2.978705708756024e-07
mutation O 0 2.2070307803545575e-09
rates O 0 1.0137070072246956e-09
in O 0 1.2227446832824285e-10
different O 0 1.2471346177989062e-10
tissues O 0 3.974280904373018e-09
were O 0 1.2793314851933246e-08
also O 0 4.1551695417751944e-10
not O 0 2.1380251735703126e-10
correlated O 0 1.1429267310347768e-08
to O 0 9.770615427839857e-10
the O 0 2.0727568994516332e-08
relative O 0 2.0381264675961575e-06
inter O 0 7.326250397454714e-06
- O 0 1.655161668168148e-06
tissue O 0 1.4820524540937186e-07
difference O 0 6.510638428380844e-08
in O 0 1.57813424550568e-08
transcriptional O 0 1.709290984308609e-07
levels O 0 9.800483979915953e-09
of O 0 6.274619046564567e-09
the O 0 1.1543607847386284e-08
three O 0 6.713373412736701e-09
genes O 0 9.98747395897226e-09
( O 0 7.034481441792195e-09
DMAHP O 0 2.9430555059661856e-06
, O 0 1.1251236387010977e-08
DMPK O 0 1.2462661288736854e-05
and O 0 1.1010009792755682e-08
59 O 0 2.4146251575984934e-07
) O 0 5.427247984357564e-09
surrounding O 0 3.811038951084811e-08
the O 0 5.914857581501565e-08
repeat O 0 3.7755080484203063e-07
. O 0 2.916245378514759e-08
. O 0 1.8007382607265754e-07

A O 0 2.93516541205463e-06
novel O 0 5.612221229966963e-07
missense O 0 3.1453557767235907e-06
mutation O 0 8.69146354887107e-09
in O 0 3.4165628104432244e-09
patients O 0 2.6601976177431652e-09
from O 0 4.605043901761974e-09
a O 0 1.613930038502076e-07
retinoblastoma B-Disease 0 0.006218568421900272
pedigree O 0 1.0956654477922712e-05
showing O 0 3.516220914434598e-08
only O 0 5.72866254433535e-10
mild O 0 1.8628394382602664e-09
expression O 0 5.969787442161589e-10
of O 0 5.315853535137194e-09
the O 0 3.9363964532412865e-08
tumor B-Disease 0 2.9171160349505953e-06
phenotype O 0 2.9738919238297967e-07
. O 0 6.979954036978597e-08

We O 0 3.0792588745498506e-07
have O 0 3.75613407044284e-09
used O 0 6.1552523078489685e-09
single O 0 4.0153977920454054e-08
strand O 0 1.2082416844805266e-07
conformation O 0 1.9424380326427126e-08
polymorphism O 0 9.142027579400747e-09
analysis O 0 1.5001347941634435e-09
to O 0 4.3515252512449365e-10
study O 0 4.993058411173479e-09
the O 0 1.6329101626411102e-08
27 O 0 2.2042642910946597e-07
exons O 0 9.663389732850192e-08
of O 0 3.648871782502283e-08
the O 0 9.46313463145998e-08
RB1 O 0 4.9043665057979524e-05
gene O 0 4.232957095950951e-09
in O 0 1.8257709788471743e-09
individuals O 0 1.0857953425258415e-09
from O 0 1.22849668215963e-08
a O 0 1.0606741795982089e-07
family O 0 5.495709842762153e-08
showing O 0 6.184109224705026e-08
mild O 0 3.360081635150891e-08
expression O 0 7.648917943470224e-09
of O 0 1.1729397897397575e-08
the O 0 6.077929981529451e-08
retinoblastoma B-Disease 0 2.196810964960605e-05
phenotype O 0 1.922428054967895e-06
. O 0 1.666736011429748e-07

In O 0 4.25993874841879e-07
this O 0 1.7053254808274687e-08
family O 0 5.236177358369787e-08
affected O 0 6.696262211391968e-09
individuals O 0 7.8424844396352e-10
developed O 0 3.504604251247656e-08
unilateral B-Disease 0 4.089637968718307e-06
tumors I-Disease 1 1.0
and O 0 2.3148921002302814e-07
, O 0 2.5826534244544064e-09
as O 0 1.6492860410721732e-09
a O 0 2.0967529934523554e-09
result O 0 5.735222297076348e-10
of O 0 2.6693871557625926e-09
linkage O 0 5.161068017400794e-08
analysis O 0 9.562323377565463e-09
, O 0 3.785086133412108e-10
unaffected O 0 4.55886777217529e-08
mutation O 0 1.0566892916230586e-09
carriers O 0 5.458222207543884e-10
were O 0 4.5681787241846905e-09
also O 0 1.169307095594263e-09
identified O 0 3.060492304030049e-08
within O 0 8.390671979441322e-08
the O 0 6.99725603681145e-07
pedigree O 0 1.4819558600720484e-05
. O 0 3.8520113321283134e-07

A O 0 6.658421170868678e-06
single O 0 1.2958659567630093e-07
band O 0 8.473612211901127e-08
shift O 0 8.784297023112231e-08
using O 0 4.026748712249173e-08
SSCP O 0 2.5289395125582814e-05
was O 0 9.77526269707596e-07
identified O 0 1.0698580155121817e-07
in O 0 6.232528448890662e-08
exon O 0 2.7157969384461467e-07
21 O 0 2.481427863187946e-08
which O 0 2.7689853188128666e-10
resulted O 0 4.254179231111266e-09
in O 0 4.389573149410353e-09
a O 0 1.9956411634325377e-08
missense O 0 1.8022518588622916e-07
mutation O 0 9.080573515340973e-10
converting O 0 2.049284830718534e-08
a O 0 2.9516119326444823e-08
cys O 0 2.74714170700463e-06
- O 0 3.2129332794283982e-06
- O 0 3.569752607290866e-06
> O 0 1.5143189102673205e-06
arg O 0 1.9362059333616344e-07
at O 0 7.451638595057375e-08
nucleotide O 0 2.919062183082133e-07
position O 0 1.1651805209567101e-07
28 O 0 1.267128908466475e-07
in O 0 2.897118456246517e-08
the O 0 2.1736549626893975e-07
exon O 0 4.614234967448283e-06
. O 0 3.88357847214138e-07

The O 0 2.070234359052847e-06
mutation O 0 3.3917234532054863e-07
destroyed O 0 2.7407162633608095e-05
an O 0 1.8317999206374225e-07
NdeI O 0 4.8051613703137264e-05
restriction O 0 3.216806874206668e-07
enzyme O 0 2.795239595343446e-07
site O 0 5.286720465846884e-07
. O 0 1.197110464090656e-07

Analysis O 0 1.0269633094139863e-05
of O 0 3.9160352116596187e-07
all O 0 6.582271794286498e-08
family O 0 2.525584932300262e-07
members O 0 4.777394924104783e-09
demonstrated O 0 1.824334283639928e-08
that O 0 1.047123054931376e-09
the O 0 3.128901227000824e-08
missense O 0 1.9369165329408133e-06
mutation O 0 2.1289366713972413e-08
co O 0 6.304327143880073e-06
- O 0 1.4303075658972375e-05
segregated O 0 5.780055403192819e-07
with O 0 3.699170081361558e-09
patients O 0 7.661243728307454e-08
with O 0 1.353354974753529e-07
tumors B-Disease 1 1.0
or O 1 0.9998375177383423
who O 0 3.0391933591999987e-07
, O 0 4.249329776939703e-09
as O 0 2.963682632639575e-09
a O 0 7.697757098412694e-09
result O 0 4.251453855630416e-09
of O 0 2.1435234032196604e-08
linkage O 0 2.980674196351174e-07
analysis O 0 5.213426135242116e-08
had O 0 9.309917281541402e-09
been O 0 1.126485038582814e-08
predicted O 0 1.1914221609288234e-08
to O 0 7.152099468221707e-10
carry O 0 9.345267670823887e-09
the O 0 8.935811024457507e-08
predisposing O 0 1.3706010577152483e-05
mutation O 0 1.2569178409194137e-07
. O 0 9.016017799012843e-08

These O 0 1.617558780253603e-07
observations O 0 3.1729946385894436e-06
point O 0 4.725671942651388e-07
to O 0 5.098184541196815e-09
another O 0 1.4334830211737426e-08
region O 0 2.0835662084550677e-08
of O 0 7.972423077262647e-08
the O 0 5.873737904948939e-07
RB1 O 0 0.0003791099588852376
gene O 0 5.776812361801831e-09
where O 0 5.796234603394623e-10
mutations O 0 1.6124014623475347e-10
only O 0 7.477055086191342e-11
modify O 0 1.790097930998158e-10
the O 0 1.4774802492567574e-09
function O 0 4.4251340369783065e-08
of O 0 1.540768401753212e-08
the O 0 1.937505800242434e-08
gene O 0 1.9683876750775653e-09
and O 0 4.105836226564463e-10
raise O 0 4.811164799889411e-09
important O 0 4.85088813562129e-09
questions O 0 6.526836848763651e-09
for O 0 7.934217727267878e-10
genetic O 0 8.551106134291331e-08
counseling O 0 1.325128664575459e-07
in O 0 2.90306889638714e-09
families O 0 4.563299738080673e-10
with O 0 3.3286991218961504e-11
these O 0 4.268123909856314e-10
distinctive O 0 8.485690372594945e-09
phenotypes O 0 1.7837508892171172e-07
. O 0 1.7383033679152504e-08
. O 0 1.7675434094144293e-07

Maternal B-Disease 0 0.4431256949901581
disomy I-Disease 0 0.44326716661453247
and O 0 4.357504440122284e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 0 0.00014750951959285885
with O 0 5.302901229242707e-09
gamete O 0 2.7507450795383193e-05
complementation O 0 1.3320608559297398e-05
in O 0 2.9793042699566286e-08
a O 0 2.5201345010827936e-08
case O 0 4.371678130610235e-08
of O 0 2.557240179612563e-07
familial O 0 1.0465281775395852e-05
translocation O 0 1.730089024931658e-06
( O 0 2.275032784382347e-08
3 O 0 1.7015111097862246e-08
; O 0 3.043154617188293e-10
15 O 0 1.0862764909802536e-08
) O 0 2.817832411849963e-09
( O 0 3.45691542058546e-09
p25 O 0 1.2549739381029212e-07
; O 0 9.196132744193619e-10
q11 O 0 4.5436459572556487e-07
. O 0 7.932043466496452e-09
2 O 0 2.0252907972917455e-07
) O 0 2.181652014598967e-08
. O 0 4.714323864618564e-08

Maternal B-Disease 1 0.9999833106994629
uniparental I-Disease 1 0.9999996423721313
disomy I-Disease 1 0.999992847442627
( I-Disease 0 0.000883039552718401
UPD I-Disease 1 1.0
) I-Disease 0 1.2730785670100886e-07
for I-Disease 0 6.124639462257164e-09
chromosome I-Disease 0 8.31975555115605e-08
15 I-Disease 0 5.296636729212878e-08
is O 0 4.262155073320173e-09
responsible O 0 2.438436652596465e-08
for O 0 5.67264724082861e-09
an O 0 2.0886513851792188e-08
estimated O 0 1.789102910265683e-08
30 O 0 9.131258416061883e-09
% O 0 4.824367016986741e-10
of O 0 7.532713341973363e-10
cases O 0 8.780168259114873e-10
of O 0 9.053530334313109e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.0003346736775711179
PWS B-Disease 1 1.0
) O 0 3.1407947176376183e-07
. O 0 8.350932745315731e-08

We O 0 3.273398306191666e-06
report O 0 4.788079763784481e-07
on O 0 3.9862172229732096e-08
an O 0 2.904353646471236e-09
unusual O 0 2.1489187318479708e-08
case O 0 6.082360215486915e-08
of O 0 4.818569436793041e-07
maternal B-Disease 0 4.197661837679334e-05
disomy I-Disease 0 0.000977681134827435
15 I-Disease 0 2.653710225786199e-06
in O 0 7.53431436351093e-07
PWS B-Disease 1 1.0
that O 0 6.4885323780572435e-09
is O 0 1.984393760423586e-09
most O 0 3.906832080069478e-10
consistent O 0 7.36302308013137e-09
with O 0 3.366075751465303e-10
adjacent O 0 1.2099631874207262e-07
- O 0 2.303005857129392e-07
1 O 0 6.75675607908488e-07
segregation O 0 9.490663899214269e-08
of O 0 2.392395437311734e-08
a O 0 1.0043927289871135e-07
paternal O 0 3.628398985711101e-07
t O 0 1.3512483576505474e-08
( O 0 7.006344948656817e-10
3 O 0 1.310833774859077e-09
; O 0 4.8658025525449844e-11
15 O 0 2.977893709399382e-09
) O 0 4.838964784426025e-10
( O 0 5.845529060799493e-10
p25 O 0 2.0795562605258056e-08
; O 0 7.018673142678011e-11
q11 O 0 1.944009753174214e-08
. O 0 3.112790580850344e-10
2 O 0 2.8005047170154285e-09
) O 0 1.1371264346804466e-10
with O 0 6.559715270970656e-11
simultaneous O 0 8.080257885012543e-08
maternal O 0 9.942828000930604e-07
meiotic O 0 7.892498615547083e-06
nondisjunction O 0 1.1116253517684527e-05
for O 0 5.30231751838528e-08
chromosome O 0 2.899186597460357e-07
15 O 0 2.3038363394789485e-07
. O 0 1.0842069997352155e-07

The O 0 5.847854481544346e-06
patient O 0 2.5688041205285117e-06
( O 0 2.2247746755965636e-08
J O 0 2.877074791740597e-07
. O 0 1.384743542054423e-09
B O 0 1.5357987592778954e-07
. O 0 7.176887972804025e-10
) O 0 9.51919099101417e-10
, O 0 4.311719314920026e-10
a O 0 7.820112557510583e-09
17 O 0 1.8687657643567945e-08
- O 0 2.1534237504283738e-08
year O 0 7.506588417527382e-08
- O 0 5.42515920187725e-07
old O 0 1.2751530675814138e-06
white O 0 1.2377569191812654e-07
male O 0 1.0242828096806988e-07
with O 0 2.877732896422458e-08
PWS B-Disease 1 1.0
, O 0 7.77488864400766e-08
was O 0 4.71699507897938e-07
found O 0 1.722822773331245e-08
to O 0 4.1274699214000066e-09
have O 0 2.5127369074340322e-09
47 O 0 1.0315270770888674e-07
chromosomes O 0 5.899523358721126e-08
with O 0 3.994755193303945e-09
a O 0 6.563804504366999e-07
supernumerary O 0 0.00043154528248123825
, O 0 3.182341501428709e-08
paternal O 0 8.114000706882507e-07
der O 0 6.742859841324389e-05
( O 0 1.9771333015228265e-08
15 O 0 8.191422651293578e-09
) O 0 3.7780031880707554e-10
consisting O 0 3.0214155621877126e-09
of O 0 2.7084015030709452e-08
the O 0 1.1235757568783811e-07
short O 0 4.784318434758461e-07
arm O 0 7.255910531966947e-06
and O 0 5.07859176934744e-08
the O 0 3.972218109993264e-06
proximal O 0 0.02210281416773796
long O 0 4.569681095745182e-06
arm O 0 1.9078870536759496e-05
of O 0 2.464002363922191e-06
chromosome O 0 1.2509606222010916e-06
15 O 0 2.0276388568163384e-07
, O 0 8.941774432003058e-09
and O 0 4.931511909944675e-08
distal O 0 0.0002921408449765295
chromosome O 0 0.023116251453757286
arm O 1 0.9998939037322998
3p O 1 1.0
. O 0 3.3066007745219395e-05

The O 0 2.976715040858835e-05
t O 0 6.860188932478195e-07
( O 0 1.1955767043048127e-08
3 O 0 1.8292261927399522e-08
; O 0 6.407970820632158e-10
15 O 0 8.976189569409598e-09
) O 0 6.486499115609945e-10
was O 0 9.761381924988655e-09
present O 0 3.2031177710223346e-09
in O 0 4.322393110101075e-09
the O 0 1.0616048484735074e-08
balanced O 0 4.068080272645602e-08
state O 0 4.102988615528602e-09
in O 0 4.321214053248923e-09
the O 0 4.33937863419942e-08
patients O 0 1.4424460736961464e-08
father O 0 1.4628066935529205e-07
and O 0 5.184718077089201e-08
a O 0 5.815225904370891e-06
sister O 0 3.762140840990469e-05
. O 0 9.823597793001682e-07

Fluorescent O 0 1.7349698282487225e-06
in O 0 4.454824775734778e-08
situ O 0 3.014707544934936e-06
hybridization O 0 7.251099987115595e-08
analysis O 0 5.921653212226374e-08
demonstrated O 0 3.6727517027657086e-08
that O 0 2.7528672674748123e-09
the O 0 3.215902211195498e-07
PWS B-Disease 1 1.0
critical O 0 1.1160716894664802e-05
region O 0 2.7816562919724674e-07
resided O 0 4.710845587396761e-06
on O 0 1.5016189536254387e-07
the O 0 4.9339206498189014e-08
derivative O 0 7.414535616590001e-07
chromosome O 0 5.6159269234967724e-08
3 O 0 1.3462268633190888e-08
and O 0 3.808142967631767e-10
that O 0 2.9040200799634874e-10
there O 0 2.5220472377185388e-09
was O 0 1.3979764901250746e-07
no O 0 2.5735726438824713e-08
deletion O 0 8.173213217332886e-08
of O 0 1.8523429901051713e-07
the O 0 3.2609473237243947e-06
PWS B-Disease 1 1.0
region O 0 1.5539601008640602e-05
on O 0 5.004378067496873e-07
the O 0 8.251642924506086e-08
normal O 0 4.0794446931613493e-07
pair O 0 4.807599296441367e-08
of O 0 4.9001204871501614e-08
15s O 0 9.526552275929134e-07
present O 0 1.6777464395545394e-07
in O 0 5.753612413172959e-07
J O 0 9.359172690892592e-05
. O 0 1.1951740361837437e-06

B O 0 0.0027295853942632675
. O 0 1.0497908078832552e-05

Methylation O 0 1.7950347682926804e-05
analysis O 0 1.5731941402918892e-06
at O 0 6.668491892014572e-07
exon O 0 4.168049372310634e-07
alpha O 0 1.0772500047551148e-07
of O 0 1.57834794123346e-08
the O 0 7.32250615698149e-09
small O 0 1.6048675277602342e-08
nuclear O 0 3.2174832540476928e-06
ribonucleoprotein O 0 0.0011526626767590642
- O 0 3.7917197914794087e-06
associated O 0 1.152764298240072e-06
polypeptide O 0 3.374913285369985e-05
N O 0 1.7614329408388585e-05
( O 0 3.6550851234551374e-08
SNRPN O 0 1.6083147784229368e-05
) O 0 3.521474667422808e-09
gene O 0 1.2963679019151186e-09
showed O 0 3.331192210964673e-09
a O 0 2.7788380485560538e-09
pattern O 0 2.0064499395289204e-08
characteristic O 0 1.0638081526792575e-08
of O 0 1.8557299696908558e-08
only O 0 4.30173274779122e-09
the O 0 4.2491862473070796e-08
maternal O 0 3.749422319287987e-07
chromosome O 0 5.0364086234822025e-08
15 O 0 2.3500993151515104e-08
in O 0 4.980704915169554e-08
J O 0 1.2006464203295764e-05
. O 0 4.4328595549814054e-07

B O 0 0.0021446736063808203
. O 0 9.165440133074299e-06

Maternal B-Disease 0 0.005741466768085957
disomy I-Disease 0 0.0002516851818654686
was O 0 2.2648014237347525e-06
confirmed O 0 2.2493257034739145e-08
by O 0 8.277632801423351e-09
polymerase O 0 6.171737254589971e-07
chain O 0 5.0372058524317254e-08
reaction O 0 4.747871873433951e-09
analysis O 0 2.124239628642499e-08
of O 0 4.1803414063679156e-08
microsatellite O 0 7.895892508713587e-07
repeats O 0 2.0667177125233138e-07
at O 0 9.863403960252981e-08
the O 0 2.0898866637253377e-08
gamma O 0 1.1400483117540716e-06
- O 0 1.3771210660706856e-07
aminobutyric O 0 1.1303267228868208e-06
acid O 0 7.694663395341195e-08
receptor O 0 1.2293597251300525e-07
beta3 O 0 8.517757805748261e-07
subunit O 0 6.336982778520905e-07
( O 0 4.468287428949225e-08
GABRB3 O 0 7.2097595875675324e-06
) O 0 5.613581777197396e-08
locus O 0 9.45290253184794e-07
. O 0 7.440829818960992e-08

A O 0 5.982428046991117e-05
niece O 0 1.488624548073858e-05
( O 0 9.482864982146566e-08
B O 0 3.908401708940801e-07
. O 0 3.1156552893207845e-09
B O 0 2.1356294155339128e-07
. O 0 3.5618413773974567e-10
) O 0 1.4930746916608229e-10
with O 0 4.4182622838118135e-11
45 O 0 2.4373751905670815e-09
chromosomes O 0 1.0028585739618734e-09
and O 0 1.2988621289622415e-10
the O 0 1.9580155274923072e-09
derivative O 0 4.6657678609562936e-08
3 O 0 8.706429355243017e-09
but O 0 4.131382458361088e-10
without O 0 1.7954057129898615e-09
the O 0 2.083852379541895e-08
der O 0 1.2449323548935354e-05
( O 0 1.6164062088819264e-08
15 O 0 1.5774599404494438e-08
) O 0 1.5801725483655105e-09
demonstrated O 0 9.83253833908293e-09
a O 0 1.3924142727717026e-08
phenotype O 0 1.507426539149037e-08
consistent O 0 2.879610505601704e-08
with O 0 8.81738571045787e-11
that O 0 2.382865849082094e-10
reported O 0 3.892612454592381e-09
for O 0 2.2758042117487776e-09
haploinsufficiency O 0 9.375214176543523e-06
of O 0 1.1860564654853079e-06
distal O 0 6.202860731718829e-06
3 O 0 8.804693607089575e-06
p O 0 6.299081724137068e-05
. O 0 4.413679164372297e-07

Uniparental B-Disease 1 1.0
disomy I-Disease 1 1.0
associated O 0 2.665693682502024e-05
with O 0 7.184564765339019e-08
unbalanced O 0 9.210966527462006e-05
segregation O 0 2.243568587800837e-06
of O 0 9.245813430425187e-07
non O 0 0.00011417071073083207
- O 0 9.76422888925299e-05
Robertsonian O 0 0.16904883086681366
translocations O 0 7.97396478446899e-06
has O 0 8.005240914599199e-09
been O 0 1.3968220358151484e-08
reported O 0 1.5053464252900994e-08
previously O 0 1.9114336780035046e-08
but O 0 9.720724225559252e-10
has O 0 6.555453957446389e-10
not O 0 1.159696338959293e-09
, O 0 1.0976644038152017e-09
to O 0 6.1725584643568254e-09
our O 0 1.2190253073640633e-07
knowledge O 0 6.599647349503357e-06
, O 0 6.108237027291352e-09
been O 0 1.186722986545874e-08
observed O 0 1.6512132106072386e-08
in O 0 2.780333296925619e-09
a O 0 2.7690619575082565e-08
case O 0 1.3124324027558032e-07
of O 0 4.313889348850353e-06
PWS B-Disease 1 1.0
. O 0 4.031255230074748e-06

Furthermore O 0 7.478958286810666e-05
, O 0 1.7765755089271806e-08
our O 0 1.9785291627272272e-08
findings O 0 2.473451665707671e-08
are O 0 1.7396060147945036e-09
best O 0 1.2824585837734048e-08
interpreted O 0 3.2534806848616427e-08
as O 0 5.273700143249016e-09
true O 0 1.0442121123332981e-07
gamete O 0 3.824798568530241e-06
complementation O 0 4.020643245894462e-06
resulting O 0 1.4656203006779833e-07
in O 0 1.6839611305385915e-07
maternal B-Disease 0 0.07864117622375488
UPD I-Disease 1 1.0
15 I-Disease 0 8.880273526301607e-05
and O 0 5.7012161960301455e-06
PWS B-Disease 1 1.0

Schwartz B-Disease 1 0.9999880790710449
- I-Disease 1 0.9999998807907104
Jampel I-Disease 1 1.0
syndrome I-Disease 1 0.9999997615814209
type I-Disease 0 0.0001385173382004723
2 I-Disease 0 4.805605931323953e-05
and O 0 5.633026489704207e-07
Stuve B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 0.9999994039535522
: O 0 1.2668407656235559e-08
a O 0 2.44544171579264e-08
case O 0 1.2041518893113334e-08
for O 0 5.168532268839954e-09
" O 0 1.2568615659347415e-07
lumping O 0 1.5520434999416466e-06
" O 0 6.896477202644746e-07
. O 0 1.5351193383139616e-07

Recent O 0 3.4588736070872983e-06
studies O 0 4.461338676264859e-07
demonstrated O 0 3.648231583497363e-08
the O 0 1.2199295795767284e-08
existence O 0 1.2433072242856724e-06
of O 0 4.768621408857143e-08
a O 0 2.3086037970188045e-08
genetically O 0 3.562683759117391e-10
distinct O 0 7.442867433482547e-10
, O 0 9.613959628396174e-11
usually O 0 1.398262616802981e-10
lethal O 0 4.119838914462548e-10
form O 0 9.494675046184398e-10
of O 0 8.660521899628293e-08
the O 0 2.6047294454656367e-07
Schwartz B-Disease 0 0.4326189458370209
- I-Disease 1 0.9975456595420837
Jampel I-Disease 1 1.0
syndrome I-Disease 1 0.9999997615814209
( O 0 1.0316101679563872e-06
SJS B-Disease 1 0.9672142863273621
) O 0 8.870665979543446e-09
of O 0 2.4457128233734693e-07
myotonia B-Disease 1 0.999935507774353
and O 0 7.390309474430978e-05
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 1.4871935150040372e-07
which O 0 1.6926257728755445e-08
we O 0 1.4474571230493893e-07
called O 0 2.115398501700838e-06
SJS B-Disease 1 0.984862744808197
type I-Disease 0 1.8680424545891583e-05
2 I-Disease 0 1.2150517250120174e-05
. O 0 3.9986227307053923e-07

This O 0 3.256089939895901e-06
disorder O 0 0.15392281115055084
is O 0 4.195646496896188e-08
reminiscent O 0 4.305749428112904e-07
of O 0 3.464019755483605e-07
another O 0 1.6776455424860615e-07
rare O 0 8.984449095805758e-08
condition O 0 6.7613600549520925e-06
, O 0 6.639109706441104e-09
the O 0 1.055304892361164e-06
Stuve B-Disease 1 0.9999996423721313
- I-Disease 1 0.9999997615814209
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.01943819224834442
SWS B-Disease 1 0.999998927116394
) O 0 1.3707171397925322e-08
, O 0 8.991555833226528e-10
which O 0 1.037708696749462e-09
comprises O 0 5.936433922215656e-08
campomelia B-Disease 0 0.0001327795907855034
at O 0 9.095780114876106e-06
birth O 0 9.62045760388719e-06
with O 0 5.477490390148887e-07
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 1.219717660205788e-06
contractures B-Disease 1 0.9995835423469543
, O 0 1.5390213548016618e-07
and O 0 2.2870409566166927e-08
early B-Disease 0 3.970369562011911e-06
death I-Disease 0 5.042064003646374e-06
. O 0 4.471842487419053e-07

To O 0 1.438307890566648e-07
test O 0 1.527644144516671e-08
for O 0 7.076953689733045e-09
possible O 0 1.6798678359464247e-07
nosologic O 0 0.00026361760683357716
identity O 0 5.030418037677009e-07
between O 0 2.9361928000071202e-08
these O 0 1.0735391242633341e-08
disorders O 0 0.0001420829794369638
, O 0 1.2463292620168431e-09
we O 0 4.838579759081085e-09
reviewed O 0 5.325303931158487e-08
the O 0 1.2296359486185793e-08
literature O 0 7.31713427626346e-08
and O 0 1.698857610143989e-09
obtained O 0 6.659455209501175e-08
a O 0 2.123526599007164e-08
follow O 0 5.595790497636699e-09
- O 0 7.365580145801687e-09
up O 0 1.7378194883121978e-08
of O 0 1.4674379045231944e-08
the O 0 6.543614539111786e-09
only O 0 1.2043671615558083e-09
two O 0 1.2986892672373074e-09
surviving O 0 3.1133990887610707e-06
patients O 0 3.484167843126329e-09
, O 0 6.828760890087437e-10
one O 0 5.144141557167359e-09
with O 0 1.3734492654293717e-08
SJS B-Disease 1 0.8469855785369873
type I-Disease 0 7.08432207829901e-06
2 I-Disease 0 5.752399943048658e-07
at O 0 1.40401837711579e-07
age O 0 2.7554321491152223e-08
10 O 0 2.4230246697953817e-09
years O 0 1.532645677038147e-09
and O 0 7.109257071924446e-10
another O 0 3.5657738095551395e-08
with O 0 3.6234052203099054e-08
SWS B-Disease 0 0.03833314776420593
at O 0 3.202597724794032e-07
age O 0 1.716267377105396e-07
7 O 0 7.444392622346641e-07
years O 0 2.0445516213385417e-07
. O 0 1.7919823847023508e-07

Patients O 0 1.0726971595431678e-05
reported O 0 1.858661988762833e-07
as O 0 9.390777933049321e-09
having O 0 9.310027593301129e-08
either O 0 6.176635361043736e-05
neonatal O 1 1.0
SJS B-Disease 1 1.0
or O 1 0.9998816251754761
SWS B-Disease 1 0.9998224377632141
presented O 0 2.716653746404063e-08
a O 0 7.146593983264893e-09
combination O 0 1.493596690771426e-09
of O 0 1.4521631008790337e-08
a O 0 2.0232400643749315e-08
severe O 0 2.0905231679080316e-07
, O 0 1.4091339650690315e-08
prenatal O 1 0.8053832054138184
- O 1 0.984411358833313
onset O 1 1.0
neuromuscular B-Disease 1 1.0
disorder I-Disease 1 1.0
( O 0 0.00016116884944494814
with O 0 1.4887849829392508e-05
congenital B-Disease 1 1.0
joint I-Disease 1 1.0
contractures I-Disease 1 1.0
, O 1 0.9999992847442627
respiratory O 1 1.0
and O 0 0.00016615298227407038
feeding O 1 0.9999980926513672
difficulties O 1 1.0
, O 0 3.7314293876988813e-07
tendency O 0 1.6577729411437758e-06
to O 0 1.0484769319418774e-07
hyperthermia B-Disease 1 0.9999998807907104
, O 0 2.9414394475679728e-08
and O 0 1.0118992754826195e-08
frequent O 0 2.2025560042493453e-07
death O 0 5.87983038258244e-07
in O 0 2.085383954408826e-07
infancy O 0 0.47583433985710144
) O 0 4.570375189416609e-09
with O 0 5.919715828639482e-10
a O 0 9.78175691557226e-08
distinct O 0 3.326349826693331e-07
campomelic B-Disease 1 0.9977738261222839
- I-Disease 1 0.9999904632568359
metaphyseal I-Disease 1 0.9999998807907104
skeletal I-Disease 1 1.0
dysplasia I-Disease 1 0.9999992847442627
. O 0 9.877682714432012e-06

The O 0 1.27984117170854e-06
similarity O 0 8.648964353596966e-07
of O 0 9.76678649067253e-08
the O 0 6.601382551707502e-08
clinical O 0 4.917197657050565e-06
and O 0 3.5299478895467473e-09
radiographic O 0 2.5744087906787172e-05
findings O 0 4.610724033682345e-07
is O 0 6.6774497042842995e-09
so O 0 6.732655544183785e-10
extensive O 0 1.505759783526628e-08
that O 0 3.0676719497968463e-10
these O 0 3.923187108512138e-09
disorders O 0 0.0003428718482609838
appear O 0 1.3293877998421522e-07
to O 0 1.588859177559243e-08
be O 0 2.1939621674960108e-08
a O 0 4.3766757329422035e-08
single O 0 2.3342847654816978e-08
entity O 0 2.358574192840024e-06
. O 0 4.0601628370495746e-07

The O 0 6.9494535637204535e-06
follow O 0 1.3003614185436163e-06
- O 0 1.5775509609738947e-06
up O 0 4.190352171917766e-07
observation O 0 1.7785607269615866e-05
of O 0 5.254024415535241e-08
an O 0 6.589730983108666e-09
identical O 0 5.904338351570004e-09
and O 0 2.793898168373943e-10
unique O 0 3.1838152114715967e-09
pattern O 0 1.6276852932151087e-07
of O 0 9.547230547468644e-06
progressive O 1 0.9999971389770508
bone B-Disease 1 1.0
dysplasia I-Disease 1 0.9999421834945679
in O 0 1.6383233969463618e-07
the O 0 1.0657175408823605e-07
two O 0 1.1214385864377618e-08
patients O 0 5.034129557657252e-09
( O 0 2.202799942452316e-09
one O 0 5.590349516637616e-09
with O 0 7.575538418791439e-09
SJS B-Disease 0 0.0505637489259243
type I-Disease 0 3.3198512028320692e-06
2 I-Disease 0 1.2462238601074205e-06
, O 0 3.6706488959481476e-09
one O 0 5.941097391826133e-09
with O 0 8.740737911239194e-09
SWS B-Disease 0 0.13922475278377533
) O 0 9.98993066048115e-09
surviving O 0 3.6997512324887794e-06
beyond O 0 1.0221208412986016e-06
infancy O 0 4.768234703078633e-06
adds O 0 1.5401925068658784e-08
to O 0 1.2943666138909293e-09
the O 0 4.362563199578062e-09
evidence O 0 8.62496420950265e-08
in O 0 6.44971409613504e-09
favor O 0 1.1865056492865733e-08
of O 0 5.639304845317383e-08
identity O 0 2.8573518306984624e-07
. O 0 2.200659992013243e-07

The O 0 2.50719062933058e-06
hypothesis O 0 4.7179228204186074e-06
that O 0 1.6093436272512918e-07
SWS B-Disease 0 0.0010132944444194436
and O 0 2.110963777113284e-07
SJS B-Disease 1 0.9369107484817505
type I-Disease 0 8.868494660418946e-06
2 I-Disease 0 1.7386602166880039e-06
are O 0 2.825415679197363e-09
the O 0 1.4226205102829681e-08
same O 0 1.5257026575454802e-07
disorder O 0 1.491054831603833e-06
should O 0 2.485855965517203e-09
be O 0 2.6032769273598433e-09
testable O 0 1.6609284614332864e-07
by O 0 6.708313904368879e-10
molecular O 0 1.8116084632424645e-08
methods O 0 2.5855138474639716e-08
. O 0 9.628760899715871e-09
. O 0 4.685083609956564e-08

A O 0 2.936873170256149e-05
mouse O 0 1.6359439314328483e-06
model O 0 1.1601564864349712e-07
of O 0 8.716934019048495e-08
severe O 0 0.006128424312919378
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 1 0.743948757648468
defects O 1 0.9999970197677612
in O 0 1.800889322112198e-06
hemostasis O 1 0.9999984502792358
and O 0 4.498766429605894e-06
thrombosis B-Disease 1 0.9999977350234985
. O 0 2.144179779861588e-05

von B-Disease 1 0.9999477863311768
Willebrand I-Disease 1 1.0
factor I-Disease 1 0.998386025428772
( I-Disease 0 7.150685269152746e-05
vWf I-Disease 1 0.9999285936355591
) I-Disease 0 3.045046832994558e-05
deficiency I-Disease 1 1.0
causes O 1 0.9746203422546387
severe O 1 1.0
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 0.0872766524553299
humans O 0 3.6900069972034544e-05
. O 0 4.2075069472957694e-07

We O 0 1.6700262222002493e-06
generated O 0 5.029766043662676e-07
a O 0 7.206097052403493e-08
mouse O 0 1.4434644590721746e-08
model O 0 1.0732150723669065e-09
for O 0 1.5107812223469352e-10
this O 0 8.45411851635447e-10
disease O 0 5.412485570843728e-09
by O 0 1.0325339472316841e-09
using O 0 1.3320918590409292e-08
gene O 0 1.640327162988342e-08
targeting O 0 9.411707679873871e-08
. O 0 5.919575229995644e-08

vWf B-Disease 1 0.9999666213989258
- I-Disease 1 0.9999998807907104
deficient I-Disease 1 0.9999059438705444
mice O 0 1.26739860206726e-06
appeared O 0 6.547649178401116e-08
normal O 0 3.853212504623116e-08
at O 0 1.174191055497431e-08
birth O 0 2.597890347288967e-09
; O 0 5.5223908779211683e-11
they O 0 1.4407894322054915e-10
were O 0 6.212053538234841e-09
viable O 0 2.404826204838173e-07
and O 0 1.7050652445504966e-08
fertile O 0 4.992916728951968e-06
. O 0 4.463091727302526e-07

Neither O 0 0.0003683794056996703
vWf O 0 0.001611656742170453
nor O 0 6.06762187089771e-05
vWf O 0 0.000538880645763129
propolypeptide O 0 0.00034937847522087395
( O 0 8.116469416563632e-07
von B-Disease 0 0.0015676857437938452
Willebrand I-Disease 1 0.6184183359146118
antigen O 0 5.3887574722466525e-06
II O 1 0.9979956150054932
) O 0 5.256039514733857e-08
were O 0 1.53865968854916e-08
detectable O 0 1.6813102377000178e-07
in O 0 4.583810664371413e-09
plasma O 0 4.2872082417488855e-07
, O 0 6.484004000384402e-09
platelets O 0 1.4238182188819337e-07
, O 0 3.5691878341737038e-09
or O 0 2.7304665195515554e-08
endothelial O 0 1.0332855282513265e-07
cells O 0 5.188108165299354e-09
of O 0 1.9501447567904506e-08
the O 0 1.2083303602139495e-07
homozygous O 0 3.2339676181436516e-07
mutant O 0 1.5997278524082503e-06
mice O 0 1.7506252447674342e-07
. O 0 2.0755500429459062e-08

The O 0 3.6368762721394887e-06
mutant O 0 5.34648061147891e-05
mice O 0 1.307505681324983e-05
exhibited O 0 1.0470851520949509e-05
defects O 0 0.03326752036809921
in O 0 2.3530355974799022e-07
hemostasis O 0 0.01810154877603054
with O 0 1.1875290972795938e-08
a O 0 7.290587973329821e-07
highly O 0 3.888691935571842e-06
prolonged O 1 0.9999969005584717
bleeding O 1 0.9989380240440369
time O 0 3.1809086067369208e-06
and O 0 9.410953794031229e-08
spontaneous O 0 4.728146450361237e-05
bleeding O 0 0.000924882828257978
events O 0 5.486587539849097e-08
in O 0 3.747489429883899e-09
approximately O 0 7.616685948619306e-09
10 O 0 1.1533792587670177e-08
% O 0 5.267427383159884e-09
of O 0 3.124750236338514e-08
neonates O 0 1.7273360981562291e-06
. O 0 2.1081835654968017e-07

As O 0 4.2777537601068616e-07
in O 0 2.4994166736291845e-08
the O 0 3.4487044331399375e-08
human O 0 1.413818893070129e-07
disease O 0 3.5507892448549683e-07
, O 0 5.883324938338319e-10
the O 0 3.064861786583606e-08
factor O 0 3.476430094906391e-07
VIII O 0 1.1980670933553483e-05
level O 0 1.3749764548265375e-05
in O 0 4.232747041754692e-09
these O 0 1.6044137129966884e-09
mice O 0 2.443175972643985e-08
was O 0 2.0858925253719462e-08
reduced O 0 6.364161198035845e-09
strongly O 0 2.2541175592749596e-09
as O 0 1.368657742695234e-09
a O 0 3.5516400931356884e-09
result O 0 3.499432521536505e-09
of O 0 9.610339191112871e-09
the O 0 2.1668471461566696e-08
lack O 0 2.4297278855556215e-07
of O 0 2.7538087365996944e-08
protection O 0 1.0860490107234e-07
provided O 0 1.725610729863547e-07
by O 0 1.0573494790833138e-07
vWf O 0 4.107221320737153e-05
. O 0 1.1773596497732797e-06

Defective O 1 0.9884780049324036
thrombosis B-Disease 1 0.9984920024871826
in O 0 3.7930001326458296e-06
mutant O 0 0.0012258744100108743
mice O 0 1.9576731574488804e-05
was O 0 3.366580756392068e-07
also O 0 1.9474080126258286e-09
evident O 0 4.801971797974147e-08
in O 0 3.4134233217741894e-09
an O 0 1.740585009457618e-09
in O 0 7.0676056118657016e-09
vivo O 0 6.063017394808412e-07
model O 0 6.368279770185836e-08
of O 0 8.175674679478107e-07
vascular B-Disease 1 0.9999926090240479
injury I-Disease 1 0.9996621608734131
. O 0 1.9269329641247168e-05

In O 0 9.891908803183469e-08
this O 0 2.575756719025435e-09
model O 0 2.032476409397077e-08
, O 0 2.9277917867887027e-09
the O 0 5.6205028187150674e-08
exteriorized O 0 1.921470175147988e-05
mesentery O 0 0.00012527775834314525
was O 0 5.63706407774589e-06
superfused O 0 7.942096090118866e-06
with O 0 3.070443455044369e-08
ferric O 0 6.795539957238361e-05
chloride O 0 7.3579963100200985e-06
and O 0 1.7517541550660098e-07
the O 0 9.818521675697411e-07
accumulation O 0 0.0008888341253623366
of O 0 6.88946747686714e-05
fluorescently O 0 0.0013558806385844946
labeled O 0 5.604542820947245e-06
platelets O 0 1.6410707530667423e-06
was O 0 4.329920955115085e-07
observed O 0 5.8958672610742724e-08
by O 0 1.524107950956477e-08
intravital O 0 8.25502229417907e-06
microscopy O 0 6.961778581171529e-06
. O 0 8.767722761149344e-07

We O 0 4.093574716534931e-06
conclude O 0 5.665395747200819e-06
that O 0 5.899734034642279e-09
these O 0 7.212777486387267e-09
mice O 0 2.066684317014733e-07
very O 0 8.272124318864371e-09
closely O 0 1.9940645756832964e-07
mimic O 0 1.0847818884940352e-05
severe O 0 0.0002935966767836362
human O 0 0.0061185723170638084
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 6.60992469647681e-08
will O 0 1.0383918169765138e-09
be O 0 1.8379473498697507e-09
very O 0 7.422693570902084e-10
useful O 0 6.749103498293607e-09
for O 0 4.3026826546110897e-10
investigating O 0 6.732212654014802e-08
the O 0 4.3640053348781294e-08
role O 0 3.204929157618608e-07
of O 0 1.031929969030898e-06
vWf O 0 1.1431869097577874e-05
in O 0 6.50990514827754e-08
normal O 0 7.435874522343511e-06
physiology O 0 7.328796345973387e-05
and O 0 7.6748722932507e-09
in O 0 3.795030067976768e-08
disease O 0 2.164315731079114e-07
models O 0 9.099093922770862e-09
. O 0 4.463395875120568e-09
. O 0 5.377912515314165e-08

Oral O 1 0.7394673824310303
contraceptives O 0 2.6005893232650124e-05
and O 0 6.309349487310101e-09
the O 0 3.2712581088389925e-08
risk O 0 5.78489743929822e-06
of O 1 0.9706610441207886
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.35977280139923096

Hereditary B-Disease 1 1.0
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 1.0
Clinical O 1 1.0
Study O 0 0.00018748610455077142
Group O 0 1.0643987025105162e-06
. O 0 1.1085556650414219e-07

BACKGROUND O 0 9.865804895525798e-05
Women O 0 2.4776776186286043e-08
with O 0 3.761795874801521e-10
mutations O 0 1.1371161789952566e-09
in O 0 5.230754496210466e-09
either O 0 2.8013340980237444e-08
the O 0 2.535629448630061e-07
BRCA1 O 0 1.9369078074760182e-07
or O 0 6.459318768747835e-08
the O 0 1.5999124514110008e-07
BRCA2 O 0 4.0404438550467603e-07
gene O 0 3.669332837574757e-09
have O 0 2.096036261223233e-10
a O 0 3.824231153970459e-09
high O 0 4.022288990768175e-08
lifetime O 0 2.427453296149906e-07
risk O 0 3.0659341518912697e-06
of O 1 0.9995729327201843
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 6.005434624967165e-05

Oral O 1 0.9767888784408569
contraceptives O 0 0.04915037378668785
protect O 0 1.3390405001700856e-05
against O 1 0.959281325340271
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 0.00011794416059274226
general O 0 3.2291213756252546e-06
, O 0 5.0051967015463106e-09
but O 0 7.469860285880259e-10
it O 0 2.365765638945305e-10
is O 0 3.4309866059345495e-10
not O 0 1.6950697789841485e-10
known O 0 1.0126093297202488e-09
whether O 0 5.413845483026591e-10
they O 0 3.283314509161528e-09
also O 0 5.305572425839955e-09
protect O 0 2.3801609572160487e-08
against O 0 3.5315792956680525e-08
hereditary B-Disease 0 0.20290420949459076
forms I-Disease 0 3.063831536564976e-05
of I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.522850743640447e-05

METHODS O 0 8.92989646672504e-06
We O 0 4.023356154903013e-07
enrolled O 0 1.3122912605467718e-06
207 O 0 5.349355092221231e-07
women O 0 7.530677414990805e-09
with O 0 1.8938402845947166e-08
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 2.576847009549965e-06
161 O 0 7.647738584637409e-07
of O 0 3.685907188355486e-07
their O 0 7.874312757394364e-08
sisters O 0 3.2596972232568078e-06
as O 0 6.630304483223881e-08
controls O 0 1.665698334818444e-07
in O 0 1.1909360608797215e-08
a O 0 7.567251714135637e-08
case O 0 2.8848145916526846e-07
- O 0 1.2341517958702752e-06
control O 0 1.2174909898021724e-06
study O 0 7.251900910887343e-07
. O 0 1.8966967729738826e-07

All O 0 9.385732369082689e-08
the O 0 4.1007844231444324e-08
patients O 0 1.5520761342813216e-09
carried O 0 1.5330461344831292e-09
a O 0 9.863715400015849e-10
pathogenic O 0 6.927743378959406e-10
mutation O 0 2.367462892394201e-10
in O 0 6.695620724528339e-10
either O 0 4.936723030368739e-09
BRCA1 O 0 9.757416208344694e-09
( O 0 2.6808675279710314e-09
179 O 0 1.5424767241256632e-08
women O 0 3.130798065242857e-09
) O 0 3.283139093923637e-09
or O 0 1.1299970736899922e-08
BRCA2 O 0 2.037926449816041e-08
( O 0 4.327788349911543e-09
28 O 0 1.0049600263073444e-07
women O 0 1.539076599499367e-08
) O 0 1.6526405133276967e-08
. O 0 9.221046326501892e-08

The O 0 5.008177595300367e-06
control O 0 1.1085594451287761e-06
women O 0 6.8382921547538444e-09
were O 0 7.713115479646149e-09
enrolled O 0 2.5742599163436353e-08
regardless O 0 1.7752748604493718e-08
of O 0 4.4157751233342424e-08
whether O 0 1.1028442159499718e-08
or O 0 1.8696429293640904e-08
not O 0 1.8733328221998136e-09
they O 0 1.5243544204679438e-09
had O 0 1.8326346662433934e-08
either O 0 3.410685067706254e-08
mutation O 0 4.229456607163229e-08
. O 0 6.743817237975236e-08

Lifetime O 0 8.168000931618735e-05
histories O 0 1.3546798982133623e-05
of O 0 4.698655629908899e-06
oral O 0 0.00017721155018080026
- O 0 4.2377825593575835e-05
contraceptive O 0 5.237760660747881e-07
use O 0 2.5162909533804623e-09
were O 0 9.590251259794513e-09
obtained O 0 1.0555178420190714e-07
by O 0 2.6785073714563623e-08
interview O 0 3.2234984814749623e-07
or O 0 6.615699099654648e-09
by O 0 6.810147445968084e-10
written O 0 1.8532673173865533e-09
questionnaire O 0 7.540029711705643e-10
and O 0 1.9504403647729873e-10
were O 0 8.963593201016806e-10
compared O 0 2.215706951247398e-09
between O 0 6.70638566901971e-09
patients O 0 1.9424002406509544e-09
and O 0 1.8632695386600062e-09
control O 0 1.2768883834723965e-06
women O 0 1.1139898781209467e-08
, O 0 6.463330426420555e-10
after O 0 8.28412449749294e-09
adjustment O 0 2.3742195764953067e-07
for O 0 1.3529705134018855e-09
year O 0 3.4677785087922075e-09
of O 0 1.5406683928631537e-08
birth O 0 4.3382698322602664e-08
and O 0 8.780808080643965e-09
parity O 0 3.0629387310909806e-06
. O 0 1.1884041839493875e-07

RESULTS O 0 6.612953711737646e-06
The O 0 4.580474524118472e-07
adjusted O 0 2.987498191941995e-06
odds O 0 4.300629370845854e-06
ratio O 0 1.5480287629543454e-06
for O 0 1.4791045259698876e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 4.506538971327245e-06
with O 0 1.3378763652482917e-09
any O 0 8.076279200963654e-09
past O 0 7.145203984038062e-09
use O 0 3.733404418948538e-10
of O 0 5.399875213640826e-09
oral O 0 3.684237697143544e-07
contraceptives O 0 4.441784540176741e-07
was O 0 3.5136272913405264e-07
0 O 0 9.300548953206089e-08
. O 0 2.4371347606688687e-08

5 O 0 1.9910328319383552e-06
( O 0 2.4285037980575908e-08
95 O 0 6.5075219879418e-08
percent O 0 6.219309067745371e-09
confidence O 0 2.1718951970228773e-08
interval O 0 9.013147206360372e-08
, O 0 1.4940925163742236e-09
0 O 0 9.310925364047762e-10
. O 0 8.60825369319862e-11
3 O 0 4.911119289019439e-10
to O 0 2.8656907402613285e-10
0 O 0 8.922569905145394e-10
. O 0 3.464120934548731e-10
8 O 0 1.2488498235541101e-08
) O 0 6.501415850124204e-09
. O 0 2.4826350752960025e-08

The O 0 2.7499568204802927e-06
risk O 0 2.7203977879253216e-06
decreased O 0 5.602210535471386e-07
with O 0 7.297391579896839e-10
increasing O 0 1.2448948538690274e-08
duration O 0 2.2855196846194303e-07
of O 0 1.3031365320159694e-08
use O 0 6.346460024175826e-10
( O 0 8.470275036920327e-10
P O 0 6.215054071390114e-08
for O 0 1.4108807178114802e-10
trend O 0 3.622263378133539e-09
, O 0 1.9521524674548374e-10
< O 0 5.758649557208173e-09
0 O 0 1.7516679773343924e-10
. O 0 2.1413626080657444e-11
001 O 0 1.2597086040955219e-08
) O 0 2.8244427630053082e-11
; O 0 6.347010590712632e-12
use O 0 4.092605074279554e-11
for O 0 2.3738022658648106e-10
six O 0 7.874009000374826e-09
or O 0 5.118411472437856e-09
more O 0 1.0863333843591505e-10
years O 0 1.644630653885315e-09
was O 0 8.338215451431097e-08
associated O 0 1.881695510519421e-08
with O 0 1.2017008499398685e-09
a O 0 3.885374511014561e-08
60 O 0 1.599080512448836e-08
percent O 0 1.0827841956384532e-09
reduction O 0 2.9109421539885716e-09
in O 0 1.2659181258811714e-08
risk O 0 4.384086764730455e-07
. O 0 2.3665316462029296e-07

Oral O 0 0.22010967135429382
- O 0 6.368462345562875e-05
contraceptive O 0 1.6662465895933565e-06
use O 0 1.3606988424896826e-08
protected O 0 8.585737305111252e-06
against O 0 0.007733843754976988
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
both O 0 1.2247206804261168e-08
for O 0 8.51405668189642e-10
carriers O 0 9.689773428078752e-10
of O 0 1.5310044787497645e-08
the O 0 3.2208060218863466e-08
BRCA1 O 0 3.252760905070318e-08
mutation O 0 9.320271221469056e-10
( O 0 2.938397303253737e-10
odds O 0 8.375605986543633e-09
ratio O 0 1.3197950510246415e-09
, O 0 2.621681344239235e-11
0 O 0 6.817525710633987e-11
. O 0 5.075483002631165e-12
5 O 0 9.007943696515142e-11
; O 0 1.0338375121266008e-11
95 O 0 1.5338417203025756e-09
percent O 0 5.943792125151504e-10
confidence O 0 3.45319861594362e-09
interval O 0 2.143572430668428e-08
, O 0 4.435997125185054e-10
0 O 0 3.4716088337383155e-10
. O 0 7.583829397805886e-11
3 O 0 2.4669236098340264e-10
to O 0 1.4019746474858152e-10
0 O 0 1.8153872849424602e-10
. O 0 2.7135939328903902e-11
9 O 0 6.01275473854912e-10
) O 0 3.5464919195815625e-11
and O 0 2.969836529476133e-11
for O 0 1.6876178232649863e-10
carriers O 0 1.0606490130626867e-09
of O 0 4.564886690872072e-09
the O 0 5.3192842131011275e-08
BRCA2 O 0 1.1492655715983346e-07
mutation O 0 3.562244277333093e-09
( O 0 9.858938110340887e-10
odds O 0 5.350380050117565e-08
ratio O 0 3.417416571949161e-09
, O 0 4.2877701389443246e-11
0 O 0 4.463868163995244e-11
. O 0 6.657182183983368e-12
4 O 0 1.4017580152181353e-10
; O 0 2.3804661367088364e-11
95 O 0 4.4150993971925345e-09
percent O 0 1.62680069415444e-09
confidence O 0 3.757339683829741e-08
interval O 0 4.846507195566119e-08
, O 0 1.1837585356389013e-09
0 O 0 1.6799205360129577e-09
. O 0 1.8003633306395983e-10
2 O 0 1.1794157872557776e-09
to O 0 7.262123680185084e-10
1 O 0 3.3092932838485467e-09
. O 0 7.78999253991941e-10
1 O 0 1.711333830201056e-08
) O 0 7.25174675864082e-09
. O 0 2.9789973154947802e-08

CONCLUSIONS O 0 0.0001061818256857805
Oral O 0 0.03415655344724655
- O 0 2.046593726845458e-05
contraceptive O 0 3.932430843178736e-07
use O 0 4.690953736563586e-10
may O 0 2.192123566002735e-10
reduce O 0 3.1887484319703674e-10
the O 0 6.583776190893786e-09
risk O 0 1.17009458335815e-05
of O 1 0.9996567964553833
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 1.7561013976319373e-07
women O 0 3.414079019492533e-10
with O 0 1.2200300665565766e-11
pathogenic O 0 1.9909968118625443e-10
mutations O 0 1.237167590595334e-10
in O 0 6.194255663949377e-10
the O 0 3.653705249462291e-08
BRCA1 O 0 1.3025207579175913e-07
or O 0 1.0778871484262709e-07
BRCA2 O 0 7.837008979549864e-07
gene O 0 6.677732358184585e-07

A O 0 0.0007021580240689218
Japanese O 0 0.0036330786533653736
family O 0 2.4747882889641915e-06
with O 0 1.228002872721845e-07
adrenoleukodystrophy B-Disease 1 1.0
with O 0 1.4898588140965785e-08
a O 0 1.4430878536586533e-07
codon O 0 1.9726344646642247e-07
291 O 0 5.3673371525064795e-08
deletion O 0 3.0174028609053494e-08
: O 0 6.361414728317527e-10
a O 0 4.388016172640619e-09
clinical O 0 1.0286389340308233e-07
, O 0 2.4339283921648303e-09
biochemical O 0 9.576347110851202e-06
, O 0 9.88726824857622e-08
pathological O 1 0.999032735824585
, O 0 1.5881683523844004e-08
and O 0 2.5936733649700727e-08
genetic O 0 3.502858362480765e-06
report O 0 8.094601753327879e-07
. O 0 3.137196245006635e-07

We O 0 2.672731397979078e-06
report O 0 1.4380735819941037e-06
a O 0 5.435319962998619e-07
Japanese O 0 1.908798913063947e-05
family O 0 3.1410311862600793e-07
with O 0 1.4636619027896813e-07
adrenoleukodystrophy B-Disease 1 1.0
( O 1 0.9999959468841553
ALD B-Disease 1 1.0
) O 0 2.214884098350467e-08
with O 0 6.602711710712583e-10
a O 0 3.126115544205277e-08
three O 0 5.44662936974305e-09
base O 0 3.1555895674273415e-08
pair O 0 1.1478054773306212e-07
deletion O 0 4.0070361251309805e-07
( O 0 4.1111533732873795e-08
delGAG O 0 1.1509374644447234e-06
291 O 0 1.230039856636722e-07
) O 0 3.509458945671895e-09
in O 0 1.4236682943646883e-08
the O 0 1.9498752408253495e-06
ALD B-Disease 1 1.0
gene O 0 5.955320830253186e-06
. O 0 7.374149504357774e-07

A O 0 8.070520379988011e-06
variety O 0 7.878909968894732e-08
of O 0 2.42842361330986e-07
phenotypes O 0 1.3164290066924877e-06
were O 0 4.7550521742323326e-08
observed O 0 4.4661316422889286e-08
within O 0 5.271058256539618e-08
this O 0 2.982966051945368e-08
family O 0 2.763069346656266e-07
. O 0 1.6781513068053755e-07

While O 0 1.995551656364114e-06
the O 0 4.90027048272168e-07
proband O 0 5.5983600759645924e-05
( O 0 1.6611186026693758e-07
patient O 0 2.2134528876449622e-07
1 O 0 2.0984509774280014e-07
) O 0 5.617841747351804e-09
was O 0 8.077483926172135e-08
classified O 0 6.898358861917586e-08
as O 0 2.1778092662572135e-09
having O 0 9.29949894867832e-09
a O 0 9.267662193224169e-09
rare O 0 1.9144721363772987e-09
intermediate O 0 1.7993764700463544e-08
type O 0 2.077629446262108e-08
of O 0 9.680583445970115e-08
adult O 0 1.928469373524422e-06
cerebral O 0 0.00024127168580889702
and O 0 1.1814341149829488e-07
cerebello O 1 0.9999997615814209
- O 1 0.9999691247940063
brain O 1 0.9945084452629089
stem O 0 1.169985807791818e-06
forms O 0 2.2180039138675056e-08
, O 0 2.8042246302817375e-09
his O 0 5.471632746889554e-08
younger O 0 4.906424067030457e-08
brother O 0 3.797108263370319e-07
( O 0 4.449763579827959e-08
patient O 0 6.478307312818288e-08
2 O 0 1.4308987772437831e-08
) O 0 5.643420175616143e-10
and O 0 1.3776280116672979e-09
nephew O 0 1.2977677215531003e-05
( O 0 5.122809056956612e-07
patient O 0 1.4799807104282081e-06
3 O 0 2.5061982000806893e-07
) O 0 4.393711172667736e-09
had O 0 1.816577110957951e-08
a O 0 3.3830204415608023e-07
childhood O 1 0.847912073135376
ALD B-Disease 1 1.0
type O 0 0.007926767691969872
. O 0 1.0280372180204722e-06

Another O 0 3.0126355341053568e-05
nephew O 0 0.00017166679026558995
( O 0 8.738939527574985e-07
patient O 0 1.624629817342793e-06
4 O 0 2.9890605901528033e-07
) O 0 6.365216798087658e-09
of O 0 5.490533894203509e-08
patient O 0 1.7338797988486476e-06
1 O 0 8.300092417812266e-07
was O 0 1.2591005997819593e-06
classified O 0 3.074962933169445e-07
as O 0 3.2530695914800845e-09
having O 0 1.6462760044078095e-08
an O 0 1.5457665369922324e-08
adolescent O 0 7.871818183957657e-07
form O 0 9.09731028286842e-08
. O 0 6.389925601979485e-07

The O 0 4.313420049584238e-06
tau O 0 4.892667220701696e-06
level O 0 5.218081469138269e-07
in O 0 1.0068398559326397e-08
the O 0 9.001069400937922e-08
cerebrospinal O 0 3.360522441653302e-06
fluid O 0 8.485112630296499e-06
( O 0 1.1352354931659647e-06
CSF O 0 0.01125961635261774
) O 0 1.0870728317513567e-07
in O 0 7.511142285920869e-08
patient O 0 5.636252353724558e-06
1 O 0 6.091811997066543e-07
was O 0 3.903558933870954e-07
as O 0 1.0549135787130126e-08
high O 0 3.3454373493668754e-08
as O 0 6.365638571814713e-10
that O 0 6.17639134281589e-11
of O 0 5.040317052618093e-09
patients O 0 9.635355624482145e-09
with O 0 2.2997832971327625e-08
Alzheimers B-Disease 1 1.0
disease I-Disease 1 0.9999915361404419
( O 0 1.6649201484142395e-07
AD B-Disease 0 2.206810222560307e-06
) O 0 2.1892386570243616e-08
. O 0 1.3144196842063138e-08

His O 0 2.0063514966750517e-05
brain O 0 1.996735045395326e-05
magnetic O 0 2.907952875830233e-06
resonance O 0 2.5813285446929513e-06
image O 0 9.072493298845075e-07
( O 0 3.781835644645071e-08
MRI O 0 5.863160822627833e-06
) O 0 1.308516406339777e-08
showed O 0 9.950133517122595e-08
abnormalities B-Disease 0 2.395654746578657e-06
in I-Disease 0 9.191051475454515e-09
the I-Disease 0 4.730121716534086e-08
bilateral I-Disease 0 1.7100774130085483e-05
cerebellar I-Disease 1 0.9955294728279114
hemispheres I-Disease 0 5.937732203165069e-05
and O 0 6.983069766874905e-08
brain O 0 0.0666014701128006
stem O 0 3.585802687666728e-06
, O 0 1.478985933722754e-09
but O 0 7.660828638123007e-10
not O 0 9.427041369747258e-10
in O 0 4.905729156234884e-09
the O 0 8.354756175776856e-08
cerebral O 0 6.535130523843691e-05
white O 0 2.0259236066522135e-08
matter O 0 6.643850269938412e-08
, O 0 1.7072838698339865e-09
where O 0 2.618365746442919e-09
marked O 0 7.983709693348828e-09
reductions O 0 1.2945402083630597e-08
of O 0 5.7181448909204846e-08
the O 0 1.2691376127804688e-07
cerebral O 0 5.3779149311594665e-06
blood O 0 2.4304046064571594e-07
flow O 0 3.662535618786933e-06
and O 0 1.7588442702276552e-08
oxygen O 0 9.76822957454715e-06
metabolism O 0 0.00014791883586440235
were O 0 2.805167831354538e-08
clearly O 0 5.445448536534059e-08
demonstrated O 0 1.6819894810282676e-08
by O 0 5.2742437084418725e-09
positron O 0 3.4003255677816924e-07
emission O 0 3.011308535860735e-08
tomography O 0 2.762916722076625e-07
( O 0 2.172893687202304e-08
PET O 0 3.845213996100938e-07
) O 0 1.0806100902982507e-08
. O 0 2.59730708052075e-08

In O 0 3.256515356042655e-06
patients O 0 6.805907304396897e-08
2 O 0 4.725820446083162e-08
and O 0 2.2519259790243495e-09
3 O 0 2.1019916474074307e-08
, O 0 5.764613786318762e-10
the O 0 2.2268962229787803e-09
autopsy O 0 1.0904577152359707e-07
findings O 0 1.5723864876804328e-08
showed O 0 9.762465680296373e-08
massive O 0 2.445554855512455e-06
demyelination B-Disease 1 1.0
of I-Disease 0 0.000643636507447809
the I-Disease 0 2.215871609223541e-05
cerebral I-Disease 0 0.01644998975098133
white I-Disease 0 4.964108057947669e-08
matter I-Disease 0 2.7748884079414893e-08
with O 0 1.2247503011764138e-09
sparing O 0 1.2405055827002798e-07
of O 0 3.942851947158488e-07
the O 0 2.3444370071956655e-06
U O 1 0.9998893737792969
- O 0 6.139516335679218e-05
fibers O 0 1.5895145679678535e-06
, O 0 5.23503596028263e-09
compatible O 0 2.916067387559451e-08
with O 0 2.4453461477946803e-10
the O 0 4.0277687851641986e-09
findings O 0 3.187717823038838e-08
of O 0 3.3321919090667507e-07
childhood O 1 0.9978888630867004
ALD B-Disease 1 1.0
. O 0 7.134187399060465e-06

Oleic O 0 0.001974261598661542
and O 0 1.3786731187792611e-06
erucic O 0 0.0025413453113287687
acids O 0 2.7426758606452495e-06
( O 0 3.601645914841356e-07
Lorenzos O 0 2.5213417757186107e-05
Oil O 0 1.035754303302383e-05
) O 0 5.435432104405891e-09
were O 0 2.3091399903307774e-09
administered O 0 8.334936296705564e-09
to O 0 4.4975272395220145e-09
patients O 0 1.8061804274438487e-09
1 O 0 1.600407806279236e-08
and O 0 2.058552661665658e-09
4 O 0 2.8395987783369492e-08
, O 0 2.1152697649018393e-10
but O 0 1.914642749900608e-10
sufficient O 0 2.9440327509178132e-08
effectiveness O 0 5.504889699636806e-08
was O 0 7.605176932656832e-08
not O 0 2.4195516701297493e-09
obtained O 0 2.728548906816286e-07
. O 0 1.6766155397363036e-07

The O 0 1.6957042134890798e-06
findings O 0 7.349569841608172e-07
in O 0 3.045794016998116e-08
this O 0 1.1987529191515023e-08
family O 0 5.100287836512507e-08
suggest O 0 4.967328237626134e-08
that O 0 7.934474743898079e-10
delGAG291 O 0 1.1458303106337553e-07
is O 0 2.8097015825068183e-09
part O 0 7.167193061263788e-09
of O 0 9.241242082680401e-08
the O 0 1.6005213865355472e-07
cause O 0 7.838974624974071e-07
of O 0 1.8484231532056583e-06
Japanese O 1 0.9991798996925354
ALD B-Disease 1 1.0
with O 0 7.789313194450642e-09
phenotypic O 0 2.8278384434088366e-07
variations O 0 6.574705366801936e-07
. O 0 2.2212071826288593e-07

Moreover O 0 1.924789830809459e-05
, O 0 1.833207896595468e-08
although O 0 2.2114763353897615e-09
the O 0 6.151156473066521e-09
scale O 0 2.5791558755372535e-07
of O 0 3.984484209240691e-08
the O 0 7.75984876355551e-09
study O 0 6.588247725147767e-09
is O 0 3.016306648895295e-10
limited O 0 1.1558033419234448e-09
, O 0 3.9514069793966655e-10
there O 0 3.1009876888532517e-09
is O 0 1.6096983745939042e-09
a O 0 8.192547085172919e-09
possibility O 0 4.3191150211896456e-08
that O 0 5.012285253513937e-09
PET O 0 4.7214058440658846e-07
can O 0 4.226785144112455e-09
detect O 0 3.3237307661693194e-07
an O 0 1.4294835182226961e-07
insidious B-Disease 0 2.2353789972839877e-05
lesion I-Disease 0 0.00012536118447314948
which O 0 3.577079965566554e-09
is O 0 8.627687453355293e-10
undetectable O 0 4.73125894018267e-08
by O 0 2.328112147509387e-09
computed O 0 6.408783548295105e-08
tomogram O 0 6.210800052031118e-07
( O 0 1.39410438748655e-08
CT O 0 5.920828698435798e-07
) O 0 1.2561929274568229e-09
or O 0 1.1935733512657976e-09
MRI O 0 1.2944060756581166e-07
analysis O 0 2.801296794530117e-08
, O 0 7.9339301795045e-10
and O 0 3.967129680315651e-10
that O 0 3.594504693893441e-10
the O 0 4.380306339868412e-09
higher O 0 6.064485802426134e-08
level O 0 1.6356415244445088e-07
of O 0 1.2981749009099985e-08
tau O 0 1.25462321420855e-07
reflects O 0 2.1494710455982613e-09
the O 0 7.609479157899557e-10
process O 0 7.587482642179566e-09
of O 0 1.3012778765641997e-07
neuronal B-Disease 0 0.1896212249994278
degeneration I-Disease 1 0.9999991655349731
in O 0 1.2552601219795179e-05
ALD B-Disease 1 1.0
. O 0 4.889836418442428e-06

Lorenzos O 0 0.0009534253622405231
Oil O 0 1.8207978428108618e-05
should O 0 1.8980280458436027e-08
be O 0 3.5035332413002607e-09
given O 0 3.40834227507969e-09
in O 0 3.127968994931507e-09
the O 0 1.2504634661070213e-08
early O 0 5.8416564030494555e-08
stage O 0 9.033300329974736e-08
. O 0 9.13547371084178e-09
. O 0 6.317251433074489e-08

Nonsense O 0 0.000166823054314591
mutation O 0 1.2517453740201745e-07
in O 0 4.5290708072798225e-08
exon O 0 4.3039796082666726e-07
4 O 0 6.40671800056225e-08
of O 0 2.5195001640554437e-08
human O 0 1.1713188641238048e-08
complement O 0 2.3291842410344543e-07
C9 O 0 0.0009780750842764974
gene O 0 2.8123787743083994e-08
is O 0 1.4784049540139677e-09
the O 0 5.7036442235869345e-09
major O 0 6.686641995656828e-08
cause O 0 2.6050622636830667e-07
of O 0 1.0795449725264916e-06
Japanese O 0 0.0004694647213909775
complement B-Disease 0 0.00012047120981151238
C9 I-Disease 1 0.9999996423721313
deficiency I-Disease 1 0.9999957084655762
. O 0 2.1025825844844803e-06

Deficiency B-Disease 1 1.0
of I-Disease 0 0.0001702033041510731
the I-Disease 0 4.356451881903922e-06
ninth I-Disease 0 5.862077159690671e-05
component I-Disease 0 1.0872032362385653e-05
of I-Disease 0 2.190901682297408e-07
human I-Disease 0 4.36163389849753e-08
complement I-Disease 0 2.3890808620308235e-07
( O 0 1.5563848876354314e-07
C9 O 0 0.00024335253692697734
) O 0 3.317787156120744e-09
is O 0 4.1597850164443173e-10
the O 0 1.0160298158368164e-09
most O 0 9.202273942854333e-10
common O 0 1.8014025826573743e-08
complement B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 2.395898809481878e-05
Japan O 0 1.423570211045444e-05
but O 0 8.966432041290773e-10
is O 0 2.656048991855897e-10
rare O 0 7.773175991765413e-10
in O 0 3.5997052560965415e-10
other O 0 1.0520553178627878e-10
countries O 0 4.216403892698395e-10
. O 0 4.972200429165241e-08

We O 0 2.402758525477111e-07
studied O 0 4.3296444118823274e-07
the O 0 3.59493341761663e-08
molecular O 0 1.7587309741884383e-07
basis O 0 1.1552614296306274e-06
of O 0 2.6292602797184372e-06
C9 B-Disease 1 0.9999977350234985
deficiency I-Disease 1 0.9998359680175781
in O 0 1.5862526936416543e-07
four O 0 1.5076126658186695e-07
Japanese O 0 0.0001352808903902769
C9 B-Disease 1 0.999982476234436
- I-Disease 1 0.9086557626724243
deficient I-Disease 0 0.17524980008602142
patients O 0 3.307073725977716e-08
who O 0 2.1085881929394645e-09
had O 0 1.7035155508438038e-07
suffered O 0 0.00015787853044457734
from O 0 3.3856475056381896e-05
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 2.2129072476673173e-06

Direct O 0 7.891465543252707e-07
sequencing O 0 1.1937304122966452e-07
of O 0 2.3651665514989872e-07
amplified O 0 1.489173428126378e-06
C9 O 0 2.6851019356399775e-05
cDNA O 0 7.93946128396783e-07
and O 0 2.0316421878163737e-09
DNA O 0 2.647918151410522e-08
revealed O 0 6.502968830091049e-08
a O 0 2.082747663223472e-08
nonsense O 0 1.2911537794479955e-07
substitution O 0 1.05204831513106e-08
( O 0 5.258684154796356e-09
CGA O 0 9.940023204535464e-08
- O 0 4.6245336449146635e-08
- O 0 1.1513245823380203e-07
> O 0 2.388734685609961e-07
TGA O 0 3.278063616107829e-07
) O 0 2.7702637406257224e-10
at O 0 2.4577619939236683e-09
codon O 0 1.5095038108370318e-08
95 O 0 5.666756663913475e-08
in O 0 7.345545505188511e-09
exon O 0 5.1928434885439856e-08
4 O 0 3.152034366848966e-08
in O 0 2.7544273528690155e-09
the O 0 2.8358858372712348e-08
four O 0 1.1436883085025329e-07
C9 B-Disease 0 0.004257751628756523
- I-Disease 0 0.001400787034071982
deficient I-Disease 0 2.930561277025845e-05
individuals O 0 2.9262132272833696e-08
. O 0 8.944336826743893e-08

An O 0 2.7139793701280723e-07
allele O 0 9.768164943579905e-08
- O 0 6.57656187286193e-08
specific O 0 1.917151415398166e-08
polymerase O 0 6.215101961970504e-07
chain O 0 5.9038907096464754e-08
reaction O 0 5.6647762036732274e-09
system O 0 8.634194692547226e-09
designed O 0 9.805008360785905e-09
to O 0 5.432664096360895e-09
detect O 0 8.141364560287911e-08
exclusively O 0 5.937452840498736e-08
only O 0 3.8734522256334e-09
one O 0 1.618651324086784e-09
of O 0 1.6477517128521413e-09
the O 0 2.9387015043624842e-09
normal O 0 1.3683713717682622e-08
and O 0 3.137378135065205e-10
mutant O 0 4.803435427191971e-09
alleles O 0 5.110319806211905e-11
indicated O 0 8.451728206182452e-11
that O 0 6.980606630929698e-12
all O 0 1.747212617642102e-11
the O 0 3.036081663854162e-10
four O 0 1.2584976394336422e-09
patients O 0 1.0504832420599186e-10
were O 0 6.637739247139507e-10
homozygous O 0 8.42729663830255e-10
for O 0 3.2793073811987483e-10
the O 0 1.2492095358140887e-08
mutation O 0 2.745259131131661e-09
in O 0 1.1394246435258992e-08
exon O 0 7.67004593171805e-08
4 O 0 4.6922917107394824e-08
and O 0 1.2527928694439083e-09
that O 0 3.518793867396397e-10
the O 0 9.110850740512433e-09
parents O 0 3.826317929167544e-09
of O 0 2.569506563077084e-08
patient O 0 1.1110852682350014e-07
2 O 0 1.9960414476827282e-07
were O 0 1.518811103551343e-07
heterozygous O 0 4.11186789506246e-07
. O 0 9.382402765822917e-08

The O 0 5.242163183538651e-07
common O 0 1.913666203279263e-08
mutation O 0 6.804632413093259e-09
at O 0 5.7329753389012694e-08
codon O 0 1.0996435406696037e-07
95 O 0 2.4444443624815904e-07
in O 0 1.0947879047762399e-08
exon O 0 7.480574737428469e-08
4 O 0 9.529095734706061e-09
might O 0 2.38643188543719e-10
be O 0 5.865531949034164e-10
responsible O 0 8.268591145110804e-09
for O 0 5.843881822897856e-09
most O 0 2.1287577922635137e-08
Japanese O 0 0.0008987520704977214
C9 B-Disease 1 0.9999992847442627
deficiency I-Disease 1 0.9999603033065796
. O 0 1.1534577026850457e-07
. O 0 1.3699492740215646e-07

BRCA1 O 0 9.114728527492844e-07
required O 0 5.0745249779993173e-08
for O 0 5.659508772737354e-08
transcription O 0 3.394395753275603e-05
- O 0 3.045284984182217e-06
coupled O 0 1.6598609363427386e-05
repair O 0 3.786353045143187e-05
of O 0 1.5220664408843732e-06
oxidative O 0 6.715024210279807e-05
DNA O 0 0.00012213882291689515
damage O 0 0.00041559000965207815
. O 0 3.7969309119034733e-07

The O 0 5.5748016166035086e-05
breast B-Disease 1 0.9999997615814209
and I-Disease 1 0.9994329810142517
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 1 0.9999954700469971
gene O 0 1.8837316702047247e-06
BRCA1 O 0 4.6617915927527065e-07
encodes O 0 6.468948043902856e-08
a O 0 2.9707925008892744e-08
zinc O 0 4.581698703987058e-06
finger O 0 5.187198439671192e-06
protein O 0 1.0108368542205426e-07
of O 0 1.9502272152749356e-07
unknown O 0 7.789984374539927e-05
function O 0 1.0071385986520909e-05
. O 0 1.7510458860670042e-07

Association O 0 1.6410695025115274e-05
of O 0 2.4141518224496394e-06
the O 0 1.1217998689971864e-06
BRCA1 O 0 1.266152906964635e-07
protein O 0 5.43004352593357e-09
with O 0 1.7664843199316493e-10
the O 0 2.3945410987380455e-08
DNA O 0 7.1659786726741e-07
repair O 0 1.4443049622059334e-05
protein O 0 1.039044036588166e-06
Rad51 O 0 5.675741249433486e-06
and O 0 5.361110999579921e-10
changes O 0 6.111205430592292e-10
in O 0 6.502429150678779e-10
the O 0 2.6145130505028646e-09
phosphorylation O 0 1.3924196018422208e-08
and O 0 1.6237100552984884e-09
cellular O 0 1.1866623594869452e-07
localization O 0 8.987086062006711e-07
of O 0 2.1496033397738756e-08
the O 0 2.0272921119612874e-08
protein O 0 2.3147634919951088e-08
after O 0 2.1854129172993453e-08
exposure O 0 4.6290875843624235e-07
to O 0 7.964652048997323e-09
DNA O 0 1.7596784118723008e-06
- O 0 1.4017215335115907e-06
damaging O 0 1.1170428706464008e-06
agents O 0 2.5838472694772463e-08
are O 0 6.494917381694165e-10
consistent O 0 1.6875551622774765e-08
with O 0 1.9172592680138933e-10
a O 0 9.65402691122108e-09
role O 0 1.666527182919708e-08
for O 0 4.717370938323029e-09
BRCA1 O 0 3.4336611776097925e-08
in O 0 2.4558840294730544e-08
DNA O 0 1.6361108237106237e-06
repair O 0 0.00012873199011664838
. O 0 1.0177427611779422e-06

Here O 0 8.333568985108286e-06
, O 0 1.4055612673757878e-08
it O 0 7.523581202484309e-10
is O 0 7.395589141090397e-10
shown O 0 1.0817726714407172e-09
that O 0 2.7718333184267863e-10
mouse O 0 2.6139558073623448e-08
embryonic O 0 2.3867254839160523e-08
stem O 0 8.45454550812974e-08
cells O 0 1.0109312853501251e-07
deficient B-Disease 0 3.6794517654925585e-07
in I-Disease 0 6.656938111859745e-09
BRCA1 I-Disease 0 1.343113265050988e-08
are O 0 2.5134883063770985e-10
defective O 0 4.060961344976022e-09
in O 0 1.6301460181722405e-09
the O 0 3.2554900997183722e-09
ability O 0 1.9590575828232204e-09
to O 0 1.204794597420289e-09
carry O 0 3.449031726887597e-09
out O 0 1.362033508200966e-08
transcription O 0 1.634977024878026e-06
- O 0 1.7394052065355936e-07
coupled O 0 7.988128913893888e-07
repair O 0 2.2750211883248994e-06
of O 0 1.5983036405486928e-07
oxidative O 0 4.463221102923853e-06
DNA O 0 4.984961833542911e-06
damage O 0 0.00010102015221491456
, O 0 2.2546595701555816e-09
and O 0 3.1308458048329157e-09
are O 0 4.541958364967513e-09
hypersensitive O 0 6.05128548158973e-07
to O 0 2.0451496496320942e-08
ionizing O 0 0.00013915807357989252
radiation O 0 7.309295324375853e-05
and O 0 7.562848125530763e-09
hydrogen O 0 5.536299596542449e-08
peroxide O 0 1.8287083776158397e-06
. O 0 1.0818288274094812e-06

These O 0 2.4674443466210505e-07
results O 0 1.6367570765396522e-07
suggest O 0 7.948614921815533e-08
that O 0 4.4534376186788904e-09
BRCA1 O 0 1.9355223201955596e-08
participates O 0 9.54758050397686e-09
, O 0 6.813863362431505e-10
directly O 0 3.429071249172466e-09
or O 0 5.30899368911264e-09
indirectly O 0 1.7223497295049128e-08
, O 0 1.433898000335887e-09
in O 0 2.945481725191712e-08
transcription O 0 7.360944437095895e-06
- O 0 5.500847919392982e-07
coupled O 0 4.872882072959328e-06
repair O 0 6.606599527003709e-06
of O 0 3.2176814102058415e-07
oxidative O 0 1.4372864825418219e-05
DNA O 0 1.0941284017462749e-05
damage O 0 1.966326635738369e-05
. O 0 1.2375511282414209e-08
. O 0 5.909196687525764e-08

Truncation O 0 0.00026615464594215155
mutations O 0 9.150350024356158e-07
in O 0 6.795504248202633e-08
the O 0 1.466702599373093e-07
transactivation O 0 6.614657468162477e-05
region O 0 6.636984721808403e-07
of O 0 1.1297371429463965e-06
PAX6 O 0 0.0027934678364545107
result O 0 2.763725603927014e-07
in O 0 5.879988052015506e-08
dominant O 0 1.2833942264478537e-06
- O 0 3.4237575619044947e-07
negative O 0 3.156114019020606e-07
mutants O 0 1.1064913678637822e-06
. O 0 1.0940744488152632e-07

PAX6 O 0 0.007585521787405014
is O 0 8.430445745943871e-07
a O 0 6.499539608739724e-07
transcription O 0 2.679259296201053e-06
factor O 0 5.0197694889675404e-08
with O 0 7.217370034950932e-10
two O 0 9.980941406695365e-09
DNA O 0 2.2417111722461414e-07
- O 0 2.022407272761484e-07
binding O 0 3.65202623697769e-08
domains O 0 4.817329113393498e-07
( O 0 6.6614851412794e-09
paired O 0 8.056677991419292e-09
box O 0 1.3868169901343208e-07
and O 0 1.128644200321105e-08
homeobox O 0 1.7175131006297306e-06
) O 0 5.124966229175243e-09
and O 0 1.5982319911955756e-09
a O 0 5.96450036027818e-08
proline O 0 4.0298613157574437e-07
- O 0 4.5757113298350305e-07
serine O 0 1.1437018656579312e-06
- O 0 1.1877984888997162e-06
threonine O 0 3.3628757591941394e-06
( O 0 5.032826777551236e-08
PST O 0 4.584776434057858e-06
) O 0 2.2959220302709582e-08
- O 0 1.0029035024672339e-07
rich O 0 2.2542526778579486e-07
transactivation O 0 0.00035885872785001993
domain O 0 2.0041887182742357e-05
. O 0 2.56696495171127e-07

PAX6 O 1 0.9999964237213135
regulates O 0 0.0007103114621713758
eye O 0 0.003767484100535512
development O 0 2.086851054627914e-06
in O 0 1.8961030079367447e-08
animals O 0 6.268781049811878e-09
ranging O 0 1.0142299800008914e-07
from O 0 2.6989644297259474e-08
jellyfish O 0 1.757251411049765e-08
to O 0 2.1534309890824943e-09
Drosophila O 0 5.5485831040869016e-08
to O 0 1.715800834745096e-09
humans O 0 4.679082366010334e-08
. O 0 4.445632129090882e-08

Heterozygous O 0 2.037252670561429e-05
mutations O 0 1.41008897003303e-07
in O 0 1.2630600565444183e-08
the O 0 4.4237836505089945e-08
human O 0 9.227908748243863e-08
PAX6 O 0 0.00026487320428714156
gene O 0 1.4783710922117166e-09
result O 0 6.890712445084546e-10
in O 0 1.1781493836071633e-10
various O 0 5.055990071056726e-10
phenotypes O 0 6.372593475134636e-08
, O 0 9.727624261657297e-10
including O 0 9.488850594152609e-09
aniridia B-Disease 1 1.0
, O 0 2.51722462962789e-06
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 5.621638479169633e-07
autosomal B-Disease 0 0.0005706304800696671
dominant I-Disease 0 0.0021109350491315126
keratitis I-Disease 1 0.999990701675415
, O 0 3.762324070066825e-07
and O 0 7.651337000424974e-06
familial B-Disease 1 1.0
foveal I-Disease 1 1.0
dysplasia I-Disease 1 1.0
. O 0 0.0007856509182602167

It O 0 2.133512282398442e-07
is O 0 1.900959034628613e-08
believed O 0 2.0172135961615822e-08
that O 0 4.787681917584052e-10
the O 0 4.428289734903501e-09
mutated O 0 1.0048140097751457e-08
allele O 0 1.361862000948122e-08
of O 0 6.292466991908441e-08
PAX6 O 0 7.055027526803315e-05
produces O 0 6.755401127378491e-09
an O 0 3.993818165071161e-09
inactive O 0 3.4386786751383625e-07
protein O 0 3.2413655048912915e-07
and O 0 4.4583099878536814e-08
aniridia B-Disease 1 1.0
is O 0 4.4267386556384736e-07
caused O 0 2.450066745041113e-07
due O 0 2.276937038914184e-07
to O 0 7.101037624579476e-08
genetic O 0 4.651205472328002e-06
haploinsufficiency O 0 0.00020664441399276257
. O 0 9.946251111614401e-07

However O 0 4.964165327692172e-07
, O 0 1.328722021298745e-08
several O 0 4.548963872252898e-09
truncation O 0 2.1304369965946535e-06
mutations O 0 2.0113162690904574e-08
have O 0 1.0901177738276147e-09
been O 0 4.463386993336371e-09
found O 0 1.338111177418e-09
to O 0 6.559956466922756e-10
occur O 0 4.133039688269946e-09
in O 0 6.712412847775795e-09
the O 0 1.1512883446584965e-07
C O 0 0.000694859481882304
- O 0 2.3111783775675576e-06
terminal O 0 6.88902275669534e-07
half O 0 3.6708886597125456e-08
of O 0 1.5198601488464192e-07
PAX6 O 0 0.0001821068290155381
in O 0 3.6668790670546514e-08
patients O 0 6.646610373195472e-09
with O 0 1.2205503274742568e-09
Aniridia B-Disease 1 1.0
resulting O 0 1.3685703947885486e-07
in O 0 5.496420207862229e-09
mutant O 0 1.518777104081437e-08
proteins O 0 8.737733869779163e-10
that O 0 5.486506041152417e-11
retain O 0 2.3032544760326346e-09
the O 0 1.2634744805950504e-08
DNA O 0 6.592348711365048e-08
- O 0 1.2382641578767561e-08
binding O 0 1.1409881928159393e-08
domains O 0 7.682051972324189e-08
but O 0 1.3724272829307438e-09
have O 0 1.0320220233950295e-09
lost O 0 3.645081392278371e-07
most O 0 1.3602724502348451e-09
of O 0 1.9411862339779873e-08
the O 0 1.5937038710944762e-07
transactivation O 0 0.00012592284474521875
domain O 0 9.030378350871615e-06
. O 0 1.5574599387946364e-07

It O 0 1.1106593689191868e-07
is O 0 8.879537105599411e-09
not O 0 8.167081455567882e-10
clear O 0 4.20209911311531e-09
whether O 0 1.6015152537462995e-09
such O 0 3.324806208127029e-09
mutants O 0 1.7698522469800082e-06
really O 0 2.1680033057691617e-07
behave O 0 2.387126230019021e-08
as O 0 1.1664319288229308e-08
loss O 0 3.4624738987076853e-07
- O 0 2.5736937914189184e-07
of O 0 3.0314697596622864e-06
- O 0 9.158196917269379e-06
function O 0 3.637226882347022e-06
mutants O 0 1.82848182816997e-07
as O 0 8.735105083701455e-09
predicted O 0 8.609728041619746e-08
by O 0 7.296424797686996e-08
haploinsufficiency O 0 6.547743396367878e-05
. O 0 1.1161579323015758e-06

Contrary O 0 1.773987060005311e-05
to O 0 1.9106098037013908e-08
this O 0 2.2074602146204825e-09
theory O 0 1.2636810708954727e-07
, O 0 7.523351386318211e-10
our O 0 1.0765943692092605e-08
data O 0 5.381154721817438e-08
showed O 0 3.404885706714822e-09
that O 0 4.980099319040754e-11
these O 0 1.3818036992407912e-10
mutants O 0 1.8176272931214044e-08
are O 0 2.4231527895324234e-10
dominant O 0 5.43590861212806e-09
- O 0 4.714725942989162e-09
negative O 0 5.396302071858372e-09
in O 0 1.7732029178318953e-09
transient O 0 5.43583837497863e-07
transfection O 0 5.151420054971823e-07
assays O 0 3.403043180583154e-08
when O 0 7.052052719558333e-09
they O 0 3.5595069114435773e-09
are O 0 2.0750701157368212e-09
coexpressed O 0 3.976744267220056e-07
with O 0 6.076188885373313e-09
wild O 0 7.038315175122989e-07
- O 0 1.252954280062113e-05
type O 0 1.557288851472549e-05
PAX6 O 0 0.020065056160092354
. O 0 1.4687492466691765e-06

We O 0 3.761592211048992e-07
found O 0 2.0604352002351334e-08
that O 0 6.844604327760351e-10
the O 0 1.9478994417454487e-08
dominant O 0 2.163830714607684e-07
- O 0 5.75894922860698e-08
negative O 0 1.5496809169235348e-08
effects O 0 3.3613570593615805e-08
result O 0 3.733491293900215e-09
from O 0 1.053449327770295e-09
the O 0 1.89067050904157e-09
enhanced O 0 1.4126323222285464e-08
DNA O 0 5.771768396556354e-09
binding O 0 5.93368798540439e-10
ability O 0 9.82810832717007e-10
of O 0 6.18021545051306e-09
these O 0 3.12911474509292e-09
mutants O 0 9.524445090391964e-07
. O 0 1.474905388931802e-07

Kinetic O 0 5.8353220083517954e-05
studies O 0 1.4855847894068575e-06
of O 0 1.2591819142926397e-07
binding O 0 5.09292874539824e-08
and O 0 2.332219750655895e-08
dissociation O 0 3.00140004583227e-06
revealed O 0 3.665369376903982e-07
that O 0 1.0684398921156912e-09
various O 0 6.9908234756610454e-09
truncation O 0 1.0176156592933694e-06
mutants O 0 1.634733877153849e-07
have O 0 1.4882987064979147e-09
3 O 0 2.664078380121282e-08
- O 0 2.1719657183894014e-08
5 O 0 9.531989775268812e-08
- O 0 2.379579910893881e-08
fold O 0 1.685104145110472e-08
higher O 0 9.157943736681773e-09
affinity O 0 1.559075313295466e-09
to O 0 1.8208698437938153e-10
various O 0 4.692063404476698e-10
DNA O 0 1.3702047496622072e-08
- O 0 2.681102895252252e-09
binding O 0 7.843037885812976e-10
sites O 0 9.924178145936935e-10
when O 0 3.744272392136594e-10
compared O 0 1.2362881829375283e-09
with O 0 4.79736909919648e-11
the O 0 2.1536621375162213e-08
wild O 0 1.5067659830947377e-07
- O 0 8.566807991883252e-07
type O 0 1.5830986512810341e-06
PAX6 O 0 0.0007159553351812065
. O 0 9.68262952483201e-07

These O 0 1.7012344244449196e-07
results O 0 9.405139422824504e-08
provide O 0 2.532170562119518e-08
a O 0 1.638713520435431e-08
new O 0 3.451163799184087e-09
insight O 0 1.6340339925591252e-07
into O 0 7.728312212407218e-09
the O 0 1.159411677775779e-08
role O 0 9.744123019572726e-08
of O 0 3.0131448625070334e-07
mutant O 0 9.450718607695308e-06
PAX6 O 0 0.0037867671344429255
in O 0 9.551915809424827e-07
causing O 0 1.8774364434648305e-05
aniridia B-Disease 1 1.0
. O 0 3.681547298128862e-07
. O 0 5.510530058927543e-07

Reversal O 0 0.00016438895545434207
of O 0 1.0403337910247501e-05
severe O 1 0.9999923706054688
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
and O 0 4.926172323393985e-07
excellent O 0 1.5758022300360608e-06
neuropsychologic O 0 1.02807844086783e-05
outcome O 0 3.335247242830519e-07
in O 0 4.2273757827615555e-08
very B-Disease 0 7.726842454758298e-08
- I-Disease 0 8.445671255685738e-07
long I-Disease 0 1.5643088318029186e-06
- I-Disease 0 1.612703499631607e-06
chain I-Disease 0 5.49787955606007e-07
acyl I-Disease 0 6.426189429475926e-07
- I-Disease 0 7.806002031429671e-07
coenzyme I-Disease 0 1.6819242318888428e-06
A I-Disease 0 7.765087502775714e-05
dehydrogenase I-Disease 0 0.00016421551117673516
deficiency I-Disease 0 0.07303968071937561
. O 0 3.893765949669614e-07

Very B-Disease 0 3.2807952266011853e-06
- I-Disease 0 4.1414332372369245e-06
long I-Disease 0 6.212879384293046e-07
- I-Disease 0 3.2497291613253765e-07
chain I-Disease 0 1.9313631582917878e-07
acyl I-Disease 0 1.862691760834423e-07
- I-Disease 0 1.4609162235501572e-07
coenzyme I-Disease 0 3.027457182724902e-07
A I-Disease 0 1.877291765595146e-06
dehydrogenase I-Disease 0 5.345076488083578e-07
( I-Disease 0 3.1611257611530164e-08
VLCAD I-Disease 0 0.0003920481540262699
) I-Disease 0 7.019419001608185e-08
deficiency I-Disease 0 2.230719655926805e-05
is O 0 1.0214787238282952e-08
a O 0 1.5206721570848458e-07
disorder O 0 0.0003449830401223153
of O 0 2.1801812181365676e-05
fatty O 0 9.38680095714517e-05
acid O 0 5.550956120714545e-05
beta O 0 2.0158990082563832e-05
oxidation O 0 4.039425860469237e-08
that O 0 8.699751474772199e-10
reportedly O 0 1.60559636697144e-08
has O 0 2.9242855359434827e-10
high O 0 6.113855643974375e-09
rates O 0 1.0204759703924537e-08
of O 0 2.1664835259116444e-08
morbidity O 0 1.1990901839453727e-05
and O 0 4.3634393875890964e-08
mortality O 0 3.097953958786093e-05
. O 0 3.190601773894741e-07

We O 0 5.590762270912819e-07
describe O 0 6.337502327369293e-07
the O 0 8.179591759471805e-08
outcome O 0 2.1290874485657696e-07
of O 0 1.1820877432455745e-07
a O 0 4.140995812917936e-08
5 O 0 3.622728073082726e-08
- O 0 4.793294650085045e-09
year O 0 7.043651439886389e-09
- O 0 4.446845025540824e-08
old O 0 4.009880285593681e-07
girl O 0 2.9308048397069797e-06
with O 0 3.290052461579762e-07
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 1.5624870002284297e-06
was O 0 3.5155017030774616e-06
first O 0 1.8804439605446532e-07
seen O 0 1.2911426949813176e-07
at O 0 1.6975766925497737e-07
5 O 0 1.3957326849833862e-08
months O 0 3.44336559265912e-09
of O 0 6.357379067623015e-09
age O 0 3.7328952373627544e-08
with O 0 1.4408018778055975e-08
severe O 1 0.999841570854187
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
, O 0 0.00015448883641511202
hepatomegaly B-Disease 1 1.0
, O 0 0.04942883178591728
encephalopathy B-Disease 1 0.9992524981498718
, O 0 1.7092482949010446e-06
and O 0 2.4570783352828585e-05
hypotonia B-Disease 1 0.9999722242355347
. O 0 9.040530858328566e-05

Biochemical O 0 0.0055654896423220634
studies O 0 0.001298641669563949
indicated O 1 0.9994230270385742
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 0.02228694222867489
by O 0 1.581602582234609e-08
a O 0 4.839080602891954e-08
stable O 0 2.86008088323797e-07
yet O 0 1.6046350026499567e-08
inactive O 0 1.912004563564551e-06
enzyme O 0 6.581191769328143e-07
. O 0 2.0361476060770656e-07

Molecular O 0 7.117072527762502e-05
genetic O 0 3.293727104392019e-06
analysis O 0 7.206701866380172e-07
of O 0 1.1785077731474303e-06
her O 0 8.093636097328272e-06
VLCAD O 1 0.9978322386741638
gene O 0 1.6350394105302257e-07
revealed O 0 1.0251324056298472e-06
a O 0 4.444030139438837e-07
T1372C O 0 2.581370381449233e-06
( O 0 5.481597753487222e-08
F458L O 0 2.1174614630581345e-06
) O 0 5.1563155523126625e-08
missense O 0 2.1254204511933494e-06
mutation O 0 5.443516570835527e-08
and O 0 2.7053088658135493e-08
a O 0 3.615991545302677e-06
1668 O 1 0.8675614595413208
ACAG O 1 0.9999825954437256
1669 O 1 0.5883991718292236
splice O 0 0.0005657734582200646
site O 0 4.524496489466401e-06
mutation O 0 3.1597818406225997e-07
. O 0 3.0171906928444514e-07

After O 0 3.3145258271360944e-07
initial O 0 1.4263270031733555e-07
treatment O 0 9.166297054719053e-09
with O 0 1.039041630512827e-09
intravenous O 0 3.82475121796233e-07
glucose O 0 3.12842939820257e-06
and O 0 3.9320871003667435e-09
carnitine O 0 3.3696398986649e-06
, O 0 2.3182704644852947e-09
the O 0 2.939762389075895e-08
patient O 0 8.733615572964482e-07
has O 0 9.928570188222352e-10
thrived O 0 8.662306072437786e-08
on O 0 1.453992304334406e-08
a O 0 4.60561722093189e-08
low O 0 8.078737891992205e-07
- O 0 1.068461159547951e-07
fat O 0 9.208967810536706e-09
diet O 0 2.297226187053525e-09
supplemented O 0 4.010956011768485e-09
with O 0 1.421179007810025e-10
medium O 0 4.038163581299159e-07
- O 0 8.923034897634352e-07
chain O 0 2.8271267638046993e-07
triglyceride O 0 4.7159025484688755e-07
oil O 0 1.1012257346010301e-06
and O 0 2.039964286382201e-08
carnitine O 0 1.0924028174486011e-05
and O 0 4.488942551006403e-08
avoidance O 0 2.9121601983206347e-06
of O 0 1.123051333706826e-06
fasting O 0 2.1315738194971345e-05
. O 0 8.326977081196674e-07

Her O 0 0.0015275445766746998
ventricular O 1 0.9916561841964722
hypertrophy O 0 0.0012313881888985634
resolved O 0 9.476313607592601e-06
significantly O 0 1.3241130147889635e-07
over O 0 9.710204196267114e-09
1 O 0 1.7242758332258745e-08
year O 0 1.2881946620524332e-09
, O 0 4.165485456564255e-10
and O 0 1.4352168342668392e-09
cognitively O 0 1.3416429283097386e-05
, O 0 3.4576341789716025e-09
she O 0 1.27035892916183e-08
is O 0 2.3595707610013505e-09
in O 0 1.0480502021792404e-09
the O 0 3.2689424500631503e-09
superior O 0 2.579656843693101e-08
range O 0 4.188290247952864e-08
for O 0 2.0361159869253243e-08
age O 0 1.7615454908082029e-06
. O 0 5.669523943652166e-07

Clinical O 0 0.012383271008729935
recognition O 0 2.328035952814389e-05
of O 1 0.999997615814209
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 5.7836559790303e-06
important O 0 9.534990397241927e-08
because O 0 1.743828415001758e-09
it O 0 2.618738836890344e-10
is O 0 9.211457707714032e-10
one O 0 7.15092651759619e-10
of O 0 3.1505422715127906e-09
the O 0 5.006723924338985e-09
few O 0 7.330960727358615e-09
directly O 0 5.8084363985244636e-08
treatable O 0 8.465041173622012e-05
causes O 0 9.111582244258898e-07
of O 0 0.00033535942202433944
cardiomyopathy B-Disease 1 1.0
in O 0 1.8393637901681359e-06
children O 0 4.341928772078063e-08
. O 0 1.4583696028580562e-08
. O 0 1.2693567441601772e-07

Cloning O 0 2.0824869352509268e-05
of O 0 4.7671662173343066e-07
a O 0 1.303460095414266e-07
novel O 0 1.4263365244460147e-07
member O 0 6.902597249336395e-08
of O 0 8.774785698051346e-08
the O 0 1.7862701895410282e-07
low O 0 5.508509730134392e-06
- O 0 8.253938403868233e-07
density O 0 3.9114667060857755e-07
lipoprotein O 0 3.685470801428892e-05
receptor O 0 3.8074463191151153e-06
family O 0 3.0175243637131643e-07
. O 0 7.832371551330652e-08

A O 0 4.939165137329837e-06
gene O 0 3.4016025551864004e-08
encoding O 0 1.4903987377579142e-08
a O 0 4.626386740369526e-08
novel O 0 2.5823109695011226e-07
transmembrane O 0 2.842302819772158e-06
protein O 0 3.0507941062296595e-08
was O 0 1.680299632766946e-08
identified O 0 7.516638422799815e-10
by O 0 1.7534462770640857e-10
DNA O 0 7.721958628081893e-10
sequence O 0 9.67603330792599e-10
analysis O 0 1.074470623585455e-09
within O 0 9.961728109075807e-10
the O 0 3.627642408687848e-09
insulin B-Disease 0 1.4695365280203987e-06
- I-Disease 0 9.811671770876274e-05
dependent I-Disease 1 0.9941337704658508
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 7.143153652577894e-06
IDDM B-Disease 0 0.12525950372219086
) O 0 8.533558570889e-08
locus O 0 1.1107044883829076e-06
IDDM4 O 0 8.418535799137317e-06
on O 0 1.7234809490673797e-07
chromosome O 0 1.1046420240745647e-06
11q13 O 0 6.899674190208316e-06
. O 0 5.619419312097307e-07

Based O 0 6.659829523414373e-07
on O 0 1.2731852905289998e-07
its O 0 5.353266274710222e-09
chromosomal O 0 4.3102727431687526e-07
position O 0 1.3774283047496283e-07
, O 0 3.5022371669413133e-09
this O 0 3.5542424559054098e-09
gene O 0 1.2722641828943893e-09
is O 0 7.76176845018739e-10
a O 0 3.3680684907722025e-09
candidate O 0 1.366602275787443e-09
for O 0 9.302137948807854e-10
conferring O 0 2.830455514413188e-07
susceptibility O 0 4.137903488299344e-06
to O 0 4.1768828396016033e-07
diabetes B-Disease 1 0.9999967813491821
. O 0 9.424710469829733e-07

The O 0 4.955569238518365e-06
gene O 0 2.844586504124891e-07
, O 0 1.8060676509890072e-08
termed O 0 7.478840302610479e-07
low O 0 2.7680864150170237e-05
- O 0 3.6960871057090117e-06
density O 0 3.950198674829153e-07
lipoprotein O 0 4.6785744416411035e-06
receptor O 0 1.9915236748602183e-07
related O 0 1.5625502669536218e-08
protein O 0 9.28190324600564e-09
5 O 0 1.5940315734042088e-08
( O 0 2.2654145226397304e-09
LRP5 O 0 1.1260777910138131e-06
) O 0 7.615896802093403e-10
, O 0 1.9291221398098912e-10
encodes O 0 6.376238648186927e-09
a O 0 1.8541512769587598e-09
protein O 0 3.936071468757518e-09
of O 0 2.289157485790838e-08
1615 O 0 2.3200329451356083e-05
amino O 0 1.6653426371249225e-07
acids O 0 6.993784218423116e-09
that O 0 1.8888170194575338e-10
contains O 0 1.2244070202171997e-09
conserved O 0 1.4636341916229867e-07
modules O 0 2.1877322353702766e-07
which O 0 3.5911468243554623e-10
are O 0 1.8332549367450213e-10
characteristic O 0 5.5766968820591956e-09
of O 0 3.826421846042649e-08
the O 0 9.029768932578008e-08
low O 0 4.045211881020805e-06
- O 0 9.302968351221352e-07
density O 0 2.7039502015213657e-07
lipoprotein O 0 9.162530659523327e-06
( O 0 2.1861909260678658e-07
LDL O 0 6.612947345274733e-06
) O 0 1.9367556447491552e-08
receptor O 0 3.2137344874172413e-07
family O 0 4.379055695835632e-08
. O 0 2.326417636311362e-08

These O 0 3.2751606227066077e-07
modules O 0 4.268761585990433e-06
include O 0 6.073144476204106e-08
a O 0 3.100753360740782e-07
putative O 0 2.7264597974863136e-06
signal O 0 2.244894687919441e-07
peptide O 0 2.5383117829846924e-08
for O 0 1.296387663884957e-09
protein O 0 9.996068861539698e-09
export O 0 3.8705515237325017e-08
, O 0 2.7898416909977186e-09
four O 0 1.0187432231134608e-08
epidermal O 0 8.702246532266145e-07
growth O 0 4.0173819826350154e-08
factor O 0 9.090459229810222e-08
( O 0 1.4631784672758386e-08
EGF O 0 1.373786858493986e-06
) O 0 6.72365996212676e-10
repeats O 0 3.1074176565226708e-09
with O 0 5.98602389878522e-10
associated O 0 2.595237731384259e-07
spacer O 0 1.1041280231438577e-05
domains O 0 9.918818477672176e-07
, O 0 9.910299247906096e-09
three O 0 4.0015365243561973e-08
LDL O 0 3.6627031931857346e-06
- O 0 7.715736956015462e-07
receptor O 0 9.878057198875467e-07
( O 0 1.035417707129227e-08
LDLR O 0 3.249215978939901e-06
) O 0 3.7430747390487795e-09
repeats O 0 2.0243207998760226e-08
, O 0 8.666958262182334e-10
a O 0 2.8622357817198463e-08
single O 0 8.712313359637847e-08
transmembrane O 0 1.865235208242666e-05
spanning O 0 7.749379619781394e-06
domain O 0 2.2092102881288156e-05
, O 0 1.1148443057606983e-08
and O 0 1.839007346404742e-08
a O 0 1.084398832063016e-06
cytoplasmic O 0 9.222576045431197e-05
domain O 0 4.0864324546419084e-05
. O 0 6.113170343269303e-07

The O 0 2.72417264568503e-06
encoded O 0 1.289500232815044e-06
protein O 0 9.65428839094784e-08
has O 0 3.96336324870461e-10
a O 0 1.011327799282924e-09
unique O 0 2.171517188287453e-09
organization O 0 1.82608186349853e-08
of O 0 1.9565513866837136e-06
EGF O 0 0.04721711575984955
and O 0 3.929914882405683e-08
LDLR O 0 0.00038113820482976735
repeats O 0 1.9841398568587465e-07
; O 0 1.0742554623632827e-09
therefore O 0 1.8069911789098114e-08
, O 0 1.4348069399261476e-08
LRP5 O 0 7.739058492006734e-05
likely O 0 4.133168118869435e-08
represents O 0 1.3477118976368274e-08
a O 0 6.690159981559418e-09
new O 0 2.278101707275937e-09
category O 0 3.8878621921867307e-07
of O 0 1.5869321146055881e-07
the O 0 1.1509989690239308e-06
LDLR O 1 0.9757071137428284
family O 0 5.614947895082878e-06
. O 0 5.174868533686094e-07

Both O 0 1.4407379467229475e-06
human O 0 5.569539780481136e-07
and O 0 8.799942463610932e-08
mouse O 0 8.200044248951599e-06
LRP5 O 0 0.2539377510547638
cDNAs O 0 6.36679251329042e-05
have O 0 2.732934767379902e-09
been O 0 2.9840343529485835e-09
isolated O 0 7.854913164351274e-09
and O 0 1.0192397620345517e-10
the O 0 2.5849549167844543e-09
encoded O 0 7.072446628342277e-09
mature O 0 1.8927632794429883e-09
proteins O 0 1.4798484659905853e-10
are O 0 1.0422725876813033e-10
95 O 0 1.7521642803330906e-08
% O 0 1.102679614284341e-09
identical O 0 3.6590452889839753e-09
, O 0 1.706561003622653e-09
indicating O 0 7.402412194323915e-08
a O 0 1.9871139400606808e-08
high O 0 1.9978692478161975e-08
degree O 0 5.411450274550589e-07
of O 0 2.631916018458469e-08
evolutionary O 0 1.2520939662863384e-07
conservation O 0 1.2857700681934148e-08
. O 0 9.759906216544323e-10
. O 0 2.684209832182205e-08

The O 0 1.5371777408290654e-05
APC B-Disease 0 6.763746114302194e-06
variants O 0 1.7908959648593736e-07
I1307K O 0 1.7561109189045965e-06
and O 0 2.6005192665934374e-08
E1317Q O 0 3.3333599276375026e-06
are O 0 9.976221626573079e-09
associated O 0 1.7381897123414092e-05
with O 1 0.9999990463256836
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 1 0.5515088438987732
but O 0 3.0554527796766706e-08
not O 0 3.739677900682636e-09
always O 0 1.957586981404802e-08
with O 0 3.85642318079249e-09
a O 0 3.8993471207504626e-07
family O 0 3.384311355603131e-07
history O 0 3.368807711012778e-06
. O 0 4.668162603138626e-07

Classical O 1 0.9999992847442627
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.9712763428688049
FAP B-Disease 0 0.0002072505740216002
) O 0 3.572472451196518e-08
is O 0 4.525666508214954e-09
a O 0 1.5742415371278184e-07
high O 0 0.2973472774028778
- O 1 1.0
penetrance O 1 1.0
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disease I-Disease 1 0.9884006977081299
that O 0 5.117952728284081e-09
predisposes O 0 4.769435690832324e-07
to O 0 4.6801686970354694e-09
hundreds O 0 4.696891320321583e-09
or O 0 1.2598360576987488e-08
thousands O 0 3.634181666711811e-08
of O 1 0.8861035704612732
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 1.0
carcinoma I-Disease 1 1.0
and O 0 1.1407576216981852e-08
that O 0 2.278695843127565e-10
results O 0 2.451913783119153e-09
from O 0 4.460416924700894e-09
truncating O 0 3.5264912412458216e-07
mutations O 0 1.2941592242299294e-09
in O 0 9.001615453030354e-09
the O 0 2.3065797449817182e-07
APC B-Disease 0 2.794892907331814e-06
gene O 0 6.135937269391434e-08
. O 0 4.4319083514210433e-08

A O 0 6.9282054937502835e-06
variant O 0 9.875109299173346e-07
of O 0 1.6148304666785407e-06
FAP B-Disease 0 6.527344521600753e-05
is O 0 9.642626537242904e-07
attenuated B-Disease 0 0.1099943146109581
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999997615814209
coli I-Disease 1 0.9999971389770508
, O 0 1.2087057577048199e-08
which O 0 4.222399652142883e-10
results O 0 1.8401747903240562e-09
from O 0 1.154726358976177e-08
germ O 0 0.00033120851730927825
- O 0 5.8156801969744265e-06
line O 0 2.611218405945692e-07
mutations O 0 2.1174344499996778e-09
in O 0 2.676437960147382e-09
the O 0 1.7017935505236892e-08
5 O 0 1.228149937304579e-08
and O 0 2.9256244649111807e-10
3 O 0 8.259227968210325e-09
regions O 0 1.4405152626295603e-09
of O 0 2.4750608673684837e-08
the O 0 4.0871316286938963e-07
APC B-Disease 0 4.071631337865256e-06
gene O 0 1.4113025770257082e-07
. O 0 4.403587894330485e-08

Attenuated B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
patients O 0 0.0012534070992842317
have O 0 5.734043906358011e-09
" O 0 1.0614088807869848e-07
multiple O 0 1.1148739758937154e-05
" O 1 0.9999990463256836
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 6.840851796141578e-08
typically O 0 1.0363024882664718e-09
fewer O 0 1.6601486851897107e-10
than O 0 1.0849771081566928e-10
100 O 0 5.305895722784726e-09
) O 0 1.830787882406426e-10
without O 0 5.78354530933467e-10
the O 0 4.384569596282972e-09
florid O 0 5.546392571886827e-07
phenotype O 0 9.241964704642669e-08
of O 0 1.011747272627872e-07
classical O 0 1.6921059796004556e-05
FAP B-Disease 0 1.6531485016457736e-05
. O 0 3.2316398801413015e-07

Another O 0 8.025383976928424e-06
group O 0 8.146754737481388e-08
of O 0 1.5745089854135585e-07
patients O 0 4.496809324905371e-08
with O 0 3.2032034802398357e-09
multiple O 0 2.869544232453336e-06
adenomas B-Disease 1 0.9681283831596375
has O 0 2.3379909119825015e-09
no O 0 2.1414057194135694e-09
mutations O 0 5.623906340623819e-10
in O 0 1.8142354285544116e-09
the O 0 6.634403604266481e-08
APC B-Disease 0 4.4893749873153865e-07
gene O 0 2.9830327097357667e-09
, O 0 2.983167879389015e-10
and O 0 3.5150976573916637e-10
their O 0 2.2545647571092786e-09
phenotype O 0 2.880170946184535e-08
probably O 0 4.9212109942686766e-09
results O 0 1.6898025201328437e-09
from O 0 3.116023661320355e-09
variation O 0 2.2623282802669564e-08
at O 0 1.7104895277952892e-07
a O 0 6.50767120191631e-08
locus O 0 9.863873629001318e-08
, O 0 4.571907574746348e-10
or O 0 6.547256070632557e-10
loci O 0 1.3672488696769847e-09
, O 0 3.670689308066244e-10
elsewhere O 0 1.0941741734882271e-08
in O 0 4.902455330579869e-09
the O 0 6.445977618341203e-08
genome O 0 2.4581672164458723e-07
. O 0 1.4718463603458076e-07

Recently O 0 8.087926289590541e-06
, O 0 1.0149940443682226e-08
however O 0 4.197501457525732e-09
, O 0 1.750523392907155e-09
a O 0 3.254634961535885e-08
missense O 0 3.4240807167407183e-07
variant O 0 6.368328087091868e-08
of O 0 2.6746308776637306e-06
APC B-Disease 0 6.772123924747575e-06
( O 0 1.6085411402855243e-07
I1307K O 0 1.8384482700639637e-06
) O 0 2.9338192319983136e-08
was O 0 3.0510099691127834e-07
described O 0 6.196364665811416e-08
that O 0 1.7344408131947375e-09
confers O 0 1.2405051208475015e-08
an O 0 8.768987758145386e-10
increased O 0 1.9500332015809363e-08
risk O 0 1.228530345542822e-05
of O 1 1.0
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 3.5996242786495714e-06
including O 0 1.490452916641516e-08
multiple O 0 4.5308550511435897e-07
adenomas B-Disease 0 0.0003846864856313914
, O 0 7.1678076807302205e-09
in O 0 9.778323573073067e-08
Ashkenazim O 0 6.861117435619235e-05
. O 0 7.488383175768831e-07

We O 0 2.292462113473448e-06
have O 0 1.8799699574856277e-08
studied O 0 2.543010566569137e-07
a O 0 3.234837109289401e-08
set O 0 1.2988337516617321e-08
of O 0 3.5922584906700195e-09
164 O 0 5.8877311914784514e-08
patients O 0 1.0585693432929588e-09
with O 0 3.8299519111717473e-10
multiple O 1 0.8980125188827515
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9998650550842285
/ I-Disease 1 1.0
or I-Disease 1 0.9801884889602661
carcinoma I-Disease 1 1.0
and O 0 1.9022973418714173e-08
analyzed O 0 7.181255341492943e-07
codons O 0 5.827550353387778e-07
1263 O 0 1.1608759450609796e-05
- O 0 3.3204040050804906e-07
1377 O 0 5.675648935721256e-06
( O 0 4.010988874370014e-08
exon O 0 1.587349771625668e-07
15G O 0 6.106574232944695e-07
) O 0 2.3747090960313244e-09
of O 0 1.2697388029891954e-08
the O 0 1.6369912714253587e-07
APC B-Disease 0 5.857879159520962e-07
gene O 0 5.002724456915075e-09
for O 0 1.1943710021000697e-08
germ O 0 0.0034346042666584253
- O 0 0.0005019274540245533
line O 0 3.0313221941469237e-06
variants O 0 6.53683059681498e-07
. O 0 2.8824550213357725e-07

Three O 0 1.8977838180944673e-06
patients O 0 1.6493686416652054e-08
with O 0 9.280181068049842e-10
the O 0 1.5315922041736485e-07
I1307K O 0 2.9210216325736837e-06
allele O 0 1.3605742310573987e-08
were O 0 7.307646487930697e-09
detected O 0 1.8604437101998883e-08
, O 0 5.806691238952055e-10
each O 0 1.4090176803094323e-09
of O 0 1.5001232611666637e-07
Ashkenazi O 0 1.9079925550613552e-05
descent O 0 5.252183473203331e-05
. O 0 1.8039180531559396e-06

Four O 0 1.0733961062214803e-05
patients O 0 5.5925816866420064e-08
had O 0 1.0771451997015902e-07
a O 0 6.252089974623232e-07
germ O 0 0.0020183452870696783
- O 0 0.00014691308024339378
line O 0 3.641270268417429e-06
E1317Q O 0 5.780877017969033e-06
missense O 0 1.4606433751396253e-06
variant O 0 1.3359586148453673e-07
of O 0 5.327905228114105e-07
APC O 0 4.6821580212963454e-07
that O 0 1.2001684090989784e-09
was O 0 6.645941397209754e-08
not O 0 1.0743661515988379e-09
present O 0 8.368021831017813e-09
in O 0 2.2664918830628267e-08
controls O 0 1.0400140837418803e-07
; O 0 7.630393539237446e-10
one O 0 1.7126979834358735e-09
of O 0 1.2321152098593302e-08
these O 0 3.3466929227898845e-09
individuals O 0 6.226477999859981e-09
had O 0 2.9429772396838416e-08
an O 0 6.598182888950532e-09
unusually O 0 1.1201772842639457e-08
large O 0 5.309722883595214e-09
number O 0 1.2842357399733828e-08
of O 0 2.95386570314804e-07
metaplastic B-Disease 0 0.0003247093700338155
polyps I-Disease 0 1.4167236486173351e-06
of I-Disease 0 6.240974244065001e-07
the I-Disease 0 2.0486459106905386e-06
colorectum I-Disease 0 0.0004849251126870513
. O 0 1.4363535001393757e-06

There O 0 1.3280046005093027e-06
is O 0 7.764600518100906e-09
increasing O 0 6.340256319958826e-09
evidence O 0 2.5747068477244284e-08
that O 0 6.494347837282533e-10
there O 0 5.546506809395169e-09
exist O 0 2.9508800736266494e-08
germ O 0 4.810488462680951e-06
- O 0 2.5274425752286334e-07
line O 0 5.1658350486150084e-08
variants O 0 6.404113239710796e-09
of O 0 1.6489535070718375e-08
the O 0 1.1207782080191464e-07
APC B-Disease 0 8.063520340328978e-07
gene O 0 2.9567266413010884e-09
that O 0 3.0309552090379555e-10
predispose O 0 6.953059994430077e-08
to O 0 1.6925830736980174e-09
the O 0 3.841220230782483e-09
development O 0 9.04059120898637e-08
of O 0 7.940611794765573e-07
multiple O 1 0.9999994039535522
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 1.0
carcinoma I-Disease 1 1.0
, O 0 1.2627686452049147e-08
but O 0 1.0795281335518325e-09
without O 0 5.0984176880319865e-09
the O 0 1.3026147271943955e-08
florid O 0 6.041609594831243e-07
phenotype O 0 5.405318148632432e-08
of O 0 5.975534378421798e-08
classical O 0 1.6191845134017058e-05
FAP B-Disease 0 1.5938574051688192e-06
, O 0 6.470324276364181e-10
and O 0 2.2290454204654253e-10
possibly O 0 6.779151462410482e-09
with O 0 6.52309928295125e-10
importance O 0 2.207965553679969e-05
for O 1 0.9902310967445374
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 1 0.9999890327453613
in O 0 1.7059891277426686e-08
the O 0 6.242959926794356e-09
general O 0 4.872847014780746e-09
population O 0 5.070978637000678e-10
. O 0 1.6316515916159346e-09
. O 0 2.8374440574907567e-08

Genomic O 0 1.68866099556908e-05
structure O 0 6.123404432401003e-07
of O 0 3.7443371070366993e-07
the O 0 3.1312649753090227e-06
human O 1 0.9995655417442322
congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 1.0
CLD B-Disease 1 1.0
) O 0 2.383828814345179e-06
gene O 0 3.631982110618992e-07
. O 0 2.7320353979121137e-07

Congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 1.0
CLD B-Disease 1 1.0
) O 0 2.8078363811800955e-06
is O 0 2.403179522048049e-08
caused O 0 4.95962169111408e-08
by O 0 7.436953719519579e-09
mutations O 0 7.279740366072929e-09
in O 0 1.0006790063243898e-08
a O 0 8.142016838519339e-08
gene O 0 3.3100822083298453e-09
which O 0 1.027730012204131e-09
encodes O 0 7.437594717885077e-08
an O 0 1.4222190536372636e-08
intestinal O 0 4.779138180310838e-06
anion O 0 6.480320007540286e-05
transporter O 0 0.002174447989091277
. O 0 1.9722385786735686e-06

We O 0 1.0020542049460346e-06
report O 0 1.797294970629082e-07
here O 0 9.488741348206986e-09
the O 0 4.069118375582548e-09
complete O 0 4.7536190095343045e-08
genomic O 0 1.8736362505933357e-07
organization O 0 3.032675621739145e-08
of O 0 3.0668417139168014e-07
the O 0 6.4482156858503e-07
human O 0 5.649840659316396e-06
CLD B-Disease 1 0.9994931221008301
gene O 0 1.1149591472303655e-08
which O 0 3.3815328315256465e-10
spans O 0 1.9855985300409884e-08
approximately O 0 8.48449133172835e-09
39kb O 0 7.086248388077365e-07
, O 0 1.6528067803278645e-09
and O 0 2.8223776649127785e-09
comprises O 0 1.5833205679882667e-07
21 O 0 1.8529042336012935e-06
exons O 0 2.21606865125068e-06
. O 0 2.274156969406249e-07

All O 0 4.529530087893363e-06
exon O 0 2.7300784495309927e-05
/ O 0 6.393658168235561e-06
intron O 0 4.662214450945612e-06
boundaries O 0 6.773635163881409e-08
conform O 0 2.1564021324138594e-07
to O 0 3.477278198715794e-08
the O 0 4.43898130697562e-07
GT O 0 8.227240323321894e-05
/ O 0 5.1747461839113384e-05
AG O 0 0.00017839217616710812
rule O 0 1.1071479093516245e-06
. O 0 4.364030701253796e-07

An O 0 2.2441925295879628e-07
analysis O 0 2.0639504327846225e-07
of O 0 6.535807983709674e-08
the O 0 2.0515851417712838e-07
putative O 0 1.562576107971836e-05
promoter O 0 3.5585219393396983e-06
region O 0 9.072150675137891e-08
sequence O 0 3.7524588947235316e-07
shows O 0 4.0556233216193505e-07
a O 0 1.0323473134121741e-06
putative O 0 2.833611870300956e-05
TATA O 0 9.510950621915981e-05
box O 0 7.722597956671962e-07
and O 0 4.985359680631518e-09
predicts O 0 1.3840768531281356e-07
multiple O 0 1.2291042139622732e-07
transcription O 0 9.189403499476612e-06
factor O 0 2.177225439936592e-07
binding O 0 3.877926246786956e-08
sites O 0 2.2682417011310463e-07
. O 0 1.343316284874163e-07

The O 0 1.5022336583569995e-06
genomic O 0 6.375310590556182e-07
structure O 0 3.366619125699799e-07
was O 0 2.763583495379862e-07
determined O 0 3.2463457699805076e-08
using O 0 5.078938158931123e-09
DNA O 0 1.2181903485952716e-08
from O 0 1.7228712900774212e-09
several O 0 6.456652434927435e-10
sources O 0 8.525468331299635e-09
including O 0 3.51336848503081e-10
multiple O 0 1.5899010996633933e-09
large O 0 3.761282840741842e-08
- O 0 6.946027610865713e-07
insert O 0 5.197946961743583e-07
libaries O 0 2.9875066047679866e-06
and O 0 3.7245582173994762e-09
genomic O 0 7.962271553196842e-08
DNA O 0 8.68742304760417e-08
from O 0 5.847397233083029e-08
Finnish O 0 0.431873083114624
CLD B-Disease 1 1.0
patients O 0 9.179245239465672e-07
and O 0 2.1048803588996634e-08
controls O 0 4.547009666566737e-07
. O 0 1.954125679048957e-07

Exon O 0 3.291495886514895e-05
- O 0 2.2358952378453978e-07
specific O 0 3.8692875570234264e-09
primers O 0 7.400746682151293e-08
developed O 0 1.063714805127347e-08
in O 0 1.1791594367593916e-09
this O 0 6.372332661541691e-10
study O 0 1.3120494690710416e-09
will O 0 5.0537119627991345e-11
facilitate O 0 1.0070698719388815e-09
mutation O 0 2.613479710422695e-10
screening O 0 3.1227453956006457e-10
studies O 0 1.6526491286583678e-09
of O 0 1.7877649360897863e-09
patients O 0 8.86822615342453e-10
with O 0 1.591872605954947e-10
the O 0 2.409039097983623e-06
disease O 0 0.03483861684799194
. O 0 1.5463628244560823e-07

Genomic O 0 4.081058250449132e-06
sequencing O 0 4.988967816643708e-07
of O 0 8.348621918230492e-07
a O 0 4.268631073500728e-06
BAC O 1 0.9290157556533813
clone O 0 0.0024645563680678606
H O 1 1.0
_ O 0 1.0996308930089072e-07
RG364P16 O 0 1.8497016753826756e-06
revealed O 0 2.08936910439661e-07
the O 0 1.378291081266525e-08
presence O 0 5.881117370876154e-09
of O 0 1.7860957157722623e-08
another O 0 1.693394402479953e-08
, O 0 2.0084285345944863e-09
highly O 0 7.647371624841526e-09
homologous O 0 3.1439526537724305e-08
gene O 0 1.5906927997022535e-09
3 O 0 2.343693594752949e-08
of O 0 4.107493367655479e-08
the O 0 5.319370757206343e-07
CLD B-Disease 1 0.9989500641822815
gene O 0 3.591534181168754e-08
, O 0 5.468309693945628e-10
with O 0 1.2631141965702142e-10
a O 0 6.190361112601295e-09
similar O 0 1.7707018074020198e-09
genomic O 0 7.66065966217866e-08
structure O 0 3.495722751267749e-07
, O 0 4.412186616065128e-09
recently O 0 1.9368073367331817e-08
identified O 0 2.8463768231290487e-08
as O 0 2.3460595244273463e-08
the O 0 2.488652626198018e-06
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 1.9327999325469136e-06
( O 0 5.639960818371037e-07
PDS B-Disease 0 2.5995332180173136e-06
) O 0 1.7015752140636664e-09
. O 0 1.4196814834832594e-09
. O 0 2.884414840309546e-08

The O 0 8.053843885136303e-06
APCI1307K O 0 0.0006684862892143428
allele O 0 3.1229990327119594e-07
and O 0 4.272249753967117e-08
cancer B-Disease 0 2.6276426069671288e-05
risk O 0 5.851553396496456e-06
in O 0 9.973904013804713e-08
a O 0 3.856220303077862e-07
community O 0 7.334163498740054e-09
- O 0 3.4036584661834013e-09
based O 0 1.4867865827383753e-09
study O 0 6.254521345283592e-09
of O 0 1.53198307373259e-08
Ashkenazi O 0 7.6281440897219e-07
Jews O 0 5.4660830528519e-07
. O 0 2.420723603790975e-07

Mutations O 0 1.8954649476654595e-06
in O 0 9.057747973884034e-08
APC O 0 3.508849033551087e-07
are O 0 9.838161396658052e-10
classically O 0 1.0068064284496359e-06
associated O 0 7.932104608698864e-07
with O 0 5.693652838090202e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.9998455047607422
FAP B-Disease 0 7.942510274006054e-05
) O 0 2.791640918431426e-09
, O 0 4.725517754877728e-10
a O 0 2.6721647117255998e-08
highly O 0 4.835698564420454e-05
penetrant O 1 1.0
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.9909317493438721
by O 0 1.8823328673533979e-06
multiple O 0 0.3164392113685608
intestinal O 1 0.9999991655349731
polyps B-Disease 0 1.874683039204683e-05
and O 0 2.6826896259990463e-08
, O 0 1.3967554224336709e-08
without O 0 3.881405064021237e-07
surgical O 1 0.9670722484588623
intervention O 1 0.7572380900382996
, O 0 2.9292342773601376e-08
the O 0 3.5040437751376885e-07
development O 1 0.9274646639823914
of O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 1 0.9999996423721313
CRC B-Disease 1 0.9997196793556213
) O 0 1.349657026139539e-07
. O 0 1.5143535847528256e-07

APC B-Disease 0 5.013793270336464e-05
is O 0 1.1886965722851528e-07
a O 0 9.341125064565858e-07
tumour O 1 1.0
- O 0 3.564931466826238e-05
suppressor O 0 3.0298799629235873e-06
gene O 0 1.8819819036508534e-09
, O 0 9.17975973013796e-11
and O 0 3.6586247920133985e-10
somatic O 0 1.758432546239419e-07
loss O 0 2.889078814405366e-06
occurs O 0 7.607968655065633e-07
in O 0 2.0520678845059592e-06
tumours B-Disease 1 1.0
. O 0 3.7423844787554117e-06

The O 0 5.956428594799945e-06
germline O 0 2.2794714823248796e-05
T O 0 1.5225178913169657e-06
- O 0 1.5910826789422572e-07
to O 0 5.736026764679991e-08
- O 0 4.4455475745053263e-07
A O 0 7.531943424510246e-07
transversion O 0 1.1567894944164436e-06
responsible O 0 5.813301839907581e-08
for O 0 5.0153263764229905e-09
the O 0 1.092491643817084e-07
APC O 0 1.0853092362594907e-06
I1307K O 0 3.741317584626813e-07
allele O 0 6.449984990553048e-09
converts O 0 4.394817398889472e-09
the O 0 3.6708029949039656e-09
wild O 0 4.582386026186214e-09
- O 0 1.5036132339218966e-08
type O 0 2.3756481226655524e-08
sequence O 0 7.529632028990818e-08
to O 0 4.8208587344333864e-08
a O 0 7.176209351200669e-07
homopolymer O 0 0.0016959822969511151
tract O 0 0.05383171886205673
( O 0 3.3420401450712234e-06
A8 O 0 3.4619824873516336e-05
) O 0 1.3828959088968418e-09
that O 0 6.945760633314535e-11
is O 0 8.107930993261903e-10
genetically O 0 2.103133667219481e-09
unstable O 0 3.4897875593742356e-06
and O 0 3.108397450546363e-08
prone O 0 2.0554209640977206e-06
to O 0 1.6558122695187194e-07
somatic O 0 1.2306246389925946e-05
mutation O 0 7.279465421561326e-07
. O 0 3.1868918881627906e-07

The O 0 6.737132480338914e-06
I1307K O 0 1.7025704437401146e-05
allele O 0 3.476818051240116e-07
was O 0 1.2421244264260167e-06
found O 0 8.812455831730404e-08
in O 0 1.7346393121897563e-07
6 O 0 4.121535766898887e-06
. O 0 1.1006429758708691e-06

1 O 0 7.224328328447882e-06
% O 0 1.2122895043376047e-07
of O 0 1.4407666526494722e-07
unselected O 1 0.5541846752166748
Ashkenazi O 0 0.00010935143654933199
Jews O 0 3.2949287742667366e-07
and O 0 6.064587942944399e-09
higher O 0 2.0715326343179186e-07
proportions O 0 2.644499090820318e-07
of O 0 6.467208777394262e-07
Ashkenazim O 0 2.048605165327899e-05
with O 0 1.9131698891783344e-08
family O 0 2.1800397007609718e-06
or O 0 2.5436679607082624e-07
personal O 0 9.757476618688088e-06
histories O 0 8.775838978181127e-06
of O 0 4.9865193432196975e-05
CRC B-Disease 0 0.0202572550624609
( O 0 4.52509880233265e-07
ref O 0 1.9090673504251754e-06
. O 0 4.534851161253073e-09
2 O 0 2.9797624279126467e-07
) O 0 3.5682912624679375e-08
. O 0 1.1200495464436244e-07

To O 0 2.541228809604945e-07
evaluate O 0 5.38840481567604e-07
the O 0 1.185997078323453e-07
role O 0 3.173547042933933e-07
of O 0 1.4613734720114735e-06
I1307K O 0 2.483273419784382e-05
in O 0 3.7623311754941824e-07
cancer B-Disease 0 1.4206202649802435e-06
, O 0 1.5431504962748477e-08
we O 0 8.588537525611173e-08
genotyped O 0 2.242713890154846e-05
5 O 0 6.278362434386509e-07
, O 0 3.824203531621606e-08
081 O 0 6.862307782284915e-05
Ashkenazi O 0 2.9672869459318463e-06
volunteers O 0 3.9932609752213466e-07
in O 0 4.2333144989470384e-08
a O 0 7.812691649178305e-08
community O 0 6.7113653301476e-08
survey O 0 4.4879024585497973e-07
. O 0 7.328727491540121e-08

Risk O 0 4.792535401065834e-05
of O 0 1.9497208540997235e-06
developing O 1 0.9988123178482056
colorectal B-Disease 1 1.0
, I-Disease 0 0.00010801886674016714
breast I-Disease 1 0.9995526671409607
and I-Disease 0 1.6171838979062159e-07
other I-Disease 0 5.78857317634629e-08
cancers I-Disease 0 0.0007708182674832642
were O 0 3.0641317039226124e-07
compared O 0 7.405984803199317e-08
between O 0 4.7113037027202154e-08
genotyped O 0 1.6706968608559691e-06
I1307K O 0 4.387554213280964e-07
carriers O 0 2.738476334585016e-09
and O 0 1.9129060557787625e-09
non O 0 4.593712219502777e-07
- O 0 1.6350206522020017e-07
carriers O 0 6.5799343751393735e-09
and O 0 2.836565871078278e-09
their O 0 7.028553294929907e-09
first O 0 6.465322144322272e-08
- O 0 2.1659035098764434e-07
degree O 0 1.3567187124863267e-05
relatives O 0 1.0243877568427706e-06
. O 0 1.2235022950335406e-07

Sperm O 0 1.0648727766238153e-06
DNA O 0 7.465950346841055e-08
analysis O 0 4.3322749831986584e-08
in O 0 9.019472280158425e-09
a O 0 7.643772050869302e-07
Friedreich B-Disease 1 0.9873033165931702
ataxia I-Disease 1 0.9392039179801941
premutation O 0 0.003335321554914117
carrier O 0 1.3609436564365751e-06
suggests O 0 8.391846222366439e-07
both O 0 2.809622934307754e-08
meiotic O 0 6.360653969750274e-06
and O 0 1.0445786102764032e-07
mitotic O 0 3.862259291054215e-06
expansion O 0 2.0459481220314046e-07
in O 0 4.332332537160255e-08
the O 0 6.331250119728793e-07
FRDA B-Disease 0 0.0015115493442863226
gene O 0 1.6189568441404845e-06
. O 0 3.4310758678657294e-07

Friedreich B-Disease 1 1.0
ataxia I-Disease 1 1.0
is O 0 2.613457945699338e-05
usually O 0 6.205844442774833e-07
caused O 0 4.7184937557176454e-07
by O 0 8.640454574049272e-09
an O 0 2.8061311496685448e-08
expansion O 0 2.7990060402771633e-07
of O 0 1.9604306089604506e-06
a O 0 6.196003141667461e-06
GAA O 0 9.262229286832735e-05
trinucleotide O 0 1.3388183106144425e-05
repeat O 0 1.040207052938058e-06
in O 0 1.4798240499658277e-07
intron O 0 4.71099383503315e-06
1 O 0 2.1492716939519596e-07
of O 0 1.242681975099913e-07
the O 0 5.099053055346303e-07
FRDA B-Disease 0 0.001858533825725317
gene O 0 6.654857998000807e-07
. O 0 1.4516734836433898e-07

Occasionally O 0 2.921158193203155e-05
, O 0 9.178862825365286e-08
a O 0 1.0286290574867962e-07
fully O 0 2.7820806280942634e-07
expanded O 0 3.710152540747913e-08
allele O 0 1.352795742093349e-08
has O 0 5.320607843195546e-10
been O 0 1.4790648705798048e-09
found O 0 9.72816271982424e-10
to O 0 1.9826533748101838e-09
arise O 0 6.069774372008396e-08
from O 0 8.740609303004021e-08
a O 0 2.1440901321057027e-07
premutation O 0 3.1178378776530735e-06
of O 0 3.9883551039565646e-07
100 O 0 3.3840564128695405e-07
or O 0 2.3367615398228736e-08
less O 0 2.8485981573567187e-08
triplet O 0 5.719710770790698e-06
repeats O 0 2.460559699102305e-06
. O 0 5.122154789205524e-07

We O 0 9.605868172002374e-07
have O 0 1.718608722001136e-08
examined O 0 1.3787057184799778e-07
the O 0 6.77995615205873e-08
sperm O 0 8.183025101970998e-08
DNA O 0 7.769285303993456e-08
of O 0 5.830980853716028e-08
a O 0 2.7969167604169343e-07
premutation O 0 2.2413176338886842e-05
carrier O 0 1.316692760156002e-06
. O 0 5.026245730732626e-07

This O 0 2.6237421479891054e-06
mans O 0 1.3549951290769968e-05
leucocyte O 0 1.2351618352113292e-05
DNA O 0 3.0919653681849013e-07
showed O 0 5.9016727504968e-08
one O 0 4.240181095127582e-09
normal O 0 2.340178184567776e-08
allele O 0 2.8990958522712162e-09
and O 0 3.300340556400272e-10
one O 0 2.881707761304142e-09
allele O 0 1.6370256261666327e-09
of O 0 2.1078854217648768e-08
approximately O 0 7.00361155736573e-08
100 O 0 4.5967451001160953e-07
repeats O 0 6.427782750506594e-07
. O 0 1.8427174097723764e-07

His O 0 5.754190169682261e-06
sperm O 0 1.6383468164349324e-06
showed O 0 8.186209754512674e-08
an O 0 9.118756860715393e-10
expanded O 0 5.62371704759812e-09
allele O 0 4.883183635229216e-09
in O 0 1.034040231218114e-08
a O 0 5.728537288973712e-08
tight O 0 2.541609376294218e-07
range O 0 5.8767248845015274e-08
centering O 0 5.128386533215235e-07
on O 0 2.099147167200499e-08
a O 0 1.1949725653437326e-08
size O 0 3.0391653638162097e-09
of O 0 2.1794477333969553e-08
approximately O 0 7.289386161346556e-08
320 O 0 8.180620056918997e-07
trinucleotide O 0 1.9358976715011522e-05
repeats O 0 7.24251276551513e-06
. O 0 8.990155038191006e-07

His O 0 0.00011297703895252198
affected O 0 6.9424645516846795e-06
son O 0 4.378762241685763e-05
has O 0 4.9318504835582644e-08
repeat O 0 1.23623280501306e-07
sizes O 0 7.906368182375445e-08
of O 0 3.1904860975373595e-07
1040 O 0 1.390945840284985e-06
and O 0 8.347699775868023e-08
540 O 0 3.113796765319421e-06
. O 0 2.2612073280470213e-07

These O 0 7.487540898409861e-08
data O 0 3.210404599940375e-07
suggest O 0 1.859195108977474e-08
that O 0 1.6651434397996212e-10
expansion O 0 8.868027201458517e-09
occurs O 0 4.5299324291647736e-09
in O 0 1.722145093197014e-09
two O 0 9.31278998361762e-10
stages O 0 2.95375741643511e-08
, O 0 1.4159765582277828e-09
the O 0 5.258262714136208e-09
first O 0 3.3837814328308014e-08
during O 0 1.2858588149811112e-07
meiosis O 0 2.9105561338838015e-07
followed O 0 7.947887326054115e-08
by O 0 6.585835432559861e-09
a O 0 3.466358577952633e-08
second O 0 2.8997675372011145e-07
mitotic O 0 2.2565550352737773e-06
expansion O 0 1.4199009683579789e-06
. O 0 4.526190764408966e-07

We O 0 1.077628667189856e-06
also O 0 1.8023614600792826e-08
show O 0 2.6864174884622116e-08
that O 0 3.5854183511041526e-10
in O 0 1.940245297760157e-09
all O 0 4.23334478583115e-09
informative O 0 2.83772607190258e-07
carrier O 0 3.653273239478949e-08
father O 0 6.39846291505819e-08
to O 0 8.712824239864858e-09
affected O 0 2.4762176309423012e-08
child O 0 1.5806848807642382e-07
transmissions O 0 1.6776007782937086e-07
, O 0 2.3317417441326427e-10
with O 0 8.142563706625694e-11
the O 0 7.611428820553101e-09
notable O 0 4.763439420685245e-08
exception O 0 2.2061733773171e-08
of O 0 2.410607358172001e-08
the O 0 7.13899481752378e-08
premutation O 0 5.251537459116662e-06
carrier O 0 1.0865317534580754e-07
, O 0 3.4668661275105705e-09
the O 0 1.237725744118734e-08
expansion O 0 1.2269563853806176e-07
size O 0 6.113425854437082e-08
decreases O 0 2.6087067794833274e-07
. O 0 8.124762196359825e-09
. O 0 6.277015529576602e-08

The O 0 2.5708261546242284e-06
R496H O 0 1.2451923794287723e-05
mutation O 0 1.1833228086288727e-07
of O 0 5.162864908925258e-07
arylsulfatase O 0 0.001253080670721829
A O 0 8.792027801973745e-05
does O 0 3.0705493259119976e-08
not O 0 2.970186407935671e-08
cause O 0 2.6764580979943275e-05
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
. O 0 4.549535788100911e-06

Deficiency B-Disease 1 1.0
of I-Disease 0 0.003566753352060914
arylsulfatase I-Disease 1 0.999862790107727
A I-Disease 1 0.9634401798248291
( O 0 1.24186708490015e-05
ARSA O 1 0.7767335176467896
) O 0 6.612245329051802e-08
enzyme O 0 2.1719827714150597e-07
activity O 0 2.7793541903520236e-06
causes O 0 8.062780580075923e-06
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 0.0011783088557422161
MLD B-Disease 1 1.0
) O 0 3.082852799707325e-07
. O 0 5.5851085534186495e-08

A O 0 3.0032010727154557e-06
number O 0 8.840672194310173e-08
of O 0 3.0310914667097677e-07
ARSA O 0 0.008080163970589638
gene O 0 8.332905565566762e-08
mutations O 0 9.613529527996434e-09
responsible O 0 1.6042119455050852e-07
for O 0 8.92628634119319e-07
MLD B-Disease 1 1.0
have O 0 2.3625987921604974e-07
been O 0 1.0245777559703129e-07
identified O 0 6.912886192367296e-07
. O 0 3.9254240391528583e-07

Recently O 0 7.809629096300341e-06
, O 0 3.987160113183563e-08
the O 0 7.54813811454369e-08
R496H O 0 4.104794243176002e-06
mutation O 0 6.04115371061198e-08
of O 0 1.1508013812999707e-06
ARSA O 1 0.8789846301078796
was O 0 1.5952564353938214e-06
proposed O 0 1.2941056226623004e-08
to O 0 6.9536940650039014e-09
be O 0 1.627751267108124e-08
a O 0 1.512696599093033e-07
cause O 0 7.807632300682599e-07
of O 0 4.4141306716483086e-05
MLD B-Disease 1 1.0
( O 0 2.4109047444653697e-05
Draghia O 0 0.0003740017709787935
et O 0 1.443452674720902e-05
al O 0 2.6634895675670123e-06
. O 0 3.333327613930237e-09
, O 0 2.2346144934459744e-09
1997 O 0 4.3247371905863474e-08
) O 0 2.135305088302175e-08
. O 0 6.529777607511278e-08

We O 0 1.3948591686130385e-06
have O 0 1.4293221717309734e-08
investigated O 0 5.957417670288123e-07
the O 0 7.630212195408603e-08
R496H O 0 1.367430400023295e-06
mutation O 0 3.6288188010047406e-09
and O 0 3.704209439181483e-10
found O 0 7.545195024327711e-10
this O 0 5.805130265379432e-10
mutation O 0 4.361496164229095e-10
at O 0 6.1368474746359425e-09
a O 0 1.960261286626519e-09
relatively O 0 1.0603152800214843e-09
high O 0 5.732794239321493e-10
frequency O 0 4.90902152261441e-10
in O 0 1.2592028808544597e-10
an O 0 2.520482988987993e-10
African O 0 1.5372831896343087e-09
American O 0 1.6265370161860915e-09
population O 0 2.8642574423365375e-11
( O 0 3.247399571471021e-11
f O 0 1.3901075845978994e-09
= O 0 1.8863912654154547e-09
0 O 0 1.5961777732886873e-10
. O 0 2.1051381124403967e-11
09 O 0 9.640668707788791e-09
, O 0 4.0034181525427925e-10
n O 0 4.296847677665028e-08
= O 0 1.35297170800186e-07
61 O 0 3.940813542158139e-08
subjects O 0 2.53543589678884e-07
) O 0 6.340489022704787e-08
. O 0 1.2313402919517102e-07

The O 0 2.707234671106562e-05
ARSA O 1 0.6651708483695984
enzyme O 0 2.370118636463303e-06
activity O 0 1.1856537867060979e-06
in O 0 5.719450690833128e-09
subjects O 0 3.1092810104382806e-08
with O 0 5.355479948399022e-10
and O 0 1.9121983996228664e-09
without O 0 3.428216643897031e-08
the O 0 7.098992682585958e-08
R496H O 0 1.0733444923971547e-06
mutation O 0 3.116986668771915e-09
was O 0 2.0937170219781365e-08
determined O 0 2.0011261980812378e-08
and O 0 2.393334419537041e-09
found O 0 8.961238862070786e-09
to O 0 5.086887799876649e-09
be O 0 4.6691770450024705e-08
normal O 0 2.4027522158576176e-06
. O 0 6.551247224706458e-07

It O 0 1.4093576794493856e-07
is O 0 1.1711491332278001e-08
therefore O 0 3.193109421317786e-08
concluded O 0 1.4275518367412587e-07
that O 0 1.0448107934379891e-09
the O 0 2.4740129944689215e-08
R496H O 0 2.4870462311810115e-06
mutation O 0 4.3406537031387415e-08
of O 0 3.335759402034455e-07
ARSA O 0 0.0037705600261688232
does O 0 7.30402405224595e-09
not O 0 1.3230262441155105e-09
negatively O 0 2.153345768363124e-08
influence O 0 1.7011283048873338e-08
the O 0 1.900915513886048e-08
activity O 0 4.2533218902462977e-07
of O 0 2.3711491792255401e-07
ARSA O 0 0.09833595156669617
and O 0 2.030112966622255e-08
is O 0 4.737649828001622e-09
not O 0 5.048187201595056e-09
a O 0 1.2531691595540906e-07
cause O 0 1.30978946799587e-06
of O 0 5.04587369505316e-05
MLD B-Disease 1 1.0

Down O 0 0.0003935515705961734
- O 0 4.655598786484916e-06
regulation O 0 3.8521471878993907e-07
of O 0 1.748015989733176e-07
transmembrane O 0 2.3223836251418106e-05
carbonic O 0 0.008055804297327995
anhydrases O 1 0.9988378882408142
in O 0 0.0006850713398307562
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 1.0
lines O 0 7.197189120233816e-07
by O 0 1.9881072788052734e-08
wild O 0 1.4767857692277175e-07
- O 0 1.3008923360757763e-06
type O 0 8.006372809177265e-06
von B-Disease 1 0.9999698400497437
Hippel I-Disease 1 0.9999995231628418
- I-Disease 1 0.9964237809181213
Lindau I-Disease 1 0.9985848665237427
transgenes O 0 0.0005570920184254646
. O 0 1.0141077382286312e-06

To O 0 1.1082296396125457e-06
discover O 0 4.908698429062497e-06
genes O 0 1.0806063954760248e-07
involved O 0 1.6921779888434685e-07
in O 0 2.4268700826723943e-07
von B-Disease 1 0.9999951124191284
Hippel I-Disease 1 1.0
- I-Disease 1 1.0
Lindau I-Disease 1 0.9999998807907104
( O 0 1.1634027941909153e-05
VHL B-Disease 0 0.0016849946696311235
) O 0 2.0453649085538927e-07
- O 0 8.670634770169272e-07
mediated O 0 2.8580761863850057e-06
carcinogenesis O 0 0.05349944531917572
, O 0 1.0721435295124593e-08
we O 0 4.6067153647300074e-08
used O 0 1.409102878824342e-05
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 1.0
lines O 0 1.8858920157072134e-05
stably O 0 0.00018082883616443723
transfected O 0 1.9680001059896313e-06
with O 0 1.8473311769184875e-09
wild O 0 8.388704486606002e-08
- O 0 1.6443229924334446e-06
type O 0 1.2983532542421017e-05
VHL O 1 0.8323656916618347
- O 0 2.2835398340248503e-05
expressing O 0 1.075058321475808e-06
transgenes O 0 4.063198866788298e-05
. O 0 4.7413720949407434e-07

Large O 0 2.178011527576018e-06
- O 0 7.691272685406148e-07
scale O 0 2.405602117505623e-06
RNA O 0 3.0505259474011837e-06
differential O 0 1.651201415597825e-07
display O 0 4.273708498203632e-08
technology O 0 2.867454895749688e-07
applied O 0 3.257957814639667e-08
to O 0 3.0558826580318055e-09
these O 0 6.682992381712438e-09
cell O 0 6.609086540265707e-07
lines O 0 1.2209888211600628e-08
identified O 0 8.23362178437037e-09
several O 0 1.5717769308309926e-09
differentially O 0 2.903425695421902e-07
expressed O 0 3.2108924408191797e-09
genes O 0 1.2895121637157558e-09
, O 0 1.7342745295412243e-10
including O 0 2.88755519495254e-10
an O 0 7.859064510284952e-09
alpha O 0 1.44670661939017e-06
carbonic O 0 2.2541789803653955e-05
anhydrase O 0 0.00010761705925688148
gene O 0 1.3571613521889958e-07
, O 0 1.851360487137299e-08
termed O 0 2.2187416561791906e-06
CA12 O 0 0.001823025057092309
. O 0 3.1205568120640237e-06

The O 0 5.19662580700242e-06
deduced O 0 1.2822678399970755e-05
protein O 0 3.307790166218183e-07
sequence O 0 1.9909424509023665e-07
was O 0 3.517909021866217e-07
classified O 0 3.4343690913374303e-07
as O 0 1.3664569920024405e-08
a O 0 9.263389699754043e-08
one O 0 4.969431799395352e-08
- O 0 4.742317685213493e-07
pass O 0 2.693174963042111e-07
transmembrane O 0 0.00026557670207694173
CA O 0 1.2712475836451631e-05
possessing O 0 8.422128985330346e-07
an O 0 5.529060587150525e-08
apparently O 0 1.0801052212627837e-06
intact O 0 1.9339529899298213e-05
catalytic O 0 7.921755695861066e-07
domain O 0 2.918855443567736e-06
in O 0 4.4621039307912724e-08
the O 0 3.1788934506948863e-07
extracellular O 0 0.032709188759326935
CA O 0 0.3625263571739197
module O 0 0.010730727575719357
. O 0 3.916848527296679e-06

Reintroduced O 0 6.0628253777395e-06
wild O 0 1.424561332896701e-06
- O 0 3.518946186886751e-06
type O 0 2.8095696507079992e-06
VHL B-Disease 0 0.0008743956568650901
strongly O 0 7.116209843616161e-08
inhibited O 0 1.5626612537289475e-07
the O 0 1.126923443450778e-08
overexpression O 0 5.855779150465423e-08
of O 0 6.35457908515491e-09
the O 0 5.0301682819053894e-08
CA12 O 0 1.8824939616024494e-05
gene O 0 6.6919212393656835e-09
in O 0 3.0950728646672587e-09
the O 0 1.1512280195802305e-07
parental O 0 0.00019124701793771237
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 1.0
lines O 0 6.277948705246672e-05
. O 0 2.160513986382284e-06

Similar O 0 1.7973481192257168e-07
results O 0 2.7780128419863104e-08
were O 0 1.0341960177129295e-08
obtained O 0 2.0955946311573825e-08
with O 0 2.317045888489133e-09
CA9 O 0 0.00204244302585721
, O 0 8.464190237589264e-09
encoding O 0 1.4145251192587693e-08
another O 0 2.0830464109167224e-07
transmembrane O 0 6.0977381508564577e-05
CA O 0 2.6425457235745853e-06
with O 0 5.725257601341127e-09
an O 0 1.479561575479238e-07
intact O 0 8.82823733263649e-05
catalytic O 0 1.3038176803092938e-05
domain O 0 3.043223659915384e-05
. O 0 3.0744641321689414e-07

Although O 0 6.598525033041369e-07
both O 0 5.983677908716345e-08
domains O 0 4.462921481263038e-07
of O 0 2.5822171778600023e-07
the O 0 4.5373974444373744e-07
VHL B-Disease 0 0.0002983564045280218
protein O 0 1.7998850410094747e-07
contribute O 0 1.4189594388369642e-08
to O 0 4.485448457103303e-09
regulation O 0 6.484550851837412e-08
of O 0 1.0876078704313841e-07
CA12 O 0 0.0022362512536346912
expression O 0 5.840993253514171e-07
, O 0 3.294895467575998e-09
the O 0 2.1068563782478122e-08
elongin O 0 1.2218341680636513e-06
binding O 0 2.9221029151926814e-08
domain O 0 5.590565024249372e-07
alone O 0 2.174025404144686e-08
could O 0 4.753979432337019e-09
effectively O 0 1.2204723986997124e-07
regulate O 0 1.1461651183708454e-06
CA9 O 1 0.9881203174591064
expression O 0 2.40186091104988e-06
. O 0 2.1974427966142684e-07

We O 0 1.8800830048348871e-06
mapped O 0 1.6987172784865834e-05
CA12 O 0 0.002209469210356474
and O 0 1.7364612858727924e-06
CA9 O 1 0.9183754920959473
loci O 0 9.249438335245941e-07
to O 0 4.734400249617465e-08
chromosome O 0 4.68497603378637e-07
bands O 0 1.1608996146605932e-06
15q22 O 0 2.495654371159617e-05
and O 0 4.2854833282035543e-07
17q21 O 0 9.812082862481475e-05
. O 0 3.8094690353318583e-06

2 O 0 3.2333803119399818e-06
respectively O 0 5.750962941419857e-07
, O 0 9.127705702383082e-09
regions O 0 1.8742309038088933e-08
prone O 0 6.74844955028675e-07
to O 0 2.430431678135392e-08
amplification O 0 1.7852598830359057e-06
in O 0 6.716167888498603e-08
some O 0 1.323731169122766e-08
human O 0 4.014881369585055e-07
cancers B-Disease 0 2.2653981432085857e-05
. O 0 2.0084223706362536e-07

Additional O 0 1.680685102201096e-07
experiments O 0 2.8362597959130653e-07
are O 0 1.1380187903142769e-09
needed O 0 6.694014675900917e-09
to O 0 5.019517690385555e-09
define O 0 6.411790565152842e-08
the O 0 6.833574417441923e-08
role O 0 6.578342777174839e-07
of O 0 1.3804024092678446e-05
CA O 0 7.072366133797914e-05
IX O 0 2.6920964955934323e-05
and O 0 1.1559266965832649e-07
CA O 0 9.297015822085086e-06
XII O 0 1.3806210517941508e-05
enzymes O 0 4.2091603091876095e-08
in O 0 7.130663615129151e-09
the O 0 1.310909425455975e-08
regulation O 0 2.517444208649522e-08
of O 0 1.7511954553128817e-08
pH O 0 2.6271570163771685e-07
in O 0 6.3619522983060506e-09
the O 0 2.0319181004424536e-08
extracellular O 0 2.045974906650372e-05
microenvironment O 0 1.4307400306279305e-05
and O 0 1.710911967656159e-09
its O 0 1.168500074477663e-09
potential O 0 1.2937798388179544e-08
impact O 0 1.6745222808367544e-07
on O 0 3.151704390802479e-07
cancer B-Disease 0 7.771204764139839e-06
cell O 0 1.5925787010928616e-05
growth O 0 3.044911807137396e-07
. O 0 5.039454364919038e-08

A O 0 5.663775027642259e-06
gene O 0 7.683223657295457e-08
encoding O 0 1.35184052396653e-07
a O 0 7.825860848242883e-08
transmembrane O 0 1.6505777011843747e-06
protein O 0 3.404159798492401e-08
is O 0 4.2705669556220016e-10
mutated O 0 9.084591967578604e-10
in O 0 9.03241370586727e-10
patients O 0 5.844149608691396e-09
with O 0 2.104115310430643e-06
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
( O 1 1.0
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 1.6232749544542457e-07
. O 0 7.276855740201427e-08

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.06924965977668762
WFS B-Disease 1 0.9999998807907104
; O 0 5.709425749955699e-07
OMIM O 1 0.9978518486022949
222300 O 0 1.5368390450021252e-05
) O 0 6.821122777722621e-09
is O 0 7.134224322413729e-10
an O 0 5.0620933222944586e-08
autosomal B-Disease 1 0.9999997615814209
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 1.0
defined O 0 7.847185770515352e-05
by O 0 1.3704483592391625e-07
young O 0 2.8044619284628425e-06
- O 0 0.00010637894592946395
onset O 1 0.9999997615814209
non O 1 0.9999998807907104
- O 0 0.08277081698179245
immune O 0 1.4170374925015494e-05
insulin B-Disease 1 0.8031618595123291
- I-Disease 1 0.9745534062385559
dependent I-Disease 1 0.9999997615814209
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 0.006873851642012596
progressive O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 0.999854564666748
. O 0 3.410605131648481e-06

Linkage O 0 0.0005839826771989465
to O 0 6.032352075635572e-07
markers O 0 2.2573944988835137e-06
on O 0 7.620458859491919e-07
chromosome O 0 9.032039997691754e-06
4p O 1 0.6343564987182617
was O 0 1.5987097867764533e-05
confirmed O 0 1.0461577204523564e-07
in O 0 3.5646447571480167e-08
five O 0 7.727874162810622e-08
families O 0 6.607202607256113e-08
. O 0 2.2854170822483866e-07

On O 0 2.200125891249627e-06
the O 0 7.140560853713396e-08
basis O 0 5.793941113552137e-07
of O 0 2.61911935695025e-07
meiotic O 0 8.702054037712514e-05
recombinants O 0 0.10634524375200272
and O 0 6.82430652432231e-07
disease O 0 0.010610119439661503
- O 0 3.2022451250668382e-06
associated O 0 2.5735830604389776e-06
haplotypes O 0 2.425500952085713e-06
, O 0 4.738354597577654e-09
the O 0 1.1794696774813929e-07
WFS B-Disease 0 0.0053125652484595776
gene O 0 1.9758591207619247e-08
was O 0 1.3310713598002621e-07
localized O 0 1.3444017099573102e-07
to O 0 1.7753492898009426e-08
a O 0 8.118420851133124e-07
BAC O 0 0.009338092058897018
/ O 0 2.354017851757817e-05
P1 O 0 4.491963773034513e-05
contig O 0 4.007692041341215e-06
of O 0 7.218257280783291e-08
less O 0 1.3246202357208858e-08
than O 0 6.924972151267639e-09
250 O 0 1.7319236178536812e-07
kb O 0 1.931917722686194e-05
. O 0 2.2980060521149426e-07

Mutations O 0 1.089110355678713e-06
in O 0 4.730076952341733e-08
a O 0 1.0434953168214633e-07
novel O 0 4.4521578956846497e-07
gene O 0 9.625036057059333e-08
( O 0 4.6971987188726416e-08
WFS1 O 0 2.2168036593939178e-05
) O 0 2.1250620818591415e-08
encoding O 0 4.2304410641236245e-08
a O 0 1.8157187753331527e-07
putative O 0 1.4688430383102968e-06
transmembrane O 0 2.1138739612069912e-06
protein O 0 6.265388918791359e-08
were O 0 7.253295741804777e-09
found O 0 1.7345500591403606e-09
in O 0 9.42439903894865e-10
all O 0 1.322635112543935e-09
affected O 0 4.273249754049857e-09
individuals O 0 1.6137530201021377e-09
in O 0 3.6710705586529e-08
six O 0 1.2095278179913294e-05
WFS B-Disease 1 1.0
families O 0 1.2122959525129318e-08
, O 0 5.15604448025897e-10
and O 0 1.209294886450607e-10
these O 0 2.6454921586704927e-10
mutations O 0 1.7558769993542e-09
were O 0 6.986557998800436e-09
associated O 0 1.4234239564814288e-08
with O 0 2.7928126478116155e-09
the O 0 1.5326135098803206e-06
disease O 0 2.2436615836340934e-05
phenotype O 0 3.52941185610689e-07
. O 0 7.650934463754311e-08

WFS1 O 0 0.004450426436960697
appears O 0 6.569215429408359e-07
to O 0 7.1301062831707895e-09
function O 0 9.065006878472559e-08
in O 0 1.0962798668856522e-08
survival O 0 2.5147619453491643e-05
of O 0 2.656721107996418e-06
islet O 0 1.3086421859043185e-05
beta O 0 6.200761163199786e-06
- O 0 4.685713577146089e-07
cells O 0 1.562392348830599e-08
and O 0 3.713803931049142e-09
neurons O 0 4.549503955786349e-07
. O 0 1.633458346361749e-08
. O 0 1.2542822958039324e-07

Stable O 0 0.001728650531731546
interaction O 0 1.634301952435635e-06
between O 0 4.385023189001913e-08
the O 0 4.722997548611829e-09
products O 0 1.1659619936210674e-09
of O 0 3.273448712093341e-08
the O 0 9.809800616267239e-08
BRCA1 O 0 9.328940109298856e-08
and O 0 7.394971746066403e-09
BRCA2 O 0 2.972992945160513e-07
tumor B-Disease 0 5.993227318867866e-07
suppressor O 0 7.638291776856931e-07
genes O 0 2.41852737836723e-09
in O 0 1.899439494579269e-09
mitotic O 0 4.2137151012866525e-07
and O 0 1.1385816733877618e-08
meiotic O 0 3.79369048459921e-05
cells O 0 3.16373075293086e-06
. O 0 4.253971042089688e-07

BRCA1 O 0 2.8140209906268865e-05
and O 0 5.800962910029739e-08
BRCA2 O 0 1.244152372237295e-07
account O 0 5.9722053968869204e-09
for O 0 1.656890319390314e-10
most O 0 1.448863667929956e-10
cases O 0 1.9111838500673883e-10
of O 0 5.20152703131771e-08
familial O 0 3.345365621498786e-05
, O 0 1.0333186750699497e-08
early O 0 1.8573131228549755e-06
onset O 1 0.9920088052749634
breast B-Disease 0 0.012713714502751827
and I-Disease 0 0.006999932695180178
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 2.0661146038492006e-07
encode O 0 1.6011741266197532e-08
products O 0 6.072455316363801e-10
that O 0 1.4232162670602122e-10
each O 0 3.340696330678128e-10
interact O 0 2.016550926242644e-09
with O 0 8.680259289128855e-10
hRAD51 O 0 1.8310765881324187e-06
. O 0 1.556426525439747e-07

Results O 0 3.7887919006607262e-06
presented O 0 9.447657589589653e-07
here O 0 4.0096162479130726e-07
show O 0 4.5730807585186994e-08
that O 0 2.5110267198868996e-09
BRCA1 O 0 2.9956179758983126e-08
and O 0 6.49467368774026e-09
BRCA2 O 0 2.4328625158887007e-07
coexist O 0 2.044873355089294e-07
in O 0 2.1628997259881544e-08
a O 0 6.655886863882188e-08
biochemical O 0 8.089400012067927e-07
complex O 0 7.908954103186261e-06
and O 0 2.739951021624165e-08
colocalize O 0 4.16670081904158e-05
in O 0 1.3350606309359137e-07
subnuclear O 0 2.0930832761223428e-05
foci O 0 6.195938112796284e-06
in O 0 6.199281976648763e-09
somatic O 0 3.2343805855816754e-08
cells O 0 7.185329220504855e-09
and O 0 5.829618454633589e-10
on O 0 6.98414615030174e-09
the O 0 8.440169452228474e-09
axial O 0 1.7107105065861106e-08
elements O 0 1.2560138706874113e-08
of O 0 4.328880010007197e-08
developing O 0 7.898151466179115e-07
synaptonemal O 0 0.00031625080737285316
complexes O 0 1.1997559340670705e-05
. O 0 3.0073829293542076e-07

Like O 0 9.489751391811296e-06
BRCA1 O 0 3.3482258459116565e-06
and O 0 2.0901325115119107e-07
RAD51 O 0 0.0015198694309219718
, O 0 1.333208246023787e-07
BRCA2 O 0 3.530913090799004e-07
relocates O 0 5.314168447512202e-07
to O 0 3.503908985180715e-08
PCNA O 0 3.595292946556583e-05
+ O 0 7.140048978726554e-07
replication O 0 9.02295127502839e-08
sites O 0 2.576277413623984e-09
following O 0 3.6392922009298445e-09
exposure O 0 1.2891162270989298e-07
of O 0 1.4271365955664805e-07
S O 0 3.7926383811281994e-06
phase O 0 1.2529866353361285e-06
cells O 0 5.559335747307159e-08
to O 0 9.16671716311157e-09
hydroxyurea O 0 2.0236027467035456e-06
or O 0 1.0349423718025719e-07
UV O 0 3.598116018110886e-05
irradiation O 0 6.040605512680486e-06
. O 0 1.8523111577906093e-07

Thus O 0 5.373490694182692e-06
, O 0 9.094430453160385e-08
BRCA1 O 0 7.073542462876503e-08
and O 0 5.496451294106919e-09
BRCA2 O 0 2.9290665892744983e-08
participate O 0 7.96258703417152e-09
, O 0 1.629735679742339e-09
together O 0 3.984725438499481e-09
, O 0 4.843657919195721e-09
in O 0 1.1445214553873484e-08
a O 0 8.929984574024274e-08
pathway O 0 1.3141294630258926e-07
( O 0 5.081922882510526e-09
s O 0 2.08399146828242e-08
) O 0 3.908121326556824e-10
associated O 0 1.7432163490482822e-09
with O 0 4.761064320568664e-10
the O 0 5.4481390066030144e-08
activation O 0 9.469761153013678e-08
of O 0 6.367660176920253e-08
double O 0 9.611790829922029e-08
- O 0 5.059496857029444e-07
strand O 0 4.618896980446152e-07
break O 0 8.236215194301622e-07
repair O 0 4.853083282796433e-06
and O 0 1.0805465677776738e-07
/ O 0 4.853555765294004e-06
or O 0 1.2741401178573142e-07
homologous O 0 6.389645363924501e-07
recombination O 0 1.4145136901788646e-06
. O 0 4.383982172839751e-07

Dysfunction O 1 0.9999995231628418
of O 0 1.976578641915694e-05
this O 0 3.498483920338913e-07
pathway O 0 3.826721240329789e-06
may O 0 1.0237296343973412e-08
be O 0 2.616099337160449e-09
a O 0 1.4048564089819138e-08
general O 0 2.9904288822990566e-08
phenomenon O 0 4.6987622681626817e-07
in O 0 3.7723020263058515e-09
the O 0 3.6733942554434407e-09
majority O 0 3.72967462469731e-10
of O 0 5.368819167017591e-09
cases O 0 3.3788587483485344e-09
of O 0 1.3275166566018015e-07
hereditary B-Disease 1 0.9999998807907104
breast I-Disease 1 0.9999980926513672
and I-Disease 1 0.9999837875366211
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.673572680578218e-06
. O 0 3.414832292492065e-07

A O 0 1.053308824339183e-05
novel O 0 4.360259026725544e-06
Arg362Ser O 0 6.804293661843985e-05
mutation O 0 2.8430564569248418e-08
in O 0 1.5896988614372276e-08
the O 0 4.696302724482848e-08
sterol O 0 5.691524052053865e-07
27 O 0 1.1606416592258029e-06
- O 0 1.0328170674256398e-06
hydroxylase O 0 6.602171652048128e-06
gene O 0 3.484461785774329e-08
( O 0 7.42708738954434e-09
CYP27 O 0 1.6683533203831757e-06
) O 0 7.700029502899497e-10
: O 0 1.205274352544805e-10
its O 0 8.532585055176511e-11
effects O 0 1.0340796663399487e-08
on O 0 1.6686772852381182e-08
pre O 0 1.9724782873709046e-07
- O 0 6.926243401039756e-08
mRNA O 0 1.0840022213187694e-07
splicing O 0 2.1833589158859468e-08
and O 0 6.032581656434388e-10
enzyme O 0 9.961086178122969e-09
activity O 0 3.3959958045670646e-07
. O 0 7.507189536681835e-08

A O 0 9.890934961731546e-06
novel O 0 1.4291824754764093e-06
C O 0 6.104348358348943e-06
to O 0 1.4805107362292347e-08
A O 0 1.7692991605144925e-07
mutation O 0 1.425422890832806e-09
in O 0 1.8795676126615035e-09
the O 0 1.543321204167114e-08
sterol O 0 4.794787855644245e-07
27 O 0 7.683457283746975e-07
- O 0 5.665221465278591e-07
hydroxylase O 0 4.980333415005589e-06
gene O 0 3.280687010942529e-08
( O 0 6.061962487535766e-09
CYP27 O 0 2.2954111500439467e-06
) O 0 8.94557428132714e-10
was O 0 2.53500109792526e-09
identified O 0 9.607878936890302e-10
by O 0 1.356241452477036e-09
sequencing O 0 4.271402431754723e-08
amplified O 0 1.029830059451342e-06
CYP27 O 0 1.4130281670077238e-05
gene O 0 5.7399089925525004e-09
products O 0 1.5553063281714685e-09
from O 0 1.2111588176821897e-08
a O 0 8.103176440954485e-08
patient O 0 3.6183709539727715e-07
with O 0 2.321329084509216e-08
cerebrotendinous B-Disease 1 1.0
xanthomatosis I-Disease 1 1.0
( O 0 2.4167215087800287e-05
CTX B-Disease 0 0.010677632875740528
) O 0 9.285076174592177e-08
. O 0 7.333047591373543e-08

The O 0 1.1389854535082122e-06
mutation O 0 8.028456477404688e-08
changed O 0 1.5687683685428055e-07
the O 0 2.561775431786373e-07
adrenodoxin O 0 1.2558707567222882e-05
cofactor O 0 1.1437050488893874e-06
binding O 0 4.180142099130535e-08
residue O 0 1.0197870778938523e-06
362Arg O 0 7.677597295696614e-07
to O 0 1.1972566937856755e-07
362Ser O 0 1.0230561201751698e-05
( O 0 6.725955472575151e-07
CGT O 0 1.3942785699327942e-05
362Arg O 0 4.3700047172023915e-06
to O 0 2.255745101820139e-07
AGT O 0 4.924988024868071e-05
362Ser O 0 4.169766896211513e-07
) O 0 3.606304366243762e-09
, O 0 4.1507339232360607e-10
and O 0 4.738948677918131e-10
was O 0 2.1620503787289636e-07
responsible O 0 2.703540360471379e-07
for O 0 1.5400580366531358e-07
deficiency O 1 0.9999346733093262
in O 0 3.852415375149576e-06
the O 0 4.72338751933421e-06
sterol O 0 3.2566833851888077e-06
27 O 0 2.751861302385805e-06
- O 0 1.118649379350245e-06
hydroxylase O 0 3.973210823460249e-06
activity O 0 6.173597171255096e-07
, O 0 2.6833932298409024e-10
as O 0 2.7599053598059697e-10
confirmed O 0 2.9399893630710494e-10
by O 0 2.6987301282588305e-10
expression O 0 2.7556410486795357e-09
of O 0 7.371609100914611e-09
mutant O 0 1.564655782715363e-08
cDNA O 0 1.0799799810001787e-07
into O 0 1.996798637549091e-08
COS O 0 8.316109415318351e-06
- O 0 2.253330535495479e-07
1 O 0 2.536865224556095e-07
cells O 0 1.5892356941549224e-07
. O 0 4.9149942782378275e-08

Quantitative O 0 8.539826922060456e-06
analysis O 0 3.330743254537083e-07
showed O 0 1.43656491147226e-08
that O 0 8.816074953399422e-11
the O 0 1.4581489349296817e-09
expression O 0 1.324845033678912e-08
of O 0 4.1981280674008303e-08
CYP27 O 0 1.0428230780235026e-05
gene O 0 5.863398655492347e-09
mRNA O 0 4.501426076330972e-08
in O 0 1.5813604870018594e-09
the O 0 7.502005239246046e-09
patient O 0 3.004630499958694e-08
represented O 0 2.1667643679279536e-08
52 O 0 9.356763257528655e-07
. O 0 2.5753215027179976e-07

5 O 0 4.774546141561586e-06
% O 0 6.98245727903668e-08
of O 0 3.197857267878135e-08
the O 0 4.0797051070740054e-08
normal O 0 1.6456016282972996e-06
level O 0 5.838275228597922e-06
. O 0 2.5652468593762023e-07

As O 0 3.559920287443674e-07
the O 0 7.228825182892251e-08
mutation O 0 2.7712809824720352e-08
occurred O 0 3.127111938283633e-07
at O 0 5.9083067327492245e-08
the O 0 2.0133390066234824e-08
penultimate O 0 1.051548679242842e-06
nucleotide O 0 3.4700704532042437e-07
of O 0 2.2146861056171474e-07
exon O 0 1.0336009381717304e-07
6 O 0 9.006548395973368e-08
( O 0 8.475498525228886e-09
- O 0 9.044313742379018e-09
2 O 0 2.439692892153289e-08
position O 0 1.2122086445742752e-07
of O 0 1.736481607395035e-07
exon O 0 6.72028761528054e-07
6 O 0 1.0544467841100413e-06
- O 0 4.881645736531937e-07
intron O 0 1.0860332622542046e-05
6 O 0 9.371739224661724e-07
splice O 0 7.08199934251752e-07
site O 0 6.251744366636558e-08
) O 0 4.4838038837369254e-10
of O 0 1.868672327987042e-09
the O 0 9.602478812098525e-09
gene O 0 6.9471983721314245e-09
, O 0 1.800522286821149e-09
we O 0 4.181886392728984e-09
hypothesized O 0 2.8490166670280814e-08
that O 0 1.2093939738555548e-10
the O 0 2.8610716018562243e-09
mutation O 0 6.944518293749979e-10
may O 0 1.51709422802071e-09
partially O 0 1.2469841692563932e-07
affect O 0 1.139194250043829e-08
the O 0 8.890246760984155e-09
normal O 0 5.539341785265606e-08
splicing O 0 2.767520079771657e-08
efficiency O 0 2.84158705454729e-08
in O 0 3.4406282267696042e-09
exon O 0 2.705339952058239e-08
6 O 0 1.7177370637000422e-08
and O 0 3.590776842532506e-10
cause O 0 2.058831549689444e-09
alternative O 0 2.9816562552298365e-09
splicing O 0 2.981845170779707e-08
elsewhere O 0 8.93824481096317e-09
, O 0 2.5710630846553784e-10
which O 0 1.1124684506924609e-10
resulted O 0 6.228283666587231e-09
in O 0 8.96404195316336e-09
decreased O 0 1.2517135701273219e-06
transcript O 0 3.6597526786863455e-07
in O 0 1.0101040004428796e-08
the O 0 5.6581054508342277e-08
patient O 0 6.430916528188391e-07
. O 0 5.921099699435217e-08

Transfection O 0 0.00890578143298626
of O 0 4.805738171853591e-06
constructed O 0 7.282586011569947e-05
minigenes O 0 0.00020392918668221682
, O 0 2.7759472942534558e-08
with O 0 1.8105436039306255e-09
or O 0 2.4646263696581627e-08
without O 0 1.0020426266521554e-08
the O 0 1.1711736469521838e-08
mutation O 0 1.180827102764681e-09
, O 0 5.327208119076943e-10
into O 0 2.145073452197721e-08
COS O 0 0.00028608413413167
- O 0 2.1186490357649745e-06
1 O 0 5.220491061663779e-07
cells O 0 1.301867058600692e-08
confirmed O 0 2.434986878796508e-09
that O 0 2.0057477900792264e-10
the O 0 5.209467079936303e-09
mutant O 0 1.0764900082449458e-07
minigene O 0 2.2919114144315245e-06
was O 0 1.1161213109289747e-07
responsible O 0 1.6554514203903636e-08
for O 0 1.0738252509412405e-09
a O 0 1.4596273523181935e-08
mRNA O 0 5.562549532101002e-08
species O 0 7.96590571283673e-11
alternatively O 0 1.877468847055752e-08
spliced O 0 7.899043197312494e-08
at O 0 1.5428511801474087e-07
an O 0 1.8047728644887684e-08
activated O 0 1.0298319921275834e-06
cryptic O 0 3.6503761293715797e-06
5 O 0 6.723582259837713e-07
splice O 0 2.5369333798153093e-06
site O 0 8.531016533197544e-07
88 O 0 7.542035973528982e-07
bp O 0 1.8119371816283092e-06
upstream O 0 1.3464858739098418e-06
from O 0 4.578754086992376e-08
the O 0 6.194568413775414e-08
3 O 0 1.220774947796599e-07
end O 0 1.9404058093641652e-07
of O 0 5.877072339899314e-07
exon O 0 2.55156942330359e-06
6 O 0 2.388293296462507e-06
. O 0 4.751933317947987e-07

Our O 0 3.4354084164078813e-06
data O 0 3.896094540323247e-07
suggest O 0 2.7781188904896226e-08
that O 0 6.029648447203328e-10
the O 0 6.411507325054799e-09
C O 0 4.0084691477204615e-07
to O 0 5.077252840379742e-09
A O 0 1.3813405530527234e-07
mutation O 0 8.775077886546967e-10
at O 0 1.4454260011120823e-08
the O 0 9.023704450328296e-09
penultimate O 0 9.871079100776115e-07
nucleotide O 0 2.899148228152626e-07
of O 0 8.51655030942311e-08
exon O 0 1.495747596891306e-07
6 O 0 4.322724933558675e-08
of O 0 2.406206434102387e-08
the O 0 5.5281113020555495e-08
CYP27 O 0 7.390605605905876e-05
gene O 0 7.685067693330438e-09
not O 0 1.1026375368317076e-09
only O 0 2.79121503687918e-09
causes O 0 1.9451743327181248e-08
the O 0 8.76312782338573e-08
deficiency B-Disease 0 0.0006126654916442931
in I-Disease 0 1.7332520485524583e-07
the I-Disease 0 6.329100870061666e-07
sterol I-Disease 0 1.4248263369154301e-06
27 I-Disease 0 1.037267907122441e-06
- I-Disease 0 4.7322654950221477e-07
hydroxylase I-Disease 0 2.20534207073797e-06
activity I-Disease 0 4.63016505136693e-07
, O 0 3.7900635407872585e-10
but O 0 3.232804302033543e-10
also O 0 7.040531491142588e-10
partially O 0 4.8810726127612725e-08
leads O 0 1.1882761441484035e-09
to O 0 3.3141298039218725e-10
alternative O 0 2.0083366081280474e-09
pre O 0 2.114453536705696e-07
- O 0 5.4249738923317636e-08
mRNA O 0 1.0644194503584004e-07
splicing O 0 6.8810784625839e-08
of O 0 1.0391016047606172e-08
the O 0 3.249424551654556e-08
gene O 0 3.702072959299585e-08
. O 0 6.089069870540698e-08

To O 0 6.866997068755154e-07
our O 0 1.730850271997042e-07
knowledge O 0 4.85600048705237e-06
, O 0 1.0731685762266352e-08
this O 0 3.3142073530001426e-09
is O 0 1.062051890876603e-09
the O 0 1.7732569856931946e-09
first O 0 3.509820212244108e-09
report O 0 2.3926314263178483e-09
regarding O 0 4.03620514788372e-09
effects O 0 2.5063243924705603e-08
on O 0 1.8826396441795623e-08
pre O 0 3.8971313642832683e-07
- O 0 5.106001665922122e-08
mRNA O 0 4.062916048042098e-08
splicing O 0 2.5288692029334925e-08
of O 0 5.386502355264611e-09
a O 0 3.748833243832905e-09
mutation O 0 2.398336806930246e-10
at O 0 8.324292366523878e-09
the O 0 2.016521172265584e-08
- O 0 9.350334551072592e-08
2 O 0 1.4742894904884452e-07
position O 0 2.869730906240875e-07
of O 0 1.8737183893335896e-07
a O 0 4.6639573270113033e-07
5 O 0 7.869813316574437e-07
splice O 0 6.396537173714023e-06
site O 0 1.6664673694322119e-06
. O 0 2.0272541689791979e-07

ATM O 0 0.000535609491635114
germline O 0 4.385995998745784e-05
mutations O 0 1.004197400789053e-07
in O 0 9.938658251940069e-08
classical O 1 0.999998927116394
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 1 0.6193323731422424
in O 0 1.4151646077209534e-08
the O 0 2.7429052806837717e-08
Dutch O 0 1.494557818659814e-05
population O 0 1.074821653901381e-08
. O 0 1.8713338434395155e-08

Germline O 0 0.0010215372312813997
mutations O 0 9.027753833379393e-08
in O 0 1.243480518553497e-08
the O 0 2.892612904759062e-08
ATM O 0 2.054290007436066e-06
gene O 0 3.917898505623185e-10
are O 0 1.660046405893567e-11
responsible O 0 8.782580218635871e-10
for O 0 3.469710740944265e-09
the O 1 0.998526930809021
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999995231628418
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.3185474472265923e-06
. O 0 4.5249004188008257e-07

In O 0 1.3637005622513243e-06
our O 0 1.6676789016401017e-07
study O 0 3.0603697354081305e-08
, O 0 7.96426868898692e-10
we O 0 1.5113785778453348e-09
have O 0 1.6896212207129224e-10
determined O 0 6.013308073704593e-09
the O 0 1.4682610682825725e-08
ATM O 0 8.589246931478556e-07
mutation O 0 6.199716295895996e-10
spectrum O 0 1.4477705700954857e-09
in O 0 3.2818494588582325e-09
19 O 0 7.184865324916245e-08
classical O 0 0.00041317607974633574
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 8.897880654501478e-09
, O 0 5.0916878352458284e-11
including O 0 4.111884444046865e-11
some O 0 2.8446031988260678e-11
immigrant O 0 2.5537127967822926e-10
populations O 0 1.134994251361654e-10
, O 0 4.965899566555798e-11
as O 0 2.0078873286255572e-10
well O 0 5.515130574451632e-10
as O 0 1.1674641253733853e-09
12 O 0 1.6491540355545453e-09
of O 0 3.7227829707831006e-09
Dutch O 0 1.4198506903539965e-07
ethnic O 0 6.557032694587406e-09
origin O 0 1.2083003753105004e-07
. O 0 1.3883891369914636e-07

Both O 0 4.305416609895474e-07
the O 0 9.213205487412779e-08
protein O 0 3.3074460503712544e-08
truncation O 0 6.91089553583879e-07
test O 0 7.093200338204042e-08
( O 0 1.4804265902057523e-07
PTT O 0 3.370757258380763e-05
) O 0 1.3153971245571938e-09
and O 0 2.7174176797650773e-10
the O 0 2.9061657524920292e-09
restriction O 0 1.4699226724701475e-08
endonuclease O 0 7.276883451368121e-08
fingerprinting O 0 3.34191057049793e-08
( O 0 6.873178914901246e-09
REF O 0 1.6678458791830053e-07
) O 0 1.1053448434328317e-10
method O 0 1.1864689231089187e-09
were O 0 7.66534447027567e-10
used O 0 1.0075309475610084e-09
and O 0 5.13275089097931e-10
compared O 0 2.2232378160680355e-09
for O 0 4.4858056158503246e-10
their O 0 8.556660935354898e-10
detection O 0 1.8926920475337283e-08
efficiency O 0 4.460535940609134e-09
, O 0 2.2085709650010443e-10
identifying O 0 3.6737448638746173e-09
76 O 0 3.753027755237781e-08
% O 0 1.4947537652076903e-09
and O 0 2.6464813673854337e-10
60 O 0 5.614799736264331e-09
% O 0 5.000937997046151e-10
of O 0 8.698739506485254e-10
the O 0 4.0124712441524935e-09
mutations O 0 3.3740223948086623e-09
, O 0 4.4977848112637275e-09
respectively O 0 8.668386044519139e-07
. O 0 3.1262501920537034e-07

Most O 0 6.282405138335889e-07
patients O 0 3.631694056593915e-08
were O 0 3.947614146682099e-08
found O 0 1.3677242449716687e-08
to O 0 9.290882729828809e-09
be O 0 1.9406390094900416e-07
compound O 0 7.330564403673634e-05
heterozygote O 0 0.00014310871483758092
. O 0 6.950374427105999e-07

Seventeen O 0 1.8622438801685348e-05
mutations O 0 8.489757163943068e-08
were O 0 2.978361202110591e-08
distinct O 0 6.3654357340681145e-09
, O 0 2.0417187940324766e-09
of O 0 3.2816007689007165e-08
which O 0 4.102472583866756e-09
10 O 0 3.172953455532479e-08
were O 0 1.137867400302639e-08
not O 0 6.046915856927626e-09
reported O 0 1.412308279213903e-07
previously O 0 5.934469413659826e-07
. O 0 3.81506850999358e-07

Mutations O 0 2.0410871002241038e-06
are O 0 1.74113061746084e-08
small O 0 5.6180052609988707e-08
deletions O 0 6.254845175135415e-07
or O 0 3.3873402571771294e-07
point O 0 4.979246114089619e-06
mutations O 0 1.716354205427706e-07
frequently O 0 3.9854310784903646e-07
affecting O 0 1.0235655736323679e-06
splice O 0 1.2654960301006213e-05
sites O 0 1.088062845155946e-06
. O 0 5.50556137568492e-07

Moreover O 0 4.458972762222402e-05
, O 0 1.3618546290672384e-07
a O 0 4.299672298202495e-07
16 O 0 1.1601636060731835e-06
. O 0 3.6981495554755384e-07

7 O 0 2.451914770063013e-05
- O 0 3.3048463592422195e-06
kb O 0 3.225034743081778e-05
genomic O 0 6.448892690968933e-07
deletion O 0 2.1145987716408854e-07
of O 0 5.6341121990044485e-08
the O 0 2.8876129931632022e-08
3 O 0 9.391945354764175e-08
end O 0 4.367877437516654e-08
of O 0 2.4836012357809523e-08
the O 0 2.354303063611951e-08
gene O 0 1.5614591841739411e-09
, O 0 3.9332251344781355e-10
most O 0 2.2784699127420538e-10
likely O 0 1.6035632821598256e-09
a O 0 5.170050609848431e-09
result O 0 6.328440882441555e-09
of O 0 1.296633200809083e-08
recombination O 0 4.896810512633465e-09
between O 0 9.187564486978772e-09
two O 0 3.845912033284549e-09
LINE O 0 1.903804331959691e-07
elements O 0 9.403560596865645e-08
, O 0 1.8065017926005567e-08
was O 0 5.586668976320652e-07
identified O 0 6.354059678415069e-07
. O 0 4.2838570379899465e-07

The O 0 1.1703629070325405e-06
most O 0 5.904586153349101e-09
frequently O 0 2.4930544295642676e-09
found O 0 5.617538656466081e-10
mutation O 0 1.5371622030802e-10
, O 0 1.0996294153020614e-10
identified O 0 2.953153499518635e-09
in O 0 6.783497319418075e-09
three O 0 1.5268284414560185e-08
unrelated O 0 7.224772389236023e-07
Turkish O 0 4.1679610149003565e-05
A B-Disease 1 1.0
- I-Disease 1 0.9999964237213135
T I-Disease 1 1.0
individuals O 0 1.9151961794250383e-08
, O 0 3.787854030434801e-09
was O 0 1.7349769620977895e-07
previously O 0 5.657782153889457e-08
described O 0 8.237894810747548e-09
to O 0 9.538474454728885e-10
be O 0 2.155144285254096e-09
a O 0 5.564204741403955e-08
Turkish O 0 2.0093873445148347e-06
A B-Disease 1 1.0
- I-Disease 1 0.9999902248382568
T I-Disease 1 0.9999990463256836
founder O 0 7.607498264405876e-05
mutation O 0 2.2517087927553803e-07
. O 0 1.3024536826833355e-07

The O 0 3.4272663924639346e-06
presence O 0 7.586414199067804e-07
of O 0 1.0718296152845141e-06
a O 0 9.510050062999653e-07
founder O 0 5.15440160597791e-06
mutation O 0 2.74435874025869e-09
among O 0 8.793503425419402e-11
relatively O 0 7.165863458169497e-10
small O 0 3.3709782187862913e-10
ethnic O 0 3.778161949963277e-10
population O 0 3.812021531768295e-11
groups O 0 1.5983948539743942e-11
in O 0 1.573404878607576e-10
Western O 0 1.2880576605311944e-08
Europe O 0 1.777999436569644e-08
could O 0 6.415091569067499e-09
indicate O 0 4.250742691169762e-08
a O 0 7.640110766260477e-09
high O 0 3.933587677806827e-09
carrier O 0 1.951810935096887e-09
frequency O 0 5.9892477644041264e-09
in O 0 1.153673490073004e-09
such O 0 3.1079747664364277e-09
communities O 0 1.9180292909481977e-08
. O 0 4.028758553431544e-07

In O 0 4.6552696630897117e-07
patients O 0 2.1172093411792048e-08
of O 0 2.4320826241819304e-08
Dutch O 0 6.374310487444745e-06
ethnic O 0 1.1423993306891589e-08
origin O 0 4.7246938805756145e-08
, O 0 2.020107858768938e-09
however O 0 6.315911793564055e-09
, O 0 1.1478219485994146e-09
no O 0 3.3646527786146407e-09
significant O 0 1.3993312286686432e-08
founder O 0 9.769428288564086e-07
effect O 0 6.165476662545188e-08
could O 0 1.6892586884864613e-08
be O 0 3.439895124301984e-08
identified O 0 5.179005597710784e-07
. O 0 3.1042918635648675e-07

The O 0 3.7346976000662835e-07
observed O 0 1.5030029487661523e-07
genetic O 0 1.156326874252045e-07
heterogeneity O 0 1.7874836544251593e-07
including O 0 3.5031455514200616e-09
the O 0 2.7509004851822283e-08
relative O 0 2.6823349799087737e-06
high O 0 5.921529009356163e-07
percentage O 0 1.779632015086463e-07
of O 0 1.4529199177104601e-07
splice O 0 3.68189171240374e-06
- O 0 1.0593847719064797e-06
site O 0 2.3287356043510954e-07
mutations O 0 5.738529651466706e-09
had O 0 3.04587537414136e-08
no O 0 1.8178873517626926e-08
reflection O 0 2.0049547799771972e-07
on O 0 6.300236776723978e-08
the O 0 1.6531835456135013e-07
phenotype O 0 8.705284813004255e-07
. O 0 1.6893302756670892e-07

All O 0 1.6540761293981632e-07
patients O 0 3.6537400660563435e-08
manifested O 0 6.766106253053294e-07
classical O 0 0.0018078619614243507
A B-Disease 1 1.0
- I-Disease 1 0.9998093247413635
T I-Disease 1 0.9999240636825562
and O 0 4.446206514074902e-09
increased O 0 9.641480858135765e-08
cellular O 0 5.81825474910147e-07
radioresistant O 0 2.376936663495144e-06
DNA O 0 3.9793127371012815e-07
synthesis O 0 5.856800839865173e-07
. O 0 4.943434817050729e-08

Determination O 0 8.762483048485592e-06
of O 0 5.870753625458747e-07
the O 0 1.3037485757649847e-07
genomic O 0 4.1171807652062853e-07
structure O 0 2.138494750170139e-07
of O 0 1.2506048108207324e-07
the O 0 2.0556998947540706e-07
COL4A4 O 0 0.0013982693199068308
gene O 0 2.5111894785823097e-09
and O 0 1.0702953801011716e-10
of O 0 5.095957877898627e-09
novel O 0 1.3859116734238341e-06
mutations O 0 1.2001436289210687e-06
causing O 0 0.00017749887774698436
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 6.204150122357532e-05

Autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 1.4264034007283044e-06
a O 0 2.7429965484770946e-05
progressive O 1 0.9999886751174927
hematuric B-Disease 1 1.0
glomerulonephritis I-Disease 1 1.0
characterized O 0 0.020827332511544228
by O 0 6.668417427135864e-06
glomerular B-Disease 1 1.0
basement I-Disease 1 1.0
membrane I-Disease 1 0.9999836683273315
abnormalities I-Disease 1 0.999980092048645
and O 0 2.2051468206996105e-08
associated O 0 6.757130108780984e-07
with O 0 4.848679679980705e-08
mutations O 0 1.188905187632372e-07
in O 0 5.043397663939686e-07
either O 0 1.2307009455980733e-06
the O 0 1.7999785995925777e-05
COL4A3 O 1 0.9965092539787292
or O 0 7.356771334343648e-07
the O 0 4.031290927741793e-07
COL4A4 O 0 0.0009714645566418767
gene O 0 2.6930099039645938e-08
, O 0 1.8563345305366852e-09
which O 0 8.679398866284771e-10
encode O 0 1.5844529244191108e-08
the O 0 5.8981619588394096e-08
alpha3 O 0 8.837560017127544e-06
and O 0 5.645040701551807e-08
alpha4 O 0 0.00019164389232173562
type O 0 0.000492031336762011
IV O 1 0.9999996423721313
collagen O 1 0.984680712223053
chains O 0 0.00013607577420771122
, O 0 1.035394490145336e-07
respectively O 0 2.3795132619852666e-06
. O 0 1.0298535926267505e-06

To O 0 1.1595226112603996e-07
date O 0 2.1864244104108366e-07
, O 0 2.5173036988235253e-09
mutation O 0 7.043929883820965e-10
screening O 0 9.859576488580046e-10
in O 0 1.384352743549755e-09
the O 0 9.016857482890828e-09
two O 0 2.560102796422825e-09
genes O 0 3.4386009595266387e-09
has O 0 3.8082009767848035e-10
been O 0 7.12628533960924e-09
hampered O 0 4.6409164156102634e-07
by O 0 3.142943905132256e-09
the O 0 3.065294151838316e-08
lack O 0 1.319812525935049e-07
of O 0 4.095984706964373e-08
genomic O 0 7.286230641057045e-08
structure O 0 2.3317822694934875e-07
information O 0 5.170034000911983e-07
. O 0 4.2156284507655073e-07

We O 0 1.3331132322491612e-06
report O 0 2.9939619139440765e-07
here O 0 3.715895857681062e-08
the O 0 1.4518916735539733e-08
complete O 0 1.7698391729936702e-07
characterization O 0 3.5919796914640756e-07
of O 0 1.3593101755304815e-07
the O 0 1.1074610029027099e-07
48 O 0 2.2780751862683246e-07
exons O 0 1.0623405444221135e-07
of O 0 1.8065705376102414e-08
the O 0 1.2577488917031587e-07
COL4A4 O 0 0.0003612370346672833
gene O 0 1.582562170199253e-08
, O 0 4.943240816679406e-10
a O 0 2.3051265340967575e-09
comprehensive O 0 1.234076663081396e-08
gene O 0 1.018474526937041e-09
screen O 0 1.6264385394038072e-08
, O 0 7.395842271940012e-10
and O 0 4.2609824002504126e-10
the O 0 6.054394319221501e-09
subsequent O 0 2.3191031317537636e-08
detection O 0 4.922302565546488e-08
of O 0 2.302621870953203e-09
10 O 0 1.9169164033883135e-09
novel O 0 5.633153055129014e-09
mutations O 0 4.1300904363161806e-10
in O 0 3.007821214318085e-10
eight O 0 1.512302105766139e-08
patients O 0 1.4015482996398987e-08
diagnosed O 0 7.047913186397636e-07
with O 0 2.406804071597435e-07
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 1.3397148904914502e-05

Furthermore O 0 2.9759644348814618e-06
, O 0 1.1399484911578384e-08
we O 0 4.046966317616807e-09
identified O 0 1.8232002574336548e-08
a O 0 2.3022629136448813e-08
glycine O 0 9.261128042226119e-08
to O 0 5.485674581251487e-09
alanine O 0 4.5520516778196907e-07
substitution O 0 1.233326401006707e-07
in O 0 3.178059415631651e-08
the O 0 2.0343753703855327e-07
collagenous O 0 0.0005117747350595891
domain O 0 3.906846814061282e-06
that O 0 2.2861150750230763e-09
is O 0 4.887740434611487e-09
apparently O 0 1.3282512156820303e-07
silent O 0 7.263501515808457e-07
in O 0 1.3289602307509085e-08
the O 0 3.1548015755333836e-08
heterozygous O 0 5.547165216057692e-08
carriers O 0 3.5444802648498808e-09
, O 0 2.7190367735130394e-09
in O 0 4.945377440890297e-08
11 O 0 1.892713839879434e-06
. O 0 7.295686259567447e-07

5 O 0 2.11433757613122e-06
% O 0 2.769949247749537e-08
of O 0 7.670335477882873e-09
all O 0 1.4014459592814887e-09
control O 0 3.83130007719501e-08
individuals O 0 2.2582617997812804e-09
, O 0 6.246625439132458e-10
and O 0 8.792636618792926e-10
in O 0 8.691927178006154e-09
one O 0 5.763737043196215e-09
control O 0 3.2911580127858997e-09
individual O 0 2.968501278122204e-10
homozygous O 0 7.898342535561653e-10
for O 0 7.425663556270834e-11
this O 0 6.923886464171858e-10
glycine O 0 9.953568991249995e-08
substitution O 0 1.3498051032456715e-07
. O 0 9.825942726138237e-08

There O 0 9.961895557353273e-07
has O 0 4.167744815930519e-09
been O 0 3.1282969548129813e-09
no O 0 1.6059323870720732e-09
previous O 0 7.557901859911453e-09
finding O 0 2.0791041777101782e-08
of O 0 1.2719300279684376e-08
a O 0 6.435582733388401e-09
glycine O 0 5.739055009001959e-09
substitution O 0 1.6076732167746854e-09
that O 0 2.3564794560115843e-10
is O 0 3.104999035663525e-10
not O 0 2.591801495643864e-10
associated O 0 2.694256817648011e-09
with O 0 4.755673077561084e-10
any O 0 2.7609088348867772e-08
obvious O 0 1.3797685483041278e-07
phenotype O 0 7.17971460062472e-08
in O 0 1.9150171226556267e-08
homozygous O 0 8.779321802876439e-08
individuals O 0 1.0035939190800036e-08
. O 0 1.4561661032530537e-07

Founder O 0 0.058524832129478455
BRCA1 O 0 1.8419530533719808e-05
and O 0 5.856337637055731e-08
BRCA2 O 0 3.873336709148134e-07
mutations O 0 6.29643803762292e-09
in O 0 7.595983397834516e-09
French O 0 4.809681286133127e-06
Canadian O 1 0.9984322190284729
breast B-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.623251020850148e-05
. O 0 2.7118397838421515e-07

We O 0 2.8560441478475695e-07
have O 0 1.576102803824142e-09
identified O 0 9.641845544194894e-09
four O 0 4.928538022141993e-09
mutations O 0 4.112906126785276e-10
in O 0 8.221126557295122e-10
each O 0 1.053059528466349e-09
of O 0 4.134429332225409e-08
the O 0 2.309785713805468e-06
breast B-Disease 1 0.9482505321502686
cancer I-Disease 0 0.00810209196060896
- O 0 2.904075699916575e-05
susceptibility O 0 2.2025255930202547e-06
genes O 0 8.533733719673364e-09
, O 0 1.0788302473585532e-09
BRCA1 O 0 3.3907057161997045e-09
and O 0 4.4003931054525935e-10
BRCA2 O 0 2.180390534789467e-09
, O 0 8.504962706323838e-11
in O 0 9.753819973923328e-10
French O 0 4.822177857022325e-07
Canadian O 0 0.00021358999947551638
breast B-Disease 1 0.9993686079978943
cancer I-Disease 0 0.48287639021873474
and O 0 0.0066864630207419395
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 9.169481245407951e-07
from O 0 1.971545628975946e-07
Quebec O 0 1.9793951651081443e-06
. O 0 4.1655380300653633e-07

To O 0 4.0104501408677606e-07
identify O 0 5.758541874456569e-07
founder O 0 2.8446147553040646e-05
effects O 0 4.7099387302296236e-05
, O 0 6.20743412227398e-09
we O 0 2.2609036864906784e-09
examined O 0 5.0989356736863556e-08
independently O 0 6.35498125234335e-08
ascertained O 0 6.604751092709193e-07
French O 0 3.6533467095978267e-07
Canadian O 0 1.198300083160575e-06
cancer B-Disease 0 1.2671979447986814e-06
families O 0 3.4493936595936248e-09
for O 0 3.2926320003845433e-10
the O 0 2.801305853949998e-09
distribution O 0 4.303965184249137e-09
of O 0 6.879973035722742e-09
these O 0 1.6046034501115969e-09
eight O 0 2.3387279668440897e-08
mutations O 0 1.56890536118226e-08
. O 0 3.8344143860058466e-08

Mutations O 0 1.8300272586202482e-06
were O 0 1.5217064230910182e-07
found O 0 1.2841279151132312e-08
in O 0 1.6395262036894565e-08
41 O 0 1.0762046542822645e-07
of O 0 2.42952836515542e-07
97 O 0 1.35046702780528e-05
families O 0 1.6295413729494612e-07
. O 0 2.67043049007043e-07

Six O 0 2.5829488095041597e-06
of O 0 3.1685237900092034e-07
eight O 0 1.3643362706261541e-07
mutations O 0 2.4601456871664595e-08
were O 0 2.2565792789919215e-08
observed O 0 6.84630805380948e-08
at O 0 3.7334868352445483e-07
least O 0 4.2030475100318654e-08
twice O 0 2.5655796775936324e-07
. O 0 1.772773430275265e-07

The O 0 2.4490407668054104e-05
BRCA1 O 0 1.2301623428356834e-05
C4446T O 0 1.6543739548069425e-05
mutation O 0 3.1602517935880314e-08
was O 0 5.74890748339385e-08
the O 0 1.2531041981844737e-08
most O 0 4.684739263183246e-10
common O 0 7.407164881456652e-10
mutation O 0 3.6433878136676867e-10
found O 0 2.280462263470895e-09
, O 0 5.940958280881148e-10
followed O 0 6.121509965595351e-09
by O 0 4.259814279095053e-09
the O 0 1.3376096319461794e-07
BRCA2 O 0 4.4262907294978504e-07
8765delAG O 0 5.937882860962418e-07
mutation O 0 3.660415259787442e-08
. O 0 4.122366092929042e-08

Together O 0 1.395910544488288e-06
, O 0 1.3736221937676873e-08
these O 0 1.719702935609746e-09
mutations O 0 6.431998933464911e-09
were O 0 3.646061230710984e-08
found O 0 1.4646053259070868e-08
in O 0 1.4702366435415115e-08
28 O 0 1.7136277108420472e-07
of O 0 1.494564259019171e-07
41 O 0 4.2976594727406336e-07
families O 0 1.0318808918441391e-08
identified O 0 5.342721820511542e-08
to O 0 1.050824938175765e-08
have O 0 2.587298153500228e-09
a O 0 1.1765207119651677e-07
mutation O 0 4.9397584689359064e-08
. O 0 1.1318211790012356e-07

The O 0 7.356971764238551e-06
odds O 0 1.6589638107689098e-05
of O 0 1.6406703196025774e-07
detection O 0 3.4454046726750676e-07
of O 0 4.976507739229419e-08
any O 0 4.5928096881198144e-08
of O 0 1.4355507005348045e-07
the O 0 1.0800253136267202e-07
four O 0 2.428979541946319e-07
BRCA1 O 0 1.1936471366880141e-07
mutations O 0 2.4271784582197142e-09
was O 0 3.3563256351953896e-07
18 O 0 5.710814434678468e-07
. O 0 2.923586919223453e-07

7x O 0 0.010427211411297321
greater O 0 1.1689796792779816e-06
if O 0 2.6037552558477728e-08
one O 0 6.302578015038307e-09
or O 0 9.063719219604138e-10
more O 0 8.085040276162303e-11
cases O 0 6.409755504144243e-10
of O 0 0.003254401031881571
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 0.0028840494342148304
also O 0 2.8599478341106988e-09
present O 0 6.087116588560093e-09
in O 0 1.3595703229896117e-08
the O 0 1.9041965515498305e-07
family O 0 5.909151923333411e-07
. O 0 2.2577766856102244e-07

The O 0 4.172549324721331e-06
odds O 0 1.5738673027954064e-05
of O 0 1.665471245360095e-07
detection O 0 2.8127442419645377e-07
of O 0 5.145204085010846e-08
any O 0 2.7828706450350182e-08
of O 0 1.4397227232620935e-07
the O 0 2.402641712251352e-07
four O 0 1.188070939406316e-07
BRCA2 O 0 1.901095458833879e-07
mutations O 0 4.037891354613521e-09
was O 0 3.4162005135840445e-07
5 O 0 4.5504671675189456e-07
. O 0 1.375901490519027e-07

3x O 0 0.0007200484396889806
greater O 0 5.043301030127623e-07
if O 0 2.7966841287252464e-08
there O 0 1.7497063353744124e-08
were O 0 1.4330400865958381e-08
at O 0 3.9032531873317566e-08
least O 0 8.186764044459949e-10
five O 0 6.319221812489673e-10
cases O 0 2.902513784874827e-10
of O 0 5.989353013546861e-08
breast B-Disease 0 0.015512901358306408
cancer I-Disease 0 0.0002041268307948485
in O 0 2.0296349703130545e-06
the O 0 2.588347160781268e-05
family O 0 7.013516551523935e-06
. O 0 2.334628277367301e-07

Interestingly O 0 1.2797027011401951e-05
, O 0 1.6010183401249378e-08
the O 0 1.161751495004637e-08
presence O 0 3.995625874608777e-08
of O 0 4.818569436793041e-07
a O 0 4.877201263298048e-06
breast B-Disease 0 4.846630690735765e-05
cancer I-Disease 0 4.732224851977662e-07
case O 0 2.5883909415824746e-07
< O 0 9.674026841821615e-07
36 O 0 9.769781428303759e-09
years O 0 1.6445711459311951e-09
of O 0 3.7179432865741546e-09
age O 0 1.4837447714910468e-08
was O 0 4.888339688591259e-08
strongly O 0 2.8343591917945332e-09
predictive O 0 1.533734206304871e-08
of O 0 1.761236823050183e-09
the O 0 2.212704242054997e-09
presence O 0 3.7979752676164935e-09
of O 0 2.874836191324448e-08
any O 0 1.777036473527005e-08
of O 0 2.4725412828274784e-08
the O 0 1.9602810041874363e-08
eight O 0 3.81758660239484e-08
mutations O 0 6.4437140068207555e-09
screened O 0 2.3511289271027636e-07
. O 0 1.8000996249156742e-07

Carriers O 0 2.7086912268714514e-06
of O 0 3.259073935168999e-07
the O 0 5.645169665058347e-08
same O 0 1.1745449945976816e-08
mutation O 0 2.8207953750580828e-09
, O 0 1.2710071883859086e-10
from O 0 1.6363631283322633e-10
different O 0 1.165252200285849e-10
families O 0 1.1900589402813466e-09
, O 0 4.2500411523427317e-10
shared O 0 7.044578254067346e-09
similar O 0 5.340294428890502e-09
haplotypes O 0 2.0414887558217742e-07
, O 0 2.5407080883610433e-09
indicating O 0 3.2585667497642135e-08
that O 0 2.560902323534009e-10
the O 0 2.0190602523229018e-09
mutant O 0 2.486824790537412e-08
alleles O 0 6.871511137873654e-10
were O 0 1.980061004047684e-09
likely O 0 1.0116903981227665e-09
to O 0 3.4100181012242103e-10
be O 0 6.62306876009211e-10
identical O 0 2.6606239433846213e-09
by O 0 4.541958364967513e-09
descent O 0 1.657404737898105e-07
for O 0 6.574113697865869e-09
a O 0 3.9814757712974824e-08
mutation O 0 3.3778599917155816e-09
in O 0 3.5872329551267512e-09
the O 0 9.696049829699405e-08
founder O 0 2.1745747289969586e-05
population O 0 1.9387366378964543e-08
. O 0 5.9600321122843525e-08

The O 0 3.322814450257283e-07
identification O 0 9.02148826753546e-08
of O 0 5.938177949360579e-08
common O 0 4.261807617922386e-08
BRCA1 O 0 8.318883004676536e-08
and O 0 5.073419462320317e-09
BRCA2 O 0 2.9313468985492364e-08
mutations O 0 5.711882078429653e-10
will O 0 1.894207152242089e-10
facilitate O 0 7.448339278681715e-09
carrier O 0 1.8184007188892792e-08
detection O 0 1.848541728577402e-07
in O 0 7.327815687574457e-09
French O 0 1.4688075680169277e-05
Canadian O 1 0.9165223240852356
breast B-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9553520083427429
and O 0 0.0014952515484765172
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.604536237209686e-06
. O 0 9.395134981105002e-08

Are O 0 2.544631570344791e-06
Dp71 O 0 0.0005203972687013447
and O 0 3.6716247109325195e-07
Dp140 O 0 0.0009565690997987986
brain O 0 0.0012632824946194887
dystrophin O 0 2.4263281375169754e-05
isoforms O 0 2.0521720500710217e-07
related O 0 7.522640999013674e-08
to O 0 8.519778660343036e-09
cognitive B-Disease 1 0.8120770454406738
impairment I-Disease 1 0.9999982118606567
in O 0 0.001149832271039486
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
? O 0 4.255556996213272e-05

Molecular O 0 3.582263889256865e-05
study O 0 1.1855853898623536e-07
and O 0 3.5412501819820363e-09
neuropsychological O 0 3.3952963462979824e-07
analysis O 0 3.7066794078555176e-08
were O 0 7.842667848478868e-09
performed O 0 8.218575153762231e-09
concurrently O 0 2.0824499458171886e-08
on O 0 2.834063472789694e-08
49 O 0 7.710617921929952e-08
patients O 0 5.722058826762577e-09
with O 0 1.2027149942639426e-08
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 3.7426747439894825e-05
DMD B-Disease 1 1.0
) O 0 2.802920118227803e-09
in O 0 8.22162782299074e-10
order O 0 2.226645756664425e-09
to O 0 1.9646706483911203e-09
find O 0 1.696190565780853e-08
a O 0 1.4130312031568337e-08
molecular O 0 4.890018345804492e-08
explanation O 0 3.010550742033047e-08
for O 0 6.205252978119802e-10
the O 0 1.691525319813536e-08
cognitive B-Disease 0 0.00019615945348050445
impairment I-Disease 0 2.401663914497476e-05
observed O 0 5.991215346057288e-08
in O 0 1.498997193039031e-08
most O 0 4.405579190347453e-08
DMD B-Disease 1 1.0
patients O 0 9.02411841252615e-07
. O 0 1.2868304111179896e-07

Complete O 0 2.8622196168726077e-06
analysis O 0 2.52384410259765e-07
of O 0 9.797945921263818e-08
the O 0 8.322580669073432e-08
dystrophin O 0 1.4308244544736226e-06
gene O 0 1.592846032849593e-08
was O 0 7.393635570451806e-08
performed O 0 7.2972423659223296e-09
to O 0 1.759715928528749e-09
define O 0 2.861564318834553e-08
the O 0 2.7874657249071788e-08
localization O 0 1.8802802514983341e-06
of O 0 3.181170171728809e-08
deletions O 0 4.2977166714308623e-08
and O 0 6.50166409599251e-09
duplications O 0 1.006614411380724e-06
in O 0 6.878519798192428e-08
relation O 0 1.0274707165081054e-06
to O 0 2.3559787010185573e-08
the O 0 2.2421815515372145e-07
different O 0 4.202337891001662e-07
DMD B-Disease 1 1.0
promoters O 0 0.00010823827324202284
. O 0 8.144173762048013e-07

Qualitative O 0 1.2490052540670149e-05
analysis O 0 2.4539534138057206e-07
of O 0 1.1513773046090137e-07
the O 0 2.00843402353712e-07
Dp71 O 0 4.093308962183073e-05
transcript O 0 1.7941780470209778e-06
and O 0 1.9155861341602076e-09
testing O 0 1.7239395466717156e-09
for O 0 5.759316912268275e-10
the O 0 5.132811953245664e-09
specific O 0 2.685335287466728e-09
first O 0 6.994120838044182e-08
exon O 0 2.3878348542893946e-07
of O 0 1.0232263747411707e-07
Dp140 O 0 1.8266865708937985e-06
were O 0 1.2155750539477594e-07
also O 0 4.302586287252552e-09
carried O 0 5.3308326641854364e-08
out O 0 4.7777163558748725e-08
. O 0 2.0672145240041573e-07

Neuropsychological O 0 7.239628757815808e-05
analysis O 0 1.373232748846931e-06
assessed O 0 2.1978798940835986e-06
verbal O 0 7.672279025427997e-06
and O 0 4.2769787000906945e-07
visuospatial O 1 0.9982832670211792
intelligence O 0 0.00015718246868345886
, O 0 8.649296745488755e-08
verbal O 0 2.6604748200043105e-05
memory O 1 0.9998188614845276
, O 0 5.131346370035317e-08
and O 0 2.9909649867931876e-08
reading O 0 2.6182822693954222e-05
skills O 0 0.0007020736811682582
. O 0 3.4182280614913907e-06

Comparison O 0 6.568051958311116e-06
of O 0 2.63375994791204e-07
molecular O 0 1.3030366972088814e-06
and O 0 2.7540398406245004e-08
psychometric O 0 1.9295459424029104e-05
findings O 0 2.8996760192967486e-07
demonstrated O 0 3.3562830736855176e-08
that O 0 9.45376332772696e-10
deletions O 0 1.093982149313888e-08
and O 0 1.1412880640548906e-09
duplications O 0 4.4026474910197066e-08
that O 0 9.71581259889831e-10
were O 0 1.1950089806589403e-08
localized O 0 6.969045784899208e-08
in O 0 2.5420810345622158e-08
the O 0 2.616859831050533e-07
distal O 0 3.059960590690025e-06
part O 0 2.1479786482814234e-07
of O 0 3.923604253941448e-06
the O 0 1.967557182069868e-06
gene O 0 3.046467966782984e-08
seemed O 0 4.309569945348812e-08
to O 0 1.0037368713966544e-09
be O 0 6.852964307135778e-10
preferentially O 0 1.1165637303633957e-08
associated O 0 3.378957202926358e-08
with O 0 1.939483773583106e-08
cognitive B-Disease 1 0.9999425411224365
impairment I-Disease 1 0.9999794960021973
. O 0 3.4927875276480336e-06

Two O 0 3.3902986160683213e-06
altered O 0 1.5583453887302312e-06
Dp71 O 0 8.919397805584595e-05
transcripts O 0 3.694434326462215e-06
and O 0 1.0160846386497724e-08
two O 0 7.707967597525567e-09
deleted O 0 3.538241344358539e-07
Dp140 O 0 2.3273324245565163e-07
DNA O 0 1.908785129955959e-08
sequences O 0 1.2548261985045883e-08
were O 0 4.434425715515999e-09
found O 0 1.3397097875511577e-09
in O 0 1.1649639031219294e-09
four O 0 1.6155617288404756e-08
patients O 0 3.2634479563142804e-09
with O 0 5.9718407996456335e-09
severe O 1 0.9999973773956299
cerebral B-Disease 1 1.0
dysfunction I-Disease 1 1.0
. O 0 7.781780368532054e-06

These O 0 8.661314865321401e-08
findings O 0 1.2087811285255157e-07
suggest O 0 3.2977009567503046e-08
that O 0 3.929730707508128e-10
some O 0 4.718718193963412e-10
sequences O 0 1.167032781523858e-08
located O 0 1.237017777100391e-08
in O 0 1.583569719798561e-09
the O 0 2.3340220423051505e-08
distal O 0 3.1226122132466116e-07
part O 0 6.28649274858617e-08
of O 0 2.3591765341279824e-07
the O 0 7.942158930518417e-08
gene O 0 2.041652624740209e-09
and O 0 2.578832425381705e-10
, O 0 1.8142207180993353e-10
in O 0 6.714189759726708e-10
particular O 0 3.758943378784352e-09
, O 0 1.3890130157179215e-09
some O 0 5.411081804851392e-09
DMD B-Disease 1 1.0
isoforms O 0 3.548939986330879e-08
expressed O 0 2.8957578557253782e-09
in O 0 3.5019098731936538e-09
the O 0 4.459543134771593e-08
brain O 0 1.2819280527764931e-05
may O 0 5.679944514724866e-09
be O 0 1.273116279065789e-09
related O 0 1.23481127545233e-08
to O 0 2.225155393276168e-09
the O 0 9.352938690199153e-08
cognitive B-Disease 1 0.9338653683662415
impairment I-Disease 0 0.07028612494468689
associated O 0 4.5591996240545996e-06
with O 0 6.721793397446163e-07
DMD B-Disease 1 1.0
. O 0 2.0016896939978324e-07
. O 0 2.4990501401589427e-07

I1307K O 0 0.00033789550070650876
APC O 0 8.263072231784463e-06
and O 0 2.188470382691321e-08
hMLH1 O 0 6.054402774680057e-07
mutations O 0 1.8766776577194832e-08
in O 0 2.5702908246216793e-08
a O 0 1.3127690579040063e-07
non O 0 7.534305768785998e-05
- O 0 1.4366587492986582e-05
Jewish O 0 1.7280563042731956e-05
family O 0 2.0721095950193558e-07
with O 0 7.058499118528516e-09
hereditary B-Disease 1 1.0
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0004867940442636609

We O 0 8.040115631047229e-07
describe O 0 7.480888370992034e-07
a O 0 2.6966213795276417e-07
French O 0 3.7617103316733846e-06
Canadian O 0 3.93157679354772e-05
hereditary B-Disease 1 1.0
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 1 1.0
HNPCC B-Disease 1 1.0
) O 0 2.0026310210141673e-07
kindred O 0 9.258686077373568e-06
which O 0 3.012881277797419e-09
carries O 0 1.6011314940556076e-08
a O 0 1.3442102542171597e-08
novel O 0 1.063674588408503e-07
truncating O 0 3.5778300571109867e-06
mutation O 0 3.983556950970524e-08
in O 0 5.685572901370506e-08
hMLH1 O 0 6.428091637644684e-06
. O 0 4.872352405982383e-07

Interestingly O 0 3.1198842407320626e-06
, O 0 1.414123129706013e-08
the O 0 4.4103128260530866e-08
I1307K O 0 5.364806384022813e-06
APC O 0 8.05319132268778e-07
polymorphism O 0 7.326406858965129e-08
, O 0 5.01976404887472e-10
associated O 0 2.2220085771351705e-09
with O 0 1.4670333003952152e-10
an O 0 2.426993050974602e-09
increased O 0 4.104994744125179e-08
risk O 0 4.307163544581272e-05
of O 1 0.9999988079071045
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 2.3479587980546057e-06
is O 0 7.933587120589891e-09
also O 0 1.6589585261073125e-10
present O 0 5.669497094018539e-10
in O 0 3.632398826169947e-09
this O 0 2.0549014934090337e-08
family O 0 4.49000452817927e-07
. O 0 1.8353757980094088e-07

The O 0 3.7840366076125065e-06
I1307K O 0 1.055958910001209e-05
polymorphism O 0 1.0882994274652447e-06
has O 0 1.2774873381360408e-09
previously O 0 7.4491341983673465e-09
only O 0 4.957952381978714e-10
been O 0 1.2228246193402015e-09
identified O 0 3.1273483802607416e-09
in O 0 9.412525203700284e-10
individuals O 0 9.895976260665407e-10
of O 0 2.5388695235051273e-07
self O 0 9.307178697781637e-05
- O 0 8.581055226386525e-06
reported O 0 5.159041052138491e-07
Ashkenazi O 0 8.647743356959836e-07
Jewish O 0 6.080934440433339e-07
origins O 0 2.712323066589306e-06
. O 0 3.1782235510036116e-07

In O 0 1.180400772682333e-06
addition O 0 1.1024913249002566e-07
, O 0 9.12199737967967e-09
in O 0 6.353124692992651e-09
this O 0 9.960592350921615e-09
family O 0 6.444429345719982e-08
, O 0 1.3721682678990987e-09
there O 0 4.6862966840421905e-09
appears O 0 3.183853181099039e-08
to O 0 6.3912271031085766e-09
be O 0 1.4150647764665791e-08
no O 0 1.8656923117532642e-08
relationship O 0 1.4805699777298287e-08
between O 0 1.6464770880020296e-08
the O 0 2.4033077750118537e-08
I1307K O 0 8.394848123316478e-07
polymorphism O 0 9.908790588042393e-08
and O 0 8.65483296141889e-10
the O 0 6.218952908199071e-09
presence O 0 1.8296308468279676e-08
or O 0 2.9783382871073627e-08
absence O 0 3.862720063807501e-07
of O 0 2.1127978016011184e-06
cancer B-Disease 0 4.60480987385381e-06
. O 0 3.896239419987069e-08
. O 0 1.5769161620937666e-07

Identification O 0 2.5370422918058466e-06
of O 0 1.6339295427769684e-07
a O 0 5.339136066595529e-08
novel O 0 8.498246018007194e-08
mutation O 0 7.270859470054347e-09
of O 0 5.609000552908583e-08
the O 0 3.900321701166831e-07
CPO O 0 0.00012114350829506293
gene O 0 5.68269982181846e-08
in O 0 4.584363821891202e-08
a O 0 2.1399384877440752e-06
Japanese O 0 0.053560469299554825
hereditary B-Disease 1 0.9999979734420776
coproporphyria I-Disease 1 0.9996933937072754
family O 0 2.3206544938148e-05
. O 0 1.0600083442113828e-06

Hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 1.0
( O 0 0.03832564502954483
HCP B-Disease 1 1.0
) O 0 3.5634016626318044e-07
is O 0 1.7713547961761833e-08
an O 0 2.056031149777482e-07
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disease I-Disease 1 0.9999996423721313
characterized O 0 1.274529381589673e-06
by O 0 4.536696707191368e-08
a O 0 1.051524577633245e-06
deficiency B-Disease 0 0.0056615835055708885
of I-Disease 0 8.570771024096757e-05
coproporphyrinogen I-Disease 0 0.21348492801189423
oxidase I-Disease 0 1.6913918443606235e-06
( O 0 1.332880117388413e-07
CPO O 0 2.8102660508011468e-05
) O 0 8.88167051016353e-09
caused O 0 2.1688112639139945e-08
by O 0 2.8376048177847224e-09
a O 0 1.3895542494424262e-08
mutation O 0 1.5260358532387386e-09
in O 0 6.860108037187729e-09
the O 0 1.303686332221332e-07
CPO O 0 4.163543417234905e-05
gene O 0 2.284998714685571e-07
. O 0 1.2356575496141886e-07

Only O 0 3.499982597077178e-07
11 O 0 3.363942653322738e-07
mutations O 0 4.8851123146675945e-09
of O 0 1.2063495979930394e-08
the O 0 9.9659558827625e-08
gene O 0 2.3402629167890154e-08
have O 0 4.823771604378635e-09
been O 0 2.1023565111022435e-08
reported O 0 8.581529442608371e-08
in O 0 1.864854937139171e-07
HCP B-Disease 1 0.9999991655349731
patients O 0 1.7969897498915088e-06
. O 0 3.4264161286046146e-07

We O 0 1.1204763268324314e-06
report O 0 2.7591144657890254e-07
another O 0 1.1727690463203544e-07
mutation O 0 1.7497363558049983e-08
in O 0 1.889982925717959e-08
a O 0 6.047206397852278e-07
Japanese O 0 0.0002134031237801537
family O 0 3.18286265610368e-06
. O 0 4.771633257405483e-07

Polymerase O 0 4.701323268818669e-05
chain O 0 1.5747026509416173e-06
reaction O 0 6.077095804357668e-08
- O 0 1.6287397386349767e-07
single O 0 3.396318959403288e-08
strand O 0 3.7943710395893504e-08
conformational O 0 7.211305330656614e-09
polymorphism O 0 7.177070049380063e-09
and O 0 1.30992341973446e-10
direct O 0 1.3915772978378982e-09
sequence O 0 4.612568993422883e-09
analyses O 0 2.720521941057541e-08
demonstrated O 0 8.112529314985295e-09
a O 0 1.8808595569907993e-08
C O 0 1.1888133144566382e-07
to O 0 4.589856050785102e-09
T O 0 2.214140693013178e-08
substitution O 0 2.512281715993936e-09
in O 0 8.31356494757074e-09
exon O 0 3.738153608878747e-08
1 O 0 9.227130171041154e-09
of O 0 6.9023444737581485e-09
the O 0 2.6245869477747874e-08
CPO O 0 1.6873544836926158e-06
gene O 0 6.788454687267631e-09
at O 0 3.6617841203678836e-08
nucleotide O 0 6.364624738353086e-08
position O 0 9.690207747325985e-08
85 O 0 1.1219397322292934e-07
, O 0 1.3896596096074632e-09
which O 0 1.0430745156497778e-09
lies O 0 9.073863083131073e-08
in O 0 1.5008740916755414e-08
the O 0 6.59062564523083e-08
putative O 0 2.152579554604017e-06
presequence O 0 1.7123842326327576e-06
for O 0 1.0895404578548096e-08
targeting O 0 4.0334672490871526e-08
to O 0 1.997583254365054e-08
mitochondria O 0 2.061325631075306e-06
. O 0 4.410682947764144e-07

This O 0 2.6797952301649275e-08
mutation O 0 1.3513457020053465e-09
changes O 0 2.7527871648835855e-10
the O 0 5.03049202293937e-09
codon O 0 4.2936935784609886e-08
for O 0 3.023070016539009e-09
glutamine O 0 5.252872625760574e-08
to O 0 3.167334394760246e-09
a O 0 2.2151461109842785e-08
termination O 0 1.023487925522204e-07
codon O 0 3.1342895567831874e-07
at O 0 1.5007857712134864e-07
amino O 0 1.08107442997607e-07
acid O 0 1.0268394134982373e-07
position O 0 8.388877859033528e-07
29 O 0 3.4953297927131644e-06
. O 0 7.107940973583027e-07

MaeI O 0 0.001352548599243164
restriction O 0 6.504692464659456e-07
analysis O 0 1.2818868810882122e-07
showed O 0 3.659898339947176e-08
two O 0 1.5570219558114218e-09
other O 0 1.0241353320949997e-09
carriers O 0 3.710872720219527e-09
in O 0 2.3858651942987308e-08
the O 0 5.99935162881593e-07
family O 0 5.829273504787125e-06
. O 0 8.742140380491037e-07

The O 0 2.0839712306042202e-05
C O 1 0.9413275122642517
- O 0 0.2683388590812683
T O 0 1.835551120166201e-05
mutation O 0 8.518023619785708e-09
is O 0 1.5175688483637373e-09
located O 0 5.687728510395118e-09
within O 0 8.090339953525927e-09
a O 0 1.192172405239944e-08
recently O 0 3.294380102047967e-09
proposed O 0 2.813740129781195e-09
putative O 0 5.5013835265071975e-08
alternative O 0 4.846467227537232e-09
translation O 0 6.03320842174071e-08
initiation O 0 4.8937788932335025e-08
codon O 0 6.136897212627446e-08
( O 0 2.7415230086091924e-09
TIC O 0 1.1511094299976321e-07
- O 0 2.315876379554993e-08
1 O 0 3.5479111204494984e-08
) O 0 1.0906272551736151e-09
, O 0 5.818009962688109e-10
supporting O 0 1.9666362760517586e-08
that O 0 4.373694295622954e-09
TIC O 0 1.440509890926478e-06
- O 0 3.096870102581306e-07
1 O 0 1.1804486632627231e-07
is O 0 2.18289963882512e-09
the O 0 9.977229709079438e-09
real O 0 1.7195028476635343e-06
TIC O 0 6.551312253577635e-06
rather O 0 5.4629772705538926e-08
than O 0 2.058475168098539e-08
TIC O 0 2.2933543277758872e-06
- O 0 1.235971041069206e-07
2 O 0 5.680391979012711e-08
. O 0 9.87243442551744e-09
. O 0 8.236578707965236e-08

Human B-Disease 0 1.7745945797287277e-06
complement I-Disease 0 5.0002936404780485e-06
factor I-Disease 0 0.19446030259132385
H I-Disease 1 1.0
deficiency I-Disease 1 1.0
associated O 1 0.5000213980674744
with O 0 0.00043411063961684704
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.10950101166963577

This O 0 2.900193294408382e-07
study O 0 9.509164300425255e-08
reports O 0 4.0984623694839684e-08
on O 0 5.032488203937646e-09
six O 0 4.6809365272793e-09
cases O 0 1.121095771772218e-09
of O 0 4.037022804936896e-08
deficiency B-Disease 1 0.735249936580658
in I-Disease 0 8.05852593543932e-08
the I-Disease 0 5.946723646843566e-08
human I-Disease 0 2.2417991907275336e-09
complement I-Disease 0 5.07640063318604e-09
regulatory I-Disease 0 1.514464109675373e-08
protein I-Disease 0 1.7781315975184953e-08
Factor I-Disease 0 1.6265819624550204e-07
H I-Disease 0 0.075063556432724
( O 0 1.560769113950755e-08
FH O 0 2.0941376988048432e-06
) O 0 1.7927322126798373e-10
in O 0 6.842381522487173e-11
the O 0 3.426343653245567e-10
context O 0 5.7177276246989095e-09
of O 0 3.660301839403246e-09
an O 0 7.258557843670133e-08
acute B-Disease 1 1.0
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 2.5845383788691834e-05

Five O 0 1.147045395555324e-06
of O 0 1.224040317993058e-07
the O 0 1.4607635989705159e-08
cases O 0 2.9270548207449565e-09
were O 0 3.719716534789086e-09
observed O 0 5.037088079973273e-09
in O 0 1.5821207677291227e-09
children O 0 1.3620431449368198e-09
presenting O 0 1.6882094655557012e-07
with O 0 1.445767338736914e-06
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 1.0
HUS B-Disease 1 1.0
) O 0 0.00040108183748088777
. O 0 5.901188160351012e-06

Two O 0 1.3594437575648044e-07
of O 0 3.895421585298209e-08
the O 0 1.784148118133544e-08
children O 0 4.5228358835913696e-09
exhibited O 0 6.745399332430679e-07
a O 0 2.3269712983164936e-06
homozygous O 0 1.6173324183910154e-05
deficiency O 0 0.15760445594787598
characterized O 0 6.043931222166066e-08
by O 0 6.084051928922918e-09
the O 0 5.100083555475976e-08
absence O 0 1.0719108445300662e-07
of O 0 7.603886587048692e-08
the O 0 4.176516199549951e-08
150 O 0 3.4158933459593754e-08
- O 0 1.1890067597164489e-08
kD O 0 1.584208689564548e-06
form O 0 8.766384063108035e-09
of O 0 4.910234565613791e-07
Factor O 0 3.52701754309237e-05
H O 1 0.9999997615814209
and O 0 3.4517497748964843e-09
the O 0 1.3619425587307887e-08
presence O 0 1.7758200243633837e-08
, O 0 7.778411248438033e-10
upon O 0 2.972810619894517e-08
immunoblotting O 0 6.29972021215508e-07
, O 0 2.277289246066516e-09
of O 0 1.1185973924909831e-08
the O 0 1.0286110629920131e-08
42 O 0 5.734090890996413e-08
- O 0 7.958900738458397e-08
kD O 0 4.8221183533314615e-05
Factor O 0 3.26672634400893e-05
H O 1 0.9994394183158875
- O 0 2.2722709047684475e-07
like O 0 6.670627161753373e-09
protein O 0 9.40384481395995e-09
1 O 0 2.1834004826359887e-08
( O 0 1.9383217253476914e-09
FHL O 0 4.21531495931049e-07
- O 0 2.2264343257916153e-08
1 O 0 8.95426754965456e-09
) O 0 2.279830491058732e-10
and O 0 2.8940005947220016e-10
other O 0 1.6727841334329696e-09
FH O 0 7.966797056724317e-06
- O 0 1.6819195991502056e-07
related O 0 1.5004624742687156e-07
protein O 0 1.8186855754720455e-07
( O 0 3.1062342031873413e-08
FHR O 0 1.7529286196804605e-05
) O 0 1.8610824881193366e-08
bands O 0 4.352754388037283e-07
. O 0 4.3345895051061234e-07

Southern O 0 3.907003247149987e-06
blot O 0 2.685201252461411e-06
and O 0 1.0450384557714187e-08
PCR O 0 1.1344125283585527e-07
analysis O 0 1.1494328155947642e-08
of O 0 8.950340912861066e-09
DNA O 0 2.414979327625133e-08
of O 0 1.7064772706021358e-08
one O 0 1.9589053934510048e-08
patient O 0 7.02558011766996e-08
with O 0 3.2349400935771655e-09
homozygous O 0 1.8663811260921648e-06
deficiency O 0 0.10424827039241791
ruled O 0 1.451150239972776e-07
out O 0 5.314119810861939e-09
the O 0 4.240796158683224e-09
presence O 0 2.408009791565746e-09
of O 0 6.106268379824087e-09
a O 0 2.78509926232573e-09
large O 0 9.950675838865664e-10
deletion O 0 1.1837479441112464e-08
of O 0 2.9418997016250614e-08
the O 0 9.03926391515597e-08
FH O 0 0.00015184018411673605
gene O 0 4.05581390694465e-09
as O 0 2.1024637586464223e-09
the O 0 1.6694222892965627e-08
underlying O 0 0.00011185918265255168
defect O 0 1.7475905451647122e-06
for O 0 2.3463551102054225e-08
the O 0 2.2450840333476663e-06
deficiency O 1 0.9999542236328125
. O 0 2.4832377221173374e-06

The O 0 7.108666864041879e-07
other O 0 1.8648409483290607e-09
four O 0 2.9818154612115677e-09
children O 0 4.317710633472416e-10
presented O 0 6.788143824820736e-09
with O 0 1.6167822636248275e-08
heterozygous O 0 1.942684866662603e-05
deficiency O 1 0.7128315567970276
and O 0 1.6298917770996013e-08
exhibited O 0 2.9312770948308753e-06
a O 0 2.47955063059635e-06
normal O 0 1.1693125088640954e-05
immunoblotting O 0 5.861193130840547e-06
pattern O 0 2.9222655939520337e-07
of O 0 9.404170953075663e-08
proteins O 0 1.8183520467118797e-08
of O 0 2.910180683102226e-06
the O 0 0.00011465435090940446
FH O 1 0.9999979734420776
family O 0 1.6808959117042832e-05
. O 0 6.171813993205433e-07

Factor B-Disease 1 1.0
H I-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 3.0128941119755837e-08
the O 0 1.6606412245323554e-08
only O 0 4.576570944436753e-08
complement B-Disease 1 0.9999997615814209
deficiency I-Disease 1 1.0
associated O 0 0.00013500408385880291
with O 0 8.85027020558482e-07
HUS B-Disease 1 1.0
. O 0 1.2048031749145593e-05

These O 0 2.724645042917473e-08
observations O 0 4.766157246649527e-07
suggest O 0 7.417958869382346e-08
a O 0 1.9137610607344868e-08
role O 0 2.4251527008800622e-08
for O 0 1.8533672374587695e-08
FH O 0 2.849407246685587e-05
and O 0 4.599743874678097e-08
/ O 0 5.9998887991241645e-06
or O 0 2.2339385452596616e-07
FH O 0 7.094007742125541e-05
receptors O 0 2.5165991957010192e-08
in O 0 1.0924510185361669e-09
the O 0 1.3013432109687528e-08
pathogenesis O 0 0.0006148028769530356
of O 0 4.8119523853529245e-05
idiopathic O 1 0.9999996423721313
HUS B-Disease 1 1.0
. O 0 7.411608748952858e-07
. O 0 5.382847803048207e-07

Further O 0 2.5827051786109223e-07
evidence O 0 3.1790264642950206e-07
for O 0 4.797520158916768e-09
a O 0 1.4455197039353607e-08
major O 0 9.653253307817522e-09
ancient O 0 2.2806952983955853e-06
mutation O 0 9.610138249627198e-07
underlying O 1 0.986465334892273
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 1.8065814799683722e-07
linkage O 0 1.5791646319485153e-06
disequilibrium O 0 4.150103450228926e-06
studies O 0 1.643126523731553e-08
in O 0 1.0309262332697244e-09
the O 0 1.126485038582814e-08
Japanese O 0 7.896509828242415e-07
population O 0 1.5178264201054503e-09
. O 0 1.0912604153645589e-08

The O 0 0.0006520659662783146
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0021876238752156496
DM B-Disease 1 1.0
) O 0 1.9438539666793986e-08
mutation O 0 1.0565763819414542e-09
is O 0 3.763877265416937e-10
an O 0 3.738123144358951e-09
unstable O 0 6.544305506395176e-06
( O 0 4.41391904359989e-07
CTG O 0 0.0004967191489413381
) O 0 4.835334621589027e-08
n O 0 3.0265189820966043e-07
repeat O 0 1.6904439803511195e-07
, O 0 3.474266874192722e-09
present O 0 2.6396882901735808e-08
at O 0 3.713477099154261e-07
a O 0 3.958531991088421e-08
copy O 0 8.061077494403435e-08
number O 0 2.3348714073279098e-09
of O 0 4.866531622127468e-09
5 O 0 3.50371536228522e-08
- O 0 1.948902728088342e-08
37 O 0 2.441606028469323e-08
repeats O 0 1.9434832410070157e-08
on O 0 6.774084404526093e-09
normal O 0 1.033904073466374e-08
chromosomes O 0 1.007748107184625e-09
but O 0 1.2128244242237685e-10
amplified O 0 3.771784218287166e-09
to O 0 2.2826991408209096e-09
50 O 0 2.3786725478203152e-08
- O 0 1.2858338394039492e-08
3000 O 0 7.71407542288216e-08
copies O 0 5.088540433462185e-08
on O 0 3.3310448088741396e-07
DM B-Disease 1 0.9979887008666992
chromosomes O 0 1.793498881852429e-06
. O 0 2.0693526892046066e-07

Previous O 0 6.9389238888106775e-06
findings O 0 2.618502321638516e-07
in O 0 1.4264081471537793e-08
Caucasian O 0 1.2183318176539615e-06
populations O 0 1.6044022999039953e-08
of O 0 3.0449695032075397e-07
a O 0 0.00017543983994983137
DM B-Disease 1 1.0
founder O 1 0.9270078539848328
chromosome O 0 4.950179572915658e-06
raise O 0 4.4152027811605876e-08
a O 0 2.2723485315623293e-08
question O 0 1.2901994139724593e-08
about O 0 5.818476811469964e-10
the O 0 3.283577632018364e-09
molecular O 0 2.1191244314877622e-08
events O 0 4.0879206686383895e-09
involved O 0 3.4867071452282516e-09
in O 0 3.734410114475395e-09
the O 0 9.94523485786658e-09
expansion O 0 1.2810338034796587e-07
mutation O 0 1.357898682385894e-08
. O 0 4.1174001097488144e-08

To O 0 9.930829492077464e-07
investigate O 0 1.4336313824969693e-06
whether O 0 1.0859806565122199e-07
a O 0 3.4241492130604456e-07
founder O 0 4.278767846699338e-06
chromosome O 0 1.0855478649318684e-07
for O 0 6.399350827024364e-09
the O 0 1.0482845027581789e-06
DM B-Disease 1 1.0
mutation O 0 1.4482490762190992e-08
exists O 0 1.255022485935342e-08
in O 0 9.091248309722744e-10
the O 0 2.037070512272976e-09
Japanese O 0 1.7567430177223287e-07
population O 0 1.1217326373325065e-10
, O 0 5.6264791437055095e-11
we O 0 1.5888976800937371e-09
genotyped O 0 5.226688131187984e-07
families O 0 9.054492156046479e-10
using O 0 2.8310203070702755e-09
polymorphic O 0 2.94744868511998e-08
markers O 0 5.419533977146784e-08
near O 0 6.828414598203381e-07
the O 0 1.576442656414656e-07
( O 0 2.788535198305908e-07
CTG O 0 0.00025938768521882594
) O 0 1.846254349402443e-08
n O 0 1.2027281570681225e-07
repeat O 0 4.677002962694132e-08
region O 0 9.8019423688811e-09
and O 0 9.945291701285441e-09
constructed O 0 1.2345423783699516e-05
haplotypes O 0 2.1362076950026676e-05
. O 0 6.798965728194162e-07

Six O 0 4.5608160803567444e-07
different O 0 4.553772914306364e-09
haplotypes O 0 2.418328506337275e-07
were O 0 3.4056537145943366e-08
found O 0 3.216018029661427e-08
and O 0 1.5436192768447654e-07
DM B-Disease 1 1.0
alleles O 0 6.959243137316662e-08
were O 0 1.6367478394840873e-07
always O 0 5.892348440283968e-07
haplotype O 0 2.134579744961229e-06
A O 0 7.188187737483531e-06
. O 0 9.50040544012154e-07

To O 0 2.3323516984419257e-07
find O 0 3.976148121864753e-08
an O 0 4.700117628431144e-09
origin O 0 3.138127757651432e-09
of O 0 5.361811616921841e-08
the O 0 1.944206644566293e-07
( O 0 1.8384186262210278e-07
CTG O 0 3.0011311537236907e-05
) O 0 6.690071163717448e-09
n O 0 4.2976182612619596e-08
repeat O 0 1.8878752783280106e-08
mutation O 0 1.2650436254091346e-09
and O 0 1.90873941652292e-10
to O 0 8.097622572478258e-10
investigate O 0 3.4802770443320696e-08
the O 0 2.4976722912128935e-08
mechanism O 0 3.108599742063234e-07
of O 0 8.194551526230498e-08
the O 0 1.0980063080978653e-08
expansion O 0 1.69903664470894e-08
mutation O 0 9.75653779988761e-10
in O 0 5.927896506996433e-10
the O 0 2.2062016657997674e-09
Japanese O 0 2.2439185443090537e-07
population O 0 4.855872995368493e-11
we O 0 1.3747268601260743e-10
have O 0 7.27701232605682e-11
studied O 0 2.3661925752094248e-08
90 O 0 9.111445109510896e-08
Japanese O 0 1.727741619106382e-05
DM B-Disease 1 1.0
families O 0 3.743531262756505e-09
comprising O 0 5.779104750303077e-09
190 O 0 1.807887350935289e-08
affected O 0 9.44179734396755e-10
and O 0 9.204521034256175e-10
130 O 0 1.5053987567625882e-07
unaffected O 0 9.412063946001581e-07
members O 0 4.74835424313369e-08
. O 0 1.821935455836865e-07

The O 0 5.237773621047381e-06
results O 0 3.709251075179054e-07
suggest O 0 1.1059115223588378e-07
that O 0 9.320484384289784e-10
a O 0 1.276747507716891e-08
few O 0 5.566239913434856e-09
common O 0 2.858786096737731e-09
ancestral O 0 4.331705270033126e-07
mutations O 0 1.9094286152210316e-09
in O 0 1.7677256325399071e-09
both O 0 5.564011029690619e-09
Caucasian O 0 2.645510676302365e-06
and O 0 5.761868759890376e-09
Japanese O 0 7.264974556164816e-06
populations O 0 8.171912035948026e-10
have O 0 7.996655421171894e-11
originated O 0 2.9481557195509822e-09
by O 0 6.102038874189475e-10
expansion O 0 1.2224801615445813e-08
of O 0 2.1311223008524394e-08
an O 0 1.6946222203273464e-08
ancestral O 0 7.047873396004434e-07
n O 0 1.273956655722941e-07
= O 0 8.315583244211666e-08
5 O 0 9.697562752819522e-09
repeat O 0 1.0403707229045267e-08
to O 0 6.567546506630606e-09
n O 0 9.678921486511172e-08
= O 0 1.7849249900336872e-07
19 O 0 7.14347621055822e-08
- O 0 6.474231639685968e-08
37 O 0 8.875781531969551e-08
copies O 0 1.0520927418156134e-07
. O 0 9.540211465264292e-08

These O 0 2.5895607436154933e-08
data O 0 1.729558363194883e-07
support O 0 4.56749971178283e-09
multistep O 0 1.451158624377058e-07
models O 0 3.0928376304473204e-08
of O 0 1.994907279367908e-07
triplet O 0 2.3256861823028885e-05
repeat O 0 7.889539688221703e-07
expansion O 0 4.837041274186049e-07
that O 0 2.7397040192056465e-09
have O 0 2.3930135650829243e-10
been O 0 9.718129634350703e-10
proposed O 0 5.061315810905853e-10
for O 0 5.725595997319033e-09
both O 0 2.4658189090587257e-07
DM B-Disease 1 1.0
and O 0 9.434242542738502e-07
Friedreichs B-Disease 1 0.9999500513076782
ataxia I-Disease 0 0.04435193911194801
. O 0 7.472175411749049e-08
. O 0 1.6834199811910366e-07

The O 0 7.458085633516021e-07
molecular O 0 1.8873263343266444e-06
basis O 0 9.039511496666819e-06
of O 0 0.15631385147571564
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 7.180070156209695e-07
the O 0 8.88001494558921e-08
western O 0 5.286442572582928e-08
Cape O 0 5.878837896489131e-07
, O 0 4.12914724634561e-09
South O 0 2.69373487071789e-07
Africa O 0 2.2094586427101603e-07
. O 0 9.536809386645473e-08

Deficiency B-Disease 1 1.0
of I-Disease 0 0.00012938027794007212
the I-Disease 0 2.649848511282471e-06
sixth I-Disease 0 1.8454944438417442e-05
component I-Disease 0 7.574770279461518e-06
of I-Disease 0 2.6198813429800794e-07
human I-Disease 0 5.975420691584077e-08
complement I-Disease 0 3.6200208342052065e-07
( O 0 4.3113624315083143e-07
C6 O 0 5.638339280267246e-05
) O 0 3.911874379980418e-09
has O 0 3.713943874661396e-10
been O 0 7.674311741645568e-10
reported O 0 2.729199977125063e-09
in O 0 5.787463286388572e-10
a O 0 3.260131720139725e-09
number O 0 1.125556647885162e-09
of O 0 3.7397636099001375e-09
families O 0 8.147975072425595e-10
from O 0 4.767054750942634e-09
the O 0 1.0490526669570954e-08
western O 0 2.8599600909728906e-08
Cape O 0 5.828645157635037e-07
, O 0 4.4338595017734406e-09
South O 0 1.4199224551703082e-07
Africa O 0 1.8714432314936857e-07
. O 0 1.4292764660694957e-07

Meningococcal B-Disease 1 0.9999996423721313
disease I-Disease 1 0.9999895095825195
is O 0 1.8361654952059325e-07
endemic O 0 3.9606925383850466e-07
in O 0 8.145492280675626e-09
the O 0 2.7113941314382828e-08
Cape O 0 1.01523698958772e-06
and O 0 1.097235302616184e-09
almost O 0 1.1465906446517238e-08
all O 0 1.1380751896439278e-09
pedigrees O 0 1.2338747978901665e-07
of O 0 7.652977984662357e-08
total O 0 0.00040206321864388883
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 2.479993418091908e-05
C6Q0 O 1 0.9986974596977234
) O 0 9.76773240068951e-09
have O 0 2.861103021167821e-10
been O 0 1.1749476946931736e-09
ascertained O 0 1.2338099963926652e-07
because O 0 2.6277615639003216e-09
of O 0 1.8593374306874466e-07
recurrent O 1 0.9999922513961792
disease O 1 0.991772472858429
. O 0 1.5508836668232107e-06

We O 0 2.69099245997495e-07
have O 0 9.017334656746812e-10
sequenced O 0 2.11036343955584e-08
the O 0 2.6523157004021414e-08
expressed O 0 2.1811858985643084e-08
exons O 0 8.643129234542357e-08
of O 0 6.75308555742049e-08
the O 0 2.3330947840349836e-07
C6 O 0 9.985769793274812e-06
gene O 0 5.698497784756285e-10
from O 0 1.6466637775547355e-10
selected O 0 3.1261243593760923e-10
cases O 0 2.9452765226700706e-10
and O 0 2.5000909675831906e-10
have O 0 2.3114433977955429e-10
found O 0 1.6947280245815932e-09
three O 0 1.2910880364813693e-08
molecular O 0 2.318283441127278e-05
defects O 0 0.0005098407855257392
leading O 0 2.2902113414602354e-06
to O 0 5.852664131111851e-08
total O 0 6.929150549694896e-05
deficiency O 1 0.9999947547912598
879delG O 0 5.536408571060747e-05
, O 0 7.015615199890135e-09
which O 0 5.039891837199661e-10
is O 0 7.026726422942886e-10
the O 0 9.50910639119229e-09
common O 0 4.1544289786088484e-08
defect O 0 5.826800020258815e-07
in O 0 4.259613461954359e-08
the O 0 2.623756927278009e-07
Cape O 0 4.90686352350167e-06
and O 0 1.6937788060999992e-08
hitherto O 0 1.1822679880424403e-05
unreported O 0 5.260851139610168e-06
, O 0 1.8799475309805302e-09
and O 0 1.5356420579593077e-09
1195delC O 0 9.045524507200753e-08
and O 0 5.913129097478986e-09
1936delG O 0 6.53727965982398e-07
, O 0 3.3255866949133406e-09
which O 0 5.153193427531733e-10
have O 0 3.8208167185693753e-10
been O 0 1.1003978839241313e-09
previously O 0 3.2112599246403306e-09
reported O 0 3.282976335228227e-09
in O 0 1.6109145128950786e-09
African O 0 2.158301271037999e-07
- O 0 8.694548796484014e-07
Americans O 0 2.1935903760095243e-07
. O 0 1.1635348329264161e-07

We O 0 1.559229986014543e-06
also O 0 1.6268295155441592e-08
show O 0 1.990193965184517e-08
that O 0 7.045138916694782e-10
the O 0 2.3111326186153747e-08
879delG O 0 4.3617632172754384e-07
and O 0 3.244470292429469e-08
1195delC O 0 2.6315447030356154e-05
defects O 0 8.783013981883414e-06
are O 0 8.476044310867792e-10
associated O 0 9.683127188964136e-09
with O 0 1.1507269803701092e-08
characteristic O 0 0.43991199135780334
C6 O 1 1.0
/ O 1 0.9994932413101196
C7 O 0 0.0058241053484380245
region O 0 3.296198656244087e-07
DNA O 0 2.462926204316318e-06
marker O 0 1.5017293435448664e-06
haplotypes O 0 3.923339875200327e-07
, O 0 5.654928192377895e-10
although O 0 7.005582780550412e-10
small O 0 1.7077267377985095e-09
variations O 0 5.738070019134511e-09
were O 0 3.8419109671394835e-08
observed O 0 2.2747948946744145e-07
. O 0 1.5502639882924996e-07

The O 0 2.009158197324723e-05
1936delG O 0 0.00011468103184597567
defect O 0 6.6441047238186e-05
was O 0 1.910251057779533e-06
observed O 0 1.4858807162454468e-07
only O 0 1.0978910225389882e-08
once O 0 2.1366494351582332e-08
in O 0 6.317731227056811e-09
the O 0 2.492946293841669e-08
Cape O 0 2.0450929696380626e-06
, O 0 3.2914908576486823e-09
but O 0 1.5718278900678229e-09
its O 0 4.066123882040529e-09
associated O 0 8.310810528655566e-08
haplotype O 0 2.0047119164701144e-07
could O 0 7.746169927713709e-09
be O 0 5.963602234260179e-08
deduced O 0 8.892469850252382e-06
. O 0 4.5332322429203487e-07

The O 0 1.8202140381617937e-06
data O 0 5.762618116023077e-07
from O 0 3.3056927861707663e-08
the O 0 5.008732628652979e-08
haplotypes O 0 9.127749649451289e-07
indicate O 0 3.961386951800705e-08
that O 0 1.7581214262207823e-10
these O 0 8.743101242991713e-10
three O 0 7.067807672456183e-09
molecular O 0 2.7872163173014997e-06
defects O 0 1.7661681113168015e-06
account O 0 2.3456614428596367e-08
for O 0 6.830835008742042e-09
the O 0 1.030802877721726e-06
defects O 0 3.707668656716123e-05
in O 0 1.8467087414819616e-08
all O 0 5.082203546891151e-09
the O 0 8.102388449060527e-08
38 O 0 4.0913786847340816e-07
unrelated O 0 8.986297075352923e-07
C6Q0 O 0 0.00028665506397373974
individuals O 0 9.733679640078208e-09
we O 0 1.0957781348963636e-08
have O 0 6.925669482349406e-10
studied O 0 4.674711107099938e-08
from O 0 2.1400182959041558e-08
the O 0 1.6762095356170903e-07
Cape O 0 8.664933375257533e-06
. O 0 5.422909339358739e-07

We O 0 1.3163587482267758e-06
have O 0 8.825639774556748e-09
also O 0 4.012501886307973e-09
observed O 0 1.981497455005865e-08
the O 0 6.073364033909456e-08
879delG O 0 1.9684634935401846e-06
defect O 0 6.334191198220651e-07
in O 0 1.4517587132445442e-08
two O 0 3.344333521226872e-08
Dutch O 1 0.9999251365661621
C6 B-Disease 1 1.0
- I-Disease 1 1.0
deficient I-Disease 1 1.0
kindreds O 0 2.0449899238883518e-05
, O 0 1.5979028100687742e-09
but O 0 5.504338096429251e-10
the O 0 1.4197039099883568e-08
879delG O 0 1.1323994613121613e-06
defect O 0 6.516396524602897e-07
in O 0 1.0887199586306906e-08
the O 0 1.7964450194085657e-07
Cape O 0 1.2697548299911432e-05
probably O 0 3.093440170687245e-07
did O 0 1.641378588601583e-08
not O 0 2.0607879847034383e-09
come O 0 3.0965372488367393e-09
from O 0 3.8107170752255115e-09
The O 0 3.148417349052579e-08
Netherlands O 0 1.979707491273075e-07
. O 0 5.137722070003292e-08
. O 0 2.140469916867005e-07

Complement B-Disease 1 0.9999997615814209
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 2.6506120320846094e-07
seven O 0 7.099967547219421e-08
further O 0 6.507584515702547e-08
molecular O 0 5.9778092690976337e-05
defects O 0 0.00010968792776111513
and O 0 4.961322463969964e-09
their O 0 3.8584488493143e-08
associated O 0 3.899372586602112e-06
marker O 0 2.1822945200256072e-05
haplotypes O 0 1.2389996300044004e-05
. O 0 5.734324872719299e-07

Seven O 0 6.860614689685463e-07
further O 0 5.7598718683493644e-08
molecular O 0 5.913960876569035e-07
bases O 0 6.628325195379148e-07
of O 1 0.9703629016876221
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 2.022404714807635e-06
described O 0 2.3824286472517997e-06
. O 0 2.4638583795422164e-07

All O 0 3.108320356659533e-08
these O 0 4.396293107333804e-09
new O 0 7.014785641246135e-09
molecular O 0 1.4688458804812399e-06
defects O 0 9.194612857754692e-07
involve O 0 6.968793542228013e-08
single O 0 4.2466950844755047e-07
- O 0 6.676738735222898e-07
nucleotide O 0 1.0085025223816046e-06
events O 0 4.157179489538976e-08
, O 0 8.318002953089376e-10
deletions O 0 5.47432321695851e-09
and O 0 6.029763355286377e-10
substitutions O 0 1.0112201742629168e-08
, O 0 2.302933843623123e-09
some O 0 1.0387641857789731e-09
of O 0 2.0703270209310176e-08
which O 0 3.266748649366491e-09
alter O 0 1.8262983303429792e-07
splice O 0 7.564379984614789e-07
sites O 0 4.543563747461121e-08
, O 0 2.138474952673164e-09
and O 0 4.6857246971399036e-09
others O 0 4.186932400784826e-08
codons O 0 9.185174008052854e-07
. O 0 5.918288366046909e-07

They O 0 1.6797909552224155e-07
are O 0 2.256526743238396e-09
distributed O 0 4.05904110323263e-09
along O 0 4.2073384776131206e-08
the O 0 1.9148606611452124e-07
C7 O 0 0.00014057337830308825
gene O 0 8.939063711466133e-09
, O 0 3.7545702658015045e-10
but O 0 2.0138515854917216e-10
predominantly O 0 2.0773827102971154e-09
towards O 0 1.636414559413879e-08
the O 0 1.8347959596098917e-08
3 O 0 9.269787426546827e-08
end O 0 2.3266865412097104e-07
. O 0 1.3703622414595884e-07

All O 0 2.2863152082663873e-07
were O 0 8.394738415518077e-08
found O 0 1.2513940994551831e-08
in O 0 3.094248057777804e-08
compound O 0 3.22552045872726e-06
heterozygous O 0 8.222389169532107e-08
individuals O 0 1.1422577550490587e-08
. O 0 1.0795928773177366e-07

The O 0 0.00026526872534304857
C6 O 1 0.9999957084655762
/ O 0 0.04304082691669464
C7 O 0 0.002389520173892379
marker O 0 2.7701798899215646e-06
haplotypes O 0 1.0148033879886498e-06
associated O 0 9.685162893902088e-08
with O 0 2.1778353342938317e-08
most O 0 8.510629641023115e-07
C7 B-Disease 1 1.0
defects I-Disease 1 0.9345799088478088
are O 0 1.4965774397524e-08
tabulated O 0 5.528497695195256e-06
. O 0 1.1180603110005904e-07
. O 0 3.069302465519286e-07

A O 0 1.2030671314278152e-05
genome O 0 1.9949604279645428e-07
- O 0 1.0801571903584772e-07
wide O 0 2.2783417819027818e-08
search O 0 1.4112217172623787e-07
for O 0 5.07642994307389e-09
chromosomal O 0 5.629199222312309e-06
loci O 0 1.5411835363465798e-07
linked O 0 1.3034095900366083e-06
to O 0 3.969904227574261e-08
mental O 1 1.0
health O 0 5.33157326572109e-05
wellness O 0 6.242898962227628e-05
in O 0 1.4474344389725502e-08
relatives O 0 2.6009059794773748e-08
at O 0 3.903707579411275e-08
high O 0 6.476874858662995e-08
risk O 0 4.885208113591943e-07
for O 0 1.8945070223708171e-06
bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
among O 0 1.2842275509683532e-07
the O 0 4.377999403004651e-07
Old O 0 2.006003342103213e-05
Order O 0 9.514594694337575e-07
Amish O 0 1.6523794329259545e-05
. O 0 2.9627864250869607e-07

Bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
( O 1 0.9999983310699463
BPAD B-Disease 1 1.0
; O 1 0.9999982118606567
manic B-Disease 1 1.0
- I-Disease 1 1.0
depressive I-Disease 1 1.0
illness I-Disease 1 1.0
) O 0 1.0536654372117482e-05
is O 0 2.110286878576062e-08
characterized O 0 2.567027834743385e-08
by O 0 7.726780104633235e-09
episodes O 0 1.1188457165189902e-06
of O 0 1.9429888197919354e-05
mania B-Disease 0 0.006165791768580675
and O 0 0.0001058793204720132
/ O 1 1.0
or O 1 0.9999189376831055
hypomania B-Disease 1 1.0
interspersed O 0 0.0005800533108413219
with O 0 2.605141169453873e-08
periods O 1 0.8106209635734558
of O 1 0.7162750363349915
depression B-Disease 1 1.0
. O 0 1.2719133337668609e-05

Compelling O 0 5.481374955706997e-06
evidence O 0 4.244035096689913e-07
supports O 0 7.861043371804044e-09
a O 0 4.331834446702487e-09
significant O 0 3.724828223639065e-09
genetic O 0 2.2551164491346753e-08
component O 0 7.56318385697341e-08
in O 0 8.577336174653283e-09
the O 0 6.255847750935573e-08
susceptibility O 0 4.117683545246109e-07
to O 0 4.2117463294744084e-08
develop O 0 2.8253576601855457e-05
BPAD B-Disease 1 1.0
. O 0 1.025488290906651e-05

To O 0 2.188454146789809e-07
date O 0 3.98460997530492e-07
, O 0 8.221977765288102e-09
however O 0 5.229457311628494e-09
, O 0 2.9554354519234494e-09
linkage O 0 3.3212020866812964e-07
studies O 0 2.2628288576242994e-08
have O 0 3.9732786505375373e-10
attempted O 0 2.55884469169132e-08
only O 0 1.3634987583444058e-09
to O 0 2.7551416703630593e-09
identify O 0 8.787062455439809e-08
chromosomal O 0 4.9839918574434705e-06
loci O 0 2.3444587782250892e-07
that O 0 5.256878932158315e-09
cause O 0 1.3627588657527667e-07
or O 0 1.4209717846824788e-08
increase O 0 4.0340806251037975e-09
the O 0 2.3477292998563826e-08
risk O 0 2.699873959954857e-07
of O 0 4.750483242332848e-07
developing O 0 5.740105552831665e-05
BPAD B-Disease 1 1.0
. O 0 4.993812126485864e-06

To O 0 9.501313513737841e-08
determine O 0 5.345637177356366e-08
whether O 0 1.6016352688552615e-08
there O 0 1.650734660074704e-08
could O 0 1.7855235512342915e-08
be O 0 7.490108977492582e-09
protective O 0 6.696035370623576e-08
alleles O 0 2.1661104021575284e-09
that O 0 2.8991609113404593e-10
prevent O 0 1.0044653109275714e-08
or O 0 8.815613128376754e-09
reduce O 0 6.794918405716999e-09
the O 0 6.035106991930661e-08
risk O 0 4.6277468754851725e-06
of O 0 3.540672196322703e-06
developing O 0 0.13960695266723633
BPAD B-Disease 1 1.0
, O 0 6.579218947422305e-09
similar O 0 2.1214678624925654e-10
to O 0 2.0197600536508986e-10
what O 0 2.1665846894336482e-10
is O 0 1.0626430291260647e-10
observed O 0 8.292103115259408e-10
in O 0 5.611927034188113e-10
other O 0 6.202120594878124e-09
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 8.300161447039045e-09
we O 0 4.06209288428272e-09
used O 0 8.15516543184458e-08
mental O 1 0.9909557700157166
health O 0 3.127180718820455e-07
wellness O 0 3.522599627103773e-06
( O 0 7.766047804835807e-10
absence O 0 2.1788688631119157e-09
of O 0 2.648093522239492e-09
any O 0 1.743769395545769e-08
psychiatric B-Disease 1 0.9985312223434448
disorder I-Disease 0 0.0004843254864681512
) O 0 3.038249651865499e-09
as O 0 1.9227752723338654e-09
the O 0 5.553832505000855e-09
phenotype O 0 1.267788274361692e-08
in O 0 2.747889027432393e-09
our O 0 2.1568274277683486e-08
genome O 0 1.0731091570903573e-08
- O 0 4.8392099216698625e-08
wide O 0 3.0737719924900375e-08
linkage O 0 9.127227826866147e-07
scan O 0 2.50735780582545e-07
of O 0 5.173762573917884e-08
several O 0 1.481940348213584e-08
large O 0 9.219322549824938e-08
multigeneration O 0 0.00016780963051132858
Old O 0 2.8896058211103082e-05
Order O 0 1.549445187265519e-06
Amish O 0 1.897270885820035e-05
pedigrees O 0 2.471976358719985e-06
exhibiting O 0 2.4872284143384604e-07
an O 0 1.0572219544258132e-08
extremely O 0 3.683569715917656e-08
high O 0 4.62058864059145e-07
incidence O 0 3.1107432732824236e-05
of O 0 5.5609329137951136e-05
BPAD B-Disease 1 1.0
. O 0 1.4693917364638764e-05

We O 0 6.947915949240269e-07
have O 0 4.343268411588497e-09
found O 0 2.7385547163305546e-09
strong O 0 1.4010932414265653e-09
evidence O 0 2.7495522303411235e-08
for O 0 4.929271213427455e-09
a O 0 8.199445034051678e-08
locus O 0 3.389595804037526e-07
on O 0 6.774474314852341e-08
chromosome O 0 1.7621323422645219e-07
4p O 0 0.00011066773004131392
at O 0 6.090375336498255e-06
D4S2949 O 0 3.835303687083069e-06
( O 0 3.216975130726496e-08
maximum O 0 1.2815787897579867e-07
GENEHUNTER O 0 4.4707903725793585e-06
- O 0 2.508869556550053e-07
PLUS O 0 4.107501752059761e-07
nonparametric O 0 1.7644979379838333e-06
linkage O 0 1.3847407842604298e-07
score O 0 2.6352314108635255e-08
= O 0 3.46443513876693e-08
4 O 0 1.1209339234596882e-08
. O 0 4.0901412812210935e-10
05 O 0 3.010691784766095e-07
, O 0 8.883127122771839e-09
P O 0 1.835916577874741e-06
= O 0 4.5478898869077966e-08
5 O 0 4.143553500313146e-09
. O 0 1.865266968659185e-10
22 O 0 1.0004493899984368e-09
x O 0 4.207616921547697e-09
10 O 0 2.3877260169058445e-09
( O 0 1.2831087303766253e-09
- O 0 3.14399906109486e-09
4 O 0 7.775997623582498e-09
) O 0 6.56974863399995e-10
; O 0 2.393460984961848e-10
SIBPAL O 0 1.4830410464128363e-06
Pempirical O 0 1.370324639538012e-06
value O 0 1.38877453537134e-07
< O 0 6.219442383326168e-08
3 O 0 1.760041445919569e-09
x O 0 3.9041596622269026e-09
10 O 0 7.273157631715321e-10
( O 0 2.4533347575683706e-10
- O 0 7.778915844802725e-10
5 O 0 2.19511631094349e-09
) O 0 1.8680226809841827e-10
) O 0 5.269683300834771e-11
and O 0 3.1967244823460916e-11
suggestive O 0 9.276080348286087e-09
evidence O 0 4.2059262739257974e-08
for O 0 7.634459286975925e-09
a O 0 1.4604690079522697e-07
locus O 0 9.735425692269928e-07
on O 0 1.5934348596147174e-07
chromosome O 0 1.1055336699428153e-06
4q O 0 1.5214715858746786e-05
at O 0 7.294740385077603e-07
D4S397 O 0 2.101921154462616e-06
( O 0 2.787965591721786e-08
maximum O 0 3.1453808446713083e-07
GENEHUNTER O 0 4.617928425432183e-06
- O 0 2.8620837611015304e-07
PLUS O 0 4.3550460304686567e-07
nonparametric O 0 7.761041729281715e-07
linkage O 0 8.369717363621021e-08
score O 0 1.5291979238440945e-08
= O 0 2.2745034300442057e-08
3 O 0 2.1044095355193804e-09
. O 0 1.2822126693734504e-10
29 O 0 3.009297477873929e-09
, O 0 4.4815468003278625e-10
P O 0 3.1024688951220014e-07
= O 0 2.0799213018563023e-08
2 O 0 2.8335267465706693e-09
. O 0 5.6600616554769445e-11
57 O 0 8.563567077679579e-10
x O 0 3.2026230556425617e-09
10 O 0 1.4353810362521813e-09
( O 0 2.7750601816478593e-10
- O 0 2.106702812199046e-09
3 O 0 5.798824975755679e-09
) O 0 3.9915085126018823e-10
; O 0 2.486603978280044e-10
SIBPAL O 0 7.483300237254298e-07
Pempirical O 0 9.541527106193826e-07
value O 0 9.090216224194592e-08
< O 0 2.5747658227714965e-08
1 O 0 2.0933883515539264e-09
x O 0 2.1697328378422753e-09
10 O 0 5.879409736841978e-10
( O 0 3.243099400140892e-10
- O 0 7.709552440893219e-10
3 O 0 3.9338199364635784e-09
) O 0 3.215560873126577e-10
) O 0 7.058208878474304e-11
that O 0 1.8402186025001654e-11
are O 0 7.685704850324271e-11
linked O 0 1.7556601505930303e-08
to O 0 4.8122043239118284e-08
mental O 1 0.9999878406524658
health O 0 5.964997035334818e-05
wellness O 0 0.00020954175852239132
. O 0 2.7625819143395347e-07

These O 0 4.800470065902118e-08
findings O 0 6.480247805029649e-08
are O 0 6.485930126309825e-10
consistent O 0 1.5143138298867598e-08
with O 0 8.332162737545445e-11
the O 0 3.848715124377122e-09
hypothesis O 0 1.5337255021563578e-08
that O 0 4.289602353879651e-11
certain O 0 1.440209618230881e-10
alleles O 0 4.729412972359626e-10
could O 0 1.7401668994665442e-09
prevent O 0 1.3741515481058286e-08
or O 0 1.4700459516348019e-08
modify O 0 8.167552856264138e-09
the O 0 4.062598435439213e-08
clinical O 0 7.525333785451949e-06
manifestations O 0 6.367970490828156e-05
of O 0 0.0019130515865981579
BPAD B-Disease 1 1.0
and O 0 2.8025473497450548e-08
perhaps O 0 2.4327784231559235e-08
other O 0 1.3976233503854019e-09
related O 0 2.7659307306748815e-05
affective B-Disease 1 0.9999988079071045
disorders I-Disease 1 1.0
. O 0 7.327130788326031e-06

Segregation O 0 0.001524153514765203
distortion O 0 0.0025910516269505024
in O 0 3.953526174882427e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 1.3317661796463653e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9998824596405029
DM B-Disease 1 1.0
) O 0 2.1564679286711907e-07
is O 0 9.869290273911702e-09
an O 0 3.782130875151779e-08
autosomal B-Disease 1 0.9140691161155701
dominant I-Disease 1 0.999955415725708
disease I-Disease 1 0.9334877133369446
which O 0 6.682915998368344e-09
, O 0 9.40588495979e-10
in O 0 6.526936324746657e-09
the O 0 8.853006505660233e-08
typical O 0 2.5752183319127653e-06
pedigree O 0 4.267412236913515e-07
, O 0 7.373363031248914e-10
shows O 0 3.019992478314748e-09
a O 0 4.140598974800014e-09
three O 0 1.7814507646818356e-09
generation O 0 6.829365872818016e-08
anticipation O 0 8.054827844716783e-07
cascade O 0 9.963624506781343e-06
. O 0 6.896121931276866e-07

This O 0 9.409302492713323e-08
results O 0 5.644222511591579e-08
in O 0 2.2730057480657706e-07
infertility B-Disease 1 0.9999903440475464
and O 0 7.229176844703034e-05
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0003926256322301924
CDM B-Disease 0 0.0009823453146964312
) O 0 1.052806508639037e-09
with O 0 2.996695114276804e-10
the O 0 9.241259846248795e-08
disappearance O 0 0.00010072111035697162
of O 0 0.0005618878058157861
DM B-Disease 1 1.0
in O 0 2.016080543398857e-06
that O 0 1.3419281685855822e-07
pedigree O 0 2.255774597870186e-05
. O 0 1.2263683402125025e-06

The O 0 1.2920630751978024e-06
concept O 0 6.015605436004989e-07
of O 0 5.886428198209614e-07
segregation O 0 1.5626776530552888e-06
distortion O 0 1.29629404455045e-06
, O 0 2.1102417591123412e-09
where O 0 3.4728884212853472e-09
there O 0 7.598601747815792e-10
is O 0 5.820074977513912e-10
preferential O 0 5.327708940683351e-09
transmission O 0 5.006096515103309e-08
of O 0 1.068456700892284e-08
the O 0 1.1091474405588997e-08
larger O 0 1.427505047502109e-08
allele O 0 3.926338809634444e-09
at O 0 8.168895959670408e-08
the O 0 1.116188855121436e-06
DM B-Disease 1 1.0
locus O 0 2.4472274162690155e-06
, O 0 1.4671964754242595e-09
has O 0 2.9784488764228456e-10
been O 0 1.0526578497760397e-09
put O 0 3.995974218184983e-09
forward O 0 1.038352603899284e-08
to O 0 1.714915143224971e-08
explain O 0 3.1880529149930226e-07
partially O 0 1.7202194158016937e-06
the O 0 1.971902747754939e-07
maintenance O 0 7.86957680247724e-05
of O 0 4.27318227593787e-05
DM B-Disease 1 1.0
in O 0 2.2453849624071154e-07
the O 0 9.458136673856643e-08
population O 0 6.665247465065249e-09
. O 0 3.3510765717892355e-08

In O 0 1.0587091310299002e-06
a O 0 5.275504122437269e-07
survey O 0 1.1054904689444811e-06
of O 0 1.4629715678893263e-06
DM B-Disease 1 1.0
in O 0 8.043934371926298e-07
Northern O 0 4.993089532945305e-07
Ireland O 0 1.893750720682874e-07
, O 0 1.5941713726874696e-08
59 O 0 5.601190196102834e-07
pedigrees O 0 1.647336716814607e-06
were O 0 2.030448484902081e-07
ascertained O 0 1.4488574379356578e-05
. O 0 4.809947427020234e-07

Sibships O 0 0.0009893883252516389
where O 0 6.362586191244191e-07
the O 0 6.779606565032736e-08
status O 0 7.566992366037084e-08
of O 0 5.590267448951636e-08
all O 0 1.284706119264456e-08
the O 0 5.209211551004955e-08
members O 0 4.960678978704891e-09
had O 0 1.976352770327594e-08
been O 0 7.574729288251092e-09
identified O 0 8.847347743312639e-09
were O 0 5.706723538168035e-09
examined O 0 2.134425436395304e-08
to O 0 3.5066620718282593e-09
determine O 0 3.150940486307263e-08
the O 0 3.953808302981088e-08
transmission O 0 1.3082451459922595e-06
of O 0 9.735779258335242e-07
the O 0 9.094816959986929e-06
DM B-Disease 1 1.0
expansion O 0 2.782698629744118e-06
from O 0 1.5687309939949046e-07
affected O 0 7.953680380978767e-08
parents O 0 8.17334999680952e-09
to O 0 4.405081188707527e-09
their O 0 2.615661642835221e-08
offspring O 0 2.6220408244626014e-07
. O 0 8.999833767120435e-08

Where O 0 2.763461907306919e-06
the O 0 1.2708928807114717e-06
transmitting O 1 0.7807990908622742
parent O 0 6.452645902754739e-05
was O 0 0.00011751442798413336
male O 0 1.5780129842823953e-06
, O 0 2.994309866721778e-08
58 O 0 1.5887961808402906e-06
. O 0 4.415022090142884e-07

3 O 0 2.586811660876265e-06
% O 0 2.998161718892334e-08
of O 0 1.5161809585606534e-08
the O 0 1.796797377551229e-08
offspring O 0 1.709663521864968e-08
were O 0 1.3682251776003795e-08
affected O 0 1.4817679527823202e-08
, O 0 4.3669901028664526e-10
and O 0 8.807709006575237e-10
in O 0 1.0873377753739533e-08
the O 0 3.528199243874042e-08
case O 0 4.756312677045571e-08
of O 0 1.633501085507305e-07
a O 0 3.9302526033679896e-07
female O 0 1.467871015847777e-07
transmitting O 0 7.407880730170291e-06
parent O 0 3.562905703802244e-07
, O 0 3.104001322640215e-08
68 O 0 3.39892903866712e-06
. O 0 6.611349476770556e-07

7 O 0 4.994326900487067e-06
% O 0 4.251326402027189e-08
were O 0 6.165218735532108e-08
affected O 0 9.29170198560314e-08
. O 0 2.4050396518759953e-07

Studies O 0 2.5132780137937516e-05
on O 0 8.569553529014229e-07
meiotic O 0 1.713799429126084e-05
drive O 0 1.5464439684365061e-06
in O 0 6.67698714096332e-07
DM B-Disease 1 1.0
have O 0 3.658110259152636e-09
shown O 0 4.542980658328588e-09
increased O 0 8.012206009766487e-09
transmission O 0 2.200071769209444e-08
of O 0 2.544029875650722e-09
the O 0 3.162137218737371e-09
larger O 0 3.305255846797195e-09
allele O 0 3.218200816945682e-09
at O 0 1.0232654545916375e-07
the O 0 1.866210510570454e-07
DM B-Disease 1 0.9999991655349731
locus O 0 3.185323862453515e-07
in O 0 1.249652825663361e-08
non O 0 1.7177637801069068e-06
- O 0 2.8634742193389684e-05
DM O 1 1.0
heterozygotes O 0 1.1065061698900536e-05
for O 0 2.7893358378605626e-07
CTGn O 0 0.00042493987712077796
. O 0 9.90081503005058e-07

This O 0 6.983043476793682e-08
study O 0 1.9229268843901082e-08
provides O 0 2.2798272159008093e-09
further O 0 3.2888033962841234e-10
evidence O 0 1.849264030795439e-08
that O 0 1.4155715488683995e-09
the O 0 3.42587696877672e-07
DM B-Disease 1 1.0
expansion O 0 1.930806547534303e-06
tends O 0 9.634219111376296e-08
to O 0 1.5969886524302979e-09
be O 0 7.284378877869813e-09
transmitted O 0 1.6940961700129264e-07
preferentially O 0 3.2618257250760507e-07
. O 0 2.160613945534351e-07

Diagnosis O 1 0.9999997615814209
of O 1 0.7396019101142883
hemochromatosis B-Disease 1 1.0
. O 0 0.000383232778403908

If O 0 9.562759805703536e-05
untreated O 1 1.0
, O 0 2.9338498279685155e-05
hemochromatosis B-Disease 1 1.0
can O 0 3.579098483896814e-05
cause O 1 0.999874472618103
serious O 1 0.9999990463256836
illness O 1 0.9999997615814209
and O 0 2.8156849296578912e-08
early B-Disease 0 1.0992446277668932e-06
death I-Disease 0 1.445115032083777e-07
, O 0 5.598509988935518e-10
but O 0 3.15322795652051e-10
the O 0 2.8797753515164004e-08
disease O 0 1.0006895081460243e-06
is O 0 2.8467719292990523e-09
still O 0 3.894521150016317e-09
substantially O 0 3.6676134129720595e-08
under O 0 2.8069130166841205e-06
- O 0 0.0004169829480815679
diagnosed O 0 1.35294476422132e-05
. O 0 2.769326954421558e-07

The O 0 6.899266736581922e-06
cornerstone O 0 3.064807606278919e-05
of O 0 3.411024067645485e-07
screening O 0 3.9307245458530815e-08
and O 0 5.198478980616983e-09
case O 0 1.9620465252501162e-08
detection O 0 2.0349517626527813e-07
is O 0 3.307589313550352e-09
the O 0 1.8444945126816492e-08
measurement O 0 1.2833072560169967e-06
of O 0 2.2727175519321463e-07
serum O 0 1.6027490346459672e-05
transferrin O 0 0.0001398140739183873
saturation O 0 2.53920370596461e-06
and O 0 1.8703232296246597e-09
the O 0 2.082898653554821e-08
serum O 0 2.8276274406380253e-06
ferritin O 0 3.7388144846772775e-05
level O 0 1.2308487384871114e-05
. O 0 1.926115231754011e-07

Once O 0 5.230510396359023e-06
the O 0 1.0541698003407873e-07
diagnosis O 0 5.424888058769284e-06
is O 0 1.1932757004728956e-08
suspected O 0 9.420729156772722e-07
, O 0 5.521596069257839e-09
physicians O 0 2.1439404918055516e-08
must O 0 9.34398425300742e-09
use O 0 2.522505404556341e-08
serum O 0 7.171506877057254e-05
ferritin O 1 0.927446186542511
levels O 0 0.00012879962741862983
and O 0 9.499392916723082e-08
hepatic O 1 0.9576166868209839
iron O 1 0.9829384684562683
stores O 0 1.8707612525759032e-06
on O 0 1.0360108149143343e-07
liver O 0 1.7698610577099316e-07
biopsy O 0 1.0408138706452519e-07
specimens O 0 6.265601815158561e-09
to O 0 5.736819908008783e-10
assess O 0 1.821504440613353e-07
patients O 0 6.334478275249467e-09
for O 0 6.822030163000647e-10
the O 0 6.40219823822008e-08
presence O 0 2.4233870021816983e-07
of O 0 1.5593353964504786e-05
iron B-Disease 1 0.9999955892562866
overload I-Disease 1 0.9998956918716431
. O 0 2.4762093744357117e-06

Liver O 1 0.9995943903923035
biopsy O 0 0.29248979687690735
is O 0 1.547216896824466e-07
also O 0 2.1323776078219225e-09
used O 0 2.4965518541364418e-09
to O 0 3.4481766331140307e-09
establish O 0 1.1863205884310446e-07
the O 0 5.504689681856689e-08
presence O 0 5.70786937714729e-08
or O 0 3.773988410671336e-08
absence O 0 6.477417855421663e-07
of O 0 1.8741950043477118e-05
cirrhosis B-Disease 1 1.0
, O 0 4.561109712142297e-09
which O 0 3.8077943576020346e-10
can O 0 7.055520612198052e-10
affect O 0 5.597864216611015e-08
prognosis O 0 6.265986303333193e-05
and O 0 2.2576298164267428e-08
management O 0 1.9233568309573457e-05
. O 0 6.93242157012719e-07

A O 0 5.723388312617317e-06
DNA O 0 2.0710743342533533e-07
- O 0 2.4463467696023145e-08
based O 0 1.5543543119278525e-09
test O 0 1.345348388248624e-09
for O 0 8.491027880808133e-10
the O 0 6.502236971073216e-08
HFE O 0 5.1354476454434916e-05
gene O 0 2.5449227170071254e-09
is O 0 1.9843850174172672e-10
commercially O 0 1.5174704826037555e-09
available O 0 6.769121374539111e-10
, O 0 8.821322838858947e-11
but O 0 8.967265124892876e-11
its O 0 3.4803268600391846e-10
place O 0 4.233037920187144e-09
in O 0 1.5383948559488658e-09
the O 0 1.1912064223906782e-08
diagnosis O 0 1.3734810636378825e-05
of O 0 8.917539162212051e-06
hemochromatosis B-Disease 1 1.0
is O 0 3.0196201805665623e-07
still O 0 1.7127446128029078e-08
being O 0 1.8299868287385834e-08
evaluated O 0 2.190525663081644e-07
. O 0 2.0160391045465076e-07

Currently O 0 1.6930799802139518e-06
, O 0 1.3805432352853586e-08
the O 0 2.042132685176057e-08
most O 0 2.1514070525086026e-09
useful O 0 2.644062213619236e-08
role O 0 2.771915497135069e-08
for O 0 2.206794968984127e-09
this O 0 8.731236289527544e-10
test O 0 1.978286645609728e-09
is O 0 7.09032610402005e-10
in O 0 1.621927148143243e-09
the O 0 1.267130755877588e-08
detection O 0 3.4256195249326993e-06
of O 0 1.823841012082994e-05
hemochromatosis B-Disease 1 1.0
in O 0 6.241357186809182e-05
the O 0 6.660243798251031e-06
family O 0 2.7757866405409004e-07
members O 0 1.7597426849036424e-09
of O 0 2.3633237589137934e-08
patients O 0 2.626628914370599e-09
with O 0 1.7717753653112567e-10
a O 0 3.9151309749740903e-08
proven O 0 6.959122629268677e-07
case O 0 1.3644568142012758e-08
of O 0 2.9800546030855912e-08
the O 0 2.0214007179220062e-07
disease O 0 3.973748334828997e-06
. O 0 1.3581816915575473e-07

It O 0 6.723730194835298e-08
is O 0 2.629587747549067e-08
crucial O 0 1.5310898788811755e-06
to O 0 1.467479364691826e-06
diagnose O 1 1.0
hemochromatosis B-Disease 1 1.0
before O 1 1.0
hepatic B-Disease 1 1.0
cirrhosis I-Disease 1 1.0
develops O 0 0.03714863583445549
because O 0 2.0902957942325884e-07
phlebotomy O 1 0.9999995231628418
therapy O 0 0.05840664729475975
can O 0 4.693658350873875e-09
avert O 0 2.00642243726179e-05
serious O 1 1.0
chronic O 1 1.0
disease O 1 1.0
and O 0 1.785080705474229e-08
can O 0 1.4195792985560729e-08
even O 0 5.5998050640937436e-09
lead O 0 1.5229892014190227e-08
to O 0 1.958919471078957e-09
normal O 0 1.8668852419523319e-07
life O 0 4.7916699941197294e-08
expectancy O 0 9.585573934600689e-08
. O 0 8.59255944174464e-10
. O 0 6.358615856072447e-09

Prevalence O 0 0.0001914720342028886
of O 0 7.262794952112017e-07
the O 0 7.785348543620785e-07
I1307K O 0 2.8126149118179455e-05
APC B-Disease 0 1.9645817701530177e-06
gene O 0 5.511652911849296e-09
variant O 0 6.486156500784546e-09
in O 0 1.7998940116115136e-09
Israeli O 0 1.516054339845141e-07
Jews O 0 2.517135833102202e-09
of O 0 2.788526354269294e-10
differing O 0 3.847793958455803e-11
ethnic O 0 3.467695922076963e-11
origin O 0 5.628005839142247e-10
and O 0 1.2065192178667417e-09
risk O 0 9.586411806594697e-07
for O 0 7.767241913825274e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 6.837068940512836e-05

BACKGROUND O 0 0.0012470566434785724
& O 0 0.00011247160728089511
AIMS O 0 1.32832128656446e-05
Israeli O 0 8.296804480778519e-06
Jews O 0 2.309901674379944e-07
of O 0 1.3594541314887465e-07
European O 0 1.624122880627965e-08
birth O 0 2.9851062066654777e-08
, O 0 1.0772140957016063e-09
i O 0 5.326906471481152e-09
. O 0 1.1584141423881533e-09
e O 0 1.0378616188688738e-08
. O 0 2.698760936947764e-10
, O 0 1.144018879628561e-09
Ashkenazim O 0 3.639405576905119e-07
, O 0 1.3650887087379715e-09
have O 0 5.223583232627504e-10
the O 0 4.1911672354899565e-08
highest O 1 0.9997718930244446
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 1 0.999987006187439
of O 0 8.362680148366053e-08
any O 0 1.567122787093922e-08
Israeli O 0 9.163064191852754e-07
ethnic O 0 2.3158365891617905e-08
group O 0 1.020231081838574e-07
. O 0 1.832219282960068e-07

The O 0 3.685488263727166e-05
I1307K O 0 0.00028972080326639116
APC B-Disease 0 1.6689018593751825e-05
gene O 0 6.634682137018899e-08
variant O 0 9.603488848597408e-08
was O 0 2.484746346453903e-07
found O 0 4.208293447049982e-08
in O 0 7.53917390738934e-08
6 O 0 4.305143193050753e-06
. O 0 4.5636269874194113e-07

1 O 0 9.951753554560128e-07
% O 0 1.6153952842046237e-08
of O 0 1.0149224571875948e-08
American O 0 8.294053444046767e-09
Jews O 0 7.021130343787263e-09
, O 0 2.268756016388096e-10
28 O 0 6.991049961158069e-09
% O 0 1.8369591403555319e-09
of O 0 3.3242990582493803e-09
their O 0 4.291393054245418e-07
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 2.584807043604087e-05
, O 0 4.017906563014151e-10
but O 0 1.055399587168715e-10
not O 0 1.3805787069109954e-10
in O 0 1.66867331063969e-09
non O 0 3.530280139329989e-07
- O 0 1.4193607000834163e-07
Jews O 0 1.427916771490345e-07
. O 0 1.5438372713560966e-07

We O 0 1.4781526260776445e-06
assessed O 0 1.8528388636696036e-06
the O 0 1.3805990306536842e-07
I1307K O 0 4.599920430337079e-06
prevalence O 0 6.576329383278789e-07
in O 0 2.5217392618515078e-09
Israeli O 0 5.289872362368442e-08
Jews O 0 1.497953205920055e-09
of O 0 2.119963232738442e-10
differing O 0 4.2621507018170135e-11
ethnic O 0 2.648302931118618e-11
origin O 0 7.865775392135177e-11
and O 0 3.147303528905354e-10
risk O 0 7.23310051853332e-08
for O 0 1.0401155122963246e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 4.621218977263197e-05

METHODS O 0 8.222418159675726e-07
DNA O 0 5.908520961384056e-08
samples O 0 3.312159879698129e-09
from O 0 9.687597390950486e-09
500 O 0 2.0081460050391797e-08
unrelated O 0 1.7172915534047206e-08
Jews O 0 2.433158918790923e-08
of O 0 1.4795933367395264e-08
European O 0 5.317425166850853e-09
or O 0 5.113444334625683e-09
non O 0 5.027377270039324e-08
- O 0 3.838818152246404e-09
European O 0 1.013937045435398e-09
origin O 0 1.5504340034055986e-09
, O 0 2.759189821066599e-10
with O 0 8.715259069980164e-11
or O 0 6.666823981760217e-09
without O 0 1.686268014111647e-08
a O 0 5.7741058157034786e-08
personal O 0 4.950572929374175e-07
and O 0 2.3807693594335433e-08
/ O 0 6.3961829255276825e-06
or O 0 1.0489690538406649e-07
family O 0 1.279810390997227e-07
history O 0 5.118390049574373e-07
of O 0 3.579914675810869e-07
neoplasia B-Disease 0 9.757973020896316e-05
, O 0 9.637763476177952e-09
were O 0 2.2354937456725565e-08
examined O 0 5.442032247060524e-08
for O 0 8.048737676347173e-09
the O 0 1.4553968696873198e-07
I1307K O 0 6.451242597904638e-07
variant O 0 7.724907824524507e-09
by O 0 1.5328415203796908e-09
the O 0 3.2159304108603237e-09
allele O 0 5.33225075205479e-10
- O 0 3.54702978100363e-09
specific O 0 2.5082933508002725e-09
oligonucleotide O 0 4.85435236896592e-07
( O 0 9.462448247177235e-08
ASO O 0 4.645540229830658e-06
) O 0 3.830399553095276e-09
method O 0 6.713555222859213e-08
. O 0 7.815568636715398e-08

RESULTS O 0 3.1236711492965696e-06
In O 0 1.2516380820670747e-07
persons O 0 8.731428380315265e-08
at O 0 9.170427262006342e-08
average O 0 1.973966874402322e-07
risk O 0 2.986430729379208e-07
for O 0 6.9772909228049684e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 4.0882023313315585e-06
I1307K O 0 3.118144377367571e-05
was O 0 5.375501928028825e-07
found O 0 1.800787607919574e-08
in O 0 1.097882673661843e-08
5 O 0 1.7377969641074742e-07
. O 0 7.154998371561305e-08

0 O 0 4.959745183441555e-07
% O 0 7.108095001484571e-09
of O 0 5.35848654337201e-09
120 O 0 1.904039770295185e-08
European O 0 9.851987670117524e-09
and O 0 9.658005062362918e-09
1 O 0 1.2722936162390397e-06
. O 0 2.8165021603854257e-07

6 O 0 6.62228694636724e-06
% O 0 5.544521286537929e-08
of O 0 4.049037372055864e-08
188 O 0 7.583305006164665e-08
non O 0 1.3191532843848108e-07
- O 0 2.1016308693333485e-08
European O 0 8.983108479299062e-09
Jews O 0 2.4804485576623847e-08
( O 0 3.3358080742118545e-09
P O 0 2.684469109226484e-07
= O 0 3.1624285412590325e-08
0 O 0 1.2937199089790852e-09
. O 0 1.3575296442525087e-10
08 O 0 2.8001428731272426e-08
) O 0 4.06606170955115e-09
. O 0 1.319231923702091e-08

It O 0 3.4709077567640634e-07
occurred O 0 3.881030352204107e-06
in O 0 9.444813997561141e-08
15 O 0 8.323833640133671e-07
. O 0 6.661836664534349e-07

4 O 0 2.395033561697346e-06
% O 0 2.400824605786056e-08
of O 0 1.886849254617573e-08
52 O 0 1.0343542555801832e-07
Ashkenazi O 0 1.3130787692716694e-06
Israelis O 0 5.482643246068619e-07
with O 0 1.1178443948267613e-08
familial O 0 1.5093292859091889e-05
cancer B-Disease 0 1.8343223473493708e-06
( O 0 8.444747123803609e-08
P O 0 3.43504871125333e-05
= O 0 1.1425370871620544e-07
0 O 0 2.0185981775000528e-09
. O 0 9.245036680649577e-11
02 O 0 5.951625681177575e-08
) O 0 2.384966391044685e-10
and O 0 9.25496970727302e-11
was O 0 1.3460830672329394e-08
not O 0 1.1539156297146747e-09
detected O 0 1.559632245573539e-08
in O 0 4.601496961242901e-09
51 O 0 1.5157753807670815e-07
non O 0 7.216754511318868e-06
- O 0 2.698409105050814e-07
European O 0 4.857908919575493e-08
Jews O 0 9.294041802831998e-08
at O 0 1.211249411880999e-07
increased O 0 1.0681127093903342e-07
cancer B-Disease 0 1.9684034668898676e-06
risk O 0 4.818008960683073e-07
. O 0 9.723903815483936e-08

Colorectal B-Disease 1 0.9999990463256836
neoplasia I-Disease 1 0.9999973773956299
occurred O 0 0.3633565902709961
personally O 0 5.789770511910319e-06
or O 0 1.848199673304407e-07
in O 0 3.4546694394066435e-08
the O 0 2.126932230339662e-07
families O 0 2.2492743667612558e-08
of O 0 2.237320160247691e-07
13 O 0 3.5331160574969545e-07
of O 0 4.274683078620001e-07
20 O 0 7.620218980264326e-07
Ashkenazi O 0 1.5620370277247275e-06
I1307K O 0 1.1654487934720237e-06
carriers O 0 1.597324583713089e-08
, O 0 5.404253933249947e-09
8 O 0 1.364790449542852e-07
of O 0 4.326502960338985e-07
whom O 0 6.977471116442757e-07
also O 0 1.3385360375650635e-07
had O 0 4.852871029470407e-07
a O 0 2.325303285033442e-06
personal O 0 0.00014030662714503706
or O 0 8.912812177186424e-07
family O 0 4.1571126985218143e-07
history O 0 2.652113835210912e-06
of O 0 5.951329512754455e-06
noncolonic O 0 0.022668618708848953
neoplasia B-Disease 1 0.9978583455085754
. O 0 8.374190656468272e-06

CONCLUSIONS O 0 0.0001793520787032321
The O 0 1.0918622137978673e-05
I1307K O 0 0.00020015159680042416
APC O 0 7.005982297414448e-06
variant O 0 7.289177972324978e-08
may O 0 3.51338380610855e-09
represent O 0 5.3319282322661365e-09
a O 0 3.694215067184814e-08
susceptibility O 0 2.5092020905503887e-07
gene O 0 6.3239760095257225e-09
for O 0 4.1452945964692844e-08
colorectal B-Disease 1 1.0
, I-Disease 0 1.4877780358801829e-06
or I-Disease 0 4.0358841602028406e-07
other I-Disease 0 5.232770217133975e-09
, I-Disease 0 7.1179715455116366e-09
cancers I-Disease 0 1.1364518286427483e-05
in O 0 2.4886213623176445e-07
Ashkenazi O 0 0.00041903546662069857
Jews O 0 1.4372441228260868e-06
, O 0 7.010880320734714e-09
and O 0 6.0883120767130094e-09
partially O 0 2.951619990199106e-06
explains O 0 7.474356777947833e-08
the O 0 6.706589950056241e-09
higher O 0 2.2856546877392248e-07
incidence O 0 1.0286865290254354e-05
of O 0 0.002363441977649927
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 5.077050900581526e-06
European O 0 2.977296844619559e-07
Israelis O 0 1.1303137625873205e-06
. O 0 7.174349292426996e-08

Systematic O 0 1.250864102075866e-06
analysis O 0 4.438964040787141e-08
of O 0 6.343488934135166e-08
coproporphyrinogen O 0 0.00018042013107333332
oxidase O 0 2.3259679437614977e-05
gene O 0 1.8004840285357204e-06
defects O 0 0.0001769829250406474
in O 0 1.683970793919798e-07
hereditary B-Disease 1 0.9999979734420776
coproporphyria I-Disease 1 0.9999830722808838
and O 0 3.750538155600225e-07
mutation O 0 2.2883506289872457e-07
update O 0 1.935948830578127e-06
. O 0 4.29109007882289e-07

Hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 0.9999924898147583
( O 0 0.00014576149987988174
HC B-Disease 1 1.0
) O 0 2.9819902920280583e-06
is O 0 3.102693213463681e-08
an O 0 2.351705177261465e-07
acute O 1 1.0
hepatic B-Disease 1 1.0
porphyria I-Disease 1 1.0
with O 0 0.06568921357393265
autosomal O 1 1.0
dominant O 1 0.9999994039535522
inheritance O 0 0.4540727734565735
caused O 0 2.9640894354088232e-05
by O 0 7.326841000576678e-08
deficient B-Disease 0 7.849654502933845e-05
activity I-Disease 0 2.142666517102043e-06
of I-Disease 0 3.4785766729328316e-06
coproporphyrinogen I-Disease 0 0.0006960313185118139
III I-Disease 1 0.9994878768920898
oxidase I-Disease 0 4.210162296658382e-05
( O 0 1.2234654604981188e-06
CPO O 0 7.137924694688991e-05
) O 0 2.2687804346332996e-07
. O 0 2.591542624941212e-07

Clinical O 0 0.14318035542964935
manifestations O 0 0.00022823057952336967
of O 0 5.805223736388143e-06
the O 0 6.223005584615748e-06
disease O 1 0.8257954716682434
are O 0 5.007925185651629e-10
characterized O 0 5.9018616660466705e-09
by O 0 1.3017793509817466e-09
acute O 0 0.0023433384485542774
attacks O 0 7.510482902262083e-08
of O 0 0.00014863681280985475
neurological B-Disease 1 1.0
dysfunction I-Disease 1 1.0
often O 0 1.089014833866031e-08
precipitated O 0 7.996423079248416e-08
by O 0 1.0298826236265768e-09
drugs O 0 3.710957763303213e-09
, O 0 2.6616695514292132e-09
fasting O 0 7.974162144819275e-06
, O 0 2.159124079526009e-08
cyclical O 0 0.08539776504039764
hormonal O 0 2.0781562852789648e-05
changes O 0 9.632653785729417e-09
, O 0 1.0585314846878191e-08
or O 0 1.374639964524249e-06
infectious B-Disease 1 0.9999576807022095
diseases I-Disease 1 0.9999997615814209
. O 0 1.6807452993816696e-05

Skin O 1 1.0
photosensitivity O 1 1.0
may O 0 2.79956675512949e-05
also O 0 5.544880465890856e-08
be O 0 3.163465933653242e-08
present O 0 2.1100260028106277e-07
. O 0 6.723210503878363e-07

The O 0 2.915005325121456e-06
seven O 0 1.0602742577248137e-06
exons O 0 4.155273813921667e-07
, O 0 7.295725357181482e-09
the O 0 1.1804869615161806e-07
exon O 0 2.0529348603304243e-06
/ O 0 1.7102626088671968e-06
intron O 0 9.887208989312057e-07
boundaries O 0 2.2743908090205878e-08
and O 0 1.6203997033059636e-09
part O 0 9.361895259019093e-09
of O 0 1.0950430606726513e-07
3 O 0 6.24851338670851e-07
noncoding O 0 1.976682369786431e-06
sequence O 0 7.654058720163448e-08
of O 0 1.0464131605658622e-07
the O 0 1.2240940350238816e-07
CPO O 0 5.231243449088652e-06
gene O 0 4.901146155589231e-09
were O 0 2.9815083735229564e-09
systematically O 0 2.6003654340911453e-08
analyzed O 0 5.717487372436381e-09
by O 0 1.4444001550373287e-09
an O 0 6.405187935598633e-09
exon O 0 4.2589228144152e-08
- O 0 2.6278780040911442e-08
by O 0 2.1124899163282862e-08
- O 0 4.825517976314586e-07
exon O 0 1.1148622434120625e-06
denaturing O 0 1.3030370610067621e-05
gradient O 0 1.5798589174664812e-06
gel O 0 1.4741109453098034e-06
electrophoresis O 0 6.234713964659022e-06
( O 0 2.133083114586043e-07
DGGE O 0 5.268662789603695e-05
) O 0 5.658167712141449e-09
strategy O 0 1.1511418485099512e-08
followed O 0 2.061751214199603e-09
by O 0 1.7499381110841483e-10
direct O 0 1.151334583227026e-09
sequencing O 0 8.728905376287344e-10
in O 0 6.022671805716584e-10
seven O 0 4.996249636235461e-09
unrelated O 0 8.642305004968875e-08
heterozygous O 0 7.040282667958309e-08
HC B-Disease 0 0.006866046693176031
patients O 0 1.2367669910418044e-07
from O 0 1.654031223097263e-08
France O 0 4.274564346928855e-08
, O 0 9.326962313593867e-09
Holland O 0 2.015817841538592e-07
, O 0 6.382103290292207e-09
and O 0 4.291587529792196e-09
Czech O 0 1.57140675582923e-06
Republic O 0 1.8644188457983546e-05
. O 0 1.9120518572890433e-06

Seven O 0 3.1969723295333097e-06
novel O 0 3.817252149929118e-07
mutations O 0 1.041293895553963e-08
and O 0 1.1180399939192398e-09
two O 0 1.579304687027161e-09
new O 0 1.070876454178915e-08
polymorphisms O 0 5.627780410577543e-07
were O 0 3.776545156597422e-07
detected O 0 2.0026302536280127e-06
. O 0 7.793549912094022e-07

Among O 0 9.086610219810609e-08
these O 0 4.111386786576077e-09
mutations O 0 4.277939336105874e-09
two O 0 2.6899846794492532e-09
are O 0 1.88837478987125e-09
missense O 0 3.082120656472398e-07
( O 0 4.8989711842750694e-08
G197W O 0 9.024351470543479e-07
, O 0 1.6303799199590685e-08
W427R O 0 5.27625900303974e-07
) O 0 5.886526821541338e-09
, O 0 8.338049140022008e-10
two O 0 1.4318481955655216e-09
are O 0 4.556170996039555e-09
nonsense O 0 4.2135566218348686e-06
( O 0 1.0947381667847367e-07
Q306X O 0 1.5709348417658475e-06
, O 0 2.2436870139586063e-08
Q385X O 0 1.1173210623383056e-06
) O 0 1.3248955710309929e-08
, O 0 1.1470384642109366e-09
two O 0 8.425207198570206e-10
are O 0 2.685246747180514e-10
small O 0 9.203226625231764e-09
deletions O 0 5.809765823983071e-08
( O 0 5.700438521216711e-08
662de14bp O 0 1.2355578746792162e-06
; O 0 1.2891145928506376e-08
1168del3bp O 0 4.494941094890237e-06
removing O 0 8.666335702400829e-07
a O 0 5.067880692877225e-07
glycine O 0 4.555087116386858e-07
at O 0 2.3269885218724085e-07
position O 0 3.558850778517808e-07
390 O 0 2.282555158217292e-07
) O 0 1.4440199036513945e-09
, O 0 2.688300970721258e-10
and O 0 2.6144716946951974e-10
one O 0 1.9325405720138633e-09
is O 0 1.283696260401257e-09
a O 0 8.861364975132346e-09
splicing O 0 1.6298917770996013e-08
mutation O 0 1.6236111344269943e-09
( O 0 3.657126601552818e-09
IVS1 O 0 9.763151638253476e-07
- O 0 9.500878661583556e-08
15c O 0 1.3491388699549134e-06
- O 0 1.1656761955691763e-07
- O 0 1.3602374338006484e-07
> O 0 1.7741163560458517e-07
g O 0 3.3241356334201555e-08
) O 0 1.2515987135586215e-09
which O 0 1.6466888963506676e-10
creates O 0 8.292819764221804e-09
a O 0 2.4307977852799922e-08
new O 0 2.186838798934332e-08
acceptor O 0 5.420463367045159e-07
splice O 0 3.8414469599956647e-05
site O 0 9.556321856507566e-06
. O 0 6.721928116348863e-07

The O 0 6.041129836376058e-06
pathological O 0 0.0001829582470236346
significance O 0 2.7360295007383684e-06
of O 0 5.907241416025499e-07
the O 0 1.3653529151724797e-07
point O 0 7.161080475270865e-07
mutations O 0 6.6157874734074085e-09
G197W O 0 1.390602193396262e-07
, O 0 5.067422925719711e-09
W427R O 0 4.750338291614753e-07
, O 0 4.1934362648987644e-09
and O 0 3.0086317881483637e-09
the O 0 6.168629340663756e-08
in O 0 2.310809463779151e-07
- O 0 5.554057338486018e-07
frame O 0 4.555305622488959e-06
deletion O 0 2.5934340897038055e-07
390delGly O 0 1.3713504642964836e-07
were O 0 9.837529013623225e-09
assessed O 0 2.7669344149217068e-08
by O 0 1.072535615875836e-09
their O 0 1.6683009418372308e-09
respective O 0 5.1393978850455824e-08
expression O 0 2.8890180914231678e-08
in O 0 6.658360085509685e-09
a O 0 1.06602824345714e-08
prokaryotic O 0 5.124438651193941e-09
system O 0 1.0106894210437645e-09
using O 0 1.6679828629406757e-09
site O 0 7.205176189017948e-08
- O 0 1.218259342294914e-07
directed O 0 1.2717582364984992e-07
mutagenesis O 0 1.4696986909257248e-05
. O 0 8.160407105606282e-07

These O 0 8.265235607041177e-08
mutations O 0 2.9254319855454014e-08
resulted O 0 1.4005439652464702e-07
in O 0 1.756514222961414e-08
the O 0 7.447432892604411e-08
absence O 0 2.15424302041356e-06
or O 0 6.814935460397464e-08
a O 0 2.1946735984101906e-08
dramatic O 0 9.359720820611983e-08
decrease O 0 1.1877644965352374e-06
of O 0 2.333086740691215e-06
CPO O 0 0.0003408682532608509
activity O 0 4.346941932453774e-05
. O 0 4.924424956698203e-07

The O 0 6.198439450599835e-07
two O 0 1.2069985899643143e-08
polymorphisms O 0 5.245403755793632e-08
were O 0 1.3908216800473383e-08
localized O 0 9.501331987848971e-08
in O 0 6.598069202112811e-09
noncoding O 0 5.978271246931399e-07
part O 0 3.687225103021774e-08
of O 0 9.472759643358586e-08
the O 0 4.107375417561343e-08
gene O 0 6.29476581970323e-10
1 O 0 3.1293951874289405e-09
) O 0 1.2039967633992177e-10
a O 0 2.309479052442498e-09
C O 0 1.4454803931585047e-07
/ O 0 8.485434221938704e-08
G O 0 3.122284510936879e-07
polymorphism O 0 1.0131820715741924e-07
in O 0 4.718261337188778e-09
the O 0 5.6744251963891656e-08
promotor O 0 2.875056816264987e-05
region O 0 1.2565499218908371e-07
, O 0 2.5860167340852058e-08
142 O 0 4.0216414731730765e-07
bp O 0 1.1908177839359269e-06
upstream O 0 1.0820186844284763e-06
from O 0 2.1600797595056065e-08
the O 0 4.399381836606153e-08
transcriptional O 0 4.713209023066156e-07
initiation O 0 2.144901500855667e-08
site O 0 1.2876376409565182e-08
( O 0 8.202158952030913e-10
- O 0 4.0371137544070734e-09
142C O 0 1.5552929255591152e-07
/ O 0 5.144036663295992e-08
G O 0 1.1915545172769271e-07
) O 0 1.0644387593572446e-09
, O 0 3.068678366968669e-10
and O 0 7.055170336833783e-10
2 O 0 2.5105393319790892e-08
) O 0 1.638125080027919e-09
a O 0 6.198158875037052e-09
6 O 0 3.214104538074025e-08
bp O 0 9.82062147159013e-08
deletion O 0 1.8746133534364162e-08
polymorphism O 0 1.9764470948757662e-08
in O 0 8.510777083081678e-10
the O 0 1.7597728829699122e-09
3 O 0 3.1969609182169734e-08
noncoding O 0 1.4837891626484634e-07
part O 0 1.398034754629407e-08
of O 0 6.404921748526249e-08
the O 0 1.6235227917604789e-07
CPO O 0 1.371890539303422e-05
gene O 0 2.5272393955333428e-08
, O 0 7.844927374378585e-09
574 O 0 8.484000204589393e-07
bp O 0 2.206044428021414e-06
downstream O 0 1.101841235140455e-06
of O 0 5.523379087435387e-08
the O 0 4.5896133116229976e-08
last O 0 2.3250246172779043e-08
base O 0 7.005535707094168e-08
of O 0 2.6098806671370767e-08
the O 0 2.49409239927445e-08
normal O 0 5.858258944613226e-08
termination O 0 7.335845708666966e-08
codon O 0 2.563160990121105e-07
( O 0 2.6255785101625406e-08
+ O 0 1.1437144564752089e-07
574 O 0 4.0166662529372843e-07
delATTCTT O 0 1.9271144537924556e-06
) O 0 2.629652939845073e-08
. O 0 3.137961712695869e-08

Five O 0 1.3309485439094715e-05
intragenic O 0 0.00010218685201834887
dimorphisms O 0 0.00016887352103367448
are O 0 2.1613079326243678e-08
now O 0 1.1592856452580236e-08
well O 0 1.4706012407827984e-08
characterized O 0 5.2582855403215945e-08
and O 0 2.3667778847880072e-09
the O 0 9.666906386485152e-09
high O 0 3.147804861214354e-08
degree O 0 6.957019422770827e-07
of O 0 3.8599726082111374e-08
allelic O 0 3.554814327344502e-07
heterogeneity O 0 1.2594920235642348e-06
in O 0 1.923393142533314e-07
HC B-Disease 1 0.9999997615814209
is O 0 2.022681258040393e-07
demonstrated O 0 2.0101081688039812e-08
with O 0 1.7415538455800572e-10
seven O 0 2.081412375787295e-09
new O 0 1.2654967351810598e-10
different O 0 9.604282646957785e-11
mutations O 0 2.8093199988532547e-10
making O 0 1.312670305786412e-09
a O 0 3.983084084779875e-09
total O 0 1.2484378864030532e-08
of O 0 1.3121307063101995e-07
nineteen O 0 1.2868263183918316e-05
CPO O 0 0.019848400726914406
gene B-Disease 0 4.895393431070261e-06
defects I-Disease 0 1.94332969840616e-05
reported O 0 6.281087649995243e-08
so O 0 2.8818838426758475e-09
far O 0 6.782746808653428e-09
. O 0 5.117191115289188e-09
. O 0 8.191645406441239e-08

Coincidence O 0 0.00014532753266394138
of O 0 4.1628814528849034e-07
two O 0 4.598103942043963e-08
novel O 0 6.143355903986958e-07
arylsulfatase O 0 1.1490564247651491e-05
A O 0 3.758895559258235e-07
alleles O 0 2.4479791527198813e-09
and O 0 8.629102432600178e-10
mutation O 0 7.671184576452106e-09
459 O 0 8.385262049159792e-07
+ O 0 3.0933420021028724e-06
1G O 0 1.274666101380717e-05
> O 0 3.0147342044983816e-07
A O 0 3.888517952077564e-08
within O 0 1.1061811910906272e-08
a O 0 3.060118913822407e-08
family O 0 3.09791552410843e-08
with O 0 5.89511106596774e-09
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
: O 0 1.0446737697122899e-08
molecular O 0 2.2596889692749755e-08
basis O 0 1.555562256783105e-08
of O 0 8.84139339518697e-09
phenotypic O 0 5.316038595992723e-07
heterogeneity O 0 1.2193373549962416e-05
. O 0 8.48261663577432e-07

In O 0 7.991321581357624e-06
a O 0 8.514810474480328e-07
family O 0 5.967447691546113e-08
with O 0 8.071024404365801e-10
three O 0 1.6698233906708992e-08
siblings O 0 9.590975196260842e-07
, O 0 2.034034496389836e-09
one O 0 2.121476994076943e-09
developed O 0 6.163899168853959e-09
classical O 0 5.478411821968621e-06
late O 0 0.0005557534168474376
infantile O 1 0.999667763710022
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 7.086900586728007e-05
MLD B-Disease 1 1.0
) O 0 8.836676812506994e-08
, O 0 4.559839617002126e-09
fatal O 0 8.862025993039424e-07
at O 0 1.388923124068242e-06
age O 0 7.65242248235154e-07
5 O 0 3.3546905342518585e-07
years O 0 2.78506906425946e-08
, O 0 2.2568968915948062e-09
with O 0 4.3823118467400946e-09
deficient O 0 0.00018211566202808172
arylsulfatase O 0 0.0001394601713400334
A O 0 0.00020421268709469587
( O 0 3.230114771213266e-07
ARSA O 0 8.827706187730655e-05
) O 0 1.9116479510472573e-09
activity O 0 1.194630794287832e-08
and O 0 8.248990379655652e-10
increased O 0 3.015999183730855e-08
galactosylsulfatide O 0 3.056720015592873e-05
( O 0 2.648158670126577e-06
GS O 1 0.9999911785125732
) O 0 3.177459007019934e-08
excretion O 0 3.4543273841336486e-07
. O 0 4.7290214411077613e-08

The O 0 2.203834355896106e-06
two O 0 4.8779359218542595e-08
other O 0 4.912564577352896e-09
siblings O 0 2.753021988155524e-07
, O 0 2.5663132063868943e-08
apparently O 0 1.6440219496871578e-06
healthy O 0 4.5215787736196944e-07
at O 0 3.97897849779838e-07
12 O 0 8.302540521754054e-08
( O 0 4.327837643813837e-09
1 O 0 2.5093042310686542e-08
/ O 0 9.491492924951217e-09
2 O 0 5.100839750582509e-09
) O 0 1.4488305000170953e-10
and O 0 6.858112688856721e-11
15 O 0 9.973819548037e-10
years O 0 7.386707912004908e-10
, O 0 5.294045757331389e-10
respectively O 0 5.602774688640011e-09
, O 0 6.614673808691407e-10
and O 0 3.129041470373295e-10
their O 0 9.441689652334162e-10
father O 0 9.13540745273167e-08
, O 0 2.685693667459077e-09
apparently O 0 9.84573560458557e-08
healthy O 0 2.066401627587311e-08
as O 0 1.6002207336995866e-09
well O 0 2.6218940352151776e-09
, O 0 1.2734198140407216e-09
presented O 0 3.202915479505464e-07
ARSA O 0 0.25212231278419495
and O 0 7.164741759879689e-07
GS O 1 0.9999994039535522
values O 0 1.853084441449937e-08
within O 0 3.71930508613616e-09
the O 0 1.8190762229863822e-09
range O 0 2.1851544573792125e-08
of O 0 4.2220415252813837e-07
MLD B-Disease 1 1.0
patients O 0 7.3503938438079786e-06
. O 0 4.376242088710569e-07

Mutation O 0 3.3175490443682065e-07
screening O 0 1.5512895856772957e-08
and O 0 8.066483592195084e-10
sequence O 0 6.738944335893393e-08
analysis O 0 4.368735773141452e-08
disclosed O 0 6.825653713349311e-07
the O 0 5.360063326520503e-08
involvement O 0 2.693436726985965e-07
of O 0 3.656647251659706e-08
three O 0 6.266103635965692e-09
different O 0 4.07091915732849e-09
ARSA O 0 0.00024078608839772642
mutations O 0 7.690639236557217e-09
being O 0 3.484745825232949e-09
the O 0 2.161141932077726e-09
molecular O 0 1.830447615702724e-08
basis O 0 4.715483825634692e-08
of O 0 3.9721157918393146e-08
intrafamilial O 0 1.1314578841847833e-05
phenotypic O 0 1.7620511698623886e-06
heterogeneity O 0 2.030549330811482e-05
. O 0 6.238653895707102e-07

The O 0 2.9749828627245734e-06
late O 0 9.033050446305424e-05
infantile O 0 0.05356426164507866
patient O 0 2.4507855414412916e-05
inherited O 0 2.886889888031874e-05
from O 0 3.1495310395257547e-06
his O 0 4.391319180285791e-06
mother O 0 1.7785100681066979e-06
the O 0 1.6366088573249726e-07
frequent O 0 3.748548849102917e-08
0 O 0 6.4854637216171795e-09
- O 0 2.975372836999668e-09
type O 0 4.124943941974379e-09
mutation O 0 1.7637244997814605e-09
459 O 0 1.2801325510736206e-07
+ O 0 2.1207281974966463e-07
1G O 0 1.150123352999799e-06
> O 0 4.032351696992009e-08
A O 0 3.2788729953381335e-08
, O 0 2.370146856556232e-10
and O 0 1.820730788359981e-10
from O 0 5.202476671684053e-09
his O 0 3.588877106608379e-08
father O 0 2.382196413464044e-07
a O 0 3.038830698187667e-08
novel O 0 1.5765277083801266e-08
, O 0 1.204344290961501e-09
single O 0 1.2029696350168706e-08
basepair O 0 7.362119731624261e-07
microdeletion O 0 9.253664075004053e-07
of O 0 1.304836985127622e-07
guanine O 0 4.982719588042528e-07
at O 0 5.49054902876378e-07
nucleotide O 0 5.170852546143578e-07
7 O 0 1.389870334378429e-07
in O 0 1.4694320427111052e-08
exon O 0 7.721686046124887e-08
1 O 0 5.956020387998251e-08
( O 0 5.006667080920124e-09
7delG O 0 1.6985676154490648e-07
) O 0 1.8377940946834315e-08
. O 0 2.614165417469394e-08

The O 0 9.850156175161828e-07
two O 0 1.1843648906051385e-07
clinically O 0 8.836179767968133e-05
unaffected O 0 4.500577233557124e-06
siblings O 0 2.662164035882597e-07
carried O 0 2.4742112358921986e-08
the O 0 2.8307947985695137e-08
maternal O 0 2.016998621456878e-07
mutation O 0 4.833773825652088e-09
459 O 0 1.9963421493685019e-07
+ O 0 1.4241645374113432e-07
1G O 0 1.4039316056368989e-06
> O 0 6.81796450408001e-08
A O 0 6.467467983384267e-08
and O 0 4.671408815326572e-10
, O 0 1.0176667286643237e-09
on O 0 7.62917551355713e-09
their O 0 2.7568554106238707e-09
paternal O 0 8.823102604083033e-08
allele O 0 1.3616092697787963e-09
, O 0 1.9488637093001415e-10
a O 0 1.7557094666997841e-09
novel O 0 1.1134183353078697e-08
cytosine O 0 4.438879486201586e-08
to O 0 3.2821247941683396e-09
thymidine O 0 3.447965468694747e-07
transition O 0 2.1762664914604102e-07
at O 0 6.369543257278565e-07
nucleotide O 0 2.8169126835564384e-06
2435 O 0 1.7911273971549235e-05
in O 0 1.979204711233251e-08
exon O 0 4.0607933016190145e-08
8 O 0 8.71995631257505e-09
, O 0 2.066127824384978e-10
resulting O 0 7.972141280454537e-10
in O 0 1.1054214210659552e-09
substitution O 0 9.95918725266165e-09
of O 0 1.0784732751289994e-07
alanine O 0 2.0857351046288386e-06
464 O 0 1.4976045576986508e-06
by O 0 7.514982769407652e-08
valine O 0 1.6828735169838183e-05
( O 0 1.555330015889922e-07
A464V O 0 5.090043487143703e-06
) O 0 7.906458421302887e-08
. O 0 1.2536018800801685e-07

The O 0 1.2212552974233404e-05
fathers O 0 1.2752923794323578e-05
genotype O 0 9.849508160186815e-07
thus O 0 3.213654906630836e-07
was O 0 4.010257271147566e-06
7delG O 0 3.1293093343265355e-05
/ O 0 3.915289926226251e-05
A464V O 0 5.180888911127113e-05
. O 0 1.2229510275574285e-06

Mutation O 0 1.9174029148416594e-05
A464V O 0 2.8363559977151453e-05
was O 0 1.352439198853972e-06
not O 0 1.0607891454128549e-08
found O 0 6.780677352935527e-09
in O 0 7.926175271677494e-09
18 O 0 1.8361882325734769e-07
unrelated O 0 0.0003337394446134567
MLD B-Disease 1 1.0
patients O 0 6.11803852734738e-06
and O 0 1.4323132901949975e-08
50 O 0 4.872571253144997e-07
controls O 0 1.0804864132296643e-06
. O 0 1.4024820416125294e-07

A464V O 0 0.00012167965905973688
, O 0 1.0049139831380671e-07
although O 0 3.50126363457548e-08
clearly O 0 2.566299031059316e-07
modifying O 0 2.2985129817243433e-06
ARSA O 1 0.9872295260429382
and O 0 4.0064460335997865e-06
GS O 1 1.0
levels O 0 1.0557595487625804e-05
, O 0 9.844661086333417e-09
apparently O 0 1.9693320041369589e-07
bears O 0 1.57688006652279e-07
little O 0 3.845356744136552e-08
significance O 0 6.448412648296653e-08
for O 0 6.153503040451369e-09
clinical O 0 1.818978603296273e-06
manifestation O 0 7.584970444440842e-05
of O 0 5.1128376071574166e-05
MLD B-Disease 1 1.0
, O 0 4.80585697459901e-07
mimicking O 0 3.5439320527075324e-06
the O 0 6.336547357932432e-07
frequent O 0 2.093810280712205e-06
ARSA O 0 0.0024126856587827206
pseudodeficiency O 0 6.746988947270438e-05
allele O 0 2.2954047835810343e-06
. O 0 6.404090981959598e-07

Our O 0 3.5896487133868504e-06
results O 0 1.0209299006191941e-07
demonstrate O 0 2.3803245596809575e-08
that O 0 2.057566339530581e-10
in O 0 6.546532205220501e-10
certain O 0 2.8158553266877107e-09
genetic O 0 5.1942301126928214e-08
conditions O 0 2.449884959787596e-06
MLD B-Disease 1 1.0
- O 0 0.002435013186186552
like O 0 3.9075965219126374e-07
ARSA O 1 0.9940699338912964
and O 0 3.3857801895464945e-07
GS O 1 1.0
values O 0 2.5682913573632504e-08
need O 0 2.578342206405182e-09
not O 0 1.8893936415409485e-10
be O 0 5.822450854786609e-10
paralleled O 0 2.737052007262264e-08
by O 0 1.6912212741360122e-09
clinical O 0 3.4523156500654295e-05
disease O 0 2.9912528134445893e-06
, O 0 4.1808476125559935e-10
a O 0 2.211472338586873e-09
finding O 0 5.273901759750288e-09
with O 0 1.1944152611409464e-10
serious O 0 8.382370708659437e-08
diagnostic O 0 4.900901444671035e-07
and O 0 1.2216503364470555e-08
prognostic O 0 0.00011210211960133165
implications O 0 1.174786689261964e-06
. O 0 3.912921897608612e-07

Moreover O 0 1.2877777407993563e-05
, O 0 2.261728582197975e-08
further O 0 3.170527804741141e-07
ARSA O 0 0.0020112989004701376
alleles O 0 7.00729998470706e-08
functionally O 0 9.733968227010337e-07
similar O 0 5.105755374046339e-09
to O 0 9.165458614290856e-09
A464V O 0 9.94174683910387e-07
might O 0 2.3117852521181703e-08
exist O 0 3.160329953288965e-08
which O 0 9.121244870513578e-10
, O 0 2.3042419361463118e-10
together O 0 7.007280311555064e-10
with O 0 1.3779040131112197e-09
0 O 0 1.0153060969742e-07
- O 0 5.853422990753643e-08
type O 0 1.9221861435880783e-08
mutations O 0 2.351492556229573e-09
, O 0 5.602067143506417e-10
may O 0 1.5029881339501117e-08
cause O 0 3.991565336036729e-06
pathological O 1 0.9998680353164673
ARSA O 1 0.999990701675415
and O 0 8.372525144295651e-07
GS O 1 1.0
levels O 0 2.7294336746308545e-07
, O 0 1.217197453939889e-10
but O 0 4.7811275771803e-11
not O 0 7.745482033527651e-11
clinical O 0 1.6682889736330253e-08
outbreak O 0 5.308821826588428e-09
of O 0 7.808234059325514e-09
the O 0 3.6442472151065886e-07
disease O 0 4.489333150559105e-06
. O 0 8.531487516449943e-09
. O 0 8.796234141073e-08

Human O 1 0.9954402446746826
MLH1 O 1 1.0
deficiency O 1 1.0
predisposes O 0 0.0019443766213953495
to O 0 9.650096899349592e-07
hematological B-Disease 1 1.0
malignancy I-Disease 1 1.0
and O 0 1.0674034456314985e-06
neurofibromatosis B-Disease 1 0.999847412109375
type I-Disease 0 0.10343844443559647
1 I-Disease 0 0.0007025656523182988
. O 0 1.0537772823226987e-06

Heterozygous O 0 2.510097147023771e-05
germ O 0 0.0001911427389131859
- O 0 4.802659532288089e-06
line O 0 1.048290982907929e-07
mutations O 0 3.943157800279096e-09
in O 0 1.7120904693967987e-09
the O 0 1.7567254317896186e-08
DNA O 0 4.3009927708226314e-07
mismatch O 0 0.027000967413187027
repair O 0 0.0015154160792008042
genes O 0 6.61550529912347e-07
lead O 0 1.4078237882131361e-06
to O 0 8.212746820390748e-07
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00017104459402617067

The O 0 5.743449946749024e-06
disease O 0 1.976695602934342e-05
susceptibility O 0 1.4977817954786588e-06
of O 0 1.5179161891865078e-06
individuals O 0 1.5985490620096243e-07
who O 0 7.246163846730269e-08
constitutionally O 0 4.847163381782593e-07
lack O 0 8.810943796788706e-08
both O 0 1.1818049872047709e-09
wild O 0 3.480474797257216e-09
- O 0 1.091002399533636e-08
type O 0 1.462051457679081e-08
alleles O 0 2.6256772311938903e-09
is O 0 2.0012393964208286e-09
unknown O 0 9.556252962283907e-07
. O 0 1.0565087649183624e-07

We O 0 7.823261967132566e-07
have O 0 3.911471591067084e-09
identified O 0 1.9057983635661913e-08
three O 0 8.15797740472135e-09
offspring O 0 1.4538424686350027e-08
in O 0 1.683504358140908e-08
a O 0 2.559871063567698e-06
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 1 1.0
who O 0 8.221736038649397e-07
developed O 0 2.1480398572748527e-05
hematological B-Disease 1 1.0
malignancy I-Disease 1 1.0
at O 0 1.9945295207435265e-05
a O 0 4.461934111077426e-08
very O 0 4.0099748521704726e-10
early O 0 9.953585511368601e-09
age O 0 5.4506333668769e-08
, O 0 1.5778353068540696e-09
and O 0 1.1841176927873676e-09
at O 0 2.3441681662461633e-07
least O 0 3.5596698921835923e-09
two O 0 5.435325522995527e-10
of O 0 3.912650647919236e-09
them O 0 1.3194023651408315e-09
displayed O 0 4.14295584505453e-07
signs O 0 4.5985427732375683e-07
of O 0 2.06046070161392e-06
neurofibromatosis B-Disease 0 0.0027263551019132137
type I-Disease 0 0.00018305142293684185
1 I-Disease 0 0.0003931765677407384
( O 0 5.891842533856106e-07
NF1 B-Disease 0 0.00013461409253068268
) O 0 8.028241893498489e-08
. O 0 7.564265303017237e-08

DNA O 0 1.366043136385997e-07
sequence O 0 1.5079729465128366e-08
analysis O 0 5.7068429981654845e-09
and O 0 7.352433939455949e-11
allele O 0 2.0287020674469858e-10
- O 0 1.261771243044052e-09
specific O 0 5.720495188654695e-10
amplification O 0 4.011248933011302e-08
in O 0 4.257815877650728e-09
two O 0 5.174864980972416e-09
siblings O 0 3.678676421259297e-07
revealed O 0 9.019524327413819e-07
a O 0 3.0788598337494477e-07
homozygous O 0 1.435708156805049e-07
MLH1 O 0 5.403563136496814e-06
mutation O 0 8.466854772848365e-09
( O 0 3.0940399131651475e-09
C676T O 0 9.985858895333877e-08
- O 0 1.3850211644239607e-06
- O 0 6.985280379012693e-06
> O 0 4.837539563595783e-06
Arg226Stop O 0 7.57578163756989e-05
) O 0 9.098021536146916e-08
. O 0 8.62039257754077e-08

Thus O 0 3.5716252568818163e-06
, O 0 1.8327330053580226e-07
a O 0 3.5022861766265123e-07
homozygous O 0 3.5882206361748104e-07
germ O 0 0.0010229991748929024
- O 0 0.00021772121544927359
line O 0 4.657126282836543e-06
MLH1 O 0 0.0010238015092909336
mutation O 0 1.7504339311358308e-08
and O 0 2.601117987666157e-09
consequent O 0 0.00018420071864966303
mismatch O 1 1.0
repair O 1 1.0
deficiency O 1 1.0
results O 0 6.179267529660137e-06
in O 0 9.66685576031523e-08
a O 0 2.8315869826656126e-07
mutator O 0 0.0005065028672106564
phenotype O 0 1.7058857793017523e-07
characterized O 0 1.801498683562386e-08
by O 0 1.7160013854322642e-08
leukemia B-Disease 1 0.9999105930328369
and O 0 0.09574832022190094
/ O 1 1.0
or O 1 1.0
lymphoma B-Disease 1 1.0
associated O 1 0.9999943971633911
with O 0 1.7975588662011432e-06
neurofibromatosis B-Disease 1 1.0
type I-Disease 1 0.9998607635498047
1 I-Disease 0 0.012945691123604774
. O 0 6.596637547318096e-08
. O 0 1.3914311125517997e-07

Missense O 0 0.0022514737211167812
mutations O 0 7.472231686733721e-07
in O 0 2.836924473115232e-08
the O 0 4.060173708353432e-08
most O 0 2.597236203882858e-09
ancient O 0 2.1545007200529653e-07
residues O 0 5.127364488544117e-07
of O 0 3.581649536954501e-07
the O 0 1.8643246448846185e-06
PAX6 O 1 0.6305885910987854
paired O 0 3.858482159557752e-06
domain O 0 6.5658600760798436e-06
underlie O 0 6.410483024410496e-07
a O 0 2.7935973534454206e-08
spectrum O 0 1.9065024048359192e-07
of O 0 4.052184976899298e-06
human O 1 0.9999991655349731
congenital B-Disease 1 1.0
eye I-Disease 1 1.0
malformations I-Disease 1 1.0
. O 0 0.00016390795644838363

Mutations O 0 1.3327802435014746e-06
of O 0 1.5913893491870112e-07
the O 0 2.7324523443894577e-07
human O 0 6.984601554904657e-07
PAX6 O 1 0.9580492973327637
gene O 0 1.5208058357529808e-05
underlie O 1 0.7926715612411499
aniridia B-Disease 1 1.0
( O 1 0.9999322891235352
congenital B-Disease 1 1.0
absence I-Disease 0 0.0003550357650965452
of I-Disease 0 0.0006404790328815579
the I-Disease 0 2.746187055890914e-05
iris I-Disease 0 4.609621100826189e-05
) O 0 1.4430740691295796e-07
, O 0 7.696450587957315e-09
a O 0 6.397022502824257e-07
rare O 0 0.00016371722449548542
dominant O 1 0.9999998807907104
malformation B-Disease 1 1.0
of I-Disease 1 0.9999998807907104
the I-Disease 1 0.9999977350234985
eye I-Disease 1 1.0
. O 0 1.1385661309759598e-05

The O 0 8.510410225426313e-07
spectrum O 0 5.867809136361757e-07
of O 0 1.3091063237880007e-06
PAX6 O 1 0.9952180981636047
mutations O 0 6.738288220731192e-07
in O 0 2.3195083542759676e-07
aniridia B-Disease 1 1.0
patients O 0 9.419429858326112e-08
is O 0 6.588081191694073e-10
highly O 0 3.6823597504564987e-09
biased O 0 2.280589583847359e-08
, O 0 1.757082257469733e-10
with O 0 9.481386509246903e-11
92 O 0 9.946889178991114e-08
% O 0 1.5530000618824147e-09
of O 0 2.07264538865104e-09
all O 0 6.828512755241434e-10
reported O 0 1.624609247130593e-08
mutations O 0 2.211151484132756e-09
leading O 0 2.985476044159441e-08
to O 0 4.212828752514497e-09
premature O 0 2.7728205509447434e-07
truncation O 0 1.4488646229438018e-06
of O 0 2.60954294617477e-07
the O 0 1.7390237871950376e-07
protein O 0 1.8865007689328195e-07
( O 0 1.6537253344495184e-08
nonsense O 0 1.0155114438248347e-07
, O 0 1.014838657553696e-09
splicing O 0 1.98891143554647e-08
, O 0 1.3053796932283035e-09
insertions O 0 1.7473418267854868e-08
and O 0 1.3129056730676325e-09
deletions O 0 1.159515594650884e-08
) O 0 1.916613090457986e-09
and O 0 2.5151201121786926e-09
just O 0 9.336755368849481e-08
2 O 0 2.4070749304883066e-07
% O 0 1.0116484538968962e-08
leading O 0 5.0106407911698625e-09
to O 0 1.378549913111371e-10
substitution O 0 1.935473337155713e-09
of O 0 3.9956717046152335e-08
one O 0 1.6902093946669083e-08
amino O 0 2.233567464315911e-08
acid O 0 8.834229348053668e-09
by O 0 9.638903897268847e-09
another O 0 2.518160613362852e-07
( O 0 1.0310353104614478e-07
missense O 0 2.006784598052036e-06
) O 0 6.207401526125977e-08
. O 0 8.593190869987666e-08

The O 0 6.621401098527713e-07
extraordinary O 0 1.094185677175119e-06
conservation O 0 4.713982093562663e-07
of O 0 7.629018483612526e-08
the O 0 1.7206856739448995e-07
PAX6 O 0 6.513274274766445e-05
protein O 0 7.722157135958696e-08
at O 0 1.7457127299280728e-08
the O 0 4.694634458957125e-09
amino O 0 5.0836703735512856e-08
acid O 0 3.4672510196287476e-08
level O 0 2.2554138467967277e-07
amongst O 0 1.0848854969935928e-07
vertebrates O 0 5.9126969063072465e-06
predicts O 0 1.8040402949281997e-07
that O 0 1.697889051577306e-09
pathological O 0 1.2083506589988247e-05
missense O 0 2.376564907535794e-06
mutations O 0 1.2545247507489421e-08
should O 0 1.611818123414821e-09
in O 0 5.84067239017827e-09
fact O 0 3.78122244626411e-08
be O 0 1.7074116342996604e-08
common O 0 5.939058134174502e-09
even O 0 2.550666566847326e-09
though O 0 1.226543422383486e-09
they O 0 8.612118240769462e-10
are O 0 7.198246443351763e-10
hardly O 0 7.532806733934194e-08
ever O 0 1.0229883429246911e-07
seen O 0 1.46494684827303e-07
in O 0 2.0145841972407652e-07
aniridia B-Disease 1 1.0
patients O 0 3.3997978334809886e-06
. O 0 4.3809689032059396e-07

This O 0 3.062098414829961e-07
indicates O 0 3.3112652886302385e-07
that O 0 1.392288728752078e-09
there O 0 3.1324585147984862e-09
is O 0 8.96378138381948e-10
a O 0 1.0692294161174232e-08
heavy O 0 6.854760954411176e-07
ascertainment O 0 0.0001521668746136129
bias O 0 4.527529142706044e-07
in O 0 1.89566096153726e-09
the O 0 6.391613904810356e-10
selection O 0 3.803685699743653e-10
of O 0 4.010803245080297e-09
patients O 0 7.612048769090052e-10
for O 0 8.965098108326686e-10
PAX6 O 0 8.243717275036033e-06
mutation O 0 7.605590601755807e-10
analysis O 0 2.6515252216086083e-09
and O 0 4.932473526841896e-11
that O 0 8.592752204217291e-11
the O 0 1.6850849604566065e-08
missing O 0 1.3612016118713655e-05
PAX6 O 0 0.3716418147087097
missense O 0 0.0001526033884147182
mutations O 0 9.616888263508372e-08
frequently O 0 1.3284027211568628e-08
may O 0 3.522712432868502e-08
underlie O 0 3.810097723544459e-06
phenotypes O 0 8.332117431564257e-07
distinct O 0 1.2200487731206522e-07
from O 0 9.870298072200967e-07
textbook O 0 0.0014805785613134503
aniridia B-Disease 1 1.0
. O 0 7.984587682585698e-06

Here O 0 1.7754224472810165e-06
we O 0 1.8387618538895367e-08
present O 0 1.2349431699476554e-08
four O 0 3.383568270010073e-08
novel O 0 9.346141496280325e-07
PAX6 O 0 0.0004692457150667906
missense O 0 8.737991265661549e-06
mutations O 0 1.1425759005589953e-08
, O 0 1.4920478186297714e-09
two O 0 2.76792011533189e-09
in O 0 1.4321630992242262e-08
association O 0 1.1237295538535363e-08
with O 0 4.044126367119816e-09
atypical O 0 1.8870707663154462e-06
phenotypes O 0 2.5990893846028484e-06
ectopia B-Disease 0 5.277135642245412e-05
pupillae I-Disease 0 6.322908302536234e-05
( O 0 4.311131718282013e-08
displaced B-Disease 0 1.587684437254211e-07
pupils I-Disease 0 9.397106026654001e-08
) O 0 7.860882078603026e-08
and O 0 6.145119755274209e-07
congenital B-Disease 1 1.0
nystagmus I-Disease 1 0.9851590991020203
( O 0 6.405675321730087e-06
searching B-Disease 0 0.00010833430133061484
gaze I-Disease 0 5.843831240781583e-05
) O 0 4.020517252456557e-08
, O 0 4.596163893921812e-09
and O 0 5.386841195331726e-09
two O 0 5.174848283218125e-08
in O 0 4.405478648550343e-07
association O 0 1.987271929237977e-07
with O 0 5.698239657903059e-09
more O 0 3.6816942383666174e-08
recognizable O 0 1.9750732462853193e-05
aniridia B-Disease 1 1.0
phenotypes O 0 8.672280091559514e-05
. O 0 9.45908936955675e-07

Strikingly O 0 2.1359284801292233e-05
, O 0 1.2134156790466477e-08
all O 0 2.5607083120604557e-09
four O 0 2.657530195904201e-09
mutations O 0 9.384094612485683e-10
are O 0 1.2892509282380615e-10
located O 0 7.883039998546337e-09
within O 0 3.0176330767517356e-08
the O 0 2.2530942089815653e-07
PAX6 O 0 0.0005871550529263914
paired O 0 6.083973289605638e-07
domain O 0 7.4779211445275e-07
and O 0 1.120672554755231e-09
affect O 0 1.1283084688784584e-08
amino O 0 1.346404143731661e-08
acids O 0 4.918583762503204e-09
which O 0 6.721313505764215e-10
are O 0 4.5192957015549595e-11
highly O 0 2.275726052047844e-09
conserved O 0 1.0873879574546663e-07
in O 0 1.3290514466746117e-08
all O 0 1.9265868900220084e-08
known O 0 7.732414530892129e-08
paired O 0 4.930045065520972e-07
domain O 0 1.8221593336420483e-06
proteins O 0 6.783978534485868e-08
. O 0 1.949117063304584e-07

Our O 0 2.94806704914663e-06
results O 0 1.0420990292914212e-07
support O 0 7.7295512213027e-09
the O 0 9.605298778581073e-09
hypothesis O 0 2.5883014842520424e-08
that O 0 4.9137027779977416e-11
the O 0 3.922062952188554e-10
under O 0 4.640683837209281e-09
- O 0 6.679627961858614e-09
representation O 0 9.65524193929923e-09
of O 0 2.3065087617624158e-08
missense O 0 1.528775783299352e-06
mutations O 0 1.3363136375232898e-08
is O 0 2.6549107356999002e-09
caused O 0 9.625124697265619e-09
by O 0 5.500426336624287e-09
ascertainment O 0 0.05198753625154495
bias O 0 5.324498488334939e-06
and O 0 1.0940572892081946e-08
suggest O 0 5.275302683571681e-08
that O 0 8.630354209060442e-10
a O 0 8.521826799778864e-09
substantial O 0 7.67792087685848e-08
burden O 0 9.319085165770957e-07
of O 0 1.1398719834687654e-05
PAX6 B-Disease 1 0.9999988079071045
- I-Disease 1 0.7005593180656433
related I-Disease 1 0.9910061955451965
disease I-Disease 1 0.9999672174453735
remains O 0 1.9054950826102868e-06
to O 0 3.4769715995253136e-09
be O 0 4.473324821674396e-09
uncovered O 0 4.501710463955533e-06
. O 0 1.020329865042413e-08
. O 0 1.0036153241799184e-07

The O 0 1.5466666809516028e-06
chromosomal O 0 9.116613910009619e-06
order O 0 1.2021730810829467e-07
of O 0 8.03924137926515e-07
genes O 0 2.2291992252121418e-07
controlling O 0 4.878105755778961e-05
the O 0 7.876242307247594e-06
major O 0 5.445388887892477e-05
histocompatibility O 0 0.3091786205768585
complex O 0 0.021605949848890305
, O 0 5.672433900372198e-08
properdin O 0 4.957795681548305e-06
factor O 0 1.3217955938671366e-06
B O 0 3.4426698221068364e-06
, O 0 3.432362838395875e-09
and O 0 1.737481269969976e-08
deficiency B-Disease 1 0.9987183809280396
of I-Disease 0 0.027582582086324692
the I-Disease 0 5.178549145057332e-06
second I-Disease 0 1.5903028725006152e-06
component I-Disease 0 3.3421356420149095e-06
of I-Disease 0 3.372924481936934e-07
complement I-Disease 0 3.1833058073971188e-06
. O 0 1.3101192735121003e-06

The O 0 6.951561317691812e-07
relationship O 0 1.0866768462847176e-07
of O 0 3.627318889698472e-08
the O 0 1.7585323419666565e-08
genes O 0 3.524054825732037e-09
coding O 0 1.5317901613798313e-08
for O 0 2.2131179111539723e-09
HLA O 0 9.885741292237071e-08
to O 0 4.5221262845451804e-10
those O 0 6.416140396758863e-10
coding O 0 2.1483041123815383e-08
for O 0 1.3760025341369442e-09
properdin O 0 1.9660119505715556e-06
Factor O 0 1.7788222521630814e-06
B O 0 6.247828423511237e-07
allotypes O 0 7.008047759882174e-07
and O 0 1.6142701619870081e-09
for O 0 4.2099452812749405e-09
deficiency B-Disease 0 0.0223951768130064
of I-Disease 0 9.233484888682142e-06
the I-Disease 0 3.765235021546687e-07
second I-Disease 0 3.953002476464462e-07
component I-Disease 0 7.106904149623006e-07
of I-Disease 0 1.458219998085042e-07
complement I-Disease 0 4.79986169921176e-07
( O 0 1.9347625368482113e-07
C2 O 0 4.400235866341973e-06
) O 0 1.4684170546175324e-09
was O 0 1.0011887319194557e-08
studied O 0 2.6608283576479153e-08
in O 0 3.957971728141274e-09
families O 0 1.8701660220443728e-09
of O 0 2.6354424420560463e-08
patients O 0 1.7233421800710857e-08
with O 0 8.647399596384275e-08
connective O 1 1.0
tissue O 1 1.0
disorders O 1 1.0
. O 0 0.0004206964513286948

Patients O 0 1.0113534472111496e-06
were O 0 1.837727481301954e-08
selected O 0 8.61984617017697e-09
because O 0 3.7906149330524386e-09
they O 0 1.9855976862714897e-09
were O 0 6.1762939651544e-08
heterozygous O 0 9.908298892469247e-08
or O 0 3.798549386146988e-08
homozygous O 0 3.003954702762712e-07
for O 0 3.4026002140308265e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 3.821103018708527e-05

12 O 0 2.746913878581836e-06
families O 0 9.969183700775375e-09
with O 0 6.196878565845054e-10
15 O 0 5.117799162235315e-08
matings O 0 2.655061962286709e-06
informative O 0 1.2132500160078052e-05
for O 0 2.0829418645007536e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 4.595780865201959e-06
found O 0 3.6273991099733394e-07
. O 0 2.912760805884318e-07

Of O 0 1.6560488802497275e-05
57 O 0 2.3811521714378614e-06
informative O 0 3.8445391510322224e-06
meioses O 0 7.0087021413201e-06
, O 0 1.4472301579360192e-08
two O 0 3.581230423321813e-09
crossovers O 0 2.727879255814969e-08
were O 0 1.7931478524246813e-08
noted O 0 3.673094894907081e-08
between O 0 9.69989670807081e-08
the O 0 7.932913831609767e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 4.205675363522232e-09
and O 0 6.001915076048192e-10
the O 0 2.6865814461984883e-08
HLA O 0 4.722261621736834e-07
- O 0 3.1005404821371485e-07
B O 0 1.5827333754714346e-06
gene O 0 1.1298370017343018e-09
, O 0 8.822332447921966e-11
with O 0 5.131827948701151e-11
a O 0 4.619506555059161e-09
recombinant O 0 1.7599878221474796e-09
fraction O 0 9.679101964366055e-09
of O 0 3.115621183269468e-08
0 O 0 1.1647216524579562e-07
. O 0 4.478406268049184e-08

035 O 0 0.06061575561761856
. O 0 3.7315090594347566e-05

A O 0 6.213689630385488e-05
lod O 0 0.00014996161917224526
score O 0 2.744397704645962e-07
of O 0 1.0596854593813987e-07
13 O 0 9.901686581770264e-08
was O 0 6.362803617321333e-08
calculated O 0 1.126282427321712e-07
for O 0 7.11808034736805e-09
linkage O 0 1.6278945622616448e-06
between O 0 3.8146642964420607e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 5.624565915240964e-07
HLA O 0 4.579785581881879e-06
- O 0 2.752378804871114e-07
B O 0 1.1764235523514799e-06
at O 0 2.8069338853242698e-08
a O 0 1.6526713331188603e-09
maximum O 0 2.9353515174079803e-09
likelihood O 0 4.668222697290503e-09
value O 0 1.8404943125105433e-09
of O 0 1.5966171718062583e-09
the O 0 1.6545447234506128e-09
recombinant O 0 1.6744983177829909e-09
fraction O 0 1.635359936358327e-08
of O 0 4.86397269128247e-08
0 O 0 5.128626412442827e-08
. O 0 3.1020245927493306e-08

04 O 0 0.0057161590084433556
. O 0 1.275208342121914e-05

18 O 0 3.62399055120477e-06
families O 0 2.1873937328109605e-08
with O 0 1.549484984764149e-09
21 O 0 8.99701930734409e-08
informative O 0 8.463483425202867e-08
matings O 0 1.4654148117188015e-07
for O 0 1.4700256567579117e-09
both O 0 8.341202395456548e-09
properdin O 0 3.2602972623863025e-06
Factor O 0 1.6333546000169008e-06
B O 0 6.319071417237865e-07
allotype O 0 9.154819053946994e-07
and O 0 1.2567615392811149e-08
HLA O 0 8.30363148907054e-07
- O 0 2.046757998641624e-07
B O 0 1.500856001257489e-06
were O 0 5.7525383567735844e-08
found O 0 5.0417426677995536e-08
. O 0 9.615879292823593e-08

Of O 0 3.704085247591138e-05
72 O 0 2.1946540073258802e-05
informative O 0 9.23464813240571e-06
meioses O 0 2.0241301172063686e-05
, O 0 2.0898546893022285e-08
three O 0 1.164811180842662e-08
recombinants O 0 3.237539658584865e-06
were O 0 9.749960128146995e-08
found O 0 3.336929665920252e-08
, O 0 2.9007056756569227e-09
giving O 0 5.3135118527336545e-09
a O 0 8.054465538975819e-09
recombinant O 0 7.923359190975532e-10
fraction O 0 1.4866795794432619e-08
of O 0 1.1260408427915536e-07
0 O 0 1.890666823101128e-07
. O 0 1.4478602849976596e-07

042 O 0 0.008563272655010223
. O 0 3.063308759010397e-05

A O 0 3.501106766634621e-05
lod O 0 9.122784103965387e-05
score O 0 1.5503216843626433e-07
of O 0 1.278487786748883e-07
16 O 0 6.452066259043931e-08
between O 0 4.105104167706486e-08
HLA O 0 2.422116267553065e-07
- O 0 9.122313571197083e-08
B O 0 3.733750304490968e-07
and O 0 4.853609070210041e-09
Factor O 0 9.055844429894933e-07
B O 0 6.615417191824235e-07
allotypes O 0 1.2270925253687892e-06
was O 0 9.944290724206439e-08
calculated O 0 7.74632056277369e-08
at O 0 1.7751462522141992e-08
a O 0 1.094386470334996e-09
maximum O 0 3.112833768526002e-09
likelihood O 0 9.579008697357949e-09
value O 0 5.452814200168632e-09
of O 0 1.5812157139194483e-09
the O 0 1.9110244497966278e-09
recombinant O 0 1.1856409187771533e-09
fraction O 0 8.11283840107535e-09
of O 0 2.3648748737059577e-08
0 O 0 4.193822178422124e-08
. O 0 2.0022371316485987e-08

04 O 0 0.0046021901071071625
. O 0 1.1591878319450188e-05

A O 0 2.9311955586308613e-05
crossover O 0 1.5149024648053455e-06
was O 0 4.991894684280851e-07
shown O 0 3.180806018576732e-08
to O 0 5.737249342274708e-09
have O 0 7.609972652034003e-10
occurred O 0 3.281976290736566e-08
between O 0 1.2641174773619923e-09
genes O 0 1.5874641878799167e-10
for O 0 1.9130291795121934e-10
Factor O 0 1.509215863393365e-08
B O 0 1.6523411972002577e-08
and O 0 1.5247294538056622e-09
HLA O 0 6.549235820330068e-08
- O 0 6.17722406559551e-08
D O 0 1.7319236178536812e-07
, O 0 1.801683358060302e-09
in O 0 3.9781640204239466e-09
which O 0 2.0077084439407145e-09
HLA O 0 8.939493767456952e-08
- O 0 4.3371279900839e-08
D O 0 2.8747766123160545e-07
segregared O 0 6.645636858593207e-07
with O 0 9.084181407104097e-09
HLA O 0 9.882212452794192e-07
- O 0 1.2833021401092992e-07
A O 0 4.937540438731958e-07
and O 0 9.354184982157676e-09
B O 0 2.546838459238643e-06
. O 0 1.8638645826740685e-07

These O 0 4.270701836617263e-08
studies O 0 6.372860639203282e-08
suggest O 0 7.74661224056672e-09
that O 0 5.7899553207452215e-11
the O 0 7.51018969236128e-10
genes O 0 3.8354491804781787e-10
for O 0 5.696845772895642e-10
Factor O 0 9.079678306989081e-07
B O 0 0.00015596332377754152
and O 0 3.0054272883717204e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 4.776237627623914e-09
located O 0 8.642630611177538e-09
outside O 0 8.349256397366389e-09
those O 0 2.778396679392614e-10
for O 0 4.933767172587977e-09
HLA O 0 2.5863528207992204e-06
, O 0 2.5671145209571478e-09
that O 0 2.42286635199207e-10
the O 0 4.97087038198174e-09
order O 0 7.33171612310457e-09
of O 0 6.974232036327521e-08
genese O 0 9.97237975752796e-07
is O 0 2.0537848754997867e-08
HLA O 0 3.795992853383723e-08
- O 0 7.388852640843879e-09
A O 0 7.161634130170569e-08
, O 0 2.3113419511666677e-10
- O 0 1.3821892519416679e-09
B O 0 3.9438514676248815e-08
, O 0 5.364773070226647e-10
- O 0 6.5787673086958876e-09
D O 0 5.203710173873333e-08
, O 0 1.6606436226140886e-09
Factor O 0 5.115774115438398e-07
B O 0 4.3831182665599044e-06
allotype O 0 0.0006585433147847652
, O 0 6.359604412864428e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
, O 0 1.5609439296682126e-09
that O 0 6.166879507052414e-11
the O 0 2.106188334849435e-09
genes O 0 5.228859123462826e-09
coding O 0 1.7924952544490225e-07
for O 0 1.525338859664771e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 5.391242439145572e-07
Factor O 0 2.08103174372809e-05
B O 0 1.8328323676541913e-06
allotypes O 0 5.977963155601174e-07
are O 0 3.8988220985025634e-10
approximately O 0 2.2302542035390616e-09
3 O 0 4.9877755259331025e-09
- O 0 5.383451462392941e-09
- O 0 1.2845149832685365e-08
5 O 0 2.0513574838787463e-08
centimorgans O 0 1.4288784200289228e-07
from O 0 2.5908535317142878e-09
the O 0 1.1288767254313825e-08
HLA O 0 4.379623419481504e-08
- O 0 1.0051455667792197e-08
A O 0 6.517359452118399e-08
and O 0 1.6254700918594267e-09
HLA O 0 1.4235928347261506e-07
- O 0 6.340162173046338e-08
B O 0 2.7913532107959327e-07
loci O 0 5.614670950393474e-09
, O 0 2.507407059759714e-10
and O 0 9.002602135987914e-11
that O 0 4.846000337122014e-11
the O 0 2.1821338069827334e-09
apparent O 0 1.0380639992035867e-07
lack O 0 1.6430395533006958e-07
of O 0 4.1125336025515935e-08
recombinants O 0 5.192338221604587e-07
between O 0 8.37428082434144e-09
the O 0 2.493811734893825e-08
Factor O 0 9.088913088817208e-07
B O 0 6.175655926199397e-06
gene O 0 9.43787824780884e-07
and O 0 1.1680675925163087e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 4.095087433597655e-07
suggests O 0 1.3043002233814605e-08
that O 0 5.6615517829428086e-11
these O 0 7.5902839569153e-11
two O 0 8.344508417579277e-10
genes O 0 6.790811468704305e-09
lie O 0 1.9435037756920792e-06
in O 0 1.2766724921675632e-07
close O 0 7.68885547586251e-06
proximity O 0 6.059335078134609e-07
to O 0 1.116968473269253e-08
one O 0 4.117729801578207e-08
another O 0 2.643498078214179e-07
. O 0 2.81377452893139e-07

Distribution O 0 3.3832313874881947e-06
of O 0 4.1907665035978425e-06
emerin O 0 0.0010232136119157076
and O 0 3.2709903052818845e-07
lamins O 0 0.29003283381462097
in O 0 4.968906068825163e-07
the O 0 1.4192918342814664e-06
heart O 0 7.654702130821534e-06
and O 0 7.678181646042503e-09
implications O 0 2.7066928964813997e-07
for O 0 1.794782349406887e-07
Emery B-Disease 1 0.9952978491783142
- I-Disease 1 1.0
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 0.9999960660934448
. O 0 9.148727144747681e-07

Emerin O 0 0.010036147199571133
is O 0 6.754038395229145e-07
a O 0 2.729675543378107e-07
nuclear O 0 1.6510093701072037e-05
membrane O 0 2.4116567146847956e-05
protein O 0 2.629052175961988e-07
which O 0 2.4172914780962174e-09
is O 0 4.21356016744312e-09
missing O 0 6.381046659953427e-07
or O 0 1.407286589483192e-07
defective O 0 9.87770931715204e-07
in O 0 6.100124778640748e-07
Emery B-Disease 1 0.9998425245285034
- I-Disease 1 1.0
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 3.010677028214559e-05
EDMD B-Disease 1 1.0
) O 0 4.4919232777829166e-07
. O 0 1.457644316360529e-07

It O 0 5.000590022063989e-07
is O 0 3.3822583844766996e-08
one O 0 1.7601161417246658e-08
member O 0 7.34693585968671e-08
of O 0 5.536710432352265e-07
a O 0 1.9281476397736697e-06
family O 0 7.194766453721968e-07
of O 0 4.33110380981816e-06
lamina O 1 0.9995844960212708
- O 0 0.0010290414793416858
associated O 0 8.123756742861588e-07
proteins O 0 1.0208244027865021e-08
which O 0 3.0005056217419224e-09
includes O 0 1.7410075159318694e-08
LAP1 O 0 0.00017089459288399667
, O 0 4.502937400729934e-08
LAP2 O 0 0.00014621822629123926
and O 0 1.248704961653857e-07
lamin O 0 4.660532431444153e-05
B O 0 5.292552668834105e-05
receptor O 0 1.3910073903389275e-05
( O 0 2.3458902376205515e-07
LBR O 0 6.289165321504697e-05
) O 0 3.873624265793296e-08
. O 0 6.116306394687854e-08

A O 0 3.6872850614599884e-05
panel O 0 1.1375352642062353e-06
of O 0 2.9532148460020835e-07
16 O 0 2.2211669659100153e-07
monoclonal O 0 5.2648488235718105e-08
antibodies O 0 6.105417948987224e-09
( O 0 1.8599964235477273e-08
mAbs O 0 4.6731869929317327e-07
) O 0 2.8651236938515012e-09
has O 0 1.8593776518471827e-10
been O 0 1.000386551375243e-09
mapped O 0 1.1549025735746454e-08
to O 0 6.421490561514531e-10
six O 0 2.1325117227632973e-09
specific O 0 5.28471322258639e-10
sites O 0 3.876904131061565e-09
throughout O 0 4.997717795163226e-09
the O 0 2.174772006924286e-08
emerin O 0 1.0824572882484063e-06
molecule O 0 3.4242042090681934e-08
using O 0 1.1402963906448349e-08
phage O 0 7.186414308080202e-08
- O 0 2.0706391268277002e-08
displayed O 0 2.1184858312039978e-08
peptide O 0 5.900266231151363e-08
libraries O 0 5.5314760771807414e-08
and O 0 9.794275390717644e-10
has O 0 8.229692483041617e-10
been O 0 3.6431815342297114e-09
used O 0 4.4451469172202e-09
to O 0 1.4612820287140948e-08
localize O 0 2.8218086299602874e-05
emerin O 0 0.00010467346146469936
in O 0 2.6311363399145193e-07
human O 0 2.79700230976232e-07
and O 0 9.79293801606218e-08
rabbit O 0 2.1594536519842222e-05
heart O 0 6.277386273723096e-05
. O 0 5.752932565883384e-07

Several O 0 5.333049557521008e-07
mAbs O 0 6.426240815926576e-06
against O 0 4.987806434542108e-08
different O 0 2.63437680558809e-08
emerin O 0 2.956053322122898e-05
epitopes O 0 8.135579264489934e-06
did O 0 2.9170799109579093e-08
not O 0 7.773699017832314e-09
recognize O 0 1.1996357685006842e-08
intercalated O 0 4.7049916247488e-06
discs O 0 3.882392320520012e-06
in O 0 7.957276437764449e-08
the O 0 2.0617116547327896e-07
heart O 0 1.5113644622033462e-05
, O 0 7.301321769404012e-09
though O 0 6.1272569240600205e-09
they O 0 2.0012167478711262e-09
recognized O 0 3.5786104746193814e-08
cardiomyocyte O 0 2.014525534832501e-06
nuclei O 0 5.4192537390918e-07
strongly O 0 7.49645820974365e-08
, O 0 3.42397998842614e-09
both O 0 7.599504137090207e-09
at O 0 1.693092940513452e-06
the O 0 6.440706101784599e-07
rim O 0 2.87481975647097e-06
and O 0 5.1229624986603994e-09
in O 0 4.6983455348481584e-08
intranuclear O 0 1.2681128282565624e-05
spots O 0 1.171355506812688e-06
or O 0 1.5713887080437416e-07
channels O 0 1.2701113973889733e-06
. O 0 3.9964913867152063e-07

A O 0 5.569807399297133e-05
polyclonal O 0 4.263986193109304e-05
rabbit O 0 1.711683694338717e-06
antiserum O 0 4.0618115235702135e-06
against O 0 1.1898852392278059e-07
emerin O 0 9.802534805203322e-06
did O 0 1.791247150606523e-08
recognize O 0 4.164685041274652e-09
both O 0 2.669376941710766e-09
nuclear O 0 9.897604513753322e-07
membrane O 0 1.9010261667062878e-06
and O 0 3.863491304656463e-09
intercalated O 0 1.7378015400026925e-06
discs O 0 1.5847074052999233e-07
but O 0 6.696412313544897e-10
, O 0 1.6437015637471575e-10
after O 0 1.6292881488411126e-09
affinity O 0 8.933728423698994e-09
purification O 0 1.7055725720638293e-08
against O 0 5.677583292396093e-09
a O 0 3.897547173892235e-08
pure O 0 1.301567522205005e-06
- O 0 2.0601216021987057e-07
emerin O 0 2.5836754957708763e-06
band O 0 1.0090549551478034e-07
on O 0 2.871219351163745e-08
a O 0 3.5302729628483576e-08
western O 0 2.601828974491127e-08
blot O 0 1.7501255342722288e-06
, O 0 1.218097356314729e-08
it O 0 1.7487979953045851e-09
stained O 0 5.596086225523322e-07
only O 0 1.3412726040940015e-08
the O 0 1.3332311254998785e-07
nuclear O 0 1.9762357624131255e-05
membrane O 0 9.434414823772386e-05
. O 0 1.5140387858991744e-06

These O 0 5.952988146873395e-08
results O 0 2.5973813322366368e-08
would O 0 3.173338924966629e-09
not O 0 1.099902613432846e-09
be O 0 2.4137576382088355e-09
expected O 0 2.816689637086256e-08
if O 0 7.45869144225253e-08
immunostaining O 0 1.7793952792999335e-05
at O 0 1.8189333559348597e-06
intercalated O 0 1.575950773258228e-05
discs O 0 1.0351302080380265e-05
were O 0 1.4760338729047362e-07
due O 0 1.0006335315893011e-07
to O 0 7.455274619871943e-09
a O 0 3.207025756069015e-08
product O 0 4.875217562982925e-09
of O 0 1.8047936478637894e-08
the O 0 7.02936091556694e-08
emerin O 0 9.151649464911316e-06
gene O 0 3.298674666751822e-09
and O 0 9.448337667805617e-10
, O 0 5.041074224720887e-10
therefore O 0 2.4573119095094853e-09
, O 0 3.3276087441080904e-10
cast O 0 4.1480610057931244e-09
some O 0 3.236284018548474e-10
doubt O 0 8.575357313134191e-09
upon O 0 7.843684812769425e-09
the O 0 4.322409541401839e-09
hypothesis O 0 3.4220299482967675e-08
that O 0 1.8579887628433767e-09
cardiac B-Disease 1 0.8322007060050964
defects I-Disease 0 0.00020209666399750859
in O 0 6.073461918276735e-06
EDMD B-Disease 1 1.0
are O 0 6.449064358093892e-07
caused O 0 4.189888613836956e-07
by O 0 1.791134351947221e-08
absence O 0 2.5590875338821206e-06
of O 0 3.2816776638355805e-06
emerin O 0 0.0002473896602168679
from O 0 2.7525700261321617e-06
intercalated O 0 0.00025126105174422264
discs O 0 0.000139839670737274
. O 0 1.3621396419694065e-06

Although O 0 1.590732153999852e-06
emerin O 0 5.052941924077459e-05
was O 0 1.6736614725232357e-06
abundant O 0 4.3407450789345603e-07
in O 0 6.086561654683464e-08
the O 0 1.860626923644304e-07
membranes O 0 1.4792511819905485e-06
of O 0 1.2657715160457883e-06
cardiomyocyte O 0 5.116144893690944e-05
nuclei O 0 1.2435119970177766e-05
, O 0 2.6117033868899853e-08
it O 0 2.7614761588523606e-09
was O 0 2.610294700389204e-07
absent O 0 1.1504575070375722e-07
from O 0 1.0963802310470783e-08
many O 0 1.1916716502469171e-09
non O 0 1.960483331231444e-07
- O 0 3.418706455704523e-07
myocyte O 0 0.00011232242832193151
cells O 0 1.193918137687433e-07
in O 0 1.8064431728248564e-08
the O 0 2.1961858465147088e-07
heart O 0 5.8956014981959015e-05
. O 0 7.055566584313056e-07

This O 0 9.21547282928259e-08
distribution O 0 5.983381612395533e-08
of O 0 1.7124661155776266e-07
emerin O 0 6.936457066331059e-05
was O 0 7.784888680362201e-07
similar O 0 4.304047340752959e-09
to O 0 3.195496312002888e-09
that O 0 1.388599790708156e-09
of O 0 1.1289848345086284e-07
lamin O 0 1.1623415048234165e-05
A O 0 2.5577746782801114e-06
, O 0 3.399512671364846e-09
a O 0 5.179842332836415e-09
candidate O 0 1.7580619182666624e-09
gene O 0 2.75249295578206e-10
for O 0 2.771695928327489e-10
an O 0 4.527271890708562e-09
autosomal O 0 2.9064500139952543e-08
form O 0 1.8202015894530632e-08
of O 0 0.2005964070558548
EDMD B-Disease 1 1.0
. O 0 2.2525327949551865e-05

In O 0 1.5018310932646273e-06
contrast O 0 8.866032885634922e-07
, O 0 2.1193716293055331e-07
lamin O 0 0.0003162653010804206
B1 O 0 0.03535199537873268
was O 0 2.1535734049393795e-06
absent O 0 8.708598215889651e-07
from O 0 1.2876074606538168e-07
cardiomyocyte O 0 1.0933960766124073e-05
nuclei O 0 1.7543599142300081e-06
, O 0 3.132962334007061e-08
showing O 0 5.783385290669685e-07
that O 0 3.1021134105913006e-08
lamin O 0 4.117382559343241e-05
B1 O 0 0.00023548312310595065
is O 0 2.338294224912829e-09
not O 0 3.482970023505061e-10
essential O 0 1.1019526624522769e-08
for O 0 7.146457647877469e-09
localization O 0 8.605066796008032e-06
of O 0 2.926817330717313e-07
emerin O 0 1.5435178283951245e-05
to O 0 3.556291972017789e-08
the O 0 1.81607717308907e-07
nuclear O 0 0.00016064396186266094
lamina O 1 0.9998769760131836
. O 0 5.4701895351172425e-06

Lamin O 1 0.999997615814209
B1 O 1 0.9999666213989258
is O 0 8.244342808438887e-08
also O 0 3.071806808918609e-09
almost O 0 3.6002170133997424e-08
completely O 0 1.2828435274059302e-06
absent O 0 2.275155793540762e-06
from O 0 6.840342052782944e-07
skeletal O 0 0.013107940554618835
muscle O 0 9.50499452301301e-06
nuclei O 0 0.0002850367745850235
. O 0 4.340072337072343e-06

In O 0 8.649897790746763e-05
EDMD B-Disease 1 1.0
, O 0 3.6898562427722936e-08
the O 0 1.3357351669185391e-08
additional O 0 6.788363648979612e-09
absence O 0 1.4948520288271538e-07
of O 0 1.7142698425232084e-06
lamin O 0 0.001963159302249551
B1 O 1 0.9987572431564331
from O 0 3.297759576526005e-06
heart O 0 0.04953385889530182
and O 0 2.3891932414699113e-06
skeletal O 1 1.0
muscle O 1 0.6035453677177429
nuclei O 1 0.9993416666984558
which O 0 4.552724135464814e-07
already O 0 1.9060388467551093e-07
lack O 0 8.98714642971754e-06
emerin O 0 7.472797733498737e-05
may O 0 7.571522075977555e-09
offer O 0 1.1154116519307422e-09
an O 0 4.3526870996402067e-10
alternative O 0 1.5971715061624536e-09
explanation O 0 1.0341111966738481e-08
of O 0 7.1504393517329845e-09
why O 0 5.375151435060843e-09
these O 0 1.1098578722723573e-09
tissues O 0 1.3868323378574132e-08
are O 0 1.4063596953661772e-09
particularly O 0 1.3930358200298087e-08
affected O 0 3.13828500964064e-08
. O 0 8.300952814010998e-09
. O 0 1.481567721839383e-07

Genetic O 0 1.3329872672329657e-05
mapping O 0 5.838681772729615e-06
of O 0 6.576235591637669e-07
the O 0 1.7819123740991927e-06
copper B-Disease 1 0.9994919300079346
toxicosis I-Disease 1 0.9999997615814209
locus O 0 0.00016889751714188606
in O 0 1.2386122989482828e-06
Bedlington O 0 0.1678699254989624
terriers O 0 3.419650602154434e-05
to O 0 4.199112879632594e-08
dog O 0 1.9513807103521685e-07
chromosome O 0 2.799961329458256e-08
10 O 0 1.0820146556511645e-08
, O 0 3.1272753830968725e-10
in O 0 3.548592975022302e-09
a O 0 8.144564134227039e-08
region O 0 1.4147470039915788e-07
syntenic O 0 1.6133210010593757e-05
to O 0 4.02896134232833e-08
human O 0 7.547346569936053e-08
chromosome O 0 1.0071936884514798e-07
region O 0 1.3056410352874082e-07
2p13 O 0 4.821221955353394e-05
- O 0 3.21403713314794e-05
p16 O 0 2.7032463549403474e-05
. O 0 2.713205731197377e-07

Abnormal O 1 1.0
hepatic B-Disease 1 1.0
copper I-Disease 1 0.9999998807907104
accumulation I-Disease 1 0.9999995231628418
is O 0 3.10362310074197e-07
recognized O 0 5.2760476876301254e-08
as O 0 5.210384301790327e-08
an O 0 2.1778246264148038e-06
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 1 0.9869664907455444
man O 1 0.9982847571372986
, O 0 1.0276618240823154e-06
mouse O 0 2.0215646145516075e-05
, O 0 1.313416504444831e-07
rat O 0 2.2379108486347832e-05
and O 0 1.4960671990138508e-07
dog O 0 4.200192779535428e-05
. O 0 7.234810937006841e-07

The O 0 5.94518633079133e-06
major O 0 5.588387011812301e-06
cause O 0 5.4445990826934576e-05
of O 0 0.002443476114422083
hepatic B-Disease 1 1.0
copper I-Disease 1 1.0
accumulation I-Disease 1 1.0
in O 0 0.00011544631706783548
man O 0 0.00046604039380326867
is O 0 1.0574301256838226e-07
a O 0 1.147209559348994e-06
dysfunctional O 0 0.00026379586779512465
ATP7B O 1 0.5433630347251892
gene O 0 3.758809441478661e-07
, O 0 2.050606262571364e-08
causing O 0 5.470893484016415e-06
Wilson B-Disease 0 0.009885407984256744
disease I-Disease 1 0.9990419745445251
( O 0 6.668605783488601e-05
WD B-Disease 1 0.9998301267623901
) O 0 4.4729347337124636e-07
. O 0 2.747445648765279e-07

Mutations O 0 3.6490396269073244e-06
in O 0 1.6187701135095267e-07
the O 0 3.392435417026718e-07
ATP7B O 1 0.6204573512077332
genes O 0 1.5808552689122735e-07
have O 0 2.1449864107125904e-09
also O 0 1.4583687590885575e-09
been O 0 6.003818775468517e-09
demonstrated O 0 5.4873094512686293e-08
in O 0 1.5314080314965395e-07
mouse O 0 1.7593462189324782e-06
and O 0 9.064314809847929e-08
rat O 0 3.7592290027532727e-05
. O 0 2.6779412110045087e-07

The O 0 1.9870567484758794e-05
ATP7B O 0 0.00741888303309679
gene O 0 1.5029227995455585e-07
has O 0 6.337632640907032e-09
been O 0 7.181355954344326e-09
excluded O 0 1.9790725502843998e-08
in O 0 1.4057133235212405e-09
the O 0 3.75654973794326e-09
much O 0 2.5103574330387346e-08
rarer O 0 5.920557555327832e-07
human O 0 1.7757159298525949e-07
copper B-Disease 1 0.9999936819076538
overload I-Disease 1 1.0
disease O 1 0.9999998807907104
non B-Disease 1 0.9994187355041504
- I-Disease 0 3.814578667515889e-05
Indian I-Disease 0 2.243533162982203e-05
childhood I-Disease 1 0.9976243376731873
cirrhosis I-Disease 1 0.9999998807907104
, O 0 4.634694850125243e-09
indicating O 0 4.45194132225879e-07
genetic O 0 3.431007087328908e-07
heterogeneity O 0 3.4400900403852575e-06
. O 0 2.3552155425932142e-07

By O 0 3.6718103046951e-07
investigating O 0 1.1747889629987185e-06
the O 0 3.5962611377726716e-07
common O 0 9.096735311686643e-07
autosomal O 0 0.00018393008213024586
recessive O 0 5.7206791097996756e-05
copper B-Disease 1 0.9999850988388062
toxicosis I-Disease 1 1.0
( O 0 0.00027588001103140414
CT B-Disease 1 0.9999865293502808
) O 0 2.8008486196995364e-07
in O 0 4.731367369004147e-07
Bedlington O 1 0.8246069550514221
terriers O 0 1.6834095731610432e-05
, O 0 4.738490488875868e-09
we O 0 4.3023482554360726e-09
have O 0 5.459305230104405e-10
identified O 0 2.6554425325286957e-09
a O 0 4.2414267653612114e-09
new O 0 1.2806099514151015e-09
locus O 0 4.3189668730292397e-08
involved O 0 1.430407614577689e-08
in O 0 2.2951390121761506e-07
progressive O 1 1.0
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 6.90635033606668e-06

We O 0 1.7926849693594704e-07
examined O 0 2.0658842458942672e-07
whether O 0 3.882767174445689e-08
the O 0 1.115234454118763e-06
WD B-Disease 0 0.001640999224036932
gene O 0 3.2165033303499513e-07
ATP7B O 0 4.2049214243888855e-05
was O 0 6.807542831666069e-07
also O 0 9.147783863738823e-09
causative O 0 1.4201378917277907e-07
for O 0 5.407780001576157e-09
CT B-Disease 0 8.597708983870689e-06
by O 0 1.1383819220611713e-08
investigating O 0 5.455806899590243e-07
the O 0 2.508663783373777e-07
chromosomal O 0 4.02991736336844e-06
co O 0 7.724932220298797e-05
- O 0 7.506329711759463e-05
localization O 0 0.0005891658365726471
of O 0 1.6053412537075928e-06
ATP7B O 0 0.0005565177998505533
and O 0 2.1517569948059645e-08
C04107 O 0 6.621306170018215e-07
, O 0 9.210386342495269e-10
using O 0 1.9560184583156115e-09
fluorescence O 0 3.1957902990598086e-08
in O 0 6.481741365860216e-09
situ O 0 7.933609822430299e-07
hybridization O 0 4.45564900530826e-08
( O 0 4.019794275222921e-09
FISH O 0 6.67983428570551e-08
) O 0 5.299362282329412e-09
. O 0 1.7284246922599777e-08

C04107 O 0 0.0005052270134910941
is O 0 5.388620820667711e-07
an O 0 9.285430024874586e-08
anonymous O 0 3.112140348093817e-06
microsatellite O 0 1.6082196452771313e-05
marker O 0 1.2815974059776636e-06
closely O 0 7.154370109674346e-07
linked O 0 3.807359007623745e-06
to O 0 6.026515393386944e-07
CT B-Disease 1 0.9998751878738403
. O 0 2.8203614874655614e-06

However O 0 3.2608322726446204e-06
, O 0 6.755345225428755e-07
BAC O 0 0.0009593451395630836
clones O 0 2.3355109988187905e-06
containing O 0 6.573357040906558e-07
ATP7B O 0 0.00019091162539552897
and O 0 6.034922961362099e-08
C04107 O 0 5.0871849452960305e-06
mapped O 0 7.052512387417664e-07
to O 0 1.733224763711405e-08
the O 0 1.4367245171342802e-07
canine O 0 3.09837582790351e-06
chromosome O 0 2.693364820061106e-07
regions O 0 6.748166470060823e-08
CFA22q11 O 0 0.0002129228669218719
and O 0 4.264092368089223e-08
CFA10q26 O 0 0.00036339910002425313
, O 0 4.749864501718548e-09
respectively O 0 4.784610752039953e-08
, O 0 2.037832125267869e-09
demonstrating O 0 1.0371773839779053e-07
that O 0 1.232944946139014e-08
WD B-Disease 0 1.01181149148033e-05
cannot O 0 2.4236081586082037e-08
be O 0 4.301790479388501e-09
homologous O 0 4.993927760210681e-08
to O 0 8.402763995718487e-08
CT B-Disease 0 0.002420988632366061
. O 0 7.922790246084332e-07

The O 0 1.2433045412763022e-05
copper O 0 0.0001058918351191096
transport O 0 7.6274700404610485e-06
genes O 0 6.097604909882648e-06
CTR1 O 1 0.90290766954422
and O 0 7.490468760806834e-07
CTR2 O 1 0.9922530055046082
were O 0 9.913853773468873e-07
also O 0 7.2793513439251e-09
excluded O 0 2.8811378172122204e-08
as O 0 4.02074551431042e-09
candidate O 0 4.164168565523596e-09
genes O 0 2.066877780038112e-09
for O 0 5.743369335675652e-09
CT B-Disease 0 0.0012299212394282222
since O 0 1.1765072116531883e-07
they O 0 2.3761952405720876e-09
both O 0 2.707258639489396e-09
mapped O 0 1.6769865851529175e-07
to O 0 7.394439194285951e-08
canine O 0 3.2597472454654053e-06
chromosome O 0 6.77686500694108e-07
region O 0 6.010673700984626e-07
CFA11q22 O 0 0.09095366299152374
. O 0 1.6646836229483597e-06

2 O 0 4.538392386166379e-05
- O 0 1.3369058251555543e-05
22 O 0 4.290933247830253e-06
. O 0 6.706873705297767e-07

5 O 0 6.256021879380569e-05
. O 0 4.96686288897763e-06

A O 0 1.8928270947071724e-05
transcribed O 0 2.838588898157468e-06
sequence O 0 2.1131290850462392e-07
identified O 0 5.5698432532835795e-08
from O 0 2.0859163285535942e-08
the O 0 4.431722544495642e-08
C04107 O 0 2.1961366201139754e-06
- O 0 5.870489871995233e-07
containing O 0 3.48000583016983e-07
BAC O 0 0.00026414869353175163
was O 0 2.8118054729020514e-07
found O 0 3.0137261575191587e-09
to O 0 1.1416299017241727e-09
be O 0 3.42055983537648e-09
homologous O 0 2.8897453319132183e-08
to O 0 8.913082716333065e-09
a O 0 5.435206773540813e-08
gene O 0 3.78539821710433e-09
expressed O 0 1.1295913093789522e-09
from O 0 8.408483687105672e-09
human O 0 9.302213221928923e-09
chromosome O 0 2.4991924973960522e-08
2p13 O 0 3.484791761820816e-07
- O 0 2.617109373659332e-07
p16 O 0 3.555434773261368e-07
, O 0 7.829406567516628e-10
a O 0 2.8864002299400227e-09
region O 0 7.228905030132182e-09
devoid O 0 4.869175427302253e-07
of O 0 2.4250741859077607e-08
any O 0 1.4803131165308514e-08
positional O 0 5.441305006570474e-07
candidate O 0 2.3064455945132067e-07
genes O 0 2.6151533916163316e-07
. O 0 1.2913396574276703e-07

Molecular O 0 1.0543107237026561e-05
analysis O 0 3.858309582938091e-07
of O 0 1.57087782781673e-07
the O 0 2.727513219724642e-07
APC B-Disease 0 4.437495704223693e-07
gene O 0 1.3992504932502925e-09
in O 0 9.2774560256359e-10
205 O 0 4.13418321798531e-09
families O 0 3.9280448338452345e-10
: O 0 3.674976434275834e-10
extended O 0 5.2872670686099354e-09
genotype O 0 3.4923797187502714e-08
- O 0 3.8905803023681074e-08
phenotype O 0 2.0488235108473418e-08
correlations O 0 1.3143989008312928e-07
in O 0 1.4178691998267823e-08
FAP B-Disease 0 1.291322462293465e-07
and O 0 1.788220960197151e-10
evidence O 0 7.562372061897804e-09
for O 0 3.634157419440953e-10
the O 0 2.723069547627688e-09
role O 0 2.071199922681899e-08
of O 0 8.231740622477446e-08
APC B-Disease 0 1.615440652358302e-07
amino O 0 1.2740958510448763e-08
acid O 0 8.174020571516394e-09
changes O 0 4.480044335508637e-09
in O 0 6.052449862181675e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 1 1.0
. O 0 2.9663251552847214e-06

BACKGROUND O 0 0.005514177493751049
/ O 0 0.00011216359416721389
AIMS O 0 3.271051355113741e-06
The O 0 2.8510044103313703e-07
development O 0 1.4430040209845174e-05
of O 1 0.9959508180618286
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.4235543410734408e-08
a O 0 5.317343898525451e-09
variable O 0 6.024742926769022e-09
range O 0 2.440957436178337e-09
of O 0 3.6692628935242055e-09
extracolonic O 0 3.11226494886796e-06
manifestations O 0 1.2421786777849775e-05
in O 0 9.091470019484404e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.0003501542378216982
FAP B-Disease 0 6.496171408798546e-06
) O 0 2.2024220225347335e-09
is O 0 3.3749086858492205e-10
the O 0 8.520945060652707e-10
result O 0 1.0796665783630033e-08
of O 0 1.7325892542885413e-07
the O 0 6.247619808164018e-07
dominant O 0 2.1175230358494446e-05
inheritance O 0 3.173904769937508e-05
of O 0 0.002256252570077777
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 0 8.606981282355264e-05
APC B-Disease 0 8.254746717284434e-06
) O 0 5.650631962339503e-08
gene O 0 4.5144780358441494e-08
mutations O 0 3.9188815748048e-08
. O 0 3.4558695460873423e-07

In O 0 1.2775592495017918e-07
this O 0 2.8821089959052415e-09
study O 0 2.9967937020813906e-09
, O 0 1.1003175454105119e-10
direct O 0 4.3361639279204667e-10
mutation O 0 7.84809162102107e-11
analysis O 0 7.832692827669518e-10
of O 0 3.9991312483778074e-09
the O 0 3.518260527357597e-08
APC B-Disease 0 2.2506095831431594e-07
gene O 0 2.5103081835453622e-09
was O 0 1.2080073830134097e-08
performed O 0 4.518541985021329e-09
to O 0 1.0711598275037204e-09
determine O 0 1.9169467790902672e-08
genotype O 0 1.8225469489152601e-07
- O 0 1.3454483394070849e-07
phenotype O 0 2.983842506409928e-08
correlations O 0 4.709542622549634e-08
for O 0 4.715868140436896e-09
nine O 0 1.8233154719382583e-07
extracolonic O 0 4.580030235956656e-06
manifestations O 0 8.985749104795104e-07
and O 0 9.381929677587664e-10
to O 0 9.960131608366396e-10
investigate O 0 1.542014871347419e-08
the O 0 1.7040736821627434e-08
incidence O 0 7.675694178033154e-07
of O 0 3.742690779517943e-08
APC B-Disease 0 6.28803960012192e-08
mutations O 0 8.01162136632172e-10
in O 0 5.0945585527983894e-09
non O 0 0.22387675940990448
- O 1 0.9999996423721313
FAP O 1 0.9999998807907104
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.571743152657291e-06

METHODS O 0 2.322625005035661e-05
The O 0 3.555662487997324e-06
APC B-Disease 0 1.4342208487505559e-06
gene O 0 2.854302127985875e-09
was O 0 7.48670991868039e-09
analysed O 0 2.5680268578298637e-08
in O 0 4.924046947962779e-09
190 O 0 6.602578395131786e-08
unrelated O 0 1.3659676767474593e-07
FAP B-Disease 0 7.758830378179482e-08
and O 0 6.201088531554433e-10
15 O 0 5.968506400222395e-08
non O 0 0.09845288097858429
- O 1 0.9999855756759644
FAP O 1 0.9999998807907104
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 1.249312475692932e-07
using O 0 9.16287046237585e-09
denaturing O 0 1.5897108823992312e-05
gradient O 0 9.563674439050374e-07
gel O 0 1.1959556900364987e-07
electrophoresis O 0 1.8107246546605893e-07
, O 0 8.724693190131916e-10
the O 0 3.4208860189011148e-09
protein O 0 5.0317203736938154e-09
truncation O 0 5.274115721931594e-08
test O 0 3.383483049290703e-09
, O 0 3.0108804338624395e-10
and O 0 5.997463636830958e-10
direct O 0 2.837698254154475e-08
sequencing O 0 1.536463827278567e-07
. O 0 1.2541747196337383e-07

RESULTS O 0 0.00012688081187661737
Chain O 0 3.7688598240492865e-05
terminating O 0 1.6043006780819269e-06
signals O 0 1.198252732592664e-07
were O 0 6.065802526933339e-09
only O 0 3.151105487653183e-10
identified O 0 1.5988478319073351e-09
in O 0 5.992309759506043e-09
patients O 0 5.331826535837081e-09
belonging O 0 7.286417940122192e-07
to O 0 9.634789677193112e-08
the O 0 3.3433534554205835e-06
FAP B-Disease 0 7.0206965574470814e-06
group O 0 7.407878399590118e-08
( O 0 1.5473593961701226e-08
105 O 0 6.727719892296591e-07
patients O 0 2.282526168073673e-08
) O 0 8.521826799778864e-09
. O 0 5.988702156400905e-08

Amino O 0 3.7223840081423987e-06
acid O 0 5.837713246137355e-08
changes O 0 2.226900441826274e-09
were O 0 9.24041021477251e-09
identified O 0 1.355807643932394e-08
in O 0 4.490207317076056e-09
four O 0 1.0692170704373893e-08
patients O 0 1.5083921889313956e-09
, O 0 2.948351007781014e-10
three O 0 5.325199836647698e-09
of O 0 4.5532715375884436e-07
whom O 0 1.235238187291543e-07
belonged O 0 4.134643677389249e-05
to O 0 8.537742246517155e-08
the O 0 5.8720632978293e-07
non O 0 0.00027911431971006095
- O 0 1.3777510503132362e-05
FAP O 0 3.926404133380856e-06
group O 0 4.04220052985238e-08
of O 0 3.9542235754197463e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.4558091163635254
. O 0 2.483646994733135e-07

Genotype O 0 0.003272851463407278
- O 0 4.584379348671064e-05
phenotype O 0 7.460511710633e-07
correlations O 0 7.145901008698274e-07
identified O 0 4.6643350515296333e-08
significant O 0 1.637557467404349e-08
differences O 0 3.1211644824225004e-08
in O 0 8.45389713788336e-09
the O 0 7.393674561484431e-09
nature O 0 1.499471835586519e-08
of O 0 1.7947620056801838e-09
certain O 0 1.2707411789492085e-09
extracolonic O 0 8.62267540924222e-07
manifestations O 0 1.4371548218150565e-07
in O 0 3.325898845218944e-08
FAP B-Disease 0 4.1279218976342236e-07
patients O 0 1.4442733675679165e-09
belonging O 0 1.790400183665497e-08
to O 0 1.1921807985260102e-09
three O 0 1.1601726690457781e-08
mutation O 0 3.737212495025233e-08
subgroups O 0 1.7884158296510577e-06
. O 0 2.3582023800372554e-07

CONCLUSIONS O 0 3.671816739370115e-05
Extended O 0 5.640301424136851e-06
genotype O 0 2.055834556813352e-06
- O 0 6.672563586107572e-07
phenotype O 0 7.310229221957343e-08
correlations O 0 1.0948280504408103e-07
made O 0 8.990153510524124e-09
in O 0 4.744088233366028e-09
this O 0 1.7302577148825549e-09
study O 0 1.3098472528838556e-08
may O 0 3.028564288243274e-09
have O 0 2.5056953734114984e-10
the O 0 8.512497373658334e-10
potential O 0 2.594582326764794e-09
to O 0 1.4832707284639923e-10
determine O 0 3.2232259083997405e-09
the O 0 3.5700864486898354e-09
most O 0 1.8472387508516874e-10
appropriate O 0 1.3435892398661053e-09
surveillance O 0 4.413291421201393e-08
and O 0 3.3075248095926213e-10
prophylactic O 0 7.063100042614678e-07
treatment O 0 2.654795672185628e-08
regimens O 0 2.0372041831251408e-07
for O 0 6.664811480483479e-10
those O 0 1.1957835832632213e-09
patients O 0 9.402441047967613e-10
with O 0 1.406616489951773e-10
mutations O 0 3.9975907029088376e-09
associated O 0 1.482622167259251e-07
with O 0 1.1127369248242758e-08
life O 0 5.944406075286679e-05
threatening O 0 1.7681870758678997e-06
conditions O 0 4.436197741597425e-06
. O 0 4.6289727606563247e-07

This O 0 5.661560109615493e-08
study O 0 1.4476222887083168e-08
also O 0 5.547498571623066e-10
provided O 0 2.9231603804191764e-09
evidence O 0 1.3179995761447572e-08
for O 0 1.3246979069236886e-09
the O 0 2.138190602352097e-08
pathological O 0 9.494286132394336e-06
nature O 0 3.974631823666641e-08
of O 0 2.8849266087149772e-08
amino O 0 3.2192279064702234e-08
acid O 0 1.3191161940540042e-08
changes O 0 3.964000239164989e-09
in O 0 2.9115435395965505e-08
APC O 0 2.747492828802933e-07
associated O 0 1.9367224268762584e-08
with O 0 2.303113921797717e-09
both O 0 3.53163329691597e-08
FAP B-Disease 0 1.0324132517780527e-06
and O 0 2.2035532509789846e-08
non O 1 0.9997517466545105
- O 1 1.0
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 4.522020390140824e-06
. O 0 5.260058166811632e-09
. O 0 5.5724679981494774e-08

Inherited B-Disease 1 1.0
colorectal I-Disease 1 1.0
polyposis I-Disease 1 1.0
and O 0 0.0001497329940320924
cancer B-Disease 1 0.999923586845398
risk O 0 0.2978734076023102
of O 0 0.019707944244146347
the O 0 0.0005198511644266546
APC O 0 5.774871533503756e-05
I1307K O 0 2.2494137738249265e-05
polymorphism O 0 5.998069354973268e-06
. O 0 2.8971800247745705e-07

Germ O 0 0.2277349829673767
- O 0 2.8521695639938116e-05
line O 0 2.7300950478093e-07
and O 0 3.095161460464624e-09
somatic O 0 1.3006203403165273e-07
truncating O 0 8.507131497026421e-07
mutations O 0 6.076096514817664e-09
of O 0 2.7834969884565908e-08
the O 0 5.5995300840550044e-08
APC B-Disease 0 3.510251360694383e-07
gene O 0 1.5875011305510611e-09
are O 0 2.2153592849072368e-10
thought O 0 4.745138060258114e-09
to O 0 4.903165873315629e-09
initiate O 0 2.1003700112487422e-06
colorectal B-Disease 1 1.0
tumor I-Disease 1 0.9578903913497925
formation O 0 0.04847490042448044
in O 1 0.9988985061645508
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 0.00010674342775018886
sporadic O 1 1.0
colorectal O 1 1.0
carcinogenesis O 1 1.0
, O 0 3.6910571452608565e-06
respectively O 0 0.00018319250375498086
. O 0 5.335427431418793e-06

Recently O 0 4.492369498620974e-06
, O 0 1.7089332615682906e-08
an O 0 2.8445642286101247e-08
isoleucine O 0 3.927580110030249e-06
- O 0 7.676875611650757e-06
- O 0 1.8113367332261987e-05
> O 0 4.367904693935998e-06
lysine O 0 8.846843684295891e-07
polymorphism O 0 1.682120114310237e-07
at O 0 9.477856366402193e-08
codon O 0 1.8282744917996752e-07
1307 O 0 2.4105536340357503e-06
( O 0 1.4448251484111552e-08
I1307K O 0 3.903953995632037e-07
) O 0 7.3835559888379976e-09
of O 0 5.13445961303205e-08
the O 0 1.9480596336052258e-07
APC B-Disease 0 1.4468004110312904e-06
gene O 0 4.574387091338394e-09
has O 0 3.931020509106986e-10
been O 0 1.2309189223458361e-09
identified O 0 2.643955054892899e-09
in O 0 4.220364502316443e-09
6 O 0 8.694301811829064e-08
% O 0 7.0780878935750025e-09
- O 0 4.764827643555236e-09
7 O 0 3.442343299298045e-08
% O 0 2.29652941108327e-09
of O 0 2.316409730696023e-09
the O 0 5.433327565640411e-09
Ashkenazi O 0 1.4029276940163982e-07
Jewish O 0 1.867985730541477e-07
population O 0 1.5191790048163512e-09
. O 0 7.120008582717219e-09

To O 0 9.576034187830373e-08
assess O 0 8.774782713771856e-07
the O 0 4.367611339262112e-08
risk O 0 1.7550668474086706e-07
of O 0 1.759156198488654e-08
this O 0 4.169080192184538e-09
common O 0 1.2075465960492693e-08
APC B-Disease 0 1.0745657874622339e-07
allelic O 0 3.015653859961276e-08
variant O 0 5.8520054579958014e-08
in O 0 2.0598544381300599e-07
colorectal O 1 1.0
carcinogenesis O 1 1.0
, O 0 1.53753248355315e-07
we O 0 2.1500953906183895e-08
have O 0 7.717069760992956e-10
analyzed O 0 1.4517421043080958e-08
a O 0 3.154089656121073e-09
large O 0 2.4185735636450545e-09
cohort O 0 1.9459095312868158e-07
of O 0 8.636322945676511e-08
unselected O 0 0.0022425265051424503
Ashkenazi O 0 1.4636351806984749e-05
Jewish O 0 7.886997082096059e-07
subjects O 0 1.752361754370213e-06
with O 0 4.662262753640789e-08
adenomatous B-Disease 0 0.00467692082747817
polyps I-Disease 0 1.9142594283039216e-06
and O 0 2.1804540395464755e-08
. O 0 2.4766316641944286e-07
or O 1 0.9999998807907104
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 7.565606097159616e-07
for O 0 1.180736930450621e-07
the O 0 5.040751602791715e-06
APC O 0 7.5761136031360365e-06
I1307K O 0 8.772617547947448e-06
polymorphism O 0 5.529499503609259e-06
. O 0 1.8762700904062513e-07

The O 0 2.783811214612797e-05
APC O 0 2.4339831725228578e-05
I1307K O 0 6.034294983692234e-06
allele O 0 1.0154572294140962e-07
was O 0 4.553618850877683e-07
identified O 0 1.2565296003685944e-07
in O 0 2.1653516313335786e-08
48 O 0 1.222972656478305e-07
( O 0 4.778616169431871e-09
10 O 0 2.0887938045888177e-09
. O 0 9.289350538788099e-11
1 O 0 6.801687657542743e-09
% O 0 1.013753414547125e-09
) O 0 2.2557035406212123e-10
of O 0 2.6832462918235933e-09
476 O 0 1.90062237948041e-07
patients O 0 5.285615856109871e-08
. O 0 4.2626776775023245e-08

Compared O 0 9.163291565528198e-07
with O 0 9.417338020512034e-10
the O 0 5.990870022287709e-09
frequency O 0 7.987395633790584e-09
in O 0 4.582785817497381e-10
two O 0 7.221952202929316e-11
separate O 0 1.9329342293428198e-10
population O 0 8.520160271752175e-11
control O 0 1.0955016893632319e-09
groups O 0 2.0457524563255447e-10
, O 0 4.965770017406612e-10
the O 0 4.0591672245682275e-08
APC O 0 5.265647473606805e-07
I1307K O 0 6.13919780789729e-07
allele O 0 1.1426761759025794e-08
is O 0 9.650652499360035e-10
associated O 0 1.5830745603295782e-09
with O 0 1.2166496976551144e-10
an O 0 4.967098288233274e-09
estimated O 0 2.5794157920699945e-08
relative O 0 3.7722401202699984e-07
risk O 0 1.2274126959255227e-07
of O 0 2.4287362521135947e-07
1 O 0 4.649989932659082e-06
. O 0 2.295149812425734e-07

5 O 0 3.222726081730798e-05
- O 0 1.2820601114071906e-05
1 O 0 4.873500074609183e-06
. O 0 6.556603011631523e-07

7 O 0 1.1161111615365371e-05
for O 0 3.950138136588066e-07
colorectal B-Disease 1 1.0
neoplasia I-Disease 1 0.8178175091743469
( O 0 2.2002077457727864e-06
both O 0 3.9342728541669203e-07
P O 0 0.0011831704759970307
= O 0 2.537901309551671e-06
. O 0 1.5216100379689124e-08
01 O 0 2.5285855826950865e-06
) O 0 2.1447585041300954e-08
. O 0 2.4616054972170787e-08

Furthermore O 0 3.902091975760413e-06
, O 0 1.4664949254949988e-08
compared O 0 2.4327691861003586e-08
with O 0 4.895036376240114e-09
noncarriers O 0 5.0911385187646374e-05
, O 0 3.642572323769855e-07
APC O 0 2.7386402052798076e-06
I1307K O 0 1.5964708381943638e-06
carriers O 0 3.602042442096831e-09
had O 0 2.2942923116886504e-09
increased O 0 2.949753108438813e-09
numbers O 0 6.008894271047893e-09
of O 0 2.863607164727e-07
adenomas B-Disease 1 0.9967079162597656
and O 0 2.3193967990664532e-06
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.9444080591201782
per O 0 2.831289066307363e-06
patient O 0 6.570787149939861e-07
( O 0 7.32300886596704e-09
P O 0 2.325941977687762e-06
= O 0 5.134577207854818e-08
. O 0 3.948242843776484e-10
03 O 0 2.735090731675882e-07
) O 0 4.2280812184714023e-10
, O 0 1.5370742179054986e-10
as O 0 5.582653783697822e-10
well O 0 2.1347950074357414e-09
as O 0 3.5670237874541044e-09
a O 0 3.004229398584357e-08
younger O 0 1.544351846405334e-08
age O 0 1.1100155461463146e-07
at O 0 1.4051572634343756e-06
diagnosis O 0 6.6392722146702e-06
. O 0 1.8362233333846234e-07

We O 0 6.588093128812034e-07
conclude O 0 1.843735049078532e-06
that O 0 3.912883883572249e-08
the O 0 2.112879258220346e-07
APC O 0 3.6581513995770365e-06
I1307K O 0 2.78838092526712e-06
variant O 0 1.6400242941472243e-07
leads O 0 9.766413455736256e-08
to O 0 6.683884556935027e-09
increased O 0 6.195726882651797e-07
adenoma B-Disease 1 1.0
formation O 0 1.7611356497582165e-06
and O 0 1.2603671883937295e-08
directly O 0 4.1189551325260254e-08
contributes O 0 1.0500115443790037e-08
to O 0 1.0372001035818812e-09
3 O 0 9.481215812456867e-09
% O 0 5.404808267606143e-10
- O 0 2.600814008602015e-10
4 O 0 1.8368260246148793e-09
% O 0 1.4351667076972774e-10
of O 0 1.841739954988597e-10
all O 0 1.0371051795132757e-09
Ashkenazi O 0 6.401968676073011e-06
Jewish O 0 0.4796392023563385
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.8648792067542672e-06

The O 0 1.1120457088509283e-07
estimated O 0 3.165711603969612e-08
relative O 0 2.7739048391595134e-07
risk O 0 5.166750938201403e-08
for O 0 3.5297931244571146e-09
carriers O 0 2.911886065604108e-09
may O 0 1.1508953789984844e-09
justify O 0 3.778446711066863e-08
specific O 0 7.366461329816332e-10
clinical O 0 1.0472993139387654e-08
screening O 0 7.260683720922145e-10
for O 0 4.2491332674643445e-10
the O 0 7.926356460075112e-09
360 O 0 1.7068092716954197e-08
, O 0 1.526829773723648e-10
000 O 0 7.218447617418633e-09
Americans O 0 2.5964425054425533e-10
expected O 0 2.4527499475901493e-10
to O 0 5.362195132363468e-10
harbor O 0 1.0445506859468878e-07
this O 0 5.938873837152414e-10
allele O 0 4.168044520636016e-10
, O 0 6.877079461453661e-11
and O 0 5.076666864667345e-11
genetic O 0 6.802150509521709e-10
testing O 0 7.913120159130926e-10
in O 0 3.300140827278142e-09
the O 0 1.9745028723150426e-08
setting O 0 4.2463264549041924e-07
of O 0 4.0242656496047857e-07
long O 0 7.835031112790602e-08
- O 0 8.358438208233565e-08
term O 0 1.610438431498551e-07
- O 0 1.546739625268856e-08
outcome O 0 1.0328062849396247e-08
studies O 0 3.678484628011347e-09
may O 0 3.0373845105735597e-10
impact O 0 2.6107704886868532e-09
significantly O 0 1.8534626278210453e-08
on O 0 4.411660484038293e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 0.042025186121463776
in O 0 8.001725948503235e-10
this O 0 5.629874344492691e-10
population O 0 8.33213498196983e-10
. O 0 5.4023368001310246e-09

Localization O 0 0.0005206732894293964
of O 0 2.131782366632251e-06
human O 0 5.382580638979562e-07
BRCA1 O 0 8.359777581290473e-08
and O 0 3.4823870453948302e-09
its O 0 6.1508864668269325e-09
loss O 0 7.463165729859611e-07
in O 0 5.706258576765322e-08
high O 0 3.633001369962585e-06
- O 0 7.375942914222833e-07
grade O 0 2.8255113647901453e-05
, O 0 6.744666336544469e-08
non B-Disease 0 0.14132024347782135
- I-Disease 1 0.5962093472480774
inherited I-Disease 1 0.9999998807907104
breast I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 3.1518234209215734e-06

Although O 0 5.870943482477742e-07
the O 0 1.4213246402050572e-07
link O 0 3.8100725419099035e-07
between O 0 9.305145454163721e-08
the O 0 1.1566262401174754e-06
BRCA1 O 0 2.0277993826312013e-05
tumour B-Disease 1 1.0
- O 0 0.0002667081425897777
suppressor O 0 4.02257101086434e-05
gene O 0 6.330350288408226e-08
and O 0 2.2197392368639157e-08
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 1.6318568668793887e-05
established O 0 4.050992572501855e-07
, O 0 1.1769639707281954e-09
the O 0 6.354505810435285e-09
role O 0 3.8256626311294895e-08
, O 0 1.5083115867398078e-09
if O 0 6.906133442896589e-10
any O 0 4.386509822040807e-09
, O 0 1.2097545187828018e-09
of O 0 2.2383909836776184e-08
BRCA1 O 0 3.3631398110856026e-08
in O 0 1.4162777972615004e-07
non B-Disease 1 0.9999885559082031
- I-Disease 1 0.9999189376831055
familial I-Disease 1 0.9999339580535889
cancers I-Disease 1 0.9898543953895569
is O 0 5.0889575220480765e-08
unclear O 0 1.0599477491268772e-06
. O 0 1.29228823197991e-07

BRCA1 O 0 1.4590127648261841e-05
mutations O 0 7.911527433179799e-08
are O 0 1.1684644363185726e-09
rare O 0 4.965118538535762e-09
in O 0 2.197693760308539e-08
sporadic B-Disease 0 0.28116390109062195
cancers I-Disease 1 0.9970821738243103
, O 0 3.297625639220314e-08
but O 0 2.1931253257889693e-08
loss O 0 8.614936632511672e-06
of O 0 1.5432646023327834e-06
BRCA1 O 0 2.863584569468003e-08
resulting O 0 2.9628008935134176e-09
from O 0 8.823851094241775e-10
reduced O 0 3.455755015480122e-09
expression O 0 2.3903825585591676e-09
or O 0 1.4049306162888797e-09
incorrect O 0 4.739134240594467e-08
subcellular O 0 1.7327128034594352e-06
localization O 0 7.22401409802842e-07
is O 0 1.6574254191326077e-09
postulated O 0 4.655447227719378e-08
to O 0 1.0559779717311812e-09
be O 0 1.8627153153261133e-09
important O 0 1.9661298367168456e-08
in O 0 9.87814487984906e-08
non B-Disease 0 0.24821563065052032
- I-Disease 1 0.6859385967254639
familial I-Disease 1 0.9999994039535522
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 2.701496305235196e-05

Epigenetic O 0 0.0021883442532271147
loss O 0 0.00011251259275013581
, O 0 3.057691699837051e-08
however O 0 4.70980303646229e-08
, O 0 4.894037175517951e-09
has O 0 5.431179950221576e-10
not O 0 1.2659795434188936e-10
received O 0 1.2114492742298921e-09
general O 0 1.533052795821277e-08
acceptance O 0 7.885104480465088e-08
due O 0 1.1716097247926882e-07
to O 0 3.667262049589226e-09
controversy O 0 1.8386531408509654e-08
regarding O 0 1.9938642736860857e-08
the O 0 4.773835726723519e-08
subcellular O 0 1.8188351532444358e-05
localization O 0 3.577192046577693e-06
of O 0 1.3138787835487165e-07
BRCA1 O 0 4.2323456739268295e-08
proteins O 0 3.784228930214795e-09
, O 0 2.8690445574852674e-09
reports O 0 2.2131906973754667e-08
of O 0 3.087285804781459e-08
which O 0 1.0328293775785369e-09
have O 0 2.2255618181699077e-10
ranged O 0 4.1410586959500506e-08
from O 0 3.94427068783898e-09
exclusively O 0 3.0253787031142565e-08
nuclear O 0 6.082477170821221e-07
, O 0 2.007333188558391e-09
to O 0 1.856699349822577e-09
conditionally O 0 9.42924387459243e-08
nuclear O 0 7.337678198382491e-07
, O 0 4.4016794653600755e-09
to O 0 4.245999996044247e-09
the O 0 3.502166237012716e-07
ER O 0 0.006561016198247671
/ O 0 5.172764758754056e-06
golgi O 0 2.8799657229683362e-05
, O 0 7.463412998731656e-09
to O 0 8.025206277295638e-09
cytoplasmic O 0 2.4820799353619805e-06
invaginations O 0 8.495622751070186e-06
into O 0 1.2491504719491786e-07
the O 0 5.10328504788049e-07
nucleus O 0 1.550816887174733e-05
. O 0 1.0383803328295471e-06

In O 0 1.486043970544415e-06
an O 0 1.1260064525231428e-07
attempt O 0 3.087542665980436e-07
to O 0 3.013595417655779e-08
resolve O 0 6.686653932774789e-07
this O 0 1.9109815951878772e-08
issue O 0 8.727914035944195e-08
, O 0 4.999147318329733e-09
we O 0 1.2283678074709314e-08
have O 0 5.120256663104783e-09
comprehensively O 0 6.826701905993104e-07
characterized O 0 2.771287199720973e-07
19 O 0 9.772522844286868e-07
anti O 0 5.806973604194354e-07
- O 0 2.3707245873083593e-06
BRCA1 O 0 1.4057199848593882e-07
antibodies O 0 1.9819585972413734e-08
. O 0 8.095576475852795e-08

These O 0 5.435331118519571e-08
reagents O 0 2.1055132037872681e-07
detect O 0 2.575328608145355e-07
a O 0 2.579372164746019e-07
220 O 0 5.218549858909682e-07
- O 0 2.0151989588157448e-07
kD O 0 2.8390324587235227e-05
protein O 0 1.1863432547443153e-07
localized O 0 6.822791220884028e-08
in O 0 1.4360956868131325e-09
discrete O 0 6.183696399375549e-08
nuclear O 0 1.4246918453864055e-06
foci O 0 3.521623511915095e-05
in O 0 1.7997196621877265e-08
all O 0 1.3727787795403401e-08
epithelial O 0 3.6415965496416902e-06
cell O 0 1.225365213031182e-05
lines O 0 1.5936878483557848e-08
, O 0 1.4520702695808296e-10
including O 0 6.265356289336665e-11
those O 0 2.972654344901571e-10
derived O 0 4.347348436795073e-08
from O 0 4.138304063872056e-07
breast B-Disease 0 0.00015502744645345956
malignancies I-Disease 0 0.00017086821026168764
. O 0 6.751752152922563e-07

Immunohistochemical O 0 0.011242291890084743
staining O 0 3.120613837381825e-05
of O 0 9.035072139340627e-07
human O 0 6.526472020595975e-07
breast O 0 2.358295205340255e-06
specimens O 0 1.3592094774139696e-06
also O 0 1.7977024313609036e-08
revealed O 0 1.0067842595162801e-06
BRCA1 O 0 1.1764129936864265e-07
nuclear O 0 8.646178685012273e-06
foci O 0 0.00047285264008678496
in O 0 3.309925844519057e-08
benign O 1 0.7966184616088867
breast O 0 0.00018284803081769496
, O 0 1.689040374230899e-07
invasive B-Disease 0 0.44012051820755005
lobular I-Disease 1 1.0
cancers I-Disease 1 0.9999914169311523
and O 0 1.1006840395566542e-05
low B-Disease 1 1.0
- I-Disease 1 1.0
grade I-Disease 1 1.0
ductal I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 1.4729355825693347e-05

Conversely O 0 3.758092498173937e-05
, O 0 6.67572024326546e-08
BRCA1 O 0 9.929790678597783e-08
expression O 0 1.7538896557312e-08
was O 0 4.276783016621266e-08
reduced O 0 6.124639462257164e-09
or O 0 4.267955322490025e-09
undetectable O 0 5.0805102347339925e-08
in O 0 2.456782333126739e-09
the O 0 4.6632742112251435e-09
majority O 0 6.917365569236722e-10
of O 0 3.40467281034762e-08
high O 0 2.4341907192138024e-06
- O 0 7.267310138558969e-06
grade O 1 0.5697879195213318
, O 0 1.2808002793462947e-05
ductal B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 0 3.543021875884733e-08
suggesting O 0 1.25351348856384e-07
that O 0 9.251603372284478e-10
absence O 0 6.436862065584137e-08
of O 0 2.731360666530236e-07
BRCA1 O 0 8.066830048392148e-08
may O 0 6.594307322416171e-09
contribute O 0 2.4477891713559075e-08
to O 0 1.6151920689821964e-08
the O 0 1.9663498562749737e-07
pathogenesis O 0 0.000626461289357394
of O 0 1.4406828086066525e-07
a O 0 1.2680301253453763e-08
significant O 0 9.746461415716112e-09
percentage O 0 5.206092623666336e-08
of O 0 1.6061047602988765e-08
sporadic B-Disease 0 0.00017291745461989194
breast I-Disease 1 0.6861646175384521
cancers I-Disease 0 0.00489704217761755
. O 0 9.197385963943816e-08
. O 0 2.5217750021511165e-07

